[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fTCzBKq7FBnZCBQqhA5Is4H3UJ_EZzBVdpZ7atkRhvk0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":87,"rows":94},"Massachusetts General Hospital",[4],2526,false,574,96,2423457,251,1556,[14,17,20,23,25,28,31,34],{"name":15,"count":16},"Depression",100,{"name":18,"count":19},"Major Depressive Disorder",64,{"name":21,"count":22},"Breast Cancer",51,{"name":24,"count":22},"Bipolar Disorder",{"name":26,"count":27},"Obesity",47,{"name":29,"count":30},"Healthy",44,{"name":32,"count":33},"Lung Cancer",36,{"name":35,"count":36},"Schizophrenia",34,[38,43,48,53,58,62,67,72,77,82],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT00977470","Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations","2015-05","Erlotinib",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT01746238","Bevacizumab\u002FDoxorubicin\u002FRadiation for Sarcoma","2016-05","Bevacizumab",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT02394769","ASPirin Intervention for the REDuction of Colorectal Cancer Risk","2019-04-11","Aspirin",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT03279692","Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma","2021-09-18","Pembrolizumab",{"nctId":59,"briefTitle":60,"date":61,"intervention":57},"NCT03149029","Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma","2021-12-31",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT03563248","Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer","2022-02-16","FOLFIRINOX",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT04060667","Wireless Physiologic Monitoring in Postpartum Women","2022-03-30","Wireless physiologic monitoring",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT04430894","KRDI in Transplant-Eligible MM","2022-07-30","Carfilzomib",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT04361162","Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer","2022-10","Nivolumab",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT03674047","Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)","2022-12-02","ruxolitinib",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,334,385,464,542,609,691,758,796,855,900,954,990,1017,1035,1063,1092,1110,1128,1162,1180,1198,1225,1253,1271,1294,1312,1330,1348,1375,1393,1411,1429,1447,1473,1491,1515,1541,1559,1584,1610,1628,1652,1677,1695,1713,1731,1749,1767,1901,1982,2015,2074,2102,2131,2149,2167,2185,2211,2234,2260,2285,2312,2340,2358,2376,2394,2460,2598,2694,2790,2900,2974,3086,3126,3189,3227,3277,3315,3359,3409,3435,3537,3593,3713,3769,3845,3879,3927,3957,3996,4039,4077,4109,4137,4159,4181,4203,4232,4260,4312,4408,4474,4548,4596,4642,4691,4725,4759,4798,4824,4850,4893,4915,4937,4968,4996,5018,5056,5078,5112,5138,5156,5174,5197,5221,5239,5264,5288,5322,5340,5358,5376,5394,5421,5439,5461,5479,5504,5528,5553,5576,5594,5619,5641,5659,5683,5701,5729,5747,5770,5788,5806,5824,5853,5871,5889,5907,5925,5950,5968,5986,6010,6031,6049,6072,6098,6123,6148,6174,6192,6218,6241,6259,6277,6300,6324,6347,6374,6392,6410,6428,6459,6477,6495,6525,6548,6571,6589,6656,6709,6763,6817,6843,6955,6988,7010,7032,7054,7096,7131,7173,7195,7221,7239,7262,7280,7298,7316,7339,7357,7381,7406,7430,7453,7476,7494,7552,7585,7609,7627,7652,7675,7693,7717,7735,7758,7782,7800,7822,7846,7871,7894,7917,7942,7999,8028,8054,8076,8151,8184,8212,8230,8253,8278,8301,8324,8348,8366,8388,8411,8435,8529,8595,8648,8698,8744,8788,8824,8866,8912,8955,8998,9040,9079,9124,9150,9186,9223,9249,9277,9307,9339,9372,9405,9427,9459,9487,9509,9537,9573,9607,9625,9647,9670,9688,9710,9732,9757,9783,9801,9825,9848,9871,9893,9917,9941,9963,9986,10008,10031,10055,10080,10106,10127,10149,10174,10192,10216,10238,10259,10282,10300,10323,10346,10367,10385,10409,10434,10452,10476,10494,10519,10537,10558,10582,10600,10618,10644,10665,10691,10716,10743,10761,10779,10805,10823,10841,10862,10880,10903,10921,10939,10961,10987,11005,11027,11050,11076,11098,11116,11134,11156,11177,11201,11219,11241,11263,11284,11307,11325,11346,11370,11393,11411,11435,11457,11475,11498,11519,11537,11560,11581,11599,11621,11643,11661,11682,11703,11726,11747,11769,11793,11816,11834,11924,11974,12039,12078,12112,12148,12181,12208,12226,12248,12270,12288,12306,12329,12353,12371,12396,12419,12437,12460,12478,12501,12525,12543,12565,12586,12604,12628,12650,12672,12698,12716,12734,12756,12774,12797,12818,12839,12861,12883,12909,12934,12952,12978,12996,13019,13045,13072,13095,13116,13140,13164,13186,13208,13233,13251,13269,13291,13313,13355,13411,13447,13481,13531,13565,13604,13637,13679,13705,13733,13771,13811,13856,13887,13919,13951,13985,14007,14029,14051,14078,14100,14125,14152,14176,14200,14237,14259,14289,14311,14335,14357,14382,14416,14444,14468,14490,14519,14554,14581,14605,14635,14669,14693,14721,14739,14757,14780,14798,14820,14844,14866,14887,14911,14929,14951,14975,14993,15011,15033,15057,15075,15097,15115,15138,15156,15180,15203,15224,15248,15269,15294,15312,15330,15355,15373,15397,15418,15439,15457,15480,15498,15520,15538,15556,15580,15601,15619,15637,15660,15678,15700,15722,15740,15762,15784,15802,15824,15842,15864,15887,15912,15930,15948,15970,15995,16013,16031,16049,16072,16093,16111,16134,16157,16179,16201,16219,16240,16261,16289,16307,16325,16343,16366,16384,16402,16420,16438,16456,16479,16502,16520,16538,16556,16578,16599,16617,16635,16657,16675,16693,16715,16733,16754,16779,16797,16815,16840,16858,16880,16904,16922,16940,16958,16976,16998,17016,17034,17052,17070,17088,17110,17131,17149,17167,17188,17211,17229,17251,17272,17290,17313,17335,17356,17378,17396,17419,17441,17459,17483,17506,17524,17546,17569,17587,17610,17631,17656,17681,17703,17725,17749,17772,17790,17814,17837,17855,17878,17900,17918,17964,18000,18033,18061,18083,18115,18138,18163,18188,18206,18227,18248,18266,18284,18302,18320,18338,18356,18374,18398,18416,18439,18462,18486,18509,18527,18548,18566,18588,18609,18631,18654,18677,18699,18720,18745,18763,18789,18807,18830,18853,18871,18889,18907,18928,18946,18964,18986,19004,19026,19049,19067,19085,19103,19121,19146,19164,19186,19208,19226,19244,19266,19288,19310,19331,19349,19372,19395,19413,19431,19453,19474,19498,19516,19543,19561,19579,19602,19623,19644,19669,19761,19845,19906,19952,20014,20057,20099,20145,20188,20222,20266,20302,20347,20394,20433,20469,20498,20534,20569,20595,20625,20655,20694,20731,20757,20781,20810,20838,20869,20893,20924,20948,20978,21004,21028,21063,21098,21127,21157,21189,21219,21247,21274,21296,21317,21341,21363,21385,21410,21432,21454,21472,21493,21517,21539,21557,21580,21608,21626,21648,21666,21687,21711,21737,21762,21783,21801,21827,21851,21874,21897,21915,21933,21955,21973,21996,22014,22036,22057,22079,22103,22124,22142,22167,22189,22210,22232,22254,22278,22296,22314,22337,22359,22377,22395,22413,22436,22454,22475,22493,22511,22534,22552,22570,22592,22613,22631,22649,22667,22694,22712,22730,22753,22775,22797,22815,22833,22855,22876,22898,22921,22942,22968,22986,23007,23029,23047,23068,23089,23110,23132],{"intervention":96,"totalTrials":97,"cells":98},"Rituximab",17,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":143,"PHASE3":289,"PHASE4":291,"NA":332},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[104,114,129],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":109,"start":110,"enrollment":101,"conditions":111,"interventions":113},"NCT00476515","Rituximab Therapy for Patients on Kidney Transplant Waiting List With Positive Donor Specific Crossmatch to Living Donor","WITHDRAWN",[89],"2007-09","2007-03",[112],"Kidney Insufficiency",[96],{"nctId":115,"briefTitle":116,"status":117,"phases":118,"primaryCompletion":119,"completion":120,"start":121,"enrollment":36,"conditions":122,"interventions":126},"NCT01400685","Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL\u002FSLL","COMPLETED",[89],"2017-12","2018-01","2012-12",[123,124,125],"Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","B Chronic Lymphocytic Leukemia",[127,128,96],"Lenalidomide","Bendamustine",{"nctId":130,"briefTitle":131,"status":117,"phases":132,"primaryCompletion":133,"completion":134,"start":135,"enrollment":136,"conditions":137,"interventions":140},"NCT02314403","Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)",[89],"2021-03","2021-07","2015-02",2,[138,139],"Kidney Failure, Chronic","Renal Insufficiency",[141,142,96],"Belatacept","ATG",{"trials":144,"activeCount":136,"soonestReadout":162},[145,157,170,186,203,220,234,244,256,264,278],{"nctId":146,"briefTitle":147,"status":117,"phases":148,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":152,"interventions":154},"NCT00869999","Everolimus Plus Rituximab for Relapsed\u002FRefractory Diffuse Large B Cell Lymphoma",[90],"2011-11","2009-05",26,[153],"Diffuse Large B-cell Lymphoma",[155,156],"Everolimus","rituximab",{"nctId":158,"briefTitle":159,"status":160,"phases":161,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":168},"NCT06561347","Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM","RECRUITING",[90],"2026-12-01","2027-12-01","2024-12-20",55,[167],"Waldenstrom Macroglobulinemia",[169,128,96],"Zanubrutinib",{"nctId":171,"briefTitle":172,"status":173,"phases":174,"primaryCompletion":175,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":183},"NCT00455897","CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma","TERMINATED",[90],"2007-11","2011-07","2006-12",3,[180,181,182],"Lymphoma, Non-Hodgkin","Lymphoma, B-Cell","Lymphoma, Diffuse",[184,185,96],"GM-CSF","CHOP",{"nctId":187,"briefTitle":188,"status":189,"phases":190,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":195,"interventions":199},"NCT05900401","Delayed Tolerance Through Mixed Chimerism","ACTIVE_NOT_RECRUITING",[89,90],"2028-12","2030-12","2023-10-01",20,[196,197,198],"Kidney Failure","Kidney Transplant; Complications","Chimera",[200,201,96,202],"Fludarabine","Cyclophosphamide","Siplizumab",{"nctId":204,"briefTitle":205,"status":173,"phases":206,"primaryCompletion":207,"completion":207,"start":208,"enrollment":209,"conditions":210,"interventions":218},"NCT03919175","Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma",[90],"2024-05-05","2019-09-01",18,[211,212,213,214,215,216,217],"Lymphoma","Follicular Lymphoma","Follicular Lymphoma, Grade 1","Follicular Lymphoma Grade 2","Follicular Lymphoma Grade IIIa","Marginal Zone Lymphoma","Marginal Zone B Cell Lymphoma",[219,96],"Umbralisib",{"nctId":221,"briefTitle":222,"status":117,"phases":223,"primaryCompletion":224,"completion":225,"start":226,"enrollment":227,"conditions":228,"interventions":233},"NCT01584388","Rituximab in IgG4-RD: A Phase 1-2 Trial",[89,90],"2014-01","2015-01","2012-04",30,[229,230,231,232],"Retroperitoneal Fibrosis","Autoimmune Pancreatitis","Sialadenitis","Pseudotumor",[96],{"nctId":235,"briefTitle":236,"status":173,"phases":237,"primaryCompletion":225,"completion":225,"start":238,"enrollment":239,"conditions":240,"interventions":241},"NCT01173679","Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL",[90],"2010-07",10,[123,124],[242,96,243],"dasatinib","fludarabine",{"nctId":245,"briefTitle":246,"status":117,"phases":247,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":255},"NCT00895661","High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas",[90],"2010-10","2015-08","2009-07",40,[253,254],"B-cell Lymphoma","Indolent B-cell Lymphoma",[156],{"nctId":257,"briefTitle":258,"status":107,"phases":259,"primaryCompletion":175,"completion":175,"start":260,"enrollment":101,"conditions":261,"interventions":263},"NCT00261547","Rituximab Treatment to Block HLA Antibodies in Renal Transplant Recipients",[89,90],"2005-12",[262,112],"Chronic Rejection",[96],{"nctId":265,"briefTitle":266,"status":117,"phases":267,"primaryCompletion":268,"completion":269,"start":149,"enrollment":270,"conditions":271,"interventions":276},"NCT01058239","Bortezomib Plus Rituximab for EBV+ PTLD",[90],"2016-12","2017-11",7,[272,273,274,275],"Post-transplant Lymphoproliferative Disease","Solid Organ Transplant","Stem Cell Transplant (Bone Marrow Transplant)","Epstein Barr Virus Infections",[277,156],"bortezomib",{"nctId":279,"briefTitle":280,"status":117,"phases":281,"primaryCompletion":282,"completion":283,"start":284,"enrollment":136,"conditions":285,"interventions":287},"NCT01780454","Renal Allograft Tolerance Through Mixed Chimerism",[89,90],"2018-06","2020-06","2013-03",[286],"End Stage Renal Disease",[288,96],"MEDI-507",{"trials":290,"activeCount":101},[],{"trials":292,"activeCount":331,"soonestReadout":320},[293,303,315],{"nctId":294,"briefTitle":295,"status":173,"phases":296,"primaryCompletion":297,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":302},"NCT02749292","Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing",[92],"2022-01-31","2016-06",115,[301],"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",[96],{"nctId":304,"briefTitle":305,"status":117,"phases":306,"primaryCompletion":307,"completion":308,"start":309,"enrollment":194,"conditions":310,"interventions":313},"NCT02169219","Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis",[92],"2016-08-17","2017-11-01","2014-06",[311,312],"Granulomatosis With Polyangiitis","Microscopic Polyangiitis",[314,96],"Glucocorticoids",{"nctId":316,"briefTitle":317,"status":318,"phases":319,"primaryCompletion":320,"completion":321,"start":322,"enrollment":323,"conditions":324,"interventions":326},"NCT07010302","Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD","NOT_YET_RECRUITING",[92],"2030-01","2030-05","2026-05",540,[325],"NMOSD",[96,327,328,329,330],"Eculizumab","Ravulizumab","Satralizumab","Inebilizumab",1,{"trials":333,"activeCount":101},[],{"intervention":335,"totalTrials":178,"cells":336},"Romosozumab",{"EARLY_PHASE1":337,"PHASE1":339,"PHASE2":341,"PHASE3":343,"PHASE4":357,"NA":383},{"trials":338,"activeCount":101},[],{"trials":340,"activeCount":101},[],{"trials":342,"activeCount":101},[],{"trials":344,"activeCount":331,"soonestReadout":349},[345],{"nctId":346,"briefTitle":347,"status":160,"phases":348,"primaryCompletion":349,"completion":350,"start":351,"enrollment":352,"conditions":353,"interventions":355},"NCT06533865","Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea",[91],"2028-10","2029-04","2025-03-19",114,[354],"FHA (Functional Hypothalamic Amenorrhea)",[335,356],"Zoledronic acid",{"trials":358,"activeCount":136,"soonestReadout":363},[359,371],{"nctId":360,"briefTitle":361,"status":189,"phases":362,"primaryCompletion":363,"completion":364,"start":365,"enrollment":366,"conditions":367,"interventions":369},"NCT05010590","Anabolic Therapy in Postmenopausal Osteoporosis",[92],"2027-10-01","2027-11-01","2022-03-24",50,[368],"Postmenopausal Osteoporosis",[335,370],"Denosumab",{"nctId":372,"briefTitle":373,"status":160,"phases":374,"primaryCompletion":375,"completion":376,"start":377,"enrollment":366,"conditions":378,"interventions":381},"NCT06558188","Combined Anabolic Therapy",[92],"2027-12-30","2028-04-01","2025-02-03",[379,380],"Osteoporosis, Postmenopausal","Osteoporosis",[335,382],"Teriparatide",{"trials":384,"activeCount":101},[],{"intervention":370,"totalTrials":270,"cells":386},{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":391,"PHASE3":403,"PHASE4":405,"NA":462},{"trials":388,"activeCount":101},[],{"trials":390,"activeCount":101},[],{"trials":392,"activeCount":101},[393],{"nctId":394,"briefTitle":395,"status":117,"phases":396,"primaryCompletion":268,"completion":268,"start":397,"enrollment":398,"conditions":399,"interventions":400},"NCT00926380","Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis",[90],"2009-06",94,[380],[401,402],"denosumab","teriparatide",{"trials":404,"activeCount":101},[],{"trials":406,"activeCount":136,"soonestReadout":444},[407,416,420,431,440,451],{"nctId":408,"briefTitle":409,"status":117,"phases":410,"primaryCompletion":411,"completion":411,"start":412,"enrollment":413,"conditions":414,"interventions":415},"NCT04026256","Bone Modeling Effects of Combined Anabolic\u002FAntiresorptive Administration",[92],"2022-04-18","2019-09-02",37,[368],[382,370],{"nctId":360,"briefTitle":361,"status":189,"phases":417,"primaryCompletion":363,"completion":364,"start":365,"enrollment":366,"conditions":418,"interventions":419},[92],[368],[335,370],{"nctId":421,"briefTitle":422,"status":117,"phases":423,"primaryCompletion":424,"completion":424,"start":425,"enrollment":33,"conditions":426,"interventions":429},"NCT04087096","Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery",[92],"2024-08-06","2020-08-24",[427,428],"Bariatric Surgery Candidate","Bone Loss",[370,430],"Zoledronic Acid",{"nctId":432,"briefTitle":433,"status":117,"phases":434,"primaryCompletion":435,"completion":435,"start":436,"enrollment":437,"conditions":438,"interventions":439},"NCT02176382","Denosumab and Teriparatide Study (DATA-HD and DATA-EX)",[92],"2020-02","2014-08",76,[368],[401,402,356],{"nctId":441,"briefTitle":442,"status":189,"phases":443,"primaryCompletion":444,"completion":445,"start":446,"enrollment":22,"conditions":447,"interventions":448},"NCT03623633","Comparative Antiresorptive Efficacy Discontinuation of Denosumab",[92],"2023-02-01","2023-08-01","2018-11-30",[379,380],[401,449,450],"alendronate","raloxifene",{"nctId":452,"briefTitle":453,"status":117,"phases":454,"primaryCompletion":455,"completion":436,"start":456,"enrollment":457,"conditions":458,"interventions":459},"NCT01750086","Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption",[92],"2014-04","2013-01",27,[368],[460,370,461],"Teriparatide 40-mcg subcutaneous","Alendronate Oral",{"trials":463,"activeCount":101},[],{"intervention":465,"totalTrials":270,"cells":466},"Buspirone",{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":491,"PHASE4":493,"NA":532},{"trials":468,"activeCount":101},[],{"trials":470,"activeCount":101},[],{"trials":472,"activeCount":101},[473,481],{"nctId":474,"briefTitle":475,"status":107,"phases":476,"primaryCompletion":477,"completion":477,"start":149,"enrollment":101,"conditions":478,"interventions":480},"NCT01395953","Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders",[90],"2013-07",[479],"Autism Spectrum Disorder (ASD)",[465],{"nctId":482,"briefTitle":483,"status":107,"phases":484,"primaryCompletion":485,"completion":485,"start":486,"enrollment":101,"conditions":487,"interventions":490},"NCT03432065","A Pilot Study of Buspirone for the Treatment of Anxiety in Youth with Autism Spectrum Disorders",[90],"2025-08","2024-12",[488,489],"Autism Spectrum Disorder","Anxiety",[465],{"trials":492,"activeCount":101},[],{"trials":494,"activeCount":136,"soonestReadout":526},[495,505,513,522],{"nctId":496,"briefTitle":497,"status":318,"phases":498,"primaryCompletion":499,"completion":500,"start":501,"enrollment":194,"conditions":502,"interventions":503},"NCT07439042","Buspirone for Anxiety in Autistic Youth",[92],"2029-02","2029-06","2026-08",[489,488],[504],"buspirone",{"nctId":506,"briefTitle":507,"status":117,"phases":508,"primaryCompletion":509,"completion":509,"start":510,"enrollment":151,"conditions":511,"interventions":512},"NCT03538431","Improving Driving in Young People With Autism Spectrum Disorders",[92],"2019-12-16","2018-10-31",[488],[465],{"nctId":514,"briefTitle":515,"status":117,"phases":516,"primaryCompletion":517,"completion":517,"start":518,"enrollment":194,"conditions":519,"interventions":521},"NCT04807517","Buspirone Treatment of Anxiety in Williams Syndrome",[92],"2023-09-11","2021-08-01",[520,489],"Williams Syndrome",[465],{"nctId":523,"briefTitle":524,"status":160,"phases":525,"primaryCompletion":526,"completion":526,"start":527,"enrollment":239,"conditions":528,"interventions":530},"NCT04400266","Buspirone and Melatonin for Depression Following Traumatic Brain Injury",[92],"2028-07-31","2020-08-01",[15,529],"Brain Injuries, Traumatic",[465,531],"Mealatonin",{"trials":533,"activeCount":101},[534],{"nctId":535,"briefTitle":536,"status":117,"phases":537,"primaryCompletion":486,"completion":486,"start":477,"enrollment":538,"conditions":539,"interventions":541},"NCT01850355","An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders",[93],9,[540,489],"Autism Spectrum Disorders",[465],{"intervention":543,"totalTrials":544,"cells":545},"Alendronate",6,{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":560,"PHASE3":585,"PHASE4":597,"NA":607},{"trials":547,"activeCount":101},[],{"trials":549,"activeCount":101},[550],{"nctId":551,"briefTitle":552,"status":117,"phases":553,"primaryCompletion":554,"completion":554,"start":455,"enrollment":555,"conditions":556,"interventions":558},"NCT02057263","The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults",[89],"2016-02",28,[557],"Hepatitis B",[543,559],"Hepatitis B Vaccine",{"trials":561,"activeCount":101},[562,574],{"nctId":563,"briefTitle":564,"status":173,"phases":565,"primaryCompletion":566,"completion":567,"start":568,"enrollment":30,"conditions":569,"interventions":572},"NCT01460654","Testosterone and Alendronate in Hypogonadal Men",[90],"2014-05","2014-12","2011-10",[570,571,380],"Hypogonadism","Osteopenia",[573,543],"Testosterone",{"nctId":575,"briefTitle":576,"status":117,"phases":577,"primaryCompletion":578,"completion":579,"start":580,"enrollment":581,"conditions":582,"interventions":583},"NCT00000400","Alendronate and\u002For Parathyroid Hormone for Osteoporosis",[90],"2006-04","2006-06","1999-08",176,[380],[584,449],"Human parathyroid hormone [hPTH-(1-34)]",{"trials":586,"activeCount":101},[587],{"nctId":588,"briefTitle":589,"status":117,"phases":590,"primaryCompletion":591,"completion":591,"start":592,"enrollment":593,"conditions":594,"interventions":595},"NCT00000427","Effects of Parathyroid Hormone in Men With Osteoporosis",[91],"2005-10","1999-09",81,[380],[596,543],"Parathyroid hormone",{"trials":598,"activeCount":331,"soonestReadout":444},[599,603],{"nctId":441,"briefTitle":442,"status":189,"phases":600,"primaryCompletion":444,"completion":445,"start":446,"enrollment":22,"conditions":601,"interventions":602},[92],[379,380],[401,449,450],{"nctId":452,"briefTitle":453,"status":117,"phases":604,"primaryCompletion":455,"completion":436,"start":456,"enrollment":457,"conditions":605,"interventions":606},[92],[368],[460,370,461],{"trials":608,"activeCount":101},[],{"intervention":610,"totalTrials":544,"cells":611},"Quetiapine",{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":618,"PHASE4":620,"NA":689},{"trials":613,"activeCount":101},[],{"trials":615,"activeCount":101},[],{"trials":617,"activeCount":101},[],{"trials":619,"activeCount":101},[],{"trials":621,"activeCount":331,"soonestReadout":659},[622,633,643,655,668,680],{"nctId":623,"briefTitle":624,"status":117,"phases":625,"primaryCompletion":626,"completion":627,"start":628,"enrollment":629,"conditions":630,"interventions":631},"NCT01331304","Comparative Effectiveness Study for Bipolar Disorder",[92],"2013-04","2013-09","2010-09",482,[24],[632,610],"Lithium",{"nctId":634,"briefTitle":635,"status":117,"phases":636,"primaryCompletion":637,"completion":637,"start":638,"enrollment":227,"conditions":639,"interventions":641},"NCT00181883","Quetiapine for Mania In Preschool Children 4 to 6 Years of Age With Bipolar Disorder",[92],"2009-04","2005-02",[24,640],"Mania",[642],"quetiapine",{"nctId":644,"briefTitle":645,"status":173,"phases":646,"primaryCompletion":456,"completion":456,"start":647,"enrollment":648,"conditions":649,"interventions":651},"NCT00955474","Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms",[92],"2008-09",32,[650],"Major Depressive Disorder With Psychotic Features",[610,652,653,654],"escitalopram","Sertraline","Citalopram",{"nctId":656,"briefTitle":657,"status":189,"phases":658,"primaryCompletion":659,"completion":659,"start":660,"enrollment":661,"conditions":662,"interventions":664},"NCT06433635","Sequential Multiple Assignment Randomized Trial for Bipolar Depression",[92],"2030-02-28","2024-10-01",2726,[663,15],"Bipolar I Disorder",[665,666,610,667],"Cariprazine","Aripiprazole\u002FEscitalopram combination","Lurasidone",{"nctId":669,"briefTitle":670,"status":117,"phases":671,"primaryCompletion":672,"start":673,"enrollment":674,"conditions":675,"interventions":677},"NCT00182013","Open-Label Comparative Study of Risperidone Versus Olanzapine Versus Quetiapine for Mania in Children and Adolescents With Bipolar I and Bipolar II Disorder",[92],"2004-02","2001-06",106,[676],"Bipolar Spectrum Disorder",[678,679,610],"Risperidone","Olanzapine",{"nctId":681,"briefTitle":682,"status":117,"phases":683,"primaryCompletion":684,"completion":175,"start":672,"enrollment":366,"conditions":685,"interventions":687},"NCT00113295","Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder",[92],"2007-02",[686],"Anxiety Disorder",[688,610],"Continued Paroxetine CR",{"trials":690,"activeCount":101},[],{"intervention":692,"totalTrials":693,"cells":694},"Propranolol",5,{"EARLY_PHASE1":695,"PHASE1":697,"PHASE2":699,"PHASE3":701,"PHASE4":713,"NA":756},{"trials":696,"activeCount":101},[],{"trials":698,"activeCount":101},[],{"trials":700,"activeCount":101},[],{"trials":702,"activeCount":101},[703],{"nctId":704,"briefTitle":705,"status":117,"phases":706,"primaryCompletion":238,"completion":707,"start":708,"enrollment":709,"conditions":710,"interventions":712},"NCT00916721","Memory Reconsolidation Blockade as a Novel Intervention for Nicotine Dependence",[91],"2011-01","2008-04",113,[711],"Smoking Cessation",[692],{"trials":714,"activeCount":331,"soonestReadout":730},[715,726,736,746],{"nctId":716,"briefTitle":717,"status":117,"phases":718,"primaryCompletion":225,"completion":225,"start":719,"enrollment":720,"conditions":721,"interventions":723},"NCT01631682","Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders",[92],"2010-11",186,[722,686],"Posttraumatic Stress Disorder",[692,724,725],"Mifepristone","Intranasal oxytocin",{"nctId":727,"briefTitle":728,"status":160,"phases":729,"primaryCompletion":730,"completion":730,"start":731,"enrollment":732,"conditions":733,"interventions":735},"NCT05853627","Mismatch vs. Standard Intervention During Memory Reconsolidation Blockade With Propranolol: Effect on Psychophysiological Reactivity During Traumatic Imagery",[92],"2026-07-01","2023-06-15",80,[734],"Stress Disorders, Post-Traumatic",[692],{"nctId":737,"briefTitle":738,"status":117,"phases":739,"primaryCompletion":740,"completion":740,"start":741,"enrollment":742,"conditions":743,"interventions":745},"NCT00158262","Effect of Propranolol on Preventing Posttraumatic Stress Disorder",[92],"2008-05","2004-09",43,[744],"Post-Traumatic Stress Disorder",[692],{"nctId":747,"briefTitle":748,"status":117,"phases":749,"primaryCompletion":750,"completion":751,"start":752,"enrollment":753,"conditions":754,"interventions":755},"NCT00709735","A Psychophysiologic Study of Weakening Traumatic Combat Memories With Post-Reactivation Propranolol",[92],"2010-02","2010-08","2007-05",23,[722],[692],{"trials":757,"activeCount":101},[],{"intervention":382,"totalTrials":693,"cells":759},{"EARLY_PHASE1":760,"PHASE1":762,"PHASE2":764,"PHASE3":778,"PHASE4":780,"NA":794},{"trials":761,"activeCount":101},[],{"trials":763,"activeCount":101},[],{"trials":765,"activeCount":101},[766,774],{"nctId":767,"briefTitle":768,"status":117,"phases":769,"primaryCompletion":770,"completion":770,"start":647,"enrollment":753,"conditions":771,"interventions":773},"NCT00759772","The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa",[90],"2016-02-22",[772,380],"Anorexia Nervosa",[382],{"nctId":394,"briefTitle":395,"status":117,"phases":775,"primaryCompletion":268,"completion":268,"start":397,"enrollment":398,"conditions":776,"interventions":777},[90],[380],[401,402],{"trials":779,"activeCount":101},[],{"trials":781,"activeCount":331,"soonestReadout":375},[782,786,790],{"nctId":408,"briefTitle":409,"status":117,"phases":783,"primaryCompletion":411,"completion":411,"start":412,"enrollment":413,"conditions":784,"interventions":785},[92],[368],[382,370],{"nctId":432,"briefTitle":433,"status":117,"phases":787,"primaryCompletion":435,"completion":435,"start":436,"enrollment":437,"conditions":788,"interventions":789},[92],[368],[401,402,356],{"nctId":372,"briefTitle":373,"status":160,"phases":791,"primaryCompletion":375,"completion":376,"start":377,"enrollment":366,"conditions":792,"interventions":793},[92],[379,380],[335,382],{"trials":795,"activeCount":101},[],{"intervention":797,"totalTrials":798,"cells":799},"Suvorexant",4,{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":806,"PHASE4":808,"NA":853},{"trials":801,"activeCount":101},[],{"trials":803,"activeCount":101},[],{"trials":805,"activeCount":101},[],{"trials":807,"activeCount":101},[],{"trials":809,"activeCount":331,"soonestReadout":837},[810,823,833,845],{"nctId":811,"briefTitle":812,"status":117,"phases":813,"primaryCompletion":814,"completion":814,"start":815,"enrollment":816,"conditions":817,"interventions":822},"NCT03818581","Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes",[92],"2021-11-03","2019-03-15",108,[818,819,820,821],"Type 2 Diabetes Mellitus","Insomnia","Sleep Disorder","Inflammation",[797],{"nctId":824,"briefTitle":825,"status":117,"phases":826,"primaryCompletion":827,"completion":827,"start":828,"enrollment":829,"conditions":830,"interventions":832},"NCT04706091","Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia",[92],"2023-10-20","2021-08-12",46,[831,819,820],"Restless Legs Syndrome",[797],{"nctId":834,"briefTitle":835,"status":160,"phases":836,"primaryCompletion":837,"completion":837,"start":838,"enrollment":194,"conditions":839,"interventions":844},"NCT06584942","Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder (Pilot Study)",[92],"2026-07","2025-03-10",[840,841,842,843],"Cue-reactivity","Cannabis Use Disorder","Functional MRI","Orexin Antagonist",[797],{"nctId":846,"briefTitle":847,"status":107,"phases":848,"primaryCompletion":849,"completion":849,"start":850,"enrollment":101,"conditions":851,"interventions":852},"NCT03764683","Suvorexant (Belsomra) for the Treatment of Bipolar Depression With Insomnia",[92],"2021-01-06","2019-02-26",[24,819],[797],{"trials":854,"activeCount":101},[],{"intervention":856,"totalTrials":178,"cells":857},"Pramipexole",{"EARLY_PHASE1":858,"PHASE1":860,"PHASE2":862,"PHASE3":864,"PHASE4":877,"NA":898},{"trials":859,"activeCount":101},[],{"trials":861,"activeCount":101},[],{"trials":863,"activeCount":101},[],{"trials":865,"activeCount":101},[866],{"nctId":867,"briefTitle":868,"status":173,"phases":869,"primaryCompletion":870,"completion":870,"start":871,"enrollment":872,"conditions":873,"interventions":876},"NCT04759703","Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD",[90,91],"2024-05-24","2022-01-24",75,[820,831,874,875],"Opioid-use Disorder","Opioid Withdrawal",[856],{"trials":878,"activeCount":331,"soonestReadout":883},[879,890],{"nctId":880,"briefTitle":881,"status":189,"phases":882,"primaryCompletion":883,"completion":884,"start":885,"enrollment":886,"conditions":887,"interventions":889},"NCT05003648","Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy",[92],"2025-07-15","2026-05-01","2023-04-01",24,[888,831],"Adrenoleukodystrophy",[856],{"nctId":891,"briefTitle":892,"status":117,"phases":893,"primaryCompletion":109,"completion":708,"start":894,"enrollment":895,"conditions":896,"interventions":897},"NCT00231959","Effectiveness of Pramipexole for Treatment-Resistant Depression",[92],"2003-09",65,[15],[856],{"trials":899,"activeCount":101},[],{"intervention":901,"totalTrials":136,"cells":902},"allopurinol",{"EARLY_PHASE1":903,"PHASE1":905,"PHASE2":929,"PHASE3":931,"PHASE4":933,"NA":952},{"trials":904,"activeCount":101},[],{"trials":906,"activeCount":101},[907],{"nctId":908,"briefTitle":909,"status":117,"phases":910,"primaryCompletion":911,"completion":911,"start":912,"enrollment":829,"conditions":913,"interventions":920},"NCT00513474","Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant",[89],"2013-02-12","2008-01",[914,915,916,211,917,918,919],"Chronic Myeloproliferative Disorders","Graft Versus Host Disease","Leukemia","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Neoplasms",[921,922,923,924,925,926,927,928,243,901],"busulfan","cyclophosphamide","cyclosporin-A","etoposide","methotrexate","rasburicase","sirolimus","tacrolimus",{"trials":930,"activeCount":101},[],{"trials":932,"activeCount":101},[],{"trials":934,"activeCount":331,"soonestReadout":939},[935],{"nctId":936,"briefTitle":937,"status":160,"phases":938,"primaryCompletion":939,"completion":940,"start":941,"enrollment":942,"conditions":943,"interventions":945},"NCT04875702","Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout",[92],"2028-09-01","2028-10-31","2024-02-22",650,[944],"Gout",[946,947,948,949,950,951],"Allopurinol","Naproxen 250 MG","Colchicine 0.6 mg","Colchicine 1.2 mg","Naproxen 500 Mg","Prednisone 40 mg",{"trials":953,"activeCount":101},[],{"intervention":955,"totalTrials":136,"cells":956},"Theophylline",{"EARLY_PHASE1":957,"PHASE1":959,"PHASE2":961,"PHASE3":972,"PHASE4":974,"NA":988},{"trials":958,"activeCount":101},[],{"trials":960,"activeCount":101},[],{"trials":962,"activeCount":101},[963],{"nctId":964,"briefTitle":965,"status":117,"phases":966,"primaryCompletion":967,"completion":967,"start":968,"enrollment":270,"conditions":969,"interventions":971},"NCT02479451","Helping Olfaction and Nutrition On Renal Replacement",[90],"2022-07","2015-10",[286,970],"Olfactory Disorders",[955],{"trials":973,"activeCount":101},[],{"trials":975,"activeCount":331,"soonestReadout":980},[976],{"nctId":977,"briefTitle":978,"status":160,"phases":979,"primaryCompletion":980,"completion":981,"start":982,"enrollment":16,"conditions":983,"interventions":987},"NCT03718403","Effect of Theophylline in Pseudohypoparathyroidism",[92],"2030-04-10","2032-04-10","2019-11-11",[984,985,986],"PHP Ia","PHP IB","Php1C",[955],{"trials":989,"activeCount":101},[],{"intervention":991,"totalTrials":331,"cells":992},"Conversion to extended-release tacrolimus",{"EARLY_PHASE1":993,"PHASE1":995,"PHASE2":997,"PHASE3":999,"PHASE4":1001,"NA":1015},{"trials":994,"activeCount":101},[],{"trials":996,"activeCount":101},[],{"trials":998,"activeCount":101},[],{"trials":1000,"activeCount":101},[],{"trials":1002,"activeCount":331,"soonestReadout":1007},[1003],{"nctId":1004,"briefTitle":1005,"status":160,"phases":1006,"primaryCompletion":1007,"completion":363,"start":1008,"enrollment":1009,"conditions":1010,"interventions":1013},"NCT06751992","Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients",[92],"2027-05-01","2026-03-17",92,[1011,1012],"Kidney Transplant Recipients","Old Age",[991,1014],"Maintenance of immediate-release tacrolimus",{"trials":1016,"activeCount":101},[],{"intervention":1014,"totalTrials":331,"cells":1018},{"EARLY_PHASE1":1019,"PHASE1":1021,"PHASE2":1023,"PHASE3":1025,"PHASE4":1027,"NA":1033},{"trials":1020,"activeCount":101},[],{"trials":1022,"activeCount":101},[],{"trials":1024,"activeCount":101},[],{"trials":1026,"activeCount":101},[],{"trials":1028,"activeCount":331,"soonestReadout":1007},[1029],{"nctId":1004,"briefTitle":1005,"status":160,"phases":1030,"primaryCompletion":1007,"completion":363,"start":1008,"enrollment":1009,"conditions":1031,"interventions":1032},[92],[1011,1012],[991,1014],{"trials":1034,"activeCount":101},[],{"intervention":1036,"totalTrials":331,"cells":1037},"Airsupra",{"EARLY_PHASE1":1038,"PHASE1":1040,"PHASE2":1042,"PHASE3":1044,"PHASE4":1046,"NA":1061},{"trials":1039,"activeCount":101},[],{"trials":1041,"activeCount":101},[],{"trials":1043,"activeCount":101},[],{"trials":1045,"activeCount":101},[],{"trials":1047,"activeCount":331,"soonestReadout":1052},[1048],{"nctId":1049,"briefTitle":1050,"status":160,"phases":1051,"primaryCompletion":1052,"completion":1052,"start":1053,"enrollment":1054,"conditions":1055,"interventions":1060},"NCT07166939","45th Multicenter Airway Research Collaboration",[92],"2027-06","2025-11-07",1860,[1056,1057,1058,1059],"Asthma Acute","Asthma Exacerbation","Asthma","Asthma Control Level",[1036],{"trials":1062,"activeCount":101},[],{"intervention":1064,"totalTrials":331,"cells":1065},"IV TXA",{"EARLY_PHASE1":1066,"PHASE1":1068,"PHASE2":1070,"PHASE3":1072,"PHASE4":1074,"NA":1090},{"trials":1067,"activeCount":101},[],{"trials":1069,"activeCount":101},[],{"trials":1071,"activeCount":101},[],{"trials":1073,"activeCount":101},[],{"trials":1075,"activeCount":331,"soonestReadout":1080},[1076],{"nctId":1077,"briefTitle":1078,"status":160,"phases":1079,"primaryCompletion":1080,"completion":1081,"start":1082,"enrollment":1083,"conditions":1084,"interventions":1087},"NCT07131592","Effect of Intravenous and Topical Tranexamic Acid on Drain Output in Breast Reduction Surgery",[92],"2027-03-01","2027-08-31","2025-11-18",160,[1085,1086],"Drain Output After Breast Reduction Surgery","Breast Reductions",[1064,1088,1089],"Topical TXA","Topical saline",{"trials":1091,"activeCount":101},[],{"intervention":1088,"totalTrials":331,"cells":1093},{"EARLY_PHASE1":1094,"PHASE1":1096,"PHASE2":1098,"PHASE3":1100,"PHASE4":1102,"NA":1108},{"trials":1095,"activeCount":101},[],{"trials":1097,"activeCount":101},[],{"trials":1099,"activeCount":101},[],{"trials":1101,"activeCount":101},[],{"trials":1103,"activeCount":331,"soonestReadout":1080},[1104],{"nctId":1077,"briefTitle":1078,"status":160,"phases":1105,"primaryCompletion":1080,"completion":1081,"start":1082,"enrollment":1083,"conditions":1106,"interventions":1107},[92],[1085,1086],[1064,1088,1089],{"trials":1109,"activeCount":101},[],{"intervention":1089,"totalTrials":331,"cells":1111},{"EARLY_PHASE1":1112,"PHASE1":1114,"PHASE2":1116,"PHASE3":1118,"PHASE4":1120,"NA":1126},{"trials":1113,"activeCount":101},[],{"trials":1115,"activeCount":101},[],{"trials":1117,"activeCount":101},[],{"trials":1119,"activeCount":101},[],{"trials":1121,"activeCount":331,"soonestReadout":1080},[1122],{"nctId":1077,"briefTitle":1078,"status":160,"phases":1123,"primaryCompletion":1080,"completion":1081,"start":1082,"enrollment":1083,"conditions":1124,"interventions":1125},[92],[1085,1086],[1064,1088,1089],{"trials":1127,"activeCount":101},[],{"intervention":1129,"totalTrials":331,"cells":1130},"Aspirin 325mg",{"EARLY_PHASE1":1131,"PHASE1":1133,"PHASE2":1135,"PHASE3":1137,"PHASE4":1139,"NA":1160},{"trials":1132,"activeCount":101},[],{"trials":1134,"activeCount":101},[],{"trials":1136,"activeCount":101},[],{"trials":1138,"activeCount":101},[],{"trials":1140,"activeCount":331,"soonestReadout":1146},[1141],{"nctId":1142,"briefTitle":1143,"status":1144,"phases":1145,"primaryCompletion":1146,"completion":1147,"start":1148,"enrollment":1149,"conditions":1150,"interventions":1158},"NCT03244020","LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology","ENROLLING_BY_INVITATION",[92],"2027-12-31","2028-07-01","2018-02-16",2868,[1151,1152,1153,1154,1155,1156,1157],"Sarcoma","Soft Tissue Sarcoma","Bone Sarcoma","Bone Metastases","Venous Thromboembolism","Hematoma","Anticoagulant-induced Bleeding",[1129,1159],"Enoxaparin 40Mg\u002F0.4mL Prefilled Syringe",{"trials":1161,"activeCount":101},[],{"intervention":1159,"totalTrials":331,"cells":1163},{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1168,"PHASE3":1170,"PHASE4":1172,"NA":1178},{"trials":1165,"activeCount":101},[],{"trials":1167,"activeCount":101},[],{"trials":1169,"activeCount":101},[],{"trials":1171,"activeCount":101},[],{"trials":1173,"activeCount":331,"soonestReadout":1146},[1174],{"nctId":1142,"briefTitle":1143,"status":1144,"phases":1175,"primaryCompletion":1146,"completion":1147,"start":1148,"enrollment":1149,"conditions":1176,"interventions":1177},[92],[1151,1152,1153,1154,1155,1156,1157],[1129,1159],{"trials":1179,"activeCount":101},[],{"intervention":450,"totalTrials":331,"cells":1181},{"EARLY_PHASE1":1182,"PHASE1":1184,"PHASE2":1186,"PHASE3":1188,"PHASE4":1190,"NA":1196},{"trials":1183,"activeCount":101},[],{"trials":1185,"activeCount":101},[],{"trials":1187,"activeCount":101},[],{"trials":1189,"activeCount":101},[],{"trials":1191,"activeCount":331,"soonestReadout":444},[1192],{"nctId":441,"briefTitle":442,"status":189,"phases":1193,"primaryCompletion":444,"completion":445,"start":446,"enrollment":22,"conditions":1194,"interventions":1195},[92],[379,380],[401,449,450],{"trials":1197,"activeCount":101},[],{"intervention":1199,"totalTrials":331,"cells":1200},"oral semaglutide",{"EARLY_PHASE1":1201,"PHASE1":1203,"PHASE2":1205,"PHASE3":1207,"PHASE4":1209,"NA":1223},{"trials":1202,"activeCount":101},[],{"trials":1204,"activeCount":101},[],{"trials":1206,"activeCount":101},[],{"trials":1208,"activeCount":101},[],{"trials":1210,"activeCount":331,"soonestReadout":1215},[1211],{"nctId":1212,"briefTitle":1213,"status":160,"phases":1214,"primaryCompletion":1215,"completion":1215,"start":1216,"enrollment":1217,"conditions":1218,"interventions":1222},"NCT06003153","GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH",[92],"2027-05-31","2024-03-12",125,[1219,1220,1221],"Genetic Predisposition","Metabolic Diseases","Type 2 Diabetes",[1199],{"trials":1224,"activeCount":101},[],{"intervention":1226,"totalTrials":331,"cells":1227},"Depot Methylprednisolone",{"EARLY_PHASE1":1228,"PHASE1":1230,"PHASE2":1232,"PHASE3":1234,"PHASE4":1236,"NA":1251},{"trials":1229,"activeCount":101},[],{"trials":1231,"activeCount":101},[],{"trials":1233,"activeCount":101},[],{"trials":1235,"activeCount":101},[],{"trials":1237,"activeCount":331,"soonestReadout":1242},[1238],{"nctId":1239,"briefTitle":1240,"status":160,"phases":1241,"primaryCompletion":1242,"completion":1243,"start":1244,"enrollment":1245,"conditions":1246,"interventions":1250},"NCT02283996","Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment",[92],"2026-12","2027-12","2014-11",260,[1247,1248,1249],"Adhesive Capsulitis","Frozen Shoulder","Shoulder Frozen",[1226],{"trials":1252,"activeCount":101},[],{"intervention":531,"totalTrials":331,"cells":1254},{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1259,"PHASE3":1261,"PHASE4":1263,"NA":1269},{"trials":1256,"activeCount":101},[],{"trials":1258,"activeCount":101},[],{"trials":1260,"activeCount":101},[],{"trials":1262,"activeCount":101},[],{"trials":1264,"activeCount":331,"soonestReadout":526},[1265],{"nctId":523,"briefTitle":524,"status":160,"phases":1266,"primaryCompletion":526,"completion":526,"start":527,"enrollment":239,"conditions":1267,"interventions":1268},[92],[15,529],[465,531],{"trials":1270,"activeCount":101},[],{"intervention":1272,"totalTrials":331,"cells":1273},"Liposomal Bupivacaine (EXPAREL®)\u002FBupivacaine",{"EARLY_PHASE1":1274,"PHASE1":1276,"PHASE2":1278,"PHASE3":1280,"PHASE4":1282,"NA":1292},{"trials":1275,"activeCount":101},[],{"trials":1277,"activeCount":101},[],{"trials":1279,"activeCount":101},[],{"trials":1281,"activeCount":101},[],{"trials":1283,"activeCount":331,"soonestReadout":1288},[1284],{"nctId":1285,"briefTitle":1286,"status":318,"phases":1287,"primaryCompletion":1288,"completion":837,"start":322,"enrollment":239,"conditions":1289,"interventions":1291},"NCT07535411","Bupivacaine Liposome Suspension Administration to Decreasre Peri-procedural Pain in Interventional Radiology (IR) Procedures",[92],"2026-06",[1290],"Analgesia Assessment",[1272],{"trials":1293,"activeCount":101},[],{"intervention":665,"totalTrials":331,"cells":1295},{"EARLY_PHASE1":1296,"PHASE1":1298,"PHASE2":1300,"PHASE3":1302,"PHASE4":1304,"NA":1310},{"trials":1297,"activeCount":101},[],{"trials":1299,"activeCount":101},[],{"trials":1301,"activeCount":101},[],{"trials":1303,"activeCount":101},[],{"trials":1305,"activeCount":331,"soonestReadout":659},[1306],{"nctId":656,"briefTitle":657,"status":189,"phases":1307,"primaryCompletion":659,"completion":659,"start":660,"enrollment":661,"conditions":1308,"interventions":1309},[92],[663,15],[665,666,610,667],{"trials":1311,"activeCount":101},[],{"intervention":666,"totalTrials":331,"cells":1313},{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1318,"PHASE3":1320,"PHASE4":1322,"NA":1328},{"trials":1315,"activeCount":101},[],{"trials":1317,"activeCount":101},[],{"trials":1319,"activeCount":101},[],{"trials":1321,"activeCount":101},[],{"trials":1323,"activeCount":331,"soonestReadout":659},[1324],{"nctId":656,"briefTitle":657,"status":189,"phases":1325,"primaryCompletion":659,"completion":659,"start":660,"enrollment":661,"conditions":1326,"interventions":1327},[92],[663,15],[665,666,610,667],{"trials":1329,"activeCount":101},[],{"intervention":667,"totalTrials":331,"cells":1331},{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1336,"PHASE3":1338,"PHASE4":1340,"NA":1346},{"trials":1333,"activeCount":101},[],{"trials":1335,"activeCount":101},[],{"trials":1337,"activeCount":101},[],{"trials":1339,"activeCount":101},[],{"trials":1341,"activeCount":331,"soonestReadout":659},[1342],{"nctId":656,"briefTitle":657,"status":189,"phases":1343,"primaryCompletion":659,"completion":659,"start":660,"enrollment":661,"conditions":1344,"interventions":1345},[92],[663,15],[665,666,610,667],{"trials":1347,"activeCount":101},[],{"intervention":1349,"totalTrials":331,"cells":1350},"Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric]",{"EARLY_PHASE1":1351,"PHASE1":1353,"PHASE2":1355,"PHASE3":1357,"PHASE4":1359,"NA":1373},{"trials":1352,"activeCount":101},[],{"trials":1354,"activeCount":101},[],{"trials":1356,"activeCount":101},[],{"trials":1358,"activeCount":101},[],{"trials":1360,"activeCount":331,"soonestReadout":1365},[1361],{"nctId":1362,"briefTitle":1363,"status":160,"phases":1364,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":1368,"conditions":1369,"interventions":1372},"NCT04945707","Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)",[92],"2026-03-31","2026-07-31","2021-11-26",66,[1370,1371],"Iron-deficiency","Heart Failure With Preserved Ejection Fraction",[1349],{"trials":1374,"activeCount":101},[],{"intervention":327,"totalTrials":331,"cells":1376},{"EARLY_PHASE1":1377,"PHASE1":1379,"PHASE2":1381,"PHASE3":1383,"PHASE4":1385,"NA":1391},{"trials":1378,"activeCount":101},[],{"trials":1380,"activeCount":101},[],{"trials":1382,"activeCount":101},[],{"trials":1384,"activeCount":101},[],{"trials":1386,"activeCount":331,"soonestReadout":320},[1387],{"nctId":316,"briefTitle":317,"status":318,"phases":1388,"primaryCompletion":320,"completion":321,"start":322,"enrollment":323,"conditions":1389,"interventions":1390},[92],[325],[96,327,328,329,330],{"trials":1392,"activeCount":101},[],{"intervention":328,"totalTrials":331,"cells":1394},{"EARLY_PHASE1":1395,"PHASE1":1397,"PHASE2":1399,"PHASE3":1401,"PHASE4":1403,"NA":1409},{"trials":1396,"activeCount":101},[],{"trials":1398,"activeCount":101},[],{"trials":1400,"activeCount":101},[],{"trials":1402,"activeCount":101},[],{"trials":1404,"activeCount":331,"soonestReadout":320},[1405],{"nctId":316,"briefTitle":317,"status":318,"phases":1406,"primaryCompletion":320,"completion":321,"start":322,"enrollment":323,"conditions":1407,"interventions":1408},[92],[325],[96,327,328,329,330],{"trials":1410,"activeCount":101},[],{"intervention":329,"totalTrials":331,"cells":1412},{"EARLY_PHASE1":1413,"PHASE1":1415,"PHASE2":1417,"PHASE3":1419,"PHASE4":1421,"NA":1427},{"trials":1414,"activeCount":101},[],{"trials":1416,"activeCount":101},[],{"trials":1418,"activeCount":101},[],{"trials":1420,"activeCount":101},[],{"trials":1422,"activeCount":331,"soonestReadout":320},[1423],{"nctId":316,"briefTitle":317,"status":318,"phases":1424,"primaryCompletion":320,"completion":321,"start":322,"enrollment":323,"conditions":1425,"interventions":1426},[92],[325],[96,327,328,329,330],{"trials":1428,"activeCount":101},[],{"intervention":330,"totalTrials":331,"cells":1430},{"EARLY_PHASE1":1431,"PHASE1":1433,"PHASE2":1435,"PHASE3":1437,"PHASE4":1439,"NA":1445},{"trials":1432,"activeCount":101},[],{"trials":1434,"activeCount":101},[],{"trials":1436,"activeCount":101},[],{"trials":1438,"activeCount":101},[],{"trials":1440,"activeCount":331,"soonestReadout":320},[1441],{"nctId":316,"briefTitle":317,"status":318,"phases":1442,"primaryCompletion":320,"completion":321,"start":322,"enrollment":323,"conditions":1443,"interventions":1444},[92],[325],[96,327,328,329,330],{"trials":1446,"activeCount":101},[],{"intervention":1448,"totalTrials":331,"cells":1449},"Rosuvastatin",{"EARLY_PHASE1":1450,"PHASE1":1452,"PHASE2":1454,"PHASE3":1456,"PHASE4":1458,"NA":1471},{"trials":1451,"activeCount":101},[],{"trials":1453,"activeCount":101},[],{"trials":1455,"activeCount":101},[],{"trials":1457,"activeCount":101},[],{"trials":1459,"activeCount":331,"soonestReadout":1464},[1460],{"nctId":1461,"briefTitle":1462,"status":160,"phases":1463,"primaryCompletion":1464,"completion":1464,"start":1465,"enrollment":1466,"conditions":1467,"interventions":1469},"NCT05850091","Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine",[92],"2027-06-01","2023-12-07",200,[1468],"Coronary Artery Disease",[1448,1470],"Colchicine",{"trials":1472,"activeCount":101},[],{"intervention":1470,"totalTrials":331,"cells":1474},{"EARLY_PHASE1":1475,"PHASE1":1477,"PHASE2":1479,"PHASE3":1481,"PHASE4":1483,"NA":1489},{"trials":1476,"activeCount":101},[],{"trials":1478,"activeCount":101},[],{"trials":1480,"activeCount":101},[],{"trials":1482,"activeCount":101},[],{"trials":1484,"activeCount":331,"soonestReadout":1464},[1485],{"nctId":1461,"briefTitle":1462,"status":160,"phases":1486,"primaryCompletion":1464,"completion":1464,"start":1465,"enrollment":1466,"conditions":1487,"interventions":1488},[92],[1468],[1448,1470],{"trials":1490,"activeCount":101},[],{"intervention":1492,"totalTrials":331,"cells":1493},"Sculptra",{"EARLY_PHASE1":1494,"PHASE1":1496,"PHASE2":1498,"PHASE3":1500,"PHASE4":1502,"NA":1513},{"trials":1495,"activeCount":101},[],{"trials":1497,"activeCount":101},[],{"trials":1499,"activeCount":101},[],{"trials":1501,"activeCount":101},[],{"trials":1503,"activeCount":331,"soonestReadout":1508},[1504],{"nctId":1505,"briefTitle":1506,"status":318,"phases":1507,"primaryCompletion":1508,"completion":1508,"start":837,"enrollment":1509,"conditions":1510,"interventions":1512},"NCT07342452","Randomized Trial of Combination Treatment With Sofwave and Sculptra",[92],"2027-04-01",13,[1511],"Skin Aging",[1492],{"trials":1514,"activeCount":101},[],{"intervention":1516,"totalTrials":331,"cells":1517},"Purified Cortophin Gel, 40 U",{"EARLY_PHASE1":1518,"PHASE1":1520,"PHASE2":1522,"PHASE3":1524,"PHASE4":1526,"NA":1539},{"trials":1519,"activeCount":101},[],{"trials":1521,"activeCount":101},[],{"trials":1523,"activeCount":101},[],{"trials":1525,"activeCount":101},[],{"trials":1527,"activeCount":331,"soonestReadout":1081},[1528],{"nctId":1529,"briefTitle":1530,"status":160,"phases":1531,"primaryCompletion":1081,"completion":1081,"start":1532,"enrollment":1533,"conditions":1534,"interventions":1537},"NCT07346079","Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares",[92],"2025-12-20",150,[1535,1536,944],"Gout Arthritis","Gout Flare",[1516,1538],"Purified Cortophin Gel 80 U",{"trials":1540,"activeCount":101},[],{"intervention":1538,"totalTrials":331,"cells":1542},{"EARLY_PHASE1":1543,"PHASE1":1545,"PHASE2":1547,"PHASE3":1549,"PHASE4":1551,"NA":1557},{"trials":1544,"activeCount":101},[],{"trials":1546,"activeCount":101},[],{"trials":1548,"activeCount":101},[],{"trials":1550,"activeCount":101},[],{"trials":1552,"activeCount":331,"soonestReadout":1081},[1553],{"nctId":1529,"briefTitle":1530,"status":160,"phases":1554,"primaryCompletion":1081,"completion":1081,"start":1532,"enrollment":1533,"conditions":1555,"interventions":1556},[92],[1535,1536,944],[1516,1538],{"trials":1558,"activeCount":101},[],{"intervention":1560,"totalTrials":331,"cells":1561},"Empagliflozin 10 mg",{"EARLY_PHASE1":1562,"PHASE1":1564,"PHASE2":1566,"PHASE3":1568,"PHASE4":1570,"NA":1582},{"trials":1563,"activeCount":101},[],{"trials":1565,"activeCount":101},[],{"trials":1567,"activeCount":101},[],{"trials":1569,"activeCount":101},[],{"trials":1571,"activeCount":331,"soonestReadout":1576},[1572],{"nctId":1573,"briefTitle":1574,"status":318,"phases":1575,"primaryCompletion":1576,"completion":1576,"start":1577,"enrollment":1578,"conditions":1579,"interventions":1581},"NCT06674109","SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial",[92],"2028-02-28","2026-04-30",60,[1580],"Gout and Hyperuricemia",[1560],{"trials":1583,"activeCount":101},[],{"intervention":1585,"totalTrials":331,"cells":1586},"GARDASIL®9",{"EARLY_PHASE1":1587,"PHASE1":1589,"PHASE2":1591,"PHASE3":1593,"PHASE4":1595,"NA":1608},{"trials":1588,"activeCount":101},[],{"trials":1590,"activeCount":101},[],{"trials":1592,"activeCount":101},[],{"trials":1594,"activeCount":101},[],{"trials":1596,"activeCount":331,"soonestReadout":1242},[1597],{"nctId":1598,"briefTitle":1599,"status":189,"phases":1600,"primaryCompletion":1242,"completion":1052,"start":1601,"enrollment":1602,"conditions":1603,"interventions":1606},"NCT06436274","Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.",[92],"2024-10-14",778,[1604,1605],"Human Papilloma Virus","Hiv",[1585,1607],"Menveo®\u002FMenactra®",{"trials":1609,"activeCount":101},[],{"intervention":1607,"totalTrials":331,"cells":1611},{"EARLY_PHASE1":1612,"PHASE1":1614,"PHASE2":1616,"PHASE3":1618,"PHASE4":1620,"NA":1626},{"trials":1613,"activeCount":101},[],{"trials":1615,"activeCount":101},[],{"trials":1617,"activeCount":101},[],{"trials":1619,"activeCount":101},[],{"trials":1621,"activeCount":331,"soonestReadout":1242},[1622],{"nctId":1598,"briefTitle":1599,"status":189,"phases":1623,"primaryCompletion":1242,"completion":1052,"start":1601,"enrollment":1602,"conditions":1624,"interventions":1625},[92],[1604,1605],[1585,1607],{"trials":1627,"activeCount":101},[],{"intervention":1629,"totalTrials":331,"cells":1630},"Esketamine",{"EARLY_PHASE1":1631,"PHASE1":1633,"PHASE2":1635,"PHASE3":1637,"PHASE4":1639,"NA":1650},{"trials":1632,"activeCount":101},[],{"trials":1634,"activeCount":101},[],{"trials":1636,"activeCount":101},[],{"trials":1638,"activeCount":101},[],{"trials":1640,"activeCount":331,"soonestReadout":1645},[1641],{"nctId":1642,"briefTitle":1643,"status":160,"phases":1644,"primaryCompletion":1645,"completion":1645,"start":1646,"enrollment":16,"conditions":1647,"interventions":1648},"NCT05450432","Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression",[92],"2026-06-01","2022-10-13",[18],[1649,1629],"Ketamine",{"trials":1651,"activeCount":101},[],{"intervention":1653,"totalTrials":331,"cells":1654},"APRETUDE",{"EARLY_PHASE1":1655,"PHASE1":1657,"PHASE2":1659,"PHASE3":1661,"PHASE4":1663,"NA":1675},{"trials":1656,"activeCount":101},[],{"trials":1658,"activeCount":101},[],{"trials":1660,"activeCount":101},[],{"trials":1662,"activeCount":101},[],{"trials":1664,"activeCount":331,"soonestReadout":191},[1665],{"nctId":1666,"briefTitle":1667,"status":160,"phases":1668,"primaryCompletion":191,"completion":191,"start":1669,"enrollment":16,"conditions":1670,"interventions":1674},"NCT07199335","Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs",[92],"2026-02-24",[1671,1672,1673],"HIV","Substance Use Disorder (SUD)","Injection Drug Use",[1653],{"trials":1676,"activeCount":101},[],{"intervention":947,"totalTrials":331,"cells":1678},{"EARLY_PHASE1":1679,"PHASE1":1681,"PHASE2":1683,"PHASE3":1685,"PHASE4":1687,"NA":1693},{"trials":1680,"activeCount":101},[],{"trials":1682,"activeCount":101},[],{"trials":1684,"activeCount":101},[],{"trials":1686,"activeCount":101},[],{"trials":1688,"activeCount":331,"soonestReadout":939},[1689],{"nctId":936,"briefTitle":937,"status":160,"phases":1690,"primaryCompletion":939,"completion":940,"start":941,"enrollment":942,"conditions":1691,"interventions":1692},[92],[944],[946,947,948,949,950,951],{"trials":1694,"activeCount":101},[],{"intervention":948,"totalTrials":331,"cells":1696},{"EARLY_PHASE1":1697,"PHASE1":1699,"PHASE2":1701,"PHASE3":1703,"PHASE4":1705,"NA":1711},{"trials":1698,"activeCount":101},[],{"trials":1700,"activeCount":101},[],{"trials":1702,"activeCount":101},[],{"trials":1704,"activeCount":101},[],{"trials":1706,"activeCount":331,"soonestReadout":939},[1707],{"nctId":936,"briefTitle":937,"status":160,"phases":1708,"primaryCompletion":939,"completion":940,"start":941,"enrollment":942,"conditions":1709,"interventions":1710},[92],[944],[946,947,948,949,950,951],{"trials":1712,"activeCount":101},[],{"intervention":949,"totalTrials":331,"cells":1714},{"EARLY_PHASE1":1715,"PHASE1":1717,"PHASE2":1719,"PHASE3":1721,"PHASE4":1723,"NA":1729},{"trials":1716,"activeCount":101},[],{"trials":1718,"activeCount":101},[],{"trials":1720,"activeCount":101},[],{"trials":1722,"activeCount":101},[],{"trials":1724,"activeCount":331,"soonestReadout":939},[1725],{"nctId":936,"briefTitle":937,"status":160,"phases":1726,"primaryCompletion":939,"completion":940,"start":941,"enrollment":942,"conditions":1727,"interventions":1728},[92],[944],[946,947,948,949,950,951],{"trials":1730,"activeCount":101},[],{"intervention":950,"totalTrials":331,"cells":1732},{"EARLY_PHASE1":1733,"PHASE1":1735,"PHASE2":1737,"PHASE3":1739,"PHASE4":1741,"NA":1747},{"trials":1734,"activeCount":101},[],{"trials":1736,"activeCount":101},[],{"trials":1738,"activeCount":101},[],{"trials":1740,"activeCount":101},[],{"trials":1742,"activeCount":331,"soonestReadout":939},[1743],{"nctId":936,"briefTitle":937,"status":160,"phases":1744,"primaryCompletion":939,"completion":940,"start":941,"enrollment":942,"conditions":1745,"interventions":1746},[92],[944],[946,947,948,949,950,951],{"trials":1748,"activeCount":101},[],{"intervention":951,"totalTrials":331,"cells":1750},{"EARLY_PHASE1":1751,"PHASE1":1753,"PHASE2":1755,"PHASE3":1757,"PHASE4":1759,"NA":1765},{"trials":1752,"activeCount":101},[],{"trials":1754,"activeCount":101},[],{"trials":1756,"activeCount":101},[],{"trials":1758,"activeCount":101},[],{"trials":1760,"activeCount":331,"soonestReadout":939},[1761],{"nctId":936,"briefTitle":937,"status":160,"phases":1762,"primaryCompletion":939,"completion":940,"start":941,"enrollment":942,"conditions":1763,"interventions":1764},[92],[944],[946,947,948,949,950,951],{"trials":1766,"activeCount":101},[],{"intervention":1649,"totalTrials":1509,"cells":1768},{"EARLY_PHASE1":1769,"PHASE1":1771,"PHASE2":1773,"PHASE3":1796,"PHASE4":1808,"NA":1855},{"trials":1770,"activeCount":101},[],{"trials":1772,"activeCount":101},[],{"trials":1774,"activeCount":101},[1775,1785],{"nctId":1776,"briefTitle":1777,"status":117,"phases":1778,"primaryCompletion":1779,"completion":1780,"start":567,"enrollment":1781,"conditions":1782,"interventions":1784},"NCT01920555","Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)",[90],"2017-01","2017-02",99,[1783],"Treatment Resistant Depression",[1649,1649,1649,1649],{"nctId":1786,"briefTitle":1787,"status":117,"phases":1788,"primaryCompletion":1789,"completion":1789,"start":1790,"enrollment":1791,"conditions":1792,"interventions":1794},"NCT03503578","EEG Studies of Sevoflurane-Induced General Anesthesia",[90],"2018-08-01","2018-05-01",12,[1793],"Anesthesia",[1795,1649],"Sevoflurane",{"trials":1797,"activeCount":101},[1798],{"nctId":1799,"briefTitle":1800,"status":117,"phases":1801,"primaryCompletion":1802,"completion":1803,"start":1804,"enrollment":1805,"conditions":1806,"interventions":1807},"NCT03553758","EEG Studies of Ketamine General Anesthesia",[90,91],"2019-02-01","2019-08-01","2018-11-01",16,[1793],[1649],{"trials":1809,"activeCount":331,"soonestReadout":1645},[1810,1819,1829,1841,1851],{"nctId":1811,"briefTitle":1812,"status":107,"phases":1813,"primaryCompletion":1814,"completion":1814,"start":1814,"enrollment":101,"conditions":1815,"interventions":1818},"NCT02295787","Intranasal Ketamine for Late-Life Depression and Suicidal Ideation",[92],"2015-07",[15,1816,1817],"Suicide","Suicidal Ideation",[1649],{"nctId":1820,"briefTitle":1821,"status":117,"phases":1822,"primaryCompletion":1823,"completion":1824,"start":1825,"enrollment":22,"conditions":1826,"interventions":1827},"NCT03149991","A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)",[92],"2019-03-31","2019-06-15","2017-09-14",[15],[1828,1649],"Brexpiprazole",{"nctId":1830,"briefTitle":1831,"status":173,"phases":1832,"primaryCompletion":1833,"completion":1834,"start":1835,"enrollment":97,"conditions":1836,"interventions":1837},"NCT01260649","N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression",[92],"2012-10-26","2012-11-01","2010-11-01",[18],[1838,1839,1840],"ketamine","Muscle Relaxant","Anesthetic Agents",{"nctId":1842,"briefTitle":1843,"status":117,"phases":1844,"primaryCompletion":1845,"completion":1845,"start":1846,"enrollment":1847,"conditions":1848,"interventions":1850},"NCT02544607","Ketamine for Depression: An MRI Study",[92],"2017-12-29","2016-03",25,[15,1849,18],"Anxious Depression",[1649],{"nctId":1642,"briefTitle":1643,"status":160,"phases":1852,"primaryCompletion":1645,"completion":1645,"start":1646,"enrollment":16,"conditions":1853,"interventions":1854},[92],[18],[1649,1629],{"trials":1856,"activeCount":101},[1857,1865,1872,1885,1893],{"nctId":1858,"briefTitle":1859,"status":107,"phases":1860,"primaryCompletion":1780,"completion":1780,"start":1861,"enrollment":101,"conditions":1862,"interventions":1863},"NCT01613820","Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder",[93],"2015-09",[18],[1649,1864],"Scopolamine",{"nctId":1866,"briefTitle":1867,"status":117,"phases":1868,"primaryCompletion":968,"completion":1869,"start":456,"enrollment":413,"conditions":1870,"interventions":1871},"NCT01667926","Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder",[93],"2015-11",[18],[1649],{"nctId":1873,"briefTitle":1874,"status":117,"phases":1875,"primaryCompletion":1876,"completion":1877,"start":647,"enrollment":1878,"conditions":1879,"interventions":1883},"NCT00833755","Effect of Ketamine on Opioid-Induced Hyperalgesia",[93],"2013-05","2016-04",79,[1880,1881,1882],"Pain","Chronic Pain","Hyperalgesia",[1649,1884],"Placebos",{"nctId":1886,"briefTitle":1887,"status":173,"phases":1888,"primaryCompletion":1780,"completion":1780,"start":1889,"enrollment":1890,"conditions":1891,"interventions":1892},"NCT02669043","Physiological and Cognitive Biomarkers for Ketamine's Antidepressant Effects",[93],"2016-07",8,[15],[1649],{"nctId":1894,"briefTitle":1895,"status":117,"phases":1896,"primaryCompletion":1897,"completion":567,"start":226,"enrollment":1898,"conditions":1899,"interventions":1900},"NCT01582945","Ketamine Infusion for Treatment-resistant Major Depressive Disorder",[93],"2014-09",14,[18],[1649],{"intervention":1902,"totalTrials":270,"cells":1903},"Varenicline",{"EARLY_PHASE1":1904,"PHASE1":1906,"PHASE2":1908,"PHASE3":1918,"PHASE4":1920,"NA":1960},{"trials":1905,"activeCount":101},[],{"trials":1907,"activeCount":101},[],{"trials":1909,"activeCount":101},[1910],{"nctId":1911,"briefTitle":1912,"status":117,"phases":1913,"primaryCompletion":226,"completion":226,"start":912,"enrollment":1914,"conditions":1915,"interventions":1916},"NCT00580398","Smoking Cessation Intervention for Thoracic Patients",[89,90],49,[32],[1917],"varenicline",{"trials":1919,"activeCount":101},[],{"trials":1921,"activeCount":331,"soonestReadout":1944},[1922,1932,1940,1952],{"nctId":1923,"briefTitle":1924,"status":117,"phases":1925,"primaryCompletion":1876,"completion":1876,"start":1926,"enrollment":1927,"conditions":1928,"interventions":1931},"NCT00621777","A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder",[92],"2008-02",247,[35,1929,24,1930],"Schizoaffective Disorder","Smoking",[1902],{"nctId":1933,"briefTitle":1934,"status":173,"phases":1935,"primaryCompletion":1936,"completion":1936,"start":637,"enrollment":136,"conditions":1937,"interventions":1939},"NCT00907218","Chantix in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD)",[92],"2010-05",[1938,711],"Attention Deficit\u002FHyperactivity Disorder",[1902],{"nctId":1941,"briefTitle":1942,"status":318,"phases":1943,"primaryCompletion":1944,"completion":163,"start":1945,"enrollment":227,"conditions":1946,"interventions":1951},"NCT07145866","Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study)",[92],"2027-09-30","2026-03-15",[1947,1948,1949,711,1950],"Nicotine Dependence","Transcranial Magnetic Stimulation","Vaping","Smoking (Tobacco) Addiction",[1917],{"nctId":1953,"briefTitle":1954,"status":173,"phases":1955,"primaryCompletion":1956,"completion":1956,"start":1957,"enrollment":693,"conditions":1958,"interventions":1959},"NCT04602494","Varenicline For Nicotine Vaping Cessation In Non Smoker Vaper Adolescents",[92],"2022-06-27","2020-12-18",[1949,1947],[1902],{"trials":1961,"activeCount":101},[1962,1971],{"nctId":1963,"briefTitle":1964,"status":117,"phases":1965,"primaryCompletion":456,"completion":456,"start":110,"enrollment":1966,"conditions":1967,"interventions":1969},"NCT00455650","Study of the Effects of Mecamylamine and Varenicline in Schizophrenia",[93],89,[1968],"Cognition in Schizophrenia",[1970,1902],"Mecamylamine",{"nctId":1972,"briefTitle":1973,"status":117,"phases":1974,"primaryCompletion":1975,"completion":1976,"start":1977,"enrollment":1978,"conditions":1979,"interventions":1981},"NCT04445662","Financial Incentives for Homeless Smokers: A Community-based RCT",[93],"2024-08-01","2024-10-24","2021-06-10",184,[1980],"Tobacco Smoking",[1902],{"intervention":1983,"totalTrials":136,"cells":1984},"Ketorolac",{"EARLY_PHASE1":1985,"PHASE1":1987,"PHASE2":1989,"PHASE3":1991,"PHASE4":1993,"NA":2006},{"trials":1986,"activeCount":101},[],{"trials":1988,"activeCount":101},[],{"trials":1990,"activeCount":101},[],{"trials":1992,"activeCount":101},[],{"trials":1994,"activeCount":331,"soonestReadout":1999},[1995],{"nctId":1996,"briefTitle":1997,"status":160,"phases":1998,"primaryCompletion":1999,"completion":1081,"start":2000,"enrollment":2001,"conditions":2002,"interventions":2005},"NCT06201676","Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients",[92],"2026-12-31","2025-02-28",458,[2003,2004],"Orthopaedic Trauma","Chronic Opioid Use",[1983],{"trials":2007,"activeCount":101},[2008],{"nctId":2009,"briefTitle":2010,"status":117,"phases":2011,"primaryCompletion":1780,"completion":1780,"start":226,"enrollment":22,"conditions":2012,"interventions":2014},"NCT01576276","A Brain Imaging Study of Opioid (Morphine) and Non-opioid (Ketorolac) Conditioning Effects",[93],[2013],"Healthy Controls",[1983],{"intervention":356,"totalTrials":270,"cells":2016},{"EARLY_PHASE1":2017,"PHASE1":2019,"PHASE2":2021,"PHASE3":2049,"PHASE4":2055,"NA":2072},{"trials":2018,"activeCount":101},[],{"trials":2020,"activeCount":101},[],{"trials":2022,"activeCount":101},[2023,2032,2042],{"nctId":2024,"briefTitle":2025,"status":117,"phases":2026,"primaryCompletion":121,"completion":121,"start":2027,"enrollment":2028,"conditions":2029,"interventions":2031},"NCT00577642","Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates",[90],"2007-10",29,[2030],"Multiple Myeloma",[356],{"nctId":2033,"briefTitle":2034,"status":117,"phases":2035,"primaryCompletion":177,"completion":177,"start":2036,"enrollment":30,"conditions":2037,"interventions":2040},"NCT00181558","Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone",[90],"2001-12",[2038,2039],"Prostate Cancer","Adenocarcinoma of the Prostate",[2041,430],"Atrasentan",{"nctId":2043,"briefTitle":2044,"status":117,"phases":2045,"primaryCompletion":2046,"start":894,"enrollment":1578,"conditions":2047,"interventions":2048},"NCT00181584","Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer",[90],"2006-02",[428,2038],[356],{"trials":2050,"activeCount":331,"soonestReadout":349},[2051],{"nctId":346,"briefTitle":347,"status":160,"phases":2052,"primaryCompletion":349,"completion":350,"start":351,"enrollment":352,"conditions":2053,"interventions":2054},[91],[354],[335,356],{"trials":2056,"activeCount":101},[2057,2061,2065],{"nctId":421,"briefTitle":422,"status":117,"phases":2058,"primaryCompletion":424,"completion":424,"start":425,"enrollment":33,"conditions":2059,"interventions":2060},[92],[427,428],[370,430],{"nctId":432,"briefTitle":433,"status":117,"phases":2062,"primaryCompletion":435,"completion":435,"start":436,"enrollment":437,"conditions":2063,"interventions":2064},[92],[368],[401,402,356],{"nctId":2066,"briefTitle":2067,"status":117,"phases":2068,"primaryCompletion":2069,"completion":2069,"start":1789,"enrollment":544,"conditions":2070,"interventions":2071},"NCT03424239","Pilot Study for Zoledronic Acid to Prevent Bone Loss After Bariatric Surgery",[92],"2020-01-01",[427],[430],{"trials":2073,"activeCount":101},[],{"intervention":2075,"totalTrials":331,"cells":2076},"Bone marrow aspirate concentrate",{"EARLY_PHASE1":2077,"PHASE1":2079,"PHASE2":2081,"PHASE3":2083,"PHASE4":2098,"NA":2100},{"trials":2078,"activeCount":101},[],{"trials":2080,"activeCount":101},[],{"trials":2082,"activeCount":101},[],{"trials":2084,"activeCount":331,"soonestReadout":2089},[2085],{"nctId":2086,"briefTitle":2087,"status":160,"phases":2088,"primaryCompletion":2089,"completion":2090,"start":2091,"enrollment":1083,"conditions":2092,"interventions":2097},"NCT06003101","Effect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies",[91],"2027-08-30","2045-08-30","2023-08-30",[2093,2094,2095,2096],"Acetabular Labrum Tear","Femoro Acetabular Impingement","Chondral Defect","Bone Marrow Aspirate Concentrate",[2075],{"trials":2099,"activeCount":101},[],{"trials":2101,"activeCount":101},[],{"intervention":2103,"totalTrials":331,"cells":2104},"Intravenous Dexmedetomidine",{"EARLY_PHASE1":2105,"PHASE1":2107,"PHASE2":2109,"PHASE3":2111,"PHASE4":2127,"NA":2129},{"trials":2106,"activeCount":101},[],{"trials":2108,"activeCount":101},[],{"trials":2110,"activeCount":101},[],{"trials":2112,"activeCount":331,"soonestReadout":2117},[2113],{"nctId":2114,"briefTitle":2115,"status":160,"phases":2116,"primaryCompletion":2117,"completion":2118,"start":2119,"enrollment":2120,"conditions":2121,"interventions":2123},"NCT06192615","Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS II)",[91],"2027-10-31","2029-03-31","2025-01-06",1800,[2122],"Delirium",[2103,2124,2125,2126],"Sublingual Dexmedetomidine","Intravenous Placebo","Sublingual Placebo",{"trials":2128,"activeCount":101},[],{"trials":2130,"activeCount":101},[],{"intervention":2124,"totalTrials":331,"cells":2132},{"EARLY_PHASE1":2133,"PHASE1":2135,"PHASE2":2137,"PHASE3":2139,"PHASE4":2145,"NA":2147},{"trials":2134,"activeCount":101},[],{"trials":2136,"activeCount":101},[],{"trials":2138,"activeCount":101},[],{"trials":2140,"activeCount":331,"soonestReadout":2117},[2141],{"nctId":2114,"briefTitle":2115,"status":160,"phases":2142,"primaryCompletion":2117,"completion":2118,"start":2119,"enrollment":2120,"conditions":2143,"interventions":2144},[91],[2122],[2103,2124,2125,2126],{"trials":2146,"activeCount":101},[],{"trials":2148,"activeCount":101},[],{"intervention":2125,"totalTrials":331,"cells":2150},{"EARLY_PHASE1":2151,"PHASE1":2153,"PHASE2":2155,"PHASE3":2157,"PHASE4":2163,"NA":2165},{"trials":2152,"activeCount":101},[],{"trials":2154,"activeCount":101},[],{"trials":2156,"activeCount":101},[],{"trials":2158,"activeCount":331,"soonestReadout":2117},[2159],{"nctId":2114,"briefTitle":2115,"status":160,"phases":2160,"primaryCompletion":2117,"completion":2118,"start":2119,"enrollment":2120,"conditions":2161,"interventions":2162},[91],[2122],[2103,2124,2125,2126],{"trials":2164,"activeCount":101},[],{"trials":2166,"activeCount":101},[],{"intervention":2126,"totalTrials":331,"cells":2168},{"EARLY_PHASE1":2169,"PHASE1":2171,"PHASE2":2173,"PHASE3":2175,"PHASE4":2181,"NA":2183},{"trials":2170,"activeCount":101},[],{"trials":2172,"activeCount":101},[],{"trials":2174,"activeCount":101},[],{"trials":2176,"activeCount":331,"soonestReadout":2117},[2177],{"nctId":2114,"briefTitle":2115,"status":160,"phases":2178,"primaryCompletion":2117,"completion":2118,"start":2119,"enrollment":2120,"conditions":2179,"interventions":2180},[91],[2122],[2103,2124,2125,2126],{"trials":2182,"activeCount":101},[],{"trials":2184,"activeCount":101},[],{"intervention":2186,"totalTrials":331,"cells":2187},"Tenapanor",{"EARLY_PHASE1":2188,"PHASE1":2190,"PHASE2":2192,"PHASE3":2194,"PHASE4":2207,"NA":2209},{"trials":2189,"activeCount":101},[],{"trials":2191,"activeCount":101},[],{"trials":2193,"activeCount":101},[],{"trials":2195,"activeCount":331,"soonestReadout":2200},[2196],{"nctId":2197,"briefTitle":2198,"status":160,"phases":2199,"primaryCompletion":2200,"completion":2201,"start":2202,"enrollment":1847,"conditions":2203,"interventions":2206},"NCT06810167","Assessing Tenapanor as a Treatment of CF-related Constipation.",[91],"2026-06-30","2027-06-30","2025-06-01",[2204,2205],"Cystic Fibrosis","Constipation",[2186],{"trials":2208,"activeCount":101},[],{"trials":2210,"activeCount":101},[],{"intervention":2212,"totalTrials":331,"cells":2213},"Estradiol patch",{"EARLY_PHASE1":2214,"PHASE1":2216,"PHASE2":2218,"PHASE3":2220,"PHASE4":2230,"NA":2232},{"trials":2215,"activeCount":101},[],{"trials":2217,"activeCount":101},[],{"trials":2219,"activeCount":101},[],{"trials":2221,"activeCount":331,"soonestReadout":1215},[2222],{"nctId":2223,"briefTitle":2224,"status":160,"phases":2225,"primaryCompletion":1215,"completion":1215,"start":2226,"enrollment":1578,"conditions":2227,"interventions":2229},"NCT04833140","Estrogen Administration for the Treatment of NASH in Postmenopausal Women",[91],"2021-12-02",[2228],"NASH - Nonalcoholic Steatohepatitis",[2212],{"trials":2231,"activeCount":101},[],{"trials":2233,"activeCount":101},[],{"intervention":2235,"totalTrials":331,"cells":2236},"Tobramycin",{"EARLY_PHASE1":2237,"PHASE1":2239,"PHASE2":2241,"PHASE3":2243,"PHASE4":2256,"NA":2258},{"trials":2238,"activeCount":101},[],{"trials":2240,"activeCount":101},[],{"trials":2242,"activeCount":101},[],{"trials":2244,"activeCount":331,"soonestReadout":837},[2245],{"nctId":2246,"briefTitle":2247,"status":189,"phases":2248,"primaryCompletion":837,"completion":837,"start":2249,"enrollment":2250,"conditions":2251,"interventions":2255},"NCT04964947","Tobramycin Injection to Prevent Infection in Open Fractures",[91],"2022-01-10",600,[2252,2253,2254],"Wound Infection","Fractures, Open","Surgical Site Infection",[2235],{"trials":2257,"activeCount":101},[],{"trials":2259,"activeCount":101},[],{"intervention":2261,"totalTrials":331,"cells":2262},"Remimazolam",{"EARLY_PHASE1":2263,"PHASE1":2265,"PHASE2":2267,"PHASE3":2269,"PHASE4":2281,"NA":2283},{"trials":2264,"activeCount":101},[],{"trials":2266,"activeCount":101},[],{"trials":2268,"activeCount":101},[],{"trials":2270,"activeCount":331,"soonestReadout":730},[2271],{"nctId":2272,"briefTitle":2273,"status":189,"phases":2274,"primaryCompletion":730,"completion":730,"start":2275,"enrollment":16,"conditions":2276,"interventions":2279},"NCT07269808","Sedation During Endoscopy Using Remimazolam: Efficacy in a Novel Exploration",[91],"2026-03-03",[1793,2277,2278],"Sedation","Endoscopy",[2261,2280],"Propofol",{"trials":2282,"activeCount":101},[],{"trials":2284,"activeCount":101},[],{"intervention":2286,"totalTrials":331,"cells":2287},"Abatacept plus",{"EARLY_PHASE1":2288,"PHASE1":2290,"PHASE2":2292,"PHASE3":2294,"PHASE4":2308,"NA":2310},{"trials":2289,"activeCount":101},[],{"trials":2291,"activeCount":101},[],{"trials":2293,"activeCount":101},[],{"trials":2295,"activeCount":331,"soonestReadout":2300},[2296],{"nctId":2297,"briefTitle":2298,"status":160,"phases":2299,"primaryCompletion":2300,"completion":2301,"start":2302,"enrollment":2303,"conditions":2304,"interventions":2307},"NCT05335928","Abatacept in Immune Checkpoint Inhibitor Myocarditis",[91],"2026-11-20","2027-04-20","2022-07-02",390,[2305,2306],"Myocarditis Acute","Cancer",[2286],{"trials":2309,"activeCount":101},[],{"trials":2311,"activeCount":101},[],{"intervention":2313,"totalTrials":331,"cells":2314},"FOLFIRI Protocol",{"EARLY_PHASE1":2315,"PHASE1":2317,"PHASE2":2319,"PHASE3":2321,"PHASE4":2336,"NA":2338},{"trials":2316,"activeCount":101},[],{"trials":2318,"activeCount":101},[],{"trials":2320,"activeCount":101},[],{"trials":2322,"activeCount":331,"soonestReadout":1242},[2323],{"nctId":2324,"briefTitle":2325,"status":160,"phases":2326,"primaryCompletion":1242,"completion":1243,"start":2327,"enrollment":2328,"conditions":2329,"interventions":2332},"NCT03803553","Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer",[91],"2020-04-16",400,[2330,2331],"Metastatic Colon Cancer","Stage III Colon Cancer",[2313,2333,2334,2335],"Nivolumab Protocol","Encorafenib\u002FBinimetinib\u002FCetuximab Protocol","Trastuzumab + Pertuzumab",{"trials":2337,"activeCount":101},[],{"trials":2339,"activeCount":101},[],{"intervention":2333,"totalTrials":331,"cells":2341},{"EARLY_PHASE1":2342,"PHASE1":2344,"PHASE2":2346,"PHASE3":2348,"PHASE4":2354,"NA":2356},{"trials":2343,"activeCount":101},[],{"trials":2345,"activeCount":101},[],{"trials":2347,"activeCount":101},[],{"trials":2349,"activeCount":331,"soonestReadout":1242},[2350],{"nctId":2324,"briefTitle":2325,"status":160,"phases":2351,"primaryCompletion":1242,"completion":1243,"start":2327,"enrollment":2328,"conditions":2352,"interventions":2353},[91],[2330,2331],[2313,2333,2334,2335],{"trials":2355,"activeCount":101},[],{"trials":2357,"activeCount":101},[],{"intervention":2334,"totalTrials":331,"cells":2359},{"EARLY_PHASE1":2360,"PHASE1":2362,"PHASE2":2364,"PHASE3":2366,"PHASE4":2372,"NA":2374},{"trials":2361,"activeCount":101},[],{"trials":2363,"activeCount":101},[],{"trials":2365,"activeCount":101},[],{"trials":2367,"activeCount":331,"soonestReadout":1242},[2368],{"nctId":2324,"briefTitle":2325,"status":160,"phases":2369,"primaryCompletion":1242,"completion":1243,"start":2327,"enrollment":2328,"conditions":2370,"interventions":2371},[91],[2330,2331],[2313,2333,2334,2335],{"trials":2373,"activeCount":101},[],{"trials":2375,"activeCount":101},[],{"intervention":2335,"totalTrials":331,"cells":2377},{"EARLY_PHASE1":2378,"PHASE1":2380,"PHASE2":2382,"PHASE3":2384,"PHASE4":2390,"NA":2392},{"trials":2379,"activeCount":101},[],{"trials":2381,"activeCount":101},[],{"trials":2383,"activeCount":101},[],{"trials":2385,"activeCount":331,"soonestReadout":1242},[2386],{"nctId":2324,"briefTitle":2325,"status":160,"phases":2387,"primaryCompletion":1242,"completion":1243,"start":2327,"enrollment":2328,"conditions":2388,"interventions":2389},[91],[2330,2331],[2313,2333,2334,2335],{"trials":2391,"activeCount":101},[],{"trials":2393,"activeCount":101},[],{"intervention":2280,"totalTrials":544,"cells":2395},{"EARLY_PHASE1":2396,"PHASE1":2398,"PHASE2":2400,"PHASE3":2423,"PHASE4":2429,"NA":2440},{"trials":2397,"activeCount":101},[],{"trials":2399,"activeCount":101},[],{"trials":2401,"activeCount":101},[2402,2412],{"nctId":2403,"briefTitle":2404,"status":107,"phases":2405,"primaryCompletion":2406,"completion":2407,"start":2408,"enrollment":101,"conditions":2409,"interventions":2410},"NCT03610282","EEG Study of IV Methylphenidate-Induced Emergence From Propofol Sedation",[89,90],"2020-11","2021-11","2019-11",[1793],[2411,2280],"IV Methylphenidate",{"nctId":2413,"briefTitle":2414,"status":107,"phases":2415,"primaryCompletion":2416,"completion":2417,"start":2418,"enrollment":101,"conditions":2419,"interventions":2421},"NCT02429076","EEG Studies of IV Methylphenidate-Induced Emergence From Anesthesia",[89,90],"2019-07","2019-12","2017-06",[2420],"Active Emergence From General Anesthesia",[2422,1795,2280],"IV methylphenidate",{"trials":2424,"activeCount":331,"soonestReadout":730},[2425],{"nctId":2272,"briefTitle":2273,"status":189,"phases":2426,"primaryCompletion":730,"completion":730,"start":2275,"enrollment":16,"conditions":2427,"interventions":2428},[91],[1793,2277,2278],[2261,2280],{"trials":2430,"activeCount":101},[2431],{"nctId":2432,"briefTitle":2433,"status":117,"phases":2434,"primaryCompletion":2435,"completion":2436,"start":456,"enrollment":209,"conditions":2437,"interventions":2439},"NCT01557920","The Effects of General Anesthetics on Upper Airway Collapsibility in Healthy Subjects",[92],"2013-11","2014-03",[2438,29],"Airway Complication of Anaesthesia",[2280,1795],{"trials":2441,"activeCount":101},[2442,2451],{"nctId":2443,"briefTitle":2444,"status":117,"phases":2445,"primaryCompletion":2446,"completion":2446,"start":2447,"enrollment":194,"conditions":2448,"interventions":2450},"NCT01793753","Effect of Propofol on Internal Anal Sphincter Pressure During ARM",[],"2013-06","2012-10",[2449],"Chronic Constipation",[2280],{"nctId":2452,"briefTitle":2453,"status":117,"phases":2454,"primaryCompletion":2455,"completion":2455,"start":2456,"enrollment":33,"conditions":2457,"interventions":2459},"NCT01543633","EEG Studies of Induction and Recovery From Propofol Induced General Anesthesia",[93],"2020-07","2005-08",[2458],"Brain Activity Under Sedation",[2280],{"intervention":57,"totalTrials":1791,"cells":2461},{"EARLY_PHASE1":2462,"PHASE1":2464,"PHASE2":2477,"PHASE3":2592,"PHASE4":2594,"NA":2596},{"trials":2463,"activeCount":101},[],{"trials":2465,"activeCount":331,"soonestReadout":2470},[2466],{"nctId":2467,"briefTitle":2468,"status":189,"phases":2469,"primaryCompletion":2470,"completion":375,"start":2471,"enrollment":194,"conditions":2472,"interventions":2475},"NCT03362060","PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer",[89],"2026-12-30","2017-12-12",[2473,2474],"Triple Negative Breast Cancer","Metastatic Breast Cancer",[57,2476],"PVX-410",{"trials":2478,"activeCount":270,"soonestReadout":56},[2479,2491,2502,2512,2520,2530,2539,2552,2566,2577,2586],{"nctId":2480,"briefTitle":2481,"status":173,"phases":2482,"primaryCompletion":2483,"completion":2483,"start":2484,"enrollment":239,"conditions":2485,"interventions":2489},"NCT04729348","Pembrolizumab And Lenvatinib In Leptomeningeal Metastases",[90],"2024-01-17","2021-03-08",[2486,2487,2488],"Solid Tumor","Solid Tumor, Adult","Leptomeningeal Metastasis",[57,2490],"Lenvatinib",{"nctId":2492,"briefTitle":2493,"status":117,"phases":2494,"primaryCompletion":2495,"completion":2495,"start":2496,"enrollment":538,"conditions":2497,"interventions":2500},"NCT04701918","Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma",[90],"2025-12-01","2021-06-04",[2498,2499],"Metastatic Urothelial Carcinoma","Bladder Cancer",[57,2501],"Avelumab",{"nctId":2503,"briefTitle":2504,"status":117,"phases":2505,"primaryCompletion":2506,"completion":2507,"start":1877,"enrollment":2508,"conditions":2509,"interventions":2511},"NCT02632344","Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients",[90],"2022-02","2025-12",21,[2510],"Recurrent Respiratory Papillomatosis",[57],{"nctId":59,"briefTitle":60,"status":189,"phases":2513,"primaryCompletion":61,"completion":1999,"start":2514,"enrollment":1805,"conditions":2515,"interventions":2517},[90],"2017-11-27",[2516],"Metastatic Melanoma",[57,2518,2519],"Dabrafenib","Trametinib",{"nctId":2521,"briefTitle":2522,"status":107,"phases":2523,"primaryCompletion":2524,"completion":2524,"start":2525,"enrollment":101,"conditions":2526,"interventions":2528},"NCT04058145","AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma",[90],"2019-10-11","2019-09-30",[2527],"Head and Neck Cancer",[2529,57],"AMD3100",{"nctId":2531,"briefTitle":2532,"status":189,"phases":2533,"primaryCompletion":2200,"completion":1146,"start":2534,"enrollment":33,"conditions":2535,"interventions":2536},"NCT05034536","PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma",[90],"2022-02-07",[2516],[57,2537,2538,81],"Infliximab","Relatlimab",{"nctId":2540,"briefTitle":2541,"status":160,"phases":2542,"primaryCompletion":349,"completion":2543,"start":2544,"enrollment":1245,"conditions":2545,"interventions":2550},"NCT04230109","Sacituzumab Govitecan In TNBC",[90],"2029-10","2020-07-14",[2546,2473,2547,2548,2549],"Invasive Breast Cancer","ER-Negative Breast Cancer","PR-Negative Breast Cancer","HER2-negative Breast Cancer",[2551,57],"Sacituzumab Govitecan",{"nctId":2553,"briefTitle":2554,"status":160,"phases":2555,"primaryCompletion":2556,"completion":2557,"start":2558,"enrollment":2559,"conditions":2560,"interventions":2564},"NCT02896335","Palbociclib and Pembrolizumab In Central Nervous System Metastases",[90],"2026-09-01","2027-09-01","2017-02-02",45,[2561,2562,2563],"Metastatic Malignant Neoplasm to Brain","Recurrent Brain Metastases","Progressive Brain Metastases",[2565,57],"Palbociclib",{"nctId":2567,"briefTitle":2568,"status":189,"phases":2569,"primaryCompletion":1577,"completion":2570,"start":2571,"enrollment":886,"conditions":2572,"interventions":2575},"NCT04430699","Cisplatin+Pembrolizumab+RT in Vulvar Cancer",[90],"2028-01-30","2020-07-29",[2573,2574],"Vulvar Cancer","Vulvar Squamous Cell Carcinoma",[2576,57],"Cisplatin",{"nctId":2578,"briefTitle":2579,"status":189,"phases":2580,"primaryCompletion":1242,"completion":1243,"start":2581,"enrollment":2582,"conditions":2583,"interventions":2585},"NCT02886585","Pembrolizumab In Central Nervous System Metastases",[90],"2016-10",101,[2584],"Brain Metastases",[57],{"nctId":54,"briefTitle":55,"status":189,"phases":2587,"primaryCompletion":56,"completion":1999,"start":2588,"enrollment":151,"conditions":2589,"interventions":2591},[90],"2017-11-07",[2590],"High Grade Meningioma",[57],{"trials":2593,"activeCount":101},[],{"trials":2595,"activeCount":101},[],{"trials":2597,"activeCount":101},[],{"intervention":2599,"totalTrials":1890,"cells":2600},"Dexamethasone",{"EARLY_PHASE1":2601,"PHASE1":2603,"PHASE2":2636,"PHASE3":2688,"PHASE4":2690,"NA":2692},{"trials":2602,"activeCount":101},[],{"trials":2604,"activeCount":136,"soonestReadout":1242},[2605,2615,2626],{"nctId":2606,"briefTitle":2607,"status":189,"phases":2608,"primaryCompletion":1242,"completion":1243,"start":2609,"enrollment":2610,"conditions":2611,"interventions":2612},"NCT01562405","Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed\u002FRefractory Multiple Myeloma",[89],"2012-05",33,[2030],[2613,127,2599,2614],"ACE-011","Pomalidomide",{"nctId":2616,"briefTitle":2617,"status":160,"phases":2618,"primaryCompletion":2619,"completion":1147,"start":2620,"enrollment":1847,"conditions":2621,"interventions":2623},"NCT07032714","Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma",[89],"2027-07-01","2025-12-19",[2622],"Relapsed Refractory Multiple Myeloma (RRMM)",[2624,2625,2599],"Talquetamab","Mezigdomide",{"nctId":2627,"briefTitle":2628,"status":107,"phases":2629,"primaryCompletion":2630,"completion":2631,"start":2632,"enrollment":101,"conditions":2633,"interventions":2634},"NCT03657420","Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma",[89],"2021-09-30","2024-09-30","2019-05-30",[2030],[2635,2614,2599],"ABI-009",{"trials":2637,"activeCount":798,"soonestReadout":75},[2638,2651,2658,2667,2673],{"nctId":2639,"briefTitle":2640,"status":160,"phases":2641,"primaryCompletion":2642,"completion":2643,"start":2644,"enrollment":366,"conditions":2645,"interventions":2648},"NCT05922501","Isatuximab, Bela Maf, Pom, and Dex in Relapsed\u002FRefractory Multiple Myeloma",[90],"2028-12-31","2030-12-31","2024-05-31",[2646,2647,2030],"Relapsed Cancer","Refractory Multiple Myeloma",[2649,2650,2614,2599],"Isatuximab","Belantamab mafodotin",{"nctId":2652,"briefTitle":2653,"status":117,"phases":2654,"primaryCompletion":268,"completion":119,"start":284,"enrollment":366,"conditions":2655,"interventions":2656},"NCT01782963","Lenalidomide\u002FBortezomib\u002FDexamethasone for Multiple Myeloma (MM)",[90],[2030],[127,2657,2599],"Bortezomib",{"nctId":2659,"briefTitle":2660,"status":189,"phases":2661,"primaryCompletion":1242,"completion":1243,"start":2662,"enrollment":2663,"conditions":2664,"interventions":2665},"NCT02718833","A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma",[90],"2016-06-21",52,[2030],[2666,2614,2657,2599],"Elotuzumab",{"nctId":73,"briefTitle":74,"status":189,"phases":2668,"primaryCompletion":75,"completion":2669,"start":2670,"enrollment":366,"conditions":2671,"interventions":2672},[90],"2026-03-30","2020-07-10",[2030],[76,2649,127,2599],{"nctId":2674,"briefTitle":2675,"status":318,"phases":2676,"primaryCompletion":2677,"completion":2678,"start":2679,"enrollment":1083,"conditions":2680,"interventions":2684},"NCT07247097","ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible\u002FDeferred Multiple Myeloma",[90],"2030-12-01","2035-12-01","2026-04-15",[2030,2681,2682,2683],"Newly Diagnosed Multiple Myeloma","Transplant Ineligible","Newly Diagnosed Multiple Myeloma (NDMM)",[2685,2686,127,2687,2599],"Elranatamab","Daratumumab and Hyaluronidase-fihj","Bortezomib for",{"trials":2689,"activeCount":101},[],{"trials":2691,"activeCount":101},[],{"trials":2693,"activeCount":101},[],{"intervention":81,"totalTrials":538,"cells":2695},{"EARLY_PHASE1":2696,"PHASE1":2698,"PHASE2":2700,"PHASE3":2784,"PHASE4":2786,"NA":2788},{"trials":2697,"activeCount":101},[],{"trials":2699,"activeCount":101},[],{"trials":2701,"activeCount":693,"soonestReadout":65},[2702,2712,2722,2733,2742,2751,2755,2766,2773],{"nctId":2703,"briefTitle":2704,"status":160,"phases":2705,"primaryCompletion":2706,"completion":2706,"start":2707,"enrollment":413,"conditions":2708,"interventions":2710},"NCT05779423","Cryoablation+Ipilimumab+Nivolumab in Melanoma",[90],"2028-01-01","2023-09-23",[2516,2709],"Skin Cancer",[2711,81],"Ipilimumab",{"nctId":2713,"briefTitle":2714,"status":117,"phases":2715,"primaryCompletion":2716,"completion":2716,"start":2717,"enrollment":538,"conditions":2718,"interventions":2719},"NCT03256136","Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC",[90],"2019-08-19","2017-11-22",[32],[2720,81,2721,2711],"Carboplatin","pemetrexed",{"nctId":2723,"briefTitle":2724,"status":173,"phases":2725,"primaryCompletion":2726,"completion":2726,"start":2727,"enrollment":2728,"conditions":2729,"interventions":2731},"NCT04057365","Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)",[90],"2022-09-25","2019-10-07",15,[2730],"Biliary Tract Cancer",[81,2732],"DKN-01",{"nctId":2734,"briefTitle":2735,"status":117,"phases":2736,"primaryCompletion":2737,"completion":2737,"start":2738,"enrollment":209,"conditions":2739,"interventions":2741},"NCT02939300","Ipilimumab and Nivolumab in Leptomeningeal Metastases",[90],"2021-07-22","2018-02-15",[2740],"Leptomeningeal Carcinomatosis",[81,2711],{"nctId":63,"briefTitle":64,"status":189,"phases":2743,"primaryCompletion":65,"completion":2744,"start":2745,"enrollment":2746,"conditions":2747,"interventions":2749},[90],"2027-04","2018-08-10",168,[2748],"Pancreatic Cancer",[66,2750,81],"Losartan",{"nctId":2531,"briefTitle":2532,"status":189,"phases":2752,"primaryCompletion":2200,"completion":1146,"start":2534,"enrollment":33,"conditions":2753,"interventions":2754},[90],[2516],[57,2537,2538,81],{"nctId":2756,"briefTitle":2757,"status":2758,"phases":2759,"primaryCompletion":2760,"completion":2761,"start":2762,"enrollment":648,"conditions":2763,"interventions":2765},"NCT04575922","Nivolumab+Ipilimumab+RT in MSS mCRC","UNKNOWN",[90],"2023-12","2024-06","2020-10-05",[2764],"Metastatic Microsatellite Stable Colorectal Cancer",[81,2711],{"nctId":78,"briefTitle":79,"status":189,"phases":2767,"primaryCompletion":80,"completion":2768,"start":2769,"enrollment":227,"conditions":2770,"interventions":2772},[90],"2026-10","2020-05-18",[2748,2771],"Metastatic Pancreatic Cancer",[81,2711],{"nctId":2774,"briefTitle":2775,"status":189,"phases":2776,"primaryCompletion":2777,"completion":2744,"start":2778,"enrollment":2779,"conditions":2780,"interventions":2783},"NCT03104439","Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer",[90],"2027-01","2017-05-10",84,[2781,2748,2782],"Microsatellite Stable Colorectal Cancer","MSI High Colorectal Cancer",[81,2711],{"trials":2785,"activeCount":101},[],{"trials":2787,"activeCount":101},[],{"trials":2789,"activeCount":101},[],{"intervention":127,"totalTrials":1791,"cells":2791},{"EARLY_PHASE1":2792,"PHASE1":2794,"PHASE2":2869,"PHASE3":2894,"PHASE4":2896,"NA":2898},{"trials":2793,"activeCount":101},[],{"trials":2795,"activeCount":136,"soonestReadout":2835},[2796,2808,2819,2823,2831,2843,2853,2865],{"nctId":2797,"briefTitle":2798,"status":117,"phases":2799,"primaryCompletion":1861,"completion":2800,"start":2801,"enrollment":33,"conditions":2802,"interventions":2804},"NCT01681537","Lenalidomide Plus Chemotherapy for AML",[89],"2015-12","2012-09",[2803],"Acute Myelogenous Leukemia",[127,2805,2806,2807],"Mitoxantrone","Etoposide","Cytarabine",{"nctId":2809,"briefTitle":2810,"status":173,"phases":2811,"primaryCompletion":268,"completion":268,"start":225,"enrollment":1890,"conditions":2812,"interventions":2817},"NCT02255162","Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML",[89],[2813,2814,2803,2815,2816],"Acute Myeloid Leukemia (AML)","Acute Myelocytic Leukemia","Acute Granulocytic Leukemia","Acute Non-Lymphocytic Leukemia",[127,2818,2807],"HLA-mismatched stem-cell Microtransplantation",{"nctId":2606,"briefTitle":2607,"status":189,"phases":2820,"primaryCompletion":1242,"completion":1243,"start":2609,"enrollment":2610,"conditions":2821,"interventions":2822},[89],[2030],[2613,127,2599,2614],{"nctId":2824,"briefTitle":2825,"status":117,"phases":2826,"primaryCompletion":2827,"completion":2827,"start":175,"enrollment":753,"conditions":2828,"interventions":2830},"NCT00580242","A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia",[89],"2012-03",[2829],"Myelodysplasia",[2657,2657,2657,127],{"nctId":2832,"briefTitle":2833,"status":189,"phases":2834,"primaryCompletion":2835,"completion":2835,"start":2836,"enrollment":2837,"conditions":2838,"interventions":2840},"NCT02886065","A Study of PVX-410, a Cancer Vaccine, and Citarinostat +\u002F- Lenalidomide for Smoldering MM",[89],"2026-09-15","2017-03-07",19,[2839],"Smoldering Multiple Myeloma",[2841,2842,127,2476],"Hiltonol","Citarinostat",{"nctId":2844,"briefTitle":2845,"status":117,"phases":2846,"primaryCompletion":2847,"completion":2847,"start":2848,"enrollment":555,"conditions":2849,"interventions":2850},"NCT00729638","RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed\u002FRefractory Multiple Myeloma",[89],"2009-11","2008-06",[2030],[2851,2852],"RAD001","lenalidomide",{"nctId":2854,"briefTitle":2855,"status":117,"phases":2856,"primaryCompletion":2857,"completion":2858,"start":135,"enrollment":2859,"conditions":2860,"interventions":2863},"NCT02312102","Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation",[89],"2017-04","2024-10-07",22,[2861,2862],"Myelodysplastic Syndrome","Acute Myeloid Leukemia",[127,2864],"Velcade",{"nctId":115,"briefTitle":116,"status":117,"phases":2866,"primaryCompletion":119,"completion":120,"start":121,"enrollment":36,"conditions":2867,"interventions":2868},[89],[123,124,125],[127,128,96],{"trials":2870,"activeCount":136,"soonestReadout":75},[2871,2875,2886,2890],{"nctId":2652,"briefTitle":2653,"status":117,"phases":2872,"primaryCompletion":268,"completion":119,"start":284,"enrollment":366,"conditions":2873,"interventions":2874},[90],[2030],[127,2657,2599],{"nctId":2876,"briefTitle":2877,"status":117,"phases":2878,"primaryCompletion":2879,"completion":2880,"start":2881,"enrollment":2882,"conditions":2883,"interventions":2885},"NCT03118466","Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia",[90],"2019-08-29","2021-08-18","2017-09-25",41,[2884],"AML",[2806,2807,127,2805],{"nctId":73,"briefTitle":74,"status":189,"phases":2887,"primaryCompletion":75,"completion":2669,"start":2670,"enrollment":366,"conditions":2888,"interventions":2889},[90],[2030],[76,2649,127,2599],{"nctId":2674,"briefTitle":2675,"status":318,"phases":2891,"primaryCompletion":2677,"completion":2678,"start":2679,"enrollment":1083,"conditions":2892,"interventions":2893},[90],[2030,2681,2682,2683],[2685,2686,127,2687,2599],{"trials":2895,"activeCount":101},[],{"trials":2897,"activeCount":101},[],{"trials":2899,"activeCount":101},[],{"intervention":2901,"totalTrials":544,"cells":2902},"Niraparib",{"EARLY_PHASE1":2903,"PHASE1":2918,"PHASE2":2938,"PHASE3":2968,"PHASE4":2970,"NA":2972},{"trials":2904,"activeCount":331,"soonestReadout":837},[2905],{"nctId":2906,"briefTitle":2907,"status":189,"phases":2908,"primaryCompletion":837,"completion":2768,"start":2909,"enrollment":1805,"conditions":2910,"interventions":2916},"NCT05406700","Niraparib In Recurrent IDH 1\u002F2 Gliomas",[88],"2023-05-18",[2911,2912,2913,2914,2915],"Low-grade Glioma","IDH2 Gene Mutation","Recurrent Glioma","IDH1 Mutation","Glioma, Malignant",[2901,2917],"Resection\u002FTreatment with Niraparib",{"trials":2919,"activeCount":331,"soonestReadout":1999},[2920,2930],{"nctId":2921,"briefTitle":2922,"status":2758,"phases":2923,"primaryCompletion":2924,"completion":2925,"start":2926,"enrollment":227,"conditions":2927,"interventions":2928},"NCT03891615","Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer",[89],"2022-04-30","2024-04-30","2019-06-06",[32],[2901,2929],"Osimertinib",{"nctId":2931,"briefTitle":2932,"status":189,"phases":2933,"primaryCompletion":1999,"completion":2642,"start":2934,"enrollment":2508,"conditions":2935,"interventions":2937},"NCT03945721","A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients",[89],"2019-07-11",[2473,2936],"Residual Disease",[2901],{"trials":2939,"activeCount":136,"soonestReadout":162},[2940,2950,2959],{"nctId":2941,"briefTitle":2942,"status":117,"phases":2943,"primaryCompletion":2944,"completion":2945,"start":2946,"enrollment":209,"conditions":2947,"interventions":2948},"NCT04409002","Niraparib + Dostarlimab + RT in Pancreatic Cancer",[90],"2022-01-19","2022-02-25","2020-07-23",[2748,2771],[2901,2949],"Dostarlimab",{"nctId":2951,"briefTitle":2952,"status":189,"phases":2953,"primaryCompletion":2954,"completion":2955,"start":2956,"enrollment":648,"conditions":2957,"interventions":2958},"NCT04837209","Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer",[90],"2027-02-01","2029-12-01","2021-07-21",[21,2473],[2901,2949],{"nctId":2960,"briefTitle":2961,"status":189,"phases":2962,"primaryCompletion":162,"completion":1464,"start":2963,"enrollment":194,"conditions":2964,"interventions":2967},"NCT04992013","Niraparib in Tumors Metastatic to the CNS",[90],"2022-04-05",[2965,2966],"Metastatic Cancer","Central Nervous System Cancer",[2901],{"trials":2969,"activeCount":101},[],{"trials":2971,"activeCount":101},[],{"trials":2973,"activeCount":101},[],{"intervention":2975,"totalTrials":538,"cells":2976},"Saline",{"EARLY_PHASE1":2977,"PHASE1":2988,"PHASE2":3008,"PHASE3":3068,"PHASE4":3070,"NA":3072},{"trials":2978,"activeCount":101},[2979],{"nctId":2980,"briefTitle":2981,"status":2758,"phases":2982,"primaryCompletion":2983,"completion":2983,"start":2984,"enrollment":227,"conditions":2985,"interventions":2986},"NCT05435560","Neurochemical Mechanisms of the Awake vs. Anesthetized Brain",[88],"2023-04","2022-04-12",[1793,29],[2987,2975],"Dexmedetomidine",{"trials":2989,"activeCount":101},[2990,3000],{"nctId":2991,"briefTitle":2992,"status":117,"phases":2993,"primaryCompletion":2994,"completion":2995,"start":175,"enrollment":1847,"conditions":2996,"interventions":2998},"NCT00607230","Determination of Dosing and Frequency of BCG Administration to Alter T-Lymphocyte Profiles in Type I Diabetics",[89],"2010-12","2011-02",[2997],"Type 1 Diabetes Mellitus",[2999,2975],"BCG",{"nctId":3001,"briefTitle":3002,"status":117,"phases":3003,"primaryCompletion":3004,"completion":3004,"start":2847,"enrollment":194,"conditions":3005,"interventions":3006},"NCT01020747","Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)",[89],"2011-03",[2510],[3007,2975],"Avastin®",{"trials":3009,"activeCount":798,"soonestReadout":3038},[3010,3020,3034,3046,3058],{"nctId":3011,"briefTitle":3012,"status":107,"phases":3013,"primaryCompletion":3014,"completion":3014,"start":3015,"enrollment":101,"conditions":3016,"interventions":3018},"NCT03582085","Phase II Clinical Trial: Multi-dosing the BCG Vaccine for Fibromyalgia",[90],"2027-01-01","2026-01-01",[3017],"Fibromyalgia",[3019,2975],"Bacillus Calmette Guerin Vaccine",{"nctId":3021,"briefTitle":3022,"status":160,"phases":3023,"primaryCompletion":3024,"completion":3025,"start":3026,"enrollment":3027,"conditions":3028,"interventions":3032},"NCT06691217","Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis",[90],"2029-01-01","2030-04-01","2026-03-24",120,[3029,3030,3031],"Vascular Inflammation","ASCVD","ASCVD Management",[3033,2975],"CANAKINUMAB",{"nctId":3035,"briefTitle":3036,"status":160,"phases":3037,"primaryCompletion":3038,"completion":3038,"start":3039,"enrollment":1533,"conditions":3040,"interventions":3044},"NCT05180591","Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes",[90],"2027-03","2022-03-22",[3041,3042,3043],"Diabetes Mellitus, Type 1","Diabetes type1","Autoimmune Diabetes",[3045,2975],"Bacillus Calmette-Guérin",{"nctId":3047,"briefTitle":3048,"status":189,"phases":3049,"primaryCompletion":3050,"completion":3051,"start":3052,"enrollment":1533,"conditions":3053,"interventions":3057},"NCT02081326","Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes",[90],"2029-07","2031-07","2015-06",[3054,3055,3043,3056],"Diabetes Mellitus, Type One","Diabetes Mellitus, Type I","Covid19",[3045,2975],{"nctId":3059,"briefTitle":3060,"status":160,"phases":3061,"primaryCompletion":3062,"completion":3062,"start":3063,"enrollment":16,"conditions":3064,"interventions":3067},"NCT05866536","Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-\u003C18 Years",[90],"2028-05","2023-05-04",[3065,3066,3042,3043],"Diabetes Mellitus","Type 1 Diabetes",[3045,2975],{"trials":3069,"activeCount":101},[],{"trials":3071,"activeCount":101},[],{"trials":3073,"activeCount":101},[3074],{"nctId":3075,"briefTitle":3076,"status":117,"phases":3077,"primaryCompletion":3078,"completion":2994,"start":3079,"enrollment":872,"conditions":3080,"interventions":3084},"NCT00182091","Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency",[93],"2009-12","2004-08",[3081,3082,3083],"Acromegaly","Growth Hormone Deficiency","Pituitary Disease",[3085,2975],"Recombinant human growth hormone",{"intervention":2614,"totalTrials":693,"cells":3087},{"EARLY_PHASE1":3088,"PHASE1":3090,"PHASE2":3100,"PHASE3":3110,"PHASE4":3112,"NA":3114},{"trials":3089,"activeCount":101},[],{"trials":3091,"activeCount":331,"soonestReadout":1242},[3092,3096],{"nctId":2606,"briefTitle":2607,"status":189,"phases":3093,"primaryCompletion":1242,"completion":1243,"start":2609,"enrollment":2610,"conditions":3094,"interventions":3095},[89],[2030],[2613,127,2599,2614],{"nctId":2627,"briefTitle":2628,"status":107,"phases":3097,"primaryCompletion":2630,"completion":2631,"start":2632,"enrollment":101,"conditions":3098,"interventions":3099},[89],[2030],[2635,2614,2599],{"trials":3101,"activeCount":136,"soonestReadout":1242},[3102,3106],{"nctId":2639,"briefTitle":2640,"status":160,"phases":3103,"primaryCompletion":2642,"completion":2643,"start":2644,"enrollment":366,"conditions":3104,"interventions":3105},[90],[2646,2647,2030],[2649,2650,2614,2599],{"nctId":2659,"briefTitle":2660,"status":189,"phases":3107,"primaryCompletion":1242,"completion":1243,"start":2662,"enrollment":2663,"conditions":3108,"interventions":3109},[90],[2030],[2666,2614,2657,2599],{"trials":3111,"activeCount":101},[],{"trials":3113,"activeCount":101},[],{"trials":3115,"activeCount":331,"soonestReadout":3120},[3116],{"nctId":3117,"briefTitle":3118,"status":189,"phases":3119,"primaryCompletion":3120,"completion":1645,"start":3121,"enrollment":3122,"conditions":3123,"interventions":3125},"NCT07018401","Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study",[],"2025-04-08","2024-05-01",62,[3124],"Hereditary Hemorrhagic Telangiectasia (HHT)",[2614],{"intervention":2750,"totalTrials":544,"cells":3127},{"EARLY_PHASE1":3128,"PHASE1":3140,"PHASE2":3142,"PHASE3":3183,"PHASE4":3185,"NA":3187},{"trials":3129,"activeCount":101},[3130],{"nctId":3131,"briefTitle":3132,"status":117,"phases":3133,"primaryCompletion":3134,"completion":3134,"start":3135,"enrollment":693,"conditions":3136,"interventions":3139},"NCT05607017","Losartan in Prevention of Radiation-Induced Heart Failure",[88],"2025-10-07","2023-09-13",[21,3137,3138],"Myocardial Fibrosis","Radiation-Induced Fibrosis",[2750],{"trials":3141,"activeCount":101},[],{"trials":3143,"activeCount":178,"soonestReadout":65},[3144,3152,3156,3166,3173],{"nctId":3145,"briefTitle":3146,"status":2758,"phases":3147,"primaryCompletion":3148,"completion":3149,"start":477,"enrollment":366,"conditions":3150,"interventions":3151},"NCT01821729","Proton w\u002FFOLFIRINOX-Losartan for Pancreatic Cancer",[90],"2018-07","2021-09",[2748],[66,2750],{"nctId":63,"briefTitle":64,"status":189,"phases":3153,"primaryCompletion":65,"completion":2744,"start":2745,"enrollment":2746,"conditions":3154,"interventions":3155},[90],[2748],[66,2750,81],{"nctId":3157,"briefTitle":3158,"status":318,"phases":3159,"primaryCompletion":375,"completion":3160,"start":501,"enrollment":457,"conditions":3161,"interventions":3163},"NCT07265739","Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer",[90],"2028-12-30",[3162],"Platinum Resistant Ovarian Cancer",[3164,3165],"losartan","Paclitaxel",{"nctId":3167,"briefTitle":3168,"status":117,"phases":3169,"primaryCompletion":238,"completion":238,"start":684,"enrollment":194,"conditions":3170,"interventions":3172},"NCT01150461","Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy",[90],[3171],"Hypertrophic Cardiomyopathy",[3164],{"nctId":3174,"briefTitle":3175,"status":189,"phases":3176,"primaryCompletion":3177,"completion":3177,"start":3178,"enrollment":227,"conditions":3179,"interventions":3182},"NCT01199978","Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma",[90],"2026-11","2011-03-08",[3180,3181],"Vestibular Schwannoma","Acoustic Neuroma",[2750],{"trials":3184,"activeCount":101},[],{"trials":3186,"activeCount":101},[],{"trials":3188,"activeCount":101},[],{"intervention":2711,"totalTrials":544,"cells":3190},{"EARLY_PHASE1":3191,"PHASE1":3193,"PHASE2":3195,"PHASE3":3221,"PHASE4":3223,"NA":3225},{"trials":3192,"activeCount":101},[],{"trials":3194,"activeCount":101},[],{"trials":3196,"activeCount":178,"soonestReadout":80},[3197,3201,3205,3209,3213,3217],{"nctId":2703,"briefTitle":2704,"status":160,"phases":3198,"primaryCompletion":2706,"completion":2706,"start":2707,"enrollment":413,"conditions":3199,"interventions":3200},[90],[2516,2709],[2711,81],{"nctId":2713,"briefTitle":2714,"status":117,"phases":3202,"primaryCompletion":2716,"completion":2716,"start":2717,"enrollment":538,"conditions":3203,"interventions":3204},[90],[32],[2720,81,2721,2711],{"nctId":2734,"briefTitle":2735,"status":117,"phases":3206,"primaryCompletion":2737,"completion":2737,"start":2738,"enrollment":209,"conditions":3207,"interventions":3208},[90],[2740],[81,2711],{"nctId":2756,"briefTitle":2757,"status":2758,"phases":3210,"primaryCompletion":2760,"completion":2761,"start":2762,"enrollment":648,"conditions":3211,"interventions":3212},[90],[2764],[81,2711],{"nctId":78,"briefTitle":79,"status":189,"phases":3214,"primaryCompletion":80,"completion":2768,"start":2769,"enrollment":227,"conditions":3215,"interventions":3216},[90],[2748,2771],[81,2711],{"nctId":2774,"briefTitle":2775,"status":189,"phases":3218,"primaryCompletion":2777,"completion":2744,"start":2778,"enrollment":2779,"conditions":3219,"interventions":3220},[90],[2781,2748,2782],[81,2711],{"trials":3222,"activeCount":101},[],{"trials":3224,"activeCount":101},[],{"trials":3226,"activeCount":101},[],{"intervention":3228,"totalTrials":798,"cells":3229},"Ruxolitinib",{"EARLY_PHASE1":3230,"PHASE1":3232,"PHASE2":3234,"PHASE3":3271,"PHASE4":3273,"NA":3275},{"trials":3231,"activeCount":101},[],{"trials":3233,"activeCount":101},[],{"trials":3235,"activeCount":178,"soonestReadout":85},[3236,3245,3254,3260],{"nctId":3237,"briefTitle":3238,"status":189,"phases":3239,"primaryCompletion":1242,"completion":1242,"start":3240,"enrollment":19,"conditions":3241,"interventions":3244},"NCT03286530","Ruxolitinib + Allogeneic Stem Cell Transplantation in AML",[90],"2017-11-03",[2862,3242,3243],"Acute Myeloid Leukemia in Remission","Allogeneic Stem Cell Transplantation",[3228],{"nctId":3246,"briefTitle":3247,"status":117,"phases":3248,"primaryCompletion":3121,"completion":3249,"start":3250,"enrollment":30,"conditions":3251,"interventions":3253},"NCT03427866","Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.",[90],"2025-05-19","2018-08-28",[3252],"Myelofibrosis",[3228],{"nctId":83,"briefTitle":84,"status":189,"phases":3255,"primaryCompletion":85,"completion":2507,"start":3256,"enrollment":366,"conditions":3257,"interventions":3259},[90],"2019-04-19",[3258],"Other Cancer",[86],{"nctId":3261,"briefTitle":3262,"status":160,"phases":3263,"primaryCompletion":3264,"completion":3265,"start":3266,"enrollment":1578,"conditions":3267,"interventions":3270},"NCT04644211","Ruxolitinib in Thrombocythemia and Polycythemia Vera",[90],"2027-07","2034-07","2022-03-21",[3268,3269],"Essential Thrombocythemia","Polycythemia Vera",[3228],{"trials":3272,"activeCount":101},[],{"trials":3274,"activeCount":101},[],{"trials":3276,"activeCount":101},[],{"intervention":2685,"totalTrials":178,"cells":3278},{"EARLY_PHASE1":3279,"PHASE1":3281,"PHASE2":3283,"PHASE3":3309,"PHASE4":3311,"NA":3313},{"trials":3280,"activeCount":101},[],{"trials":3282,"activeCount":101},[],{"trials":3284,"activeCount":178,"soonestReadout":3300},[3285,3296,3305],{"nctId":3286,"briefTitle":3287,"status":160,"phases":3288,"primaryCompletion":162,"completion":3289,"start":3290,"enrollment":227,"conditions":3291,"interventions":3293},"NCT06832865","ELISA in Relapsed\u002FRefractory MM",[90],"2028-12-01","2025-08-14",[2622,3292],"Relapsed Refractory Multiple Myeloma",[3294,3295],"elranatamab","Isatuximab SC",{"nctId":3297,"briefTitle":3298,"status":160,"phases":3299,"primaryCompletion":3300,"completion":3289,"start":3301,"enrollment":648,"conditions":3302,"interventions":3304},"NCT06138275","Elranatamab in R\u002FR Multiple Myeloma",[90],"2026-08-01","2024-03-08",[2647,3303,2030],"Relapse Multiple Myeloma",[2685],{"nctId":2674,"briefTitle":2675,"status":318,"phases":3306,"primaryCompletion":2677,"completion":2678,"start":2679,"enrollment":1083,"conditions":3307,"interventions":3308},[90],[2030,2681,2682,2683],[2685,2686,127,2687,2599],{"trials":3310,"activeCount":101},[],{"trials":3312,"activeCount":101},[],{"trials":3314,"activeCount":101},[],{"intervention":3316,"totalTrials":178,"cells":3317},"[68Ga]CBP8",{"EARLY_PHASE1":3318,"PHASE1":3320,"PHASE2":3329,"PHASE3":3353,"PHASE4":3355,"NA":3357},{"trials":3319,"activeCount":101},[],{"trials":3321,"activeCount":331,"soonestReadout":2201},[3322],{"nctId":3323,"briefTitle":3324,"status":160,"phases":3325,"primaryCompletion":2201,"completion":2201,"start":1789,"enrollment":16,"conditions":3326,"interventions":3328},"NCT03535545","Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients",[89],[3327,32],"Pulmonary Fibrosis",[3316],{"trials":3330,"activeCount":136,"soonestReadout":3347},[3331,3343],{"nctId":3332,"briefTitle":3333,"status":160,"phases":3334,"primaryCompletion":3335,"completion":3264,"start":3336,"enrollment":3337,"conditions":3338,"interventions":3342},"NCT04485286","Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury",[90],"2027-05","2020-07-19",72,[32,3339,3340,3341],"Radiation Fibrosis","Radiation Induced Lung Injury","Pancreas Cancer",[3316],{"nctId":3344,"briefTitle":3345,"status":160,"phases":3346,"primaryCompletion":3347,"completion":162,"start":3348,"enrollment":227,"conditions":3349,"interventions":3351},"NCT05417776","Collagen-targeted PET Imaging for Early Interstitial Lung Disease",[90],"2026-10-01","2022-09-28",[3350],"Interstitial Lung Disease",[3316,3352],"Dotarem",{"trials":3354,"activeCount":101},[],{"trials":3356,"activeCount":101},[],{"trials":3358,"activeCount":101},[],{"intervention":3360,"totalTrials":178,"cells":3361},"Venetoclax",{"EARLY_PHASE1":3362,"PHASE1":3376,"PHASE2":3378,"PHASE3":3403,"PHASE4":3405,"NA":3407},{"trials":3363,"activeCount":331,"soonestReadout":191},[3364],{"nctId":3365,"briefTitle":3366,"status":318,"phases":3367,"primaryCompletion":191,"completion":3368,"start":837,"enrollment":178,"conditions":3369,"interventions":3375},"NCT07358195","Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation",[88],"2029-12",[3370,3371,3372,3373,3374],"Kidney Failure Chronic","Stem Cell Transplant","Stem Cell Transplant Complications","Tolerance","Hematologic Cancer",[3360],{"trials":3377,"activeCount":101},[],{"trials":3379,"activeCount":136,"soonestReadout":3014},[3380,3392],{"nctId":3381,"briefTitle":3382,"status":189,"phases":3383,"primaryCompletion":3014,"completion":2706,"start":3384,"enrollment":3385,"conditions":3386,"interventions":3387},"NCT04801797","Venetoclax + Azacitidine vs. Induction Chemotherapy in AML",[90],"2021-05-20",172,[2862],[2807,3388,3389,3390,3360,3391],"Idarubicin","Daunorubicin","Liposomal daunorubicin and cytarabine","Azacitidine",{"nctId":3393,"briefTitle":3394,"status":160,"phases":3395,"primaryCompletion":3396,"completion":3397,"start":3398,"enrollment":251,"conditions":3399,"interventions":3400},"NCT04560322","Venetoclax-Obinutuzumab +\u002F- Acalabrutinib in R\u002FR CLL",[90],"2028-03-01","2029-03-01","2020-10-19",[123,124],[3360,3401,3402],"Obinutuzumab","Acalabrutinib",{"trials":3404,"activeCount":101},[],{"trials":3406,"activeCount":101},[],{"trials":3408,"activeCount":101},[],{"intervention":3045,"totalTrials":178,"cells":3410},{"EARLY_PHASE1":3411,"PHASE1":3413,"PHASE2":3415,"PHASE3":3429,"PHASE4":3431,"NA":3433},{"trials":3412,"activeCount":101},[],{"trials":3414,"activeCount":101},[],{"trials":3416,"activeCount":178,"soonestReadout":3038},[3417,3421,3425],{"nctId":3035,"briefTitle":3036,"status":160,"phases":3418,"primaryCompletion":3038,"completion":3038,"start":3039,"enrollment":1533,"conditions":3419,"interventions":3420},[90],[3041,3042,3043],[3045,2975],{"nctId":3047,"briefTitle":3048,"status":189,"phases":3422,"primaryCompletion":3050,"completion":3051,"start":3052,"enrollment":1533,"conditions":3423,"interventions":3424},[90],[3054,3055,3043,3056],[3045,2975],{"nctId":3059,"briefTitle":3060,"status":160,"phases":3426,"primaryCompletion":3062,"completion":3062,"start":3063,"enrollment":16,"conditions":3427,"interventions":3428},[90],[3065,3066,3042,3043],[3045,2975],{"trials":3430,"activeCount":101},[],{"trials":3432,"activeCount":101},[],{"trials":3434,"activeCount":101},[],{"intervention":2576,"totalTrials":239,"cells":3436},{"EARLY_PHASE1":3437,"PHASE1":3439,"PHASE2":3458,"PHASE3":3521,"PHASE4":3523,"NA":3525},{"trials":3438,"activeCount":101},[],{"trials":3440,"activeCount":101},[3441,3451],{"nctId":3442,"briefTitle":3443,"status":117,"phases":3444,"primaryCompletion":248,"completion":2447,"start":578,"enrollment":36,"conditions":3445,"interventions":3447},"NCT00513383","Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck",[89],[3446],"Squamous Cell Carcinoma of the Head and Neck",[3448,2720,3165,3449,3450,2576],"Panitumumab","5-Fluorouracil","Docetaxel",{"nctId":3452,"briefTitle":3453,"status":173,"phases":3454,"primaryCompletion":3052,"completion":3052,"start":2827,"enrollment":798,"conditions":3455,"interventions":3457},"NCT01565772","Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer",[89],[3456],"Non-Small Cell Lung Cancer",[2576,2806],{"trials":3459,"activeCount":178,"soonestReadout":486},[3460,3469,3479,3487,3497,3501,3512],{"nctId":3461,"briefTitle":3462,"status":107,"phases":3463,"primaryCompletion":238,"start":3464,"enrollment":101,"conditions":3465,"interventions":3467},"NCT00916669","A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)",[90],"2008-07",[3466],"Small Cell Lung Cancer",[2806,2576,3468],"enoxaparin sodium",{"nctId":3470,"briefTitle":3471,"status":117,"phases":3472,"primaryCompletion":2994,"completion":283,"start":109,"enrollment":22,"conditions":3473,"interventions":3474},"NCT00580333","Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer",[90],[21],[3475,3476,3477,922,3478],"cisplatin","bevacizumab","doxorubicin","paclitaxel",{"nctId":3480,"briefTitle":3481,"status":189,"phases":3482,"primaryCompletion":486,"completion":486,"start":226,"enrollment":2837,"conditions":3483,"interventions":3484},"NCT01553942","Afatinib With CT and RT for EGFR-Mutant NSCLC",[90],[32],[3485,2576,3486],"Afatinib","Pemetrexed",{"nctId":3488,"briefTitle":3489,"status":117,"phases":3490,"primaryCompletion":3491,"completion":3491,"start":3492,"enrollment":1847,"conditions":3493,"interventions":3495},"NCT00592501","Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma",[90],"2019-04","2006-10",[3494],"Nasopharyngeal Carcinoma",[2576,3496],"Fluorouracil",{"nctId":2567,"briefTitle":2568,"status":189,"phases":3498,"primaryCompletion":1577,"completion":2570,"start":2571,"enrollment":886,"conditions":3499,"interventions":3500},[90],[2573,2574],[2576,57],{"nctId":3502,"briefTitle":3503,"status":318,"phases":3504,"primaryCompletion":1146,"completion":3505,"start":3506,"enrollment":151,"conditions":3507,"interventions":3510},"NCT07214987","PDT For Induction Therapy For Head And Neck Cancer",[90],"2029-09-01","2026-03-09",[3508,3509,2527],"Squamous Cell Carcinoma","Head and Neck Cancer Squamous Cell Carcinoma",[3511,2576,3450],"Toripalimab-tpzi",{"nctId":3513,"briefTitle":3514,"status":117,"phases":3515,"primaryCompletion":309,"completion":2418,"start":3516,"enrollment":3517,"conditions":3518,"interventions":3519},"NCT00483223","Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63\u002Fp73 as a Biomarker of Response",[90],"2007-06",86,[21],[2576,3520],"carboplatin",{"trials":3522,"activeCount":101},[],{"trials":3524,"activeCount":101},[],{"trials":3526,"activeCount":101},[3527],{"nctId":3528,"briefTitle":3529,"status":173,"phases":3530,"primaryCompletion":1846,"completion":1846,"start":3531,"enrollment":178,"conditions":3532,"interventions":3535},"NCT02256982","A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma",[93],"2014-10",[3533,3534],"Unresectable Intrahepatic Cholangiocarcinoma","Resectable Intrahepatic Cholangiocarcinoma",[3536,2576],"Gemcitabine",{"intervention":2537,"totalTrials":798,"cells":3538},{"EARLY_PHASE1":3539,"PHASE1":3541,"PHASE2":3543,"PHASE3":3577,"PHASE4":3579,"NA":3581},{"trials":3540,"activeCount":101},[],{"trials":3542,"activeCount":101},[],{"trials":3544,"activeCount":178,"soonestReadout":2200},[3545,3555,3559],{"nctId":3546,"briefTitle":3547,"status":160,"phases":3548,"primaryCompletion":3549,"completion":3550,"start":3551,"enrollment":16,"conditions":3552,"interventions":3554},"NCT06136546","Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab",[90],"2028-08-31","2029-01-31","2025-01-23",[3553,821],"Depressive Disorder, Major",[2537],{"nctId":2531,"briefTitle":2532,"status":189,"phases":3556,"primaryCompletion":2200,"completion":1146,"start":2534,"enrollment":33,"conditions":3557,"interventions":3558},[90],[2516],[57,2537,2538,81],{"nctId":3560,"briefTitle":3561,"status":189,"phases":3562,"primaryCompletion":3563,"completion":3563,"start":3564,"enrollment":3565,"conditions":3566,"interventions":3574},"NCT04305145","Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis",[90],"2030-06-30","2020-08-31",42,[3567,3568,3569,3570,3571,3572,3573],"Melanoma Stage III","Melanoma Stage IV","Skin Cancer Stage III","Skin Cancer Stage IV","Drug-Induced Colitis","Drug Toxicity","Immune-related Adverse Event",[2537,3575,3576],"Methylprednisolone","Prednisone",{"trials":3578,"activeCount":101},[],{"trials":3580,"activeCount":101},[],{"trials":3582,"activeCount":101},[3583],{"nctId":3584,"briefTitle":3585,"status":2758,"phases":3586,"primaryCompletion":3587,"completion":3588,"start":3589,"enrollment":3027,"conditions":3590,"interventions":3592},"NCT04655729","Biomarkers to Predict and Monitor Response to Infliximab",[],"2022-11-30","2023-01-01","2019-11-18",[3591],"Crohn Disease",[2537],{"intervention":2720,"totalTrials":1791,"cells":3594},{"EARLY_PHASE1":3595,"PHASE1":3597,"PHASE2":3628,"PHASE3":3698,"PHASE4":3700,"NA":3711},{"trials":3596,"activeCount":101},[],{"trials":3598,"activeCount":101},[3599,3603,3615],{"nctId":3442,"briefTitle":3443,"status":117,"phases":3600,"primaryCompletion":248,"completion":2447,"start":578,"enrollment":36,"conditions":3601,"interventions":3602},[89],[3446],[3448,2720,3165,3449,3450,2576],{"nctId":3604,"briefTitle":3605,"status":2758,"phases":3606,"primaryCompletion":3607,"completion":3608,"start":1926,"enrollment":829,"conditions":3609,"interventions":3613},"NCT00652119","Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin",[89],"2009-08","2021-08",[3610,3611,3612],"Ovarian Cancer","Peritoneal Cancer","Fallopian Tube Cancer",[3165,2720,3614],"Avastin",{"nctId":3616,"briefTitle":3617,"status":117,"phases":3618,"primaryCompletion":3619,"completion":3620,"start":3621,"enrollment":1847,"conditions":3622,"interventions":3624},"NCT03279237","A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers",[89],"2018-09-26","2026-04-01","2017-10-24",[3623],"GastroEsophageal Cancer",[3625,3626,3627,3449,3165,2720],"Irinotecan","Oxaliplatin","Leucovorin",{"trials":3629,"activeCount":136,"soonestReadout":2925},[3630,3640,3650,3654,3662,3676,3685,3694],{"nctId":3631,"briefTitle":3632,"status":160,"phases":3633,"primaryCompletion":2925,"completion":1243,"start":3634,"enrollment":251,"conditions":3635,"interventions":3638},"NCT04656041","Folfox+Irinotecan+Chemort In Esophageal Cancer",[90],"2021-06-29",[3636,3637],"Gastroesophageal Junction Adenocarcinoma","Esophagogastric Cancer",[3639,3165,2720],"FOLFOX\u002F nal-IRI",{"nctId":3641,"briefTitle":3642,"status":117,"phases":3643,"primaryCompletion":1889,"completion":3644,"start":751,"enrollment":366,"conditions":3645,"interventions":3646},"NCT01188876","Carboplatin\u002FPralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer",[89,90],"2017-07",[3610,3612,3611],[3520,3647,3648,3649],"pralatrexate","Folic Acid","Vitamin B12",{"nctId":2713,"briefTitle":2714,"status":117,"phases":3651,"primaryCompletion":2716,"completion":2716,"start":2717,"enrollment":538,"conditions":3652,"interventions":3653},[90],[32],[2720,81,2721,2711],{"nctId":3655,"briefTitle":3656,"status":117,"phases":3657,"primaryCompletion":3658,"completion":3658,"start":3659,"enrollment":3122,"conditions":3660,"interventions":3661},"NCT00129727","Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)",[90],"2009-02","2005-06",[3610],[3165,2720,47],{"nctId":3663,"briefTitle":3664,"status":318,"phases":3665,"primaryCompletion":3396,"completion":3397,"start":3666,"enrollment":829,"conditions":3667,"interventions":3674},"NCT07405190","Ivonescimab Alone And With Carboplatin\u002FPemetrexed For NSCLC",[90],"2026-08-04",[3668,3669,3670,3671,3672,3673],"Lung Cancer (NSCLC)","Lung Cancer Non-Small Cell Cancer (NSCLC)","Lung Cancer (Non-Small Cell)","Lung Cancer - Non Small Cell","Lung Cancer Non Small Cell","Genomic Alterations",[3675,3520,2721],"Ivonescimab",{"nctId":3677,"briefTitle":3678,"status":117,"phases":3679,"primaryCompletion":3680,"completion":3680,"start":708,"enrollment":33,"conditions":3681,"interventions":3683},"NCT00642759","Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer",[90],"2015-04",[3682],"Non-small Cell Lung Cancer",[3520,3684,47],"Nab-paclitaxel",{"nctId":3686,"briefTitle":3687,"status":117,"phases":3688,"primaryCompletion":3689,"completion":3689,"start":3690,"enrollment":829,"conditions":3691,"interventions":3693},"NCT00181701","Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin",[90],"2006-05","2004-10",[3692],"Ovarian Carcinoma",[3165,2720],{"nctId":3513,"briefTitle":3514,"status":117,"phases":3695,"primaryCompletion":309,"completion":2418,"start":3516,"enrollment":3517,"conditions":3696,"interventions":3697},[90],[21],[2576,3520],{"trials":3699,"activeCount":101},[],{"trials":3701,"activeCount":101},[3702],{"nctId":3703,"briefTitle":3704,"status":173,"phases":3705,"primaryCompletion":3706,"completion":298,"start":224,"enrollment":2728,"conditions":3707,"interventions":3710},"NCT02035345","Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment",[92],"2015-03",[3708,3709],"Recurrent Ovarian Cancer","Platinum Sensitive Ovarian Cancer",[2720],{"trials":3712,"activeCount":101},[],{"intervention":3165,"totalTrials":538,"cells":3714},{"EARLY_PHASE1":3715,"PHASE1":3717,"PHASE2":3731,"PHASE3":3763,"PHASE4":3765,"NA":3767},{"trials":3716,"activeCount":101},[],{"trials":3718,"activeCount":101},[3719,3723,3727],{"nctId":3442,"briefTitle":3443,"status":117,"phases":3720,"primaryCompletion":248,"completion":2447,"start":578,"enrollment":36,"conditions":3721,"interventions":3722},[89],[3446],[3448,2720,3165,3449,3450,2576],{"nctId":3604,"briefTitle":3605,"status":2758,"phases":3724,"primaryCompletion":3607,"completion":3608,"start":1926,"enrollment":829,"conditions":3725,"interventions":3726},[89],[3610,3611,3612],[3165,2720,3614],{"nctId":3616,"briefTitle":3617,"status":117,"phases":3728,"primaryCompletion":3619,"completion":3620,"start":3621,"enrollment":1847,"conditions":3729,"interventions":3730},[89],[3623],[3625,3626,3627,3449,3165,2720],{"trials":3732,"activeCount":136,"soonestReadout":2925},[3733,3737,3747,3751,3755,3759],{"nctId":3631,"briefTitle":3632,"status":160,"phases":3734,"primaryCompletion":2925,"completion":1243,"start":3634,"enrollment":251,"conditions":3735,"interventions":3736},[90],[3636,3637],[3639,3165,2720],{"nctId":3738,"briefTitle":3739,"status":117,"phases":3740,"primaryCompletion":3741,"completion":3741,"start":3742,"enrollment":413,"conditions":3743,"interventions":3745},"NCT00003193","Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer",[89,90],"2005-09","1998-01",[2527,3744],"Oral Complications",[3746,3478],"amifostine trihydrate",{"nctId":3655,"briefTitle":3656,"status":117,"phases":3748,"primaryCompletion":3658,"completion":3658,"start":3659,"enrollment":3122,"conditions":3749,"interventions":3750},[90],[3610],[3165,2720,47],{"nctId":3470,"briefTitle":3471,"status":117,"phases":3752,"primaryCompletion":2994,"completion":283,"start":109,"enrollment":22,"conditions":3753,"interventions":3754},[90],[21],[3475,3476,3477,922,3478],{"nctId":3157,"briefTitle":3158,"status":318,"phases":3756,"primaryCompletion":375,"completion":3160,"start":501,"enrollment":457,"conditions":3757,"interventions":3758},[90],[3162],[3164,3165],{"nctId":3686,"briefTitle":3687,"status":117,"phases":3760,"primaryCompletion":3689,"completion":3689,"start":3690,"enrollment":829,"conditions":3761,"interventions":3762},[90],[3692],[3165,2720],{"trials":3764,"activeCount":101},[],{"trials":3766,"activeCount":101},[],{"trials":3768,"activeCount":101},[],{"intervention":3770,"totalTrials":270,"cells":3771},"Doxorubicin",{"EARLY_PHASE1":3772,"PHASE1":3774,"PHASE2":3794,"PHASE3":3839,"PHASE4":3841,"NA":3843},{"trials":3773,"activeCount":101},[],{"trials":3775,"activeCount":331,"soonestReadout":46},[3776,3790],{"nctId":3777,"briefTitle":3778,"status":117,"phases":3779,"primaryCompletion":2581,"completion":2408,"start":567,"enrollment":2837,"conditions":3780,"interventions":3785},"NCT02228772","Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults",[89],[3781,3782,3783,3784],"Acute Lymphoblastic Leukemia","Lymphoblastic Lymphoma","B-cell Adult Acute Lymphoblastic Leukemia","T-cell Adult Acute Lymphoblastic Leukemia",[3786,3787,2807,3770,3788,201,3789],"MLN 9708","Vincristine","Mercaptopurine","Methotrexate",{"nctId":44,"briefTitle":45,"status":189,"phases":3791,"primaryCompletion":46,"completion":1242,"start":284,"enrollment":1898,"conditions":3792,"interventions":3793},[89],[1151],[47,3770],{"trials":3795,"activeCount":331,"soonestReadout":837},[3796,3804,3816,3820,3830],{"nctId":3797,"briefTitle":3798,"status":117,"phases":3799,"primaryCompletion":3706,"completion":3706,"start":3658,"enrollment":194,"conditions":3800,"interventions":3801},"NCT01027910","PCI-24781 in Combination With Doxorubicin to Treat Sarcoma",[89,90],[1151],[3802,3770,3803],"PCI-24781","GCSF",{"nctId":3805,"briefTitle":3806,"status":189,"phases":3807,"primaryCompletion":837,"completion":3264,"start":3808,"enrollment":3122,"conditions":3809,"interventions":3814},"NCT05099666","Lurbinectedin + Doxorubicin In Leiomyosarcoma",[89,90],"2022-02-04",[3810,3811,3812,3813],"Advanced Soft-tissue Sarcoma","Metastatic Soft-tissue Sarcoma","Advanced Leiomyosarcoma","Leiomyosarcoma Metastatic",[3815,3770],"Lurbinectedin",{"nctId":3470,"briefTitle":3471,"status":117,"phases":3817,"primaryCompletion":2994,"completion":283,"start":109,"enrollment":22,"conditions":3818,"interventions":3819},[90],[21],[3475,3476,3477,922,3478],{"nctId":3821,"briefTitle":3822,"status":117,"phases":3823,"primaryCompletion":567,"completion":1877,"start":3607,"enrollment":227,"conditions":3824,"interventions":3825},"NCT00973752","Treatment of Older Adults With Acute Lymphoblastic Leukemia",[90],[3781],[3576,3787,3770,3826,2807,3789,3827,3828,3829],"PEG-asparaginase","Imatinib","Clofarabine","6 Mercaptopurine",{"nctId":3831,"briefTitle":3832,"status":117,"phases":3833,"primaryCompletion":1780,"completion":3834,"start":249,"enrollment":3565,"conditions":3835,"interventions":3837},"NCT02448537","A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and\u002For Unresectable Sarcomas",[90],"2019-04-01",[3836],"Metastatic Sarcoma",[3838,3770,3536],"PM01183",{"trials":3840,"activeCount":101},[],{"trials":3842,"activeCount":101},[],{"trials":3844,"activeCount":101},[],{"intervention":2721,"totalTrials":798,"cells":3846},{"EARLY_PHASE1":3847,"PHASE1":3849,"PHASE2":3859,"PHASE3":3873,"PHASE4":3875,"NA":3877},{"trials":3848,"activeCount":101},[],{"trials":3850,"activeCount":101},[3851],{"nctId":3852,"briefTitle":3853,"status":117,"phases":3854,"primaryCompletion":1861,"completion":1861,"start":3855,"enrollment":209,"conditions":3856,"interventions":3858},"NCT00916630","Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)",[89],"2009-01",[3857],"Central Nervous System Lymphoma",[2721],{"trials":3860,"activeCount":136,"soonestReadout":486},[3861,3865,3869],{"nctId":2713,"briefTitle":2714,"status":117,"phases":3862,"primaryCompletion":2716,"completion":2716,"start":2717,"enrollment":538,"conditions":3863,"interventions":3864},[90],[32],[2720,81,2721,2711],{"nctId":3663,"briefTitle":3664,"status":318,"phases":3866,"primaryCompletion":3396,"completion":3397,"start":3666,"enrollment":829,"conditions":3867,"interventions":3868},[90],[3668,3669,3670,3671,3672,3673],[3675,3520,2721],{"nctId":3480,"briefTitle":3481,"status":189,"phases":3870,"primaryCompletion":486,"completion":486,"start":226,"enrollment":2837,"conditions":3871,"interventions":3872},[90],[32],[3485,2576,3486],{"trials":3874,"activeCount":101},[],{"trials":3876,"activeCount":101},[],{"trials":3878,"activeCount":101},[],{"intervention":2518,"totalTrials":798,"cells":3880},{"EARLY_PHASE1":3881,"PHASE1":3883,"PHASE2":3904,"PHASE3":3921,"PHASE4":3923,"NA":3925},{"trials":3882,"activeCount":101},[],{"trials":3884,"activeCount":331,"soonestReadout":3889},[3885,3893],{"nctId":3886,"briefTitle":3887,"status":189,"phases":3888,"primaryCompletion":3889,"completion":2835,"start":3890,"enrollment":227,"conditions":3891,"interventions":3892},"NCT03091257","A Study of Dabrafenib and\u002For Trametinib in Patients With Relapsed and\u002For Refractory Multiple Myeloma",[89],"2026-07-15","2017-06-21",[2030],[2518,2519],{"nctId":3894,"briefTitle":3895,"status":173,"phases":3896,"primaryCompletion":3897,"completion":3898,"start":3899,"enrollment":331,"conditions":3900,"interventions":3902},"NCT03272464","INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.",[89],"2019-07-24","2019-12-27","2019-05-29",[3901],"Melanoma",[2519,2518,3903],"INCB039110",{"trials":3905,"activeCount":331,"soonestReadout":61},[3906,3910],{"nctId":59,"briefTitle":60,"status":189,"phases":3907,"primaryCompletion":61,"completion":1999,"start":2514,"enrollment":1805,"conditions":3908,"interventions":3909},[90],[2516],[57,2518,2519],{"nctId":3911,"briefTitle":3912,"status":2758,"phases":3913,"primaryCompletion":3914,"completion":3915,"start":3916,"enrollment":1847,"conditions":3917,"interventions":3919},"NCT03668431","Dabrafenib + Trametinib + PDR001 In Colorectal Cancer",[90],"2022-09-01","2022-12-01","2018-10-15",[3918],"Metastatic Colorectal Cancer",[2518,2519,3920],"PDR001",{"trials":3922,"activeCount":101},[],{"trials":3924,"activeCount":101},[],{"trials":3926,"activeCount":101},[],{"intervention":2519,"totalTrials":798,"cells":3928},{"EARLY_PHASE1":3929,"PHASE1":3931,"PHASE2":3941,"PHASE3":3951,"PHASE4":3953,"NA":3955},{"trials":3930,"activeCount":101},[],{"trials":3932,"activeCount":331,"soonestReadout":3889},[3933,3937],{"nctId":3886,"briefTitle":3887,"status":189,"phases":3934,"primaryCompletion":3889,"completion":2835,"start":3890,"enrollment":227,"conditions":3935,"interventions":3936},[89],[2030],[2518,2519],{"nctId":3894,"briefTitle":3895,"status":173,"phases":3938,"primaryCompletion":3897,"completion":3898,"start":3899,"enrollment":331,"conditions":3939,"interventions":3940},[89],[3901],[2519,2518,3903],{"trials":3942,"activeCount":331,"soonestReadout":61},[3943,3947],{"nctId":59,"briefTitle":60,"status":189,"phases":3944,"primaryCompletion":61,"completion":1999,"start":2514,"enrollment":1805,"conditions":3945,"interventions":3946},[90],[2516],[57,2518,2519],{"nctId":3911,"briefTitle":3912,"status":2758,"phases":3948,"primaryCompletion":3914,"completion":3915,"start":3916,"enrollment":1847,"conditions":3949,"interventions":3950},[90],[3918],[2518,2519,3920],{"trials":3952,"activeCount":101},[],{"trials":3954,"activeCount":101},[],{"trials":3956,"activeCount":101},[],{"intervention":3958,"totalTrials":178,"cells":3959},"Talazoparib",{"EARLY_PHASE1":3960,"PHASE1":3962,"PHASE2":3964,"PHASE3":3990,"PHASE4":3992,"NA":3994},{"trials":3961,"activeCount":101},[],{"trials":3963,"activeCount":101},[],{"trials":3965,"activeCount":136,"soonestReadout":1288},[3966,3974,3981],{"nctId":3967,"briefTitle":3968,"status":2758,"phases":3969,"primaryCompletion":61,"completion":61,"start":134,"enrollment":227,"conditions":3970,"interventions":3972},"NCT04824937","Telaglenastat + Talazoparib In Prostate Cancer",[90],[3971],"Prostate Cancer Metastatic",[3973,3958],"Telaglenastat",{"nctId":3975,"briefTitle":3976,"status":189,"phases":3977,"primaryCompletion":1288,"completion":1242,"start":3978,"enrollment":872,"conditions":3979,"interventions":3980},"NCT04039230","Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.",[89,90],"2019-10-09",[21],[3958,2551],{"nctId":3982,"briefTitle":3983,"status":160,"phases":3984,"primaryCompletion":3985,"completion":3986,"start":3987,"enrollment":227,"conditions":3988,"interventions":3989},"NCT03990896","Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial",[90],"2027-03-31","2028-04-30","2021-11-18",[21],[3958],{"trials":3991,"activeCount":101},[],{"trials":3993,"activeCount":101},[],{"trials":3995,"activeCount":101},[],{"intervention":3997,"totalTrials":178,"cells":3998},"Durvalumab",{"EARLY_PHASE1":3999,"PHASE1":4001,"PHASE2":4022,"PHASE3":4033,"PHASE4":4035,"NA":4037},{"trials":4000,"activeCount":101},[],{"trials":4002,"activeCount":331,"soonestReadout":1242},[4003,4014],{"nctId":4004,"briefTitle":4005,"status":117,"phases":4006,"primaryCompletion":4007,"completion":4007,"start":4008,"enrollment":1509,"conditions":4009,"interventions":4010},"NCT03019003","Oral Decitabine (ASTX727) and Durvalumab in Recurrent and\u002For Metastatic Head and Neck Cancer Patients",[89],"2024-09-24","2017-03-20",[2527],[4011,3997,4012,4013],"Oral Decitabine","5' Azacitidine","Tremelimumab",{"nctId":4015,"briefTitle":4016,"status":189,"phases":4017,"primaryCompletion":1242,"completion":4018,"start":4019,"enrollment":2859,"conditions":4020,"interventions":4021},"NCT02826434","Adjuvant PVX-410 Vaccine and Durvalumab in Stage II\u002FIII Triple Negative Breast Cancer",[89],"2027-09","2016-08-18",[21],[2476,3997,2841],{"trials":4023,"activeCount":331,"soonestReadout":4028},[4024],{"nctId":4025,"briefTitle":4026,"status":189,"phases":4027,"primaryCompletion":4028,"completion":1577,"start":4029,"enrollment":413,"conditions":4030,"interventions":4032},"NCT03482102","Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer",[90],"2024-02-28","2018-05-14",[4031,2730],"Hepatocellular Carcinoma",[4013,3997],{"trials":4034,"activeCount":101},[],{"trials":4036,"activeCount":101},[],{"trials":4038,"activeCount":101},[],{"intervention":3485,"totalTrials":178,"cells":4040},{"EARLY_PHASE1":4041,"PHASE1":4043,"PHASE2":4058,"PHASE3":4071,"PHASE4":4073,"NA":4075},{"trials":4042,"activeCount":101},[],{"trials":4044,"activeCount":331,"soonestReadout":163},[4045],{"nctId":4046,"briefTitle":4047,"status":160,"phases":4048,"primaryCompletion":163,"completion":163,"start":4049,"enrollment":4050,"conditions":4051,"interventions":4056},"NCT06302621","Pemigatinib + Afatinib in Advanced Refractory Solid Tumors",[89],"2024-04-17",70,[4052,4053,4054,4055],"Advanced Solid Tumor","Unresectable Solid Tumor","Metastatic Solid Tumor","Cholangiocarcinoma",[3485,4057],"Pemigatinib",{"trials":4059,"activeCount":331,"soonestReadout":486},[4060,4067],{"nctId":4061,"briefTitle":4062,"status":2758,"phases":4063,"primaryCompletion":2406,"completion":2407,"start":456,"enrollment":1009,"conditions":4064,"interventions":4066},"NCT01746251","Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation",[90],[4065],"Non Small Cell Lung Cancer",[3485],{"nctId":3480,"briefTitle":3481,"status":189,"phases":4068,"primaryCompletion":486,"completion":486,"start":226,"enrollment":2837,"conditions":4069,"interventions":4070},[90],[32],[3485,2576,3486],{"trials":4072,"activeCount":101},[],{"trials":4074,"activeCount":101},[],{"trials":4076,"activeCount":101},[],{"intervention":4078,"totalTrials":136,"cells":4079},"Tirzepatide",{"EARLY_PHASE1":4080,"PHASE1":4082,"PHASE2":4092,"PHASE3":4103,"PHASE4":4105,"NA":4107},{"trials":4081,"activeCount":101},[],{"trials":4083,"activeCount":331,"soonestReadout":3985},[4084],{"nctId":4085,"briefTitle":4086,"status":160,"phases":4087,"primaryCompletion":3985,"completion":2642,"start":1669,"enrollment":194,"conditions":4088,"interventions":4091},"NCT07095517","Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors",[89],[4089,4090],"Colorectal Cancer Prevention","Colorectal Adenoma",[4078],{"trials":4093,"activeCount":331,"soonestReadout":2642},[4094],{"nctId":4095,"briefTitle":4096,"status":160,"phases":4097,"primaryCompletion":2642,"completion":2118,"start":4098,"enrollment":4099,"conditions":4100,"interventions":4101},"NCT05933499","Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity",[90],"2025-11-05",63,[26],[4102,4078],"Bimagrumab",{"trials":4104,"activeCount":101},[],{"trials":4106,"activeCount":101},[],{"trials":4108,"activeCount":101},[],{"intervention":169,"totalTrials":136,"cells":4110},{"EARLY_PHASE1":4111,"PHASE1":4113,"PHASE2":4115,"PHASE3":4131,"PHASE4":4133,"NA":4135},{"trials":4112,"activeCount":101},[],{"trials":4114,"activeCount":101},[],{"trials":4116,"activeCount":136,"soonestReadout":162},[4117,4121],{"nctId":158,"briefTitle":159,"status":160,"phases":4118,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":4119,"interventions":4120},[90],[167],[169,128,96],{"nctId":4122,"briefTitle":4123,"status":160,"phases":4124,"primaryCompletion":3396,"completion":4125,"start":4126,"enrollment":251,"conditions":4127,"interventions":4129},"NCT06849713","Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL",[90],"2030-03-01","2025-05-16",[123,4128],"Small Lymphocytic Lymphoma (SLL)",[169,4130,3401],"Sonrotoclax",{"trials":4132,"activeCount":101},[],{"trials":4134,"activeCount":101},[],{"trials":4136,"activeCount":101},[],{"intervention":2649,"totalTrials":136,"cells":4138},{"EARLY_PHASE1":4139,"PHASE1":4141,"PHASE2":4143,"PHASE3":4153,"PHASE4":4155,"NA":4157},{"trials":4140,"activeCount":101},[],{"trials":4142,"activeCount":101},[],{"trials":4144,"activeCount":136,"soonestReadout":75},[4145,4149],{"nctId":2639,"briefTitle":2640,"status":160,"phases":4146,"primaryCompletion":2642,"completion":2643,"start":2644,"enrollment":366,"conditions":4147,"interventions":4148},[90],[2646,2647,2030],[2649,2650,2614,2599],{"nctId":73,"briefTitle":74,"status":189,"phases":4150,"primaryCompletion":75,"completion":2669,"start":2670,"enrollment":366,"conditions":4151,"interventions":4152},[90],[2030],[76,2649,127,2599],{"trials":4154,"activeCount":101},[],{"trials":4156,"activeCount":101},[],{"trials":4158,"activeCount":101},[],{"intervention":3401,"totalTrials":136,"cells":4160},{"EARLY_PHASE1":4161,"PHASE1":4163,"PHASE2":4165,"PHASE3":4175,"PHASE4":4177,"NA":4179},{"trials":4162,"activeCount":101},[],{"trials":4164,"activeCount":101},[],{"trials":4166,"activeCount":136,"soonestReadout":3396},[4167,4171],{"nctId":3393,"briefTitle":3394,"status":160,"phases":4168,"primaryCompletion":3396,"completion":3397,"start":3398,"enrollment":251,"conditions":4169,"interventions":4170},[90],[123,124],[3360,3401,3402],{"nctId":4122,"briefTitle":4123,"status":160,"phases":4172,"primaryCompletion":3396,"completion":4125,"start":4126,"enrollment":251,"conditions":4173,"interventions":4174},[90],[123,4128],[169,4130,3401],{"trials":4176,"activeCount":101},[],{"trials":4178,"activeCount":101},[],{"trials":4180,"activeCount":101},[],{"intervention":2551,"totalTrials":136,"cells":4182},{"EARLY_PHASE1":4183,"PHASE1":4185,"PHASE2":4187,"PHASE3":4197,"PHASE4":4199,"NA":4201},{"trials":4184,"activeCount":101},[],{"trials":4186,"activeCount":101},[],{"trials":4188,"activeCount":136,"soonestReadout":1288},[4189,4193],{"nctId":3975,"briefTitle":3976,"status":189,"phases":4190,"primaryCompletion":1288,"completion":1242,"start":3978,"enrollment":872,"conditions":4191,"interventions":4192},[89,90],[21],[3958,2551],{"nctId":2540,"briefTitle":2541,"status":160,"phases":4194,"primaryCompletion":349,"completion":2543,"start":2544,"enrollment":1245,"conditions":4195,"interventions":4196},[90],[2546,2473,2547,2548,2549],[2551,57],{"trials":4198,"activeCount":101},[],{"trials":4200,"activeCount":101},[],{"trials":4202,"activeCount":101},[],{"intervention":2565,"totalTrials":136,"cells":4204},{"EARLY_PHASE1":4205,"PHASE1":4207,"PHASE2":4220,"PHASE3":4226,"PHASE4":4228,"NA":4230},{"trials":4206,"activeCount":101},[],{"trials":4208,"activeCount":331,"soonestReadout":4213},[4209],{"nctId":4210,"briefTitle":4211,"status":189,"phases":4212,"primaryCompletion":4213,"completion":837,"start":2632,"enrollment":4214,"conditions":4215,"interventions":4216},"NCT03959891","AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4\u002F6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)",[89],"2022-12-25",77,[21],[4217,4218,4219,2565],"Ipatasertib","Fulvestrant","Aromatase Inhibitor",{"trials":4221,"activeCount":331,"soonestReadout":2556},[4222],{"nctId":2553,"briefTitle":2554,"status":160,"phases":4223,"primaryCompletion":2556,"completion":2557,"start":2558,"enrollment":2559,"conditions":4224,"interventions":4225},[90],[2561,2562,2563],[2565,57],{"trials":4227,"activeCount":101},[],{"trials":4229,"activeCount":101},[],{"trials":4231,"activeCount":101},[],{"intervention":3675,"totalTrials":136,"cells":4233},{"EARLY_PHASE1":4234,"PHASE1":4236,"PHASE2":4238,"PHASE3":4254,"PHASE4":4256,"NA":4258},{"trials":4235,"activeCount":101},[],{"trials":4237,"activeCount":101},[],{"trials":4239,"activeCount":136,"soonestReadout":162},[4240,4244],{"nctId":3663,"briefTitle":3664,"status":318,"phases":4241,"primaryCompletion":3396,"completion":3397,"start":3666,"enrollment":829,"conditions":4242,"interventions":4243},[90],[3668,3669,3670,3671,3672,3673],[3675,3520,2721],{"nctId":4245,"briefTitle":4246,"status":160,"phases":4247,"primaryCompletion":162,"completion":939,"start":4248,"enrollment":251,"conditions":4249,"interventions":4253},"NCT07070466","Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA",[90],"2025-10-10",[4250,4251,4252],"Stomach Cancer Stage IV","Esophagus Cancer","Stomach Cancer",[3675,3449,3626,3627],{"trials":4255,"activeCount":101},[],{"trials":4257,"activeCount":101},[],{"trials":4259,"activeCount":101},[],{"intervention":4261,"totalTrials":798,"cells":4262},"Hydroxychloroquine",{"EARLY_PHASE1":4263,"PHASE1":4265,"PHASE2":4277,"PHASE3":4294,"PHASE4":4308,"NA":4310},{"trials":4264,"activeCount":101},[],{"trials":4266,"activeCount":101},[4267],{"nctId":4268,"briefTitle":4269,"status":173,"phases":4270,"primaryCompletion":4271,"completion":4271,"start":4272,"enrollment":457,"conditions":4273,"interventions":4274},"NCT01026844","Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)",[89],"2012-11","2007-07",[3682],[4275,4276],"erlotinib","hydroxychloroquine",{"trials":4278,"activeCount":331,"soonestReadout":41},[4279,4284],{"nctId":39,"briefTitle":40,"status":189,"phases":4280,"primaryCompletion":41,"completion":1243,"start":4281,"enrollment":437,"conditions":4282,"interventions":4283},[90],"2009-10",[3682],[42,4261],{"nctId":4285,"briefTitle":4286,"status":2758,"phases":4287,"primaryCompletion":4288,"completion":4289,"start":4290,"enrollment":366,"conditions":4291,"interventions":4292},"NCT01494155","Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer",[90],"2022-01","2023-01","2011-12",[2748],[4293,4261],"Capecitabine",{"trials":4295,"activeCount":101},[4296],{"nctId":4297,"briefTitle":4298,"status":117,"phases":4299,"primaryCompletion":4300,"completion":2946,"start":4301,"enrollment":4302,"conditions":4303,"interventions":4307},"NCT04332991","Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease",[91],"2020-06-19","2020-04-02",479,[4304,4305,4306],"Coronavirus","Acute Respiratory Infection","SARS-CoV Infection",[4261],{"trials":4309,"activeCount":101},[],{"trials":4311,"activeCount":101},[],{"intervention":2807,"totalTrials":1509,"cells":4313},{"EARLY_PHASE1":4314,"PHASE1":4316,"PHASE2":4373,"PHASE3":4402,"PHASE4":4404,"NA":4406},{"trials":4315,"activeCount":101},[],{"trials":4317,"activeCount":101},[4318,4322,4326,4330,4339,4347,4357,4365],{"nctId":2797,"briefTitle":2798,"status":117,"phases":4319,"primaryCompletion":1861,"completion":2800,"start":2801,"enrollment":33,"conditions":4320,"interventions":4321},[89],[2803],[127,2805,2806,2807],{"nctId":3777,"briefTitle":3778,"status":117,"phases":4323,"primaryCompletion":2581,"completion":2408,"start":567,"enrollment":2837,"conditions":4324,"interventions":4325},[89],[3781,3782,3783,3784],[3786,3787,2807,3770,3788,201,3789],{"nctId":2809,"briefTitle":2810,"status":173,"phases":4327,"primaryCompletion":268,"completion":268,"start":225,"enrollment":1890,"conditions":4328,"interventions":4329},[89],[2813,2814,2803,2815,2816],[127,2818,2807],{"nctId":4331,"briefTitle":4332,"status":117,"phases":4333,"primaryCompletion":4334,"completion":4335,"start":1876,"enrollment":2859,"conditions":4336,"interventions":4337},"NCT01830777","Brentuximab Vedotin + Re-induction Chemotherapy for AML",[89],"2018-04","2019-05",[2803],[4338,2805,2806,2807],"Brentuximab Vedotin",{"nctId":4340,"briefTitle":4341,"status":117,"phases":4342,"primaryCompletion":3741,"start":4343,"enrollment":33,"conditions":4344,"interventions":4345},"NCT00505700","VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia",[89],"2003-07",[916],[4346,3388,2807],"velcade",{"nctId":4348,"briefTitle":4349,"status":117,"phases":4350,"primaryCompletion":4351,"completion":4351,"start":4352,"enrollment":4353,"conditions":4354,"interventions":4355},"NCT02582359","MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age",[89],"2022-04","2016-01",39,[2862],[4356,2807,3389],"MLN9708",{"nctId":4358,"briefTitle":4359,"status":117,"phases":4360,"primaryCompletion":1869,"completion":4361,"start":626,"enrollment":2859,"conditions":4362,"interventions":4363},"NCT01779843","Alisertib for Acute Myeloid Leukemia",[89],"2016-11",[2803],[2807,3388,4364],"Alisertib",{"nctId":4366,"briefTitle":4367,"status":107,"phases":4368,"primaryCompletion":1780,"completion":1780,"start":4369,"enrollment":101,"conditions":4370,"interventions":4371},"NCT02905994","Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia",[89],"2016-09",[2884],[4372,2807,3388],"Volasertib",{"trials":4374,"activeCount":331,"soonestReadout":3014},[4375,4383,4387,4394,4398],{"nctId":4376,"briefTitle":4377,"status":117,"phases":4378,"primaryCompletion":4379,"completion":4380,"start":2800,"enrollment":3565,"conditions":4381,"interventions":4382},"NCT02560025","Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML",[90],"2017-10","2018-12",[2862],[4364,2807,3388,3389],{"nctId":2876,"briefTitle":2877,"status":117,"phases":4384,"primaryCompletion":2879,"completion":2880,"start":2881,"enrollment":2882,"conditions":4385,"interventions":4386},[90],[2884],[2806,2807,127,2805],{"nctId":4388,"briefTitle":4389,"status":107,"phases":4390,"primaryCompletion":224,"completion":224,"start":224,"enrollment":101,"conditions":4391,"interventions":4392},"NCT01843179","Sulindac for Patients With AML",[90],[2862],[2807,4393],"Sulindac",{"nctId":3381,"briefTitle":3382,"status":189,"phases":4395,"primaryCompletion":3014,"completion":2706,"start":3384,"enrollment":3385,"conditions":4396,"interventions":4397},[90],[2862],[2807,3388,3389,3390,3360,3391],{"nctId":3821,"briefTitle":3822,"status":117,"phases":4399,"primaryCompletion":567,"completion":1877,"start":3607,"enrollment":227,"conditions":4400,"interventions":4401},[90],[3781],[3576,3787,3770,3826,2807,3789,3827,3828,3829],{"trials":4403,"activeCount":101},[],{"trials":4405,"activeCount":101},[],{"trials":4407,"activeCount":101},[],{"intervention":3626,"totalTrials":270,"cells":4409},{"EARLY_PHASE1":4410,"PHASE1":4412,"PHASE2":4418,"PHASE3":4468,"PHASE4":4470,"NA":4472},{"trials":4411,"activeCount":101},[],{"trials":4413,"activeCount":101},[4414],{"nctId":3616,"briefTitle":3617,"status":117,"phases":4415,"primaryCompletion":3619,"completion":3620,"start":3621,"enrollment":1847,"conditions":4416,"interventions":4417},[89],[3623],[3625,3626,3627,3449,3165,2720],{"trials":4419,"activeCount":331,"soonestReadout":162},[4420,4429,4437,4446,4455,4459],{"nctId":4421,"briefTitle":4422,"status":117,"phases":4423,"primaryCompletion":4272,"completion":4424,"start":4425,"enrollment":1890,"conditions":4426,"interventions":4428},"NCT00142480","Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer",[90],"2011-04","2004-12",[2730,4427],"Gallbladder Adenocarcinoma",[4293,3626,47],{"nctId":4430,"briefTitle":4431,"status":117,"phases":4432,"primaryCompletion":3148,"completion":2417,"start":456,"enrollment":251,"conditions":4433,"interventions":4435},"NCT01775501","Sorafenib + mFOLFOX for Hepatocellular Carcinoma",[90],[4434],"Hepatocellular Cancer",[3627,3496,3626,4436],"Sorafenib",{"nctId":4438,"briefTitle":4439,"status":117,"phases":4440,"primaryCompletion":4441,"completion":4442,"start":3689,"enrollment":4443,"conditions":4444,"interventions":4445},"NCT00361231","Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer",[90],"2009-03","2012-08",35,[2730,4427],[47,3536,3626],{"nctId":4447,"briefTitle":4448,"status":173,"phases":4449,"primaryCompletion":4450,"completion":250,"start":3689,"enrollment":2663,"conditions":4451,"interventions":4453},"NCT00307723","Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer",[89,90],"2007-08",[2748,4452],"Pancreatic Ductal Adenocarcinoma",[3476,3449,3626,4454],"gemcitabine",{"nctId":4245,"briefTitle":4246,"status":160,"phases":4456,"primaryCompletion":162,"completion":939,"start":4248,"enrollment":251,"conditions":4457,"interventions":4458},[90],[4250,4251,4252],[3675,3449,3626,3627],{"nctId":4460,"briefTitle":4461,"status":117,"phases":4462,"primaryCompletion":4463,"completion":4464,"start":4465,"enrollment":2610,"conditions":4466,"interventions":4467},"NCT00142467","Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma",[90],"2006-08","2011-06","2004-04",[4031],[3536,3626,47],{"trials":4469,"activeCount":101},[],{"trials":4471,"activeCount":101},[],{"trials":4473,"activeCount":101},[],{"intervention":200,"totalTrials":270,"cells":4475},{"EARLY_PHASE1":4476,"PHASE1":4478,"PHASE2":4484,"PHASE3":4542,"PHASE4":4544,"NA":4546},{"trials":4477,"activeCount":101},[],{"trials":4479,"activeCount":101},[4480],{"nctId":908,"briefTitle":909,"status":117,"phases":4481,"primaryCompletion":911,"completion":911,"start":912,"enrollment":829,"conditions":4482,"interventions":4483},[89],[914,915,916,211,917,918,919],[921,922,923,924,925,926,927,928,243,901],{"trials":4485,"activeCount":331,"soonestReadout":191},[4486,4495,4505,4519,4523,4538],{"nctId":4487,"briefTitle":4488,"status":107,"phases":4489,"primaryCompletion":2417,"completion":4490,"start":4491,"enrollment":101,"conditions":4492,"interventions":4493},"NCT02724904","Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma",[89,90],"2021-12","2017-05",[211],[200,4494,3789],"Thiotepa",{"nctId":4496,"briefTitle":4497,"status":117,"phases":4498,"primaryCompletion":2418,"completion":2418,"start":4290,"enrollment":2610,"conditions":4499,"interventions":4502},"NCT01408563","Reduced Intensity Double Umbilical Cord Blood Transplantation",[90],[4500,4501,2030,123,2803],"Non-Hodgkin's Lymphoma","Hodgkin's Lymphoma",[200,4503,4504],"Melphalan","Cord Blood",{"nctId":4506,"briefTitle":4507,"status":117,"phases":4508,"primaryCompletion":175,"completion":149,"start":2456,"enrollment":648,"conditions":4509,"interventions":4513},"NCT00133367","Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus",[90],[2030,4500,4510,4511,4512],"Hodgkin's Disease","Myelogenous Leukemia","Lymphoblastic Leukemia",[4514,4515,4516,4517,4518,200,4503],"Tacrolimus","Sirolimus","G-CSF","Antithymocyte globulin","Thymoglobulin",{"nctId":187,"briefTitle":188,"status":189,"phases":4520,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":4521,"interventions":4522},[89,90],[196,197,198],[200,201,96,202],{"nctId":4524,"briefTitle":4525,"status":117,"phases":4526,"primaryCompletion":4527,"completion":554,"start":751,"enrollment":3565,"conditions":4528,"interventions":4534},"NCT01181271","Tandem Auto-Allo Transplant for Lymphoma",[90],"2014-02",[4529,4530,4531,4532,4501,123,4533],"Diffuse, Large B-Cell, Lymphoma","Lymphoma, Low-Grade","T-Cell Lymphoma","Mantle-Cell Lymphoma","Lymphoma, Small Lymphocytic",[4535,2806,201,4536,4537,200,4535,4514,4515,3789],"Busulfan","Mesna","Neupogen",{"nctId":235,"briefTitle":236,"status":173,"phases":4539,"primaryCompletion":225,"completion":225,"start":238,"enrollment":239,"conditions":4540,"interventions":4541},[90],[123,124],[242,96,243],{"trials":4543,"activeCount":101},[],{"trials":4545,"activeCount":101},[],{"trials":4547,"activeCount":101},[],{"intervention":3449,"totalTrials":544,"cells":4549},{"EARLY_PHASE1":4550,"PHASE1":4561,"PHASE2":4571,"PHASE3":4590,"PHASE4":4592,"NA":4594},{"trials":4551,"activeCount":101},[4552],{"nctId":4553,"briefTitle":4554,"status":117,"phases":4555,"primaryCompletion":3644,"completion":2407,"start":477,"enrollment":1847,"conditions":4556,"interventions":4558},"NCT01858025","Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma",[88],[4557],"Carcinoma of the Anal Canal",[4559,4560],"5-fluorouracil","Mitomycin-C",{"trials":4562,"activeCount":101},[4563,4567],{"nctId":3442,"briefTitle":3443,"status":117,"phases":4564,"primaryCompletion":248,"completion":2447,"start":578,"enrollment":36,"conditions":4565,"interventions":4566},[89],[3446],[3448,2720,3165,3449,3450,2576],{"nctId":3616,"briefTitle":3617,"status":117,"phases":4568,"primaryCompletion":3619,"completion":3620,"start":3621,"enrollment":1847,"conditions":4569,"interventions":4570},[89],[3623],[3625,3626,3627,3449,3165,2720],{"trials":4572,"activeCount":331,"soonestReadout":162},[4573,4577,4586],{"nctId":4447,"briefTitle":4448,"status":173,"phases":4574,"primaryCompletion":4450,"completion":250,"start":3689,"enrollment":2663,"conditions":4575,"interventions":4576},[89,90],[2748,4452],[3476,3449,3626,4454],{"nctId":4578,"briefTitle":4579,"status":117,"phases":4580,"primaryCompletion":4581,"completion":176,"start":3689,"enrollment":648,"conditions":4582,"interventions":4585},"NCT00307736","Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer",[89,90],"2010-04",[4583,4584],"Rectal Cancer","Adenocarcinoma of the Rectum",[4559,3476,4275],{"nctId":4245,"briefTitle":4246,"status":160,"phases":4587,"primaryCompletion":162,"completion":939,"start":4248,"enrollment":251,"conditions":4588,"interventions":4589},[90],[4250,4251,4252],[3675,3449,3626,3627],{"trials":4591,"activeCount":101},[],{"trials":4593,"activeCount":101},[],{"trials":4595,"activeCount":101},[],{"intervention":277,"totalTrials":544,"cells":4597},{"EARLY_PHASE1":4598,"PHASE1":4600,"PHASE2":4622,"PHASE3":4636,"PHASE4":4638,"NA":4640},{"trials":4599,"activeCount":101},[],{"trials":4601,"activeCount":101},[4602,4609,4613],{"nctId":4603,"briefTitle":4604,"status":173,"phases":4605,"completion":4606,"start":3659,"enrollment":555,"conditions":4607,"interventions":4608},"NCT00271804","Study of Velcade and Thalidomide in Patients With Myelodysplasia",[89],"2007-04",[2861],[277],{"nctId":2824,"briefTitle":2825,"status":117,"phases":4610,"primaryCompletion":2827,"completion":2827,"start":175,"enrollment":753,"conditions":4611,"interventions":4612},[89],[2829],[2657,2657,2657,127],{"nctId":4614,"briefTitle":4615,"status":117,"phases":4616,"primaryCompletion":4617,"completion":298,"start":628,"enrollment":4618,"conditions":4619,"interventions":4620},"NCT01078961","An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma",[89],"2013-02",11,[3901],[277,4621],"sorafenib",{"trials":4623,"activeCount":331,"soonestReadout":1242},[4624,4628,4632],{"nctId":2652,"briefTitle":2653,"status":117,"phases":4625,"primaryCompletion":268,"completion":119,"start":284,"enrollment":366,"conditions":4626,"interventions":4627},[90],[2030],[127,2657,2599],{"nctId":2659,"briefTitle":2660,"status":189,"phases":4629,"primaryCompletion":1242,"completion":1243,"start":2662,"enrollment":2663,"conditions":4630,"interventions":4631},[90],[2030],[2666,2614,2657,2599],{"nctId":265,"briefTitle":266,"status":117,"phases":4633,"primaryCompletion":268,"completion":269,"start":149,"enrollment":270,"conditions":4634,"interventions":4635},[90],[272,273,274,275],[277,156],{"trials":4637,"activeCount":101},[],{"trials":4639,"activeCount":101},[],{"trials":4641,"activeCount":101},[],{"intervention":42,"totalTrials":544,"cells":4643},{"EARLY_PHASE1":4644,"PHASE1":4646,"PHASE2":4652,"PHASE3":4685,"PHASE4":4687,"NA":4689},{"trials":4645,"activeCount":101},[],{"trials":4647,"activeCount":101},[4648],{"nctId":4268,"briefTitle":4269,"status":173,"phases":4649,"primaryCompletion":4271,"completion":4271,"start":4272,"enrollment":457,"conditions":4650,"interventions":4651},[89],[3682],[4275,4276],{"trials":4653,"activeCount":331,"soonestReadout":41},[4654,4662,4669,4673,4681],{"nctId":4655,"briefTitle":4656,"status":117,"phases":4657,"primaryCompletion":4658,"completion":176,"start":4463,"enrollment":648,"conditions":4659,"interventions":4661},"NCT00366457","Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer",[90],"2008-08",[2748,4660],"Adenocarcinoma of the Pancreas",[47,42,3536],{"nctId":4663,"briefTitle":4664,"status":117,"phases":4665,"primaryCompletion":119,"completion":119,"start":4666,"enrollment":16,"conditions":4667,"interventions":4668},"NCT00567359","Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR",[90],"2007-12",[3682],[42],{"nctId":39,"briefTitle":40,"status":189,"phases":4670,"primaryCompletion":41,"completion":1243,"start":4281,"enrollment":437,"conditions":4671,"interventions":4672},[90],[3682],[42,4261],{"nctId":4674,"briefTitle":4675,"status":173,"phases":4676,"primaryCompletion":4442,"completion":4677,"start":3492,"enrollment":33,"conditions":4678,"interventions":4680},"NCT00392665","Bevacizumab\u002FTarceva and Tarceva\u002FSulindac in Squamous Cell Carcinoma of the Head and Neck",[90],"2013-12",[4679],"Squamous Cell Carcinoma of the Head and Neck (SCCHN)",[47,4275,4393],{"nctId":4578,"briefTitle":4579,"status":117,"phases":4682,"primaryCompletion":4581,"completion":176,"start":3689,"enrollment":648,"conditions":4683,"interventions":4684},[89,90],[4583,4584],[4559,3476,4275],{"trials":4686,"activeCount":101},[],{"trials":4688,"activeCount":101},[],{"trials":4690,"activeCount":101},[],{"intervention":3388,"totalTrials":693,"cells":4692},{"EARLY_PHASE1":4693,"PHASE1":4695,"PHASE2":4709,"PHASE3":4719,"PHASE4":4721,"NA":4723},{"trials":4694,"activeCount":101},[],{"trials":4696,"activeCount":101},[4697,4701,4705],{"nctId":4340,"briefTitle":4341,"status":117,"phases":4698,"primaryCompletion":3741,"start":4343,"enrollment":33,"conditions":4699,"interventions":4700},[89],[916],[4346,3388,2807],{"nctId":4358,"briefTitle":4359,"status":117,"phases":4702,"primaryCompletion":1869,"completion":4361,"start":626,"enrollment":2859,"conditions":4703,"interventions":4704},[89],[2803],[2807,3388,4364],{"nctId":4366,"briefTitle":4367,"status":107,"phases":4706,"primaryCompletion":1780,"completion":1780,"start":4369,"enrollment":101,"conditions":4707,"interventions":4708},[89],[2884],[4372,2807,3388],{"trials":4710,"activeCount":331,"soonestReadout":3014},[4711,4715],{"nctId":4376,"briefTitle":4377,"status":117,"phases":4712,"primaryCompletion":4379,"completion":4380,"start":2800,"enrollment":3565,"conditions":4713,"interventions":4714},[90],[2862],[4364,2807,3388,3389],{"nctId":3381,"briefTitle":3382,"status":189,"phases":4716,"primaryCompletion":3014,"completion":2706,"start":3384,"enrollment":3385,"conditions":4717,"interventions":4718},[90],[2862],[2807,3388,3389,3390,3360,3391],{"trials":4720,"activeCount":101},[],{"trials":4722,"activeCount":101},[],{"trials":4724,"activeCount":101},[],{"intervention":201,"totalTrials":693,"cells":4726},{"EARLY_PHASE1":4727,"PHASE1":4729,"PHASE2":4739,"PHASE3":4753,"PHASE4":4755,"NA":4757},{"trials":4728,"activeCount":101},[],{"trials":4730,"activeCount":101},[4731,4735],{"nctId":3777,"briefTitle":3778,"status":117,"phases":4732,"primaryCompletion":2581,"completion":2408,"start":567,"enrollment":2837,"conditions":4733,"interventions":4734},[89],[3781,3782,3783,3784],[3786,3787,2807,3770,3788,201,3789],{"nctId":908,"briefTitle":909,"status":117,"phases":4736,"primaryCompletion":911,"completion":911,"start":912,"enrollment":829,"conditions":4737,"interventions":4738},[89],[914,915,916,211,917,918,919],[921,922,923,924,925,926,927,928,243,901],{"trials":4740,"activeCount":331,"soonestReadout":191},[4741,4745,4749],{"nctId":187,"briefTitle":188,"status":189,"phases":4742,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":4743,"interventions":4744},[89,90],[196,197,198],[200,201,96,202],{"nctId":4524,"briefTitle":4525,"status":117,"phases":4746,"primaryCompletion":4527,"completion":554,"start":751,"enrollment":3565,"conditions":4747,"interventions":4748},[90],[4529,4530,4531,4532,4501,123,4533],[4535,2806,201,4536,4537,200,4535,4514,4515,3789],{"nctId":3470,"briefTitle":3471,"status":117,"phases":4750,"primaryCompletion":2994,"completion":283,"start":109,"enrollment":22,"conditions":4751,"interventions":4752},[90],[21],[3475,3476,3477,922,3478],{"trials":4754,"activeCount":101},[],{"trials":4756,"activeCount":101},[],{"trials":4758,"activeCount":101},[],{"intervention":66,"totalTrials":798,"cells":4760},{"EARLY_PHASE1":4761,"PHASE1":4763,"PHASE2":4765,"PHASE3":4792,"PHASE4":4794,"NA":4796},{"trials":4762,"activeCount":101},[],{"trials":4764,"activeCount":101},[],{"trials":4766,"activeCount":331,"soonestReadout":65},[4767,4775,4779,4783],{"nctId":4768,"briefTitle":4769,"status":2758,"phases":4770,"primaryCompletion":4771,"completion":4288,"start":2609,"enrollment":4772,"conditions":4773,"interventions":4774},"NCT01591733","FOLFIRINOX + RT for Pancreatic Cancer",[90],"2017-03",48,[2748],[66,4293],{"nctId":3145,"briefTitle":3146,"status":2758,"phases":4776,"primaryCompletion":3148,"completion":3149,"start":477,"enrollment":366,"conditions":4777,"interventions":4778},[90],[2748],[66,2750],{"nctId":63,"briefTitle":64,"status":189,"phases":4780,"primaryCompletion":65,"completion":2744,"start":2745,"enrollment":2746,"conditions":4781,"interventions":4782},[90],[2748],[66,2750,81],{"nctId":4784,"briefTitle":4785,"status":173,"phases":4786,"primaryCompletion":298,"completion":298,"start":1897,"enrollment":270,"conditions":4787,"interventions":4790},"NCT02243007","Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine\u002FNab-Paclitaxel in Patients With Resectable Pancreatic Cancer",[90],[4788,4789],"Resectable Pancreatic Cancer","Pancreatic Ductal Carcinoma",[66,4791,4293],"Gemcitabine\u002Fnab-Paclitaxel",{"trials":4793,"activeCount":101},[],{"trials":4795,"activeCount":101},[],{"trials":4797,"activeCount":101},[],{"intervention":3389,"totalTrials":178,"cells":4799},{"EARLY_PHASE1":4800,"PHASE1":4802,"PHASE2":4808,"PHASE3":4818,"PHASE4":4820,"NA":4822},{"trials":4801,"activeCount":101},[],{"trials":4803,"activeCount":101},[4804],{"nctId":4348,"briefTitle":4349,"status":117,"phases":4805,"primaryCompletion":4351,"completion":4351,"start":4352,"enrollment":4353,"conditions":4806,"interventions":4807},[89],[2862],[4356,2807,3389],{"trials":4809,"activeCount":331,"soonestReadout":3014},[4810,4814],{"nctId":4376,"briefTitle":4377,"status":117,"phases":4811,"primaryCompletion":4379,"completion":4380,"start":2800,"enrollment":3565,"conditions":4812,"interventions":4813},[90],[2862],[4364,2807,3388,3389],{"nctId":3381,"briefTitle":3382,"status":189,"phases":4815,"primaryCompletion":3014,"completion":2706,"start":3384,"enrollment":3385,"conditions":4816,"interventions":4817},[90],[2862],[2807,3388,3389,3390,3360,3391],{"trials":4819,"activeCount":101},[],{"trials":4821,"activeCount":101},[],{"trials":4823,"activeCount":101},[],{"intervention":3627,"totalTrials":178,"cells":4825},{"EARLY_PHASE1":4826,"PHASE1":4828,"PHASE2":4834,"PHASE3":4844,"PHASE4":4846,"NA":4848},{"trials":4827,"activeCount":101},[],{"trials":4829,"activeCount":101},[4830],{"nctId":3616,"briefTitle":3617,"status":117,"phases":4831,"primaryCompletion":3619,"completion":3620,"start":3621,"enrollment":1847,"conditions":4832,"interventions":4833},[89],[3623],[3625,3626,3627,3449,3165,2720],{"trials":4835,"activeCount":331,"soonestReadout":162},[4836,4840],{"nctId":4430,"briefTitle":4431,"status":117,"phases":4837,"primaryCompletion":3148,"completion":2417,"start":456,"enrollment":251,"conditions":4838,"interventions":4839},[90],[4434],[3627,3496,3626,4436],{"nctId":4245,"briefTitle":4246,"status":160,"phases":4841,"primaryCompletion":162,"completion":939,"start":4248,"enrollment":251,"conditions":4842,"interventions":4843},[90],[4250,4251,4252],[3675,3449,3626,3627],{"trials":4845,"activeCount":101},[],{"trials":4847,"activeCount":101},[],{"trials":4849,"activeCount":101},[],{"intervention":4851,"totalTrials":178,"cells":4852},"Oxytocin nasal spray",{"EARLY_PHASE1":4853,"PHASE1":4863,"PHASE2":4865,"PHASE3":4887,"PHASE4":4889,"NA":4891},{"trials":4854,"activeCount":101},[4855],{"nctId":4856,"briefTitle":4857,"status":117,"phases":4858,"primaryCompletion":4859,"completion":4859,"start":4860,"enrollment":886,"conditions":4861,"interventions":4862},"NCT03136263","Oxytocin and Cognitive Control in Adult ADHD",[88],"2020-11-05","2017-12-14",[1938],[4851],{"trials":4864,"activeCount":101},[],{"trials":4866,"activeCount":331,"soonestReadout":2200},[4867,4878],{"nctId":4868,"briefTitle":4869,"status":117,"phases":4870,"primaryCompletion":4871,"completion":4872,"start":4873,"enrollment":4874,"conditions":4875,"interventions":4876},"NCT03043053","The Effects of Oxytocin in Obese Adults",[90],"2022-05-20","2022-07-07","2017-07-01",61,[26],[4877],"oxytocin nasal spray",{"nctId":4879,"briefTitle":4880,"status":160,"phases":4881,"primaryCompletion":2200,"completion":3985,"start":4882,"enrollment":872,"conditions":4883,"interventions":4886},"NCT04551482","Oxytocin for Weight Loss in Adolescents",[90],"2021-07-28",[4884,4885],"Obesity, Adolescent","Oxytocin",[4851],{"trials":4888,"activeCount":101},[],{"trials":4890,"activeCount":101},[],{"trials":4892,"activeCount":101},[],{"intervention":3450,"totalTrials":136,"cells":4894},{"EARLY_PHASE1":4895,"PHASE1":4897,"PHASE2":4903,"PHASE3":4909,"PHASE4":4911,"NA":4913},{"trials":4896,"activeCount":101},[],{"trials":4898,"activeCount":101},[4899],{"nctId":3442,"briefTitle":3443,"status":117,"phases":4900,"primaryCompletion":248,"completion":2447,"start":578,"enrollment":36,"conditions":4901,"interventions":4902},[89],[3446],[3448,2720,3165,3449,3450,2576],{"trials":4904,"activeCount":331,"soonestReadout":1146},[4905],{"nctId":3502,"briefTitle":3503,"status":318,"phases":4906,"primaryCompletion":1146,"completion":3505,"start":3506,"enrollment":151,"conditions":4907,"interventions":4908},[90],[3508,3509,2527],[3511,2576,3450],{"trials":4910,"activeCount":101},[],{"trials":4912,"activeCount":101},[],{"trials":4914,"activeCount":101},[],{"intervention":128,"totalTrials":136,"cells":4916},{"EARLY_PHASE1":4917,"PHASE1":4919,"PHASE2":4925,"PHASE3":4931,"PHASE4":4933,"NA":4935},{"trials":4918,"activeCount":101},[],{"trials":4920,"activeCount":101},[4921],{"nctId":115,"briefTitle":116,"status":117,"phases":4922,"primaryCompletion":119,"completion":120,"start":121,"enrollment":36,"conditions":4923,"interventions":4924},[89],[123,124,125],[127,128,96],{"trials":4926,"activeCount":331,"soonestReadout":162},[4927],{"nctId":158,"briefTitle":159,"status":160,"phases":4928,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":4929,"interventions":4930},[90],[167],[169,128,96],{"trials":4932,"activeCount":101},[],{"trials":4934,"activeCount":101},[],{"trials":4936,"activeCount":101},[],{"intervention":4938,"totalTrials":136,"cells":4939},"Alectinib",{"EARLY_PHASE1":4940,"PHASE1":4942,"PHASE2":4944,"PHASE3":4962,"PHASE4":4964,"NA":4966},{"trials":4941,"activeCount":101},[],{"trials":4943,"activeCount":101},[],{"trials":4945,"activeCount":331,"soonestReadout":3024},[4946,4954],{"nctId":4947,"briefTitle":4948,"status":189,"phases":4949,"primaryCompletion":3024,"completion":4950,"start":1825,"enrollment":1805,"conditions":4951,"interventions":4952},"NCT03202940","A Phase IB\u002FII Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC",[89,90],"2031-01-01",[3682],[4938,4953],"Cobimetinib",{"nctId":4955,"briefTitle":4956,"status":173,"phases":4957,"primaryCompletion":4351,"completion":4351,"start":4958,"enrollment":4618,"conditions":4959,"interventions":4961},"NCT02521051","Phase I\u002FII Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer",[89,90],"2015-09-28",[4960],"Non-Small Cell Lung Cancer (NSCLC)",[4938,47],{"trials":4963,"activeCount":101},[],{"trials":4965,"activeCount":101},[],{"trials":4967,"activeCount":101},[],{"intervention":76,"totalTrials":136,"cells":4969},{"EARLY_PHASE1":4970,"PHASE1":4972,"PHASE2":4984,"PHASE3":4990,"PHASE4":4992,"NA":4994},{"trials":4971,"activeCount":101},[],{"trials":4973,"activeCount":101},[4974],{"nctId":4975,"briefTitle":4976,"status":117,"phases":4977,"primaryCompletion":4771,"completion":120,"start":3531,"enrollment":2837,"conditions":4978,"interventions":4982},"NCT02142530","Carfilzomib Plus Belinostat in Relapsed\u002FRefractory NHL",[89],[4979,153,4980,212,4981],"Non-Hodgkin Lymphoma","Mantle Cell Lymphoma","Peripheral T-cell Lymphoma",[76,4983],"Belinostat",{"trials":4985,"activeCount":331,"soonestReadout":75},[4986],{"nctId":73,"briefTitle":74,"status":189,"phases":4987,"primaryCompletion":75,"completion":2669,"start":2670,"enrollment":366,"conditions":4988,"interventions":4989},[90],[2030],[76,2649,127,2599],{"trials":4991,"activeCount":101},[],{"trials":4993,"activeCount":101},[],{"trials":4995,"activeCount":101},[],{"intervention":4013,"totalTrials":136,"cells":4997},{"EARLY_PHASE1":4998,"PHASE1":5000,"PHASE2":5006,"PHASE3":5012,"PHASE4":5014,"NA":5016},{"trials":4999,"activeCount":101},[],{"trials":5001,"activeCount":101},[5002],{"nctId":4004,"briefTitle":4005,"status":117,"phases":5003,"primaryCompletion":4007,"completion":4007,"start":4008,"enrollment":1509,"conditions":5004,"interventions":5005},[89],[2527],[4011,3997,4012,4013],{"trials":5007,"activeCount":331,"soonestReadout":4028},[5008],{"nctId":4025,"briefTitle":4026,"status":189,"phases":5009,"primaryCompletion":4028,"completion":1577,"start":4029,"enrollment":413,"conditions":5010,"interventions":5011},[90],[4031,2730],[4013,3997],{"trials":5013,"activeCount":101},[],{"trials":5015,"activeCount":101},[],{"trials":5017,"activeCount":101},[],{"intervention":5019,"totalTrials":136,"cells":5020},"Larazotide Acetate",{"EARLY_PHASE1":5021,"PHASE1":5023,"PHASE2":5025,"PHASE3":5050,"PHASE4":5052,"NA":5054},{"trials":5022,"activeCount":101},[],{"trials":5024,"activeCount":101},[],{"trials":5026,"activeCount":331,"soonestReadout":5040},[5027,5036],{"nctId":5028,"briefTitle":5029,"status":173,"phases":5030,"primaryCompletion":5031,"completion":5031,"start":5032,"enrollment":1791,"conditions":5033,"interventions":5035},"NCT05022303","AT1001 for the Treatment of COVID-19 Related MIS-C",[90],"2024-05-15","2021-10-01",[3056,5034],"Multisystem Inflammatory Syndrome in Children",[5019],{"nctId":5037,"briefTitle":5038,"status":189,"phases":5039,"primaryCompletion":5040,"completion":5041,"start":5042,"enrollment":5043,"conditions":5044,"interventions":5049},"NCT05747534","AT1001 for the Treatment of Long COVID",[90],"2026-06-05","2026-09-30","2023-05-31",107,[5045,5046,5047,5048],"Long COVID","Long COVID-19","Post Acute COVID-19 Syndrome","Post Acute Sequelae of COVID-19",[5019],{"trials":5051,"activeCount":101},[],{"trials":5053,"activeCount":101},[],{"trials":5055,"activeCount":101},[],{"intervention":2949,"totalTrials":136,"cells":5057},{"EARLY_PHASE1":5058,"PHASE1":5060,"PHASE2":5062,"PHASE3":5072,"PHASE4":5074,"NA":5076},{"trials":5059,"activeCount":101},[],{"trials":5061,"activeCount":101},[],{"trials":5063,"activeCount":331,"soonestReadout":2954},[5064,5068],{"nctId":2941,"briefTitle":2942,"status":117,"phases":5065,"primaryCompletion":2944,"completion":2945,"start":2946,"enrollment":209,"conditions":5066,"interventions":5067},[90],[2748,2771],[2901,2949],{"nctId":2951,"briefTitle":2952,"status":189,"phases":5069,"primaryCompletion":2954,"completion":2955,"start":2956,"enrollment":648,"conditions":5070,"interventions":5071},[90],[21,2473],[2901,2949],{"trials":5073,"activeCount":101},[],{"trials":5075,"activeCount":101},[],{"trials":5077,"activeCount":101},[],{"intervention":5079,"totalTrials":136,"cells":5080},"Ivosidenib",{"EARLY_PHASE1":5081,"PHASE1":5083,"PHASE2":5095,"PHASE3":5106,"PHASE4":5108,"NA":5110},{"trials":5082,"activeCount":101},[],{"trials":5084,"activeCount":101},[5085],{"nctId":5086,"briefTitle":5087,"status":117,"phases":5088,"primaryCompletion":5089,"completion":5090,"start":5091,"enrollment":209,"conditions":5092,"interventions":5094},"NCT03564821","IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation",[89],"2022-05-22","2023-06-06","2019-01-16",[5093],"IDH1 Mutation Myeloid Neoplasms",[5079],{"trials":5096,"activeCount":331,"soonestReadout":2706},[5097],{"nctId":5098,"briefTitle":5099,"status":160,"phases":5100,"primaryCompletion":2706,"completion":5101,"start":5102,"enrollment":872,"conditions":5103,"interventions":5105},"NCT06707493","Ivosidenib as Post-HSCT Maintenance for AML",[90],"2030-01-01","2026-01-16",[2914,2813,5104],"Hematopoietic Stem Cell Transplant (HSCT)",[5079],{"trials":5107,"activeCount":101},[],{"trials":5109,"activeCount":101},[],{"trials":5111,"activeCount":101},[],{"intervention":5113,"totalTrials":331,"cells":5114},"Azithromycin",{"EARLY_PHASE1":5115,"PHASE1":5117,"PHASE2":5119,"PHASE3":5132,"PHASE4":5134,"NA":5136},{"trials":5116,"activeCount":101},[],{"trials":5118,"activeCount":101},[],{"trials":5120,"activeCount":331,"soonestReadout":5125},[5121],{"nctId":5122,"briefTitle":5123,"status":189,"phases":5124,"primaryCompletion":5125,"completion":5126,"start":5127,"enrollment":5128,"conditions":5129,"interventions":5131},"NCT04326478","Single Dose Azithromycin to Prevent Cholera in Children",[90],"2025-05-31","2026-05-31","2021-10-31",920,[5130],"Cholera",[5113],{"trials":5133,"activeCount":101},[],{"trials":5135,"activeCount":101},[],{"trials":5137,"activeCount":101},[],{"intervention":4102,"totalTrials":331,"cells":5139},{"EARLY_PHASE1":5140,"PHASE1":5142,"PHASE2":5144,"PHASE3":5150,"PHASE4":5152,"NA":5154},{"trials":5141,"activeCount":101},[],{"trials":5143,"activeCount":101},[],{"trials":5145,"activeCount":331,"soonestReadout":2642},[5146],{"nctId":4095,"briefTitle":4096,"status":160,"phases":5147,"primaryCompletion":2642,"completion":2118,"start":4098,"enrollment":4099,"conditions":5148,"interventions":5149},[90],[26],[4102,4078],{"trials":5151,"activeCount":101},[],{"trials":5153,"activeCount":101},[],{"trials":5155,"activeCount":101},[],{"intervention":3295,"totalTrials":331,"cells":5157},{"EARLY_PHASE1":5158,"PHASE1":5160,"PHASE2":5162,"PHASE3":5168,"PHASE4":5170,"NA":5172},{"trials":5159,"activeCount":101},[],{"trials":5161,"activeCount":101},[],{"trials":5163,"activeCount":331,"soonestReadout":162},[5164],{"nctId":3286,"briefTitle":3287,"status":160,"phases":5165,"primaryCompletion":162,"completion":3289,"start":3290,"enrollment":227,"conditions":5166,"interventions":5167},[90],[2622,3292],[3294,3295],{"trials":5169,"activeCount":101},[],{"trials":5171,"activeCount":101},[],{"trials":5173,"activeCount":101},[],{"intervention":5175,"totalTrials":331,"cells":5176},"ICG Intervention",{"EARLY_PHASE1":5177,"PHASE1":5179,"PHASE2":5181,"PHASE3":5191,"PHASE4":5193,"NA":5195},{"trials":5178,"activeCount":101},[],{"trials":5180,"activeCount":101},[],{"trials":5182,"activeCount":331,"soonestReadout":3014},[5183],{"nctId":5184,"briefTitle":5185,"status":160,"phases":5186,"primaryCompletion":3014,"completion":3024,"start":5187,"enrollment":16,"conditions":5188,"interventions":5190},"NCT03097575","Bronchial NIR Image-guided Resection",[89,90],"2015-01-06",[5189],"Sentinel Lymph Node",[5175],{"trials":5192,"activeCount":101},[],{"trials":5194,"activeCount":101},[],{"trials":5196,"activeCount":101},[],{"intervention":5198,"totalTrials":331,"cells":5199},"Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer.",{"EARLY_PHASE1":5200,"PHASE1":5202,"PHASE2":5204,"PHASE3":5215,"PHASE4":5217,"NA":5219},{"trials":5201,"activeCount":101},[],{"trials":5203,"activeCount":101},[],{"trials":5205,"activeCount":331,"soonestReadout":5210},[5206],{"nctId":5207,"briefTitle":5208,"status":160,"phases":5209,"primaryCompletion":5210,"completion":5210,"start":5211,"enrollment":9,"conditions":5212,"interventions":5214},"NCT07079761","Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.",[90],"2027-04-30","2025-08-04",[5213],"Post Traumatic Stress Disorder",[5198,5198],{"trials":5216,"activeCount":101},[],{"trials":5218,"activeCount":101},[],{"trials":5220,"activeCount":101},[],{"intervention":3639,"totalTrials":331,"cells":5222},{"EARLY_PHASE1":5223,"PHASE1":5225,"PHASE2":5227,"PHASE3":5233,"PHASE4":5235,"NA":5237},{"trials":5224,"activeCount":101},[],{"trials":5226,"activeCount":101},[],{"trials":5228,"activeCount":331,"soonestReadout":2925},[5229],{"nctId":3631,"briefTitle":3632,"status":160,"phases":5230,"primaryCompletion":2925,"completion":1243,"start":3634,"enrollment":251,"conditions":5231,"interventions":5232},[90],[3636,3637],[3639,3165,2720],{"trials":5234,"activeCount":101},[],{"trials":5236,"activeCount":101},[],{"trials":5238,"activeCount":101},[],{"intervention":5240,"totalTrials":331,"cells":5241},"17-β estradiol transdermal patches with cyclic progesterone",{"EARLY_PHASE1":5242,"PHASE1":5244,"PHASE2":5246,"PHASE3":5258,"PHASE4":5260,"NA":5262},{"trials":5243,"activeCount":101},[],{"trials":5245,"activeCount":101},[],{"trials":5247,"activeCount":331,"soonestReadout":5252},[5248],{"nctId":5249,"briefTitle":5250,"status":189,"phases":5251,"primaryCompletion":5252,"completion":1999,"start":5253,"enrollment":3027,"conditions":5254,"interventions":5257},"NCT03740204","The Role of Estrogen in the Neurobiology of Eating Disorders",[90],"2025-12-30","2019-06-13",[5255,5256],"Eating Disorders","Hypoestrogenemia",[5240],{"trials":5259,"activeCount":101},[],{"trials":5261,"activeCount":101},[],{"trials":5263,"activeCount":101},[],{"intervention":5265,"totalTrials":331,"cells":5266},"Pregnenolone",{"EARLY_PHASE1":5267,"PHASE1":5269,"PHASE2":5271,"PHASE3":5282,"PHASE4":5284,"NA":5286},{"trials":5268,"activeCount":101},[],{"trials":5270,"activeCount":101},[],{"trials":5272,"activeCount":331,"soonestReadout":2201},[5273],{"nctId":5274,"briefTitle":5275,"status":160,"phases":5276,"primaryCompletion":2201,"completion":5277,"start":5278,"enrollment":3027,"conditions":5279,"interventions":5281},"NCT05570812","Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV",[90],"2028-01-31","2023-03-03",[18,5280,1671],"Anxiety Depression",[5265],{"trials":5283,"activeCount":101},[],{"trials":5285,"activeCount":101},[],{"trials":5287,"activeCount":101},[],{"intervention":5289,"totalTrials":331,"cells":5290},"Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing",{"EARLY_PHASE1":5291,"PHASE1":5293,"PHASE2":5295,"PHASE3":5316,"PHASE4":5318,"NA":5320},{"trials":5292,"activeCount":101},[],{"trials":5294,"activeCount":101},[],{"trials":5296,"activeCount":331,"soonestReadout":1147},[5297],{"nctId":5298,"briefTitle":5299,"status":160,"phases":5300,"primaryCompletion":1147,"completion":2642,"start":5301,"enrollment":5302,"conditions":5303,"interventions":5311},"NCT06406114","Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing",[90],"2025-05-05",300,[5304,5305,5306,5307,5308,5309,5310],"Drug Allergy","Cephalosporin Allergy","Drug Hypersensitivity","Antibiotic Allergy","Beta Lactam Adverse Reaction","Drug-Induced Anaphylaxis","Cephalosporin Reaction",[5289,5312,5313,5314,5315],"Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge","Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge","Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge","Amoxicillin double-blind placebo-controlled drug challenge",{"trials":5317,"activeCount":101},[],{"trials":5319,"activeCount":101},[],{"trials":5321,"activeCount":101},[],{"intervention":5312,"totalTrials":331,"cells":5323},{"EARLY_PHASE1":5324,"PHASE1":5326,"PHASE2":5328,"PHASE3":5334,"PHASE4":5336,"NA":5338},{"trials":5325,"activeCount":101},[],{"trials":5327,"activeCount":101},[],{"trials":5329,"activeCount":331,"soonestReadout":1147},[5330],{"nctId":5298,"briefTitle":5299,"status":160,"phases":5331,"primaryCompletion":1147,"completion":2642,"start":5301,"enrollment":5302,"conditions":5332,"interventions":5333},[90],[5304,5305,5306,5307,5308,5309,5310],[5289,5312,5313,5314,5315],{"trials":5335,"activeCount":101},[],{"trials":5337,"activeCount":101},[],{"trials":5339,"activeCount":101},[],{"intervention":5313,"totalTrials":331,"cells":5341},{"EARLY_PHASE1":5342,"PHASE1":5344,"PHASE2":5346,"PHASE3":5352,"PHASE4":5354,"NA":5356},{"trials":5343,"activeCount":101},[],{"trials":5345,"activeCount":101},[],{"trials":5347,"activeCount":331,"soonestReadout":1147},[5348],{"nctId":5298,"briefTitle":5299,"status":160,"phases":5349,"primaryCompletion":1147,"completion":2642,"start":5301,"enrollment":5302,"conditions":5350,"interventions":5351},[90],[5304,5305,5306,5307,5308,5309,5310],[5289,5312,5313,5314,5315],{"trials":5353,"activeCount":101},[],{"trials":5355,"activeCount":101},[],{"trials":5357,"activeCount":101},[],{"intervention":5314,"totalTrials":331,"cells":5359},{"EARLY_PHASE1":5360,"PHASE1":5362,"PHASE2":5364,"PHASE3":5370,"PHASE4":5372,"NA":5374},{"trials":5361,"activeCount":101},[],{"trials":5363,"activeCount":101},[],{"trials":5365,"activeCount":331,"soonestReadout":1147},[5366],{"nctId":5298,"briefTitle":5299,"status":160,"phases":5367,"primaryCompletion":1147,"completion":2642,"start":5301,"enrollment":5302,"conditions":5368,"interventions":5369},[90],[5304,5305,5306,5307,5308,5309,5310],[5289,5312,5313,5314,5315],{"trials":5371,"activeCount":101},[],{"trials":5373,"activeCount":101},[],{"trials":5375,"activeCount":101},[],{"intervention":5315,"totalTrials":331,"cells":5377},{"EARLY_PHASE1":5378,"PHASE1":5380,"PHASE2":5382,"PHASE3":5388,"PHASE4":5390,"NA":5392},{"trials":5379,"activeCount":101},[],{"trials":5381,"activeCount":101},[],{"trials":5383,"activeCount":331,"soonestReadout":1147},[5384],{"nctId":5298,"briefTitle":5299,"status":160,"phases":5385,"primaryCompletion":1147,"completion":2642,"start":5301,"enrollment":5302,"conditions":5386,"interventions":5387},[90],[5304,5305,5306,5307,5308,5309,5310],[5289,5312,5313,5314,5315],{"trials":5389,"activeCount":101},[],{"trials":5391,"activeCount":101},[],{"trials":5393,"activeCount":101},[],{"intervention":5395,"totalTrials":331,"cells":5396},"Granulocyte Colony Stimulating Factor",{"EARLY_PHASE1":5397,"PHASE1":5399,"PHASE2":5401,"PHASE3":5415,"PHASE4":5417,"NA":5419},{"trials":5398,"activeCount":101},[],{"trials":5400,"activeCount":101},[],{"trials":5402,"activeCount":331,"soonestReadout":5407},[5403],{"nctId":5404,"briefTitle":5405,"status":160,"phases":5406,"primaryCompletion":5407,"completion":5408,"start":5409,"enrollment":1578,"conditions":5410,"interventions":5414},"NCT06649851","G-CSF After Chemo-radiation in Patients With Glioblastoma",[90],"2027-01-31","2030-01-31","2025-04-02",[5411,5412,5413],"MGMT-Methylated Glioblastoma","Glioblastoma (GBM)","Newly Diagnosed Glioblastoma Multiforme",[5395],{"trials":5416,"activeCount":101},[],{"trials":5418,"activeCount":101},[],{"trials":5420,"activeCount":101},[],{"intervention":2650,"totalTrials":331,"cells":5422},{"EARLY_PHASE1":5423,"PHASE1":5425,"PHASE2":5427,"PHASE3":5433,"PHASE4":5435,"NA":5437},{"trials":5424,"activeCount":101},[],{"trials":5426,"activeCount":101},[],{"trials":5428,"activeCount":331,"soonestReadout":2642},[5429],{"nctId":2639,"briefTitle":2640,"status":160,"phases":5430,"primaryCompletion":2642,"completion":2643,"start":2644,"enrollment":366,"conditions":5431,"interventions":5432},[90],[2646,2647,2030],[2649,2650,2614,2599],{"trials":5434,"activeCount":101},[],{"trials":5436,"activeCount":101},[],{"trials":5438,"activeCount":101},[],{"intervention":5440,"totalTrials":331,"cells":5441},"Activin ligand-trap biological therapy",{"EARLY_PHASE1":5442,"PHASE1":5444,"PHASE2":5446,"PHASE3":5455,"PHASE4":5457,"NA":5459},{"trials":5443,"activeCount":101},[],{"trials":5445,"activeCount":101},[],{"trials":5447,"activeCount":331,"soonestReadout":3264},[5448],{"nctId":5449,"briefTitle":5450,"status":318,"phases":5451,"primaryCompletion":3264,"completion":5452,"start":730,"enrollment":4772,"conditions":5453,"interventions":5454},"NCT07202000","EXercise and Activin Inhibition to Modulate InflammatioN Effects on Heart Failure and Cognition (EXAMINE-HFC)",[90],"2027-08",[1371],[5440],{"trials":5456,"activeCount":101},[],{"trials":5458,"activeCount":101},[],{"trials":5460,"activeCount":101},[],{"intervention":4953,"totalTrials":331,"cells":5462},{"EARLY_PHASE1":5463,"PHASE1":5465,"PHASE2":5467,"PHASE3":5473,"PHASE4":5475,"NA":5477},{"trials":5464,"activeCount":101},[],{"trials":5466,"activeCount":101},[],{"trials":5468,"activeCount":331,"soonestReadout":3024},[5469],{"nctId":4947,"briefTitle":4948,"status":189,"phases":5470,"primaryCompletion":3024,"completion":4950,"start":1825,"enrollment":1805,"conditions":5471,"interventions":5472},[89,90],[3682],[4938,4953],{"trials":5474,"activeCount":101},[],{"trials":5476,"activeCount":101},[],{"trials":5478,"activeCount":101},[],{"intervention":5480,"totalTrials":331,"cells":5481},"CBD",{"EARLY_PHASE1":5482,"PHASE1":5484,"PHASE2":5486,"PHASE3":5498,"PHASE4":5500,"NA":5502},{"trials":5483,"activeCount":101},[],{"trials":5485,"activeCount":101},[],{"trials":5487,"activeCount":331,"soonestReadout":2556},[5488],{"nctId":5489,"briefTitle":5490,"status":160,"phases":5491,"primaryCompletion":2556,"completion":5492,"start":5493,"enrollment":732,"conditions":5494,"interventions":5497},"NCT05066308","Cannabidiol for Reduction of Brain Neuroinflammation",[90],"2026-12-15","2022-01-04",[5495,5496],"Back Pain","Depressive Symptoms",[5480],{"trials":5499,"activeCount":101},[],{"trials":5501,"activeCount":101},[],{"trials":5503,"activeCount":101},[],{"intervention":5505,"totalTrials":331,"cells":5506},"elinzanetant - reference formulation",{"EARLY_PHASE1":5507,"PHASE1":5509,"PHASE2":5511,"PHASE3":5522,"PHASE4":5524,"NA":5526},{"trials":5508,"activeCount":101},[],{"trials":5510,"activeCount":101},[],{"trials":5512,"activeCount":331,"soonestReadout":500},[5513],{"nctId":5514,"briefTitle":5515,"status":160,"phases":5516,"primaryCompletion":500,"completion":5517,"start":5518,"enrollment":732,"conditions":5519,"interventions":5521},"NCT07077395","Finding Links Between Hot flASHes and CardioVascular Disease",[90],"2029-09","2026-03-01",[5520],"Menopause-related Hot Flashes",[5505],{"trials":5523,"activeCount":101},[],{"trials":5525,"activeCount":101},[],{"trials":5527,"activeCount":101},[],{"intervention":5529,"totalTrials":331,"cells":5530},"64Cu-FBP8",{"EARLY_PHASE1":5531,"PHASE1":5533,"PHASE2":5535,"PHASE3":5547,"PHASE4":5549,"NA":5551},{"trials":5532,"activeCount":101},[],{"trials":5534,"activeCount":101},[],{"trials":5536,"activeCount":331,"soonestReadout":5541},[5537],{"nctId":5538,"briefTitle":5539,"status":160,"phases":5540,"primaryCompletion":5541,"completion":5541,"start":5542,"enrollment":227,"conditions":5543,"interventions":5546},"NCT05336695","Assess Fibrin in Brains With AD\u002FADRD",[89,90],"2026-09-28","2022-03-29",[5544,5545],"Alzheimer Disease","Dementia of Alzheimer Type",[5529],{"trials":5548,"activeCount":101},[],{"trials":5550,"activeCount":101},[],{"trials":5552,"activeCount":101},[],{"intervention":5554,"totalTrials":331,"cells":5555},"Vedolizumab",{"EARLY_PHASE1":5556,"PHASE1":5558,"PHASE2":5560,"PHASE3":5570,"PHASE4":5572,"NA":5574},{"trials":5557,"activeCount":101},[],{"trials":5559,"activeCount":101},[],{"trials":5561,"activeCount":331,"soonestReadout":2507},[5562],{"nctId":5563,"briefTitle":5564,"status":189,"phases":5565,"primaryCompletion":2507,"completion":2768,"start":5566,"enrollment":4618,"conditions":5567,"interventions":5569},"NCT06317220","Vedolizumab for the Treatment of Collagenous Gastritis",[90],"2024-12-03",[5568],"Collagenous Gastritis",[5554],{"trials":5571,"activeCount":101},[],{"trials":5573,"activeCount":101},[],{"trials":5575,"activeCount":101},[],{"intervention":2666,"totalTrials":331,"cells":5577},{"EARLY_PHASE1":5578,"PHASE1":5580,"PHASE2":5582,"PHASE3":5588,"PHASE4":5590,"NA":5592},{"trials":5579,"activeCount":101},[],{"trials":5581,"activeCount":101},[],{"trials":5583,"activeCount":331,"soonestReadout":1242},[5584],{"nctId":2659,"briefTitle":2660,"status":189,"phases":5585,"primaryCompletion":1242,"completion":1243,"start":2662,"enrollment":2663,"conditions":5586,"interventions":5587},[90],[2030],[2666,2614,2657,2599],{"trials":5589,"activeCount":101},[],{"trials":5591,"activeCount":101},[],{"trials":5593,"activeCount":101},[],{"intervention":5595,"totalTrials":331,"cells":5596},"Digoxin",{"EARLY_PHASE1":5597,"PHASE1":5599,"PHASE2":5601,"PHASE3":5613,"PHASE4":5615,"NA":5617},{"trials":5598,"activeCount":101},[],{"trials":5600,"activeCount":101},[],{"trials":5602,"activeCount":331,"soonestReadout":5607},[5603],{"nctId":5604,"briefTitle":5605,"status":189,"phases":5606,"primaryCompletion":5607,"completion":5608,"start":5609,"enrollment":251,"conditions":5610,"interventions":5612},"NCT07047209","Trial of Oral Digoxin in Individuals With Amyotrophic Lateral Sclerosis (ALS)",[90],"2026-03","2026-04","2025-05-27",[5611],"ALS (Amyotrophic Lateral Sclerosis)",[5595],{"trials":5614,"activeCount":101},[],{"trials":5616,"activeCount":101},[],{"trials":5618,"activeCount":101},[],{"intervention":5620,"totalTrials":331,"cells":5621},"Setmelanotide",{"EARLY_PHASE1":5622,"PHASE1":5624,"PHASE2":5626,"PHASE3":5635,"PHASE4":5637,"NA":5639},{"trials":5623,"activeCount":101},[],{"trials":5625,"activeCount":101},[],{"trials":5627,"activeCount":331,"soonestReadout":3347},[5628],{"nctId":5629,"briefTitle":5630,"status":318,"phases":5631,"primaryCompletion":3347,"completion":3347,"start":3620,"enrollment":331,"conditions":5632,"interventions":5634},"NCT07496463","Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)",[90],[5633,26],"Pseudohypoparathyroidism Type 1a",[5620],{"trials":5636,"activeCount":101},[],{"trials":5638,"activeCount":101},[],{"trials":5640,"activeCount":101},[],{"intervention":3033,"totalTrials":331,"cells":5642},{"EARLY_PHASE1":5643,"PHASE1":5645,"PHASE2":5647,"PHASE3":5653,"PHASE4":5655,"NA":5657},{"trials":5644,"activeCount":101},[],{"trials":5646,"activeCount":101},[],{"trials":5648,"activeCount":331,"soonestReadout":3024},[5649],{"nctId":3021,"briefTitle":3022,"status":160,"phases":5650,"primaryCompletion":3024,"completion":3025,"start":3026,"enrollment":3027,"conditions":5651,"interventions":5652},[90],[3029,3030,3031],[3033,2975],{"trials":5654,"activeCount":101},[],{"trials":5656,"activeCount":101},[],{"trials":5658,"activeCount":101},[],{"intervention":5660,"totalTrials":331,"cells":5661},"Opioid-Sparing Protocol",{"EARLY_PHASE1":5662,"PHASE1":5664,"PHASE2":5666,"PHASE3":5677,"PHASE4":5679,"NA":5681},{"trials":5663,"activeCount":101},[],{"trials":5665,"activeCount":101},[],{"trials":5667,"activeCount":331,"soonestReadout":2744},[5668],{"nctId":5669,"briefTitle":5670,"status":318,"phases":5671,"primaryCompletion":2744,"completion":3335,"start":322,"enrollment":3027,"conditions":5672,"interventions":5675},"NCT07588802","Effect of Opioid-Sparing Anesthesia on Postoperative Opioid Consumption and Pain in Elderly Patients Undergoing Spine Surgery",[90],[5673,5674],"Opoid Managment","Pain Management",[5660,5676],"Routine anesthesia protocol",{"trials":5678,"activeCount":101},[],{"trials":5680,"activeCount":101},[],{"trials":5682,"activeCount":101},[],{"intervention":5676,"totalTrials":331,"cells":5684},{"EARLY_PHASE1":5685,"PHASE1":5687,"PHASE2":5689,"PHASE3":5695,"PHASE4":5697,"NA":5699},{"trials":5686,"activeCount":101},[],{"trials":5688,"activeCount":101},[],{"trials":5690,"activeCount":331,"soonestReadout":2744},[5691],{"nctId":5669,"briefTitle":5670,"status":318,"phases":5692,"primaryCompletion":2744,"completion":3335,"start":322,"enrollment":3027,"conditions":5693,"interventions":5694},[90],[5673,5674],[5660,5676],{"trials":5696,"activeCount":101},[],{"trials":5698,"activeCount":101},[],{"trials":5700,"activeCount":101},[],{"intervention":5702,"totalTrials":331,"cells":5703},"Siltuximab",{"EARLY_PHASE1":5704,"PHASE1":5706,"PHASE2":5708,"PHASE3":5723,"PHASE4":5725,"NA":5727},{"trials":5705,"activeCount":101},[],{"trials":5707,"activeCount":101},[],{"trials":5709,"activeCount":331,"soonestReadout":5714},[5710],{"nctId":5711,"briefTitle":5712,"status":160,"phases":5713,"primaryCompletion":5714,"completion":5715,"start":5716,"enrollment":251,"conditions":5717,"interventions":5721},"NCT05684692","Screening Trial for Pain Relief in Schwannomatosis (STARFISH)",[90],"2026-11-30","2027-11-30","2023-08-31",[5718,5719,5720],"Schwannomatosis","Schwannomas","Pain, Chronic",[5702,5722],"Erenumab-Aooe",{"trials":5724,"activeCount":101},[],{"trials":5726,"activeCount":101},[],{"trials":5728,"activeCount":101},[],{"intervention":5722,"totalTrials":331,"cells":5730},{"EARLY_PHASE1":5731,"PHASE1":5733,"PHASE2":5735,"PHASE3":5741,"PHASE4":5743,"NA":5745},{"trials":5732,"activeCount":101},[],{"trials":5734,"activeCount":101},[],{"trials":5736,"activeCount":331,"soonestReadout":5714},[5737],{"nctId":5711,"briefTitle":5712,"status":160,"phases":5738,"primaryCompletion":5714,"completion":5715,"start":5716,"enrollment":251,"conditions":5739,"interventions":5740},[90],[5718,5719,5720],[5702,5722],{"trials":5742,"activeCount":101},[],{"trials":5744,"activeCount":101},[],{"trials":5746,"activeCount":101},[],{"intervention":5748,"totalTrials":331,"cells":5749},"Antisense oligonucleotide treatment",{"EARLY_PHASE1":5750,"PHASE1":5752,"PHASE2":5754,"PHASE3":5764,"PHASE4":5766,"NA":5768},{"trials":5751,"activeCount":101},[],{"trials":5753,"activeCount":101},[],{"trials":5755,"activeCount":331,"soonestReadout":1288},[5756],{"nctId":5757,"briefTitle":5758,"status":1144,"phases":5759,"primaryCompletion":1288,"completion":1288,"start":5760,"enrollment":331,"conditions":5761,"interventions":5763},"NCT06369974","Single Participant Study of an Experimental ASO Treatment for TUBB4A-related Leukodystrophy",[89,90],"2024-09-18",[5762],"Genetic Disease",[5748],{"trials":5765,"activeCount":101},[],{"trials":5767,"activeCount":101},[],{"trials":5769,"activeCount":101},[],{"intervention":3390,"totalTrials":331,"cells":5771},{"EARLY_PHASE1":5772,"PHASE1":5774,"PHASE2":5776,"PHASE3":5782,"PHASE4":5784,"NA":5786},{"trials":5773,"activeCount":101},[],{"trials":5775,"activeCount":101},[],{"trials":5777,"activeCount":331,"soonestReadout":3014},[5778],{"nctId":3381,"briefTitle":3382,"status":189,"phases":5779,"primaryCompletion":3014,"completion":2706,"start":3384,"enrollment":3385,"conditions":5780,"interventions":5781},[90],[2862],[2807,3388,3389,3390,3360,3391],{"trials":5783,"activeCount":101},[],{"trials":5785,"activeCount":101},[],{"trials":5787,"activeCount":101},[],{"intervention":3391,"totalTrials":331,"cells":5789},{"EARLY_PHASE1":5790,"PHASE1":5792,"PHASE2":5794,"PHASE3":5800,"PHASE4":5802,"NA":5804},{"trials":5791,"activeCount":101},[],{"trials":5793,"activeCount":101},[],{"trials":5795,"activeCount":331,"soonestReadout":3014},[5796],{"nctId":3381,"briefTitle":3382,"status":189,"phases":5797,"primaryCompletion":3014,"completion":2706,"start":3384,"enrollment":3385,"conditions":5798,"interventions":5799},[90],[2862],[2807,3388,3389,3390,3360,3391],{"trials":5801,"activeCount":101},[],{"trials":5803,"activeCount":101},[],{"trials":5805,"activeCount":101},[],{"intervention":3815,"totalTrials":331,"cells":5807},{"EARLY_PHASE1":5808,"PHASE1":5810,"PHASE2":5812,"PHASE3":5818,"PHASE4":5820,"NA":5822},{"trials":5809,"activeCount":101},[],{"trials":5811,"activeCount":101},[],{"trials":5813,"activeCount":331,"soonestReadout":837},[5814],{"nctId":3805,"briefTitle":3806,"status":189,"phases":5815,"primaryCompletion":837,"completion":3264,"start":3808,"enrollment":3122,"conditions":5816,"interventions":5817},[89,90],[3810,3811,3812,3813],[3815,3770],{"trials":5819,"activeCount":101},[],{"trials":5821,"activeCount":101},[],{"trials":5823,"activeCount":101},[],{"intervention":5825,"totalTrials":331,"cells":5826},"Eplerenone 100 mg daily",{"EARLY_PHASE1":5827,"PHASE1":5829,"PHASE2":5831,"PHASE3":5847,"PHASE4":5849,"NA":5851},{"trials":5828,"activeCount":101},[],{"trials":5830,"activeCount":101},[],{"trials":5832,"activeCount":331,"soonestReadout":5837},[5833],{"nctId":5834,"briefTitle":5835,"status":160,"phases":5836,"primaryCompletion":5837,"completion":5838,"start":5839,"enrollment":5840,"conditions":5841,"interventions":5843},"NCT07238400","Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia",[90],"2029-03-16","2029-03-30","2026-03-20",90,[5842],"Hypertension",[5825,5844,5845,5846],"Chlorthalidone 25 mg daily","Potassium Placebo","Potassium Chloride",{"trials":5848,"activeCount":101},[],{"trials":5850,"activeCount":101},[],{"trials":5852,"activeCount":101},[],{"intervention":5844,"totalTrials":331,"cells":5854},{"EARLY_PHASE1":5855,"PHASE1":5857,"PHASE2":5859,"PHASE3":5865,"PHASE4":5867,"NA":5869},{"trials":5856,"activeCount":101},[],{"trials":5858,"activeCount":101},[],{"trials":5860,"activeCount":331,"soonestReadout":5837},[5861],{"nctId":5834,"briefTitle":5835,"status":160,"phases":5862,"primaryCompletion":5837,"completion":5838,"start":5839,"enrollment":5840,"conditions":5863,"interventions":5864},[90],[5842],[5825,5844,5845,5846],{"trials":5866,"activeCount":101},[],{"trials":5868,"activeCount":101},[],{"trials":5870,"activeCount":101},[],{"intervention":5845,"totalTrials":331,"cells":5872},{"EARLY_PHASE1":5873,"PHASE1":5875,"PHASE2":5877,"PHASE3":5883,"PHASE4":5885,"NA":5887},{"trials":5874,"activeCount":101},[],{"trials":5876,"activeCount":101},[],{"trials":5878,"activeCount":331,"soonestReadout":5837},[5879],{"nctId":5834,"briefTitle":5835,"status":160,"phases":5880,"primaryCompletion":5837,"completion":5838,"start":5839,"enrollment":5840,"conditions":5881,"interventions":5882},[90],[5842],[5825,5844,5845,5846],{"trials":5884,"activeCount":101},[],{"trials":5886,"activeCount":101},[],{"trials":5888,"activeCount":101},[],{"intervention":5846,"totalTrials":331,"cells":5890},{"EARLY_PHASE1":5891,"PHASE1":5893,"PHASE2":5895,"PHASE3":5901,"PHASE4":5903,"NA":5905},{"trials":5892,"activeCount":101},[],{"trials":5894,"activeCount":101},[],{"trials":5896,"activeCount":331,"soonestReadout":5837},[5897],{"nctId":5834,"briefTitle":5835,"status":160,"phases":5898,"primaryCompletion":5837,"completion":5838,"start":5839,"enrollment":5840,"conditions":5899,"interventions":5900},[90],[5842],[5825,5844,5845,5846],{"trials":5902,"activeCount":101},[],{"trials":5904,"activeCount":101},[],{"trials":5906,"activeCount":101},[],{"intervention":202,"totalTrials":331,"cells":5908},{"EARLY_PHASE1":5909,"PHASE1":5911,"PHASE2":5913,"PHASE3":5919,"PHASE4":5921,"NA":5923},{"trials":5910,"activeCount":101},[],{"trials":5912,"activeCount":101},[],{"trials":5914,"activeCount":331,"soonestReadout":191},[5915],{"nctId":187,"briefTitle":188,"status":189,"phases":5916,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":5917,"interventions":5918},[89,90],[196,197,198],[200,201,96,202],{"trials":5920,"activeCount":101},[],{"trials":5922,"activeCount":101},[],{"trials":5924,"activeCount":101},[],{"intervention":5926,"totalTrials":331,"cells":5927},"5mg\u002Fkg omalizumab",{"EARLY_PHASE1":5928,"PHASE1":5930,"PHASE2":5932,"PHASE3":5944,"PHASE4":5946,"NA":5948},{"trials":5929,"activeCount":101},[],{"trials":5931,"activeCount":101},[],{"trials":5933,"activeCount":331,"soonestReadout":1007},[5934],{"nctId":5935,"briefTitle":5936,"status":160,"phases":5937,"primaryCompletion":1007,"completion":376,"start":5938,"enrollment":227,"conditions":5939,"interventions":5942},"NCT06943534","Omalizumab Weight-Based Dosing Efficacy Trial",[90],"2025-07-03",[5940,5941],"Allergies","Food Allergy",[5926,5943],"15mg\u002Fkg omalizumab",{"trials":5945,"activeCount":101},[],{"trials":5947,"activeCount":101},[],{"trials":5949,"activeCount":101},[],{"intervention":5943,"totalTrials":331,"cells":5951},{"EARLY_PHASE1":5952,"PHASE1":5954,"PHASE2":5956,"PHASE3":5962,"PHASE4":5964,"NA":5966},{"trials":5953,"activeCount":101},[],{"trials":5955,"activeCount":101},[],{"trials":5957,"activeCount":331,"soonestReadout":1007},[5958],{"nctId":5935,"briefTitle":5936,"status":160,"phases":5959,"primaryCompletion":1007,"completion":376,"start":5938,"enrollment":227,"conditions":5960,"interventions":5961},[90],[5940,5941],[5926,5943],{"trials":5963,"activeCount":101},[],{"trials":5965,"activeCount":101},[],{"trials":5967,"activeCount":101},[],{"intervention":3402,"totalTrials":331,"cells":5969},{"EARLY_PHASE1":5970,"PHASE1":5972,"PHASE2":5974,"PHASE3":5980,"PHASE4":5982,"NA":5984},{"trials":5971,"activeCount":101},[],{"trials":5973,"activeCount":101},[],{"trials":5975,"activeCount":331,"soonestReadout":3396},[5976],{"nctId":3393,"briefTitle":3394,"status":160,"phases":5977,"primaryCompletion":3396,"completion":3397,"start":3398,"enrollment":251,"conditions":5978,"interventions":5979},[90],[123,124],[3360,3401,3402],{"trials":5981,"activeCount":101},[],{"trials":5983,"activeCount":101},[],{"trials":5985,"activeCount":101},[],{"intervention":5987,"totalTrials":331,"cells":5988},"Truvada",{"EARLY_PHASE1":5989,"PHASE1":5991,"PHASE2":5993,"PHASE3":6004,"PHASE4":6006,"NA":6008},{"trials":5990,"activeCount":101},[],{"trials":5992,"activeCount":101},[],{"trials":5994,"activeCount":331,"soonestReadout":5999},[5995],{"nctId":5996,"briefTitle":5997,"status":1144,"phases":5998,"primaryCompletion":5999,"completion":1999,"start":6000,"enrollment":366,"conditions":6001,"interventions":6003},"NCT05957913","Effects of Antiviral Therapies on Epstein-Barr Virus Replication",[90],"2026-06-04","2023-06-05",[6002],"Multiple Sclerosis",[5987],{"trials":6005,"activeCount":101},[],{"trials":6007,"activeCount":101},[],{"trials":6009,"activeCount":101},[],{"intervention":6011,"totalTrials":331,"cells":6012},"Ribociclib",{"EARLY_PHASE1":6013,"PHASE1":6015,"PHASE2":6017,"PHASE3":6025,"PHASE4":6027,"NA":6029},{"trials":6014,"activeCount":101},[],{"trials":6016,"activeCount":101},[],{"trials":6018,"activeCount":331,"soonestReadout":5608},[6019],{"nctId":6020,"briefTitle":6021,"status":189,"phases":6022,"primaryCompletion":5608,"completion":2768,"start":2471,"enrollment":3027,"conditions":6023,"interventions":6024},"NCT03285412","CDK 4\u002F6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer",[90],[21],[6011],{"trials":6026,"activeCount":101},[],{"trials":6028,"activeCount":101},[],{"trials":6030,"activeCount":101},[],{"intervention":2538,"totalTrials":331,"cells":6032},{"EARLY_PHASE1":6033,"PHASE1":6035,"PHASE2":6037,"PHASE3":6043,"PHASE4":6045,"NA":6047},{"trials":6034,"activeCount":101},[],{"trials":6036,"activeCount":101},[],{"trials":6038,"activeCount":331,"soonestReadout":2200},[6039],{"nctId":2531,"briefTitle":2532,"status":189,"phases":6040,"primaryCompletion":2200,"completion":1146,"start":2534,"enrollment":33,"conditions":6041,"interventions":6042},[90],[2516],[57,2537,2538,81],{"trials":6044,"activeCount":101},[],{"trials":6046,"activeCount":101},[],{"trials":6048,"activeCount":101},[],{"intervention":6050,"totalTrials":331,"cells":6051},"TNX-1900",{"EARLY_PHASE1":6052,"PHASE1":6054,"PHASE2":6056,"PHASE3":6066,"PHASE4":6068,"NA":6070},{"trials":6053,"activeCount":101},[],{"trials":6055,"activeCount":101},[],{"trials":6057,"activeCount":331,"soonestReadout":1242},[6058],{"nctId":6059,"briefTitle":6060,"status":160,"phases":6061,"primaryCompletion":1242,"completion":1242,"start":6062,"enrollment":1578,"conditions":6063,"interventions":6065},"NCT05664516","A Study of the Effects of Oxytocin in Adults With Binge-eating Disorder",[90],"2023-03-07",[6064],"Binge-eating Disorder",[6050],{"trials":6067,"activeCount":101},[],{"trials":6069,"activeCount":101},[],{"trials":6071,"activeCount":101},[],{"intervention":6073,"totalTrials":331,"cells":6074},"89Zr-Girentuximab",{"EARLY_PHASE1":6075,"PHASE1":6077,"PHASE2":6079,"PHASE3":6092,"PHASE4":6094,"NA":6096},{"trials":6076,"activeCount":101},[],{"trials":6078,"activeCount":101},[],{"trials":6080,"activeCount":331,"soonestReadout":6085},[6081],{"nctId":6082,"briefTitle":6083,"status":318,"phases":6084,"primaryCompletion":6085,"completion":6086,"start":6087,"enrollment":239,"conditions":6088,"interventions":6091},"NCT07077083","CAIX PET\u002FCT for Residual or Recurrent Post-ablative ccRCC",[90],"2027-08-01","2028-08-01","2026-03-16",[6089,6090],"Clear Cell Renal Cell Carcinoma (ccRCC)","ccRCC",[6073],{"trials":6093,"activeCount":101},[],{"trials":6095,"activeCount":101},[],{"trials":6097,"activeCount":101},[],{"intervention":6099,"totalTrials":331,"cells":6100},"PBR28 TSPO PET",{"EARLY_PHASE1":6101,"PHASE1":6103,"PHASE2":6105,"PHASE3":6117,"PHASE4":6119,"NA":6121},{"trials":6102,"activeCount":101},[],{"trials":6104,"activeCount":101},[],{"trials":6106,"activeCount":331,"soonestReadout":6111},[6107],{"nctId":6108,"briefTitle":6109,"status":160,"phases":6110,"primaryCompletion":6111,"completion":6112,"start":6113,"enrollment":16,"conditions":6114,"interventions":6116},"NCT07131475","Precision Biomarkers to Detect Brain Injury in Active-Duty United States Special Operations Forces With Repeated Blast Exposure",[90],"2029-04-30","2029-08-31","2025-10-14",[6115],"Blast Injury",[6099],{"trials":6118,"activeCount":101},[],{"trials":6120,"activeCount":101},[],{"trials":6122,"activeCount":101},[],{"intervention":6124,"totalTrials":331,"cells":6125},"Epcoritamab",{"EARLY_PHASE1":6126,"PHASE1":6128,"PHASE2":6130,"PHASE3":6142,"PHASE4":6144,"NA":6146},{"trials":6127,"activeCount":101},[],{"trials":6129,"activeCount":101},[],{"trials":6131,"activeCount":331,"soonestReadout":3347},[6132],{"nctId":6133,"briefTitle":6134,"status":160,"phases":6135,"primaryCompletion":3347,"completion":6136,"start":6137,"enrollment":227,"conditions":6138,"interventions":6141},"NCT06811272","Outpatient Epcoritamab as 2L in NTE R\u002FR DLBCL",[90],"2028-10-01","2025-06-05",[6139,6140],"Relapsed Large B-cell Lymphoma","Refractory Large B-cell Lymphoma",[6124],{"trials":6143,"activeCount":101},[],{"trials":6145,"activeCount":101},[],{"trials":6147,"activeCount":101},[],{"intervention":6149,"totalTrials":331,"cells":6150},"Vancomycin plus VE416 before PNOIT",{"EARLY_PHASE1":6151,"PHASE1":6153,"PHASE2":6155,"PHASE3":6168,"PHASE4":6170,"NA":6172},{"trials":6152,"activeCount":101},[],{"trials":6154,"activeCount":101},[],{"trials":6156,"activeCount":331,"soonestReadout":6161},[6157],{"nctId":6158,"briefTitle":6159,"status":160,"phases":6160,"primaryCompletion":6161,"completion":6162,"start":6163,"enrollment":1578,"conditions":6164,"interventions":6166},"NCT03936998","VE416 for Treatment of Food Allergy",[89,90],"2023-11-01","2024-01-01","2019-06-28",[6165],"Peanut Allergy",[6149,6167],"Vancomycin plus VE416 with PNOIT",{"trials":6169,"activeCount":101},[],{"trials":6171,"activeCount":101},[],{"trials":6173,"activeCount":101},[],{"intervention":6167,"totalTrials":331,"cells":6175},{"EARLY_PHASE1":6176,"PHASE1":6178,"PHASE2":6180,"PHASE3":6186,"PHASE4":6188,"NA":6190},{"trials":6177,"activeCount":101},[],{"trials":6179,"activeCount":101},[],{"trials":6181,"activeCount":331,"soonestReadout":6161},[6182],{"nctId":6158,"briefTitle":6159,"status":160,"phases":6183,"primaryCompletion":6161,"completion":6162,"start":6163,"enrollment":1578,"conditions":6184,"interventions":6185},[89,90],[6165],[6149,6167],{"trials":6187,"activeCount":101},[],{"trials":6189,"activeCount":101},[],{"trials":6191,"activeCount":101},[],{"intervention":6193,"totalTrials":331,"cells":6194},"Eribulin",{"EARLY_PHASE1":6195,"PHASE1":6197,"PHASE2":6199,"PHASE3":6212,"PHASE4":6214,"NA":6216},{"trials":6196,"activeCount":101},[],{"trials":6198,"activeCount":101},[],{"trials":6200,"activeCount":331,"soonestReadout":6205},[6201],{"nctId":6202,"briefTitle":6203,"status":189,"phases":6204,"primaryCompletion":6205,"completion":6206,"start":6207,"enrollment":1509,"conditions":6208,"interventions":6211},"NCT03331250","Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)",[90],"2023-07-21","2026-02-01","2018-01-18",[6209,6210],"Angiosarcoma","Epithelioid Hemangioendothelioma",[6193],{"trials":6213,"activeCount":101},[],{"trials":6215,"activeCount":101},[],{"trials":6217,"activeCount":101},[],{"intervention":6219,"totalTrials":331,"cells":6220},"18F-TPP",{"EARLY_PHASE1":6221,"PHASE1":6223,"PHASE2":6225,"PHASE3":6235,"PHASE4":6237,"NA":6239},{"trials":6222,"activeCount":101},[],{"trials":6224,"activeCount":101},[],{"trials":6226,"activeCount":331,"soonestReadout":2201},[6227],{"nctId":6228,"briefTitle":6229,"status":189,"phases":6230,"primaryCompletion":2201,"completion":2201,"start":6231,"enrollment":36,"conditions":6232,"interventions":6234},"NCT03265431","Evaluation of PET\u002FMR in Patients Selected for Ablation Therapy",[90],"2017-07-14",[6233],"Arrhythmias, Cardiac",[6219],{"trials":6236,"activeCount":101},[],{"trials":6238,"activeCount":101},[],{"trials":6240,"activeCount":101},[],{"intervention":3575,"totalTrials":331,"cells":6242},{"EARLY_PHASE1":6243,"PHASE1":6245,"PHASE2":6247,"PHASE3":6253,"PHASE4":6255,"NA":6257},{"trials":6244,"activeCount":101},[],{"trials":6246,"activeCount":101},[],{"trials":6248,"activeCount":331,"soonestReadout":3563},[6249],{"nctId":3560,"briefTitle":3561,"status":189,"phases":6250,"primaryCompletion":3563,"completion":3563,"start":3564,"enrollment":3565,"conditions":6251,"interventions":6252},[90],[3567,3568,3569,3570,3571,3572,3573],[2537,3575,3576],{"trials":6254,"activeCount":101},[],{"trials":6256,"activeCount":101},[],{"trials":6258,"activeCount":101},[],{"intervention":3352,"totalTrials":331,"cells":6260},{"EARLY_PHASE1":6261,"PHASE1":6263,"PHASE2":6265,"PHASE3":6271,"PHASE4":6273,"NA":6275},{"trials":6262,"activeCount":101},[],{"trials":6264,"activeCount":101},[],{"trials":6266,"activeCount":331,"soonestReadout":3347},[6267],{"nctId":3344,"briefTitle":3345,"status":160,"phases":6268,"primaryCompletion":3347,"completion":162,"start":3348,"enrollment":227,"conditions":6269,"interventions":6270},[90],[3350],[3316,3352],{"trials":6272,"activeCount":101},[],{"trials":6274,"activeCount":101},[],{"trials":6276,"activeCount":101},[],{"intervention":6278,"totalTrials":331,"cells":6279},"natural product combination-1",{"EARLY_PHASE1":6280,"PHASE1":6282,"PHASE2":6284,"PHASE3":6294,"PHASE4":6296,"NA":6298},{"trials":6281,"activeCount":101},[],{"trials":6283,"activeCount":101},[],{"trials":6285,"activeCount":331,"soonestReadout":1052},[6286],{"nctId":6287,"briefTitle":6288,"status":160,"phases":6289,"primaryCompletion":1052,"completion":1052,"start":3620,"enrollment":251,"conditions":6290,"interventions":6293},"NCT07236190","Biomarker-based Trial of NPC-1 for Alzheimer's Pathology",[90],[5544,6291,6292],"Mild Cognitive Impairment (MCI)","Subjective Cognitive Decline (SCD)",[6278],{"trials":6295,"activeCount":101},[],{"trials":6297,"activeCount":101},[],{"trials":6299,"activeCount":101},[],{"intervention":6301,"totalTrials":331,"cells":6302},"Bezafibrate",{"EARLY_PHASE1":6303,"PHASE1":6305,"PHASE2":6307,"PHASE3":6318,"PHASE4":6320,"NA":6322},{"trials":6304,"activeCount":101},[],{"trials":6306,"activeCount":101},[],{"trials":6308,"activeCount":331,"soonestReadout":6313},[6309],{"nctId":6310,"briefTitle":6311,"status":160,"phases":6312,"primaryCompletion":6313,"completion":6313,"start":6314,"enrollment":227,"conditions":6315,"interventions":6317},"NCT02481245","BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study",[90],"2026-02-28","2018-01-11",[24,6316],"Depressive Episode",[6301],{"trials":6319,"activeCount":101},[],{"trials":6321,"activeCount":101},[],{"trials":6323,"activeCount":101},[],{"intervention":6325,"totalTrials":331,"cells":6326},"NanoDOX® Hydrogel",{"EARLY_PHASE1":6327,"PHASE1":6329,"PHASE2":6331,"PHASE3":6341,"PHASE4":6343,"NA":6345},{"trials":6328,"activeCount":101},[],{"trials":6330,"activeCount":101},[],{"trials":6332,"activeCount":331,"soonestReadout":5608},[6333],{"nctId":6334,"briefTitle":6335,"status":189,"phases":6336,"primaryCompletion":5608,"completion":5608,"start":6337,"enrollment":239,"conditions":6338,"interventions":6340},"NCT05411484","Investigation of Laser Assisted Drug Delivery of NanoDOX®",[90],"2023-11-29",[6339],"Wounds and Injury",[6325],{"trials":6342,"activeCount":101},[],{"trials":6344,"activeCount":101},[],{"trials":6346,"activeCount":101},[],{"intervention":6348,"totalTrials":331,"cells":6349},"spironolactone 25 mg orally once daily",{"EARLY_PHASE1":6350,"PHASE1":6352,"PHASE2":6354,"PHASE3":6368,"PHASE4":6370,"NA":6372},{"trials":6351,"activeCount":101},[],{"trials":6353,"activeCount":101},[],{"trials":6355,"activeCount":331,"soonestReadout":6360},[6356],{"nctId":6357,"briefTitle":6358,"status":160,"phases":6359,"primaryCompletion":6360,"completion":6361,"start":6362,"enrollment":6363,"conditions":6364,"interventions":6367},"NCT07041281","Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories",[90],"2027-12-02","2029-03-02","2025-10-16",204,[6365,6366],"Preeclampsia","Gestational Hypertension",[6348],{"trials":6369,"activeCount":101},[],{"trials":6371,"activeCount":101},[],{"trials":6373,"activeCount":101},[],{"intervention":2686,"totalTrials":331,"cells":6375},{"EARLY_PHASE1":6376,"PHASE1":6378,"PHASE2":6380,"PHASE3":6386,"PHASE4":6388,"NA":6390},{"trials":6377,"activeCount":101},[],{"trials":6379,"activeCount":101},[],{"trials":6381,"activeCount":331,"soonestReadout":2677},[6382],{"nctId":2674,"briefTitle":2675,"status":318,"phases":6383,"primaryCompletion":2677,"completion":2678,"start":2679,"enrollment":1083,"conditions":6384,"interventions":6385},[90],[2030,2681,2682,2683],[2685,2686,127,2687,2599],{"trials":6387,"activeCount":101},[],{"trials":6389,"activeCount":101},[],{"trials":6391,"activeCount":101},[],{"intervention":2687,"totalTrials":331,"cells":6393},{"EARLY_PHASE1":6394,"PHASE1":6396,"PHASE2":6398,"PHASE3":6404,"PHASE4":6406,"NA":6408},{"trials":6395,"activeCount":101},[],{"trials":6397,"activeCount":101},[],{"trials":6399,"activeCount":331,"soonestReadout":2677},[6400],{"nctId":2674,"briefTitle":2675,"status":318,"phases":6401,"primaryCompletion":2677,"completion":2678,"start":2679,"enrollment":1083,"conditions":6402,"interventions":6403},[90],[2030,2681,2682,2683],[2685,2686,127,2687,2599],{"trials":6405,"activeCount":101},[],{"trials":6407,"activeCount":101},[],{"trials":6409,"activeCount":101},[],{"intervention":4130,"totalTrials":331,"cells":6411},{"EARLY_PHASE1":6412,"PHASE1":6414,"PHASE2":6416,"PHASE3":6422,"PHASE4":6424,"NA":6426},{"trials":6413,"activeCount":101},[],{"trials":6415,"activeCount":101},[],{"trials":6417,"activeCount":331,"soonestReadout":3396},[6418],{"nctId":4122,"briefTitle":4123,"status":160,"phases":6419,"primaryCompletion":3396,"completion":4125,"start":4126,"enrollment":251,"conditions":6420,"interventions":6421},[90],[123,4128],[169,4130,3401],{"trials":6423,"activeCount":101},[],{"trials":6425,"activeCount":101},[],{"trials":6427,"activeCount":101},[],{"intervention":6429,"totalTrials":331,"cells":6430},"Selpercatinib",{"EARLY_PHASE1":6431,"PHASE1":6433,"PHASE2":6435,"PHASE3":6453,"PHASE4":6455,"NA":6457},{"trials":6432,"activeCount":101},[],{"trials":6434,"activeCount":101},[],{"trials":6436,"activeCount":331,"soonestReadout":6441},[6437],{"nctId":6438,"briefTitle":6439,"status":160,"phases":6440,"primaryCompletion":6441,"completion":3015,"start":6442,"enrollment":227,"conditions":6443,"interventions":6450},"NCT05668962","Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC",[90],"2025-03-01","2023-03-01",[6444,6445,6446,6447,6448,6449],"Thyroid Cancer","Thyroid Carcinoma","Metastatic Thyroid Cancer","Follicular Thyroid Cancer","Unresectable Thyroid Gland Carcinoma","Papillary Thyroid Cancer",[6429,6451,6452],"Sodium Iodine I-131","rhTSH",{"trials":6454,"activeCount":101},[],{"trials":6456,"activeCount":101},[],{"trials":6458,"activeCount":101},[],{"intervention":6451,"totalTrials":331,"cells":6460},{"EARLY_PHASE1":6461,"PHASE1":6463,"PHASE2":6465,"PHASE3":6471,"PHASE4":6473,"NA":6475},{"trials":6462,"activeCount":101},[],{"trials":6464,"activeCount":101},[],{"trials":6466,"activeCount":331,"soonestReadout":6441},[6467],{"nctId":6438,"briefTitle":6439,"status":160,"phases":6468,"primaryCompletion":6441,"completion":3015,"start":6442,"enrollment":227,"conditions":6469,"interventions":6470},[90],[6444,6445,6446,6447,6448,6449],[6429,6451,6452],{"trials":6472,"activeCount":101},[],{"trials":6474,"activeCount":101},[],{"trials":6476,"activeCount":101},[],{"intervention":6452,"totalTrials":331,"cells":6478},{"EARLY_PHASE1":6479,"PHASE1":6481,"PHASE2":6483,"PHASE3":6489,"PHASE4":6491,"NA":6493},{"trials":6480,"activeCount":101},[],{"trials":6482,"activeCount":101},[],{"trials":6484,"activeCount":331,"soonestReadout":6441},[6485],{"nctId":6438,"briefTitle":6439,"status":160,"phases":6486,"primaryCompletion":6441,"completion":3015,"start":6442,"enrollment":227,"conditions":6487,"interventions":6488},[90],[6444,6445,6446,6447,6448,6449],[6429,6451,6452],{"trials":6490,"activeCount":101},[],{"trials":6492,"activeCount":101},[],{"trials":6494,"activeCount":101},[],{"intervention":6496,"totalTrials":331,"cells":6497},"Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.",{"EARLY_PHASE1":6498,"PHASE1":6500,"PHASE2":6502,"PHASE3":6519,"PHASE4":6521,"NA":6523},{"trials":6499,"activeCount":101},[],{"trials":6501,"activeCount":101},[],{"trials":6503,"activeCount":331,"soonestReadout":6508},[6504],{"nctId":6505,"briefTitle":6506,"status":160,"phases":6507,"primaryCompletion":6508,"completion":3549,"start":6509,"enrollment":732,"conditions":6510,"interventions":6518},"NCT05692024","COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER",[89,90],"2028-03-31","2024-03-21",[6511,6512,6513,6514,6515,6516,6517],"Colorectal Cancer","Coffee","Gastrointestinal Microbiome","Stenosis","Fibrosis, Liver","Ultrasound Elastography","Proton Magnetic Resonance Spectroscopy",[6496],{"trials":6520,"activeCount":101},[],{"trials":6522,"activeCount":101},[],{"trials":6524,"activeCount":101},[],{"intervention":6526,"totalTrials":331,"cells":6527},"Positron Emission Tomography \u002F Magnetic Resonance Imaging",{"EARLY_PHASE1":6528,"PHASE1":6530,"PHASE2":6532,"PHASE3":6542,"PHASE4":6544,"NA":6546},{"trials":6529,"activeCount":101},[],{"trials":6531,"activeCount":101},[],{"trials":6533,"activeCount":331,"soonestReadout":1081},[6534],{"nctId":6535,"briefTitle":6536,"status":160,"phases":6537,"primaryCompletion":1081,"completion":1081,"start":6538,"enrollment":6539,"conditions":6540,"interventions":6541},"NCT05661903","From Nerve to Brain: Toward a Mechanistic Understanding of Spinal Cord Stimulation in Human Subjects",[90],"2023-06-08",180,[1881],[6526],{"trials":6543,"activeCount":101},[],{"trials":6545,"activeCount":101},[],{"trials":6547,"activeCount":101},[],{"intervention":6549,"totalTrials":331,"cells":6550},"Fecal Microbiota Transplant (FMT) oral",{"EARLY_PHASE1":6551,"PHASE1":6553,"PHASE2":6555,"PHASE3":6565,"PHASE4":6567,"NA":6569},{"trials":6552,"activeCount":101},[],{"trials":6554,"activeCount":101},[],{"trials":6556,"activeCount":331,"soonestReadout":1999},[6557],{"nctId":6558,"briefTitle":6559,"status":189,"phases":6560,"primaryCompletion":1999,"completion":5407,"start":6561,"enrollment":227,"conditions":6562,"interventions":6564},"NCT03420482","Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy",[90],"2018-04-01",[6563],"Hepatic Encephalopathy",[6549],{"trials":6566,"activeCount":101},[],{"trials":6568,"activeCount":101},[],{"trials":6570,"activeCount":101},[],{"intervention":3511,"totalTrials":331,"cells":6572},{"EARLY_PHASE1":6573,"PHASE1":6575,"PHASE2":6577,"PHASE3":6583,"PHASE4":6585,"NA":6587},{"trials":6574,"activeCount":101},[],{"trials":6576,"activeCount":101},[],{"trials":6578,"activeCount":331,"soonestReadout":1146},[6579],{"nctId":3502,"briefTitle":3503,"status":318,"phases":6580,"primaryCompletion":1146,"completion":3505,"start":3506,"enrollment":151,"conditions":6581,"interventions":6582},[90],[3508,3509,2527],[3511,2576,3450],{"trials":6584,"activeCount":101},[],{"trials":6586,"activeCount":101},[],{"trials":6588,"activeCount":101},[],{"intervention":6590,"totalTrials":693,"cells":6591},"Tesamorelin",{"EARLY_PHASE1":6592,"PHASE1":6594,"PHASE2":6596,"PHASE3":6625,"PHASE4":6627,"NA":6629},{"trials":6593,"activeCount":101},[],{"trials":6595,"activeCount":101},[],{"trials":6597,"activeCount":331,"soonestReadout":6602},[6598,6611],{"nctId":6599,"briefTitle":6600,"status":160,"phases":6601,"primaryCompletion":6602,"completion":3289,"start":6603,"enrollment":16,"conditions":6604,"interventions":6610},"NCT06554717","Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV",[90],"2028-06-16","2025-07-10",[6605,6606,6607,6608,6609],"HIV-1-infection","Frailty","Impaired Physical Function","Abdominal Obesity","Aging",[6590],{"nctId":6612,"briefTitle":6613,"status":117,"phases":6614,"primaryCompletion":6615,"completion":6616,"start":6617,"enrollment":22,"conditions":6618,"interventions":6623},"NCT03375788","Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk",[90],"2024-07-10","2025-01-10","2019-01-17",[6619,26,6620,6621,6622],"Non-Alcoholic Fatty Liver Disease","Obesity, Abdominal","Liver Fat","Fatty Liver",[6590,6624],"Identical Placebo",{"trials":6626,"activeCount":101},[],{"trials":6628,"activeCount":101},[],{"trials":6630,"activeCount":101},[6631,6637,6648],{"nctId":6632,"briefTitle":6633,"status":107,"phases":6634,"primaryCompletion":224,"completion":224,"start":224,"enrollment":101,"conditions":6635,"interventions":6636},"NCT01632592","Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue",[93],[6608],[6590],{"nctId":6638,"briefTitle":6639,"status":117,"phases":6640,"primaryCompletion":5091,"completion":3897,"start":6641,"enrollment":4874,"conditions":6642,"interventions":6646},"NCT02196831","Tesamorelin Effects on Liver Fat and Histology in HIV",[93],"2015-07-01",[6643,6644,6645],"Human Immunodeficiency Virus (HIV)","Nonalcoholic Fatty Liver Disease (NAFLD)","Nonalcoholic Steatohepatitis (NASH)",[6647],"tesamorelin",{"nctId":6649,"briefTitle":6650,"status":117,"phases":6651,"primaryCompletion":4527,"completion":4527,"start":2994,"enrollment":6652,"conditions":6653,"interventions":6655},"NCT01263717","Effects of Growth Hormone Releasing Hormone in HIV",[93],54,[1671,6654],"HIV Lipodystrophy",[6647],{"intervention":6657,"totalTrials":693,"cells":6658},"Memantine",{"EARLY_PHASE1":6659,"PHASE1":6661,"PHASE2":6663,"PHASE3":6672,"PHASE4":6682,"NA":6699},{"trials":6660,"activeCount":101},[],{"trials":6662,"activeCount":101},[],{"trials":6664,"activeCount":331,"soonestReadout":1146},[6665],{"nctId":6666,"briefTitle":6667,"status":160,"phases":6668,"primaryCompletion":1146,"completion":1146,"start":6669,"enrollment":2882,"conditions":6670,"interventions":6671},"NCT05013892","NTS-WBRT in Brain Metastases",[90],"2022-02-08",[2584],[6657],{"trials":6673,"activeCount":101},[6674],{"nctId":6675,"briefTitle":6676,"status":117,"phases":6677,"primaryCompletion":6678,"completion":6678,"start":6679,"enrollment":2779,"conditions":6680,"interventions":6681},"NCT01972074","Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder",[91],"2018-05-07","2015-02-17",[488],[6657],{"trials":6683,"activeCount":101},[6684,6691],{"nctId":6685,"briefTitle":6686,"status":117,"phases":6687,"primaryCompletion":3078,"completion":3078,"start":6688,"enrollment":3337,"conditions":6689,"interventions":6690},"NCT00586066","Memantine and Cognitive Dysfunction in Bipolar Disorder",[92],"2005-11",[24],[6657],{"nctId":6692,"briefTitle":6693,"status":117,"phases":6694,"primaryCompletion":6695,"completion":6695,"start":6696,"enrollment":1847,"conditions":6697,"interventions":6698},"NCT01333865","A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders",[92],"2014-07","2010-01",[540],[6657],{"trials":6700,"activeCount":101},[6701],{"nctId":6702,"briefTitle":6703,"status":107,"phases":6704,"primaryCompletion":3706,"start":477,"enrollment":101,"conditions":6705,"interventions":6708},"NCT01844427","Memantine Monotherapy for Executive Dysfunction and ADHD",[93],[6706,6707],"ADHD","Executive Function Deficits (EFD's)",[6657],{"intervention":3576,"totalTrials":693,"cells":6710},{"EARLY_PHASE1":6711,"PHASE1":6713,"PHASE2":6715,"PHASE3":6738,"PHASE4":6740,"NA":6752},{"trials":6712,"activeCount":101},[],{"trials":6714,"activeCount":101},[],{"trials":6716,"activeCount":331,"soonestReadout":3563},[6717,6730,6734],{"nctId":6718,"briefTitle":6719,"status":173,"phases":6720,"primaryCompletion":6721,"completion":6722,"start":6723,"enrollment":1509,"conditions":6724,"interventions":6728},"NCT02955147","Ustekinumab for the Treatment of Giant Cell Arteritis",[89,90],"2019-07-25","2019-09-19","2016-12-01",[6725,6726,6727],"Giant Cell Arteritis","Temporal Arteritis","Horton's Disease",[6729,3576],"Ustekinumab",{"nctId":3821,"briefTitle":3822,"status":117,"phases":6731,"primaryCompletion":567,"completion":1877,"start":3607,"enrollment":227,"conditions":6732,"interventions":6733},[90],[3781],[3576,3787,3770,3826,2807,3789,3827,3828,3829],{"nctId":3560,"briefTitle":3561,"status":189,"phases":6735,"primaryCompletion":3563,"completion":3563,"start":3564,"enrollment":3565,"conditions":6736,"interventions":6737},[90],[3567,3568,3569,3570,3571,3572,3573],[2537,3575,3576],{"trials":6739,"activeCount":101},[],{"trials":6741,"activeCount":101},[6742],{"nctId":6743,"briefTitle":6744,"status":117,"phases":6745,"primaryCompletion":6746,"completion":6747,"start":6748,"enrollment":227,"conditions":6749,"interventions":6750},"NCT03726749","Tocilizumab Plus a Short Prednisone Taper for GCA",[92],"2021-12-15","2021-12-29","2018-11-28",[6725],[6751,3576],"Tocilizumab",{"trials":6753,"activeCount":101},[6754],{"nctId":6755,"briefTitle":6756,"status":117,"phases":6757,"primaryCompletion":6758,"completion":2644,"start":6759,"enrollment":251,"conditions":6760,"interventions":6761},"NCT01961843","Abiraterone Acetate for Castrate Resistant Prostate Cancer",[93],"2023-04-06","2014-01-14",[2038],[6762,3576],"Abiraterone",{"intervention":6764,"totalTrials":798,"cells":6765},"Indocyanine green",{"EARLY_PHASE1":6766,"PHASE1":6768,"PHASE2":6779,"PHASE3":6801,"PHASE4":6803,"NA":6805},{"trials":6767,"activeCount":101},[],{"trials":6769,"activeCount":101},[6770],{"nctId":6771,"briefTitle":6772,"status":117,"phases":6773,"primaryCompletion":4352,"completion":4352,"start":1876,"enrollment":693,"conditions":6774,"interventions":6778},"NCT01873716","Indocyanine Green Fluorescence Uptake in Human Carotid Artery Plaque",[89],[6775,6776,6777],"Atherosclerosis","Atherosclerotic Plaque","Carotid Stenosis",[6764],{"trials":6780,"activeCount":331,"soonestReadout":376},[6781,6790],{"nctId":6782,"briefTitle":6783,"status":160,"phases":6784,"primaryCompletion":376,"completion":3025,"start":6785,"enrollment":16,"conditions":6786,"interventions":6789},"NCT04752137","Intraoperative Tumor Margin Identification With ICG Dye Imaging",[90],"2022-05-25",[6787,6788],"Benign Neoplasm","Malignant Neoplasm",[6764],{"nctId":6791,"briefTitle":6792,"status":117,"phases":6793,"primaryCompletion":6794,"completion":6794,"start":6795,"enrollment":6796,"conditions":6797,"interventions":6800},"NCT05346380","Near-Infrared Perfusion During Minimally Invasive Thoracic Surgery Download",[89,90],"2025-06-03","2020-10-29",38,[6798,6799],"Lung Neoplasms","Esophageal Lesion",[6764],{"trials":6802,"activeCount":101},[],{"trials":6804,"activeCount":101},[],{"trials":6806,"activeCount":101},[6807],{"nctId":6808,"briefTitle":6809,"status":117,"phases":6810,"primaryCompletion":2994,"completion":626,"start":750,"enrollment":798,"conditions":6811,"interventions":6815},"NCT01112514","Indocyanine Green Fluorescent Molecular Imaging of the Gastrointestinal Tract",[93],[6812,6813,6814],"High Risk Polyposis Syndrome","Distal Colonic Lesions","Colorectal Polyps",[6816],"indocyanine green",{"intervention":2476,"totalTrials":178,"cells":6818},{"EARLY_PHASE1":6819,"PHASE1":6821,"PHASE2":6835,"PHASE3":6837,"PHASE4":6839,"NA":6841},{"trials":6820,"activeCount":101},[],{"trials":6822,"activeCount":178,"soonestReadout":2835},[6823,6827,6831],{"nctId":2467,"briefTitle":2468,"status":189,"phases":6824,"primaryCompletion":2470,"completion":375,"start":2471,"enrollment":194,"conditions":6825,"interventions":6826},[89],[2473,2474],[57,2476],{"nctId":2832,"briefTitle":2833,"status":189,"phases":6828,"primaryCompletion":2835,"completion":2835,"start":2836,"enrollment":2837,"conditions":6829,"interventions":6830},[89],[2839],[2841,2842,127,2476],{"nctId":4015,"briefTitle":4016,"status":189,"phases":6832,"primaryCompletion":1242,"completion":4018,"start":4019,"enrollment":2859,"conditions":6833,"interventions":6834},[89],[21],[2476,3997,2841],{"trials":6836,"activeCount":101},[],{"trials":6838,"activeCount":101},[],{"trials":6840,"activeCount":101},[],{"trials":6842,"activeCount":101},[],{"intervention":47,"totalTrials":97,"cells":6844},{"EARLY_PHASE1":6845,"PHASE1":6858,"PHASE2":6873,"PHASE3":6941,"PHASE4":6943,"NA":6945},{"trials":6846,"activeCount":331,"soonestReadout":6851},[6847],{"nctId":6848,"briefTitle":6849,"status":189,"phases":6850,"primaryCompletion":6851,"completion":6852,"start":6853,"enrollment":194,"conditions":6854,"interventions":6856},"NCT04857684","SBRT + Atezolizumab + Bevacizumab in Resectable HCC",[88],"2026-04-29","2027-04-29","2021-06-18",[4031,6855],"Resectable Hepatocellular Carcinoma",[6857,47],"Atezolizumab",{"trials":6859,"activeCount":136,"soonestReadout":46},[6860,6864],{"nctId":44,"briefTitle":45,"status":189,"phases":6861,"primaryCompletion":46,"completion":1242,"start":284,"enrollment":1898,"conditions":6862,"interventions":6863},[89],[1151],[47,3770],{"nctId":6865,"briefTitle":6866,"status":160,"phases":6867,"primaryCompletion":5407,"completion":6868,"start":6869,"enrollment":194,"conditions":6870,"interventions":6872},"NCT05096715","Atezolizumab+Bevacizumab+SBRT in Unresectable HCC",[89],"2032-01-31","2022-08-23",[6871],"Unresectable Hepatocellular Carcinoma",[6857,47],{"trials":6874,"activeCount":101},[6875,6879,6883,6887,6896,6909,6913,6917,6921,6925,6929,6933,6937],{"nctId":4421,"briefTitle":4422,"status":117,"phases":6876,"primaryCompletion":4272,"completion":4424,"start":4425,"enrollment":1890,"conditions":6877,"interventions":6878},[90],[2730,4427],[4293,3626,47],{"nctId":4438,"briefTitle":4439,"status":117,"phases":6880,"primaryCompletion":4441,"completion":4442,"start":3689,"enrollment":4443,"conditions":6881,"interventions":6882},[90],[2730,4427],[47,3536,3626],{"nctId":4655,"briefTitle":4656,"status":117,"phases":6884,"primaryCompletion":4658,"completion":176,"start":4463,"enrollment":648,"conditions":6885,"interventions":6886},[90],[2748,4660],[47,42,3536],{"nctId":6888,"briefTitle":6889,"status":107,"phases":6890,"primaryCompletion":6891,"completion":6891,"start":6891,"enrollment":101,"conditions":6892,"interventions":6894},"NCT00556205","Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma",[90],"2009-09",[6893],"Renal Cell Carcinoma",[6895,47],"Sunitinib",{"nctId":6897,"briefTitle":6898,"status":117,"phases":6899,"primaryCompletion":6900,"completion":6900,"start":6901,"enrollment":194,"conditions":6902,"interventions":6908},"NCT00356031","Bevacizumab and Radiation Therapy for Sarcomas",[90],"2010-03","2006-07",[1152,6903,6904,6905,6906,6907],"Fibrous Histiocytoma","Liposarcoma","Leiomyosarcoma","Fibrosarcoma","Synovial Sarcoma",[47],{"nctId":3655,"briefTitle":3656,"status":117,"phases":6910,"primaryCompletion":3658,"completion":3658,"start":3659,"enrollment":3122,"conditions":6911,"interventions":6912},[90],[3610],[3165,2720,47],{"nctId":4674,"briefTitle":4675,"status":173,"phases":6914,"primaryCompletion":4442,"completion":4677,"start":3492,"enrollment":33,"conditions":6915,"interventions":6916},[90],[4679],[47,4275,4393],{"nctId":3470,"briefTitle":3471,"status":117,"phases":6918,"primaryCompletion":2994,"completion":283,"start":109,"enrollment":22,"conditions":6919,"interventions":6920},[90],[21],[3475,3476,3477,922,3478],{"nctId":4447,"briefTitle":4448,"status":173,"phases":6922,"primaryCompletion":4450,"completion":250,"start":3689,"enrollment":2663,"conditions":6923,"interventions":6924},[89,90],[2748,4452],[3476,3449,3626,4454],{"nctId":3677,"briefTitle":3678,"status":117,"phases":6926,"primaryCompletion":3680,"completion":3680,"start":708,"enrollment":33,"conditions":6927,"interventions":6928},[90],[3682],[3520,3684,47],{"nctId":4578,"briefTitle":4579,"status":117,"phases":6930,"primaryCompletion":4581,"completion":176,"start":3689,"enrollment":648,"conditions":6931,"interventions":6932},[89,90],[4583,4584],[4559,3476,4275],{"nctId":4460,"briefTitle":4461,"status":117,"phases":6934,"primaryCompletion":4463,"completion":4464,"start":4465,"enrollment":2610,"conditions":6935,"interventions":6936},[90],[4031],[3536,3626,47],{"nctId":4955,"briefTitle":4956,"status":173,"phases":6938,"primaryCompletion":4351,"completion":4351,"start":4958,"enrollment":4618,"conditions":6939,"interventions":6940},[89,90],[4960],[4938,47],{"trials":6942,"activeCount":101},[],{"trials":6944,"activeCount":101},[],{"trials":6946,"activeCount":101},[6947],{"nctId":6948,"briefTitle":6949,"status":117,"phases":6950,"primaryCompletion":3491,"completion":3491,"start":4527,"enrollment":4618,"conditions":6951,"interventions":6953},"NCT02076152","FMISO PET Study of Glioblastoma",[93],[6952],"Recurrent Glioblastoma",[47,6954],"CCNU",{"intervention":6956,"totalTrials":136,"cells":6957},"Ziftomenib",{"EARLY_PHASE1":6958,"PHASE1":6960,"PHASE2":6980,"PHASE3":6982,"PHASE4":6984,"NA":6986},{"trials":6959,"activeCount":101},[],{"trials":6961,"activeCount":136,"soonestReadout":2556},[6962,6971],{"nctId":6963,"briefTitle":6964,"status":318,"phases":6965,"primaryCompletion":2619,"completion":2706,"start":6966,"enrollment":886,"conditions":6967,"interventions":6970},"NCT07355335","Ziftomenib + Mezigdomide in Adolesc. and Adults w\u002F R\u002FR AML",[89],"2026-07-09",[6968,6969],"KMT2A-rearranged","NPM1-mutant Refractory or Relapsed AML",[6956,2625],{"nctId":6972,"briefTitle":6973,"status":160,"phases":6974,"primaryCompletion":2556,"completion":2557,"start":6975,"enrollment":2859,"conditions":6976,"interventions":6979},"NCT06440135","Ziftomenib Maintenance Post Allo-HCT",[89],"2024-06-11",[2862,3242,6977,6978],"NPM1 Mutation","KMT2A Rearrangement",[6956],{"trials":6981,"activeCount":101},[],{"trials":6983,"activeCount":101},[],{"trials":6985,"activeCount":101},[],{"trials":6987,"activeCount":101},[],{"intervention":2625,"totalTrials":136,"cells":6989},{"EARLY_PHASE1":6990,"PHASE1":6992,"PHASE2":7002,"PHASE3":7004,"PHASE4":7006,"NA":7008},{"trials":6991,"activeCount":101},[],{"trials":6993,"activeCount":136,"soonestReadout":2619},[6994,6998],{"nctId":6963,"briefTitle":6964,"status":318,"phases":6995,"primaryCompletion":2619,"completion":2706,"start":6966,"enrollment":886,"conditions":6996,"interventions":6997},[89],[6968,6969],[6956,2625],{"nctId":2616,"briefTitle":2617,"status":160,"phases":6999,"primaryCompletion":2619,"completion":1147,"start":2620,"enrollment":1847,"conditions":7000,"interventions":7001},[89],[2622],[2624,2625,2599],{"trials":7003,"activeCount":101},[],{"trials":7005,"activeCount":101},[],{"trials":7007,"activeCount":101},[],{"trials":7009,"activeCount":101},[],{"intervention":2841,"totalTrials":136,"cells":7011},{"EARLY_PHASE1":7012,"PHASE1":7014,"PHASE2":7024,"PHASE3":7026,"PHASE4":7028,"NA":7030},{"trials":7013,"activeCount":101},[],{"trials":7015,"activeCount":136,"soonestReadout":2835},[7016,7020],{"nctId":2832,"briefTitle":2833,"status":189,"phases":7017,"primaryCompletion":2835,"completion":2835,"start":2836,"enrollment":2837,"conditions":7018,"interventions":7019},[89],[2839],[2841,2842,127,2476],{"nctId":4015,"briefTitle":4016,"status":189,"phases":7021,"primaryCompletion":1242,"completion":4018,"start":4019,"enrollment":2859,"conditions":7022,"interventions":7023},[89],[21],[2476,3997,2841],{"trials":7025,"activeCount":101},[],{"trials":7027,"activeCount":101},[],{"trials":7029,"activeCount":101},[],{"trials":7031,"activeCount":101},[],{"intervention":6857,"totalTrials":136,"cells":7033},{"EARLY_PHASE1":7034,"PHASE1":7040,"PHASE2":7046,"PHASE3":7048,"PHASE4":7050,"NA":7052},{"trials":7035,"activeCount":331,"soonestReadout":6851},[7036],{"nctId":6848,"briefTitle":6849,"status":189,"phases":7037,"primaryCompletion":6851,"completion":6852,"start":6853,"enrollment":194,"conditions":7038,"interventions":7039},[88],[4031,6855],[6857,47],{"trials":7041,"activeCount":331,"soonestReadout":5407},[7042],{"nctId":6865,"briefTitle":6866,"status":160,"phases":7043,"primaryCompletion":5407,"completion":6868,"start":6869,"enrollment":194,"conditions":7044,"interventions":7045},[89],[6871],[6857,47],{"trials":7047,"activeCount":101},[],{"trials":7049,"activeCount":101},[],{"trials":7051,"activeCount":101},[],{"trials":7053,"activeCount":101},[],{"intervention":4218,"totalTrials":178,"cells":7055},{"EARLY_PHASE1":7056,"PHASE1":7058,"PHASE2":7064,"PHASE3":7090,"PHASE4":7092,"NA":7094},{"trials":7057,"activeCount":101},[],{"trials":7059,"activeCount":331,"soonestReadout":4213},[7060],{"nctId":4210,"briefTitle":4211,"status":189,"phases":7061,"primaryCompletion":4213,"completion":837,"start":2632,"enrollment":4214,"conditions":7062,"interventions":7063},[89],[21],[4217,4218,4219,2565],{"trials":7065,"activeCount":101},[7066,7080],{"nctId":7067,"briefTitle":7068,"status":107,"phases":7069,"primaryCompletion":7070,"completion":7071,"start":7072,"enrollment":101,"conditions":7073,"interventions":7077},"NCT04901299","Fulvestrant + Neratinib In Breast Cancer",[90],"2024-07-01","2025-07-01","2023-07",[7074,2474,7075,7076,2549,2546],"Stage IV (Metastatic) Breast Cancer","ER Positive Breast Cancer","PR-Positive Breast Cancer",[7078,7079],"NERATINIB","FULVESTRANT",{"nctId":7081,"briefTitle":7082,"status":117,"phases":7083,"primaryCompletion":7084,"completion":7085,"start":568,"enrollment":7086,"conditions":7087,"interventions":7088},"NCT01441947","Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer",[90],"2016-12-12","2019-08-09",68,[21],[7089,4218],"Cabozantinib",{"trials":7091,"activeCount":101},[],{"trials":7093,"activeCount":101},[],{"trials":7095,"activeCount":101},[],{"intervention":7097,"totalTrials":136,"cells":7098},"Methylphenidate",{"EARLY_PHASE1":7099,"PHASE1":7101,"PHASE2":7114,"PHASE3":7125,"PHASE4":7127,"NA":7129},{"trials":7100,"activeCount":101},[],{"trials":7102,"activeCount":331,"soonestReadout":7107},[7103],{"nctId":7104,"briefTitle":7105,"status":189,"phases":7106,"primaryCompletion":7107,"completion":2200,"start":425,"enrollment":239,"conditions":7108,"interventions":7113},"NCT03814356","Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness",[89],"2024-04-01",[7109,7110,7111,7112],"Brain Injury Traumatic Severe (Diagnosis)","Coma","Consciousness, Level Altered","Anoxic Brain Injury",[7097],{"trials":7115,"activeCount":101},[7116],{"nctId":7117,"briefTitle":7118,"status":117,"phases":7119,"primaryCompletion":7120,"completion":7120,"start":1244,"enrollment":648,"conditions":7121,"interventions":7124},"NCT02051452","Reversal of General Anesthesia With Methylphenidate",[89,90],"2018-05",[7122,7123],"Post Operative Cognitive Dysfunction","Emergence From Anesthesia",[7097],{"trials":7126,"activeCount":101},[],{"trials":7128,"activeCount":101},[],{"trials":7130,"activeCount":101},[],{"intervention":7132,"totalTrials":178,"cells":7133},"Kybella",{"EARLY_PHASE1":7134,"PHASE1":7136,"PHASE2":7165,"PHASE3":7167,"PHASE4":7169,"NA":7171},{"trials":7135,"activeCount":101},[],{"trials":7137,"activeCount":331,"soonestReadout":7161},[7138,7148,7157],{"nctId":7139,"briefTitle":7140,"status":117,"phases":7141,"primaryCompletion":7142,"completion":7142,"start":7143,"enrollment":194,"conditions":7144,"interventions":7146},"NCT06120036","Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas",[89],"2025-01-09","2022-12-06",[7145],"Neurofibromatosis 1",[7132,7147],"Asclera",{"nctId":7149,"briefTitle":7150,"status":117,"phases":7151,"primaryCompletion":7152,"completion":7152,"start":7153,"enrollment":36,"conditions":7154,"interventions":7156},"NCT04730583","Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas",[89],"2024-04-19","2021-06-02",[7155],"Cutaneous Neurofibroma",[7132],{"nctId":7158,"briefTitle":7159,"status":1144,"phases":7160,"primaryCompletion":7161,"completion":7161,"start":3120,"enrollment":2728,"conditions":7162,"interventions":7164},"NCT06300502","Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)",[89],"2027-02",[7163,7145],"Neurofibromas, Cutaneous",[7132],{"trials":7166,"activeCount":101},[],{"trials":7168,"activeCount":101},[],{"trials":7170,"activeCount":101},[],{"trials":7172,"activeCount":101},[],{"intervention":7174,"totalTrials":331,"cells":7175},"F-18 3F4AP",{"EARLY_PHASE1":7176,"PHASE1":7178,"PHASE2":7187,"PHASE3":7189,"PHASE4":7191,"NA":7193},{"trials":7177,"activeCount":101},[],{"trials":7179,"activeCount":331,"soonestReadout":5714},[7180],{"nctId":7181,"briefTitle":7182,"status":160,"phases":7183,"primaryCompletion":5714,"completion":5714,"start":7184,"enrollment":1578,"conditions":7185,"interventions":7186},"NCT04699747","Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects",[89],"2021-03-25",[6002],[7174],{"trials":7188,"activeCount":101},[],{"trials":7190,"activeCount":101},[],{"trials":7192,"activeCount":101},[],{"trials":7194,"activeCount":101},[],{"intervention":7196,"totalTrials":331,"cells":7197},"[64Cu]FBP8",{"EARLY_PHASE1":7198,"PHASE1":7200,"PHASE2":7213,"PHASE3":7215,"PHASE4":7217,"NA":7219},{"trials":7199,"activeCount":101},[],{"trials":7201,"activeCount":331,"soonestReadout":5407},[7202],{"nctId":7203,"briefTitle":7204,"status":160,"phases":7205,"primaryCompletion":5407,"completion":5407,"start":7206,"enrollment":7207,"conditions":7208,"interventions":7212},"NCT03830320","Positron Emission Tomography (PET) Imaging of Thrombosis",[89],"2016-04-01",165,[7209,7210,2306,7211],"Atrial Fibrillation","COVID-19","Thrombosis",[7196],{"trials":7214,"activeCount":101},[],{"trials":7216,"activeCount":101},[],{"trials":7218,"activeCount":101},[],{"trials":7220,"activeCount":101},[],{"intervention":2613,"totalTrials":331,"cells":7222},{"EARLY_PHASE1":7223,"PHASE1":7225,"PHASE2":7231,"PHASE3":7233,"PHASE4":7235,"NA":7237},{"trials":7224,"activeCount":101},[],{"trials":7226,"activeCount":331,"soonestReadout":1242},[7227],{"nctId":2606,"briefTitle":2607,"status":189,"phases":7228,"primaryCompletion":1242,"completion":1243,"start":2609,"enrollment":2610,"conditions":7229,"interventions":7230},[89],[2030],[2613,127,2599,2614],{"trials":7232,"activeCount":101},[],{"trials":7234,"activeCount":101},[],{"trials":7236,"activeCount":101},[],{"trials":7238,"activeCount":101},[],{"intervention":7240,"totalTrials":331,"cells":7241},"ASTX727",{"EARLY_PHASE1":7242,"PHASE1":7244,"PHASE2":7254,"PHASE3":7256,"PHASE4":7258,"NA":7260},{"trials":7243,"activeCount":101},[],{"trials":7245,"activeCount":331,"soonestReadout":3014},[7246],{"nctId":7247,"briefTitle":7248,"status":160,"phases":7249,"primaryCompletion":3014,"completion":6086,"start":7250,"enrollment":209,"conditions":7251,"interventions":7253},"NCT03922555","ASTX727 in Recurrent\u002FProgressive Non-enhancing IDH Mutant Gliomas",[89],"2019-07-12",[7252],"Neurological Cancer",[7240],{"trials":7255,"activeCount":101},[],{"trials":7257,"activeCount":101},[],{"trials":7259,"activeCount":101},[],{"trials":7261,"activeCount":101},[],{"intervention":2842,"totalTrials":331,"cells":7263},{"EARLY_PHASE1":7264,"PHASE1":7266,"PHASE2":7272,"PHASE3":7274,"PHASE4":7276,"NA":7278},{"trials":7265,"activeCount":101},[],{"trials":7267,"activeCount":331,"soonestReadout":2835},[7268],{"nctId":2832,"briefTitle":2833,"status":189,"phases":7269,"primaryCompletion":2835,"completion":2835,"start":2836,"enrollment":2837,"conditions":7270,"interventions":7271},[89],[2839],[2841,2842,127,2476],{"trials":7273,"activeCount":101},[],{"trials":7275,"activeCount":101},[],{"trials":7277,"activeCount":101},[],{"trials":7279,"activeCount":101},[],{"intervention":4217,"totalTrials":331,"cells":7281},{"EARLY_PHASE1":7282,"PHASE1":7284,"PHASE2":7290,"PHASE3":7292,"PHASE4":7294,"NA":7296},{"trials":7283,"activeCount":101},[],{"trials":7285,"activeCount":331,"soonestReadout":4213},[7286],{"nctId":4210,"briefTitle":4211,"status":189,"phases":7287,"primaryCompletion":4213,"completion":837,"start":2632,"enrollment":4214,"conditions":7288,"interventions":7289},[89],[21],[4217,4218,4219,2565],{"trials":7291,"activeCount":101},[],{"trials":7293,"activeCount":101},[],{"trials":7295,"activeCount":101},[],{"trials":7297,"activeCount":101},[],{"intervention":4219,"totalTrials":331,"cells":7299},{"EARLY_PHASE1":7300,"PHASE1":7302,"PHASE2":7308,"PHASE3":7310,"PHASE4":7312,"NA":7314},{"trials":7301,"activeCount":101},[],{"trials":7303,"activeCount":331,"soonestReadout":4213},[7304],{"nctId":4210,"briefTitle":4211,"status":189,"phases":7305,"primaryCompletion":4213,"completion":837,"start":2632,"enrollment":4214,"conditions":7306,"interventions":7307},[89],[21],[4217,4218,4219,2565],{"trials":7309,"activeCount":101},[],{"trials":7311,"activeCount":101},[],{"trials":7313,"activeCount":101},[],{"trials":7315,"activeCount":101},[],{"intervention":7317,"totalTrials":331,"cells":7318},"ketamin",{"EARLY_PHASE1":7319,"PHASE1":7321,"PHASE2":7331,"PHASE3":7333,"PHASE4":7335,"NA":7337},{"trials":7320,"activeCount":101},[],{"trials":7322,"activeCount":331,"soonestReadout":7327},[7323],{"nctId":7324,"briefTitle":7325,"status":189,"phases":7326,"primaryCompletion":7327,"completion":3563,"start":7328,"enrollment":3027,"conditions":7329,"interventions":7330},"NCT06698848","Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome",[89],"2030-06-01","2025-01-01",[15,1816],[7317],{"trials":7332,"activeCount":101},[],{"trials":7334,"activeCount":101},[],{"trials":7336,"activeCount":101},[],{"trials":7338,"activeCount":101},[],{"intervention":2624,"totalTrials":331,"cells":7340},{"EARLY_PHASE1":7341,"PHASE1":7343,"PHASE2":7349,"PHASE3":7351,"PHASE4":7353,"NA":7355},{"trials":7342,"activeCount":101},[],{"trials":7344,"activeCount":331,"soonestReadout":2619},[7345],{"nctId":2616,"briefTitle":2617,"status":160,"phases":7346,"primaryCompletion":2619,"completion":1147,"start":2620,"enrollment":1847,"conditions":7347,"interventions":7348},[89],[2622],[2624,2625,2599],{"trials":7350,"activeCount":101},[],{"trials":7352,"activeCount":101},[],{"trials":7354,"activeCount":101},[],{"trials":7356,"activeCount":101},[],{"intervention":7358,"totalTrials":331,"cells":7359},"LCFA-01",{"EARLY_PHASE1":7360,"PHASE1":7362,"PHASE2":7373,"PHASE3":7375,"PHASE4":7377,"NA":7379},{"trials":7361,"activeCount":101},[],{"trials":7363,"activeCount":331,"soonestReadout":7368},[7364],{"nctId":7365,"briefTitle":7366,"status":318,"phases":7367,"primaryCompletion":7368,"completion":1366,"start":7369,"enrollment":227,"conditions":7370,"interventions":7372},"NCT07514416","To Test a New Drug (LCFA-01) for Safety and PK in Healthy Adults for Bacterial Vaginosis Infection.",[89],"2026-07-17","2026-05-06",[7371],"Bacterial Vaginosis Treatment",[7358],{"trials":7374,"activeCount":101},[],{"trials":7376,"activeCount":101},[],{"trials":7378,"activeCount":101},[],{"trials":7380,"activeCount":101},[],{"intervention":7382,"totalTrials":331,"cells":7383},"Inqovi",{"EARLY_PHASE1":7384,"PHASE1":7386,"PHASE2":7398,"PHASE3":7400,"PHASE4":7402,"NA":7404},{"trials":7385,"activeCount":101},[],{"trials":7387,"activeCount":331,"soonestReadout":7392},[7388],{"nctId":7389,"briefTitle":7390,"status":189,"phases":7391,"primaryCompletion":7392,"completion":3177,"start":7393,"enrollment":2859,"conditions":7394,"interventions":7397},"NCT04980404","Inqovi Maintenance Therapy in Myeloid Neoplasms",[89],"2023-08-24","2021-09-17",[918,7395,7396],"Chronic Myelomonocytic Leukemia","Stem Cell Leukemia",[7382],{"trials":7399,"activeCount":101},[],{"trials":7401,"activeCount":101},[],{"trials":7403,"activeCount":101},[],{"trials":7405,"activeCount":101},[],{"intervention":7407,"totalTrials":331,"cells":7408},"Momelotinib",{"EARLY_PHASE1":7409,"PHASE1":7411,"PHASE2":7422,"PHASE3":7424,"PHASE4":7426,"NA":7428},{"trials":7410,"activeCount":101},[],{"trials":7412,"activeCount":331,"soonestReadout":7417},[7413],{"nctId":7414,"briefTitle":7415,"status":160,"phases":7416,"primaryCompletion":7417,"completion":320,"start":7418,"enrollment":555,"conditions":7419,"interventions":7421},"NCT07104799","Momelotinib During and After HCT in Myelofibrosis",[89],"2028-01","2026-02-23",[3252,7420],"Hematopoietic Cell Transplantation (HCT)",[7407],{"trials":7423,"activeCount":101},[],{"trials":7425,"activeCount":101},[],{"trials":7427,"activeCount":101},[],{"trials":7429,"activeCount":101},[],{"intervention":7431,"totalTrials":331,"cells":7432},"AZD6738",{"EARLY_PHASE1":7433,"PHASE1":7435,"PHASE2":7445,"PHASE3":7447,"PHASE4":7449,"NA":7451},{"trials":7434,"activeCount":101},[],{"trials":7436,"activeCount":331,"soonestReadout":7441},[7437],{"nctId":7438,"briefTitle":7439,"status":189,"phases":7440,"primaryCompletion":7441,"completion":5126,"start":7442,"enrollment":2663,"conditions":7443,"interventions":7444},"NCT03770429","AZD6738 for Patients With Progressive MDS or CMML",[89],"2025-04-09","2019-08-05",[916,2861],[7431],{"trials":7446,"activeCount":101},[],{"trials":7448,"activeCount":101},[],{"trials":7450,"activeCount":101},[],{"trials":7452,"activeCount":101},[],{"intervention":7454,"totalTrials":331,"cells":7455},"Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab",{"EARLY_PHASE1":7456,"PHASE1":7458,"PHASE2":7468,"PHASE3":7470,"PHASE4":7472,"NA":7474},{"trials":7457,"activeCount":101},[],{"trials":7459,"activeCount":331,"soonestReadout":2777},[7460],{"nctId":7461,"briefTitle":7462,"status":189,"phases":7463,"primaryCompletion":2777,"completion":1052,"start":7464,"enrollment":194,"conditions":7465,"interventions":7467},"NCT04540380","Renal Allograft Tolerance Through Mixed Chimerism - SMC\u002FMGH",[89],"2021-09-01",[7466],"Renal Failure",[7454],{"trials":7469,"activeCount":101},[],{"trials":7471,"activeCount":101},[],{"trials":7473,"activeCount":101},[],{"trials":7475,"activeCount":101},[],{"intervention":4057,"totalTrials":331,"cells":7477},{"EARLY_PHASE1":7478,"PHASE1":7480,"PHASE2":7486,"PHASE3":7488,"PHASE4":7490,"NA":7492},{"trials":7479,"activeCount":101},[],{"trials":7481,"activeCount":331,"soonestReadout":163},[7482],{"nctId":4046,"briefTitle":4047,"status":160,"phases":7483,"primaryCompletion":163,"completion":163,"start":4049,"enrollment":4050,"conditions":7484,"interventions":7485},[89],[4052,4053,4054,4055],[3485,4057],{"trials":7487,"activeCount":101},[],{"trials":7489,"activeCount":101},[],{"trials":7491,"activeCount":101},[],{"trials":7493,"activeCount":101},[],{"intervention":52,"totalTrials":798,"cells":7495},{"EARLY_PHASE1":7496,"PHASE1":7507,"PHASE2":7509,"PHASE3":7511,"PHASE4":7513,"NA":7515},{"trials":7497,"activeCount":331,"soonestReadout":7502},[7498],{"nctId":7499,"briefTitle":7500,"status":189,"phases":7501,"primaryCompletion":7502,"completion":1999,"start":7503,"enrollment":7504,"conditions":7505,"interventions":7506},"NCT05056896","ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension",[88],"2024-11-27","2022-06-03",161,[6511],[52],{"trials":7508,"activeCount":101},[],{"trials":7510,"activeCount":101},[],{"trials":7512,"activeCount":101},[],{"trials":7514,"activeCount":101},[],{"trials":7516,"activeCount":178,"soonestReadout":51},[7517,7522,7539],{"nctId":49,"briefTitle":50,"status":189,"phases":7518,"primaryCompletion":51,"completion":3050,"start":7519,"enrollment":6539,"conditions":7520,"interventions":7521},[93],"2015-07-06",[6511],[52],{"nctId":7523,"briefTitle":7524,"status":189,"phases":7525,"primaryCompletion":7526,"completion":1288,"start":7527,"enrollment":7528,"conditions":7529,"interventions":7536},"NCT07597239","Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization",[93],"2026-02-17","2022-12-14",130,[7211,7530,7531,7532,7533,7534,7535],"Arterial Occlusive Diseases","Thromboelastography (TEG)","Peripheral Arterial Disease(PAD)","Stent Thrombosis","Platelet Inhibition","PRU(Platelet Reactivity Unit)",[52,7537,7538],"Clopidogrel","Ticagrelor",{"nctId":7540,"briefTitle":7541,"status":160,"phases":7542,"primaryCompletion":6852,"completion":2201,"start":7543,"enrollment":7544,"conditions":7545,"interventions":7550},"NCT07613840","Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease",[93],"2025-04-29",484,[7546,7547,7211,7548,7549,7531,7535],"Peripheral Arterial Disease (PAD)","Amputation","Thrombosis (Stent Thrombosis)","Platelet Aggregation Inhibitors",[52,7537,7538,7551],"Rivaroxaban",{"intervention":7553,"totalTrials":136,"cells":7554},"Fecal Microbiota Transplantation",{"EARLY_PHASE1":7555,"PHASE1":7575,"PHASE2":7577,"PHASE3":7579,"PHASE4":7581,"NA":7583},{"trials":7556,"activeCount":331,"soonestReadout":6112},[7557,7564],{"nctId":7558,"briefTitle":7559,"status":117,"phases":7560,"primaryCompletion":268,"completion":119,"start":46,"enrollment":209,"conditions":7561,"interventions":7563},"NCT02733744","Fecal Microbiota Transplantation After HSCT",[88],[7562],"Bone Marrow Transplantation",[7553],{"nctId":7565,"briefTitle":7566,"status":189,"phases":7567,"primaryCompletion":6112,"completion":7568,"start":7569,"enrollment":1890,"conditions":7570,"interventions":7573},"NCT06083142","Fecal Microbiota Transplant for Autobrewery Syndrome",[88],"2030-08-31","2025-02-14",[7571,7572],"Auto-Brewery Syndrome","Gut Fermentation Syndrome",[7574],"Fecal microbiota transplantation",{"trials":7576,"activeCount":101},[],{"trials":7578,"activeCount":101},[],{"trials":7580,"activeCount":101},[],{"trials":7582,"activeCount":101},[],{"trials":7584,"activeCount":101},[],{"intervention":7586,"totalTrials":331,"cells":7587},"Xenon",{"EARLY_PHASE1":7588,"PHASE1":7599,"PHASE2":7601,"PHASE3":7603,"PHASE4":7605,"NA":7607},{"trials":7589,"activeCount":331,"soonestReadout":2556},[7590],{"nctId":7591,"briefTitle":7592,"status":160,"phases":7593,"primaryCompletion":2556,"completion":162,"start":7594,"enrollment":194,"conditions":7595,"interventions":7597},"NCT03748446","Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder",[88],"2019-12-05",[18,7596],"Bipolar Depression",[7586,7598],"Nitrogen gas",{"trials":7600,"activeCount":101},[],{"trials":7602,"activeCount":101},[],{"trials":7604,"activeCount":101},[],{"trials":7606,"activeCount":101},[],{"trials":7608,"activeCount":101},[],{"intervention":7598,"totalTrials":331,"cells":7610},{"EARLY_PHASE1":7611,"PHASE1":7617,"PHASE2":7619,"PHASE3":7621,"PHASE4":7623,"NA":7625},{"trials":7612,"activeCount":331,"soonestReadout":2556},[7613],{"nctId":7591,"briefTitle":7592,"status":160,"phases":7614,"primaryCompletion":2556,"completion":162,"start":7594,"enrollment":194,"conditions":7615,"interventions":7616},[88],[18,7596],[7586,7598],{"trials":7618,"activeCount":101},[],{"trials":7620,"activeCount":101},[],{"trials":7622,"activeCount":101},[],{"trials":7624,"activeCount":101},[],{"trials":7626,"activeCount":101},[],{"intervention":7628,"totalTrials":331,"cells":7629},"Gadolinium DOTA Meglumine",{"EARLY_PHASE1":7630,"PHASE1":7642,"PHASE2":7644,"PHASE3":7646,"PHASE4":7648,"NA":7650},{"trials":7631,"activeCount":331,"soonestReadout":1146},[7632],{"nctId":7633,"briefTitle":7634,"status":160,"phases":7635,"primaryCompletion":1146,"completion":2642,"start":7636,"enrollment":1083,"conditions":7637,"interventions":7641},"NCT02973633","Diffusion MRI in Heart Failure",[88],"2017-06-30",[7638,7639,7640],"Heart Failure","Myocardial Infarction","Left Ventricular Hypertrophy",[7628],{"trials":7643,"activeCount":101},[],{"trials":7645,"activeCount":101},[],{"trials":7647,"activeCount":101},[],{"trials":7649,"activeCount":101},[],{"trials":7651,"activeCount":101},[],{"intervention":7653,"totalTrials":331,"cells":7654},"Squaric Acid Dibutyl Ester",{"EARLY_PHASE1":7655,"PHASE1":7665,"PHASE2":7667,"PHASE3":7669,"PHASE4":7671,"NA":7673},{"trials":7656,"activeCount":331,"soonestReadout":5101},[7657],{"nctId":7658,"briefTitle":7659,"status":318,"phases":7660,"primaryCompletion":5101,"completion":7327,"start":3014,"enrollment":227,"conditions":7661,"interventions":7663},"NCT04999631","SADBE for Congenital Melanocytic Nevi",[88],[7662],"Congenital Melanocytic Nevus",[7653,7664],"Ethanol Solution",{"trials":7666,"activeCount":101},[],{"trials":7668,"activeCount":101},[],{"trials":7670,"activeCount":101},[],{"trials":7672,"activeCount":101},[],{"trials":7674,"activeCount":101},[],{"intervention":7664,"totalTrials":331,"cells":7676},{"EARLY_PHASE1":7677,"PHASE1":7683,"PHASE2":7685,"PHASE3":7687,"PHASE4":7689,"NA":7691},{"trials":7678,"activeCount":331,"soonestReadout":5101},[7679],{"nctId":7658,"briefTitle":7659,"status":318,"phases":7680,"primaryCompletion":5101,"completion":7327,"start":3014,"enrollment":227,"conditions":7681,"interventions":7682},[88],[7662],[7653,7664],{"trials":7684,"activeCount":101},[],{"trials":7686,"activeCount":101},[],{"trials":7688,"activeCount":101},[],{"trials":7690,"activeCount":101},[],{"trials":7692,"activeCount":101},[],{"intervention":7694,"totalTrials":331,"cells":7695},"Pegulicianine",{"EARLY_PHASE1":7696,"PHASE1":7707,"PHASE2":7709,"PHASE3":7711,"PHASE4":7713,"NA":7715},{"trials":7697,"activeCount":331,"soonestReadout":7702},[7698],{"nctId":7699,"briefTitle":7700,"status":318,"phases":7701,"primaryCompletion":7702,"completion":3368,"start":1288,"enrollment":1847,"conditions":7703,"interventions":7706},"NCT06957821","Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques",[88],"2028-07",[7704,7705],"Carotid Artery Diseases","Peripheral Arterial Disease",[7694],{"trials":7708,"activeCount":101},[],{"trials":7710,"activeCount":101},[],{"trials":7712,"activeCount":101},[],{"trials":7714,"activeCount":101},[],{"trials":7716,"activeCount":101},[],{"intervention":2917,"totalTrials":331,"cells":7718},{"EARLY_PHASE1":7719,"PHASE1":7725,"PHASE2":7727,"PHASE3":7729,"PHASE4":7731,"NA":7733},{"trials":7720,"activeCount":331,"soonestReadout":837},[7721],{"nctId":2906,"briefTitle":2907,"status":189,"phases":7722,"primaryCompletion":837,"completion":2768,"start":2909,"enrollment":1805,"conditions":7723,"interventions":7724},[88],[2911,2912,2913,2914,2915],[2901,2917],{"trials":7726,"activeCount":101},[],{"trials":7728,"activeCount":101},[],{"trials":7730,"activeCount":101},[],{"trials":7732,"activeCount":101},[],{"trials":7734,"activeCount":101},[],{"intervention":7736,"totalTrials":331,"cells":7737},"18F-FDG",{"EARLY_PHASE1":7738,"PHASE1":7748,"PHASE2":7750,"PHASE3":7752,"PHASE4":7754,"NA":7756},{"trials":7739,"activeCount":331,"soonestReadout":3051},[7740],{"nctId":7741,"briefTitle":7742,"status":318,"phases":7743,"primaryCompletion":3051,"completion":3051,"start":837,"enrollment":1578,"conditions":7744,"interventions":7747},"NCT07604207","Multi-organ Imaging of Microvascular and Metabolic Function",[88],[7745,7746],"Healthy Subjects (HS)","Cardiovascular Diseases (CVD)",[7736],{"trials":7749,"activeCount":101},[],{"trials":7751,"activeCount":101},[],{"trials":7753,"activeCount":101},[],{"trials":7755,"activeCount":101},[],{"trials":7757,"activeCount":101},[],{"intervention":7759,"totalTrials":331,"cells":7760},"Botensilimab",{"EARLY_PHASE1":7761,"PHASE1":7772,"PHASE2":7774,"PHASE3":7776,"PHASE4":7778,"NA":7780},{"trials":7762,"activeCount":331,"soonestReadout":3014},[7763],{"nctId":7764,"briefTitle":7765,"status":160,"phases":7766,"primaryCompletion":3014,"completion":4018,"start":7767,"enrollment":2728,"conditions":7768,"interventions":7770},"NCT07128355","Botensilimab, Balstilimab, and SBRT in Colorectal Cancer",[88],"2026-05-12",[7769],"Non-MSI-H or pMMR Colorectal Cancer With Liver Metastasis",[7759,7771],"Balstilimab",{"trials":7773,"activeCount":101},[],{"trials":7775,"activeCount":101},[],{"trials":7777,"activeCount":101},[],{"trials":7779,"activeCount":101},[],{"trials":7781,"activeCount":101},[],{"intervention":7771,"totalTrials":331,"cells":7783},{"EARLY_PHASE1":7784,"PHASE1":7790,"PHASE2":7792,"PHASE3":7794,"PHASE4":7796,"NA":7798},{"trials":7785,"activeCount":331,"soonestReadout":3014},[7786],{"nctId":7764,"briefTitle":7765,"status":160,"phases":7787,"primaryCompletion":3014,"completion":4018,"start":7767,"enrollment":2728,"conditions":7788,"interventions":7789},[88],[7769],[7759,7771],{"trials":7791,"activeCount":101},[],{"trials":7793,"activeCount":101},[],{"trials":7795,"activeCount":101},[],{"trials":7797,"activeCount":101},[],{"trials":7799,"activeCount":101},[],{"intervention":7801,"totalTrials":331,"cells":7802},"N-Acetyl Cysteine",{"EARLY_PHASE1":7803,"PHASE1":7812,"PHASE2":7814,"PHASE3":7816,"PHASE4":7818,"NA":7820},{"trials":7804,"activeCount":331,"soonestReadout":5101},[7805],{"nctId":7806,"briefTitle":7807,"status":318,"phases":7808,"primaryCompletion":5101,"completion":5101,"start":3014,"enrollment":3027,"conditions":7809,"interventions":7811},"NCT07323446","The MIND Study: The MGH\u002FMIT Investigation of NAC on Dysregulation",[88],[7810],"Emotional Dysregulation",[7801],{"trials":7813,"activeCount":101},[],{"trials":7815,"activeCount":101},[],{"trials":7817,"activeCount":101},[],{"trials":7819,"activeCount":101},[],{"trials":7821,"activeCount":101},[],{"intervention":7823,"totalTrials":331,"cells":7824},"Oxygen Therapy",{"EARLY_PHASE1":7825,"PHASE1":7836,"PHASE2":7838,"PHASE3":7840,"PHASE4":7842,"NA":7844},{"trials":7826,"activeCount":331,"soonestReadout":2201},[7827],{"nctId":7828,"briefTitle":7829,"status":160,"phases":7830,"primaryCompletion":2201,"completion":2201,"start":193,"enrollment":732,"conditions":7831,"interventions":7835},"NCT05891886","Supplemental Oxygen in Pulmonary Embolism (SO-PE)",[88],[7832,1155,7833,7834],"Pulmonary Embolism","Metabolomics","Oxygen Inhalation Therapy",[7823],{"trials":7837,"activeCount":101},[],{"trials":7839,"activeCount":101},[],{"trials":7841,"activeCount":101},[],{"trials":7843,"activeCount":101},[],{"trials":7845,"activeCount":101},[],{"intervention":7847,"totalTrials":331,"cells":7848},"Norethindrone Acetate-Ethinyl Estradiol",{"EARLY_PHASE1":7849,"PHASE1":7861,"PHASE2":7863,"PHASE3":7865,"PHASE4":7867,"NA":7869},{"trials":7850,"activeCount":331,"soonestReadout":2744},[7851],{"nctId":7852,"briefTitle":7853,"status":160,"phases":7854,"primaryCompletion":2744,"completion":2744,"start":322,"enrollment":194,"conditions":7855,"interventions":7860},"NCT07568509","Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease",[88],[7856,7857,7858,7859],"Arginine Vasopressin Deficiency","Oxytocin Deficiency","Pediatric Disease","Hypopituitarism",[7847],{"trials":7862,"activeCount":101},[],{"trials":7864,"activeCount":101},[],{"trials":7866,"activeCount":101},[],{"trials":7868,"activeCount":101},[],{"trials":7870,"activeCount":101},[],{"intervention":7872,"totalTrials":331,"cells":7873},"Inhaled Nitric Oxide",{"EARLY_PHASE1":7874,"PHASE1":7884,"PHASE2":7886,"PHASE3":7888,"PHASE4":7890,"NA":7892},{"trials":7875,"activeCount":331,"soonestReadout":3177},[7876],{"nctId":7877,"briefTitle":7878,"status":189,"phases":7879,"primaryCompletion":3177,"completion":1243,"start":7880,"enrollment":239,"conditions":7881,"interventions":7883},"NCT05612074","Methemoglobin Concentration in High Dose Inhaled Nitric Oxide",[88],"2023-10-16",[7882],"Healthy Subjects",[7872],{"trials":7885,"activeCount":101},[],{"trials":7887,"activeCount":101},[],{"trials":7889,"activeCount":101},[],{"trials":7891,"activeCount":101},[],{"trials":7893,"activeCount":101},[],{"intervention":7895,"totalTrials":331,"cells":7896},"High dose inhaled nitric oxide",{"EARLY_PHASE1":7897,"PHASE1":7907,"PHASE2":7909,"PHASE3":7911,"PHASE4":7913,"NA":7915},{"trials":7898,"activeCount":331,"soonestReadout":1242},[7899],{"nctId":7900,"briefTitle":7901,"status":160,"phases":7902,"primaryCompletion":1242,"completion":1242,"start":7418,"enrollment":36,"conditions":7903,"interventions":7906},"NCT06950294","iNO300 Therapy in Critically Ill Patients With Pneumonia",[88],[7904,7905],"Critical Illness","Pneumonia",[7895],{"trials":7908,"activeCount":101},[],{"trials":7910,"activeCount":101},[],{"trials":7912,"activeCount":101},[],{"trials":7914,"activeCount":101},[],{"trials":7916,"activeCount":101},[],{"intervention":7918,"totalTrials":331,"cells":7919},"C11-SY08",{"EARLY_PHASE1":7920,"PHASE1":7932,"PHASE2":7934,"PHASE3":7936,"PHASE4":7938,"NA":7940},{"trials":7921,"activeCount":331,"soonestReadout":3177},[7922],{"nctId":7923,"briefTitle":7924,"status":160,"phases":7925,"primaryCompletion":3177,"completion":7926,"start":3121,"enrollment":251,"conditions":7927,"interventions":7931},"NCT06098612","PET Imaging Evaluation of [11C]SY08",[88],"2027-11",[7928,7929,7930,2013],"Parkinson's Disease","Multiple System Atrophy","Dementia With Lewy Bodies",[7918],{"trials":7933,"activeCount":101},[],{"trials":7935,"activeCount":101},[],{"trials":7937,"activeCount":101},[],{"trials":7939,"activeCount":101},[],{"trials":7941,"activeCount":101},[],{"intervention":7943,"totalTrials":798,"cells":7944},"Radiotracer",{"EARLY_PHASE1":7945,"PHASE1":7947,"PHASE2":7949,"PHASE3":7951,"PHASE4":7953,"NA":7955},{"trials":7946,"activeCount":101},[],{"trials":7948,"activeCount":101},[],{"trials":7950,"activeCount":101},[],{"trials":7952,"activeCount":101},[],{"trials":7954,"activeCount":101},[],{"trials":7956,"activeCount":798,"soonestReadout":7961},[7957,7969,7979,7988],{"nctId":7958,"briefTitle":7959,"status":160,"phases":7960,"primaryCompletion":7961,"completion":7961,"start":7962,"enrollment":2559,"conditions":7963,"interventions":7967},"NCT06265272","Value of [68Ga]Ga-PSMA-11 PET\u002FMRI in the Assessment of Liver Cirrhosis",[],"2026-12-19","2023-12-10",[7964,7965,7966],"Liver Cirrhosis","Hepatic Cell Carcinoma","Portal Hypertension",[7968,7943],"Injection of a gadolinium contrast agen",{"nctId":7970,"briefTitle":7971,"status":1144,"phases":7972,"primaryCompletion":7973,"completion":7974,"start":2119,"enrollment":1578,"conditions":7975,"interventions":7978},"NCT06377553","PET\u002FMRI for Evaluation of Endometriosis",[],"2028-01-03","2029-05-03",[7976,7977],"Endometriosis","Endometrioma",[7943],{"nctId":7980,"briefTitle":7981,"status":318,"phases":7982,"primaryCompletion":6111,"completion":6111,"start":7983,"enrollment":239,"conditions":7984,"interventions":7986},"NCT06252610","PET\u002FMRI of Primary Sclerosing Cholangitis",[],"2026-05-10",[7985],"PSC",[7943,7987],"Contrast Media, Magnetic Resonance",{"nctId":7989,"briefTitle":7990,"status":160,"phases":7991,"primaryCompletion":7992,"completion":7993,"start":7994,"enrollment":1847,"conditions":7995,"interventions":7996},"NCT06252493","Value of PET\u002FMR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.",[],"2027-12-19","2029-12-19","2023-12-19",[3591],[7943,7987,7997,7998],"Glucagon","Oral contrast media application",{"intervention":7538,"totalTrials":178,"cells":8000},{"EARLY_PHASE1":8001,"PHASE1":8003,"PHASE2":8005,"PHASE3":8007,"PHASE4":8009,"NA":8018},{"trials":8002,"activeCount":101},[],{"trials":8004,"activeCount":101},[],{"trials":8006,"activeCount":101},[],{"trials":8008,"activeCount":101},[],{"trials":8010,"activeCount":101},[8011],{"nctId":8012,"briefTitle":8013,"status":107,"phases":8014,"primaryCompletion":566,"completion":566,"start":1876,"enrollment":101,"conditions":8015,"interventions":8017},"NCT01826175","Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During PCI: an OCT Study",[92],[8016,1468],"Acute Coronary Syndrome",[7538,7537],{"trials":8019,"activeCount":136,"soonestReadout":7526},[8020,8024],{"nctId":7523,"briefTitle":7524,"status":189,"phases":8021,"primaryCompletion":7526,"completion":1288,"start":7527,"enrollment":7528,"conditions":8022,"interventions":8023},[93],[7211,7530,7531,7532,7533,7534,7535],[52,7537,7538],{"nctId":7540,"briefTitle":7541,"status":160,"phases":8025,"primaryCompletion":6852,"completion":2201,"start":7543,"enrollment":7544,"conditions":8026,"interventions":8027},[93],[7546,7547,7211,7548,7549,7531,7535],[52,7537,7538,7551],{"intervention":7537,"totalTrials":178,"cells":8029},{"EARLY_PHASE1":8030,"PHASE1":8032,"PHASE2":8034,"PHASE3":8036,"PHASE4":8038,"NA":8044},{"trials":8031,"activeCount":101},[],{"trials":8033,"activeCount":101},[],{"trials":8035,"activeCount":101},[],{"trials":8037,"activeCount":101},[],{"trials":8039,"activeCount":101},[8040],{"nctId":8012,"briefTitle":8013,"status":107,"phases":8041,"primaryCompletion":566,"completion":566,"start":1876,"enrollment":101,"conditions":8042,"interventions":8043},[92],[8016,1468],[7538,7537],{"trials":8045,"activeCount":136,"soonestReadout":7526},[8046,8050],{"nctId":7523,"briefTitle":7524,"status":189,"phases":8047,"primaryCompletion":7526,"completion":1288,"start":7527,"enrollment":7528,"conditions":8048,"interventions":8049},[93],[7211,7530,7531,7532,7533,7534,7535],[52,7537,7538],{"nctId":7540,"briefTitle":7541,"status":160,"phases":8051,"primaryCompletion":6852,"completion":2201,"start":7543,"enrollment":7544,"conditions":8052,"interventions":8053},[93],[7546,7547,7211,7548,7549,7531,7535],[52,7537,7538,7551],{"intervention":7987,"totalTrials":136,"cells":8055},{"EARLY_PHASE1":8056,"PHASE1":8058,"PHASE2":8060,"PHASE3":8062,"PHASE4":8064,"NA":8066},{"trials":8057,"activeCount":101},[],{"trials":8059,"activeCount":101},[],{"trials":8061,"activeCount":101},[],{"trials":8063,"activeCount":101},[],{"trials":8065,"activeCount":101},[],{"trials":8067,"activeCount":136,"soonestReadout":7992},[8068,8072],{"nctId":7980,"briefTitle":7981,"status":318,"phases":8069,"primaryCompletion":6111,"completion":6111,"start":7983,"enrollment":239,"conditions":8070,"interventions":8071},[],[7985],[7943,7987],{"nctId":7989,"briefTitle":7990,"status":160,"phases":8073,"primaryCompletion":7992,"completion":7993,"start":7994,"enrollment":1847,"conditions":8074,"interventions":8075},[],[3591],[7943,7987,7997,7998],{"intervention":8077,"totalTrials":270,"cells":8078},"Metformin",{"EARLY_PHASE1":8079,"PHASE1":8099,"PHASE2":8110,"PHASE3":8118,"PHASE4":8120,"NA":8122},{"trials":8080,"activeCount":101},[8081,8088],{"nctId":8082,"briefTitle":8083,"status":173,"phases":8084,"primaryCompletion":8085,"completion":8085,"start":2514,"enrollment":2508,"conditions":8086,"interventions":8087},"NCT03349775","Cardiometabolic Disease and Pulmonary Hypertension",[88],"2020-12-22",[26],[8077],{"nctId":8089,"briefTitle":8090,"status":117,"phases":8091,"primaryCompletion":1846,"completion":1846,"start":436,"enrollment":194,"conditions":8092,"interventions":8098},"NCT02184832","Dietary Intake of Tryptophan and Metformin Response",[88],[8093,8094,8095,8096,8097],"Metformin Response","Fasting Glucose","Tryptophan Concentration","Metformin Concentration","Diet Tolerability",[8077],{"trials":8100,"activeCount":101},[8101],{"nctId":8102,"briefTitle":8103,"status":117,"phases":8104,"primaryCompletion":2800,"completion":2507,"start":912,"enrollment":8105,"conditions":8106,"interventions":8108},"NCT01762046","Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans",[89],1033,[8107],"Diabetes Mellitus, Type 2",[8109,8077],"Glipizide",{"trials":8111,"activeCount":101},[8112],{"nctId":8113,"briefTitle":8114,"status":173,"phases":8115,"primaryCompletion":225,"completion":225,"start":628,"enrollment":2508,"conditions":8116,"interventions":8117},"NCT01215032","Metformin in Castration-Resistant Prostate Cancer",[90],[2038],[8077],{"trials":8119,"activeCount":101},[],{"trials":8121,"activeCount":101},[],{"trials":8123,"activeCount":331,"soonestReadout":1242},[8124,8133,8142],{"nctId":8125,"briefTitle":8126,"status":2758,"phases":8127,"primaryCompletion":8128,"completion":8128,"start":4464,"enrollment":1466,"conditions":8129,"interventions":8131},"NCT01389778","Polycystic Ovary Syndrome Genetics and Treatment Response",[93],"2019-10",[8130],"Polycystic Ovary Syndrome",[8132,8077],"Metformin ER",{"nctId":8134,"briefTitle":8135,"status":117,"phases":8136,"primaryCompletion":4464,"completion":8137,"start":177,"enrollment":366,"conditions":8138,"interventions":8141},"NCT00399360","Lifestyle Modification and Metformin Use in the Treatment of HIV",[93],"2012-06",[8139,8140],"HIV Infections","Metabolic Syndrome X",[8077],{"nctId":8143,"briefTitle":8144,"status":189,"phases":8145,"primaryCompletion":1242,"completion":1242,"start":455,"enrollment":8146,"conditions":8147,"interventions":8150},"NCT02087826","Study of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS",[93],1017,[8148,8149,1221],"Genetics","Metabolism",[8077],{"intervention":7997,"totalTrials":178,"cells":8152},{"EARLY_PHASE1":8153,"PHASE1":8155,"PHASE2":8157,"PHASE3":8159,"PHASE4":8161,"NA":8170},{"trials":8154,"activeCount":101},[],{"trials":8156,"activeCount":101},[],{"trials":8158,"activeCount":101},[],{"trials":8160,"activeCount":101},[],{"trials":8162,"activeCount":101},[8163],{"nctId":8164,"briefTitle":8165,"status":117,"phases":8166,"primaryCompletion":4491,"completion":2418,"start":1846,"enrollment":151,"conditions":8167,"interventions":8168},"NCT02516150","Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon",[92],[2997],[8169,7997],"Ethanol",{"trials":8171,"activeCount":331,"soonestReadout":7992},[8172,8176],{"nctId":7989,"briefTitle":7990,"status":160,"phases":8173,"primaryCompletion":7992,"completion":7993,"start":7994,"enrollment":1847,"conditions":8174,"interventions":8175},[],[3591],[7943,7987,7997,7998],{"nctId":8177,"briefTitle":8178,"status":173,"phases":8179,"primaryCompletion":8180,"completion":8180,"start":8181,"enrollment":2859,"conditions":8182,"interventions":8183},"NCT03217175","Efficacy of Glucagon In the Prevention of Hypoglycemia During Mild Exercise",[93],"2018-03-09","2017-08-18",[2997],[7997],{"intervention":7551,"totalTrials":136,"cells":8185},{"EARLY_PHASE1":8186,"PHASE1":8188,"PHASE2":8190,"PHASE3":8192,"PHASE4":8204,"NA":8206},{"trials":8187,"activeCount":101},[],{"trials":8189,"activeCount":101},[],{"trials":8191,"activeCount":101},[],{"trials":8193,"activeCount":101},[8194],{"nctId":8195,"briefTitle":8196,"status":117,"phases":8197,"primaryCompletion":193,"completion":193,"start":8198,"enrollment":16,"conditions":8199,"interventions":8202},"NCT03702582","Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation",[91],"2019-04-30",[7209,8200,8201],"Stroke","Bleeding",[7551,8203],"Warfarin",{"trials":8205,"activeCount":101},[],{"trials":8207,"activeCount":331,"soonestReadout":6852},[8208],{"nctId":7540,"briefTitle":7541,"status":160,"phases":8209,"primaryCompletion":6852,"completion":2201,"start":7543,"enrollment":7544,"conditions":8210,"interventions":8211},[93],[7546,7547,7211,7548,7549,7531,7535],[52,7537,7538,7551],{"intervention":7968,"totalTrials":331,"cells":8213},{"EARLY_PHASE1":8214,"PHASE1":8216,"PHASE2":8218,"PHASE3":8220,"PHASE4":8222,"NA":8224},{"trials":8215,"activeCount":101},[],{"trials":8217,"activeCount":101},[],{"trials":8219,"activeCount":101},[],{"trials":8221,"activeCount":101},[],{"trials":8223,"activeCount":101},[],{"trials":8225,"activeCount":331,"soonestReadout":7961},[8226],{"nctId":7958,"briefTitle":7959,"status":160,"phases":8227,"primaryCompletion":7961,"completion":7961,"start":7962,"enrollment":2559,"conditions":8228,"interventions":8229},[],[7964,7965,7966],[7968,7943],{"intervention":8231,"totalTrials":331,"cells":8232},"BMAC",{"EARLY_PHASE1":8233,"PHASE1":8235,"PHASE2":8237,"PHASE3":8239,"PHASE4":8241,"NA":8243},{"trials":8234,"activeCount":101},[],{"trials":8236,"activeCount":101},[],{"trials":8238,"activeCount":101},[],{"trials":8240,"activeCount":101},[],{"trials":8242,"activeCount":101},[],{"trials":8244,"activeCount":331,"soonestReadout":2200},[8245],{"nctId":8246,"briefTitle":8247,"status":160,"phases":8248,"primaryCompletion":2200,"completion":2201,"start":8249,"enrollment":2328,"conditions":8250,"interventions":8252},"NCT03909139","Use of BMAC With Hip Arthroscopy Treatment of FAI and Labral Tear",[],"2019-09-06",[2093,2094,2095,2096,8251],"Mesenchymal Stromal Cell",[8231],{"intervention":8254,"totalTrials":331,"cells":8255},"11C-Martinostat",{"EARLY_PHASE1":8256,"PHASE1":8258,"PHASE2":8260,"PHASE3":8262,"PHASE4":8264,"NA":8266},{"trials":8257,"activeCount":101},[],{"trials":8259,"activeCount":101},[],{"trials":8261,"activeCount":101},[],{"trials":8263,"activeCount":101},[],{"trials":8265,"activeCount":101},[],{"trials":8267,"activeCount":331,"soonestReadout":5518},[8268],{"nctId":8269,"briefTitle":8270,"status":160,"phases":8271,"primaryCompletion":5518,"completion":2556,"start":8272,"enrollment":9,"conditions":8273,"interventions":8277},"NCT03549559","Imaging Histone Deacetylase in the Heart",[93],"2018-09-07",[8274,7640,8275,8276],"Heart Failure With Normal Ejection Fraction","Aortic Valve Stenosis","Diabetes",[8254],{"intervention":71,"totalTrials":331,"cells":8279},{"EARLY_PHASE1":8280,"PHASE1":8282,"PHASE2":8284,"PHASE3":8286,"PHASE4":8288,"NA":8290},{"trials":8281,"activeCount":101},[],{"trials":8283,"activeCount":101},[],{"trials":8285,"activeCount":101},[],{"trials":8287,"activeCount":101},[],{"trials":8289,"activeCount":101},[],{"trials":8291,"activeCount":331,"soonestReadout":70},[8292],{"nctId":68,"briefTitle":69,"status":189,"phases":8293,"primaryCompletion":70,"completion":8294,"start":8295,"enrollment":8296,"conditions":8297,"interventions":8300},[93],"2025-12-31","2020-01-21",3191,[8298,8299],"Maternal Death During Childbirth","Pregnancy Complications",[71],{"intervention":8302,"totalTrials":331,"cells":8303},"topical timolol maleate",{"EARLY_PHASE1":8304,"PHASE1":8306,"PHASE2":8308,"PHASE3":8310,"PHASE4":8312,"NA":8314},{"trials":8305,"activeCount":101},[],{"trials":8307,"activeCount":101},[],{"trials":8309,"activeCount":101},[],{"trials":8311,"activeCount":101},[],{"trials":8313,"activeCount":101},[],{"trials":8315,"activeCount":331,"soonestReadout":2507},[8316],{"nctId":8317,"briefTitle":8318,"status":160,"phases":8319,"primaryCompletion":2507,"completion":191,"start":2995,"enrollment":8320,"conditions":8321,"interventions":8323},"NCT01873131","A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn",[93],126,[8322],"Hemangioma",[8302],{"intervention":8325,"totalTrials":331,"cells":8326},"oral cholera vaccine or typhoid conjugate vaccine",{"EARLY_PHASE1":8327,"PHASE1":8329,"PHASE2":8331,"PHASE3":8333,"PHASE4":8335,"NA":8337},{"trials":8328,"activeCount":101},[],{"trials":8330,"activeCount":101},[],{"trials":8332,"activeCount":101},[],{"trials":8334,"activeCount":101},[],{"trials":8336,"activeCount":101},[],{"trials":8338,"activeCount":331,"soonestReadout":2642},[8339],{"nctId":8340,"briefTitle":8341,"status":160,"phases":8342,"primaryCompletion":2642,"completion":8343,"start":8344,"enrollment":8345,"conditions":8346,"interventions":8347},"NCT06455852","Vaccine- and Infection-derived Correlates of Protection for Cholera",[93],"2029-05-01","2025-03-02",1221,[5130],[8325],{"intervention":7998,"totalTrials":331,"cells":8349},{"EARLY_PHASE1":8350,"PHASE1":8352,"PHASE2":8354,"PHASE3":8356,"PHASE4":8358,"NA":8360},{"trials":8351,"activeCount":101},[],{"trials":8353,"activeCount":101},[],{"trials":8355,"activeCount":101},[],{"trials":8357,"activeCount":101},[],{"trials":8359,"activeCount":101},[],{"trials":8361,"activeCount":331,"soonestReadout":7992},[8362],{"nctId":7989,"briefTitle":7990,"status":160,"phases":8363,"primaryCompletion":7992,"completion":7993,"start":7994,"enrollment":1847,"conditions":8364,"interventions":8365},[],[3591],[7943,7987,7997,7998],{"intervention":8367,"totalTrials":331,"cells":8368},"Dual NRT",{"EARLY_PHASE1":8369,"PHASE1":8371,"PHASE2":8373,"PHASE3":8375,"PHASE4":8377,"NA":8379},{"trials":8370,"activeCount":101},[],{"trials":8372,"activeCount":101},[],{"trials":8374,"activeCount":101},[],{"trials":8376,"activeCount":101},[],{"trials":8378,"activeCount":101},[],{"trials":8380,"activeCount":331,"soonestReadout":2706},[8381],{"nctId":8382,"briefTitle":8383,"status":318,"phases":8384,"primaryCompletion":2706,"completion":2706,"start":730,"enrollment":1578,"conditions":8385,"interventions":8387},"NCT06965153","Peer Recovery Coaching for Tobacco Abstinence in People With Opioid Use Disorder",[93],[8386],"Peer Recovery Coaching for TUD",[8367],{"intervention":8389,"totalTrials":331,"cells":8390},"Peanut oral immunotherapy",{"EARLY_PHASE1":8391,"PHASE1":8393,"PHASE2":8395,"PHASE3":8397,"PHASE4":8399,"NA":8401},{"trials":8392,"activeCount":101},[],{"trials":8394,"activeCount":101},[],{"trials":8396,"activeCount":101},[],{"trials":8398,"activeCount":101},[],{"trials":8400,"activeCount":101},[],{"trials":8402,"activeCount":331,"soonestReadout":1242},[8403],{"nctId":8404,"briefTitle":8405,"status":189,"phases":8406,"primaryCompletion":1242,"completion":1242,"start":8407,"enrollment":8408,"conditions":8409,"interventions":8410},"NCT04222491","Food Oral Immunotherapy for Peanut Allergy",[],"2020-06-25",500,[6165],[8389],{"intervention":8412,"totalTrials":331,"cells":8413},"Melphalan through Percutaneous Hepatic Perfusion",{"EARLY_PHASE1":8414,"PHASE1":8416,"PHASE2":8418,"PHASE3":8420,"PHASE4":8422,"NA":8424},{"trials":8415,"activeCount":101},[],{"trials":8417,"activeCount":101},[],{"trials":8419,"activeCount":101},[],{"trials":8421,"activeCount":101},[],{"trials":8423,"activeCount":101},[],{"trials":8425,"activeCount":331,"soonestReadout":1243},[8426],{"nctId":8427,"briefTitle":8428,"status":160,"phases":8429,"primaryCompletion":1243,"completion":8430,"start":8431,"enrollment":239,"conditions":8432,"interventions":8434},"NCT07364474","Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver",[93],"2028-09","2026-01-27",[8433],"Uveal Melanoma",[8412],{"intervention":8436,"totalTrials":4618,"cells":8437},"Escitalopram",{"EARLY_PHASE1":8438,"PHASE1":8440,"PHASE2":8442,"PHASE3":8444,"PHASE4":8461,"NA":8527},{"trials":8439,"activeCount":101},[],{"trials":8441,"activeCount":101},[],{"trials":8443,"activeCount":101},[],{"trials":8445,"activeCount":101},[8446,8455],{"nctId":8447,"briefTitle":8448,"status":117,"phases":8449,"primaryCompletion":284,"completion":284,"start":8450,"enrollment":16,"conditions":8451,"interventions":8454},"NCT00149799","Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder",[91],"2005-05",[8452,8453],"Anxiety Disorders","Somatoform Disorders",[8436],{"nctId":8456,"briefTitle":8457,"status":173,"phases":8458,"completion":3516,"start":3659,"enrollment":1578,"conditions":8459,"interventions":8460},"NCT00114374","SSRI Administration to Reduce Acute Stress Disorder Symptoms and Prevent Depression and PTSD in Physical Trauma Victims",[91],[686],[8436],{"trials":8462,"activeCount":101},[8463,8469,8476,8483,8492,8500,8507,8515,8519],{"nctId":8464,"briefTitle":8465,"status":117,"phases":8466,"primaryCompletion":3004,"completion":3004,"start":3464,"enrollment":4353,"conditions":8467,"interventions":8468},"NCT00824044","Quantitative Electroencephalogram (QEEG) Predictors of Response to Psychotherapy Versus Antidepressant Treatment in Depression",[92],[18],[8436],{"nctId":8470,"briefTitle":8471,"status":117,"phases":8472,"primaryCompletion":397,"completion":397,"start":4343,"enrollment":8473,"conditions":8474,"interventions":8475},"NCT00183677","Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram",[92],97,[15],[8436],{"nctId":8477,"briefTitle":8478,"status":117,"phases":8479,"primaryCompletion":4424,"completion":4424,"start":3855,"enrollment":270,"conditions":8480,"interventions":8482},"NCT00833469","Escitalopram (Lexapro) for the Treatment of Postpartum Depression",[92],[8481],"Postpartum Depression",[8436],{"nctId":8484,"briefTitle":8485,"status":117,"phases":8486,"primaryCompletion":1936,"completion":1936,"start":110,"enrollment":753,"conditions":8487,"interventions":8490},"NCT00452543","Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism",[92],[18,8488,8489],"Alcohol Abuse","Alcohol Dependence",[8491,652],"acamprosate",{"nctId":8493,"briefTitle":8494,"status":117,"phases":8495,"completion":684,"start":8496,"enrollment":227,"conditions":8497,"interventions":8499},"NCT00116532","Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD)",[92],"2002-10",[8498],"Obsessive Compulsive Disorder",[8436],{"nctId":8501,"briefTitle":8502,"status":117,"phases":8503,"primaryCompletion":6891,"completion":6891,"start":8504,"enrollment":251,"conditions":8505,"interventions":8506},"NCT00464711","Brain GABA Levels and Treatment Response in Major Depressive Disorder",[92],"2006-09",[18],[8436],{"nctId":8508,"briefTitle":8509,"status":117,"phases":8510,"primaryCompletion":4464,"completion":4464,"start":8511,"enrollment":895,"conditions":8512,"interventions":8514},"NCT01398514","Influence of Escitalopram on Fear Conditioning",[92],"2008-10",[8513],"Fear Conditioning",[8436],{"nctId":644,"briefTitle":645,"status":173,"phases":8516,"primaryCompletion":456,"completion":456,"start":647,"enrollment":648,"conditions":8517,"interventions":8518},[92],[650],[610,652,653,654],{"nctId":8520,"briefTitle":8521,"status":117,"phases":8522,"completion":6688,"start":8523,"enrollment":227,"conditions":8524,"interventions":8526},"NCT00115011","Escitalopram for the Treatment of Self-Injurious Skin Picking",[92],"2002-09",[8525],"Impulse Control Disorders",[8436],{"trials":8528,"activeCount":101},[],{"intervention":8530,"totalTrials":544,"cells":8531},"Aripiprazole",{"EARLY_PHASE1":8532,"PHASE1":8534,"PHASE2":8536,"PHASE3":8538,"PHASE4":8548,"NA":8593},{"trials":8533,"activeCount":101},[],{"trials":8535,"activeCount":101},[],{"trials":8537,"activeCount":101},[],{"trials":8539,"activeCount":101},[8540],{"nctId":8541,"briefTitle":8542,"status":117,"phases":8543,"primaryCompletion":912,"completion":912,"start":8544,"enrollment":1805,"conditions":8545,"interventions":8547},"NCT00556140","The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression",[91],"2003-06",[8546],"Psychotic Depression",[8530],{"trials":8549,"activeCount":101},[8550,8557,8568,8576,8584],{"nctId":8551,"briefTitle":8552,"status":173,"phases":8553,"primaryCompletion":4581,"completion":4581,"start":4666,"enrollment":194,"conditions":8554,"interventions":8556},"NCT00592683","Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents",[92],[8555],"Pediatric Bipolar Disorder",[8530],{"nctId":8558,"briefTitle":8559,"status":117,"phases":8560,"primaryCompletion":8561,"completion":8561,"start":8562,"enrollment":8563,"conditions":8564,"interventions":8566},"NCT02977299","Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD",[92],"2022-04-24","2017-05-01",278,[8565],"Treatment Resistant Major Depressive Disorder",[8530,8567],"Venlafaxine XR",{"nctId":8569,"briefTitle":8570,"status":117,"phases":8571,"primaryCompletion":177,"completion":177,"start":8572,"enrollment":194,"conditions":8573,"interventions":8574},"NCT00181779","Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar Disorder",[92],"2003-02",[24,640],[8575],"aripiprazole",{"nctId":8577,"briefTitle":8578,"status":117,"phases":8579,"primaryCompletion":4281,"completion":248,"start":8580,"enrollment":6796,"conditions":8581,"interventions":8583},"NCT00345033","Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia",[92],"2005-03",[35,8582],"Insulin Resistance",[8530],{"nctId":8585,"briefTitle":8586,"status":117,"phases":8587,"completion":3516,"start":8588,"conditions":8589,"interventions":8592},"NCT00438386","Aripiprazole for the Treatment of Refractory Anxiety",[92],"2005-04",[8590,8591],"Generalized Anxiety Disorder","Panic Disorder",[8530],{"trials":8594,"activeCount":101},[],{"intervention":8596,"totalTrials":693,"cells":8597},"Duloxetine",{"EARLY_PHASE1":8598,"PHASE1":8600,"PHASE2":8602,"PHASE3":8604,"PHASE4":8614,"NA":8646},{"trials":8599,"activeCount":101},[],{"trials":8601,"activeCount":101},[],{"trials":8603,"activeCount":101},[],{"trials":8605,"activeCount":101},[8606],{"nctId":8607,"briefTitle":8608,"status":117,"phases":8609,"primaryCompletion":8610,"completion":238,"start":8611,"enrollment":555,"conditions":8612,"interventions":8613},"NCT00114127","Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome",[91],"2008-11","2004-06",[686],[8596,8596],{"trials":8615,"activeCount":101},[8616,8624,8630,8636],{"nctId":8617,"briefTitle":8618,"status":117,"phases":8619,"primaryCompletion":4464,"completion":4464,"start":3607,"enrollment":2028,"conditions":8620,"interventions":8623},"NCT01117857","Duloxetine for Menopausal Depression",[92],[15,8621,8622],"Menopause","Vasomotor Symptoms",[8596],{"nctId":8625,"briefTitle":8626,"status":117,"phases":8627,"primaryCompletion":4677,"completion":4677,"start":260,"enrollment":194,"conditions":8628,"interventions":8629},"NCT00464698","Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD)",[92],[8498],[8596],{"nctId":8631,"briefTitle":8632,"status":117,"phases":8633,"primaryCompletion":3855,"completion":3855,"start":4463,"enrollment":2728,"conditions":8634,"interventions":8635},"NCT00438971","The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder",[92],[8591],[8596],{"nctId":8637,"briefTitle":8638,"status":117,"phases":8639,"primaryCompletion":2963,"completion":2963,"start":8640,"enrollment":593,"conditions":8641,"interventions":8644},"NCT03249558","Effect of Combined Morphine and Duloxetine on Chronic Pain",[92],"2018-03-12",[8642,8643],"Chronic Low Back Pain","Chronic Neck Pain",[8645,8596],"Morphine",{"trials":8647,"activeCount":101},[],{"intervention":653,"totalTrials":693,"cells":8649},{"EARLY_PHASE1":8650,"PHASE1":8652,"PHASE2":8654,"PHASE3":8656,"PHASE4":8666,"NA":8696},{"trials":8651,"activeCount":101},[],{"trials":8653,"activeCount":101},[],{"trials":8655,"activeCount":101},[],{"trials":8657,"activeCount":101},[8658],{"nctId":8659,"briefTitle":8660,"status":117,"phases":8661,"primaryCompletion":2027,"completion":2027,"start":8662,"enrollment":829,"conditions":8663,"interventions":8664},"NCT00118417","Therapies for Treatment-Resistant Panic Disorder Symptoms",[90,91],"1999-03",[8591],[8665,653],"Clonazepam",{"trials":8667,"activeCount":101},[8668,8675,8679,8686],{"nctId":8669,"briefTitle":8670,"status":117,"phases":8671,"primaryCompletion":4465,"completion":3079,"start":8672,"enrollment":872,"conditions":8673,"interventions":8674},"NCT00118014","Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania",[92],"2000-01",[8525],[653],{"nctId":644,"briefTitle":645,"status":173,"phases":8676,"primaryCompletion":456,"completion":456,"start":647,"enrollment":648,"conditions":8677,"interventions":8678},[92],[650],[610,652,653,654],{"nctId":8680,"briefTitle":8681,"status":117,"phases":8682,"primaryCompletion":6901,"completion":6901,"start":8683,"enrollment":151,"conditions":8684,"interventions":8685},"NCT00182078","A Study of Sertraline to Prevent PTSD",[92],"2002-11",[722,15],[653],{"nctId":8687,"briefTitle":8688,"status":117,"phases":8689,"primaryCompletion":4290,"completion":4290,"start":8690,"enrollment":8691,"conditions":8692,"interventions":8694},"NCT00282828","Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder",[92],"2006-03",397,[8693],"Social Phobia",[653,8695,8665],"Venlafaxine",{"trials":8697,"activeCount":101},[],{"intervention":8699,"totalTrials":798,"cells":8700},"Atomoxetine",{"EARLY_PHASE1":8701,"PHASE1":8703,"PHASE2":8705,"PHASE3":8707,"PHASE4":8716,"NA":8742},{"trials":8702,"activeCount":101},[],{"trials":8704,"activeCount":101},[],{"trials":8706,"activeCount":101},[],{"trials":8708,"activeCount":101},[8709],{"nctId":8710,"briefTitle":8711,"status":117,"phases":8712,"primaryCompletion":968,"completion":968,"start":4272,"enrollment":1578,"conditions":8713,"interventions":8715},"NCT00498173","Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism",[91],[8714],"Autism",[8699],{"trials":8717,"activeCount":101},[8718,8728,8734],{"nctId":8719,"briefTitle":8720,"status":117,"phases":8721,"completion":8722,"start":8723,"enrollment":227,"conditions":8724,"interventions":8726},"NCT00181740","Concerta Treatment in Adults With ADHD NOS",[92],"2005-07","2003-12",[8725],"ADHD NOS",[8727],"atomoxetine",{"nctId":8729,"briefTitle":8730,"status":117,"phases":8731,"primaryCompletion":109,"completion":109,"start":741,"enrollment":227,"conditions":8732,"interventions":8733},"NCT00181948","Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy",[92],[6706],[8727],{"nctId":8735,"briefTitle":8736,"status":107,"phases":8737,"enrollment":101,"conditions":8738,"interventions":8741},"NCT01207622","Efficacy of Atomoxetine for ADHD in Adolescents and Young Adults With SUD",[92],[8739,8740],"Attention Deficit Hyperactivity Disorder","Substance Use Disorder",[8699],{"trials":8743,"activeCount":101},[],{"intervention":8745,"totalTrials":798,"cells":8746},"Naltrexone",{"EARLY_PHASE1":8747,"PHASE1":8749,"PHASE2":8751,"PHASE3":8762,"PHASE4":8764,"NA":8786},{"trials":8748,"activeCount":101},[],{"trials":8750,"activeCount":101},[],{"trials":8752,"activeCount":101},[8753],{"nctId":8754,"briefTitle":8755,"status":117,"phases":8756,"primaryCompletion":3052,"completion":3052,"start":2446,"enrollment":1791,"conditions":8757,"interventions":8761},"NCT01874951","Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence",[90],[18,8758,8759,8760],"Depression, Unipolar","Recurrence","Relapse",[8745],{"trials":8763,"activeCount":101},[],{"trials":8765,"activeCount":101},[8766,8772,8780],{"nctId":8767,"briefTitle":8768,"status":117,"phases":8769,"primaryCompletion":298,"completion":298,"start":2435,"enrollment":178,"conditions":8770,"interventions":8771},"NCT01873729","An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.",[92],[8739],[8745],{"nctId":8773,"briefTitle":8774,"status":117,"phases":8775,"primaryCompletion":3052,"completion":3052,"start":2801,"enrollment":413,"conditions":8776,"interventions":8778},"NCT01673594","Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist",[92],[6706,8777],"Stimulant-Induced Euphoria",[8779,8745],"SODAS MPH",{"nctId":8781,"briefTitle":8782,"status":173,"phases":8783,"primaryCompletion":135,"completion":135,"start":4271,"enrollment":178,"conditions":8784,"interventions":8785},"NCT01721330","A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder",[92],[6706,8739],[8745],{"trials":8787,"activeCount":101},[],{"intervention":4436,"totalTrials":798,"cells":8789},{"EARLY_PHASE1":8790,"PHASE1":8792,"PHASE2":8806,"PHASE3":8812,"PHASE4":8814,"NA":8822},{"trials":8791,"activeCount":101},[],{"trials":8793,"activeCount":101},[8794,8802],{"nctId":8795,"briefTitle":8796,"status":117,"phases":8797,"primaryCompletion":1861,"completion":8798,"start":8799,"enrollment":2859,"conditions":8800,"interventions":8801},"NCT01398501","Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant",[89],"2016-08","2011-08",[2862],[4436],{"nctId":4614,"briefTitle":4615,"status":117,"phases":8803,"primaryCompletion":4617,"completion":298,"start":628,"enrollment":4618,"conditions":8804,"interventions":8805},[89],[3901],[277,4621],{"trials":8807,"activeCount":101},[8808],{"nctId":4430,"briefTitle":4431,"status":117,"phases":8809,"primaryCompletion":3148,"completion":2417,"start":456,"enrollment":251,"conditions":8810,"interventions":8811},[90],[4434],[3627,3496,3626,4436],{"trials":8813,"activeCount":101},[],{"trials":8815,"activeCount":101},[8816],{"nctId":8817,"briefTitle":8818,"status":173,"phases":8819,"primaryCompletion":268,"completion":1779,"start":1876,"enrollment":178,"conditions":8820,"interventions":8821},"NCT01849588","HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)",[92],[4434],[4436],{"trials":8823,"activeCount":101},[],{"intervention":678,"totalTrials":798,"cells":8825},{"EARLY_PHASE1":8826,"PHASE1":8828,"PHASE2":8830,"PHASE3":8840,"PHASE4":8842,"NA":8864},{"trials":8827,"activeCount":101},[],{"trials":8829,"activeCount":101},[],{"trials":8831,"activeCount":101},[8832],{"nctId":8833,"briefTitle":8834,"status":117,"phases":8835,"primaryCompletion":628,"completion":628,"start":3741,"enrollment":8836,"conditions":8837,"interventions":8839},"NCT00385801","Study of the Effects of Risperdal Consta on Brain Reward Circuitry Function, Craving and Cocaine Use in Active Cocaine Dependence",[90],31,[8838],"Cocaine Dependence",[678],{"trials":8841,"activeCount":101},[],{"trials":8843,"activeCount":101},[8844,8850,8860],{"nctId":8845,"briefTitle":8846,"status":117,"phases":8847,"primaryCompletion":110,"completion":110,"start":8572,"enrollment":886,"conditions":8848,"interventions":8849},"NCT00289861","Risperidone Augmentation in Patients With Schizophrenia",[92],[35],[678],{"nctId":8851,"briefTitle":8852,"status":117,"phases":8853,"completion":8854,"start":8855,"enrollment":251,"conditions":8856,"interventions":8857},"NCT00181935","Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Disorder",[92],"2004-07","2001-03",[24,640],[8858,8859],"risperidone","olanzapine",{"nctId":669,"briefTitle":670,"status":117,"phases":8861,"primaryCompletion":672,"start":673,"enrollment":674,"conditions":8862,"interventions":8863},[92],[676],[678,679,610],{"trials":8865,"activeCount":101},[],{"intervention":6751,"totalTrials":798,"cells":8867},{"EARLY_PHASE1":8868,"PHASE1":8870,"PHASE2":8872,"PHASE3":8881,"PHASE4":8894,"NA":8910},{"trials":8869,"activeCount":101},[],{"trials":8871,"activeCount":101},[],{"trials":8873,"activeCount":101},[8874],{"nctId":8875,"briefTitle":8876,"status":8877,"phases":8878,"primaryCompletion":3289,"completion":3397,"start":162,"enrollment":4443,"conditions":8879,"interventions":8880},"NCT03787290","Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder","SUSPENDED",[90],[18],[6751],{"trials":8882,"activeCount":101},[8883],{"nctId":8884,"briefTitle":8885,"status":117,"phases":8886,"primaryCompletion":8887,"completion":8888,"start":8889,"enrollment":8890,"conditions":8891,"interventions":8893},"NCT04356937","Efficacy of Tocilizumab on Patients With COVID-19",[91],"2020-07-13","2020-08-27","2020-04-20",243,[8892],"SARS-CoV 2",[6751,1884],{"trials":8895,"activeCount":101},[8896,8900],{"nctId":6743,"briefTitle":6744,"status":117,"phases":8897,"primaryCompletion":6746,"completion":6747,"start":6748,"enrollment":227,"conditions":8898,"interventions":8899},[92],[6725],[6751,3576],{"nctId":8901,"briefTitle":8902,"status":173,"phases":8903,"primaryCompletion":8904,"completion":8904,"start":8905,"enrollment":1805,"conditions":8906,"interventions":8908},"NCT02659150","Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis",[92],"2019-11-16","2016-05-18",[8907],"Rheumatoid Arthritis",[8909],"tocilizumab",{"trials":8911,"activeCount":101},[],{"intervention":8913,"totalTrials":798,"cells":8914},"Ziprasidone",{"EARLY_PHASE1":8915,"PHASE1":8917,"PHASE2":8919,"PHASE3":8935,"PHASE4":8937,"NA":8953},{"trials":8916,"activeCount":101},[],{"trials":8918,"activeCount":101},[],{"trials":8920,"activeCount":101},[8921,8929],{"nctId":8922,"briefTitle":8923,"status":117,"phases":8924,"primaryCompletion":8925,"completion":8925,"start":8926,"enrollment":3027,"conditions":8927,"interventions":8928},"NCT00555997","A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder",[90],"2010-06","2008-03",[18],[8913,8913],{"nctId":8930,"briefTitle":8931,"status":117,"phases":8932,"primaryCompletion":2436,"completion":2436,"start":3464,"enrollment":2001,"conditions":8933,"interventions":8934},"NCT00633399","Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs",[90],[18],[8913],{"trials":8936,"activeCount":101},[],{"trials":8938,"activeCount":101},[8939,8945],{"nctId":8940,"briefTitle":8941,"status":173,"phases":8942,"primaryCompletion":2027,"completion":8610,"start":2046,"enrollment":178,"conditions":8943,"interventions":8944},"NCT00374543","Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder",[92],[8590,24],[8913],{"nctId":8946,"briefTitle":8947,"status":117,"phases":8948,"completion":4425,"start":8949,"enrollment":194,"conditions":8950,"interventions":8951},"NCT00181922","Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Disorder",[92],"2002-03",[24,640],[8952],"ziprasidone",{"trials":8954,"activeCount":101},[],{"intervention":8956,"totalTrials":798,"cells":8957},"OROS methylphenidate hydrochloride",{"EARLY_PHASE1":8958,"PHASE1":8960,"PHASE2":8962,"PHASE3":8964,"PHASE4":8980,"NA":8996},{"trials":8959,"activeCount":101},[],{"trials":8961,"activeCount":101},[],{"trials":8963,"activeCount":101},[],{"trials":8965,"activeCount":101},[8966,8973],{"nctId":8967,"briefTitle":8968,"status":117,"phases":8969,"primaryCompletion":684,"completion":1926,"start":579,"enrollment":194,"conditions":8970,"interventions":8971},"NCT00302393","Study Examining Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults",[91],[29],[8956,8972],"methylphenidate hydrochloride",{"nctId":8974,"briefTitle":8975,"status":117,"phases":8976,"primaryCompletion":260,"completion":260,"start":8580,"enrollment":251,"conditions":8977,"interventions":8979},"NCT00301639","A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults",[91],[8978],"Healthy Volunteers",[8956,8972],{"trials":8981,"activeCount":101},[8982,8988],{"nctId":8983,"briefTitle":8984,"status":117,"phases":8985,"primaryCompletion":175,"completion":175,"start":4343,"enrollment":366,"conditions":8986,"interventions":8987},"NCT00302406","Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate",[92],[8739],[8972,8956],{"nctId":8989,"briefTitle":8990,"status":117,"phases":8991,"primaryCompletion":4465,"completion":4465,"start":8992,"enrollment":194,"conditions":8993,"interventions":8994},"NCT00302367","An Open Label Phase I\u002FII Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects",[92],"2004-01",[8978],[8956,8995],"immediate release methylphenidate hydrochloride",{"trials":8997,"activeCount":101},[],{"intervention":8999,"totalTrials":178,"cells":9000},"buprenorphine\u002Fnaloxone",{"EARLY_PHASE1":9001,"PHASE1":9003,"PHASE2":9005,"PHASE3":9007,"PHASE4":9009,"NA":9038},{"trials":9002,"activeCount":101},[],{"trials":9004,"activeCount":101},[],{"trials":9006,"activeCount":101},[],{"trials":9008,"activeCount":101},[],{"trials":9010,"activeCount":101},[9011,9021,9029],{"nctId":9012,"briefTitle":9013,"status":2758,"phases":9014,"primaryCompletion":61,"completion":9015,"start":9016,"enrollment":437,"conditions":9017,"interventions":9020},"NCT03266445","Effect of Buprenorphine\u002FNaloxone Continuation on Pain Control and Opioid Use",[92],"2022-02-26","2018-10-05",[874,9018,9019],"Pain, Acute","Surgery",[8999],{"nctId":9022,"briefTitle":9023,"status":107,"phases":9024,"primaryCompletion":2507,"completion":2507,"start":8128,"enrollment":101,"conditions":9025,"interventions":9027},"NCT04091009","Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine\u002FNaloxone in the Perioperative Period on Pain Control and Post-Operative Opioid Use Disorder Symptoms",[92],[874,9026],"Opioid Use Disorder, Mild",[9028],"Buprenorphine\u002Fnaloxone",{"nctId":9030,"briefTitle":9031,"status":107,"phases":9032,"primaryCompletion":2495,"completion":2495,"start":9033,"enrollment":101,"conditions":9034,"interventions":9036},"NCT04771689","Buprenorphine\u002FNaloxone Micro-Dosing for Postoperative Pain Management in Opioid-Tolerant Patients",[92],"2022-07-01",[9035],"Post-operative Pain",[9037],"Buprenorphine\u002FNaloxone",{"trials":9039,"activeCount":101},[],{"intervention":9041,"totalTrials":178,"cells":9042},"Fluoxetine",{"EARLY_PHASE1":9043,"PHASE1":9045,"PHASE2":9047,"PHASE3":9056,"PHASE4":9058,"NA":9077},{"trials":9044,"activeCount":101},[],{"trials":9046,"activeCount":101},[],{"trials":9048,"activeCount":101},[9049],{"nctId":9050,"briefTitle":9051,"status":117,"phases":9052,"primaryCompletion":4463,"completion":4463,"start":9053,"enrollment":1533,"conditions":9054,"interventions":9055},"NCT00338767","Antidepressant Medication Plus Directly Observed Therapy for Improving Adherence to Antiretroviral Therapy",[90],"2001-01",[8139,15],[9041],{"trials":9057,"activeCount":101},[],{"trials":9059,"activeCount":101},[9060,9068],{"nctId":9061,"briefTitle":9062,"status":173,"phases":9063,"primaryCompletion":628,"completion":628,"start":260,"enrollment":1509,"conditions":9064,"interventions":9066},"NCT00592852","Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder",[92],[8555,9065],"Pediatric OCD",[9067],"fluoxetine",{"nctId":9069,"briefTitle":9070,"status":117,"phases":9071,"primaryCompletion":9072,"completion":9072,"start":9073,"enrollment":798,"conditions":9074,"interventions":9076},"NCT05458479","Fluoxetine Treatment of Depression in Down Syndrome",[92],"2024-02-26","2022-12-05",[9075,15],"Down Syndrome",[9041],{"trials":9078,"activeCount":101},[],{"intervention":9080,"totalTrials":178,"cells":9081},"Open-label Treatment with N-acetylcysteine",{"EARLY_PHASE1":9082,"PHASE1":9084,"PHASE2":9086,"PHASE3":9088,"PHASE4":9090,"NA":9122},{"trials":9083,"activeCount":101},[],{"trials":9085,"activeCount":101},[],{"trials":9087,"activeCount":101},[],{"trials":9089,"activeCount":101},[],{"trials":9091,"activeCount":101},[9092,9100,9110],{"nctId":9093,"briefTitle":9094,"status":117,"phases":9095,"primaryCompletion":9096,"completion":9096,"start":224,"enrollment":251,"conditions":9097,"interventions":9098},"NCT02357290","Open-Label Study of N-Acetylcysteine in Children and Adolescents 5-17 With Bipolar Spectrum Disorders",[92],"2018-09-24",[24],[9099],"Open-label Treatment with N-Acetylcysteine",{"nctId":9101,"briefTitle":9102,"status":117,"phases":9103,"primaryCompletion":9104,"completion":9104,"start":9105,"enrollment":6652,"conditions":9106,"interventions":9108},"NCT03757585","Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and\u002For Autism Spectrum Disorders (ASD)",[92],"2024-05-06","2019-05-20",[9107,488,8714],"Non-verbal Learning Disorder",[9109,9080],"Open-label Treatment with Omega-3 Fatty Acids + Inositol",{"nctId":9111,"briefTitle":9112,"status":117,"phases":9113,"primaryCompletion":9114,"completion":9114,"start":9115,"enrollment":457,"conditions":9116,"interventions":9121},"NCT03911414","A Clinical Trial Via Telepsychiatry of Treatments for the Management of Emotional Dysregulation in Youth",[92],"2024-12-04","2019-06-18",[9117,9118,9119,9120],"Mood Disturbance","Mood Disorders","Natural Supplements","Alternative Treatment",[9109,9080],{"trials":9123,"activeCount":101},[],{"intervention":1795,"totalTrials":178,"cells":9125},{"EARLY_PHASE1":9126,"PHASE1":9128,"PHASE2":9130,"PHASE3":9140,"PHASE4":9142,"NA":9148},{"trials":9127,"activeCount":101},[],{"trials":9129,"activeCount":101},[],{"trials":9131,"activeCount":101},[9132,9136],{"nctId":1786,"briefTitle":1787,"status":117,"phases":9133,"primaryCompletion":1789,"completion":1789,"start":1790,"enrollment":1791,"conditions":9134,"interventions":9135},[90],[1793],[1795,1649],{"nctId":2413,"briefTitle":2414,"status":107,"phases":9137,"primaryCompletion":2416,"completion":2417,"start":2418,"enrollment":101,"conditions":9138,"interventions":9139},[89,90],[2420],[2422,1795,2280],{"trials":9141,"activeCount":101},[],{"trials":9143,"activeCount":101},[9144],{"nctId":2432,"briefTitle":2433,"status":117,"phases":9145,"primaryCompletion":2435,"completion":2436,"start":456,"enrollment":209,"conditions":9146,"interventions":9147},[92],[2438,29],[2280,1795],{"trials":9149,"activeCount":101},[],{"intervention":9151,"totalTrials":178,"cells":9152},"sildenafil",{"EARLY_PHASE1":9153,"PHASE1":9155,"PHASE2":9157,"PHASE3":9159,"PHASE4":9175,"NA":9184},{"trials":9154,"activeCount":101},[],{"trials":9156,"activeCount":101},[],{"trials":9158,"activeCount":101},[],{"trials":9160,"activeCount":101},[9161,9168],{"nctId":9162,"briefTitle":9163,"status":117,"phases":9164,"completion":2046,"start":2036,"enrollment":251,"conditions":9165,"interventions":9167},"NCT00309816","Study of Sildenafil in Patient With Heart Failure.",[91],[9166],"Congestive Heart Failure",[9151],{"nctId":9169,"briefTitle":9170,"status":117,"phases":9171,"completion":8690,"start":9172,"enrollment":251,"conditions":9173,"interventions":9174},"NCT00309790","Study of Sildenafil in Advanced Heart Failure.",[91],"2003-05",[9166],[9151],{"trials":9176,"activeCount":101},[9177],{"nctId":9178,"briefTitle":9179,"status":117,"phases":9180,"primaryCompletion":109,"completion":647,"start":2046,"enrollment":209,"conditions":9181,"interventions":9182},"NCT00455715","A Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia",[92],[35],[9183],"Sildenafil",{"trials":9185,"activeCount":101},[],{"intervention":9187,"totalTrials":178,"cells":9188},"methylphenidate HCl",{"EARLY_PHASE1":9189,"PHASE1":9191,"PHASE2":9193,"PHASE3":9195,"PHASE4":9197,"NA":9221},{"trials":9190,"activeCount":101},[],{"trials":9192,"activeCount":101},[],{"trials":9194,"activeCount":101},[],{"trials":9196,"activeCount":101},[],{"trials":9198,"activeCount":101},[9199,9207,9214],{"nctId":9200,"briefTitle":9201,"status":117,"phases":9202,"primaryCompletion":707,"completion":707,"start":9203,"enrollment":9204,"conditions":9205,"interventions":9206},"NCT00181714","Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta",[92],"2003-11",203,[6706],[9187],{"nctId":9208,"briefTitle":9209,"status":117,"phases":9210,"primaryCompletion":2456,"completion":2456,"start":9211,"enrollment":2028,"conditions":9212,"interventions":9213},"NCT00181987","Concerta in the Treatment of ADHD in Youth and Adults With Bipolar Disorder",[92],"2002-08",[6706,24],[9187],{"nctId":9215,"briefTitle":9216,"status":117,"phases":9217,"primaryCompletion":4450,"completion":4450,"start":8544,"enrollment":9218,"conditions":9219,"interventions":9220},"NCT00181571","A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder",[92],297,[6706],[9187],{"trials":9222,"activeCount":101},[],{"intervention":8972,"totalTrials":178,"cells":9224},{"EARLY_PHASE1":9225,"PHASE1":9227,"PHASE2":9229,"PHASE3":9231,"PHASE4":9241,"NA":9247},{"trials":9226,"activeCount":101},[],{"trials":9228,"activeCount":101},[],{"trials":9230,"activeCount":101},[],{"trials":9232,"activeCount":101},[9233,9237],{"nctId":8967,"briefTitle":8968,"status":117,"phases":9234,"primaryCompletion":684,"completion":1926,"start":579,"enrollment":194,"conditions":9235,"interventions":9236},[91],[29],[8956,8972],{"nctId":8974,"briefTitle":8975,"status":117,"phases":9238,"primaryCompletion":260,"completion":260,"start":8580,"enrollment":251,"conditions":9239,"interventions":9240},[91],[8978],[8956,8972],{"trials":9242,"activeCount":101},[9243],{"nctId":8983,"briefTitle":8984,"status":117,"phases":9244,"primaryCompletion":175,"completion":175,"start":4343,"enrollment":366,"conditions":9245,"interventions":9246},[92],[8739],[8972,8956],{"trials":9248,"activeCount":101},[],{"intervention":9250,"totalTrials":136,"cells":9251},"Gadolinium",{"EARLY_PHASE1":9252,"PHASE1":9254,"PHASE2":9256,"PHASE3":9258,"PHASE4":9260,"NA":9275},{"trials":9253,"activeCount":101},[],{"trials":9255,"activeCount":101},[],{"trials":9257,"activeCount":101},[],{"trials":9259,"activeCount":101},[],{"trials":9261,"activeCount":101},[9262,9268],{"nctId":9263,"briefTitle":9264,"status":107,"phases":9265,"primaryCompletion":4380,"completion":2417,"start":3644,"enrollment":101,"conditions":9266,"interventions":9267},"NCT02234375","Use of Gadolinium in CT Pulmonary Angiography",[92],[7832],[9250],{"nctId":9269,"briefTitle":9270,"status":107,"phases":9271,"primaryCompletion":4380,"completion":4380,"start":268,"enrollment":101,"conditions":9272,"interventions":9274},"NCT02163005","A Feasibility Study to Assess the Use of Gadolinium in Computed Tomography",[92],[9273],"Contrast Media Allergy",[9250],{"trials":9276,"activeCount":101},[],{"intervention":9278,"totalTrials":136,"cells":9279},"rosiglitazone",{"EARLY_PHASE1":9280,"PHASE1":9282,"PHASE2":9284,"PHASE3":9286,"PHASE4":9297,"NA":9305},{"trials":9281,"activeCount":101},[],{"trials":9283,"activeCount":101},[],{"trials":9285,"activeCount":101},[],{"trials":9287,"activeCount":101},[9288],{"nctId":9289,"briefTitle":9290,"status":117,"phases":9291,"primaryCompletion":9292,"completion":9292,"start":9293,"enrollment":16,"conditions":9294,"interventions":9295},"NCT00182052","Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer",[91],"2003-08","2000-09",[2039,2038],[9296],"Rosiglitazone",{"trials":9298,"activeCount":101},[9299],{"nctId":9300,"briefTitle":9301,"status":117,"phases":9302,"primaryCompletion":707,"completion":707,"start":894,"enrollment":194,"conditions":9303,"interventions":9304},"NCT00337350","Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment",[92],[35],[9278],{"trials":9306,"activeCount":101},[],{"intervention":9308,"totalTrials":136,"cells":9309},"ADHD Medication",{"EARLY_PHASE1":9310,"PHASE1":9312,"PHASE2":9314,"PHASE3":9326,"PHASE4":9328,"NA":9337},{"trials":9311,"activeCount":101},[],{"trials":9313,"activeCount":101},[],{"trials":9315,"activeCount":101},[9316],{"nctId":9317,"briefTitle":9318,"status":117,"phases":9319,"primaryCompletion":269,"completion":269,"start":9320,"enrollment":136,"conditions":9321,"interventions":9324},"NCT01399827","Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits",[90],"2012-02",[9322,9323],"Attention Deficit Hyperactivity Disorder (ADHD)","Deficient Emotional Self-Regulation (DESR)",[9308,9325],"Omega-3 Fatty Acids",{"trials":9327,"activeCount":101},[],{"trials":9329,"activeCount":101},[9330],{"nctId":9331,"briefTitle":9332,"status":117,"phases":9333,"primaryCompletion":46,"completion":8798,"start":6695,"enrollment":2508,"conditions":9334,"interventions":9336},"NCT02204410","Omega-3 Supplementation to ADHD Medication in Children",[92],[8739,9335],"Deficient Emotional Self-Regulation",[9308],{"trials":9338,"activeCount":101},[],{"intervention":9340,"totalTrials":136,"cells":9341},"Mailed nicotine replacement therapy",{"EARLY_PHASE1":9342,"PHASE1":9344,"PHASE2":9346,"PHASE3":9348,"PHASE4":9350,"NA":9370},{"trials":9343,"activeCount":101},[],{"trials":9345,"activeCount":101},[],{"trials":9347,"activeCount":101},[],{"trials":9349,"activeCount":101},[],{"trials":9351,"activeCount":101},[9352,9361],{"nctId":9353,"briefTitle":9354,"status":117,"phases":9355,"primaryCompletion":9356,"completion":9356,"start":9357,"enrollment":4443,"conditions":9358,"interventions":9360},"NCT04020718","Engagement With an Adaptive Mobile Health Smoking Cessation Intervention",[92],"2020-11-30","2020-01-31",[9359],"Tobacco Use Cessation",[9340],{"nctId":9362,"briefTitle":9363,"status":117,"phases":9364,"primaryCompletion":6617,"completion":9365,"start":9366,"enrollment":9367,"conditions":9368,"interventions":9369},"NCT03174158","A Text Messaging Program for Smokers in Primary Care",[92],"2019-02-28","2017-11-06",153,[711],[9340],{"trials":9371,"activeCount":101},[],{"intervention":9373,"totalTrials":136,"cells":9374},"leuprolide acetate",{"EARLY_PHASE1":9375,"PHASE1":9384,"PHASE2":9386,"PHASE3":9388,"PHASE4":9390,"NA":9403},{"trials":9376,"activeCount":101},[9377],{"nctId":9378,"briefTitle":9379,"status":107,"phases":9380,"primaryCompletion":554,"completion":554,"start":309,"enrollment":101,"conditions":9381,"interventions":9382},"NCT01763541","Study of the Effect of Testosterone and Estradiol on NP Responses to Acute and Chronic Salt Loading",[88],[5842],[9373,9383],"Anastrozole",{"trials":9385,"activeCount":101},[],{"trials":9387,"activeCount":101},[],{"trials":9389,"activeCount":101},[],{"trials":9391,"activeCount":101},[9392],{"nctId":9393,"briefTitle":9394,"status":117,"phases":9395,"primaryCompletion":9396,"completion":9397,"start":9398,"enrollment":194,"conditions":9399,"interventions":9401},"NCT00455689","Understanding Experimentally Induced Hot Flushes",[92],"2007-07-24","2007-09-02","2005-11-28",[9400],"Hot Flashes",[9402],"Leuprolide acetate",{"trials":9404,"activeCount":101},[],{"intervention":9109,"totalTrials":136,"cells":9406},{"EARLY_PHASE1":9407,"PHASE1":9409,"PHASE2":9411,"PHASE3":9413,"PHASE4":9415,"NA":9425},{"trials":9408,"activeCount":101},[],{"trials":9410,"activeCount":101},[],{"trials":9412,"activeCount":101},[],{"trials":9414,"activeCount":101},[],{"trials":9416,"activeCount":101},[9417,9421],{"nctId":9101,"briefTitle":9102,"status":117,"phases":9418,"primaryCompletion":9104,"completion":9104,"start":9105,"enrollment":6652,"conditions":9419,"interventions":9420},[92],[9107,488,8714],[9109,9080],{"nctId":9111,"briefTitle":9112,"status":117,"phases":9422,"primaryCompletion":9114,"completion":9114,"start":9115,"enrollment":457,"conditions":9423,"interventions":9424},[92],[9117,9118,9119,9120],[9109,9080],{"trials":9426,"activeCount":101},[],{"intervention":9428,"totalTrials":136,"cells":9429},"Botulinum toxin type A",{"EARLY_PHASE1":9430,"PHASE1":9432,"PHASE2":9442,"PHASE3":9444,"PHASE4":9446,"NA":9457},{"trials":9431,"activeCount":101},[],{"trials":9433,"activeCount":101},[9434],{"nctId":9435,"briefTitle":9436,"status":2758,"phases":9437,"primaryCompletion":9438,"completion":9438,"start":7153,"enrollment":555,"conditions":9439,"interventions":9441},"NCT04917731","Botulinum Toxin Type A for Cold Intolerance Secondary to Digital Amputations and Replantations: A Pilot Study",[89],"2023-06-02",[9440],"Cold Intolerance",[9428],{"trials":9443,"activeCount":101},[],{"trials":9445,"activeCount":101},[],{"trials":9447,"activeCount":101},[9448],{"nctId":9449,"briefTitle":9450,"status":117,"phases":9451,"primaryCompletion":445,"completion":9452,"start":9453,"enrollment":413,"conditions":9454,"interventions":9456},"NCT03381261","(Botox) Mechanisms of Action in Altering the Molecular Environment in Which Pain Fibers Exist",[92],"2023-12-01","2017-12-01",[9455],"Migraine",[9428],{"trials":9458,"activeCount":101},[],{"intervention":9460,"totalTrials":136,"cells":9461},"armodafinil",{"EARLY_PHASE1":9462,"PHASE1":9464,"PHASE2":9466,"PHASE3":9474,"PHASE4":9476,"NA":9485},{"trials":9463,"activeCount":101},[],{"trials":9465,"activeCount":101},[],{"trials":9467,"activeCount":101},[9468],{"nctId":9469,"briefTitle":9470,"status":117,"phases":9471,"primaryCompletion":740,"completion":1936,"start":2027,"enrollment":1791,"conditions":9472,"interventions":9473},"NCT00592943","PET Study Examining the Dopaminergic Activity of Armodafinil in Adults",[89,90],[29],[9460],{"trials":9475,"activeCount":101},[],{"trials":9477,"activeCount":101},[9478],{"nctId":9479,"briefTitle":9480,"status":117,"phases":9481,"primaryCompletion":1876,"completion":4677,"start":568,"enrollment":1847,"conditions":9482,"interventions":9483},"NCT01460628","Effect of Nuvigil on Fatigue",[92],[8621],[9484],"Armodafinil",{"trials":9486,"activeCount":101},[],{"intervention":8665,"totalTrials":136,"cells":9488},{"EARLY_PHASE1":9489,"PHASE1":9491,"PHASE2":9493,"PHASE3":9495,"PHASE4":9501,"NA":9507},{"trials":9490,"activeCount":101},[],{"trials":9492,"activeCount":101},[],{"trials":9494,"activeCount":101},[],{"trials":9496,"activeCount":101},[9497],{"nctId":8659,"briefTitle":8660,"status":117,"phases":9498,"primaryCompletion":2027,"completion":2027,"start":8662,"enrollment":829,"conditions":9499,"interventions":9500},[90,91],[8591],[8665,653],{"trials":9502,"activeCount":101},[9503],{"nctId":8687,"briefTitle":8688,"status":117,"phases":9504,"primaryCompletion":4290,"completion":4290,"start":8690,"enrollment":8691,"conditions":9505,"interventions":9506},[92],[8693],[653,8695,8665],{"trials":9508,"activeCount":101},[],{"intervention":8645,"totalTrials":136,"cells":9510},{"EARLY_PHASE1":9511,"PHASE1":9513,"PHASE2":9515,"PHASE3":9517,"PHASE4":9519,"NA":9535},{"trials":9512,"activeCount":101},[],{"trials":9514,"activeCount":101},[],{"trials":9516,"activeCount":101},[],{"trials":9518,"activeCount":101},[],{"trials":9520,"activeCount":101},[9521,9531],{"nctId":9522,"briefTitle":9523,"status":173,"phases":9524,"primaryCompletion":9525,"completion":2760,"start":1897,"enrollment":9526,"conditions":9527,"interventions":9528},"NCT01681264","Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance",[92],"2022-12",137,[1881],[8645,9529,9530],"Guanfacine 1mg","Guanfacine 2mg",{"nctId":8637,"briefTitle":8638,"status":117,"phases":9532,"primaryCompletion":2963,"completion":2963,"start":8640,"enrollment":593,"conditions":9533,"interventions":9534},[92],[8642,8643],[8645,8596],{"trials":9536,"activeCount":101},[],{"intervention":9538,"totalTrials":136,"cells":9539},"Vortioxetine",{"EARLY_PHASE1":9540,"PHASE1":9542,"PHASE2":9544,"PHASE3":9546,"PHASE4":9548,"NA":9571},{"trials":9541,"activeCount":101},[],{"trials":9543,"activeCount":101},[],{"trials":9545,"activeCount":101},[],{"trials":9547,"activeCount":101},[],{"trials":9549,"activeCount":101},[9550,9560],{"nctId":9551,"briefTitle":9552,"status":173,"phases":9553,"primaryCompletion":9554,"completion":9554,"start":9555,"enrollment":136,"conditions":9556,"interventions":9559},"NCT02969876","Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine",[92],"2018-08-06","2017-08-24",[9557,9558,15,8758],"Depressive Disorder","Major Depression",[9538],{"nctId":9561,"briefTitle":9562,"status":117,"phases":9563,"primaryCompletion":9564,"completion":9564,"start":9565,"enrollment":27,"conditions":9566,"interventions":9569},"NCT02234362","Vortioxetine for Menopausal Depression",[92],"2016-09-29","2015-06-12",[15,8621,9567,9400,9568],"Vasomotor Disturbance","Sleep",[9570],"vortioxetine",{"trials":9572,"activeCount":101},[],{"intervention":9574,"totalTrials":136,"cells":9575},"Acetaminophen",{"EARLY_PHASE1":9576,"PHASE1":9578,"PHASE2":9580,"PHASE3":9592,"PHASE4":9594,"NA":9605},{"trials":9577,"activeCount":101},[],{"trials":9579,"activeCount":101},[],{"trials":9581,"activeCount":101},[9582],{"nctId":9583,"briefTitle":9584,"status":117,"phases":9585,"primaryCompletion":9586,"completion":9587,"start":9588,"enrollment":1578,"conditions":9589,"interventions":9591},"NCT05764707","Assessing Efficacy of Intravenous Acetaminophen for Perioperative Pain Treatment in Spinal Surgery",[90],"2023-01-31","2023-02-03","2020-01-10",[9590],"Lumbar; Injury",[9574],{"trials":9593,"activeCount":101},[],{"trials":9595,"activeCount":101},[9596],{"nctId":9597,"briefTitle":9598,"status":173,"phases":9599,"primaryCompletion":4352,"completion":4352,"start":9600,"enrollment":270,"conditions":9601,"interventions":9603},"NCT01588158","Patient Satisfaction With Pain Relief After Ambulatory Hand Surgery",[92],"2012-07",[9602],"Carpal Tunnel Syndrome",[9574,9604],"Vicodin",{"trials":9606,"activeCount":101},[],{"intervention":724,"totalTrials":331,"cells":9608},{"EARLY_PHASE1":9609,"PHASE1":9611,"PHASE2":9613,"PHASE3":9615,"PHASE4":9617,"NA":9623},{"trials":9610,"activeCount":101},[],{"trials":9612,"activeCount":101},[],{"trials":9614,"activeCount":101},[],{"trials":9616,"activeCount":101},[],{"trials":9618,"activeCount":101},[9619],{"nctId":716,"briefTitle":717,"status":117,"phases":9620,"primaryCompletion":225,"completion":225,"start":719,"enrollment":720,"conditions":9621,"interventions":9622},[92],[722,686],[692,724,725],{"trials":9624,"activeCount":101},[],{"intervention":9626,"totalTrials":331,"cells":9627},"Methylphenidate extended-release liquid formulation",{"EARLY_PHASE1":9628,"PHASE1":9630,"PHASE2":9632,"PHASE3":9634,"PHASE4":9636,"NA":9645},{"trials":9629,"activeCount":101},[],{"trials":9631,"activeCount":101},[],{"trials":9633,"activeCount":101},[],{"trials":9635,"activeCount":101},[],{"trials":9637,"activeCount":101},[9638],{"nctId":9639,"briefTitle":9640,"status":117,"phases":9641,"primaryCompletion":120,"completion":120,"start":566,"enrollment":2728,"conditions":9642,"interventions":9644},"NCT02096952","Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD",[92],[9643,488],"Attention-deficit\u002FHyperactivity Disorder",[9626],{"trials":9646,"activeCount":101},[],{"intervention":9648,"totalTrials":331,"cells":9649},"mometasone furoate",{"EARLY_PHASE1":9650,"PHASE1":9652,"PHASE2":9654,"PHASE3":9656,"PHASE4":9658,"NA":9668},{"trials":9651,"activeCount":101},[],{"trials":9653,"activeCount":101},[],{"trials":9655,"activeCount":101},[],{"trials":9657,"activeCount":101},[],{"trials":9659,"activeCount":101},[9660],{"nctId":9661,"briefTitle":9662,"status":173,"phases":9663,"primaryCompletion":1779,"completion":9664,"start":477,"enrollment":4618,"conditions":9665,"interventions":9667},"NCT01616160","An Open-label Study to Identify Molecular Markers of Steroid Resistance",[92],"2018-01-09",[9666],"Nasal Polyps",[9648],{"trials":9669,"activeCount":101},[],{"intervention":632,"totalTrials":331,"cells":9671},{"EARLY_PHASE1":9672,"PHASE1":9674,"PHASE2":9676,"PHASE3":9678,"PHASE4":9680,"NA":9686},{"trials":9673,"activeCount":101},[],{"trials":9675,"activeCount":101},[],{"trials":9677,"activeCount":101},[],{"trials":9679,"activeCount":101},[],{"trials":9681,"activeCount":101},[9682],{"nctId":623,"briefTitle":624,"status":117,"phases":9683,"primaryCompletion":626,"completion":627,"start":628,"enrollment":629,"conditions":9684,"interventions":9685},[92],[24],[632,610],{"trials":9687,"activeCount":101},[],{"intervention":9689,"totalTrials":331,"cells":9690},"Tretinoin cream 0.05",{"EARLY_PHASE1":9691,"PHASE1":9693,"PHASE2":9695,"PHASE3":9697,"PHASE4":9699,"NA":9708},{"trials":9692,"activeCount":101},[],{"trials":9694,"activeCount":101},[],{"trials":9696,"activeCount":101},[],{"trials":9698,"activeCount":101},[],{"trials":9700,"activeCount":101},[9701],{"nctId":9702,"briefTitle":9703,"status":117,"phases":9704,"primaryCompletion":4290,"completion":4290,"start":8925,"enrollment":732,"conditions":9705,"interventions":9707},"NCT01149876","Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots",[92],[9706],"Hyperpigmentation",[9689],{"trials":9709,"activeCount":101},[],{"intervention":9711,"totalTrials":331,"cells":9712},"Vilazodone",{"EARLY_PHASE1":9713,"PHASE1":9715,"PHASE2":9717,"PHASE3":9719,"PHASE4":9721,"NA":9730},{"trials":9714,"activeCount":101},[],{"trials":9716,"activeCount":101},[],{"trials":9718,"activeCount":101},[],{"trials":9720,"activeCount":101},[],{"trials":9722,"activeCount":101},[9723],{"nctId":9724,"briefTitle":9725,"status":107,"phases":9726,"primaryCompletion":135,"completion":3680,"start":626,"enrollment":101,"conditions":9727,"interventions":9729},"NCT02028026","The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives",[92],[18,489,9728],"Comorbidity",[9711,654],{"trials":9731,"activeCount":101},[],{"intervention":9733,"totalTrials":331,"cells":9734},"Nitroglycerin",{"EARLY_PHASE1":9735,"PHASE1":9737,"PHASE2":9739,"PHASE3":9741,"PHASE4":9743,"NA":9755},{"trials":9736,"activeCount":101},[],{"trials":9738,"activeCount":101},[],{"trials":9740,"activeCount":101},[],{"trials":9742,"activeCount":101},[],{"trials":9744,"activeCount":101},[9745],{"nctId":9746,"briefTitle":9747,"status":117,"phases":9748,"primaryCompletion":9749,"completion":9750,"start":9751,"enrollment":9752,"conditions":9753,"interventions":9754},"NCT02961946","Effects of Sublingual and Transdermal Administration of Nitroglycerin for Coronary CT Angiography on Image Quality",[92],"2017-10-31","2018-08-02","2017-03-15",198,[1468],[9733],{"trials":9756,"activeCount":101},[],{"intervention":9758,"totalTrials":331,"cells":9759},"Double Blind Varenicline",{"EARLY_PHASE1":9760,"PHASE1":9762,"PHASE2":9764,"PHASE3":9766,"PHASE4":9768,"NA":9781},{"trials":9761,"activeCount":101},[],{"trials":9763,"activeCount":101},[],{"trials":9765,"activeCount":101},[],{"trials":9767,"activeCount":101},[],{"trials":9769,"activeCount":101},[9770],{"nctId":9771,"briefTitle":9772,"status":117,"phases":9773,"primaryCompletion":9774,"completion":9775,"start":9776,"enrollment":9777,"conditions":9778,"interventions":9779},"NCT05367492","Varenicline for Nicotine Vaping Cessation in Adolescents",[92],"2024-03-20","2024-05-28","2022-06-22",261,[1949,1947],[9758,9780],"Double Blind Placebo",{"trials":9782,"activeCount":101},[],{"intervention":9780,"totalTrials":331,"cells":9784},{"EARLY_PHASE1":9785,"PHASE1":9787,"PHASE2":9789,"PHASE3":9791,"PHASE4":9793,"NA":9799},{"trials":9786,"activeCount":101},[],{"trials":9788,"activeCount":101},[],{"trials":9790,"activeCount":101},[],{"trials":9792,"activeCount":101},[],{"trials":9794,"activeCount":101},[9795],{"nctId":9771,"briefTitle":9772,"status":117,"phases":9796,"primaryCompletion":9774,"completion":9775,"start":9776,"enrollment":9777,"conditions":9797,"interventions":9798},[92],[1949,1947],[9758,9780],{"trials":9800,"activeCount":101},[],{"intervention":9802,"totalTrials":331,"cells":9803},"Glecaprevir and Pibrentasvir",{"EARLY_PHASE1":9804,"PHASE1":9806,"PHASE2":9808,"PHASE3":9810,"PHASE4":9812,"NA":9823},{"trials":9805,"activeCount":101},[],{"trials":9807,"activeCount":101},[],{"trials":9809,"activeCount":101},[],{"trials":9811,"activeCount":101},[],{"trials":9813,"activeCount":101},[9814],{"nctId":9815,"briefTitle":9816,"status":173,"phases":9817,"primaryCompletion":5716,"completion":5716,"start":9818,"enrollment":136,"conditions":9819,"interventions":9822},"NCT04515797","QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir\u002FPibrentasvir",[92],"2021-05-01",[196,9820,9821],"Hepatitis C","Kidney Disease, Chronic",[9802],{"trials":9824,"activeCount":101},[],{"intervention":9826,"totalTrials":331,"cells":9827},"Atomoxetine hydrochloride",{"EARLY_PHASE1":9828,"PHASE1":9830,"PHASE2":9832,"PHASE3":9834,"PHASE4":9836,"NA":9846},{"trials":9829,"activeCount":101},[],{"trials":9831,"activeCount":101},[],{"trials":9833,"activeCount":101},[],{"trials":9835,"activeCount":101},[],{"trials":9837,"activeCount":101},[9838],{"nctId":9839,"briefTitle":9840,"status":117,"phases":9841,"primaryCompletion":8690,"completion":578,"start":741,"enrollment":816,"conditions":9842,"interventions":9845},"NCT00218322","Effectiveness of ATMX in Treating Adolescents With ADHD and SUD",[92],[9843,9844],"Attention Deficit Disorder With Hyperactivity","Substance-Related Disorders",[9826],{"trials":9847,"activeCount":101},[],{"intervention":9849,"totalTrials":331,"cells":9850},"Vyvanse",{"EARLY_PHASE1":9851,"PHASE1":9853,"PHASE2":9855,"PHASE3":9857,"PHASE4":9859,"NA":9869},{"trials":9852,"activeCount":101},[],{"trials":9854,"activeCount":101},[],{"trials":9856,"activeCount":101},[],{"trials":9858,"activeCount":101},[],{"trials":9860,"activeCount":101},[9861],{"nctId":9862,"briefTitle":9863,"status":117,"phases":9864,"primaryCompletion":238,"completion":238,"start":9865,"enrollment":872,"conditions":9866,"interventions":9868},"NCT00801229","Effect of Vyvanse on Driving in Young Adults With ADHD",[92],"2008-12",[9867],"Attention Deficit\u002FHyperactivity Disorder(ADHD)",[9849],{"trials":9870,"activeCount":101},[],{"intervention":9872,"totalTrials":331,"cells":9873},"Osmotic Release Methylphenidate",{"EARLY_PHASE1":9874,"PHASE1":9876,"PHASE2":9878,"PHASE3":9880,"PHASE4":9882,"NA":9891},{"trials":9875,"activeCount":101},[],{"trials":9877,"activeCount":101},[],{"trials":9879,"activeCount":101},[],{"trials":9881,"activeCount":101},[],{"trials":9883,"activeCount":101},[9884],{"nctId":9885,"briefTitle":9886,"status":117,"phases":9887,"primaryCompletion":9320,"completion":9320,"start":6891,"enrollment":9888,"conditions":9889,"interventions":9890},"NCT01063153","Diagnostic Utility of Attention Deficit Hyperactivity Disorder (ADHD) by Brain Activity Flow Patterns Analysis Using Evoked Response Potentials",[92],71,[8739],[9872],{"trials":9892,"activeCount":101},[],{"intervention":9894,"totalTrials":331,"cells":9895},"elbasvir",{"EARLY_PHASE1":9896,"PHASE1":9898,"PHASE2":9900,"PHASE3":9902,"PHASE4":9904,"NA":9915},{"trials":9897,"activeCount":101},[],{"trials":9899,"activeCount":101},[],{"trials":9901,"activeCount":101},[],{"trials":9903,"activeCount":101},[],{"trials":9905,"activeCount":101},[9906],{"nctId":9907,"briefTitle":9908,"status":117,"phases":9909,"primaryCompletion":9910,"completion":9911,"start":9912,"enrollment":1890,"conditions":9913,"interventions":9914},"NCT02945150","Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant",[92],"2019-08-20","2020-03-05","2017-02-01",[7466],[9894],{"trials":9916,"activeCount":101},[],{"intervention":9918,"totalTrials":331,"cells":9919},"Cannabidiol",{"EARLY_PHASE1":9920,"PHASE1":9922,"PHASE2":9924,"PHASE3":9926,"PHASE4":9928,"NA":9939},{"trials":9921,"activeCount":101},[],{"trials":9923,"activeCount":101},[],{"trials":9925,"activeCount":101},[],{"trials":9927,"activeCount":101},[],{"trials":9929,"activeCount":101},[9930],{"nctId":9931,"briefTitle":9932,"status":173,"phases":9933,"primaryCompletion":9934,"completion":9934,"start":9935,"enrollment":270,"conditions":9936,"interventions":9938},"NCT03891264","Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain",[92],"2020-11-23","2019-11-13",[9937],"Back Pain, Low",[9918],{"trials":9940,"activeCount":101},[],{"intervention":9942,"totalTrials":331,"cells":9943},"Naproxen",{"EARLY_PHASE1":9944,"PHASE1":9946,"PHASE2":9948,"PHASE3":9950,"PHASE4":9952,"NA":9961},{"trials":9945,"activeCount":101},[],{"trials":9947,"activeCount":101},[],{"trials":9949,"activeCount":101},[],{"trials":9951,"activeCount":101},[],{"trials":9953,"activeCount":101},[9954],{"nctId":9955,"briefTitle":9956,"status":107,"phases":9957,"primaryCompletion":6696,"completion":248,"start":2027,"enrollment":101,"conditions":9958,"interventions":9960},"NCT00586365","Naproxen for the Prevention of HO After Complex Elbow Trauma",[92],[9959],"Heterotopic Ossification",[9942],{"trials":9962,"activeCount":101},[],{"intervention":9964,"totalTrials":331,"cells":9965},"Argatroban and warfarin",{"EARLY_PHASE1":9966,"PHASE1":9968,"PHASE2":9970,"PHASE3":9972,"PHASE4":9974,"NA":9984},{"trials":9967,"activeCount":101},[],{"trials":9969,"activeCount":101},[],{"trials":9971,"activeCount":101},[],{"trials":9973,"activeCount":101},[],{"trials":9975,"activeCount":101},[9976],{"nctId":9977,"briefTitle":9978,"status":173,"phases":9979,"primaryCompletion":176,"completion":176,"start":719,"enrollment":538,"conditions":9980,"interventions":9983},"NCT01246011","Significance of Antibodies to Heparin\u002FPlatelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion",[92],[9981,9982],"Coronary Artery Bypass Graft Surgery","Presence of Heparin\u002FPlatelet Factor 4 Antibody",[9964],{"trials":9985,"activeCount":101},[],{"intervention":9987,"totalTrials":331,"cells":9988},"Medication augmentation",{"EARLY_PHASE1":9989,"PHASE1":9991,"PHASE2":9993,"PHASE3":9995,"PHASE4":9997,"NA":10006},{"trials":9990,"activeCount":101},[],{"trials":9992,"activeCount":101},[],{"trials":9994,"activeCount":101},[],{"trials":9996,"activeCount":101},[],{"trials":9998,"activeCount":101},[9999],{"nctId":10000,"briefTitle":10001,"status":173,"phases":10002,"primaryCompletion":2436,"completion":2436,"start":226,"enrollment":352,"conditions":10003,"interventions":10005},"NCT01542372","Two Stepped Care Models for Posttraumatic Stress Disorder (PTSD) Among Cambodian Refugees With PTSD",[92],[10004],"Posttraumatic Stress Disorder (PTSD)",[9987],{"trials":10007,"activeCount":101},[],{"intervention":10009,"totalTrials":331,"cells":10010},"Latuda",{"EARLY_PHASE1":10011,"PHASE1":10013,"PHASE2":10015,"PHASE3":10017,"PHASE4":10019,"NA":10029},{"trials":10012,"activeCount":101},[],{"trials":10014,"activeCount":101},[],{"trials":10016,"activeCount":101},[],{"trials":10018,"activeCount":101},[],{"trials":10020,"activeCount":101},[10021],{"nctId":10022,"briefTitle":10023,"status":107,"phases":10024,"primaryCompletion":3148,"completion":3148,"start":1779,"enrollment":101,"conditions":10025,"interventions":10028},"NCT01932541","Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old",[92],[640,10026,10027,676,24],"Bipolar I","Bipolar II",[10009],{"trials":10030,"activeCount":101},[],{"intervention":10032,"totalTrials":331,"cells":10033},"Glecaprevir \u002F Pibrentasvir Oral Tablet [Mavyret]",{"EARLY_PHASE1":10034,"PHASE1":10036,"PHASE2":10038,"PHASE3":10040,"PHASE4":10042,"NA":10053},{"trials":10035,"activeCount":101},[],{"trials":10037,"activeCount":101},[],{"trials":10039,"activeCount":101},[],{"trials":10041,"activeCount":101},[],{"trials":10043,"activeCount":101},[10044],{"nctId":10045,"briefTitle":10046,"status":107,"phases":10047,"primaryCompletion":10048,"completion":10048,"start":10049,"enrollment":101,"conditions":10050,"interventions":10052},"NCT04614142","Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access",[92],"2021-08-04","2020-11-13",[286,10051],"Chronic Hepatitis c",[10032],{"trials":10054,"activeCount":101},[],{"intervention":10056,"totalTrials":331,"cells":10057},"Clinically prescribed direct acting antiviral",{"EARLY_PHASE1":10058,"PHASE1":10060,"PHASE2":10062,"PHASE3":10064,"PHASE4":10066,"NA":10078},{"trials":10059,"activeCount":101},[],{"trials":10061,"activeCount":101},[],{"trials":10063,"activeCount":101},[],{"trials":10065,"activeCount":101},[],{"trials":10067,"activeCount":101},[10068],{"nctId":10069,"briefTitle":10070,"status":173,"phases":10071,"primaryCompletion":10072,"completion":10073,"start":10074,"enrollment":251,"conditions":10075,"interventions":10077},"NCT03208244","DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant",[92],"2021-04-20","2021-04-28","2017-11-09",[10076,9820],"End Stage Heart Disease",[10056],{"trials":10079,"activeCount":101},[],{"intervention":10081,"totalTrials":331,"cells":10082},"INF108F probiotic",{"EARLY_PHASE1":10083,"PHASE1":10085,"PHASE2":10087,"PHASE3":10089,"PHASE4":10091,"NA":10104},{"trials":10084,"activeCount":101},[],{"trials":10086,"activeCount":101},[],{"trials":10088,"activeCount":101},[],{"trials":10090,"activeCount":101},[],{"trials":10092,"activeCount":101},[10093],{"nctId":10094,"briefTitle":10095,"status":117,"phases":10096,"primaryCompletion":10097,"completion":10097,"start":10098,"enrollment":194,"conditions":10099,"interventions":10103},"NCT05793112","INF108F in Infants With Food Protein Induced Proctocolitis",[92],"2024-09-27","2023-09-09",[10100,10101,10102],"Infant Development","Gut Microbiome","Food Protein Induced Allergic Proctocolitis",[10081],{"trials":10105,"activeCount":101},[],{"intervention":10107,"totalTrials":331,"cells":10108},"Paroxetine",{"EARLY_PHASE1":10109,"PHASE1":10111,"PHASE2":10113,"PHASE3":10115,"PHASE4":10117,"NA":10125},{"trials":10110,"activeCount":101},[],{"trials":10112,"activeCount":101},[],{"trials":10114,"activeCount":101},[],{"trials":10116,"activeCount":101},[],{"trials":10118,"activeCount":101},[10119],{"nctId":10120,"briefTitle":10121,"status":117,"phases":10122,"completion":8504,"start":741,"enrollment":19,"conditions":10123,"interventions":10124},"NCT00225914","Study of Paxil Use in Menopausal Women",[92],[8621],[10107],{"trials":10126,"activeCount":101},[],{"intervention":10128,"totalTrials":331,"cells":10129},"Welbutrin XL",{"EARLY_PHASE1":10130,"PHASE1":10132,"PHASE2":10134,"PHASE3":10136,"PHASE4":10138,"NA":10147},{"trials":10131,"activeCount":101},[],{"trials":10133,"activeCount":101},[],{"trials":10135,"activeCount":101},[],{"trials":10137,"activeCount":101},[],{"trials":10139,"activeCount":101},[10140],{"nctId":10141,"briefTitle":10142,"status":117,"phases":10143,"primaryCompletion":10144,"completion":10144,"start":8798,"enrollment":437,"conditions":10145,"interventions":10146},"NCT02562430","Neurobiological Underpinnings of Placebo Response in Depression",[92],"2022-08",[15],[10128],{"trials":10148,"activeCount":101},[],{"intervention":10150,"totalTrials":331,"cells":10151},"Viekira Pak ± ribavirin",{"EARLY_PHASE1":10152,"PHASE1":10154,"PHASE2":10156,"PHASE3":10158,"PHASE4":10160,"NA":10172},{"trials":10153,"activeCount":101},[],{"trials":10155,"activeCount":101},[],{"trials":10157,"activeCount":101},[],{"trials":10159,"activeCount":101},[],{"trials":10161,"activeCount":101},[10162],{"nctId":10163,"briefTitle":10164,"status":117,"phases":10165,"primaryCompletion":10166,"completion":10166,"start":9912,"enrollment":239,"conditions":10167,"interventions":10170},"NCT02946034","Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C",[92],"2020-09-16",[10168,10169],"Chronic Kidney Disease","Chronic Hepatitis C",[10150,10171],"Mavyret",{"trials":10173,"activeCount":101},[],{"intervention":10171,"totalTrials":331,"cells":10175},{"EARLY_PHASE1":10176,"PHASE1":10178,"PHASE2":10180,"PHASE3":10182,"PHASE4":10184,"NA":10190},{"trials":10177,"activeCount":101},[],{"trials":10179,"activeCount":101},[],{"trials":10181,"activeCount":101},[],{"trials":10183,"activeCount":101},[],{"trials":10185,"activeCount":101},[10186],{"nctId":10163,"briefTitle":10164,"status":117,"phases":10187,"primaryCompletion":10166,"completion":10166,"start":9912,"enrollment":239,"conditions":10188,"interventions":10189},[92],[10168,10169],[10150,10171],{"trials":10191,"activeCount":101},[],{"intervention":10193,"totalTrials":331,"cells":10194},"Sofosbuvir\u002FVelpatasvir Treatment for 14 days",{"EARLY_PHASE1":10195,"PHASE1":10197,"PHASE2":10199,"PHASE3":10201,"PHASE4":10203,"NA":10214},{"trials":10196,"activeCount":101},[],{"trials":10198,"activeCount":101},[],{"trials":10200,"activeCount":101},[],{"trials":10202,"activeCount":101},[],{"trials":10204,"activeCount":101},[10205],{"nctId":10206,"briefTitle":10207,"status":107,"phases":10208,"primaryCompletion":10209,"completion":10210,"start":10211,"enrollment":101,"conditions":10212,"interventions":10213},"NCT03313414","HCV Post-Exposure Prophylaxis for Health Care Workers",[92],"2020-01","2020-01-16","2019-08-13",[9820],[10193],{"trials":10215,"activeCount":101},[],{"intervention":10217,"totalTrials":331,"cells":10218},"Nebivolol",{"EARLY_PHASE1":10219,"PHASE1":10221,"PHASE2":10223,"PHASE3":10225,"PHASE4":10227,"NA":10236},{"trials":10220,"activeCount":101},[],{"trials":10222,"activeCount":101},[],{"trials":10224,"activeCount":101},[],{"trials":10226,"activeCount":101},[],{"trials":10228,"activeCount":101},[10229],{"nctId":10230,"briefTitle":10231,"status":117,"phases":10232,"primaryCompletion":41,"completion":41,"start":626,"enrollment":1791,"conditions":10233,"interventions":10235},"NCT01665508","Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease",[92],[10234],"Microvascular Angina",[10217],{"trials":10237,"activeCount":101},[],{"intervention":10239,"totalTrials":331,"cells":10240},"Methylphenidate Transdermal System",{"EARLY_PHASE1":10241,"PHASE1":10243,"PHASE2":10245,"PHASE3":10247,"PHASE4":10249,"NA":10257},{"trials":10242,"activeCount":101},[],{"trials":10244,"activeCount":101},[],{"trials":10246,"activeCount":101},[],{"trials":10248,"activeCount":101},[],{"trials":10250,"activeCount":101},[10251],{"nctId":10252,"briefTitle":10253,"status":117,"phases":10254,"primaryCompletion":9865,"completion":9865,"start":8504,"enrollment":33,"conditions":10255,"interventions":10256},"NCT00586157","Study of Medication Patch to Treat Children Ages 6-12 With ADHD",[92],[6706,8739],[10239],{"trials":10258,"activeCount":101},[],{"intervention":10260,"totalTrials":331,"cells":10261},"Depakote ER",{"EARLY_PHASE1":10262,"PHASE1":10264,"PHASE2":10266,"PHASE3":10268,"PHASE4":10270,"NA":10280},{"trials":10263,"activeCount":101},[],{"trials":10265,"activeCount":101},[],{"trials":10267,"activeCount":101},[],{"trials":10269,"activeCount":101},[],{"trials":10271,"activeCount":101},[10272],{"nctId":10273,"briefTitle":10274,"status":117,"phases":10275,"completion":109,"start":579,"enrollment":693,"conditions":10276,"interventions":10278},"NCT00334347","A Comparison Study of the Efficacy and Tolerability of Depakote ER and Depakote DR",[92],[640,10277],"Mixed Mania",[10260,10279],"Depakote DR",{"trials":10281,"activeCount":101},[],{"intervention":10279,"totalTrials":331,"cells":10283},{"EARLY_PHASE1":10284,"PHASE1":10286,"PHASE2":10288,"PHASE3":10290,"PHASE4":10292,"NA":10298},{"trials":10285,"activeCount":101},[],{"trials":10287,"activeCount":101},[],{"trials":10289,"activeCount":101},[],{"trials":10291,"activeCount":101},[],{"trials":10293,"activeCount":101},[10294],{"nctId":10273,"briefTitle":10274,"status":117,"phases":10295,"completion":109,"start":579,"enrollment":693,"conditions":10296,"interventions":10297},[92],[640,10277],[10260,10279],{"trials":10299,"activeCount":101},[],{"intervention":10301,"totalTrials":331,"cells":10302},"Lovaza",{"EARLY_PHASE1":10303,"PHASE1":10305,"PHASE2":10307,"PHASE3":10309,"PHASE4":10311,"NA":10321},{"trials":10304,"activeCount":101},[],{"trials":10306,"activeCount":101},[],{"trials":10308,"activeCount":101},[],{"trials":10310,"activeCount":101},[],{"trials":10312,"activeCount":101},[10313],{"nctId":10314,"briefTitle":10315,"status":117,"phases":10316,"primaryCompletion":284,"completion":284,"start":250,"enrollment":895,"conditions":10317,"interventions":10320},"NCT00833976","Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia",[92],[10318,10319,35,1929,24],"High Triglycerides","Hypercholesterolemia",[10301],{"trials":10322,"activeCount":101},[],{"intervention":10324,"totalTrials":331,"cells":10325},"Crisaborole 2% Top Oint",{"EARLY_PHASE1":10326,"PHASE1":10328,"PHASE2":10330,"PHASE3":10332,"PHASE4":10334,"NA":10344},{"trials":10327,"activeCount":101},[],{"trials":10329,"activeCount":101},[],{"trials":10331,"activeCount":101},[],{"trials":10333,"activeCount":101},[],{"trials":10335,"activeCount":101},[10336],{"nctId":10337,"briefTitle":10338,"status":2758,"phases":10339,"primaryCompletion":134,"completion":3608,"start":10340,"enrollment":1533,"conditions":10341,"interventions":10343},"NCT04214197","Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis",[92],"2020-02-03",[10342],"Atopic Dermatitis",[10324],{"trials":10345,"activeCount":101},[],{"intervention":10347,"totalTrials":331,"cells":10348},"Escitalopram 10mg",{"EARLY_PHASE1":10349,"PHASE1":10351,"PHASE2":10353,"PHASE3":10355,"PHASE4":10357,"NA":10365},{"trials":10350,"activeCount":101},[],{"trials":10352,"activeCount":101},[],{"trials":10354,"activeCount":101},[],{"trials":10356,"activeCount":101},[],{"trials":10358,"activeCount":101},[10359],{"nctId":10360,"briefTitle":10361,"status":173,"phases":10362,"primaryCompletion":8798,"completion":8798,"start":4271,"enrollment":194,"conditions":10363,"interventions":10364},"NCT01787240","Neurobiological Bases of Placebo Response in Major Depressive Disorder",[92],[18],[10347],{"trials":10366,"activeCount":101},[],{"intervention":8491,"totalTrials":331,"cells":10368},{"EARLY_PHASE1":10369,"PHASE1":10371,"PHASE2":10373,"PHASE3":10375,"PHASE4":10377,"NA":10383},{"trials":10370,"activeCount":101},[],{"trials":10372,"activeCount":101},[],{"trials":10374,"activeCount":101},[],{"trials":10376,"activeCount":101},[],{"trials":10378,"activeCount":101},[10379],{"nctId":8484,"briefTitle":8485,"status":117,"phases":10380,"primaryCompletion":1936,"completion":1936,"start":110,"enrollment":753,"conditions":10381,"interventions":10382},[92],[18,8488,8489],[8491,652],{"trials":10384,"activeCount":101},[],{"intervention":10386,"totalTrials":331,"cells":10387},"Nicotine replacement therapy",{"EARLY_PHASE1":10388,"PHASE1":10390,"PHASE2":10392,"PHASE3":10394,"PHASE4":10396,"NA":10407},{"trials":10389,"activeCount":101},[],{"trials":10391,"activeCount":101},[],{"trials":10393,"activeCount":101},[],{"trials":10395,"activeCount":101},[],{"trials":10397,"activeCount":101},[10398],{"nctId":10399,"briefTitle":10400,"status":117,"phases":10401,"primaryCompletion":10402,"completion":10402,"start":10403,"enrollment":10404,"conditions":10405,"interventions":10406},"NCT03603496","Post-Discharge Smoking Cessation Strategies: Helping HAND 4",[92],"2020-11-17","2018-09-01",1416,[711],[10386],{"trials":10408,"activeCount":101},[],{"intervention":10410,"totalTrials":331,"cells":10411},"Ketones",{"EARLY_PHASE1":10412,"PHASE1":10414,"PHASE2":10416,"PHASE3":10418,"PHASE4":10420,"NA":10432},{"trials":10413,"activeCount":101},[],{"trials":10415,"activeCount":101},[],{"trials":10417,"activeCount":101},[],{"trials":10419,"activeCount":101},[],{"trials":10421,"activeCount":101},[10422],{"nctId":10423,"briefTitle":10424,"status":2758,"phases":10425,"primaryCompletion":10426,"completion":10426,"start":10427,"enrollment":732,"conditions":10428,"interventions":10430},"NCT04840095","Dynamic Connectivity Under Metabolic Constraints",[92],"2023-09","2015-06-19",[8582,29,10429,6609],"Diet Modification",[10410,10431],"Glucose",{"trials":10433,"activeCount":101},[],{"intervention":10431,"totalTrials":331,"cells":10435},{"EARLY_PHASE1":10436,"PHASE1":10438,"PHASE2":10440,"PHASE3":10442,"PHASE4":10444,"NA":10450},{"trials":10437,"activeCount":101},[],{"trials":10439,"activeCount":101},[],{"trials":10441,"activeCount":101},[],{"trials":10443,"activeCount":101},[],{"trials":10445,"activeCount":101},[10446],{"nctId":10423,"briefTitle":10424,"status":2758,"phases":10447,"primaryCompletion":10426,"completion":10426,"start":10427,"enrollment":732,"conditions":10448,"interventions":10449},[92],[8582,29,10429,6609],[10410,10431],{"trials":10451,"activeCount":101},[],{"intervention":10453,"totalTrials":331,"cells":10454},"Tranexamic Acid",{"EARLY_PHASE1":10455,"PHASE1":10457,"PHASE2":10459,"PHASE3":10461,"PHASE4":10463,"NA":10474},{"trials":10456,"activeCount":101},[],{"trials":10458,"activeCount":101},[],{"trials":10460,"activeCount":101},[],{"trials":10462,"activeCount":101},[],{"trials":10464,"activeCount":101},[10465],{"nctId":10466,"briefTitle":10467,"status":117,"phases":10468,"primaryCompletion":10469,"completion":10469,"start":4442,"enrollment":2028,"conditions":10470,"interventions":10473},"NCT02063035","Effectiveness Study of the Drug Tranexamic Acid to Reduce Post-surgery Blood Loss in Spinal Surgery",[92],"2015-04-22",[10471,10472],"Lumbar Spinal Stenosis","Thoracic Spinal Stenosis",[10453],{"trials":10475,"activeCount":101},[],{"intervention":1828,"totalTrials":331,"cells":10477},{"EARLY_PHASE1":10478,"PHASE1":10480,"PHASE2":10482,"PHASE3":10484,"PHASE4":10486,"NA":10492},{"trials":10479,"activeCount":101},[],{"trials":10481,"activeCount":101},[],{"trials":10483,"activeCount":101},[],{"trials":10485,"activeCount":101},[],{"trials":10487,"activeCount":101},[10488],{"nctId":1820,"briefTitle":1821,"status":117,"phases":10489,"primaryCompletion":1823,"completion":1824,"start":1825,"enrollment":22,"conditions":10490,"interventions":10491},[92],[15],[1828,1649],{"trials":10493,"activeCount":101},[],{"intervention":10495,"totalTrials":331,"cells":10496},"Omega-3",{"EARLY_PHASE1":10497,"PHASE1":10499,"PHASE2":10501,"PHASE3":10503,"PHASE4":10505,"NA":10517},{"trials":10498,"activeCount":101},[],{"trials":10500,"activeCount":101},[],{"trials":10502,"activeCount":101},[],{"trials":10504,"activeCount":101},[],{"trials":10506,"activeCount":101},[10507],{"nctId":10508,"briefTitle":10509,"status":117,"phases":10510,"primaryCompletion":51,"completion":51,"start":10511,"enrollment":10512,"conditions":10513,"interventions":10515},"NCT01396486","Inositol and Omega-3 Fatty Acids in Pediatric Mania",[92],"2012-02-03",69,[10514],"Pediatric Bipolar Spectrum Disorders",[10495,10516],"Inositol",{"trials":10518,"activeCount":101},[],{"intervention":10516,"totalTrials":331,"cells":10520},{"EARLY_PHASE1":10521,"PHASE1":10523,"PHASE2":10525,"PHASE3":10527,"PHASE4":10529,"NA":10535},{"trials":10522,"activeCount":101},[],{"trials":10524,"activeCount":101},[],{"trials":10526,"activeCount":101},[],{"trials":10528,"activeCount":101},[],{"trials":10530,"activeCount":101},[10531],{"nctId":10508,"briefTitle":10509,"status":117,"phases":10532,"primaryCompletion":51,"completion":51,"start":10511,"enrollment":10512,"conditions":10533,"interventions":10534},[92],[10514],[10495,10516],{"trials":10536,"activeCount":101},[],{"intervention":10538,"totalTrials":331,"cells":10539},"Superparamagnetic Iron Oxide Magnetic Resonance Imaging",{"EARLY_PHASE1":10540,"PHASE1":10542,"PHASE2":10544,"PHASE3":10546,"PHASE4":10548,"NA":10556},{"trials":10541,"activeCount":101},[],{"trials":10543,"activeCount":101},[],{"trials":10545,"activeCount":101},[],{"trials":10547,"activeCount":101},[],{"trials":10549,"activeCount":101},[10550],{"nctId":10551,"briefTitle":10552,"status":117,"phases":10553,"primaryCompletion":9320,"completion":4617,"start":3464,"enrollment":4443,"conditions":10554,"interventions":10555},"NCT00920023","Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)",[92],[2748],[10538],{"trials":10557,"activeCount":101},[],{"intervention":10559,"totalTrials":331,"cells":10560},"Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks",{"EARLY_PHASE1":10561,"PHASE1":10563,"PHASE2":10565,"PHASE3":10567,"PHASE4":10569,"NA":10580},{"trials":10562,"activeCount":101},[],{"trials":10564,"activeCount":101},[],{"trials":10566,"activeCount":101},[],{"trials":10568,"activeCount":101},[],{"trials":10570,"activeCount":101},[10571],{"nctId":10572,"briefTitle":10573,"status":173,"phases":10574,"primaryCompletion":10575,"completion":10575,"start":10576,"enrollment":2837,"conditions":10577,"interventions":10579},"NCT03625687","Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant",[92],"2022-04-04","2019-02-05",[10578,9820],"Respiratory Failure",[10559],{"trials":10581,"activeCount":101},[],{"intervention":9529,"totalTrials":331,"cells":10583},{"EARLY_PHASE1":10584,"PHASE1":10586,"PHASE2":10588,"PHASE3":10590,"PHASE4":10592,"NA":10598},{"trials":10585,"activeCount":101},[],{"trials":10587,"activeCount":101},[],{"trials":10589,"activeCount":101},[],{"trials":10591,"activeCount":101},[],{"trials":10593,"activeCount":101},[10594],{"nctId":9522,"briefTitle":9523,"status":173,"phases":10595,"primaryCompletion":9525,"completion":2760,"start":1897,"enrollment":9526,"conditions":10596,"interventions":10597},[92],[1881],[8645,9529,9530],{"trials":10599,"activeCount":101},[],{"intervention":9530,"totalTrials":331,"cells":10601},{"EARLY_PHASE1":10602,"PHASE1":10604,"PHASE2":10606,"PHASE3":10608,"PHASE4":10610,"NA":10616},{"trials":10603,"activeCount":101},[],{"trials":10605,"activeCount":101},[],{"trials":10607,"activeCount":101},[],{"trials":10609,"activeCount":101},[],{"trials":10611,"activeCount":101},[10612],{"nctId":9522,"briefTitle":9523,"status":173,"phases":10613,"primaryCompletion":9525,"completion":2760,"start":1897,"enrollment":9526,"conditions":10614,"interventions":10615},[92],[1881],[8645,9529,9530],{"trials":10617,"activeCount":101},[],{"intervention":10619,"totalTrials":331,"cells":10620},"Naproxen Sodium",{"EARLY_PHASE1":10621,"PHASE1":10623,"PHASE2":10625,"PHASE3":10627,"PHASE4":10629,"NA":10642},{"trials":10622,"activeCount":101},[],{"trials":10624,"activeCount":101},[],{"trials":10626,"activeCount":101},[],{"trials":10628,"activeCount":101},[],{"trials":10630,"activeCount":101},[10631],{"nctId":10632,"briefTitle":10633,"status":173,"phases":10634,"primaryCompletion":10635,"completion":10635,"start":10636,"enrollment":136,"conditions":10637,"interventions":10641},"NCT04015596","Trial of Naproxen Sodium for the Treatment of OCD in Children With PANDAS",[92],"2025-04-30","2020-10-20",[10638,686,10639,10640],"PANDAS","Autoimmune Diseases","Obsessive-Compulsive Disorder",[10619],{"trials":10643,"activeCount":101},[],{"intervention":10645,"totalTrials":331,"cells":10646},"Atomoxetine and OROS Methylphenidate",{"EARLY_PHASE1":10647,"PHASE1":10649,"PHASE2":10651,"PHASE3":10653,"PHASE4":10655,"NA":10663},{"trials":10648,"activeCount":101},[],{"trials":10650,"activeCount":101},[],{"trials":10652,"activeCount":101},[],{"trials":10654,"activeCount":101},[],{"trials":10656,"activeCount":101},[10657],{"nctId":10658,"briefTitle":10659,"status":117,"phases":10660,"primaryCompletion":4666,"completion":4666,"start":8992,"enrollment":398,"conditions":10661,"interventions":10662},"NCT00585910","Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD",[92],[6706,8739],[10645],{"trials":10664,"activeCount":101},[],{"intervention":10666,"totalTrials":331,"cells":10667},"EnBrace HR Softgel",{"EARLY_PHASE1":10668,"PHASE1":10670,"PHASE2":10672,"PHASE3":10674,"PHASE4":10676,"NA":10689},{"trials":10669,"activeCount":101},[],{"trials":10671,"activeCount":101},[],{"trials":10673,"activeCount":101},[],{"trials":10675,"activeCount":101},[],{"trials":10677,"activeCount":101},[10678],{"nctId":10679,"briefTitle":10680,"status":107,"phases":10681,"primaryCompletion":2407,"completion":10682,"start":2408,"enrollment":101,"conditions":10683,"interventions":10688},"NCT04123483","EnBrace HR for PMS With Prominent Mood Symptoms or Menstrual Related Mood Disorders",[92],"2022-11",[10684,10685,10686,10687],"Premenstrual Syndrome","Premenstrual Dysphoric Disorder","Premenstrual Tension","Menstrual Related Mood Disorder",[10666],{"trials":10690,"activeCount":101},[],{"intervention":10692,"totalTrials":331,"cells":10693},"Immunosuppression reduction",{"EARLY_PHASE1":10694,"PHASE1":10696,"PHASE2":10698,"PHASE3":10700,"PHASE4":10702,"NA":10714},{"trials":10695,"activeCount":101},[],{"trials":10697,"activeCount":101},[],{"trials":10699,"activeCount":101},[],{"trials":10701,"activeCount":101},[],{"trials":10703,"activeCount":101},[10704],{"nctId":10705,"briefTitle":10706,"status":117,"phases":10707,"primaryCompletion":2630,"completion":10708,"start":10709,"enrollment":97,"conditions":10710,"interventions":10713},"NCT04177095","Immune Monitoring to Facilitate Belatacept Monotherapy",[92],"2023-06-01","2020-02-11",[10711,10712],"Kidney Transplant Rejection","Immunosuppression",[10692],{"trials":10715,"activeCount":101},[],{"intervention":10717,"totalTrials":331,"cells":10718},"immediate Gardasil 9, delayed MenVeo vaccine",{"EARLY_PHASE1":10719,"PHASE1":10721,"PHASE2":10723,"PHASE3":10725,"PHASE4":10727,"NA":10741},{"trials":10720,"activeCount":101},[],{"trials":10722,"activeCount":101},[],{"trials":10724,"activeCount":101},[],{"trials":10726,"activeCount":101},[],{"trials":10728,"activeCount":101},[10729],{"nctId":10730,"briefTitle":10731,"status":2758,"phases":10732,"primaryCompletion":10733,"completion":10733,"start":10734,"enrollment":10735,"conditions":10736,"interventions":10738},"NCT03675256","The KEN SHE Study on HPV-vaccine Efficacy",[92],"2024-02-15","2018-12-19",2275,[10737],"Papillomavirus Infections",[10717,10739,10740],"immediate MenVeo vaccine, delayed Gardasil 9","immediate Cervarix, delayed MenVeo vaccine",{"trials":10742,"activeCount":101},[],{"intervention":10739,"totalTrials":331,"cells":10744},{"EARLY_PHASE1":10745,"PHASE1":10747,"PHASE2":10749,"PHASE3":10751,"PHASE4":10753,"NA":10759},{"trials":10746,"activeCount":101},[],{"trials":10748,"activeCount":101},[],{"trials":10750,"activeCount":101},[],{"trials":10752,"activeCount":101},[],{"trials":10754,"activeCount":101},[10755],{"nctId":10730,"briefTitle":10731,"status":2758,"phases":10756,"primaryCompletion":10733,"completion":10733,"start":10734,"enrollment":10735,"conditions":10757,"interventions":10758},[92],[10737],[10717,10739,10740],{"trials":10760,"activeCount":101},[],{"intervention":10740,"totalTrials":331,"cells":10762},{"EARLY_PHASE1":10763,"PHASE1":10765,"PHASE2":10767,"PHASE3":10769,"PHASE4":10771,"NA":10777},{"trials":10764,"activeCount":101},[],{"trials":10766,"activeCount":101},[],{"trials":10768,"activeCount":101},[],{"trials":10770,"activeCount":101},[],{"trials":10772,"activeCount":101},[10773],{"nctId":10730,"briefTitle":10731,"status":2758,"phases":10774,"primaryCompletion":10733,"completion":10733,"start":10734,"enrollment":10735,"conditions":10775,"interventions":10776},[92],[10737],[10717,10739,10740],{"trials":10778,"activeCount":101},[],{"intervention":10780,"totalTrials":331,"cells":10781},"Zepatier",{"EARLY_PHASE1":10782,"PHASE1":10784,"PHASE2":10786,"PHASE3":10788,"PHASE4":10790,"NA":10803},{"trials":10783,"activeCount":101},[],{"trials":10785,"activeCount":101},[],{"trials":10787,"activeCount":101},[],{"trials":10789,"activeCount":101},[],{"trials":10791,"activeCount":101},[10792],{"nctId":10793,"briefTitle":10794,"status":107,"phases":10795,"primaryCompletion":10796,"completion":10797,"start":10798,"enrollment":101,"conditions":10799,"interventions":10801},"NCT03093740","Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant",[92],"2020-12-31","2021-01-31","2018-10-01",[10800,9820],"Renal Failure Chronic",[10780,10802],"Zepatier plus Sofosbuvir",{"trials":10804,"activeCount":101},[],{"intervention":10802,"totalTrials":331,"cells":10806},{"EARLY_PHASE1":10807,"PHASE1":10809,"PHASE2":10811,"PHASE3":10813,"PHASE4":10815,"NA":10821},{"trials":10808,"activeCount":101},[],{"trials":10810,"activeCount":101},[],{"trials":10812,"activeCount":101},[],{"trials":10814,"activeCount":101},[],{"trials":10816,"activeCount":101},[10817],{"nctId":10793,"briefTitle":10794,"status":107,"phases":10818,"primaryCompletion":10796,"completion":10797,"start":10798,"enrollment":101,"conditions":10819,"interventions":10820},[92],[10800,9820],[10780,10802],{"trials":10822,"activeCount":101},[],{"intervention":314,"totalTrials":331,"cells":10824},{"EARLY_PHASE1":10825,"PHASE1":10827,"PHASE2":10829,"PHASE3":10831,"PHASE4":10833,"NA":10839},{"trials":10826,"activeCount":101},[],{"trials":10828,"activeCount":101},[],{"trials":10830,"activeCount":101},[],{"trials":10832,"activeCount":101},[],{"trials":10834,"activeCount":101},[10835],{"nctId":304,"briefTitle":305,"status":117,"phases":10836,"primaryCompletion":307,"completion":308,"start":309,"enrollment":194,"conditions":10837,"interventions":10838},[92],[311,312],[314,96],{"trials":10840,"activeCount":101},[],{"intervention":10842,"totalTrials":331,"cells":10843},"Folate",{"EARLY_PHASE1":10844,"PHASE1":10846,"PHASE2":10848,"PHASE3":10850,"PHASE4":10852,"NA":10860},{"trials":10845,"activeCount":101},[],{"trials":10847,"activeCount":101},[],{"trials":10849,"activeCount":101},[],{"trials":10851,"activeCount":101},[],{"trials":10853,"activeCount":101},[10854],{"nctId":10855,"briefTitle":10856,"status":117,"phases":10857,"primaryCompletion":2848,"completion":2848,"start":8723,"enrollment":829,"conditions":10858,"interventions":10859},"NCT00249288","Folate Supplementation in Schizophrenia",[92],[35],[10842],{"trials":10861,"activeCount":101},[],{"intervention":8567,"totalTrials":331,"cells":10863},{"EARLY_PHASE1":10864,"PHASE1":10866,"PHASE2":10868,"PHASE3":10870,"PHASE4":10872,"NA":10878},{"trials":10865,"activeCount":101},[],{"trials":10867,"activeCount":101},[],{"trials":10869,"activeCount":101},[],{"trials":10871,"activeCount":101},[],{"trials":10873,"activeCount":101},[10874],{"nctId":8558,"briefTitle":8559,"status":117,"phases":10875,"primaryCompletion":8561,"completion":8561,"start":8562,"enrollment":8563,"conditions":10876,"interventions":10877},[92],[8565],[8530,8567],{"trials":10879,"activeCount":101},[],{"intervention":10881,"totalTrials":331,"cells":10882},"Pravastatin",{"EARLY_PHASE1":10883,"PHASE1":10885,"PHASE2":10887,"PHASE3":10889,"PHASE4":10891,"NA":10901},{"trials":10884,"activeCount":101},[],{"trials":10886,"activeCount":101},[],{"trials":10888,"activeCount":101},[],{"trials":10890,"activeCount":101},[],{"trials":10892,"activeCount":101},[10893],{"nctId":10894,"briefTitle":10895,"status":117,"phases":10896,"primaryCompletion":2801,"completion":2801,"start":8925,"enrollment":1578,"conditions":10897,"interventions":10900},"NCT01082588","Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia",[92],[35,10898,10899],"Schizoaffective Disorders","Schizophreniform Disorders",[10881],{"trials":10902,"activeCount":101},[],{"intervention":1839,"totalTrials":331,"cells":10904},{"EARLY_PHASE1":10905,"PHASE1":10907,"PHASE2":10909,"PHASE3":10911,"PHASE4":10913,"NA":10919},{"trials":10906,"activeCount":101},[],{"trials":10908,"activeCount":101},[],{"trials":10910,"activeCount":101},[],{"trials":10912,"activeCount":101},[],{"trials":10914,"activeCount":101},[10915],{"nctId":1830,"briefTitle":1831,"status":173,"phases":10916,"primaryCompletion":1833,"completion":1834,"start":1835,"enrollment":97,"conditions":10917,"interventions":10918},[92],[18],[1838,1839,1840],{"trials":10920,"activeCount":101},[],{"intervention":1840,"totalTrials":331,"cells":10922},{"EARLY_PHASE1":10923,"PHASE1":10925,"PHASE2":10927,"PHASE3":10929,"PHASE4":10931,"NA":10937},{"trials":10924,"activeCount":101},[],{"trials":10926,"activeCount":101},[],{"trials":10928,"activeCount":101},[],{"trials":10930,"activeCount":101},[],{"trials":10932,"activeCount":101},[10933],{"nctId":1830,"briefTitle":1831,"status":173,"phases":10934,"primaryCompletion":1833,"completion":1834,"start":1835,"enrollment":97,"conditions":10935,"interventions":10936},[92],[18],[1838,1839,1840],{"trials":10938,"activeCount":101},[],{"intervention":10940,"totalTrials":331,"cells":10941},"divalproex sodium extended release",{"EARLY_PHASE1":10942,"PHASE1":10944,"PHASE2":10946,"PHASE3":10948,"PHASE4":10950,"NA":10959},{"trials":10943,"activeCount":101},[],{"trials":10945,"activeCount":101},[],{"trials":10947,"activeCount":101},[],{"trials":10949,"activeCount":101},[],{"trials":10951,"activeCount":101},[10952],{"nctId":10953,"briefTitle":10954,"status":117,"phases":10955,"primaryCompletion":10956,"completion":10956,"start":8992,"enrollment":1898,"conditions":10957,"interventions":10958},"NCT00181727","Study of Depakote ER for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder",[92],"2006-11",[24,640],[10940],{"trials":10960,"activeCount":101},[],{"intervention":10962,"totalTrials":331,"cells":10963},"IV Acetaminophen",{"EARLY_PHASE1":10964,"PHASE1":10966,"PHASE2":10968,"PHASE3":10970,"PHASE4":10972,"NA":10985},{"trials":10965,"activeCount":101},[],{"trials":10967,"activeCount":101},[],{"trials":10969,"activeCount":101},[],{"trials":10971,"activeCount":101},[],{"trials":10973,"activeCount":101},[10974],{"nctId":10975,"briefTitle":10976,"status":117,"phases":10977,"primaryCompletion":10978,"completion":10979,"start":208,"enrollment":7504,"conditions":10980,"interventions":10983},"NCT03073980","Assessing Efficacy of Intravenous Acetaminophen for Perioperative Pain Control for Oocyte Retrieval",[92],"2020-11-01","2020-12-01",[10981,10982],"Infertility, Female","Pain, Postoperative",[10962,10984],"PO Acetaminophen",{"trials":10986,"activeCount":101},[],{"intervention":10984,"totalTrials":331,"cells":10988},{"EARLY_PHASE1":10989,"PHASE1":10991,"PHASE2":10993,"PHASE3":10995,"PHASE4":10997,"NA":11003},{"trials":10990,"activeCount":101},[],{"trials":10992,"activeCount":101},[],{"trials":10994,"activeCount":101},[],{"trials":10996,"activeCount":101},[],{"trials":10998,"activeCount":101},[10999],{"nctId":10975,"briefTitle":10976,"status":117,"phases":11000,"primaryCompletion":10978,"completion":10979,"start":208,"enrollment":7504,"conditions":11001,"interventions":11002},[92],[10981,10982],[10962,10984],{"trials":11004,"activeCount":101},[],{"intervention":11006,"totalTrials":331,"cells":11007},"Telaprevir",{"EARLY_PHASE1":11008,"PHASE1":11010,"PHASE2":11012,"PHASE3":11014,"PHASE4":11016,"NA":11025},{"trials":11009,"activeCount":101},[],{"trials":11011,"activeCount":101},[],{"trials":11013,"activeCount":101},[],{"trials":11015,"activeCount":101},[],{"trials":11017,"activeCount":101},[11018],{"nctId":11019,"briefTitle":11020,"status":107,"phases":11021,"primaryCompletion":566,"completion":566,"start":626,"enrollment":101,"conditions":11022,"interventions":11024},"NCT01766115","Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers",[92],[11023],"Viral Hepatitis C",[11006],{"trials":11026,"activeCount":101},[],{"intervention":11028,"totalTrials":331,"cells":11029},"Direct Acting Antivirals",{"EARLY_PHASE1":11030,"PHASE1":11032,"PHASE2":11034,"PHASE3":11036,"PHASE4":11038,"NA":11048},{"trials":11031,"activeCount":101},[],{"trials":11033,"activeCount":101},[],{"trials":11035,"activeCount":101},[],{"trials":11037,"activeCount":101},[],{"trials":11039,"activeCount":101},[11040],{"nctId":11041,"briefTitle":11042,"status":107,"phases":11043,"primaryCompletion":11044,"completion":11044,"start":11045,"enrollment":101,"conditions":11046,"interventions":11047},"NCT04320290","HCV + to HCV - Kidney Transplant",[92],"2020-06-16","2020-05-21",[196,9820],[11028],{"trials":11049,"activeCount":101},[],{"intervention":11051,"totalTrials":331,"cells":11052},"Niagen",{"EARLY_PHASE1":11053,"PHASE1":11055,"PHASE2":11057,"PHASE3":11059,"PHASE4":11061,"NA":11074},{"trials":11054,"activeCount":101},[],{"trials":11056,"activeCount":101},[],{"trials":11058,"activeCount":101},[],{"trials":11060,"activeCount":101},[],{"trials":11062,"activeCount":101},[11063],{"nctId":11064,"briefTitle":11065,"status":117,"phases":11066,"primaryCompletion":11067,"completion":11068,"start":11069,"enrollment":3337,"conditions":11070,"interventions":11073},"NCT04809974","Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19",[92],"2023-10-05","2024-02-23","2021-08-28",[3056,11071,11072],"Sequelae of; Infection","Cognitive Symptom",[11051],{"trials":11075,"activeCount":101},[],{"intervention":11077,"totalTrials":331,"cells":11078},"OROS methylphenidate HCl",{"EARLY_PHASE1":11079,"PHASE1":11081,"PHASE2":11083,"PHASE3":11085,"PHASE4":11087,"NA":11096},{"trials":11080,"activeCount":101},[],{"trials":11082,"activeCount":101},[],{"trials":11084,"activeCount":101},[],{"trials":11086,"activeCount":101},[],{"trials":11088,"activeCount":101},[11089],{"nctId":11090,"briefTitle":11091,"status":117,"phases":11092,"primaryCompletion":3741,"completion":3741,"start":4425,"enrollment":366,"conditions":11093,"interventions":11094},"NCT00302354","A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults",[92],[8978],[11077,11095],"SODAS methylphenidate HCl",{"trials":11097,"activeCount":101},[],{"intervention":11095,"totalTrials":331,"cells":11099},{"EARLY_PHASE1":11100,"PHASE1":11102,"PHASE2":11104,"PHASE3":11106,"PHASE4":11108,"NA":11114},{"trials":11101,"activeCount":101},[],{"trials":11103,"activeCount":101},[],{"trials":11105,"activeCount":101},[],{"trials":11107,"activeCount":101},[],{"trials":11109,"activeCount":101},[11110],{"nctId":11090,"briefTitle":11091,"status":117,"phases":11111,"primaryCompletion":3741,"completion":3741,"start":4425,"enrollment":366,"conditions":11112,"interventions":11113},[92],[8978],[11077,11095],{"trials":11115,"activeCount":101},[],{"intervention":460,"totalTrials":331,"cells":11117},{"EARLY_PHASE1":11118,"PHASE1":11120,"PHASE2":11122,"PHASE3":11124,"PHASE4":11126,"NA":11132},{"trials":11119,"activeCount":101},[],{"trials":11121,"activeCount":101},[],{"trials":11123,"activeCount":101},[],{"trials":11125,"activeCount":101},[],{"trials":11127,"activeCount":101},[11128],{"nctId":452,"briefTitle":453,"status":117,"phases":11129,"primaryCompletion":455,"completion":436,"start":456,"enrollment":457,"conditions":11130,"interventions":11131},[92],[368],[460,370,461],{"trials":11133,"activeCount":101},[],{"intervention":11135,"totalTrials":331,"cells":11136},"galantamine HBr",{"EARLY_PHASE1":11137,"PHASE1":11139,"PHASE2":11141,"PHASE3":11143,"PHASE4":11145,"NA":11154},{"trials":11138,"activeCount":101},[],{"trials":11140,"activeCount":101},[],{"trials":11142,"activeCount":101},[],{"trials":11144,"activeCount":101},[],{"trials":11146,"activeCount":101},[11147],{"nctId":11148,"briefTitle":11149,"status":117,"phases":11150,"completion":894,"start":11151,"enrollment":251,"conditions":11152,"interventions":11153},"NCT00181675","A Double-Blind Comparison of Galantamine HBr and Placebo in Adults With Attention Deficit Hyperactivity Disorder",[92],"2002-12",[6706],[11135],{"trials":11155,"activeCount":101},[],{"intervention":11157,"totalTrials":331,"cells":11158},"paliperidone",{"EARLY_PHASE1":11159,"PHASE1":11161,"PHASE2":11163,"PHASE3":11165,"PHASE4":11167,"NA":11175},{"trials":11160,"activeCount":101},[],{"trials":11162,"activeCount":101},[],{"trials":11164,"activeCount":101},[],{"trials":11166,"activeCount":101},[],{"trials":11168,"activeCount":101},[11169],{"nctId":11170,"briefTitle":11171,"status":173,"phases":11172,"primaryCompletion":3078,"completion":3078,"start":175,"enrollment":97,"conditions":11173,"interventions":11174},"NCT00592358","Invega (Paliperidone) for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar Disorder",[92],[8555],[11157],{"trials":11176,"activeCount":101},[],{"intervention":11178,"totalTrials":331,"cells":11179},"MOVANTIK™",{"EARLY_PHASE1":11180,"PHASE1":11182,"PHASE2":11184,"PHASE3":11186,"PHASE4":11188,"NA":11199},{"trials":11181,"activeCount":101},[],{"trials":11183,"activeCount":101},[],{"trials":11185,"activeCount":101},[],{"trials":11187,"activeCount":101},[],{"trials":11189,"activeCount":101},[11190],{"nctId":11191,"briefTitle":11192,"status":173,"phases":11193,"primaryCompletion":11194,"completion":11194,"start":1779,"enrollment":11195,"conditions":11196,"interventions":11197},"NCT02946580","Naloxegol for the Prevention of Constipation in Postoperative Spinal Surgery Patients",[92],"2018-02",53,[2205],[11178,11198],"Sugar Pill",{"trials":11200,"activeCount":101},[],{"intervention":11198,"totalTrials":331,"cells":11202},{"EARLY_PHASE1":11203,"PHASE1":11205,"PHASE2":11207,"PHASE3":11209,"PHASE4":11211,"NA":11217},{"trials":11204,"activeCount":101},[],{"trials":11206,"activeCount":101},[],{"trials":11208,"activeCount":101},[],{"trials":11210,"activeCount":101},[],{"trials":11212,"activeCount":101},[11213],{"nctId":11191,"briefTitle":11192,"status":173,"phases":11214,"primaryCompletion":11194,"completion":11194,"start":1779,"enrollment":11195,"conditions":11215,"interventions":11216},[92],[2205],[11178,11198],{"trials":11218,"activeCount":101},[],{"intervention":11220,"totalTrials":331,"cells":11221},"Minocycline",{"EARLY_PHASE1":11222,"PHASE1":11224,"PHASE2":11226,"PHASE3":11228,"PHASE4":11230,"NA":11239},{"trials":11223,"activeCount":101},[],{"trials":11225,"activeCount":101},[],{"trials":11227,"activeCount":101},[],{"trials":11229,"activeCount":101},[],{"trials":11231,"activeCount":101},[11232],{"nctId":11233,"briefTitle":11234,"status":8877,"phases":11235,"primaryCompletion":1288,"completion":501,"start":11236,"enrollment":251,"conditions":11237,"interventions":11238},"NCT02719392","A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression",[92],"2017-08-09",[24,7596],[11220],{"trials":11240,"activeCount":101},[],{"intervention":11242,"totalTrials":331,"cells":11243},"Ganeden BC30",{"EARLY_PHASE1":11244,"PHASE1":11246,"PHASE2":11248,"PHASE3":11250,"PHASE4":11252,"NA":11261},{"trials":11245,"activeCount":101},[],{"trials":11247,"activeCount":101},[],{"trials":11249,"activeCount":101},[],{"trials":11251,"activeCount":101},[],{"trials":11253,"activeCount":101},[11254],{"nctId":11255,"briefTitle":11256,"status":173,"phases":11257,"primaryCompletion":9320,"completion":9320,"start":4464,"enrollment":693,"conditions":11258,"interventions":11260},"NCT01337609","Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder",[92],[18,11259],"Irritable Bowel Syndrome",[11242],{"trials":11262,"activeCount":101},[],{"intervention":11264,"totalTrials":331,"cells":11265},"folate with B12",{"EARLY_PHASE1":11266,"PHASE1":11268,"PHASE2":11270,"PHASE3":11272,"PHASE4":11274,"NA":11282},{"trials":11267,"activeCount":101},[],{"trials":11269,"activeCount":101},[],{"trials":11271,"activeCount":101},[],{"trials":11273,"activeCount":101},[],{"trials":11275,"activeCount":101},[11276],{"nctId":11277,"briefTitle":11278,"status":117,"phases":11279,"primaryCompletion":4771,"completion":119,"start":567,"enrollment":1466,"conditions":11280,"interventions":11281},"NCT01724476","A Trial of Folate With B12 in Patients With Schizophrenia With Residual Symptoms in Ethiopia",[92],[35],[11264],{"trials":11283,"activeCount":101},[],{"intervention":11285,"totalTrials":331,"cells":11286},"Immediate Release Methylphenidate",{"EARLY_PHASE1":11287,"PHASE1":11289,"PHASE2":11291,"PHASE3":11293,"PHASE4":11295,"NA":11305},{"trials":11288,"activeCount":101},[],{"trials":11290,"activeCount":101},[],{"trials":11292,"activeCount":101},[],{"trials":11294,"activeCount":101},[],{"trials":11296,"activeCount":101},[11297],{"nctId":11298,"briefTitle":11299,"status":117,"phases":11300,"primaryCompletion":3516,"completion":3516,"start":11301,"enrollment":30,"conditions":11302,"interventions":11303},"NCT00302458","A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults",[92],"2006-01",[29],[11304,11285],"OROS-Methylphenidate",{"trials":11306,"activeCount":101},[],{"intervention":688,"totalTrials":331,"cells":11308},{"EARLY_PHASE1":11309,"PHASE1":11311,"PHASE2":11313,"PHASE3":11315,"PHASE4":11317,"NA":11323},{"trials":11310,"activeCount":101},[],{"trials":11312,"activeCount":101},[],{"trials":11314,"activeCount":101},[],{"trials":11316,"activeCount":101},[],{"trials":11318,"activeCount":101},[11319],{"nctId":681,"briefTitle":682,"status":117,"phases":11320,"primaryCompletion":684,"completion":175,"start":672,"enrollment":366,"conditions":11321,"interventions":11322},[92],[686],[688,610],{"trials":11324,"activeCount":101},[],{"intervention":11326,"totalTrials":331,"cells":11327},"OROS-MPH",{"EARLY_PHASE1":11328,"PHASE1":11330,"PHASE2":11332,"PHASE3":11334,"PHASE4":11336,"NA":11344},{"trials":11329,"activeCount":101},[],{"trials":11331,"activeCount":101},[],{"trials":11333,"activeCount":101},[],{"trials":11335,"activeCount":101},[],{"trials":11337,"activeCount":101},[11338],{"nctId":11339,"briefTitle":11340,"status":107,"phases":11341,"primaryCompletion":3680,"completion":3680,"start":3680,"enrollment":101,"conditions":11342,"interventions":11343},"NCT01858064","Predicting Treatment Response to Stimulants in Adult ADHD Using Functional Magnetic Resonance Imaging",[92],[6706],[11326],{"trials":11345,"activeCount":101},[],{"intervention":11347,"totalTrials":331,"cells":11348},"Nicotine patch",{"EARLY_PHASE1":11349,"PHASE1":11351,"PHASE2":11353,"PHASE3":11355,"PHASE4":11357,"NA":11368},{"trials":11350,"activeCount":101},[],{"trials":11352,"activeCount":101},[],{"trials":11354,"activeCount":101},[],{"trials":11356,"activeCount":101},[],{"trials":11358,"activeCount":101},[11359],{"nctId":11360,"briefTitle":11361,"status":117,"phases":11362,"primaryCompletion":11363,"completion":11363,"start":3834,"enrollment":11364,"conditions":11365,"interventions":11367},"NCT03611881","Assessing the Integration of Tobacco Cessation Treatment Into Lung Cancer Screening (LCS)",[92],"2024-01-31",642,[11366],"Smoking, Tobacco",[11347],{"trials":11369,"activeCount":101},[],{"intervention":11371,"totalTrials":331,"cells":11372},"Treatment with Direct Acting Antiviral",{"EARLY_PHASE1":11373,"PHASE1":11375,"PHASE2":11377,"PHASE3":11379,"PHASE4":11381,"NA":11391},{"trials":11374,"activeCount":101},[],{"trials":11376,"activeCount":101},[],{"trials":11378,"activeCount":101},[],{"trials":11380,"activeCount":101},[],{"trials":11382,"activeCount":101},[11383],{"nctId":11384,"briefTitle":11385,"status":173,"phases":11386,"primaryCompletion":2496,"completion":2496,"start":11387,"enrollment":2610,"conditions":11388,"interventions":11390},"NCT03208127","DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant",[92],"2017-11-21",[11389,9820],"End Stage Liver Disease",[11371],{"trials":11392,"activeCount":101},[],{"intervention":8779,"totalTrials":331,"cells":11394},{"EARLY_PHASE1":11395,"PHASE1":11397,"PHASE2":11399,"PHASE3":11401,"PHASE4":11403,"NA":11409},{"trials":11396,"activeCount":101},[],{"trials":11398,"activeCount":101},[],{"trials":11400,"activeCount":101},[],{"trials":11402,"activeCount":101},[],{"trials":11404,"activeCount":101},[11405],{"nctId":8773,"briefTitle":8774,"status":117,"phases":11406,"primaryCompletion":3052,"completion":3052,"start":2801,"enrollment":413,"conditions":11407,"interventions":11408},[92],[6706,8777],[8779,8745],{"trials":11410,"activeCount":101},[],{"intervention":11412,"totalTrials":331,"cells":11413},"Moxifloxacin 400mg once time",{"EARLY_PHASE1":11414,"PHASE1":11416,"PHASE2":11418,"PHASE3":11420,"PHASE4":11422,"NA":11433},{"trials":11415,"activeCount":101},[],{"trials":11417,"activeCount":101},[],{"trials":11419,"activeCount":101},[],{"trials":11421,"activeCount":101},[],{"trials":11423,"activeCount":101},[11424],{"nctId":11425,"briefTitle":11426,"status":173,"phases":11427,"primaryCompletion":11428,"completion":11428,"start":11429,"enrollment":22,"conditions":11430,"interventions":11432},"NCT01936480","Genetics of QT Response to Moxifloxacin",[92],"2019-06-19","2013-10",[11431],"Cardiac Arrhythmias",[11412],{"trials":11434,"activeCount":101},[],{"intervention":11436,"totalTrials":331,"cells":11437},"NRT",{"EARLY_PHASE1":11438,"PHASE1":11440,"PHASE2":11442,"PHASE3":11444,"PHASE4":11446,"NA":11455},{"trials":11439,"activeCount":101},[],{"trials":11441,"activeCount":101},[],{"trials":11443,"activeCount":101},[],{"trials":11445,"activeCount":101},[],{"trials":11447,"activeCount":101},[11448],{"nctId":11449,"briefTitle":11450,"status":173,"phases":11451,"primaryCompletion":2027,"completion":2027,"start":260,"enrollment":97,"conditions":11452,"interventions":11453},"NCT01576640","Extended Duration Nicotine Replacement Therapy and Bupropion in Smokers With Schizophrenia",[92],[1947,35],[11436,11454],"Bupropion SR 150mg bid",{"trials":11456,"activeCount":101},[],{"intervention":11454,"totalTrials":331,"cells":11458},{"EARLY_PHASE1":11459,"PHASE1":11461,"PHASE2":11463,"PHASE3":11465,"PHASE4":11467,"NA":11473},{"trials":11460,"activeCount":101},[],{"trials":11462,"activeCount":101},[],{"trials":11464,"activeCount":101},[],{"trials":11466,"activeCount":101},[],{"trials":11468,"activeCount":101},[11469],{"nctId":11449,"briefTitle":11450,"status":173,"phases":11470,"primaryCompletion":2027,"completion":2027,"start":260,"enrollment":97,"conditions":11471,"interventions":11472},[92],[1947,35],[11436,11454],{"trials":11474,"activeCount":101},[],{"intervention":11476,"totalTrials":331,"cells":11477},"11C-PBR28",{"EARLY_PHASE1":11478,"PHASE1":11480,"PHASE2":11482,"PHASE3":11484,"PHASE4":11486,"NA":11496},{"trials":11479,"activeCount":101},[],{"trials":11481,"activeCount":101},[],{"trials":11483,"activeCount":101},[],{"trials":11485,"activeCount":101},[],{"trials":11487,"activeCount":101},[11488],{"nctId":11489,"briefTitle":11490,"status":117,"phases":11491,"primaryCompletion":11492,"completion":10635,"start":11493,"enrollment":2859,"conditions":11494,"interventions":11495},"NCT04230174","Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation",[92],"2024-10-09","2020-12-29",[6002],[11476],{"trials":11497,"activeCount":101},[],{"intervention":11499,"totalTrials":331,"cells":11500},"Lisdexamfetamine",{"EARLY_PHASE1":11501,"PHASE1":11503,"PHASE2":11505,"PHASE3":11507,"PHASE4":11509,"NA":11517},{"trials":11502,"activeCount":101},[],{"trials":11504,"activeCount":101},[],{"trials":11506,"activeCount":101},[],{"trials":11508,"activeCount":101},[],{"trials":11510,"activeCount":101},[11511],{"nctId":11512,"briefTitle":11513,"status":117,"phases":11514,"primaryCompletion":3004,"completion":3004,"start":708,"enrollment":886,"conditions":11515,"interventions":11516},"NCT00753012","Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults",[92],[9322],[11499],{"trials":11518,"activeCount":101},[],{"intervention":8995,"totalTrials":331,"cells":11520},{"EARLY_PHASE1":11521,"PHASE1":11523,"PHASE2":11525,"PHASE3":11527,"PHASE4":11529,"NA":11535},{"trials":11522,"activeCount":101},[],{"trials":11524,"activeCount":101},[],{"trials":11526,"activeCount":101},[],{"trials":11528,"activeCount":101},[],{"trials":11530,"activeCount":101},[11531],{"nctId":8989,"briefTitle":8990,"status":117,"phases":11532,"primaryCompletion":4465,"completion":4465,"start":8992,"enrollment":194,"conditions":11533,"interventions":11534},[92],[8978],[8956,8995],{"trials":11536,"activeCount":101},[],{"intervention":11538,"totalTrials":331,"cells":11539},"Amiodarone",{"EARLY_PHASE1":11540,"PHASE1":11542,"PHASE2":11544,"PHASE3":11546,"PHASE4":11548,"NA":11558},{"trials":11541,"activeCount":101},[],{"trials":11543,"activeCount":101},[],{"trials":11545,"activeCount":101},[],{"trials":11547,"activeCount":101},[],{"trials":11549,"activeCount":101},[11550],{"nctId":11551,"briefTitle":11552,"status":107,"phases":11553,"primaryCompletion":2777,"completion":1243,"start":11554,"enrollment":101,"conditions":11555,"interventions":11557},"NCT05543278","Pragmatic Amiodarone Trial to Reduce Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery",[92],"2026-01",[11556,7209],"Surgery, Cardiac",[11538],{"trials":11559,"activeCount":101},[],{"intervention":11561,"totalTrials":331,"cells":11562},"carbamazepine ER",{"EARLY_PHASE1":11563,"PHASE1":11565,"PHASE2":11567,"PHASE3":11569,"PHASE4":11571,"NA":11579},{"trials":11564,"activeCount":101},[],{"trials":11566,"activeCount":101},[],{"trials":11568,"activeCount":101},[],{"trials":11570,"activeCount":101},[],{"trials":11572,"activeCount":101},[11573],{"nctId":11574,"briefTitle":11575,"status":117,"phases":11576,"primaryCompletion":4450,"start":8722,"enrollment":2610,"conditions":11577,"interventions":11578},"NCT00181870","Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder",[92],[24,640],[11561],{"trials":11580,"activeCount":101},[],{"intervention":9604,"totalTrials":331,"cells":11582},{"EARLY_PHASE1":11583,"PHASE1":11585,"PHASE2":11587,"PHASE3":11589,"PHASE4":11591,"NA":11597},{"trials":11584,"activeCount":101},[],{"trials":11586,"activeCount":101},[],{"trials":11588,"activeCount":101},[],{"trials":11590,"activeCount":101},[],{"trials":11592,"activeCount":101},[11593],{"nctId":9597,"briefTitle":9598,"status":173,"phases":11594,"primaryCompletion":4352,"completion":4352,"start":9600,"enrollment":270,"conditions":11595,"interventions":11596},[92],[9602],[9574,9604],{"trials":11598,"activeCount":101},[],{"intervention":11600,"totalTrials":331,"cells":11601},"Icatibant",{"EARLY_PHASE1":11602,"PHASE1":11604,"PHASE2":11606,"PHASE3":11608,"PHASE4":11610,"NA":11619},{"trials":11603,"activeCount":101},[],{"trials":11605,"activeCount":101},[],{"trials":11607,"activeCount":101},[],{"trials":11609,"activeCount":101},[],{"trials":11611,"activeCount":101},[11612],{"nctId":11613,"briefTitle":11614,"status":117,"phases":11615,"primaryCompletion":455,"completion":455,"start":4290,"enrollment":2837,"conditions":11616,"interventions":11618},"NCT01457430","Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE",[92],[11617],"Hereditary Angioedema",[11600],{"trials":11620,"activeCount":101},[],{"intervention":11622,"totalTrials":331,"cells":11623},"Ticagrelor- Delayed Administration",{"EARLY_PHASE1":11624,"PHASE1":11626,"PHASE2":11628,"PHASE3":11630,"PHASE4":11632,"NA":11641},{"trials":11625,"activeCount":101},[],{"trials":11627,"activeCount":101},[],{"trials":11629,"activeCount":101},[],{"trials":11631,"activeCount":101},[],{"trials":11633,"activeCount":101},[11634],{"nctId":11635,"briefTitle":11636,"status":107,"phases":11637,"primaryCompletion":135,"start":4527,"enrollment":101,"conditions":11638,"interventions":11639},"NCT01916902","Effect of Pretreatment With Ticagrelor on Residual Thrombus After PCI in Patients Presenting With ACS in Comparison With Delayed Treatment at the Time of PCI: an OCT Study",[92],[8016,1468],[11622,11640],"Ticagrelor- Immediate Administration",{"trials":11642,"activeCount":101},[],{"intervention":11640,"totalTrials":331,"cells":11644},{"EARLY_PHASE1":11645,"PHASE1":11647,"PHASE2":11649,"PHASE3":11651,"PHASE4":11653,"NA":11659},{"trials":11646,"activeCount":101},[],{"trials":11648,"activeCount":101},[],{"trials":11650,"activeCount":101},[],{"trials":11652,"activeCount":101},[],{"trials":11654,"activeCount":101},[11655],{"nctId":11635,"briefTitle":11636,"status":107,"phases":11656,"primaryCompletion":135,"start":4527,"enrollment":101,"conditions":11657,"interventions":11658},[92],[8016,1468],[11622,11640],{"trials":11660,"activeCount":101},[],{"intervention":11662,"totalTrials":331,"cells":11663},"buprenorphine transdermal delivery system",{"EARLY_PHASE1":11664,"PHASE1":11666,"PHASE2":11668,"PHASE3":11670,"PHASE4":11672,"NA":11680},{"trials":11665,"activeCount":101},[],{"trials":11667,"activeCount":101},[],{"trials":11669,"activeCount":101},[],{"trials":11671,"activeCount":101},[],{"trials":11673,"activeCount":101},[11674],{"nctId":11675,"briefTitle":11676,"status":107,"phases":11677,"primaryCompletion":268,"completion":268,"start":455,"enrollment":101,"conditions":11678,"interventions":11679},"NCT02138357","Butrans for Treatment of Restless Legs Syndrome",[92],[831],[11662],{"trials":11681,"activeCount":101},[],{"intervention":11683,"totalTrials":331,"cells":11684},"OROS methylphenidate",{"EARLY_PHASE1":11685,"PHASE1":11687,"PHASE2":11689,"PHASE3":11691,"PHASE4":11693,"NA":11701},{"trials":11686,"activeCount":101},[],{"trials":11688,"activeCount":101},[],{"trials":11690,"activeCount":101},[],{"trials":11692,"activeCount":101},[],{"trials":11694,"activeCount":101},[11695],{"nctId":11696,"briefTitle":11697,"status":117,"phases":11698,"primaryCompletion":150,"completion":150,"start":10956,"enrollment":4353,"conditions":11699,"interventions":11700},"NCT00593112","Proton Magnetic Spectroscopy in Children and Adolescents With ADHD Before and After Treatment With OROS Methylphenidate",[92],[6706],[11683],{"trials":11702,"activeCount":101},[],{"intervention":11704,"totalTrials":331,"cells":11705},"Selective serotonin reuptake inhibitors",{"EARLY_PHASE1":11706,"PHASE1":11708,"PHASE2":11710,"PHASE3":11712,"PHASE4":11714,"NA":11724},{"trials":11707,"activeCount":101},[],{"trials":11709,"activeCount":101},[],{"trials":11711,"activeCount":101},[],{"trials":11713,"activeCount":101},[],{"trials":11715,"activeCount":101},[11716],{"nctId":11717,"briefTitle":11718,"status":117,"phases":11719,"primaryCompletion":4463,"completion":4463,"start":11720,"enrollment":11721,"conditions":11722,"interventions":11723},"NCT00157547","Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Depression",[92],"2003-04",95,[18],[11704],{"trials":11725,"activeCount":101},[],{"intervention":11727,"totalTrials":331,"cells":11728},"Strattera",{"EARLY_PHASE1":11729,"PHASE1":11731,"PHASE2":11733,"PHASE3":11735,"PHASE4":11737,"NA":11745},{"trials":11730,"activeCount":101},[],{"trials":11732,"activeCount":101},[],{"trials":11734,"activeCount":101},[],{"trials":11736,"activeCount":101},[],{"trials":11738,"activeCount":101},[11739],{"nctId":11740,"briefTitle":11741,"status":117,"phases":11742,"primaryCompletion":3464,"completion":3464,"start":8723,"enrollment":2559,"conditions":11743,"interventions":11744},"NCT00181766","Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)",[92],[8725],[11727],{"trials":11746,"activeCount":101},[],{"intervention":11748,"totalTrials":331,"cells":11749},"Reactivation Mismatch",{"EARLY_PHASE1":11750,"PHASE1":11752,"PHASE2":11754,"PHASE3":11756,"PHASE4":11758,"NA":11767},{"trials":11751,"activeCount":101},[],{"trials":11753,"activeCount":101},[],{"trials":11755,"activeCount":101},[],{"trials":11757,"activeCount":101},[],{"trials":11759,"activeCount":101},[11760],{"nctId":11761,"briefTitle":11762,"status":2758,"phases":11763,"primaryCompletion":2408,"completion":2408,"start":11764,"enrollment":4618,"conditions":11765,"interventions":11766},"NCT03652922","Propranolol Reactivation Mismatch (PRM) Treatment for PTSD",[92],"2018-09",[734],[11748],{"trials":11768,"activeCount":101},[],{"intervention":11770,"totalTrials":331,"cells":11771},"Methylphenidate Extended Release Oral",{"EARLY_PHASE1":11772,"PHASE1":11774,"PHASE2":11776,"PHASE3":11778,"PHASE4":11780,"NA":11791},{"trials":11773,"activeCount":101},[],{"trials":11775,"activeCount":101},[],{"trials":11777,"activeCount":101},[],{"trials":11779,"activeCount":101},[],{"trials":11781,"activeCount":101},[11782],{"nctId":11783,"briefTitle":11784,"status":117,"phases":11785,"primaryCompletion":11786,"completion":11786,"start":11787,"enrollment":4618,"conditions":11788,"interventions":11790},"NCT03811847","A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.",[92],"2021-08-30","2019-11-01",[11789],"Alzheimer Dementia",[11770],{"trials":11792,"activeCount":101},[],{"intervention":11794,"totalTrials":331,"cells":11795},"Vancomycin continuous",{"EARLY_PHASE1":11796,"PHASE1":11798,"PHASE2":11800,"PHASE3":11802,"PHASE4":11804,"NA":11814},{"trials":11797,"activeCount":101},[],{"trials":11799,"activeCount":101},[],{"trials":11801,"activeCount":101},[],{"trials":11803,"activeCount":101},[],{"trials":11805,"activeCount":101},[11806],{"nctId":11807,"briefTitle":11808,"status":173,"phases":11809,"primaryCompletion":298,"completion":298,"start":627,"enrollment":30,"conditions":11810,"interventions":11812},"NCT01786161","Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients",[92],[11811],"MRSA - Methicillin Resistant Staphylococcus Aureus Infection",[11794,11813],"Vancomycin intermittent dosing interval",{"trials":11815,"activeCount":101},[],{"intervention":11813,"totalTrials":331,"cells":11817},{"EARLY_PHASE1":11818,"PHASE1":11820,"PHASE2":11822,"PHASE3":11824,"PHASE4":11826,"NA":11832},{"trials":11819,"activeCount":101},[],{"trials":11821,"activeCount":101},[],{"trials":11823,"activeCount":101},[],{"trials":11825,"activeCount":101},[],{"trials":11827,"activeCount":101},[11828],{"nctId":11807,"briefTitle":11808,"status":173,"phases":11829,"primaryCompletion":298,"completion":298,"start":627,"enrollment":30,"conditions":11830,"interventions":11831},[92],[11811],[11794,11813],{"trials":11833,"activeCount":101},[],{"intervention":11835,"totalTrials":270,"cells":11836},"GnRH",{"EARLY_PHASE1":11837,"PHASE1":11839,"PHASE2":11886,"PHASE3":11908,"PHASE4":11920,"NA":11922},{"trials":11838,"activeCount":101},[],{"trials":11840,"activeCount":101},[11841,11852,11862,11876],{"nctId":11842,"briefTitle":11843,"status":117,"phases":11844,"primaryCompletion":1877,"completion":1877,"start":11845,"enrollment":9,"conditions":11846,"interventions":11850},"NCT01438073","Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling",[89],"2011-09",[11847,11848,11849],"Hypogonadotropic Hypogonadism","Healthy Postmenopausal Women","Agonadism",[11851,11835],"kisspeptin 112-121",{"nctId":11853,"briefTitle":11854,"status":117,"phases":11855,"primaryCompletion":11856,"completion":11856,"start":11857,"enrollment":4874,"conditions":11858,"interventions":11859},"NCT01952782","Neuropeptides in Human Reproduction",[89],"2016-05-31","2014-04-30",[11847],[11860,11861,11835],"Kisspeptin 112-121","Naloxone",{"nctId":11863,"briefTitle":11864,"status":117,"phases":11865,"primaryCompletion":11866,"completion":11866,"start":11867,"enrollment":11868,"conditions":11869,"interventions":11875},"NCT00914823","Kisspeptin Administration in the Adult",[89],"2021-10-22","2009-06-23",256,[11847,11870,11871,11872,11873,11874],"Kallmann Syndrome","GnRH Deficiency","PCOS","Polycystic Ovarian Syndrome","Hyperprolactinemia",[11851,11835],{"nctId":11877,"briefTitle":11878,"status":117,"phases":11879,"primaryCompletion":11880,"completion":11881,"start":11882,"enrollment":886,"conditions":11883,"interventions":11885},"NCT01438034","Kisspeptin in the Evaluation of Delayed Puberty",[89],"2019-09-08","2021-09-10","2013-06-08",[11884,11870,11847,11871],"Delayed Puberty",[11851,11835],{"trials":11887,"activeCount":101},[11888,11899],{"nctId":11889,"briefTitle":11890,"status":2758,"phases":11891,"primaryCompletion":11892,"completion":11892,"start":11893,"enrollment":11894,"conditions":11895,"interventions":11898},"NCT00383656","Pulsatile GnRH in Anovulatory Infertility",[90],"2020-09","1989-01",270,[11847,11896,11897],"Amenorrhea","Kallmann's Syndrome",[11835],{"nctId":11900,"briefTitle":11901,"status":117,"phases":11902,"primaryCompletion":11903,"completion":11904,"start":11905,"enrollment":33,"conditions":11906,"interventions":11907},"NCT02956447","Administration of Kisspeptin in Patients With Hyperprolactinemia",[90],"2023-06-28","2023-07-29","2017-11-17",[11874,570],[11860,11835],{"trials":11909,"activeCount":101},[11910],{"nctId":11911,"briefTitle":11912,"status":2758,"phases":11913,"primaryCompletion":11914,"completion":120,"start":11915,"enrollment":2837,"conditions":11916,"interventions":11917},"NCT00386022","The Effects of Aging and Estrogen on the Pituitary",[90,91],"2012-01","2002-01",[29],[11835,11918,11919],"NAL-GLU GnRH antagonist","Estrogen patch",{"trials":11921,"activeCount":101},[],{"trials":11923,"activeCount":101},[],{"intervention":11925,"totalTrials":693,"cells":11926},"Creatine monohydrate",{"EARLY_PHASE1":11927,"PHASE1":11929,"PHASE2":11931,"PHASE3":11961,"PHASE4":11970,"NA":11972},{"trials":11928,"activeCount":101},[],{"trials":11930,"activeCount":101},[],{"trials":11932,"activeCount":101},[11933,11940,11947,11954],{"nctId":11934,"briefTitle":11935,"status":117,"phases":11936,"primaryCompletion":1876,"completion":1876,"start":4581,"enrollment":886,"conditions":11937,"interventions":11939},"NCT01411163","Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability",[90],[11938],"Huntington's Disease",[11925],{"nctId":11941,"briefTitle":11942,"status":117,"phases":11943,"primaryCompletion":2801,"completion":2801,"start":4666,"enrollment":19,"conditions":11944,"interventions":11946},"NCT00592995","Creatine Safety and Tolerability in Premanifest HD: PRECREST",[90],[11945],"Huntington Disease",[11925],{"nctId":11948,"briefTitle":11949,"status":117,"phases":11950,"primaryCompletion":149,"completion":149,"start":8588,"enrollment":239,"conditions":11951,"interventions":11953},"NCT01412151","Creatine Safety & Tolerability in Huntington's Disease",[90],[11952],"Huntington's Disease (HD)",[11925],{"nctId":11955,"briefTitle":11956,"status":117,"phases":11957,"primaryCompletion":2801,"completion":2801,"start":150,"enrollment":6796,"conditions":11958,"interventions":11959},"NCT01411150","Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study",[90],[11938],[11960],"Creatine Monohydrate",{"trials":11962,"activeCount":101},[11963],{"nctId":11964,"briefTitle":11965,"status":173,"phases":11966,"primaryCompletion":567,"completion":225,"start":6891,"enrollment":11967,"conditions":11968,"interventions":11969},"NCT00712426","Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)",[91],553,[11938],[11960],{"trials":11971,"activeCount":101},[],{"trials":11973,"activeCount":101},[],{"intervention":11975,"totalTrials":693,"cells":11976},"Nitric Oxide",{"EARLY_PHASE1":11977,"PHASE1":11979,"PHASE2":11981,"PHASE3":12023,"PHASE4":12035,"NA":12037},{"trials":11978,"activeCount":101},[],{"trials":11980,"activeCount":101},[],{"trials":11982,"activeCount":101},[11983,11994,12004,12012],{"nctId":11984,"briefTitle":11985,"status":107,"phases":11986,"primaryCompletion":11987,"completion":11987,"start":6721,"enrollment":101,"conditions":11988,"interventions":11992},"NCT04022161","Effects of Prolonged Delivery of Nitric Oxide Gas on Plasma Reduction-Oxidation Reactions in Cardiac Surgical Patients",[90],"2025-11-24",[11989,11990,11991],"Cardiovascular Diseases","Oxidative Stress","Endothelial Dysfunction",[11993,11975],"Nitrogen Gas for Inhalation",{"nctId":11995,"briefTitle":11996,"status":107,"phases":11997,"primaryCompletion":11998,"completion":11998,"start":11999,"enrollment":101,"conditions":12000,"interventions":12003},"NCT03748082","Effects of Nitric Oxide on the Endothelium During Hemolysis.",[90],"2023-11","2018-12-05",[11991,12001,11989,12002],"Hemolysis Intravascular","Cardiovascular Risk Factor",[11975],{"nctId":12005,"briefTitle":12006,"status":107,"phases":12007,"primaryCompletion":268,"completion":2857,"start":1846,"enrollment":101,"conditions":12008,"interventions":12011},"NCT02217683","Use of Inhaled Nitric Oxide to Prevent Pulmonary Hypertension Associated to Stored Blood Transfusion",[90],[12009,12010],"Hypertension, Pulmonary","Hemolysis",[11975],{"nctId":12013,"briefTitle":12014,"status":173,"phases":12015,"primaryCompletion":12016,"completion":12016,"start":12017,"enrollment":3122,"conditions":12018,"interventions":12022},"NCT04305457","Nitric Oxide Gas Inhalation Therapy for Mild\u002FModerate COVID-19",[90],"2023-08-23","2020-03-21",[12019,12020,12021],"Coronavirus Infections","Pneumonia, Viral","Acute Respiratory Distress Syndrome",[11975],{"trials":12024,"activeCount":101},[12025],{"nctId":12026,"briefTitle":12027,"status":117,"phases":12028,"primaryCompletion":12029,"completion":12029,"start":12030,"enrollment":12031,"conditions":12032,"interventions":12034},"NCT02836899","Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction.",[91],"2025-08-15","2017-02-08",250,[12033],"Acute Kidney Injury",[11975],{"trials":12036,"activeCount":101},[],{"trials":12038,"activeCount":101},[],{"intervention":12040,"totalTrials":178,"cells":12041},"Maca Root",{"EARLY_PHASE1":12042,"PHASE1":12044,"PHASE2":12046,"PHASE3":12048,"PHASE4":12074,"NA":12076},{"trials":12043,"activeCount":101},[],{"trials":12045,"activeCount":101},[],{"trials":12047,"activeCount":101},[],{"trials":12049,"activeCount":101},[12050,12059,12065],{"nctId":12051,"briefTitle":12052,"status":173,"phases":12053,"primaryCompletion":12054,"completion":12054,"start":12055,"enrollment":1890,"conditions":12056,"interventions":12058},"NCT00575328","Study of Maca Root to Treat Sexual Dysfunction Associated With the Treatment Regimen for Bipolar Disorder in Females",[91],"2010-04-26","2008-02-26",[12057,24],"Sexual Dysfunction",[12040],{"nctId":12060,"briefTitle":12061,"status":117,"phases":12062,"primaryCompletion":8925,"completion":8925,"start":4666,"enrollment":194,"conditions":12063,"interventions":12064},"NCT00181961","Safety and Effectiveness Study of Maca Root to Treat Antidepressant-Induced Sexual Dysfunction",[91],[15,12057],[12040],{"nctId":12066,"briefTitle":12067,"status":117,"phases":12068,"primaryCompletion":12069,"completion":12069,"start":12070,"enrollment":2559,"conditions":12071,"interventions":12073},"NCT00568126","Study of Maca Root for the Treatment of Antidepressant-Induced Sexual Dysfunction in Females",[91],"2010-10-05","2007-12-27",[12072],"Antidepressant Induced Sexual Dysfunction",[12040],{"trials":12075,"activeCount":101},[],{"trials":12077,"activeCount":101},[],{"intervention":12079,"totalTrials":136,"cells":12080},"Liposomal bupivacaine",{"EARLY_PHASE1":12081,"PHASE1":12083,"PHASE2":12085,"PHASE3":12087,"PHASE4":12108,"NA":12110},{"trials":12082,"activeCount":101},[],{"trials":12084,"activeCount":101},[],{"trials":12086,"activeCount":101},[],{"trials":12088,"activeCount":101},[12089,12096],{"nctId":12090,"briefTitle":12091,"status":117,"phases":12092,"primaryCompletion":2881,"completion":3240,"start":12093,"enrollment":732,"conditions":12094,"interventions":12095},"NCT02959996","Liposomal Bupivacaine at Cesarean Delivery to Decrease Post-operative Pain",[90,91],"2017-03-08",[10982],[12079],{"nctId":12097,"briefTitle":12098,"status":2758,"phases":12099,"primaryCompletion":119,"completion":119,"start":1780,"enrollment":1466,"conditions":12100,"interventions":12104},"NCT03036085","Liposomal Bupivacaine for Pain Control Following Thoracic Surgery.",[90,91],[10982,12101,12102,12103],"Thoracic Diseases","Local Anesthetics Causing Adverse Effects in Therapeutic Use","Opioid Dependence",[12079,12105,12106,12107],"Bupivacaine","Epinephrine","Normal saline",{"trials":12109,"activeCount":101},[],{"trials":12111,"activeCount":101},[],{"intervention":12113,"totalTrials":136,"cells":12114},"vitamin D3",{"EARLY_PHASE1":12115,"PHASE1":12117,"PHASE2":12119,"PHASE3":12121,"PHASE4":12144,"NA":12146},{"trials":12116,"activeCount":101},[],{"trials":12118,"activeCount":101},[],{"trials":12120,"activeCount":101},[],{"trials":12122,"activeCount":101},[12123,12133],{"nctId":12124,"briefTitle":12125,"status":107,"phases":12126,"primaryCompletion":967,"completion":9525,"start":119,"enrollment":101,"conditions":12127,"interventions":12132},"NCT02684487","Vitamin D Status in Patients With Severe Sepsis",[91],[12128,12129,12130,12131],"Sepsis","Severe Sepsis","End Organ Damage","Multi Organ Failure",[12113],{"nctId":12134,"briefTitle":12135,"status":117,"phases":12136,"primaryCompletion":12137,"completion":12137,"start":12138,"enrollment":12139,"conditions":12140,"interventions":12142},"NCT03096314","Vitamin D to Improve Outcomes by Leveraging Early Treatment",[91],"2018-12-11","2017-04-27",1358,[12021,12141,7904],"Vitamin D Deficiency",[12143],"Vitamin D3",{"trials":12145,"activeCount":101},[],{"trials":12147,"activeCount":101},[],{"intervention":12149,"totalTrials":136,"cells":12150},"warfarin",{"EARLY_PHASE1":12151,"PHASE1":12153,"PHASE2":12155,"PHASE3":12157,"PHASE4":12177,"NA":12179},{"trials":12152,"activeCount":101},[],{"trials":12154,"activeCount":101},[],{"trials":12156,"activeCount":101},[],{"trials":12158,"activeCount":101},[12159,12173],{"nctId":12160,"briefTitle":12161,"status":117,"phases":12162,"primaryCompletion":12163,"completion":12163,"start":12164,"conditions":12165,"interventions":12172},"NCT00000517","Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)",[91],"1991-06","1985-07",[12166,7209,11989,12167,12168,12169,12170,12171],"Arrhythmia","Cerebral Embolism and Thrombosis","Cerebrovascular Disorders","Heart Diseases","Thrombophlebitis","Cerebrovascular Accident",[12149],{"nctId":8195,"briefTitle":8196,"status":117,"phases":12174,"primaryCompletion":193,"completion":193,"start":8198,"enrollment":16,"conditions":12175,"interventions":12176},[91],[7209,8200,8201],[7551,8203],{"trials":12178,"activeCount":101},[],{"trials":12180,"activeCount":101},[],{"intervention":11918,"totalTrials":136,"cells":12182},{"EARLY_PHASE1":12183,"PHASE1":12185,"PHASE2":12187,"PHASE3":12198,"PHASE4":12204,"NA":12206},{"trials":12184,"activeCount":101},[],{"trials":12186,"activeCount":101},[],{"trials":12188,"activeCount":101},[12189],{"nctId":12190,"briefTitle":12191,"status":2758,"phases":12192,"primaryCompletion":12193,"start":12194,"enrollment":2728,"conditions":12195,"interventions":12196},"NCT00351416","Letrozole Treatment in Normal and GnRH Deficient Women",[89,90],"2009-06-29","2004-01-21",[8978],[12197,11918],"Letrozole",{"trials":12199,"activeCount":101},[12200],{"nctId":11911,"briefTitle":11912,"status":2758,"phases":12201,"primaryCompletion":11914,"completion":120,"start":11915,"enrollment":2837,"conditions":12202,"interventions":12203},[90,91],[29],[11835,11918,11919],{"trials":12205,"activeCount":101},[],{"trials":12207,"activeCount":101},[],{"intervention":596,"totalTrials":331,"cells":12209},{"EARLY_PHASE1":12210,"PHASE1":12212,"PHASE2":12214,"PHASE3":12216,"PHASE4":12222,"NA":12224},{"trials":12211,"activeCount":101},[],{"trials":12213,"activeCount":101},[],{"trials":12215,"activeCount":101},[],{"trials":12217,"activeCount":101},[12218],{"nctId":588,"briefTitle":589,"status":117,"phases":12219,"primaryCompletion":591,"completion":591,"start":592,"enrollment":593,"conditions":12220,"interventions":12221},[91],[380],[596,543],{"trials":12223,"activeCount":101},[],{"trials":12225,"activeCount":101},[],{"intervention":12227,"totalTrials":331,"cells":12228},"Estrogen",{"EARLY_PHASE1":12229,"PHASE1":12231,"PHASE2":12233,"PHASE3":12235,"PHASE4":12244,"NA":12246},{"trials":12230,"activeCount":101},[],{"trials":12232,"activeCount":101},[],{"trials":12234,"activeCount":101},[],{"trials":12236,"activeCount":101},[12237],{"nctId":12238,"briefTitle":12239,"status":107,"phases":12240,"primaryCompletion":12241,"completion":225,"start":9865,"enrollment":101,"conditions":12242,"interventions":12243},"NCT00827151","Bone Mass Accrual in Adolescent Athletes",[91],"2011-05",[11896,428],[12227],{"trials":12245,"activeCount":101},[],{"trials":12247,"activeCount":101},[],{"intervention":12249,"totalTrials":331,"cells":12250},"Levetiracetam 1 g IV + Lorazepam 2 mg IV",{"EARLY_PHASE1":12251,"PHASE1":12253,"PHASE2":12255,"PHASE3":12257,"PHASE4":12266,"NA":12268},{"trials":12252,"activeCount":101},[],{"trials":12254,"activeCount":101},[],{"trials":12256,"activeCount":101},[],{"trials":12258,"activeCount":101},[12259],{"nctId":12260,"briefTitle":12261,"status":107,"phases":12262,"primaryCompletion":1936,"completion":1936,"start":912,"enrollment":101,"conditions":12263,"interventions":12265},"NCT00465244","Seizure Therapy With Intravenous Levetiracetam and Lorazepam",[90,91],[12264],"Seizures",[12249],{"trials":12267,"activeCount":101},[],{"trials":12269,"activeCount":101},[],{"intervention":12105,"totalTrials":331,"cells":12271},{"EARLY_PHASE1":12272,"PHASE1":12274,"PHASE2":12276,"PHASE3":12278,"PHASE4":12284,"NA":12286},{"trials":12273,"activeCount":101},[],{"trials":12275,"activeCount":101},[],{"trials":12277,"activeCount":101},[],{"trials":12279,"activeCount":101},[12280],{"nctId":12097,"briefTitle":12098,"status":2758,"phases":12281,"primaryCompletion":119,"completion":119,"start":1780,"enrollment":1466,"conditions":12282,"interventions":12283},[90,91],[10982,12101,12102,12103],[12079,12105,12106,12107],{"trials":12285,"activeCount":101},[],{"trials":12287,"activeCount":101},[],{"intervention":12106,"totalTrials":331,"cells":12289},{"EARLY_PHASE1":12290,"PHASE1":12292,"PHASE2":12294,"PHASE3":12296,"PHASE4":12302,"NA":12304},{"trials":12291,"activeCount":101},[],{"trials":12293,"activeCount":101},[],{"trials":12295,"activeCount":101},[],{"trials":12297,"activeCount":101},[12298],{"nctId":12097,"briefTitle":12098,"status":2758,"phases":12299,"primaryCompletion":119,"completion":119,"start":1780,"enrollment":1466,"conditions":12300,"interventions":12301},[90,91],[10982,12101,12102,12103],[12079,12105,12106,12107],{"trials":12303,"activeCount":101},[],{"trials":12305,"activeCount":101},[],{"intervention":12307,"totalTrials":331,"cells":12308},"RBC transfusion",{"EARLY_PHASE1":12309,"PHASE1":12311,"PHASE2":12313,"PHASE3":12315,"PHASE4":12325,"NA":12327},{"trials":12310,"activeCount":101},[],{"trials":12312,"activeCount":101},[],{"trials":12314,"activeCount":101},[],{"trials":12316,"activeCount":101},[12317],{"nctId":12318,"briefTitle":12319,"status":117,"phases":12320,"primaryCompletion":41,"completion":1877,"start":4617,"enrollment":12321,"conditions":12322,"interventions":12324},"NCT01586923","RBC Transfusion in Severe Anemia With Lactic Acidosis",[91],290,[12323],"Anemia",[12307],{"trials":12326,"activeCount":101},[],{"trials":12328,"activeCount":101},[],{"intervention":12330,"totalTrials":331,"cells":12331},"Glycine",{"EARLY_PHASE1":12332,"PHASE1":12334,"PHASE2":12336,"PHASE3":12338,"PHASE4":12349,"NA":12351},{"trials":12333,"activeCount":101},[],{"trials":12335,"activeCount":101},[],{"trials":12337,"activeCount":101},[],{"trials":12339,"activeCount":101},[12340],{"nctId":12341,"briefTitle":12342,"status":107,"phases":12343,"primaryCompletion":6688,"completion":6688,"start":12344,"enrollment":101,"conditions":12345,"interventions":12346},"NCT00000372","Glycine and D-Cycloserine in Schizophrenia",[91],"1998-03",[35],[12347,12330,12348],"D-cycloserine","Clozapine",{"trials":12350,"activeCount":101},[],{"trials":12352,"activeCount":101},[],{"intervention":12348,"totalTrials":331,"cells":12354},{"EARLY_PHASE1":12355,"PHASE1":12357,"PHASE2":12359,"PHASE3":12361,"PHASE4":12367,"NA":12369},{"trials":12356,"activeCount":101},[],{"trials":12358,"activeCount":101},[],{"trials":12360,"activeCount":101},[],{"trials":12362,"activeCount":101},[12363],{"nctId":12341,"briefTitle":12342,"status":107,"phases":12364,"primaryCompletion":6688,"completion":6688,"start":12344,"enrollment":101,"conditions":12365,"interventions":12366},[91],[35],[12347,12330,12348],{"trials":12368,"activeCount":101},[],{"trials":12370,"activeCount":101},[],{"intervention":12372,"totalTrials":331,"cells":12373},"Cisatracurium Besylate",{"EARLY_PHASE1":12374,"PHASE1":12376,"PHASE2":12378,"PHASE3":12380,"PHASE4":12392,"NA":12394},{"trials":12375,"activeCount":101},[],{"trials":12377,"activeCount":101},[],{"trials":12379,"activeCount":101},[],{"trials":12381,"activeCount":101},[12382],{"nctId":12383,"briefTitle":12384,"status":117,"phases":12385,"primaryCompletion":12386,"completion":12387,"start":12388,"enrollment":12389,"conditions":12390,"interventions":12391},"NCT02509078","Reevaluation Of Systemic Early Neuromuscular Blockade",[91],"2018-07-03","2019-04-04","2016-01-04",1008,[12021],[12372],{"trials":12393,"activeCount":101},[],{"trials":12395,"activeCount":101},[],{"intervention":12397,"totalTrials":331,"cells":12398},"Aripiprazole 5mg",{"EARLY_PHASE1":12399,"PHASE1":12401,"PHASE2":12403,"PHASE3":12405,"PHASE4":12415,"NA":12417},{"trials":12400,"activeCount":101},[],{"trials":12402,"activeCount":101},[],{"trials":12404,"activeCount":101},[],{"trials":12406,"activeCount":101},[12407],{"nctId":12408,"briefTitle":12409,"status":117,"phases":12410,"primaryCompletion":6891,"completion":6891,"start":647,"enrollment":12411,"conditions":12412,"interventions":12413},"NCT00683852","A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy",[91],225,[18],[12397,12414],"Aripiprazole 2mg",{"trials":12416,"activeCount":101},[],{"trials":12418,"activeCount":101},[],{"intervention":12414,"totalTrials":331,"cells":12420},{"EARLY_PHASE1":12421,"PHASE1":12423,"PHASE2":12425,"PHASE3":12427,"PHASE4":12433,"NA":12435},{"trials":12422,"activeCount":101},[],{"trials":12424,"activeCount":101},[],{"trials":12426,"activeCount":101},[],{"trials":12428,"activeCount":101},[12429],{"nctId":12408,"briefTitle":12409,"status":117,"phases":12430,"primaryCompletion":6891,"completion":6891,"start":647,"enrollment":12411,"conditions":12431,"interventions":12432},[91],[18],[12397,12414],{"trials":12434,"activeCount":101},[],{"trials":12436,"activeCount":101},[],{"intervention":12438,"totalTrials":331,"cells":12439},"Lithium Carbonate",{"EARLY_PHASE1":12440,"PHASE1":12442,"PHASE2":12444,"PHASE3":12446,"PHASE4":12456,"NA":12458},{"trials":12441,"activeCount":101},[],{"trials":12443,"activeCount":101},[],{"trials":12445,"activeCount":101},[],{"trials":12447,"activeCount":101},[12448],{"nctId":12449,"briefTitle":12450,"status":173,"phases":12451,"primaryCompletion":4281,"completion":4281,"start":3855,"enrollment":2779,"conditions":12452,"interventions":12454},"NCT00818389","Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)",[90,91],[12453],"Amyotrophic Lateral Sclerosis",[12438,12455],"Riluzole",{"trials":12457,"activeCount":101},[],{"trials":12459,"activeCount":101},[],{"intervention":12455,"totalTrials":331,"cells":12461},{"EARLY_PHASE1":12462,"PHASE1":12464,"PHASE2":12466,"PHASE3":12468,"PHASE4":12474,"NA":12476},{"trials":12463,"activeCount":101},[],{"trials":12465,"activeCount":101},[],{"trials":12467,"activeCount":101},[],{"trials":12469,"activeCount":101},[12470],{"nctId":12449,"briefTitle":12450,"status":173,"phases":12471,"primaryCompletion":4281,"completion":4281,"start":3855,"enrollment":2779,"conditions":12472,"interventions":12473},[90,91],[12453],[12438,12455],{"trials":12475,"activeCount":101},[],{"trials":12477,"activeCount":101},[],{"intervention":12479,"totalTrials":331,"cells":12480},"RhIGF-1 with transdermal 17-beta estradiol",{"EARLY_PHASE1":12481,"PHASE1":12483,"PHASE2":12485,"PHASE3":12487,"PHASE4":12497,"NA":12499},{"trials":12482,"activeCount":101},[],{"trials":12484,"activeCount":101},[],{"trials":12486,"activeCount":101},[],{"trials":12488,"activeCount":101},[12489],{"nctId":12490,"briefTitle":12491,"status":117,"phases":12492,"primaryCompletion":12493,"completion":12494,"start":2995,"enrollment":872,"conditions":12495,"interventions":12496},"NCT01301183","Effects of Anorexia Nervosa on Peak Bone Mass",[91],"2019-03","2020-03",[772],[12479],{"trials":12498,"activeCount":101},[],{"trials":12500,"activeCount":101},[],{"intervention":12502,"totalTrials":331,"cells":12503},"Solriamfetol 75 MG",{"EARLY_PHASE1":12504,"PHASE1":12506,"PHASE2":12508,"PHASE3":12510,"PHASE4":12521,"NA":12523},{"trials":12505,"activeCount":101},[],{"trials":12507,"activeCount":101},[],{"trials":12509,"activeCount":101},[],{"trials":12511,"activeCount":101},[12512],{"nctId":12513,"briefTitle":12514,"status":117,"phases":12515,"primaryCompletion":12516,"completion":12516,"start":12517,"enrollment":1368,"conditions":12518,"interventions":12519},"NCT04839562","A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults",[90,91],"2023-01-27","2021-08-06",[8739],[12502,12520],"Solriamfetol 150 MG",{"trials":12522,"activeCount":101},[],{"trials":12524,"activeCount":101},[],{"intervention":12520,"totalTrials":331,"cells":12526},{"EARLY_PHASE1":12527,"PHASE1":12529,"PHASE2":12531,"PHASE3":12533,"PHASE4":12539,"NA":12541},{"trials":12528,"activeCount":101},[],{"trials":12530,"activeCount":101},[],{"trials":12532,"activeCount":101},[],{"trials":12534,"activeCount":101},[12535],{"nctId":12513,"briefTitle":12514,"status":117,"phases":12536,"primaryCompletion":12516,"completion":12516,"start":12517,"enrollment":1368,"conditions":12537,"interventions":12538},[90,91],[8739],[12502,12520],{"trials":12540,"activeCount":101},[],{"trials":12542,"activeCount":101},[],{"intervention":12544,"totalTrials":331,"cells":12545},"Lantus",{"EARLY_PHASE1":12546,"PHASE1":12548,"PHASE2":12550,"PHASE3":12552,"PHASE4":12561,"NA":12563},{"trials":12547,"activeCount":101},[],{"trials":12549,"activeCount":101},[],{"trials":12551,"activeCount":101},[],{"trials":12553,"activeCount":101},[12554],{"nctId":12555,"briefTitle":12556,"status":117,"phases":12557,"primaryCompletion":719,"completion":719,"start":3659,"enrollment":457,"conditions":12558,"interventions":12560},"NCT00694122","Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon",[91],[3066,12559],"Dawn Phenomenon",[12544],{"trials":12562,"activeCount":101},[],{"trials":12564,"activeCount":101},[],{"intervention":12566,"totalTrials":331,"cells":12567},"seromycin",{"EARLY_PHASE1":12568,"PHASE1":12570,"PHASE2":12572,"PHASE3":12574,"PHASE4":12582,"NA":12584},{"trials":12569,"activeCount":101},[],{"trials":12571,"activeCount":101},[],{"trials":12573,"activeCount":101},[],{"trials":12575,"activeCount":101},[12576],{"nctId":12577,"briefTitle":12578,"status":117,"phases":12579,"primaryCompletion":912,"start":9203,"enrollment":2610,"conditions":12580,"interventions":12581},"NCT00182000","Effectiveness of D-Cycloserine as an Aid to Enhance Learning for Individuals With OCD Receiving Behavior Therapy",[91],[10640],[12566],{"trials":12583,"activeCount":101},[],{"trials":12585,"activeCount":101},[],{"intervention":11919,"totalTrials":331,"cells":12587},{"EARLY_PHASE1":12588,"PHASE1":12590,"PHASE2":12592,"PHASE3":12594,"PHASE4":12600,"NA":12602},{"trials":12589,"activeCount":101},[],{"trials":12591,"activeCount":101},[],{"trials":12593,"activeCount":101},[],{"trials":12595,"activeCount":101},[12596],{"nctId":11911,"briefTitle":11912,"status":2758,"phases":12597,"primaryCompletion":11914,"completion":120,"start":11915,"enrollment":2837,"conditions":12598,"interventions":12599},[90,91],[29],[11835,11918,11919],{"trials":12601,"activeCount":101},[],{"trials":12603,"activeCount":101},[],{"intervention":12605,"totalTrials":331,"cells":12606},"iLet Bionic Pancreas insulin-only configuration with Fiasp",{"EARLY_PHASE1":12607,"PHASE1":12609,"PHASE2":12611,"PHASE3":12613,"PHASE4":12624,"NA":12626},{"trials":12608,"activeCount":101},[],{"trials":12610,"activeCount":101},[],{"trials":12612,"activeCount":101},[],{"trials":12614,"activeCount":101},[12615],{"nctId":12616,"briefTitle":12617,"status":117,"phases":12618,"primaryCompletion":12619,"completion":12619,"start":12620,"enrollment":33,"conditions":12621,"interventions":12623},"NCT03565666","The Insulin-Only Bionic Pancreas Bridging Study",[90,91],"2018-11-19","2018-07-09",[12622],"Type1 Diabetes Mellitus",[12605],{"trials":12625,"activeCount":101},[],{"trials":12627,"activeCount":101},[],{"intervention":12629,"totalTrials":331,"cells":12630},"Physiologic Estrogen\u002Fprogesterone",{"EARLY_PHASE1":12631,"PHASE1":12633,"PHASE2":12635,"PHASE3":12637,"PHASE4":12646,"NA":12648},{"trials":12632,"activeCount":101},[],{"trials":12634,"activeCount":101},[],{"trials":12636,"activeCount":101},[],{"trials":12638,"activeCount":101},[12639],{"nctId":12640,"briefTitle":12641,"status":117,"phases":12642,"primaryCompletion":2995,"completion":4464,"start":4343,"enrollment":12643,"conditions":12644,"interventions":12645},"NCT00088153","Effects of Anorexia Nervosa on Bone Mass in Adolescents",[90,91],110,[772],[12629],{"trials":12647,"activeCount":101},[],{"trials":12649,"activeCount":101},[],{"intervention":12651,"totalTrials":331,"cells":12652},"azathioprine",{"EARLY_PHASE1":12653,"PHASE1":12655,"PHASE2":12657,"PHASE3":12659,"PHASE4":12668,"NA":12670},{"trials":12654,"activeCount":101},[],{"trials":12656,"activeCount":101},[],{"trials":12658,"activeCount":101},[],{"trials":12660,"activeCount":101},[12661],{"nctId":12662,"briefTitle":12663,"status":173,"phases":12664,"primaryCompletion":4272,"completion":4272,"start":8588,"enrollment":8836,"conditions":12665,"interventions":12667},"NCT00098111","Imuran (Azathioprine) Dose-Ranging Study in Crohn's Disease",[91],[12666],"Crohn's Disease",[12651],{"trials":12669,"activeCount":101},[],{"trials":12671,"activeCount":101},[],{"intervention":12673,"totalTrials":331,"cells":12674},"EPA 1 g\u002Fday",{"EARLY_PHASE1":12675,"PHASE1":12677,"PHASE2":12679,"PHASE3":12681,"PHASE4":12694,"NA":12696},{"trials":12676,"activeCount":101},[],{"trials":12678,"activeCount":101},[],{"trials":12680,"activeCount":101},[],{"trials":12682,"activeCount":101},[12683],{"nctId":12684,"briefTitle":12685,"status":117,"phases":12686,"primaryCompletion":12687,"completion":12688,"start":2800,"enrollment":4874,"conditions":12689,"interventions":12691},"NCT02553915","Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach",[90,91],"2018-07-13","2022-03-31",[18,12690,821],"Overweight",[12673,12692,12693],"EPA 2 g\u002Fday","EPA 4 g\u002Fday",{"trials":12695,"activeCount":101},[],{"trials":12697,"activeCount":101},[],{"intervention":12692,"totalTrials":331,"cells":12699},{"EARLY_PHASE1":12700,"PHASE1":12702,"PHASE2":12704,"PHASE3":12706,"PHASE4":12712,"NA":12714},{"trials":12701,"activeCount":101},[],{"trials":12703,"activeCount":101},[],{"trials":12705,"activeCount":101},[],{"trials":12707,"activeCount":101},[12708],{"nctId":12684,"briefTitle":12685,"status":117,"phases":12709,"primaryCompletion":12687,"completion":12688,"start":2800,"enrollment":4874,"conditions":12710,"interventions":12711},[90,91],[18,12690,821],[12673,12692,12693],{"trials":12713,"activeCount":101},[],{"trials":12715,"activeCount":101},[],{"intervention":12693,"totalTrials":331,"cells":12717},{"EARLY_PHASE1":12718,"PHASE1":12720,"PHASE2":12722,"PHASE3":12724,"PHASE4":12730,"NA":12732},{"trials":12719,"activeCount":101},[],{"trials":12721,"activeCount":101},[],{"trials":12723,"activeCount":101},[],{"trials":12725,"activeCount":101},[12726],{"nctId":12684,"briefTitle":12685,"status":117,"phases":12727,"primaryCompletion":12687,"completion":12688,"start":2800,"enrollment":4874,"conditions":12728,"interventions":12729},[90,91],[18,12690,821],[12673,12692,12693],{"trials":12731,"activeCount":101},[],{"trials":12733,"activeCount":101},[],{"intervention":12735,"totalTrials":331,"cells":12736},"Polyethylene glycol",{"EARLY_PHASE1":12737,"PHASE1":12739,"PHASE2":12741,"PHASE3":12743,"PHASE4":12752,"NA":12754},{"trials":12738,"activeCount":101},[],{"trials":12740,"activeCount":101},[],{"trials":12742,"activeCount":101},[],{"trials":12744,"activeCount":101},[12745],{"nctId":12746,"briefTitle":12747,"status":107,"phases":12748,"primaryCompletion":3491,"completion":2417,"start":4491,"enrollment":101,"conditions":12749,"interventions":12750},"NCT02705378","The Effect of Naloxegol on Refractory Constipation in the Intensive Care Unit",[91],[2205,7904],[12735,12751],"naloxegol",{"trials":12753,"activeCount":101},[],{"trials":12755,"activeCount":101},[],{"intervention":12751,"totalTrials":331,"cells":12757},{"EARLY_PHASE1":12758,"PHASE1":12760,"PHASE2":12762,"PHASE3":12764,"PHASE4":12770,"NA":12772},{"trials":12759,"activeCount":101},[],{"trials":12761,"activeCount":101},[],{"trials":12763,"activeCount":101},[],{"trials":12765,"activeCount":101},[12766],{"nctId":12746,"briefTitle":12747,"status":107,"phases":12767,"primaryCompletion":3491,"completion":2417,"start":4491,"enrollment":101,"conditions":12768,"interventions":12769},[91],[2205,7904],[12735,12751],{"trials":12771,"activeCount":101},[],{"trials":12773,"activeCount":101},[],{"intervention":12775,"totalTrials":331,"cells":12776},"ceftriaxone",{"EARLY_PHASE1":12777,"PHASE1":12779,"PHASE2":12781,"PHASE3":12783,"PHASE4":12793,"NA":12795},{"trials":12778,"activeCount":101},[],{"trials":12780,"activeCount":101},[],{"trials":12782,"activeCount":101},[],{"trials":12784,"activeCount":101},[12785],{"nctId":12786,"briefTitle":12787,"status":117,"phases":12788,"primaryCompletion":4271,"completion":4271,"start":6901,"enrollment":12789,"conditions":12790,"interventions":12792},"NCT00349622","Clinical Trial Ceftriaxone in Subjects With ALS",[91],513,[12453,12791],"ALS",[12775],{"trials":12794,"activeCount":101},[],{"trials":12796,"activeCount":101},[],{"intervention":12798,"totalTrials":331,"cells":12799},"Actonel",{"EARLY_PHASE1":12800,"PHASE1":12802,"PHASE2":12804,"PHASE3":12806,"PHASE4":12814,"NA":12816},{"trials":12801,"activeCount":101},[],{"trials":12803,"activeCount":101},[],{"trials":12805,"activeCount":101},[],{"trials":12807,"activeCount":101},[12808],{"nctId":12809,"briefTitle":12810,"status":117,"phases":12811,"primaryCompletion":708,"completion":708,"start":8544,"enrollment":4214,"conditions":12812,"interventions":12813},"NCT00089843","Bone Loss in Women With Anorexia Nervosa",[90,91],[772],[573,12798],{"trials":12815,"activeCount":101},[],{"trials":12817,"activeCount":101},[],{"intervention":12819,"totalTrials":331,"cells":12820},"open-label selective serotonin reuptake inhibitor",{"EARLY_PHASE1":12821,"PHASE1":12823,"PHASE2":12825,"PHASE3":12827,"PHASE4":12835,"NA":12837},{"trials":12822,"activeCount":101},[],{"trials":12824,"activeCount":101},[],{"trials":12826,"activeCount":101},[],{"trials":12828,"activeCount":101},[12829],{"nctId":12830,"briefTitle":12831,"status":117,"phases":12832,"primaryCompletion":9865,"completion":9865,"start":591,"enrollment":3337,"conditions":12833,"interventions":12834},"NCT00361218","Biological Markers of Response to Treatment in Major Depressive Disorder",[91],[18],[12819],{"trials":12836,"activeCount":101},[],{"trials":12838,"activeCount":101},[],{"intervention":12840,"totalTrials":331,"cells":12841},"100,000 IU cholecalciferol",{"EARLY_PHASE1":12842,"PHASE1":12844,"PHASE2":12846,"PHASE3":12848,"PHASE4":12857,"NA":12859},{"trials":12843,"activeCount":101},[],{"trials":12845,"activeCount":101},[],{"trials":12847,"activeCount":101},[],{"trials":12849,"activeCount":101},[12850],{"nctId":12851,"briefTitle":12852,"status":117,"phases":12853,"primaryCompletion":41,"completion":41,"start":456,"enrollment":1578,"conditions":12854,"interventions":12856},"NCT01689779","High Dose Preoperative Cholecalciferol Supplementation and Perioperative Vitamin D Status",[91],[12855],"Hypovitaminosis D",[12840],{"trials":12858,"activeCount":101},[],{"trials":12860,"activeCount":101},[],{"intervention":12862,"totalTrials":331,"cells":12863},"L-methylfolate",{"EARLY_PHASE1":12864,"PHASE1":12866,"PHASE2":12868,"PHASE3":12870,"PHASE4":12879,"NA":12881},{"trials":12865,"activeCount":101},[],{"trials":12867,"activeCount":101},[],{"trials":12869,"activeCount":101},[],{"trials":12871,"activeCount":101},[12872],{"nctId":12873,"briefTitle":12874,"status":117,"phases":12875,"primaryCompletion":1780,"completion":12876,"start":566,"enrollment":27,"conditions":12877,"interventions":12878},"NCT01853280","L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults",[90,91],"2017-09",[8739],[12862,11304],{"trials":12880,"activeCount":101},[],{"trials":12882,"activeCount":101},[],{"intervention":12884,"totalTrials":331,"cells":12885},"IV Preoperative antibiotic or placebo",{"EARLY_PHASE1":12886,"PHASE1":12888,"PHASE2":12890,"PHASE3":12892,"PHASE4":12905,"NA":12907},{"trials":12887,"activeCount":101},[],{"trials":12889,"activeCount":101},[],{"trials":12891,"activeCount":101},[],{"trials":12893,"activeCount":101},[12894],{"nctId":12895,"briefTitle":12896,"status":117,"phases":12897,"primaryCompletion":579,"completion":579,"start":12898,"enrollment":12899,"conditions":12900,"interventions":12904},"NCT00118820","Antibiotic Efficacy in Third Molar Surgery",[91],"2004-03",132,[12901,12902,12903],"Alveolar Osteitis","Dry Socket","Infection",[12884],{"trials":12906,"activeCount":101},[],{"trials":12908,"activeCount":101},[],{"intervention":12910,"totalTrials":331,"cells":12911},"Transdermal 17Beta-estradiol, progesterone",{"EARLY_PHASE1":12912,"PHASE1":12914,"PHASE2":12916,"PHASE3":12918,"PHASE4":12930,"NA":12932},{"trials":12913,"activeCount":101},[],{"trials":12915,"activeCount":101},[],{"trials":12917,"activeCount":101},[],{"trials":12919,"activeCount":101},[12920],{"nctId":12921,"briefTitle":12922,"status":117,"phases":12923,"primaryCompletion":435,"completion":12924,"start":150,"enrollment":12925,"conditions":12926,"interventions":12928},"NCT00946192","Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes",[91],"2021-04",121,[12927],"Exercise-related Amenorrhea",[12910,12929],"Ethinyl Estradiol + Desogestrel",{"trials":12931,"activeCount":101},[],{"trials":12933,"activeCount":101},[],{"intervention":12929,"totalTrials":331,"cells":12935},{"EARLY_PHASE1":12936,"PHASE1":12938,"PHASE2":12940,"PHASE3":12942,"PHASE4":12948,"NA":12950},{"trials":12937,"activeCount":101},[],{"trials":12939,"activeCount":101},[],{"trials":12941,"activeCount":101},[],{"trials":12943,"activeCount":101},[12944],{"nctId":12921,"briefTitle":12922,"status":117,"phases":12945,"primaryCompletion":435,"completion":12924,"start":150,"enrollment":12925,"conditions":12946,"interventions":12947},[91],[12927],[12910,12929],{"trials":12949,"activeCount":101},[],{"trials":12951,"activeCount":101},[],{"intervention":12953,"totalTrials":331,"cells":12954},"Denosumab 60 MG [Prolia]",{"EARLY_PHASE1":12955,"PHASE1":12957,"PHASE2":12959,"PHASE3":12961,"PHASE4":12974,"NA":12976},{"trials":12956,"activeCount":101},[],{"trials":12958,"activeCount":101},[],{"trials":12960,"activeCount":101},[],{"trials":12962,"activeCount":101},[12963],{"nctId":12964,"briefTitle":12965,"status":117,"phases":12966,"primaryCompletion":2737,"completion":2737,"start":12967,"enrollment":227,"conditions":12968,"interventions":12972},"NCT03292146","Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study",[91],"2017-10-25",[12969,428,772,12970,12971],"Bone Density","Eating Disorder","Atypical Anorexia Nervosa",[12953,12973],"Alendronate 70Mg Tab",{"trials":12975,"activeCount":101},[],{"trials":12977,"activeCount":101},[],{"intervention":12973,"totalTrials":331,"cells":12979},{"EARLY_PHASE1":12980,"PHASE1":12982,"PHASE2":12984,"PHASE3":12986,"PHASE4":12992,"NA":12994},{"trials":12981,"activeCount":101},[],{"trials":12983,"activeCount":101},[],{"trials":12985,"activeCount":101},[],{"trials":12987,"activeCount":101},[12988],{"nctId":12964,"briefTitle":12965,"status":117,"phases":12989,"primaryCompletion":2737,"completion":2737,"start":12967,"enrollment":227,"conditions":12990,"interventions":12991},[91],[12969,428,772,12970,12971],[12953,12973],{"trials":12993,"activeCount":101},[],{"trials":12995,"activeCount":101},[],{"intervention":12997,"totalTrials":331,"cells":12998},"Dasiglucagon",{"EARLY_PHASE1":12999,"PHASE1":13001,"PHASE2":13003,"PHASE3":13005,"PHASE4":13015,"NA":13017},{"trials":13000,"activeCount":101},[],{"trials":13002,"activeCount":101},[],{"trials":13004,"activeCount":101},[],{"trials":13006,"activeCount":101},[13007],{"nctId":13008,"briefTitle":13009,"status":117,"phases":13010,"primaryCompletion":13011,"completion":13011,"start":13012,"enrollment":1791,"conditions":13013,"interventions":13014},"NCT03840278","The Bihormonal iLet Bionic Pancreas Feasibility Study",[90,91],"2019-07-03","2019-05-15",[2997],[12997],{"trials":13016,"activeCount":101},[],{"trials":13018,"activeCount":101},[],{"intervention":13020,"totalTrials":331,"cells":13021},"Early Vasopressors",{"EARLY_PHASE1":13022,"PHASE1":13024,"PHASE2":13026,"PHASE3":13028,"PHASE4":13041,"NA":13043},{"trials":13023,"activeCount":101},[],{"trials":13025,"activeCount":101},[],{"trials":13027,"activeCount":101},[],{"trials":13029,"activeCount":101},[13030],{"nctId":13031,"briefTitle":13032,"status":117,"phases":13033,"primaryCompletion":13034,"completion":13035,"start":13036,"enrollment":13037,"conditions":13038,"interventions":13040},"NCT03434028","Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis",[91],"2022-05-10","2022-08-24","2018-03-07",1563,[13039],"Septic Shock",[13020],{"trials":13042,"activeCount":101},[],{"trials":13044,"activeCount":101},[],{"intervention":13046,"totalTrials":331,"cells":13047},"escitalopram oxalate",{"EARLY_PHASE1":13048,"PHASE1":13050,"PHASE2":13052,"PHASE3":13054,"PHASE4":13068,"NA":13070},{"trials":13049,"activeCount":101},[],{"trials":13051,"activeCount":101},[],{"trials":13053,"activeCount":101},[],{"trials":13055,"activeCount":101},[13056],{"nctId":13057,"briefTitle":13058,"status":173,"phases":13059,"primaryCompletion":4424,"completion":4424,"start":8690,"enrollment":886,"conditions":13060,"interventions":13067},"NCT00387348","Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer",[91],[6511,15,13061,13062,13063,13064,13065,13066,32,2748],"Esophageal Cancer","Extrahepatic Bile Duct Cancer","Fatigue","Gallbladder Cancer","Gastric Cancer","Liver Cancer",[13046],{"trials":13069,"activeCount":101},[],{"trials":13071,"activeCount":101},[],{"intervention":13073,"totalTrials":331,"cells":13074},"Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel",{"EARLY_PHASE1":13075,"PHASE1":13077,"PHASE2":13079,"PHASE3":13081,"PHASE4":13091,"NA":13093},{"trials":13076,"activeCount":101},[],{"trials":13078,"activeCount":101},[],{"trials":13080,"activeCount":101},[],{"trials":13082,"activeCount":101},[13083],{"nctId":13084,"briefTitle":13085,"status":117,"phases":13086,"primaryCompletion":248,"completion":248,"start":3658,"enrollment":13087,"conditions":13088,"interventions":13090},"NCT00823901","Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea",[90,91],83,[13089],"Rosacea",[13073],{"trials":13092,"activeCount":101},[],{"trials":13094,"activeCount":101},[],{"intervention":13096,"totalTrials":331,"cells":13097},"Razadyne",{"EARLY_PHASE1":13098,"PHASE1":13100,"PHASE2":13102,"PHASE3":13104,"PHASE4":13112,"NA":13114},{"trials":13099,"activeCount":101},[],{"trials":13101,"activeCount":101},[],{"trials":13103,"activeCount":101},[],{"trials":13105,"activeCount":101},[13106],{"nctId":13107,"briefTitle":13108,"status":117,"phases":13109,"primaryCompletion":912,"completion":912,"start":8854,"enrollment":4353,"conditions":13110,"interventions":13111},"NCT00566735","The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning",[91],[9558,7596,1929],[13096],{"trials":13113,"activeCount":101},[],{"trials":13115,"activeCount":101},[],{"intervention":13117,"totalTrials":331,"cells":13118},"Midodrine",{"EARLY_PHASE1":13119,"PHASE1":13121,"PHASE2":13123,"PHASE3":13125,"PHASE4":13136,"NA":13138},{"trials":13120,"activeCount":101},[],{"trials":13122,"activeCount":101},[],{"trials":13124,"activeCount":101},[],{"trials":13126,"activeCount":101},[13127],{"nctId":13128,"briefTitle":13129,"status":117,"phases":13130,"primaryCompletion":13131,"completion":13131,"start":226,"enrollment":13132,"conditions":13133,"interventions":13135},"NCT01531959","Midodrine for the Treatment of Refractory Hypotension",[91],"2019-06",139,[13134,7904],"Hypotension",[13117],{"trials":13137,"activeCount":101},[],{"trials":13139,"activeCount":101},[],{"intervention":13141,"totalTrials":331,"cells":13142},"THC or Placebo",{"EARLY_PHASE1":13143,"PHASE1":13145,"PHASE2":13147,"PHASE3":13149,"PHASE4":13160,"NA":13162},{"trials":13144,"activeCount":101},[],{"trials":13146,"activeCount":101},[],{"trials":13148,"activeCount":101},[],{"trials":13150,"activeCount":101},[13151],{"nctId":13152,"briefTitle":13153,"status":107,"phases":13154,"primaryCompletion":13155,"completion":13155,"start":13156,"enrollment":101,"conditions":13157,"interventions":13159},"NCT04340700","Characterization of the Pharmacodynamic Response to Vaped THC",[91],"2025-10-01","2022-11-01",[1949,13158],"THC",[13141],{"trials":13161,"activeCount":101},[],{"trials":13163,"activeCount":101},[],{"intervention":13165,"totalTrials":331,"cells":13166},"Mirtazapine",{"EARLY_PHASE1":13167,"PHASE1":13169,"PHASE2":13171,"PHASE3":13173,"PHASE4":13182,"NA":13184},{"trials":13168,"activeCount":101},[],{"trials":13170,"activeCount":101},[],{"trials":13172,"activeCount":101},[],{"trials":13174,"activeCount":101},[13175],{"nctId":13176,"briefTitle":13177,"status":117,"phases":13178,"primaryCompletion":13179,"completion":13179,"start":751,"enrollment":227,"conditions":13180,"interventions":13181},"NCT01302964","Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders",[91],"2017-10-10",[540],[13165],{"trials":13183,"activeCount":101},[],{"trials":13185,"activeCount":101},[],{"intervention":13187,"totalTrials":331,"cells":13188},"Tadalafil",{"EARLY_PHASE1":13189,"PHASE1":13191,"PHASE2":13193,"PHASE3":13195,"PHASE4":13204,"NA":13206},{"trials":13190,"activeCount":101},[],{"trials":13192,"activeCount":101},[],{"trials":13194,"activeCount":101},[],{"trials":13196,"activeCount":101},[13197],{"nctId":13198,"briefTitle":13199,"status":107,"phases":13200,"primaryCompletion":119,"completion":7120,"start":11429,"enrollment":101,"conditions":13201,"interventions":13203},"NCT01960153","Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage",[91],[7638,13202],"Pulmonary Hypertension",[13187],{"trials":13205,"activeCount":101},[],{"trials":13207,"activeCount":101},[],{"intervention":13209,"totalTrials":331,"cells":13210},"Humalog",{"EARLY_PHASE1":13211,"PHASE1":13213,"PHASE2":13215,"PHASE3":13217,"PHASE4":13229,"NA":13231},{"trials":13212,"activeCount":101},[],{"trials":13214,"activeCount":101},[],{"trials":13216,"activeCount":101},[],{"trials":13218,"activeCount":101},[13219],{"nctId":13220,"briefTitle":13221,"status":173,"phases":13222,"primaryCompletion":13223,"completion":13223,"start":13224,"enrollment":194,"conditions":13225,"interventions":13226},"NCT03262116","Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas",[90,91],"2019-07-23","2019-03-19",[2997],[13209,13227,13228],"Novolog","BC222 insulin lispro",{"trials":13230,"activeCount":101},[],{"trials":13232,"activeCount":101},[],{"intervention":13227,"totalTrials":331,"cells":13234},{"EARLY_PHASE1":13235,"PHASE1":13237,"PHASE2":13239,"PHASE3":13241,"PHASE4":13247,"NA":13249},{"trials":13236,"activeCount":101},[],{"trials":13238,"activeCount":101},[],{"trials":13240,"activeCount":101},[],{"trials":13242,"activeCount":101},[13243],{"nctId":13220,"briefTitle":13221,"status":173,"phases":13244,"primaryCompletion":13223,"completion":13223,"start":13224,"enrollment":194,"conditions":13245,"interventions":13246},[90,91],[2997],[13209,13227,13228],{"trials":13248,"activeCount":101},[],{"trials":13250,"activeCount":101},[],{"intervention":13228,"totalTrials":331,"cells":13252},{"EARLY_PHASE1":13253,"PHASE1":13255,"PHASE2":13257,"PHASE3":13259,"PHASE4":13265,"NA":13267},{"trials":13254,"activeCount":101},[],{"trials":13256,"activeCount":101},[],{"trials":13258,"activeCount":101},[],{"trials":13260,"activeCount":101},[13261],{"nctId":13220,"briefTitle":13221,"status":173,"phases":13262,"primaryCompletion":13223,"completion":13223,"start":13224,"enrollment":194,"conditions":13263,"interventions":13264},[90,91],[2997],[13209,13227,13228],{"trials":13266,"activeCount":101},[],{"trials":13268,"activeCount":101},[],{"intervention":13270,"totalTrials":331,"cells":13271},"coenzyme Q10",{"EARLY_PHASE1":13272,"PHASE1":13274,"PHASE2":13276,"PHASE3":13278,"PHASE4":13287,"NA":13289},{"trials":13273,"activeCount":101},[],{"trials":13275,"activeCount":101},[],{"trials":13277,"activeCount":101},[],{"trials":13279,"activeCount":101},[13280],{"nctId":13281,"briefTitle":13282,"status":173,"phases":13283,"primaryCompletion":1244,"completion":41,"start":8926,"enrollment":13284,"conditions":13285,"interventions":13286},"NCT00608881","Coenzyme Q10 in Huntington's Disease (HD)",[91],609,[11938],[13270],{"trials":13288,"activeCount":101},[],{"trials":13290,"activeCount":101},[],{"intervention":13292,"totalTrials":331,"cells":13293},"Ketamine Hydrochloride",{"EARLY_PHASE1":13294,"PHASE1":13296,"PHASE2":13298,"PHASE3":13300,"PHASE4":13309,"NA":13311},{"trials":13295,"activeCount":101},[],{"trials":13297,"activeCount":101},[],{"trials":13299,"activeCount":101},[],{"trials":13301,"activeCount":101},[13302],{"nctId":13303,"briefTitle":13304,"status":107,"phases":13305,"primaryCompletion":1780,"completion":13306,"start":1780,"enrollment":101,"conditions":13307,"interventions":13308},"NCT02532153","The Impact of Ketamine on the Reward Circuitry of Suicidal Patients",[91],"2017-02-28",[1817,1816],[13292],{"trials":13310,"activeCount":101},[],{"trials":13312,"activeCount":101},[],{"intervention":2806,"totalTrials":270,"cells":13314},{"EARLY_PHASE1":13315,"PHASE1":13317,"PHASE2":13335,"PHASE3":13349,"PHASE4":13351,"NA":13353},{"trials":13316,"activeCount":101},[],{"trials":13318,"activeCount":101},[13319,13323,13327,13331],{"nctId":2797,"briefTitle":2798,"status":117,"phases":13320,"primaryCompletion":1861,"completion":2800,"start":2801,"enrollment":33,"conditions":13321,"interventions":13322},[89],[2803],[127,2805,2806,2807],{"nctId":908,"briefTitle":909,"status":117,"phases":13324,"primaryCompletion":911,"completion":911,"start":912,"enrollment":829,"conditions":13325,"interventions":13326},[89],[914,915,916,211,917,918,919],[921,922,923,924,925,926,927,928,243,901],{"nctId":4331,"briefTitle":4332,"status":117,"phases":13328,"primaryCompletion":4334,"completion":4335,"start":1876,"enrollment":2859,"conditions":13329,"interventions":13330},[89],[2803],[4338,2805,2806,2807],{"nctId":3452,"briefTitle":3453,"status":173,"phases":13332,"primaryCompletion":3052,"completion":3052,"start":2827,"enrollment":798,"conditions":13333,"interventions":13334},[89],[3456],[2576,2806],{"trials":13336,"activeCount":101},[13337,13341,13345],{"nctId":2876,"briefTitle":2877,"status":117,"phases":13338,"primaryCompletion":2879,"completion":2880,"start":2881,"enrollment":2882,"conditions":13339,"interventions":13340},[90],[2884],[2806,2807,127,2805],{"nctId":4524,"briefTitle":4525,"status":117,"phases":13342,"primaryCompletion":4527,"completion":554,"start":751,"enrollment":3565,"conditions":13343,"interventions":13344},[90],[4529,4530,4531,4532,4501,123,4533],[4535,2806,201,4536,4537,200,4535,4514,4515,3789],{"nctId":3461,"briefTitle":3462,"status":107,"phases":13346,"primaryCompletion":238,"start":3464,"enrollment":101,"conditions":13347,"interventions":13348},[90],[3466],[2806,2576,3468],{"trials":13350,"activeCount":101},[],{"trials":13352,"activeCount":101},[],{"trials":13354,"activeCount":101},[],{"intervention":7089,"totalTrials":544,"cells":13356},{"EARLY_PHASE1":13357,"PHASE1":13359,"PHASE2":13383,"PHASE3":13405,"PHASE4":13407,"NA":13409},{"trials":13358,"activeCount":101},[],{"trials":13360,"activeCount":101},[13361,13367,13376],{"nctId":13362,"briefTitle":13363,"status":117,"phases":13364,"primaryCompletion":436,"completion":1244,"start":8137,"enrollment":798,"conditions":13365,"interventions":13366},"NCT01582295","XL184 For Relapsed\u002FRefractory Multiple Myeloma (MM) With Bone Disease",[89],[2030],[7089],{"nctId":13368,"briefTitle":13369,"status":117,"phases":13370,"primaryCompletion":46,"completion":1779,"start":2435,"enrollment":209,"conditions":13371,"interventions":13374},"NCT01961765","Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia",[89],[13372,13373],"Relapsed Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia",[13375],"cabozantinib",{"nctId":13377,"briefTitle":13378,"status":117,"phases":13379,"primaryCompletion":1876,"completion":1876,"start":4424,"enrollment":36,"conditions":13380,"interventions":13382},"NCT01347788","Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer",[89],[13381],"Prostate Adenocarcinoma",[13375],{"trials":13384,"activeCount":101},[13385,13394,13398],{"nctId":13386,"briefTitle":13387,"status":117,"phases":13388,"primaryCompletion":3052,"completion":298,"start":627,"enrollment":2837,"conditions":13389,"interventions":13393},"NCT01954745","Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma",[90],[13390,13391,13392],"Bile Duct Cancer","Intrahepatic Cholangiocarcinoma","Cholangiocarcinoma of the Extrahepatic Bile Duct",[7089],{"nctId":7081,"briefTitle":7082,"status":117,"phases":13395,"primaryCompletion":7084,"completion":7085,"start":568,"enrollment":7086,"conditions":13396,"interventions":13397},[90],[21],[7089,4218],{"nctId":13399,"briefTitle":13400,"status":117,"phases":13401,"primaryCompletion":1779,"completion":13131,"start":8137,"enrollment":413,"conditions":13402,"interventions":13404},"NCT01588821","Cabozantinib in Advanced Solid Malignancies",[90],[32,13403],"Solid Tumor (Not Breast or Prostate Cancers)",[7089],{"trials":13406,"activeCount":101},[],{"trials":13408,"activeCount":101},[],{"trials":13410,"activeCount":101},[],{"intervention":4293,"totalTrials":693,"cells":13412},{"EARLY_PHASE1":13413,"PHASE1":13415,"PHASE2":13417,"PHASE3":13441,"PHASE4":13443,"NA":13445},{"trials":13414,"activeCount":101},[],{"trials":13416,"activeCount":101},[],{"trials":13418,"activeCount":101},[13419,13423,13427,13431,13435],{"nctId":4421,"briefTitle":4422,"status":117,"phases":13420,"primaryCompletion":4272,"completion":4424,"start":4425,"enrollment":1890,"conditions":13421,"interventions":13422},[90],[2730,4427],[4293,3626,47],{"nctId":4768,"briefTitle":4769,"status":2758,"phases":13424,"primaryCompletion":4771,"completion":4288,"start":2609,"enrollment":4772,"conditions":13425,"interventions":13426},[90],[2748],[66,4293],{"nctId":4784,"briefTitle":4785,"status":173,"phases":13428,"primaryCompletion":298,"completion":298,"start":1897,"enrollment":270,"conditions":13429,"interventions":13430},[90],[4788,4789],[66,4791,4293],{"nctId":4285,"briefTitle":4286,"status":2758,"phases":13432,"primaryCompletion":4288,"completion":4289,"start":4290,"enrollment":366,"conditions":13433,"interventions":13434},[90],[2748],[4293,4261],{"nctId":13436,"briefTitle":13437,"status":117,"phases":13438,"primaryCompletion":119,"completion":119,"start":4666,"enrollment":366,"conditions":13439,"interventions":13440},"NCT00438256","Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer",[89,90],[2748],[4293],{"trials":13442,"activeCount":101},[],{"trials":13444,"activeCount":101},[],{"trials":13446,"activeCount":101},[],{"intervention":3789,"totalTrials":693,"cells":13448},{"EARLY_PHASE1":13449,"PHASE1":13451,"PHASE2":13461,"PHASE3":13475,"PHASE4":13477,"NA":13479},{"trials":13450,"activeCount":101},[],{"trials":13452,"activeCount":101},[13453,13457],{"nctId":3777,"briefTitle":3778,"status":117,"phases":13454,"primaryCompletion":2581,"completion":2408,"start":567,"enrollment":2837,"conditions":13455,"interventions":13456},[89],[3781,3782,3783,3784],[3786,3787,2807,3770,3788,201,3789],{"nctId":908,"briefTitle":909,"status":117,"phases":13458,"primaryCompletion":911,"completion":911,"start":912,"enrollment":829,"conditions":13459,"interventions":13460},[89],[914,915,916,211,917,918,919],[921,922,923,924,925,926,927,928,243,901],{"trials":13462,"activeCount":101},[13463,13467,13471],{"nctId":4487,"briefTitle":4488,"status":107,"phases":13464,"primaryCompletion":2417,"completion":4490,"start":4491,"enrollment":101,"conditions":13465,"interventions":13466},[89,90],[211],[200,4494,3789],{"nctId":4524,"briefTitle":4525,"status":117,"phases":13468,"primaryCompletion":4527,"completion":554,"start":751,"enrollment":3565,"conditions":13469,"interventions":13470},[90],[4529,4530,4531,4532,4501,123,4533],[4535,2806,201,4536,4537,200,4535,4514,4515,3789],{"nctId":3821,"briefTitle":3822,"status":117,"phases":13472,"primaryCompletion":567,"completion":1877,"start":3607,"enrollment":227,"conditions":13473,"interventions":13474},[90],[3781],[3576,3787,3770,3826,2807,3789,3827,3828,3829],{"trials":13476,"activeCount":101},[],{"trials":13478,"activeCount":101},[],{"trials":13480,"activeCount":101},[],{"intervention":4338,"totalTrials":693,"cells":13482},{"EARLY_PHASE1":13483,"PHASE1":13485,"PHASE2":13506,"PHASE3":13525,"PHASE4":13527,"NA":13529},{"trials":13484,"activeCount":101},[],{"trials":13486,"activeCount":101},[13487,13491,13498],{"nctId":4331,"briefTitle":4332,"status":117,"phases":13488,"primaryCompletion":4334,"completion":4335,"start":1876,"enrollment":2859,"conditions":13489,"interventions":13490},[89],[2803],[4338,2805,2806,2807],{"nctId":13492,"briefTitle":13493,"status":117,"phases":13494,"primaryCompletion":298,"completion":268,"start":9600,"enrollment":4443,"conditions":13495,"interventions":13497},"NCT01596218","Brentuximab Vedotin for Steroid Refractory GvHD",[89],[13496],"Graft vs. Host Disease",[4338],{"nctId":13499,"briefTitle":13500,"status":173,"phases":13501,"primaryCompletion":268,"completion":268,"start":11429,"enrollment":2837,"conditions":13502,"interventions":13505},"NCT01940796","Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)",[89],[13503,13504],"Graft-vs-Host Disease","GVHD",[4338],{"trials":13507,"activeCount":101},[13508,13516],{"nctId":13509,"briefTitle":13510,"status":117,"phases":13511,"primaryCompletion":225,"completion":120,"start":2827,"enrollment":36,"conditions":13512,"interventions":13514},"NCT01534078","Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma",[90],[13513],"Hodgkin Lymphoma",[4338,13515],"Adriamycin, vinblastine, and dacarbazine",{"nctId":13517,"briefTitle":13518,"status":117,"phases":13519,"primaryCompletion":13131,"completion":13131,"start":13520,"enrollment":36,"conditions":13521,"interventions":13522},"NCT02505269","Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma",[90],"2015-08-07",[13513],[4338,13523,13524],"Adriamycin","Dacarbazine",{"trials":13526,"activeCount":101},[],{"trials":13528,"activeCount":101},[],{"trials":13530,"activeCount":101},[],{"intervention":11851,"totalTrials":693,"cells":13532},{"EARLY_PHASE1":13533,"PHASE1":13535,"PHASE2":13553,"PHASE3":13559,"PHASE4":13561,"NA":13563},{"trials":13534,"activeCount":101},[],{"trials":13536,"activeCount":101},[13537,13541,13545,13549],{"nctId":11842,"briefTitle":11843,"status":117,"phases":13538,"primaryCompletion":1877,"completion":1877,"start":11845,"enrollment":9,"conditions":13539,"interventions":13540},[89],[11847,11848,11849],[11851,11835],{"nctId":11853,"briefTitle":11854,"status":117,"phases":13542,"primaryCompletion":11856,"completion":11856,"start":11857,"enrollment":4874,"conditions":13543,"interventions":13544},[89],[11847],[11860,11861,11835],{"nctId":11863,"briefTitle":11864,"status":117,"phases":13546,"primaryCompletion":11866,"completion":11866,"start":11867,"enrollment":11868,"conditions":13547,"interventions":13548},[89],[11847,11870,11871,11872,11873,11874],[11851,11835],{"nctId":11877,"briefTitle":11878,"status":117,"phases":13550,"primaryCompletion":11880,"completion":11881,"start":11882,"enrollment":886,"conditions":13551,"interventions":13552},[89],[11884,11870,11847,11871],[11851,11835],{"trials":13554,"activeCount":101},[13555],{"nctId":11900,"briefTitle":11901,"status":117,"phases":13556,"primaryCompletion":11903,"completion":11904,"start":11905,"enrollment":33,"conditions":13557,"interventions":13558},[90],[11874,570],[11860,11835],{"trials":13560,"activeCount":101},[],{"trials":13562,"activeCount":101},[],{"trials":13564,"activeCount":101},[],{"intervention":6895,"totalTrials":798,"cells":13566},{"EARLY_PHASE1":13567,"PHASE1":13577,"PHASE2":13579,"PHASE3":13598,"PHASE4":13600,"NA":13602},{"trials":13568,"activeCount":101},[13569],{"nctId":13570,"briefTitle":13571,"status":117,"phases":13572,"primaryCompletion":12241,"completion":1876,"start":752,"enrollment":1890,"conditions":13573,"interventions":13576},"NCT00864864","Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma",[88],[13574,13575],"Glioblastoma","Brain Tumor",[6895],{"trials":13578,"activeCount":101},[],{"trials":13580,"activeCount":101},[13581,13587,13591],{"nctId":13582,"briefTitle":13583,"status":117,"phases":13584,"primaryCompletion":2848,"completion":2848,"start":8690,"enrollment":33,"conditions":13585,"interventions":13586},"NCT00299741","Study of SU11248 in Men With Advanced Prostate Cancer",[90],[2038],[6895],{"nctId":6888,"briefTitle":6889,"status":107,"phases":13588,"primaryCompletion":6891,"completion":6891,"start":6891,"enrollment":101,"conditions":13589,"interventions":13590},[90],[6893],[6895,47],{"nctId":13592,"briefTitle":13593,"status":117,"phases":13594,"primaryCompletion":4677,"completion":567,"start":4666,"enrollment":3337,"conditions":13595,"interventions":13597},"NCT00556049","Combination Sunitinib and Gemcitabine in Sarcomatoid and\u002For Poor-risk Patients With Metastatic Renal Cell Carcinoma",[90],[6893,13596],"Neoplasm Metastases",[3536,6895],{"trials":13599,"activeCount":101},[],{"trials":13601,"activeCount":101},[],{"trials":13603,"activeCount":101},[],{"intervention":4515,"totalTrials":798,"cells":13605},{"EARLY_PHASE1":13606,"PHASE1":13608,"PHASE2":13621,"PHASE3":13631,"PHASE4":13633,"NA":13635},{"trials":13607,"activeCount":101},[],{"trials":13609,"activeCount":101},[13610,13614],{"nctId":908,"briefTitle":909,"status":117,"phases":13611,"primaryCompletion":911,"completion":911,"start":912,"enrollment":829,"conditions":13612,"interventions":13613},[89],[914,915,916,211,917,918,919],[921,922,923,924,925,926,927,928,243,901],{"nctId":13615,"briefTitle":13616,"status":117,"phases":13617,"primaryCompletion":135,"completion":135,"start":8511,"enrollment":2610,"conditions":13618,"interventions":13619},"NCT00821080","Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma",[89],[13574],[4515,13620],"Vandetanib",{"trials":13622,"activeCount":101},[13623,13627],{"nctId":4506,"briefTitle":4507,"status":117,"phases":13624,"primaryCompletion":175,"completion":149,"start":2456,"enrollment":648,"conditions":13625,"interventions":13626},[90],[2030,4500,4510,4511,4512],[4514,4515,4516,4517,4518,200,4503],{"nctId":4524,"briefTitle":4525,"status":117,"phases":13628,"primaryCompletion":4527,"completion":554,"start":751,"enrollment":3565,"conditions":13629,"interventions":13630},[90],[4529,4530,4531,4532,4501,123,4533],[4535,2806,201,4536,4537,200,4535,4514,4515,3789],{"trials":13632,"activeCount":101},[],{"trials":13634,"activeCount":101},[],{"trials":13636,"activeCount":101},[],{"intervention":13638,"totalTrials":798,"cells":13639},"Recombinant Human Prolactin",{"EARLY_PHASE1":13640,"PHASE1":13642,"PHASE2":13644,"PHASE3":13673,"PHASE4":13675,"NA":13677},{"trials":13641,"activeCount":101},[],{"trials":13643,"activeCount":101},[],{"trials":13645,"activeCount":101},[13646,13654,13661,13668],{"nctId":13647,"briefTitle":13648,"status":117,"phases":13649,"primaryCompletion":12241,"completion":12241,"start":13650,"enrollment":544,"conditions":13651,"interventions":13653},"NCT00181623","Recombinant Human Prolactin for Lactation Induction",[90],"2005-01",[13652],"Lactation",[13638],{"nctId":13655,"briefTitle":13656,"status":117,"phases":13657,"primaryCompletion":3004,"completion":3004,"start":13658,"enrollment":2508,"conditions":13659,"interventions":13660},"NCT00438490","The Safety and Efficacy of Recombinant Human Prolactin",[90],"2002-04",[29],[13638],{"nctId":13662,"briefTitle":13648,"status":117,"phases":13663,"primaryCompletion":628,"completion":628,"start":741,"enrollment":4618,"conditions":13664,"interventions":13665},"NCT00181610",[90],[13652],[13638,13666,13667],"Recombinant human prolactin","Normal Saline",{"nctId":13669,"briefTitle":13648,"status":107,"phases":13670,"primaryCompletion":12241,"completion":12241,"start":8504,"enrollment":101,"conditions":13671,"interventions":13672},"NCT00181649",[90],[13652],[13666],{"trials":13674,"activeCount":101},[],{"trials":13676,"activeCount":101},[],{"trials":13678,"activeCount":101},[],{"intervention":2805,"totalTrials":178,"cells":13680},{"EARLY_PHASE1":13681,"PHASE1":13683,"PHASE2":13693,"PHASE3":13699,"PHASE4":13701,"NA":13703},{"trials":13682,"activeCount":101},[],{"trials":13684,"activeCount":101},[13685,13689],{"nctId":2797,"briefTitle":2798,"status":117,"phases":13686,"primaryCompletion":1861,"completion":2800,"start":2801,"enrollment":33,"conditions":13687,"interventions":13688},[89],[2803],[127,2805,2806,2807],{"nctId":4331,"briefTitle":4332,"status":117,"phases":13690,"primaryCompletion":4334,"completion":4335,"start":1876,"enrollment":2859,"conditions":13691,"interventions":13692},[89],[2803],[4338,2805,2806,2807],{"trials":13694,"activeCount":101},[13695],{"nctId":2876,"briefTitle":2877,"status":117,"phases":13696,"primaryCompletion":2879,"completion":2880,"start":2881,"enrollment":2882,"conditions":13697,"interventions":13698},[90],[2884],[2806,2807,127,2805],{"trials":13700,"activeCount":101},[],{"trials":13702,"activeCount":101},[],{"trials":13704,"activeCount":101},[],{"intervention":4535,"totalTrials":178,"cells":13706},{"EARLY_PHASE1":13707,"PHASE1":13709,"PHASE2":13715,"PHASE3":13727,"PHASE4":13729,"NA":13731},{"trials":13708,"activeCount":101},[],{"trials":13710,"activeCount":101},[13711],{"nctId":908,"briefTitle":909,"status":117,"phases":13712,"primaryCompletion":911,"completion":911,"start":912,"enrollment":829,"conditions":13713,"interventions":13714},[89],[914,915,916,211,917,918,919],[921,922,923,924,925,926,927,928,243,901],{"trials":13716,"activeCount":101},[13717,13721],{"nctId":4524,"briefTitle":4525,"status":117,"phases":13718,"primaryCompletion":4527,"completion":554,"start":751,"enrollment":3565,"conditions":13719,"interventions":13720},[90],[4529,4530,4531,4532,4501,123,4533],[4535,2806,201,4536,4537,200,4535,4514,4515,3789],{"nctId":13722,"briefTitle":13723,"status":117,"phases":13724,"primaryCompletion":8798,"completion":8798,"start":9600,"enrollment":36,"conditions":13725,"interventions":13726},"NCT01643668","Busulfan\u002FClofarabine + Allogeneic Stem Cell Transplantation",[90],[2862,3781,2861],[4535,3828],{"trials":13728,"activeCount":101},[],{"trials":13730,"activeCount":101},[],{"trials":13732,"activeCount":101},[],{"intervention":13734,"totalTrials":178,"cells":13735},"Gefitinib",{"EARLY_PHASE1":13736,"PHASE1":13738,"PHASE2":13740,"PHASE3":13765,"PHASE4":13767,"NA":13769},{"trials":13737,"activeCount":101},[],{"trials":13739,"activeCount":101},[],{"trials":13741,"activeCount":101},[13742,13750,13758],{"nctId":13743,"briefTitle":13744,"status":117,"phases":13745,"primaryCompletion":13746,"completion":121,"start":3741,"enrollment":36,"conditions":13747,"interventions":13748},"NCT00411047","Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[90],"2007-01",[32],[13749],"gefitinib",{"nctId":13751,"briefTitle":13752,"status":173,"phases":13753,"primaryCompletion":61,"completion":13754,"start":9749,"enrollment":4618,"conditions":13755,"interventions":13756},"NCT03292133","A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer",[90],"2025-03-04",[32],[13757,13734],"EGF816",{"nctId":13759,"briefTitle":13760,"status":117,"phases":13761,"primaryCompletion":3004,"completion":3004,"start":13762,"enrollment":457,"conditions":13763,"interventions":13764},"NCT00095836","Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy",[90],"2003-03",[2527],[13734],{"trials":13766,"activeCount":101},[],{"trials":13768,"activeCount":101},[],{"trials":13770,"activeCount":101},[],{"intervention":3625,"totalTrials":178,"cells":13772},{"EARLY_PHASE1":13773,"PHASE1":13775,"PHASE2":13794,"PHASE3":13805,"PHASE4":13807,"NA":13809},{"trials":13774,"activeCount":101},[],{"trials":13776,"activeCount":101},[13777,13790],{"nctId":13778,"briefTitle":13779,"status":117,"phases":13780,"primaryCompletion":13781,"completion":13782,"start":13783,"enrollment":1914,"conditions":13784,"interventions":13787},"NCT01858168","Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma",[89],"2024-11-01","2025-12-12","2013-07-01",[13785,13786],"Ewing Sarcoma","Rhabdomyosarcoma",[13788,13789,3625],"Olaparib","Temozolomide",{"nctId":3616,"briefTitle":3617,"status":117,"phases":13791,"primaryCompletion":3619,"completion":3620,"start":3621,"enrollment":1847,"conditions":13792,"interventions":13793},[89],[3623],[3625,3626,3627,3449,3165,2720],{"trials":13795,"activeCount":101},[13796],{"nctId":13797,"briefTitle":13798,"status":173,"phases":13799,"primaryCompletion":2027,"completion":751,"start":6901,"enrollment":544,"conditions":13800,"interventions":13802},"NCT00361244","SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer",[89,90],[13801],"Colorectal Carcinoma",[13803,3625,13804],"SU011248","Cetuximab",{"trials":13806,"activeCount":101},[],{"trials":13808,"activeCount":101},[],{"trials":13810,"activeCount":101},[],{"intervention":13812,"totalTrials":178,"cells":13813},"Estradiol",{"EARLY_PHASE1":13814,"PHASE1":13816,"PHASE2":13818,"PHASE3":13850,"PHASE4":13852,"NA":13854},{"trials":13815,"activeCount":101},[],{"trials":13817,"activeCount":101},[],{"trials":13819,"activeCount":101},[13820,13830,13843],{"nctId":13821,"briefTitle":13822,"status":117,"phases":13823,"primaryCompletion":684,"completion":13824,"start":13825,"enrollment":194,"conditions":13826,"interventions":13828},"NCT00455741","Postmenopausal Women Estrogen and Progesterone Infusion",[89,90],"2015-08-22","2000-11",[13827,6609],"Postmenopause",[13812,13829],"Progesterone",{"nctId":13831,"briefTitle":13832,"status":117,"phases":13833,"primaryCompletion":13834,"completion":13834,"start":2847,"enrollment":6796,"conditions":13835,"interventions":13839},"NCT01268046","Aging and Estrogen on Cortical Function",[89,90],"2013-12-02",[13836,13837,13838],"Memory Loss","Cognitive Changes","Postmenopausal Symptoms",[13840,13841,13842],"Estradiol oral","transderman estrogen patch","trasdermal placebo patch",{"nctId":13844,"briefTitle":13845,"status":173,"phases":13846,"primaryCompletion":2995,"completion":2995,"start":1936,"enrollment":136,"conditions":13847,"interventions":13849},"NCT01126801","Effects of Estrogen and Hot Flashes on Mood in Postmenopausal Women",[90],[13848],"Menopausal Depression",[13812],{"trials":13851,"activeCount":101},[],{"trials":13853,"activeCount":101},[],{"trials":13855,"activeCount":101},[],{"intervention":13857,"totalTrials":178,"cells":13858},"Dasatinib",{"EARLY_PHASE1":13859,"PHASE1":13861,"PHASE2":13863,"PHASE3":13881,"PHASE4":13883,"NA":13885},{"trials":13860,"activeCount":101},[],{"trials":13862,"activeCount":101},[],{"trials":13864,"activeCount":101},[13865,13871,13877],{"nctId":13866,"briefTitle":13867,"status":117,"phases":13868,"primaryCompletion":11194,"completion":11194,"start":3680,"enrollment":1890,"conditions":13869,"interventions":13870},"NCT02428855","Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma",[90],[4055],[13857],{"nctId":13872,"briefTitle":13873,"status":117,"phases":13874,"primaryCompletion":248,"completion":284,"start":177,"enrollment":2728,"conditions":13875,"interventions":13876},"NCT00438854","Dasatinib in Relapsed Chronic Lymphocytic Leukemia",[90],[123],[13857],{"nctId":235,"briefTitle":236,"status":173,"phases":13878,"primaryCompletion":225,"completion":225,"start":238,"enrollment":239,"conditions":13879,"interventions":13880},[90],[123,124],[242,96,243],{"trials":13882,"activeCount":101},[],{"trials":13884,"activeCount":101},[],{"trials":13886,"activeCount":101},[],{"intervention":3828,"totalTrials":178,"cells":13888},{"EARLY_PHASE1":13889,"PHASE1":13891,"PHASE2":13893,"PHASE3":13913,"PHASE4":13915,"NA":13917},{"trials":13890,"activeCount":101},[],{"trials":13892,"activeCount":101},[],{"trials":13894,"activeCount":101},[13895,13905,13909],{"nctId":13896,"briefTitle":13897,"status":117,"phases":13898,"primaryCompletion":4677,"completion":134,"start":2848,"enrollment":366,"conditions":13899,"interventions":13904},"NCT00644189","Oral Clofarabine for Relapsed\u002FRefractory Non-Hodgkin Lymphoma",[89,90],[212,216,4980,124,13900,13901,153,4981,13902,13903],"Lymphoplasmacytic Lymphoma","Low Grade B-cell Lymphoma, Not Otherwise Specified","Angioimmunoblastic T-cell Lymphoma","Anaplastic Large-cell Lymphoma",[3828],{"nctId":13722,"briefTitle":13723,"status":117,"phases":13906,"primaryCompletion":8798,"completion":8798,"start":9600,"enrollment":36,"conditions":13907,"interventions":13908},[90],[2862,3781,2861],[4535,3828],{"nctId":3821,"briefTitle":3822,"status":117,"phases":13910,"primaryCompletion":567,"completion":1877,"start":3607,"enrollment":227,"conditions":13911,"interventions":13912},[90],[3781],[3576,3787,3770,3826,2807,3789,3827,3828,3829],{"trials":13914,"activeCount":101},[],{"trials":13916,"activeCount":101},[],{"trials":13918,"activeCount":101},[],{"intervention":13920,"totalTrials":136,"cells":13921},"Room air",{"EARLY_PHASE1":13922,"PHASE1":13924,"PHASE2":13926,"PHASE3":13945,"PHASE4":13947,"NA":13949},{"trials":13923,"activeCount":101},[],{"trials":13925,"activeCount":101},[],{"trials":13927,"activeCount":101},[13928,13935],{"nctId":13929,"briefTitle":13930,"status":117,"phases":13931,"primaryCompletion":1861,"completion":1861,"start":9600,"enrollment":2859,"conditions":13932,"interventions":13933},"NCT01542307","Normobaric Oxygen (NBO) Therapy in Acute Migraine",[90],[9455],[13934,13920],"Oxygen",{"nctId":13936,"briefTitle":13937,"status":173,"phases":13938,"primaryCompletion":397,"completion":397,"start":13746,"enrollment":13939,"conditions":13940,"interventions":13942},"NCT00414726","Normobaric Oxygen Therapy in Acute Ischemic Stroke Trial",[90],85,[13941],"Ischemic Stroke",[13943,13944],"NBO","Room Air",{"trials":13946,"activeCount":101},[],{"trials":13948,"activeCount":101},[],{"trials":13950,"activeCount":101},[],{"intervention":13952,"totalTrials":136,"cells":13953},"Calcipotriol Only Product in Cutaneous Dose Form",{"EARLY_PHASE1":13954,"PHASE1":13956,"PHASE2":13958,"PHASE3":13979,"PHASE4":13981,"NA":13983},{"trials":13955,"activeCount":101},[],{"trials":13957,"activeCount":101},[],{"trials":13959,"activeCount":101},[13960,13973],{"nctId":13961,"briefTitle":13962,"status":107,"phases":13963,"primaryCompletion":13964,"completion":320,"start":11554,"enrollment":101,"conditions":13965,"interventions":13970},"NCT04642287","Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients",[90],"2029-01",[13966,13967,13968,13969,2709],"Immunotherapy","Cutaneous Squamous Cell Carcinoma","Actinic Keratoses","Organ Transplant Recipients",[13952,13971,13972],"Vaseline","Topical 5FU",{"nctId":13974,"briefTitle":13975,"status":107,"phases":13976,"primaryCompletion":13964,"completion":320,"start":3015,"enrollment":101,"conditions":13977,"interventions":13978},"NCT04329221","Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients",[90],[13967,13968,2709,13969,13966],[13952,13971,13972],{"trials":13980,"activeCount":101},[],{"trials":13982,"activeCount":101},[],{"trials":13984,"activeCount":101},[],{"intervention":13971,"totalTrials":136,"cells":13986},{"EARLY_PHASE1":13987,"PHASE1":13989,"PHASE2":13991,"PHASE3":14001,"PHASE4":14003,"NA":14005},{"trials":13988,"activeCount":101},[],{"trials":13990,"activeCount":101},[],{"trials":13992,"activeCount":101},[13993,13997],{"nctId":13961,"briefTitle":13962,"status":107,"phases":13994,"primaryCompletion":13964,"completion":320,"start":11554,"enrollment":101,"conditions":13995,"interventions":13996},[90],[13966,13967,13968,13969,2709],[13952,13971,13972],{"nctId":13974,"briefTitle":13975,"status":107,"phases":13998,"primaryCompletion":13964,"completion":320,"start":3015,"enrollment":101,"conditions":13999,"interventions":14000},[90],[13967,13968,2709,13969,13966],[13952,13971,13972],{"trials":14002,"activeCount":101},[],{"trials":14004,"activeCount":101},[],{"trials":14006,"activeCount":101},[],{"intervention":13972,"totalTrials":136,"cells":14008},{"EARLY_PHASE1":14009,"PHASE1":14011,"PHASE2":14013,"PHASE3":14023,"PHASE4":14025,"NA":14027},{"trials":14010,"activeCount":101},[],{"trials":14012,"activeCount":101},[],{"trials":14014,"activeCount":101},[14015,14019],{"nctId":13961,"briefTitle":13962,"status":107,"phases":14016,"primaryCompletion":13964,"completion":320,"start":11554,"enrollment":101,"conditions":14017,"interventions":14018},[90],[13966,13967,13968,13969,2709],[13952,13971,13972],{"nctId":13974,"briefTitle":13975,"status":107,"phases":14020,"primaryCompletion":13964,"completion":320,"start":3015,"enrollment":101,"conditions":14021,"interventions":14022},[90],[13967,13968,2709,13969,13966],[13952,13971,13972],{"trials":14024,"activeCount":101},[],{"trials":14026,"activeCount":101},[],{"trials":14028,"activeCount":101},[],{"intervention":4364,"totalTrials":136,"cells":14030},{"EARLY_PHASE1":14031,"PHASE1":14033,"PHASE2":14039,"PHASE3":14045,"PHASE4":14047,"NA":14049},{"trials":14032,"activeCount":101},[],{"trials":14034,"activeCount":101},[14035],{"nctId":4358,"briefTitle":4359,"status":117,"phases":14036,"primaryCompletion":1869,"completion":4361,"start":626,"enrollment":2859,"conditions":14037,"interventions":14038},[89],[2803],[2807,3388,4364],{"trials":14040,"activeCount":101},[14041],{"nctId":4376,"briefTitle":4377,"status":117,"phases":14042,"primaryCompletion":4379,"completion":4380,"start":2800,"enrollment":3565,"conditions":14043,"interventions":14044},[90],[2862],[4364,2807,3388,3389],{"trials":14046,"activeCount":101},[],{"trials":14048,"activeCount":101},[],{"trials":14050,"activeCount":101},[],{"intervention":14052,"totalTrials":136,"cells":14053},"AUY922",{"EARLY_PHASE1":14054,"PHASE1":14056,"PHASE2":14058,"PHASE3":14072,"PHASE4":14074,"NA":14076},{"trials":14055,"activeCount":101},[],{"trials":14057,"activeCount":101},[],{"trials":14059,"activeCount":101},[14060,14066],{"nctId":14061,"briefTitle":14062,"status":117,"phases":14063,"primaryCompletion":4771,"completion":4771,"start":477,"enrollment":2028,"conditions":14064,"interventions":14065},"NCT01854034","Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR",[90],[4065],[14052],{"nctId":14067,"briefTitle":14068,"status":117,"phases":14069,"primaryCompletion":2418,"completion":269,"start":456,"enrollment":544,"conditions":14070,"interventions":14071},"NCT01752400","AUY922 for Advanced ALK-positive NSCLC",[90],[4065],[14052],{"trials":14073,"activeCount":101},[],{"trials":14075,"activeCount":101},[],{"trials":14077,"activeCount":101},[],{"intervention":2411,"totalTrials":136,"cells":14079},{"EARLY_PHASE1":14080,"PHASE1":14082,"PHASE2":14084,"PHASE3":14094,"PHASE4":14096,"NA":14098},{"trials":14081,"activeCount":101},[],{"trials":14083,"activeCount":101},[],{"trials":14085,"activeCount":101},[14086,14090],{"nctId":2403,"briefTitle":2404,"status":107,"phases":14087,"primaryCompletion":2406,"completion":2407,"start":2408,"enrollment":101,"conditions":14088,"interventions":14089},[89,90],[1793],[2411,2280],{"nctId":2413,"briefTitle":2414,"status":107,"phases":14091,"primaryCompletion":2416,"completion":2417,"start":2418,"enrollment":101,"conditions":14092,"interventions":14093},[89,90],[2420],[2422,1795,2280],{"trials":14095,"activeCount":101},[],{"trials":14097,"activeCount":101},[],{"trials":14099,"activeCount":101},[],{"intervention":3448,"totalTrials":136,"cells":14101},{"EARLY_PHASE1":14102,"PHASE1":14104,"PHASE2":14110,"PHASE3":14119,"PHASE4":14121,"NA":14123},{"trials":14103,"activeCount":101},[],{"trials":14105,"activeCount":101},[14106],{"nctId":3442,"briefTitle":3443,"status":117,"phases":14107,"primaryCompletion":248,"completion":2447,"start":578,"enrollment":36,"conditions":14108,"interventions":14109},[89],[3446],[3448,2720,3165,3449,3450,2576],{"trials":14111,"activeCount":101},[14112],{"nctId":14113,"briefTitle":14114,"status":117,"phases":14115,"primaryCompletion":4290,"completion":4290,"start":150,"enrollment":194,"conditions":14116,"interventions":14117},"NCT00842257","Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer",[90],[6511],[14118],"panitumumab",{"trials":14120,"activeCount":101},[],{"trials":14122,"activeCount":101},[],{"trials":14124,"activeCount":101},[],{"intervention":3803,"totalTrials":136,"cells":14126},{"EARLY_PHASE1":14127,"PHASE1":14129,"PHASE2":14131,"PHASE3":14146,"PHASE4":14148,"NA":14150},{"trials":14128,"activeCount":101},[],{"trials":14130,"activeCount":101},[],{"trials":14132,"activeCount":101},[14133,14137],{"nctId":3797,"briefTitle":3798,"status":117,"phases":14134,"primaryCompletion":3706,"completion":3706,"start":3658,"enrollment":194,"conditions":14135,"interventions":14136},[89,90],[1151],[3802,3770,3803],{"nctId":14138,"briefTitle":14139,"status":117,"phases":14140,"primaryCompletion":14141,"completion":3491,"start":11429,"enrollment":8836,"conditions":14142,"interventions":14144},"NCT02003625","Meloxicam vs Placebo for Mobilization",[90],"2019-02",[4500,4501,2030,14143],"Hematopoietic Stem Cells",[3803,14145],"meloxicam",{"trials":14147,"activeCount":101},[],{"trials":14149,"activeCount":101},[],{"trials":14151,"activeCount":101},[],{"intervention":2851,"totalTrials":136,"cells":14153},{"EARLY_PHASE1":14154,"PHASE1":14156,"PHASE2":14162,"PHASE3":14170,"PHASE4":14172,"NA":14174},{"trials":14155,"activeCount":101},[],{"trials":14157,"activeCount":101},[14158],{"nctId":2844,"briefTitle":2845,"status":117,"phases":14159,"primaryCompletion":2847,"completion":2847,"start":2848,"enrollment":555,"conditions":14160,"interventions":14161},[89],[2030],[2851,2852],{"trials":14163,"activeCount":101},[14164],{"nctId":14165,"briefTitle":14166,"status":117,"phases":14167,"primaryCompletion":6696,"completion":149,"start":4450,"enrollment":555,"conditions":14168,"interventions":14169},"NCT00516165","RAD001 in Advanced Hepatocellular Carcinoma",[89,90],[4031],[2851],{"trials":14171,"activeCount":101},[],{"trials":14173,"activeCount":101},[],{"trials":14175,"activeCount":101},[],{"intervention":3614,"totalTrials":136,"cells":14177},{"EARLY_PHASE1":14178,"PHASE1":14180,"PHASE2":14186,"PHASE3":14194,"PHASE4":14196,"NA":14198},{"trials":14179,"activeCount":101},[],{"trials":14181,"activeCount":101},[14182],{"nctId":3604,"briefTitle":3605,"status":2758,"phases":14183,"primaryCompletion":3607,"completion":3608,"start":1926,"enrollment":829,"conditions":14184,"interventions":14185},[89],[3610,3611,3612],[3165,2720,3614],{"trials":14187,"activeCount":101},[14188],{"nctId":14189,"briefTitle":14190,"status":173,"phases":14191,"primaryCompletion":1869,"completion":1869,"start":647,"enrollment":1847,"conditions":14192,"interventions":14193},"NCT00722865","Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma",[90],[13513],[3614],{"trials":14195,"activeCount":101},[],{"trials":14197,"activeCount":101},[],{"trials":14199,"activeCount":101},[],{"intervention":14201,"totalTrials":136,"cells":14202},"Lorlatinib",{"EARLY_PHASE1":14203,"PHASE1":14205,"PHASE2":14207,"PHASE3":14231,"PHASE4":14233,"NA":14235},{"trials":14204,"activeCount":101},[],{"trials":14206,"activeCount":101},[],{"trials":14208,"activeCount":101},[14209,14216],{"nctId":14210,"briefTitle":14211,"status":2758,"phases":14212,"primaryCompletion":4288,"completion":14213,"start":2581,"enrollment":227,"conditions":14214,"interventions":14215},"NCT02927340","A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions",[90],"2023-05",[4960],[14201],{"nctId":14217,"briefTitle":14218,"status":2758,"phases":14219,"primaryCompletion":3915,"completion":6442,"start":14220,"enrollment":9,"conditions":14221,"interventions":14227},"NCT04292119","Lorlatinib Combinations in Lung Cancer",[89,90],"2020-05-01",[32,14222,14223,2646,14224,14225,14226],"Anaplastic Lymphoma Kinase Gene Translocation","ROS1 Rearrangement","MET Amplification","Resistant Cancer","NSCLC",[14201,14228,14229,14230],"Crizotinib","Binimetinib","TNO155",{"trials":14232,"activeCount":101},[],{"trials":14234,"activeCount":101},[],{"trials":14236,"activeCount":101},[],{"intervention":3496,"totalTrials":136,"cells":14238},{"EARLY_PHASE1":14239,"PHASE1":14241,"PHASE2":14243,"PHASE3":14253,"PHASE4":14255,"NA":14257},{"trials":14240,"activeCount":101},[],{"trials":14242,"activeCount":101},[],{"trials":14244,"activeCount":101},[14245,14249],{"nctId":4430,"briefTitle":4431,"status":117,"phases":14246,"primaryCompletion":3148,"completion":2417,"start":456,"enrollment":251,"conditions":14247,"interventions":14248},[90],[4434],[3627,3496,3626,4436],{"nctId":3488,"briefTitle":3489,"status":117,"phases":14250,"primaryCompletion":3491,"completion":3491,"start":3492,"enrollment":1847,"conditions":14251,"interventions":14252},[90],[3494],[2576,3496],{"trials":14254,"activeCount":101},[],{"trials":14256,"activeCount":101},[],{"trials":14258,"activeCount":101},[],{"intervention":14260,"totalTrials":136,"cells":14261},"Inosine",{"EARLY_PHASE1":14262,"PHASE1":14264,"PHASE2":14272,"PHASE3":14283,"PHASE4":14285,"NA":14287},{"trials":14263,"activeCount":101},[],{"trials":14265,"activeCount":101},[14266],{"nctId":14267,"briefTitle":14268,"status":117,"phases":14269,"primaryCompletion":1846,"completion":1846,"start":225,"enrollment":648,"conditions":14270,"interventions":14271},"NCT02288091","A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)",[89],[12453],[14260],{"trials":14273,"activeCount":101},[14274],{"nctId":14275,"briefTitle":14276,"status":117,"phases":14277,"primaryCompletion":14278,"completion":14279,"start":14280,"enrollment":4772,"conditions":14281,"interventions":14282},"NCT03168711","Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)",[90],"2019-12-10","2020-01-07","2017-10-01",[12453],[14260],{"trials":14284,"activeCount":101},[],{"trials":14286,"activeCount":101},[],{"trials":14288,"activeCount":101},[],{"intervention":3787,"totalTrials":136,"cells":14290},{"EARLY_PHASE1":14291,"PHASE1":14293,"PHASE2":14299,"PHASE3":14305,"PHASE4":14307,"NA":14309},{"trials":14292,"activeCount":101},[],{"trials":14294,"activeCount":101},[14295],{"nctId":3777,"briefTitle":3778,"status":117,"phases":14296,"primaryCompletion":2581,"completion":2408,"start":567,"enrollment":2837,"conditions":14297,"interventions":14298},[89],[3781,3782,3783,3784],[3786,3787,2807,3770,3788,201,3789],{"trials":14300,"activeCount":101},[14301],{"nctId":3821,"briefTitle":3822,"status":117,"phases":14302,"primaryCompletion":567,"completion":1877,"start":3607,"enrollment":227,"conditions":14303,"interventions":14304},[90],[3781],[3576,3787,3770,3826,2807,3789,3827,3828,3829],{"trials":14306,"activeCount":101},[],{"trials":14308,"activeCount":101},[],{"trials":14310,"activeCount":101},[],{"intervention":13803,"totalTrials":136,"cells":14312},{"EARLY_PHASE1":14313,"PHASE1":14315,"PHASE2":14317,"PHASE3":14329,"PHASE4":14331,"NA":14333},{"trials":14314,"activeCount":101},[],{"trials":14316,"activeCount":101},[],{"trials":14318,"activeCount":101},[14319,14325],{"nctId":14320,"briefTitle":14321,"status":117,"phases":14322,"primaryCompletion":175,"completion":4441,"start":578,"enrollment":36,"conditions":14323,"interventions":14324},"NCT00361309","SU011248 in Advanced Hepatocellular Carcinoma",[90],[4031,13066],[13803],{"nctId":13797,"briefTitle":13798,"status":173,"phases":14326,"primaryCompletion":2027,"completion":751,"start":6901,"enrollment":544,"conditions":14327,"interventions":14328},[89,90],[13801],[13803,3625,13804],{"trials":14330,"activeCount":101},[],{"trials":14332,"activeCount":101},[],{"trials":14334,"activeCount":101},[],{"intervention":4503,"totalTrials":136,"cells":14336},{"EARLY_PHASE1":14337,"PHASE1":14339,"PHASE2":14341,"PHASE3":14351,"PHASE4":14353,"NA":14355},{"trials":14338,"activeCount":101},[],{"trials":14340,"activeCount":101},[],{"trials":14342,"activeCount":101},[14343,14347],{"nctId":4496,"briefTitle":4497,"status":117,"phases":14344,"primaryCompletion":2418,"completion":2418,"start":4290,"enrollment":2610,"conditions":14345,"interventions":14346},[90],[4500,4501,2030,123,2803],[200,4503,4504],{"nctId":4506,"briefTitle":4507,"status":117,"phases":14348,"primaryCompletion":175,"completion":149,"start":2456,"enrollment":648,"conditions":14349,"interventions":14350},[90],[2030,4500,4510,4511,4512],[4514,4515,4516,4517,4518,200,4503],{"trials":14352,"activeCount":101},[],{"trials":14354,"activeCount":101},[],{"trials":14356,"activeCount":101},[],{"intervention":13788,"totalTrials":136,"cells":14358},{"EARLY_PHASE1":14359,"PHASE1":14361,"PHASE2":14367,"PHASE3":14376,"PHASE4":14378,"NA":14380},{"trials":14360,"activeCount":101},[],{"trials":14362,"activeCount":101},[14363],{"nctId":13778,"briefTitle":13779,"status":117,"phases":14364,"primaryCompletion":13781,"completion":13782,"start":13783,"enrollment":1914,"conditions":14365,"interventions":14366},[89],[13785,13786],[13788,13789,3625],{"trials":14368,"activeCount":101},[14369],{"nctId":14370,"briefTitle":14371,"status":117,"phases":14372,"primaryCompletion":224,"completion":1244,"start":2609,"enrollment":1791,"conditions":14373,"interventions":14375},"NCT01583543","Olaparib in Adults With Recurrent\u002FMetastatic Ewing's Sarcoma",[90],[14374],"Ewing's Sarcoma",[13788],{"trials":14377,"activeCount":101},[],{"trials":14379,"activeCount":101},[],{"trials":14381,"activeCount":101},[],{"intervention":14383,"totalTrials":136,"cells":14384},"Nitric Oxide Gas",{"EARLY_PHASE1":14385,"PHASE1":14387,"PHASE2":14389,"PHASE3":14410,"PHASE4":14412,"NA":14414},{"trials":14386,"activeCount":101},[],{"trials":14388,"activeCount":101},[],{"trials":14390,"activeCount":101},[14391,14400],{"nctId":14392,"briefTitle":14393,"status":117,"phases":14394,"primaryCompletion":14395,"completion":14396,"start":12017,"enrollment":1466,"conditions":14397,"interventions":14399},"NCT04306393","Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19",[90],"2021-12-21","2022-06-15",[14398,4304],"SARS (Severe Acute Respiratory Syndrome)",[14383],{"nctId":14401,"briefTitle":14402,"status":173,"phases":14403,"primaryCompletion":14404,"completion":14405,"start":14406,"enrollment":27,"conditions":14407,"interventions":14409},"NCT04338828","Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED",[90],"2021-01-14","2021-03-01","2020-04-18",[14408],"COVID19",[14383],{"trials":14411,"activeCount":101},[],{"trials":14413,"activeCount":101},[],{"trials":14415,"activeCount":101},[],{"intervention":4518,"totalTrials":136,"cells":14417},{"EARLY_PHASE1":14418,"PHASE1":14420,"PHASE2":14422,"PHASE3":14438,"PHASE4":14440,"NA":14442},{"trials":14419,"activeCount":101},[],{"trials":14421,"activeCount":101},[],{"trials":14423,"activeCount":101},[14424,14428],{"nctId":4506,"briefTitle":4507,"status":117,"phases":14425,"primaryCompletion":175,"completion":149,"start":2456,"enrollment":648,"conditions":14426,"interventions":14427},[90],[2030,4500,4510,4511,4512],[4514,4515,4516,4517,4518,200,4503],{"nctId":14429,"briefTitle":14430,"status":117,"phases":14431,"primaryCompletion":10682,"completion":9525,"start":1779,"enrollment":136,"conditions":14432,"interventions":14434},"NCT02464878","Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant",[90],[14433,3066],"Kidney Transplant",[14435,4518,14436,14437],"Alpha 1-Antitrypsin","Basiliximab","Etanercept",{"trials":14439,"activeCount":101},[],{"trials":14441,"activeCount":101},[],{"trials":14443,"activeCount":101},[],{"intervention":12197,"totalTrials":136,"cells":14445},{"EARLY_PHASE1":14446,"PHASE1":14448,"PHASE2":14450,"PHASE3":14462,"PHASE4":14464,"NA":14466},{"trials":14447,"activeCount":101},[],{"trials":14449,"activeCount":101},[],{"trials":14451,"activeCount":101},[14452,14458],{"nctId":14453,"briefTitle":14454,"status":173,"phases":14455,"primaryCompletion":1936,"completion":627,"start":2027,"enrollment":178,"conditions":14456,"interventions":14457},"NCT00549822","Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer",[90],[21],[12197],{"nctId":12190,"briefTitle":12191,"status":2758,"phases":14459,"primaryCompletion":12193,"start":12194,"enrollment":2728,"conditions":14460,"interventions":14461},[89,90],[8978],[12197,11918],{"trials":14463,"activeCount":101},[],{"trials":14465,"activeCount":101},[],{"trials":14467,"activeCount":101},[],{"intervention":4393,"totalTrials":136,"cells":14469},{"EARLY_PHASE1":14470,"PHASE1":14472,"PHASE2":14474,"PHASE3":14484,"PHASE4":14486,"NA":14488},{"trials":14471,"activeCount":101},[],{"trials":14473,"activeCount":101},[],{"trials":14475,"activeCount":101},[14476,14480],{"nctId":4388,"briefTitle":4389,"status":107,"phases":14477,"primaryCompletion":224,"completion":224,"start":224,"enrollment":101,"conditions":14478,"interventions":14479},[90],[2862],[2807,4393],{"nctId":4674,"briefTitle":4675,"status":173,"phases":14481,"primaryCompletion":4442,"completion":4677,"start":3492,"enrollment":33,"conditions":14482,"interventions":14483},[90],[4679],[47,4275,4393],{"trials":14485,"activeCount":101},[],{"trials":14487,"activeCount":101},[],{"trials":14489,"activeCount":101},[],{"intervention":14491,"totalTrials":136,"cells":14492},"Vemurafenib",{"EARLY_PHASE1":14493,"PHASE1":14495,"PHASE2":14504,"PHASE3":14513,"PHASE4":14515,"NA":14517},{"trials":14494,"activeCount":101},[],{"trials":14496,"activeCount":101},[14497],{"nctId":14498,"briefTitle":14499,"status":173,"phases":14500,"primaryCompletion":224,"completion":224,"start":9600,"enrollment":178,"conditions":14501,"interventions":14502},"NCT01611675","Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma",[89],[3901],[14491,14503],"Leflunomide",{"trials":14505,"activeCount":101},[14506],{"nctId":14507,"briefTitle":14508,"status":173,"phases":14509,"primaryCompletion":135,"completion":1846,"start":456,"enrollment":544,"conditions":14510,"interventions":14511},"NCT01754376","Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma",[90],[3901],[14512,14491],"Aldesleukin",{"trials":14514,"activeCount":101},[],{"trials":14516,"activeCount":101},[],{"trials":14518,"activeCount":101},[],{"intervention":14520,"totalTrials":136,"cells":14521},"AZD2014",{"EARLY_PHASE1":14522,"PHASE1":14524,"PHASE2":14526,"PHASE3":14548,"PHASE4":14550,"NA":14552},{"trials":14523,"activeCount":101},[],{"trials":14525,"activeCount":101},[],{"trials":14527,"activeCount":101},[14528,14539],{"nctId":14529,"briefTitle":14530,"status":117,"phases":14531,"primaryCompletion":14532,"completion":14533,"start":14534,"enrollment":209,"conditions":14535,"interventions":14538},"NCT02831257","AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas",[90],"2019-05-31","2020-10-01","2016-08-31",[14536,14537],"Neurofibromatosis 2","Meningioma",[14520],{"nctId":14540,"briefTitle":14541,"status":2758,"phases":14542,"primaryCompletion":14543,"completion":14544,"start":14545,"enrollment":555,"conditions":14546,"interventions":14547},"NCT03071874","Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas",[90],"2022-06-30","2024-07-25","2017-10-17",[14537],[14520],{"trials":14549,"activeCount":101},[],{"trials":14551,"activeCount":101},[],{"trials":14553,"activeCount":101},[],{"intervention":14555,"totalTrials":136,"cells":14556},"STA-9090",{"EARLY_PHASE1":14557,"PHASE1":14559,"PHASE2":14567,"PHASE3":14575,"PHASE4":14577,"NA":14579},{"trials":14558,"activeCount":101},[],{"trials":14560,"activeCount":101},[14561],{"nctId":14562,"briefTitle":14563,"status":117,"phases":14564,"primaryCompletion":477,"completion":2436,"start":751,"enrollment":1805,"conditions":14565,"interventions":14566},"NCT01665937","STA-9090 in Patients With Advanced Hepatocellular Cancer",[89],[4031],[14555],{"trials":14568,"activeCount":101},[14569],{"nctId":14570,"briefTitle":14571,"status":117,"phases":14572,"primaryCompletion":46,"completion":2857,"start":751,"enrollment":555,"conditions":14573,"interventions":14574},"NCT01167114","STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer",[90],[3637],[14555],{"trials":14576,"activeCount":101},[],{"trials":14578,"activeCount":101},[],{"trials":14580,"activeCount":101},[],{"intervention":288,"totalTrials":136,"cells":14582},{"EARLY_PHASE1":14583,"PHASE1":14585,"PHASE2":14587,"PHASE3":14599,"PHASE4":14601,"NA":14603},{"trials":14584,"activeCount":101},[],{"trials":14586,"activeCount":101},[],{"trials":14588,"activeCount":101},[14589,14595],{"nctId":14590,"briefTitle":14591,"status":173,"phases":14592,"primaryCompletion":4666,"completion":4666,"start":8683,"enrollment":1898,"conditions":14593,"interventions":14594},"NCT00113646","Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies",[90],[211,916,2030,2861],[288],{"nctId":279,"briefTitle":280,"status":117,"phases":14596,"primaryCompletion":282,"completion":283,"start":284,"enrollment":136,"conditions":14597,"interventions":14598},[89,90],[286],[288,96],{"trials":14600,"activeCount":101},[],{"trials":14602,"activeCount":101},[],{"trials":14604,"activeCount":101},[],{"intervention":14606,"totalTrials":136,"cells":14607},"Tivozanib",{"EARLY_PHASE1":14608,"PHASE1":14610,"PHASE2":14612,"PHASE3":14629,"PHASE4":14631,"NA":14633},{"trials":14609,"activeCount":101},[],{"trials":14611,"activeCount":101},[],{"trials":14613,"activeCount":101},[14614,14623],{"nctId":14615,"briefTitle":14616,"status":173,"phases":14617,"primaryCompletion":14618,"completion":14618,"start":14619,"enrollment":693,"conditions":14620,"interventions":14621},"NCT01885949","Tivozanib + Enzalutamide in Adv Prostate Cancer",[90],"2024-05-23","2013-09-03",[2038],[14606,14622],"Enzalutamide",{"nctId":14624,"briefTitle":14625,"status":117,"phases":14626,"primaryCompletion":1897,"completion":46,"start":2446,"enrollment":239,"conditions":14627,"interventions":14628},"NCT01846871","Tivozanib for Recurrent Glioblastoma",[90],[13574],[14606],{"trials":14630,"activeCount":101},[],{"trials":14632,"activeCount":101},[],{"trials":14634,"activeCount":101},[],{"intervention":14636,"totalTrials":136,"cells":14637},"AMR101",{"EARLY_PHASE1":14638,"PHASE1":14640,"PHASE2":14642,"PHASE3":14663,"PHASE4":14665,"NA":14667},{"trials":14639,"activeCount":101},[],{"trials":14641,"activeCount":101},[],{"trials":14643,"activeCount":101},[14644,14654],{"nctId":14645,"briefTitle":14646,"status":117,"phases":14647,"primaryCompletion":14648,"completion":14648,"start":14649,"enrollment":593,"conditions":14650,"interventions":14653},"NCT04216251","PRevention Using EPA Against coloREctal Cancer",[89,90],"2022-09-30","2020-12-09",[4090,6511,14651,14652,6513],"Endoscopic Surgery","Eicosapentaenoic Acid",[14636],{"nctId":14655,"briefTitle":14656,"status":107,"phases":14657,"primaryCompletion":14658,"completion":14658,"start":14659,"enrollment":101,"conditions":14660,"interventions":14662},"NCT03661047","OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer",[90],"2021-11-30","2019-11-30",[14661],"Colon Cancer",[14636],{"trials":14664,"activeCount":101},[],{"trials":14666,"activeCount":101},[],{"trials":14668,"activeCount":101},[],{"intervention":13804,"totalTrials":136,"cells":14670},{"EARLY_PHASE1":14671,"PHASE1":14673,"PHASE2":14675,"PHASE3":14687,"PHASE4":14689,"NA":14691},{"trials":14672,"activeCount":101},[],{"trials":14674,"activeCount":101},[],{"trials":14676,"activeCount":101},[14677,14681],{"nctId":13797,"briefTitle":13798,"status":173,"phases":14678,"primaryCompletion":2027,"completion":751,"start":6901,"enrollment":544,"conditions":14679,"interventions":14680},[89,90],[13801],[13803,3625,13804],{"nctId":14682,"briefTitle":14683,"status":117,"phases":14684,"primaryCompletion":591,"completion":8511,"start":13650,"enrollment":227,"conditions":14685,"interventions":14686},"NCT00142428","Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma",[90],[4031],[13804],{"trials":14688,"activeCount":101},[],{"trials":14690,"activeCount":101},[],{"trials":14692,"activeCount":101},[],{"intervention":14694,"totalTrials":331,"cells":14695},"Induced, sustained hypernatremia using hypertonic saline",{"EARLY_PHASE1":14696,"PHASE1":14698,"PHASE2":14700,"PHASE3":14715,"PHASE4":14717,"NA":14719},{"trials":14697,"activeCount":101},[],{"trials":14699,"activeCount":101},[],{"trials":14701,"activeCount":101},[14702],{"nctId":14703,"briefTitle":14704,"status":107,"phases":14705,"primaryCompletion":477,"completion":14706,"start":9600,"enrollment":101,"conditions":14707,"interventions":14713},"NCT01605357","Hypernatremia for the Prevention and Treatment of Cerebral Edema in Traumatic Brain Injury",[89,90],"2013-08",[14708,14709,14710,14711,14712],"Traumatic Brain Injury","Subdural Hematoma","Cerebral Contusion","Head Injury","Cerebral Edema",[14694,14714],"Standard of care",{"trials":14716,"activeCount":101},[],{"trials":14718,"activeCount":101},[],{"trials":14720,"activeCount":101},[],{"intervention":14714,"totalTrials":331,"cells":14722},{"EARLY_PHASE1":14723,"PHASE1":14725,"PHASE2":14727,"PHASE3":14733,"PHASE4":14735,"NA":14737},{"trials":14724,"activeCount":101},[],{"trials":14726,"activeCount":101},[],{"trials":14728,"activeCount":101},[14729],{"nctId":14703,"briefTitle":14704,"status":107,"phases":14730,"primaryCompletion":477,"completion":14706,"start":9600,"enrollment":101,"conditions":14731,"interventions":14732},[89,90],[14708,14709,14710,14711,14712],[14694,14714],{"trials":14734,"activeCount":101},[],{"trials":14736,"activeCount":101},[],{"trials":14738,"activeCount":101},[],{"intervention":13934,"totalTrials":331,"cells":14740},{"EARLY_PHASE1":14741,"PHASE1":14743,"PHASE2":14745,"PHASE3":14751,"PHASE4":14753,"NA":14755},{"trials":14742,"activeCount":101},[],{"trials":14744,"activeCount":101},[],{"trials":14746,"activeCount":101},[14747],{"nctId":13929,"briefTitle":13930,"status":117,"phases":14748,"primaryCompletion":1861,"completion":1861,"start":9600,"enrollment":2859,"conditions":14749,"interventions":14750},[90],[9455],[13934,13920],{"trials":14752,"activeCount":101},[],{"trials":14754,"activeCount":101},[],{"trials":14756,"activeCount":101},[],{"intervention":14758,"totalTrials":331,"cells":14759},"CRLX101",{"EARLY_PHASE1":14760,"PHASE1":14762,"PHASE2":14764,"PHASE3":14774,"PHASE4":14776,"NA":14778},{"trials":14761,"activeCount":101},[],{"trials":14763,"activeCount":101},[],{"trials":14765,"activeCount":101},[14766],{"nctId":14767,"briefTitle":14768,"status":117,"phases":14769,"primaryCompletion":14770,"completion":14770,"start":226,"enrollment":4099,"conditions":14771,"interventions":14773},"NCT01652079","CRLX101 in Combination With Bevacizumab for Recurrent Ovarian\u002FTubal\u002FPeritoneal Cancer",[90],"2018-03",[3610,3612,14772],"Primary Peritoneal Cancer",[14758],{"trials":14775,"activeCount":101},[],{"trials":14777,"activeCount":101},[],{"trials":14779,"activeCount":101},[],{"intervention":155,"totalTrials":331,"cells":14781},{"EARLY_PHASE1":14782,"PHASE1":14784,"PHASE2":14786,"PHASE3":14792,"PHASE4":14794,"NA":14796},{"trials":14783,"activeCount":101},[],{"trials":14785,"activeCount":101},[],{"trials":14787,"activeCount":101},[14788],{"nctId":146,"briefTitle":147,"status":117,"phases":14789,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":14790,"interventions":14791},[90],[153],[155,156],{"trials":14793,"activeCount":101},[],{"trials":14795,"activeCount":101},[],{"trials":14797,"activeCount":101},[],{"intervention":14799,"totalTrials":331,"cells":14800},"Acipimox",{"EARLY_PHASE1":14801,"PHASE1":14803,"PHASE2":14805,"PHASE3":14814,"PHASE4":14816,"NA":14818},{"trials":14802,"activeCount":101},[],{"trials":14804,"activeCount":101},[],{"trials":14806,"activeCount":101},[14807],{"nctId":14808,"briefTitle":14809,"status":117,"phases":14810,"primaryCompletion":225,"completion":225,"start":2609,"enrollment":4353,"conditions":14811,"interventions":14813},"NCT01488409","Effects of Acipimox on Mitochondrial Function in Obesity",[90],[6608,8582,14812],"Hypertriglyceridemia",[14799],{"trials":14815,"activeCount":101},[],{"trials":14817,"activeCount":101},[],{"trials":14819,"activeCount":101},[],{"intervention":14821,"totalTrials":331,"cells":14822},"Sacubitril-Valsartan 49-51Mg Oral",{"EARLY_PHASE1":14823,"PHASE1":14825,"PHASE2":14827,"PHASE3":14838,"PHASE4":14840,"NA":14842},{"trials":14824,"activeCount":101},[],{"trials":14826,"activeCount":101},[],{"trials":14828,"activeCount":101},[14829],{"nctId":14830,"briefTitle":14831,"status":117,"phases":14832,"primaryCompletion":14833,"completion":14833,"start":14834,"enrollment":4353,"conditions":14835,"interventions":14837},"NCT04153136","The ENCHANTMENT HIV Study",[90],"2025-07-09","2020-09-11",[14836,1371],"HIV\u002FAIDS",[14821],{"trials":14839,"activeCount":101},[],{"trials":14841,"activeCount":101},[],{"trials":14843,"activeCount":101},[],{"intervention":14845,"totalTrials":331,"cells":14846},"Imatinib mesylate",{"EARLY_PHASE1":14847,"PHASE1":14849,"PHASE2":14851,"PHASE3":14860,"PHASE4":14862,"NA":14864},{"trials":14848,"activeCount":101},[],{"trials":14850,"activeCount":101},[],{"trials":14852,"activeCount":101},[14853],{"nctId":14854,"briefTitle":14855,"status":117,"phases":14856,"primaryCompletion":250,"completion":250,"start":4666,"enrollment":1791,"conditions":14857,"interventions":14859},"NCT00677092","Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis",[90],[14858],"Nephrogenic Systemic Fibrosis",[14845],{"trials":14861,"activeCount":101},[],{"trials":14863,"activeCount":101},[],{"trials":14865,"activeCount":101},[],{"intervention":14867,"totalTrials":331,"cells":14868},"Combination Product: BCI-024 + BCI-049",{"EARLY_PHASE1":14869,"PHASE1":14871,"PHASE2":14873,"PHASE3":14881,"PHASE4":14883,"NA":14885},{"trials":14870,"activeCount":101},[],{"trials":14872,"activeCount":101},[],{"trials":14874,"activeCount":101},[14875],{"nctId":14876,"briefTitle":14877,"status":117,"phases":14878,"primaryCompletion":9865,"completion":3855,"start":3464,"enrollment":593,"conditions":14879,"interventions":14880},"NCT00731653","Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)",[90],[18],[14867],{"trials":14882,"activeCount":101},[],{"trials":14884,"activeCount":101},[],{"trials":14886,"activeCount":101},[],{"intervention":14888,"totalTrials":331,"cells":14889},"Radium-223 dichloride",{"EARLY_PHASE1":14890,"PHASE1":14892,"PHASE2":14894,"PHASE3":14905,"PHASE4":14907,"NA":14909},{"trials":14891,"activeCount":101},[],{"trials":14893,"activeCount":101},[],{"trials":14895,"activeCount":101},[14896],{"nctId":14897,"briefTitle":14898,"status":117,"phases":14899,"primaryCompletion":8128,"completion":14900,"start":3680,"enrollment":2859,"conditions":14901,"interventions":14904},"NCT02346526","A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer",[90],"2020-12",[2038,14902,14903],"Castration-resistant Prostate Cancer","Castration-resistant Prostate Cancer Metastatic to Bone",[14888],{"trials":14906,"activeCount":101},[],{"trials":14908,"activeCount":101},[],{"trials":14910,"activeCount":101},[],{"intervention":2490,"totalTrials":331,"cells":14912},{"EARLY_PHASE1":14913,"PHASE1":14915,"PHASE2":14917,"PHASE3":14923,"PHASE4":14925,"NA":14927},{"trials":14914,"activeCount":101},[],{"trials":14916,"activeCount":101},[],{"trials":14918,"activeCount":101},[14919],{"nctId":2480,"briefTitle":2481,"status":173,"phases":14920,"primaryCompletion":2483,"completion":2483,"start":2484,"enrollment":239,"conditions":14921,"interventions":14922},[90],[2486,2487,2488],[57,2490],{"trials":14924,"activeCount":101},[],{"trials":14926,"activeCount":101},[],{"trials":14928,"activeCount":101},[],{"intervention":14930,"totalTrials":331,"cells":14931},"ET 743",{"EARLY_PHASE1":14932,"PHASE1":14934,"PHASE2":14936,"PHASE3":14945,"PHASE4":14947,"NA":14949},{"trials":14933,"activeCount":101},[],{"trials":14935,"activeCount":101},[],{"trials":14937,"activeCount":101},[14938],{"nctId":14939,"briefTitle":14940,"status":117,"phases":14941,"primaryCompletion":708,"completion":708,"start":14942,"enrollment":366,"conditions":14943,"interventions":14944},"NCT00147212","ET 743 (Yondelis) in Men With Advanced Prostate Cancer",[90],"2002-06",[2038],[14930],{"trials":14946,"activeCount":101},[],{"trials":14948,"activeCount":101},[],{"trials":14950,"activeCount":101},[],{"intervention":14952,"totalTrials":331,"cells":14953},"Lamivudine",{"EARLY_PHASE1":14954,"PHASE1":14956,"PHASE2":14958,"PHASE3":14969,"PHASE4":14971,"NA":14973},{"trials":14955,"activeCount":101},[],{"trials":14957,"activeCount":101},[],{"trials":14959,"activeCount":101},[14960],{"nctId":14961,"briefTitle":14962,"status":117,"phases":14963,"primaryCompletion":14964,"completion":14965,"start":9749,"enrollment":33,"conditions":14966,"interventions":14968},"NCT03144804","A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer",[90],"2020-03-26","2022-09-27",[14967],"Colorectal Cancer Metastatic",[14952],{"trials":14970,"activeCount":101},[],{"trials":14972,"activeCount":101},[],{"trials":14974,"activeCount":101},[],{"intervention":3802,"totalTrials":331,"cells":14976},{"EARLY_PHASE1":14977,"PHASE1":14979,"PHASE2":14981,"PHASE3":14987,"PHASE4":14989,"NA":14991},{"trials":14978,"activeCount":101},[],{"trials":14980,"activeCount":101},[],{"trials":14982,"activeCount":101},[14983],{"nctId":3797,"briefTitle":3798,"status":117,"phases":14984,"primaryCompletion":3706,"completion":3706,"start":3658,"enrollment":194,"conditions":14985,"interventions":14986},[89,90],[1151],[3802,3770,3803],{"trials":14988,"activeCount":101},[],{"trials":14990,"activeCount":101},[],{"trials":14992,"activeCount":101},[],{"intervention":2501,"totalTrials":331,"cells":14994},{"EARLY_PHASE1":14995,"PHASE1":14997,"PHASE2":14999,"PHASE3":15005,"PHASE4":15007,"NA":15009},{"trials":14996,"activeCount":101},[],{"trials":14998,"activeCount":101},[],{"trials":15000,"activeCount":101},[15001],{"nctId":2492,"briefTitle":2493,"status":117,"phases":15002,"primaryCompletion":2495,"completion":2495,"start":2496,"enrollment":538,"conditions":15003,"interventions":15004},[90],[2498,2499],[57,2501],{"trials":15006,"activeCount":101},[],{"trials":15008,"activeCount":101},[],{"trials":15010,"activeCount":101},[],{"intervention":15012,"totalTrials":331,"cells":15013},"Panobinostat with Rituximab",{"EARLY_PHASE1":15014,"PHASE1":15016,"PHASE2":15018,"PHASE3":15027,"PHASE4":15029,"NA":15031},{"trials":15015,"activeCount":101},[],{"trials":15017,"activeCount":101},[],{"trials":15019,"activeCount":101},[15020],{"nctId":15021,"briefTitle":15022,"status":173,"phases":15023,"primaryCompletion":14706,"completion":436,"start":4464,"enrollment":209,"conditions":15024,"interventions":15026},"NCT01282476","Panobinostat With Rituximab for Relapsed\u002FRefractory Diffuse Large B Cell Lymphoma",[90],[15025],"Diffuse Large B Cell Lymphoma",[15012],{"trials":15028,"activeCount":101},[],{"trials":15030,"activeCount":101},[],{"trials":15032,"activeCount":101},[],{"intervention":15034,"totalTrials":331,"cells":15035},"Ritlecitinib",{"EARLY_PHASE1":15036,"PHASE1":15038,"PHASE2":15040,"PHASE3":15051,"PHASE4":15053,"NA":15055},{"trials":15037,"activeCount":101},[],{"trials":15039,"activeCount":101},[],{"trials":15041,"activeCount":101},[15042],{"nctId":15043,"briefTitle":15044,"status":117,"phases":15045,"primaryCompletion":15046,"completion":15047,"start":6442,"enrollment":3122,"conditions":15048,"interventions":15050},"NCT05636293","Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission",[90],"2025-12-09","2026-04-09",[15049],"Celiac Disease",[15034],{"trials":15052,"activeCount":101},[],{"trials":15054,"activeCount":101},[],{"trials":15056,"activeCount":101},[],{"intervention":3019,"totalTrials":331,"cells":15058},{"EARLY_PHASE1":15059,"PHASE1":15061,"PHASE2":15063,"PHASE3":15069,"PHASE4":15071,"NA":15073},{"trials":15060,"activeCount":101},[],{"trials":15062,"activeCount":101},[],{"trials":15064,"activeCount":101},[15065],{"nctId":3011,"briefTitle":3012,"status":107,"phases":15066,"primaryCompletion":3014,"completion":3014,"start":3015,"enrollment":101,"conditions":15067,"interventions":15068},[90],[3017],[3019,2975],{"trials":15070,"activeCount":101},[],{"trials":15072,"activeCount":101},[],{"trials":15074,"activeCount":101},[],{"intervention":15076,"totalTrials":331,"cells":15077},"Ponatinib",{"EARLY_PHASE1":15078,"PHASE1":15080,"PHASE2":15082,"PHASE3":15091,"PHASE4":15093,"NA":15095},{"trials":15079,"activeCount":101},[],{"trials":15081,"activeCount":101},[],{"trials":15083,"activeCount":101},[15084],{"nctId":15085,"briefTitle":15086,"status":117,"phases":15087,"primaryCompletion":282,"completion":15088,"start":627,"enrollment":538,"conditions":15089,"interventions":15090},"NCT01813734","Ponatinib in Advanced NSCLC w\u002F RET Translocations",[90],"2018-08",[4065],[15076],{"trials":15092,"activeCount":101},[],{"trials":15094,"activeCount":101},[],{"trials":15096,"activeCount":101},[],{"intervention":4494,"totalTrials":331,"cells":15098},{"EARLY_PHASE1":15099,"PHASE1":15101,"PHASE2":15103,"PHASE3":15109,"PHASE4":15111,"NA":15113},{"trials":15100,"activeCount":101},[],{"trials":15102,"activeCount":101},[],{"trials":15104,"activeCount":101},[15105],{"nctId":4487,"briefTitle":4488,"status":107,"phases":15106,"primaryCompletion":2417,"completion":4490,"start":4491,"enrollment":101,"conditions":15107,"interventions":15108},[89,90],[211],[200,4494,3789],{"trials":15110,"activeCount":101},[],{"trials":15112,"activeCount":101},[],{"trials":15114,"activeCount":101},[],{"intervention":15116,"totalTrials":331,"cells":15117},"S-adenosyl methione",{"EARLY_PHASE1":15118,"PHASE1":15120,"PHASE2":15122,"PHASE3":15132,"PHASE4":15134,"NA":15136},{"trials":15119,"activeCount":101},[],{"trials":15121,"activeCount":101},[],{"trials":15123,"activeCount":101},[15124],{"nctId":15125,"briefTitle":15126,"status":117,"phases":15127,"primaryCompletion":3658,"completion":3658,"start":15128,"enrollment":15129,"conditions":15130,"interventions":15131},"NCT00093847","Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression",[90],"2004-05",73,[15],[15116],{"trials":15133,"activeCount":101},[],{"trials":15135,"activeCount":101},[],{"trials":15137,"activeCount":101},[],{"intervention":11993,"totalTrials":331,"cells":15139},{"EARLY_PHASE1":15140,"PHASE1":15142,"PHASE2":15144,"PHASE3":15150,"PHASE4":15152,"NA":15154},{"trials":15141,"activeCount":101},[],{"trials":15143,"activeCount":101},[],{"trials":15145,"activeCount":101},[15146],{"nctId":11984,"briefTitle":11985,"status":107,"phases":15147,"primaryCompletion":11987,"completion":11987,"start":6721,"enrollment":101,"conditions":15148,"interventions":15149},[90],[11989,11990,11991],[11993,11975],{"trials":15151,"activeCount":101},[],{"trials":15153,"activeCount":101},[],{"trials":15155,"activeCount":101},[],{"intervention":15157,"totalTrials":331,"cells":15158},"PF-00299804",{"EARLY_PHASE1":15159,"PHASE1":15161,"PHASE2":15163,"PHASE3":15174,"PHASE4":15176,"NA":15178},{"trials":15160,"activeCount":101},[],{"trials":15162,"activeCount":101},[],{"trials":15164,"activeCount":101},[15165],{"nctId":15166,"briefTitle":15167,"status":117,"phases":15168,"primaryCompletion":1861,"completion":1861,"start":4581,"enrollment":15169,"conditions":15170,"interventions":15173},"NCT01112527","PF-00299804 in Adult Patients With Relapsed\u002FRecurrent Glioblastoma",[90],58,[13574,15171,15172],"GBM","Glioblastoma Multiforme",[15157],{"trials":15175,"activeCount":101},[],{"trials":15177,"activeCount":101},[],{"trials":15179,"activeCount":101},[],{"intervention":15181,"totalTrials":331,"cells":15182},"Inhaled Nitric Oxide (iNO) administration",{"EARLY_PHASE1":15183,"PHASE1":15185,"PHASE2":15187,"PHASE3":15197,"PHASE4":15199,"NA":15201},{"trials":15184,"activeCount":101},[],{"trials":15186,"activeCount":101},[],{"trials":15188,"activeCount":101},[15189],{"nctId":15190,"briefTitle":15191,"status":117,"phases":15192,"primaryCompletion":4677,"completion":4677,"start":2827,"enrollment":1898,"conditions":15193,"interventions":15196},"NCT01529502","Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting",[90],[15194,15195,11975,13202],"Blood Transfusion","Endothelial Physiopathology",[15181],{"trials":15198,"activeCount":101},[],{"trials":15200,"activeCount":101},[],{"trials":15202,"activeCount":101},[],{"intervention":15204,"totalTrials":331,"cells":15205},"GSK598809",{"EARLY_PHASE1":15206,"PHASE1":15208,"PHASE2":15210,"PHASE3":15218,"PHASE4":15220,"NA":15222},{"trials":15207,"activeCount":101},[],{"trials":15209,"activeCount":101},[],{"trials":15211,"activeCount":101},[15212],{"nctId":15213,"briefTitle":15214,"status":117,"phases":15215,"primaryCompletion":1876,"completion":1876,"start":751,"enrollment":2779,"conditions":15216,"interventions":15217},"NCT01188967","Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention",[90],[1947],[15204],{"trials":15219,"activeCount":101},[],{"trials":15221,"activeCount":101},[],{"trials":15223,"activeCount":101},[],{"intervention":15225,"totalTrials":331,"cells":15226},"Fluoxetine 20 MG Oral",{"EARLY_PHASE1":15227,"PHASE1":15229,"PHASE2":15231,"PHASE3":15242,"PHASE4":15244,"NA":15246},{"trials":15228,"activeCount":101},[],{"trials":15230,"activeCount":101},[],{"trials":15232,"activeCount":101},[15233],{"nctId":15234,"briefTitle":15235,"status":117,"phases":15236,"primaryCompletion":849,"completion":849,"start":15237,"enrollment":36,"conditions":15238,"interventions":15241},"NCT03728153","Measuring Ambulation, Motor, and Behavioral Outcomes With Post-Stroke Fluoxetine in Tanzania",[90],"2019-11-26",[15239,15240],"Acute Stroke","Stroke, Ischemic",[15225],{"trials":15243,"activeCount":101},[],{"trials":15245,"activeCount":101},[],{"trials":15247,"activeCount":101},[],{"intervention":15249,"totalTrials":331,"cells":15250},"Gilenya",{"EARLY_PHASE1":15251,"PHASE1":15253,"PHASE2":15255,"PHASE3":15263,"PHASE4":15265,"NA":15267},{"trials":15252,"activeCount":101},[],{"trials":15254,"activeCount":101},[],{"trials":15256,"activeCount":101},[15257],{"nctId":15258,"briefTitle":15259,"status":117,"phases":15260,"primaryCompletion":1897,"completion":41,"start":14706,"enrollment":227,"conditions":15261,"interventions":15262},"NCT01786174","Gilenya in Amyotrophic Lateral Sclerosis (ALS)",[90],[12453],[15249],{"trials":15264,"activeCount":101},[],{"trials":15266,"activeCount":101},[],{"trials":15268,"activeCount":101},[],{"intervention":15270,"totalTrials":331,"cells":15271},"Abatacept",{"EARLY_PHASE1":15272,"PHASE1":15274,"PHASE2":15276,"PHASE3":15288,"PHASE4":15290,"NA":15292},{"trials":15273,"activeCount":101},[],{"trials":15275,"activeCount":101},[],{"trials":15277,"activeCount":101},[15278],{"nctId":15279,"briefTitle":15280,"status":117,"phases":15281,"primaryCompletion":15282,"completion":15283,"start":15284,"enrollment":239,"conditions":15285,"interventions":15287},"NCT03669861","Safety and Efficacy of Abatacept in IgG4-Related Disease",[90],"2020-04-10","2020-11-10","2018-11-13",[15286],"IgG4-related Disease",[15270],{"trials":15289,"activeCount":101},[],{"trials":15291,"activeCount":101},[],{"trials":15293,"activeCount":101},[],{"intervention":184,"totalTrials":331,"cells":15295},{"EARLY_PHASE1":15296,"PHASE1":15298,"PHASE2":15300,"PHASE3":15306,"PHASE4":15308,"NA":15310},{"trials":15297,"activeCount":101},[],{"trials":15299,"activeCount":101},[],{"trials":15301,"activeCount":101},[15302],{"nctId":171,"briefTitle":172,"status":173,"phases":15303,"primaryCompletion":175,"completion":176,"start":177,"enrollment":178,"conditions":15304,"interventions":15305},[90],[180,181,182],[184,185,96],{"trials":15307,"activeCount":101},[],{"trials":15309,"activeCount":101},[],{"trials":15311,"activeCount":101},[],{"intervention":185,"totalTrials":331,"cells":15313},{"EARLY_PHASE1":15314,"PHASE1":15316,"PHASE2":15318,"PHASE3":15324,"PHASE4":15326,"NA":15328},{"trials":15315,"activeCount":101},[],{"trials":15317,"activeCount":101},[],{"trials":15319,"activeCount":101},[15320],{"nctId":171,"briefTitle":172,"status":173,"phases":15321,"primaryCompletion":175,"completion":176,"start":177,"enrollment":178,"conditions":15322,"interventions":15323},[90],[180,181,182],[184,185,96],{"trials":15325,"activeCount":101},[],{"trials":15327,"activeCount":101},[],{"trials":15329,"activeCount":101},[],{"intervention":15331,"totalTrials":331,"cells":15332},"Apixaban",{"EARLY_PHASE1":15333,"PHASE1":15335,"PHASE2":15337,"PHASE3":15349,"PHASE4":15351,"NA":15353},{"trials":15334,"activeCount":101},[],{"trials":15336,"activeCount":101},[],{"trials":15338,"activeCount":101},[15339],{"nctId":15340,"briefTitle":15341,"status":173,"phases":15342,"primaryCompletion":15343,"completion":15343,"start":15344,"enrollment":693,"conditions":15345,"interventions":15348},"NCT03594045","Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)",[90],"2019-10-30","2018-12-18",[15346,15347],"Heparin-induced Thrombocytopenia","Heparin-induced Thrombocytopenia and Thrombosis",[15331],{"trials":15350,"activeCount":101},[],{"trials":15352,"activeCount":101},[],{"trials":15354,"activeCount":101},[],{"intervention":4504,"totalTrials":331,"cells":15356},{"EARLY_PHASE1":15357,"PHASE1":15359,"PHASE2":15361,"PHASE3":15367,"PHASE4":15369,"NA":15371},{"trials":15358,"activeCount":101},[],{"trials":15360,"activeCount":101},[],{"trials":15362,"activeCount":101},[15363],{"nctId":4496,"briefTitle":4497,"status":117,"phases":15364,"primaryCompletion":2418,"completion":2418,"start":4290,"enrollment":2610,"conditions":15365,"interventions":15366},[90],[4500,4501,2030,123,2803],[200,4503,4504],{"trials":15368,"activeCount":101},[],{"trials":15370,"activeCount":101},[],{"trials":15372,"activeCount":101},[],{"intervention":15374,"totalTrials":331,"cells":15375},"Photodynamic Therapy",{"EARLY_PHASE1":15376,"PHASE1":15378,"PHASE2":15380,"PHASE3":15391,"PHASE4":15393,"NA":15395},{"trials":15377,"activeCount":101},[],{"trials":15379,"activeCount":101},[],{"trials":15381,"activeCount":101},[15382],{"nctId":15383,"briefTitle":15384,"status":117,"phases":15385,"primaryCompletion":15386,"completion":15386,"start":15387,"enrollment":227,"conditions":15388,"interventions":15390},"NCT03638622","Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer.",[89,90],"2020-10-12","2017-03-10",[15389],"Oral Cancer",[15374],{"trials":15392,"activeCount":101},[],{"trials":15394,"activeCount":101},[],{"trials":15396,"activeCount":101},[],{"intervention":15398,"totalTrials":331,"cells":15399},"Growth hormone releasing hormone (GHRH) 1-44",{"EARLY_PHASE1":15400,"PHASE1":15402,"PHASE2":15404,"PHASE3":15412,"PHASE4":15414,"NA":15416},{"trials":15401,"activeCount":101},[],{"trials":15403,"activeCount":101},[],{"trials":15405,"activeCount":101},[15406],{"nctId":15407,"briefTitle":15408,"status":117,"phases":15409,"primaryCompletion":11914,"completion":11914,"start":3464,"enrollment":1578,"conditions":15410,"interventions":15411},"NCT00675506","Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese",[90],[6608,3082],[15398],{"trials":15413,"activeCount":101},[],{"trials":15415,"activeCount":101},[],{"trials":15417,"activeCount":101},[],{"intervention":15419,"totalTrials":331,"cells":15420},"bosutinib",{"EARLY_PHASE1":15421,"PHASE1":15423,"PHASE2":15425,"PHASE3":15433,"PHASE4":15435,"NA":15437},{"trials":15422,"activeCount":101},[],{"trials":15424,"activeCount":101},[],{"trials":15426,"activeCount":101},[15427],{"nctId":15428,"briefTitle":15429,"status":117,"phases":15430,"primaryCompletion":567,"completion":567,"start":4424,"enrollment":33,"conditions":15431,"interventions":15432},"NCT01331291","Bosutinib in Adult Patients With Recurrent Glioblastoma",[90],[13574],[15419],{"trials":15434,"activeCount":101},[],{"trials":15436,"activeCount":101},[],{"trials":15438,"activeCount":101},[],{"intervention":2041,"totalTrials":331,"cells":15440},{"EARLY_PHASE1":15441,"PHASE1":15443,"PHASE2":15445,"PHASE3":15451,"PHASE4":15453,"NA":15455},{"trials":15442,"activeCount":101},[],{"trials":15444,"activeCount":101},[],{"trials":15446,"activeCount":101},[15447],{"nctId":2033,"briefTitle":2034,"status":117,"phases":15448,"primaryCompletion":177,"completion":177,"start":2036,"enrollment":30,"conditions":15449,"interventions":15450},[90],[2038,2039],[2041,430],{"trials":15452,"activeCount":101},[],{"trials":15454,"activeCount":101},[],{"trials":15456,"activeCount":101},[],{"intervention":15458,"totalTrials":331,"cells":15459},"Estradiol steroid",{"EARLY_PHASE1":15460,"PHASE1":15462,"PHASE2":15464,"PHASE3":15474,"PHASE4":15476,"NA":15478},{"trials":15461,"activeCount":101},[],{"trials":15463,"activeCount":101},[],{"trials":15465,"activeCount":101},[15466],{"nctId":15467,"briefTitle":15468,"status":117,"phases":15469,"primaryCompletion":4290,"completion":4290,"start":13650,"enrollment":753,"conditions":15470,"interventions":15472},"NCT00455962","Effect of Race on Gonadotropin Responses",[89,90],[15471,29],"Premenopause",[15458,15473],"Progesterone steroid",{"trials":15475,"activeCount":101},[],{"trials":15477,"activeCount":101},[],{"trials":15479,"activeCount":101},[],{"intervention":15473,"totalTrials":331,"cells":15481},{"EARLY_PHASE1":15482,"PHASE1":15484,"PHASE2":15486,"PHASE3":15492,"PHASE4":15494,"NA":15496},{"trials":15483,"activeCount":101},[],{"trials":15485,"activeCount":101},[],{"trials":15487,"activeCount":101},[15488],{"nctId":15467,"briefTitle":15468,"status":117,"phases":15489,"primaryCompletion":4290,"completion":4290,"start":13650,"enrollment":753,"conditions":15490,"interventions":15491},[89,90],[15471,29],[15458,15473],{"trials":15493,"activeCount":101},[],{"trials":15495,"activeCount":101},[],{"trials":15497,"activeCount":101},[],{"intervention":15499,"totalTrials":331,"cells":15500},"Bacillus Calmette-Guerin",{"EARLY_PHASE1":15501,"PHASE1":15503,"PHASE2":15505,"PHASE3":15514,"PHASE4":15516,"NA":15518},{"trials":15502,"activeCount":101},[],{"trials":15504,"activeCount":101},[],{"trials":15506,"activeCount":101},[15507],{"nctId":15508,"briefTitle":15509,"status":117,"phases":15510,"primaryCompletion":15511,"completion":15511,"start":14405,"enrollment":194,"conditions":15512,"interventions":15513},"NCT04507126","A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults.",[90],"2022-12-09",[29],[15499],{"trials":15515,"activeCount":101},[],{"trials":15517,"activeCount":101},[],{"trials":15519,"activeCount":101},[],{"intervention":13515,"totalTrials":331,"cells":15521},{"EARLY_PHASE1":15522,"PHASE1":15524,"PHASE2":15526,"PHASE3":15532,"PHASE4":15534,"NA":15536},{"trials":15523,"activeCount":101},[],{"trials":15525,"activeCount":101},[],{"trials":15527,"activeCount":101},[15528],{"nctId":13509,"briefTitle":13510,"status":117,"phases":15529,"primaryCompletion":225,"completion":120,"start":2827,"enrollment":36,"conditions":15530,"interventions":15531},[90],[13513],[4338,13515],{"trials":15533,"activeCount":101},[],{"trials":15535,"activeCount":101},[],{"trials":15537,"activeCount":101},[],{"intervention":13829,"totalTrials":331,"cells":15539},{"EARLY_PHASE1":15540,"PHASE1":15542,"PHASE2":15544,"PHASE3":15550,"PHASE4":15552,"NA":15554},{"trials":15541,"activeCount":101},[],{"trials":15543,"activeCount":101},[],{"trials":15545,"activeCount":101},[15546],{"nctId":13821,"briefTitle":13822,"status":117,"phases":15547,"primaryCompletion":684,"completion":13824,"start":13825,"enrollment":194,"conditions":15548,"interventions":15549},[89,90],[13827,6609],[13812,13829],{"trials":15551,"activeCount":101},[],{"trials":15553,"activeCount":101},[],{"trials":15555,"activeCount":101},[],{"intervention":15557,"totalTrials":331,"cells":15558},"TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]",{"EARLY_PHASE1":15559,"PHASE1":15561,"PHASE2":15563,"PHASE3":15574,"PHASE4":15576,"NA":15578},{"trials":15560,"activeCount":101},[],{"trials":15562,"activeCount":101},[],{"trials":15564,"activeCount":101},[15565],{"nctId":15566,"briefTitle":15567,"status":107,"phases":15568,"primaryCompletion":15569,"completion":7569,"start":15570,"enrollment":101,"conditions":15571,"interventions":15573},"NCT04880577","Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis",[90],"2024-02-14","2022-09-15",[15572,13063],"Multiple Sclerosis, Relapsing-Remitting",[15557],{"trials":15575,"activeCount":101},[],{"trials":15577,"activeCount":101},[],{"trials":15579,"activeCount":101},[],{"intervention":15581,"totalTrials":331,"cells":15582},"Purified Pancreatic Islets",{"EARLY_PHASE1":15583,"PHASE1":15585,"PHASE2":15587,"PHASE3":15595,"PHASE4":15597,"NA":15599},{"trials":15584,"activeCount":101},[],{"trials":15586,"activeCount":101},[],{"trials":15588,"activeCount":101},[15589],{"nctId":15590,"briefTitle":15591,"status":117,"phases":15592,"primaryCompletion":436,"completion":8798,"start":150,"enrollment":270,"conditions":15593,"interventions":15594},"NCT00888628","Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients",[89,90],[3055],[15581,14437],{"trials":15596,"activeCount":101},[],{"trials":15598,"activeCount":101},[],{"trials":15600,"activeCount":101},[],{"intervention":4516,"totalTrials":331,"cells":15602},{"EARLY_PHASE1":15603,"PHASE1":15605,"PHASE2":15607,"PHASE3":15613,"PHASE4":15615,"NA":15617},{"trials":15604,"activeCount":101},[],{"trials":15606,"activeCount":101},[],{"trials":15608,"activeCount":101},[15609],{"nctId":4506,"briefTitle":4507,"status":117,"phases":15610,"primaryCompletion":175,"completion":149,"start":2456,"enrollment":648,"conditions":15611,"interventions":15612},[90],[2030,4500,4510,4511,4512],[4514,4515,4516,4517,4518,200,4503],{"trials":15614,"activeCount":101},[],{"trials":15616,"activeCount":101},[],{"trials":15618,"activeCount":101},[],{"intervention":4517,"totalTrials":331,"cells":15620},{"EARLY_PHASE1":15621,"PHASE1":15623,"PHASE2":15625,"PHASE3":15631,"PHASE4":15633,"NA":15635},{"trials":15622,"activeCount":101},[],{"trials":15624,"activeCount":101},[],{"trials":15626,"activeCount":101},[15627],{"nctId":4506,"briefTitle":4507,"status":117,"phases":15628,"primaryCompletion":175,"completion":149,"start":2456,"enrollment":648,"conditions":15629,"interventions":15630},[90],[2030,4500,4510,4511,4512],[4514,4515,4516,4517,4518,200,4503],{"trials":15632,"activeCount":101},[],{"trials":15634,"activeCount":101},[],{"trials":15636,"activeCount":101},[],{"intervention":15638,"totalTrials":331,"cells":15639},"Inhaled nitric oxide gas",{"EARLY_PHASE1":15640,"PHASE1":15642,"PHASE2":15644,"PHASE3":15654,"PHASE4":15656,"NA":15658},{"trials":15641,"activeCount":101},[],{"trials":15643,"activeCount":101},[],{"trials":15645,"activeCount":101},[15646],{"nctId":15647,"briefTitle":15648,"status":173,"phases":15649,"primaryCompletion":2249,"completion":2249,"start":15650,"enrollment":886,"conditions":15651,"interventions":15653},"NCT04312243","NO Prevention of COVID-19 for Healthcare Providers",[90],"2020-04-07",[12019,15652],"Healthcare Associated Infection",[15638],{"trials":15655,"activeCount":101},[],{"trials":15657,"activeCount":101},[],{"trials":15659,"activeCount":101},[],{"intervention":3973,"totalTrials":331,"cells":15661},{"EARLY_PHASE1":15662,"PHASE1":15664,"PHASE2":15666,"PHASE3":15672,"PHASE4":15674,"NA":15676},{"trials":15663,"activeCount":101},[],{"trials":15665,"activeCount":101},[],{"trials":15667,"activeCount":101},[15668],{"nctId":3967,"briefTitle":3968,"status":2758,"phases":15669,"primaryCompletion":61,"completion":61,"start":134,"enrollment":227,"conditions":15670,"interventions":15671},[90],[3971],[3973,3958],{"trials":15673,"activeCount":101},[],{"trials":15675,"activeCount":101},[],{"trials":15677,"activeCount":101},[],{"intervention":15679,"totalTrials":331,"cells":15680},"Denosumab Q4W",{"EARLY_PHASE1":15681,"PHASE1":15683,"PHASE2":15685,"PHASE3":15694,"PHASE4":15696,"NA":15698},{"trials":15682,"activeCount":101},[],{"trials":15684,"activeCount":101},[],{"trials":15686,"activeCount":101},[15687],{"nctId":15688,"briefTitle":15689,"status":117,"phases":15690,"primaryCompletion":15691,"completion":15691,"start":8798,"enrollment":165,"conditions":15692,"interventions":15693},"NCT02833610","A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency",[90],"2023-03-20",[2030],[15679],{"trials":15695,"activeCount":101},[],{"trials":15697,"activeCount":101},[],{"trials":15699,"activeCount":101},[],{"intervention":15701,"totalTrials":331,"cells":15702},"BKM120",{"EARLY_PHASE1":15703,"PHASE1":15705,"PHASE2":15707,"PHASE3":15716,"PHASE4":15718,"NA":15720},{"trials":15704,"activeCount":101},[],{"trials":15706,"activeCount":101},[],{"trials":15708,"activeCount":101},[15709],{"nctId":15710,"briefTitle":15711,"status":107,"phases":15712,"primaryCompletion":14706,"completion":14706,"start":11914,"enrollment":101,"conditions":15713,"interventions":15715},"NCT01501604","BKM120 in Cancers With PIK3CA Activating Mutations",[90],[32,21,6511,4055,15714],"Solid Tumors",[15701],{"trials":15717,"activeCount":101},[],{"trials":15719,"activeCount":101},[],{"trials":15721,"activeCount":101},[],{"intervention":6729,"totalTrials":331,"cells":15723},{"EARLY_PHASE1":15724,"PHASE1":15726,"PHASE2":15728,"PHASE3":15734,"PHASE4":15736,"NA":15738},{"trials":15725,"activeCount":101},[],{"trials":15727,"activeCount":101},[],{"trials":15729,"activeCount":101},[15730],{"nctId":6718,"briefTitle":6719,"status":173,"phases":15731,"primaryCompletion":6721,"completion":6722,"start":6723,"enrollment":1509,"conditions":15732,"interventions":15733},[89,90],[6725,6726,6727],[6729,3576],{"trials":15735,"activeCount":101},[],{"trials":15737,"activeCount":101},[],{"trials":15739,"activeCount":101},[],{"intervention":15741,"totalTrials":331,"cells":15742},"Teduglutide",{"EARLY_PHASE1":15743,"PHASE1":15745,"PHASE2":15747,"PHASE3":15756,"PHASE4":15758,"NA":15760},{"trials":15744,"activeCount":101},[],{"trials":15746,"activeCount":101},[],{"trials":15748,"activeCount":101},[15749],{"nctId":15750,"briefTitle":15751,"status":117,"phases":15752,"primaryCompletion":8295,"completion":15753,"start":2800,"enrollment":648,"conditions":15754,"interventions":15755},"NCT02431325","A Study of the Gut Barrier and Blood Vessel Inflammation in Individuals With and Without HIV",[90],"2021-01-21",[1671],[15741],{"trials":15757,"activeCount":101},[],{"trials":15759,"activeCount":101},[],{"trials":15761,"activeCount":101},[],{"intervention":15763,"totalTrials":331,"cells":15764},"5-FU",{"EARLY_PHASE1":15765,"PHASE1":15767,"PHASE2":15769,"PHASE3":15778,"PHASE4":15780,"NA":15782},{"trials":15766,"activeCount":101},[],{"trials":15768,"activeCount":101},[],{"trials":15770,"activeCount":101},[15771],{"nctId":15772,"briefTitle":15773,"status":173,"phases":15774,"primaryCompletion":8137,"completion":2435,"start":3607,"enrollment":239,"conditions":15775,"interventions":15776},"NCT00948688","Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas",[89,90],[2748,4660],[15763,15777],"Vorinostat",{"trials":15779,"activeCount":101},[],{"trials":15781,"activeCount":101},[],{"trials":15783,"activeCount":101},[],{"intervention":15777,"totalTrials":331,"cells":15785},{"EARLY_PHASE1":15786,"PHASE1":15788,"PHASE2":15790,"PHASE3":15796,"PHASE4":15798,"NA":15800},{"trials":15787,"activeCount":101},[],{"trials":15789,"activeCount":101},[],{"trials":15791,"activeCount":101},[15792],{"nctId":15772,"briefTitle":15773,"status":173,"phases":15793,"primaryCompletion":8137,"completion":2435,"start":3607,"enrollment":239,"conditions":15794,"interventions":15795},[89,90],[2748,4660],[15763,15777],{"trials":15797,"activeCount":101},[],{"trials":15799,"activeCount":101},[],{"trials":15801,"activeCount":101},[],{"intervention":15803,"totalTrials":331,"cells":15804},"dex-methylphenidate",{"EARLY_PHASE1":15805,"PHASE1":15807,"PHASE2":15809,"PHASE3":15818,"PHASE4":15820,"NA":15822},{"trials":15806,"activeCount":101},[],{"trials":15808,"activeCount":101},[],{"trials":15810,"activeCount":101},[15811],{"nctId":15812,"briefTitle":15813,"status":117,"phases":15814,"primaryCompletion":4666,"completion":3078,"start":177,"enrollment":753,"conditions":15815,"interventions":15817},"NCT00593138","Study of Dopamine Transporter Receptor Occupancy With Long-acting Dex-methylphenidate",[89,90],[15816],"Drug Binding to DAT Receptors",[15803],{"trials":15819,"activeCount":101},[],{"trials":15821,"activeCount":101},[],{"trials":15823,"activeCount":101},[],{"intervention":13757,"totalTrials":331,"cells":15825},{"EARLY_PHASE1":15826,"PHASE1":15828,"PHASE2":15830,"PHASE3":15836,"PHASE4":15838,"NA":15840},{"trials":15827,"activeCount":101},[],{"trials":15829,"activeCount":101},[],{"trials":15831,"activeCount":101},[15832],{"nctId":13751,"briefTitle":13752,"status":173,"phases":15833,"primaryCompletion":61,"completion":13754,"start":9749,"enrollment":4618,"conditions":15834,"interventions":15835},[90],[32],[13757,13734],{"trials":15837,"activeCount":101},[],{"trials":15839,"activeCount":101},[],{"trials":15841,"activeCount":101},[],{"intervention":15843,"totalTrials":331,"cells":15844},"FMT",{"EARLY_PHASE1":15845,"PHASE1":15847,"PHASE2":15849,"PHASE3":15858,"PHASE4":15860,"NA":15862},{"trials":15846,"activeCount":101},[],{"trials":15848,"activeCount":101},[],{"trials":15850,"activeCount":101},[15851],{"nctId":15852,"briefTitle":15853,"status":117,"phases":15854,"primaryCompletion":15855,"completion":15855,"start":298,"enrollment":886,"conditions":15856,"interventions":15857},"NCT02530385","Fecal Microbiota Transplant for Improvement of Metabolism",[89,90],"2018-06-27",[26],[15843],{"trials":15859,"activeCount":101},[],{"trials":15861,"activeCount":101},[],{"trials":15863,"activeCount":101},[],{"intervention":15865,"totalTrials":331,"cells":15866},"Bavituximab",{"EARLY_PHASE1":15867,"PHASE1":15869,"PHASE2":15871,"PHASE3":15881,"PHASE4":15883,"NA":15885},{"trials":15868,"activeCount":101},[],{"trials":15870,"activeCount":101},[],{"trials":15872,"activeCount":101},[15873],{"nctId":15874,"briefTitle":15875,"status":117,"phases":15876,"primaryCompletion":15877,"completion":15877,"start":15878,"enrollment":33,"conditions":15879,"interventions":15880},"NCT03139916","Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma",[90],"2022-08-31","2017-09-13",[13574],[13789,15865],{"trials":15882,"activeCount":101},[],{"trials":15884,"activeCount":101},[],{"trials":15886,"activeCount":101},[],{"intervention":15888,"totalTrials":331,"cells":15889},"Zimberelimab",{"EARLY_PHASE1":15890,"PHASE1":15892,"PHASE2":15894,"PHASE3":15906,"PHASE4":15908,"NA":15910},{"trials":15891,"activeCount":101},[],{"trials":15893,"activeCount":101},[],{"trials":15895,"activeCount":101},[15896],{"nctId":15897,"briefTitle":15898,"status":107,"phases":15899,"primaryCompletion":162,"completion":2955,"start":6206,"enrollment":101,"conditions":15900,"interventions":15903},"NCT07283848","Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma",[90],[15901,15902],"Adenocarcinoma Stomach","Adenocarcinoma Gastroesophageal Junction",[15888,15904,15905],"Domvanalimab","FLOT",{"trials":15907,"activeCount":101},[],{"trials":15909,"activeCount":101},[],{"trials":15911,"activeCount":101},[],{"intervention":15904,"totalTrials":331,"cells":15913},{"EARLY_PHASE1":15914,"PHASE1":15916,"PHASE2":15918,"PHASE3":15924,"PHASE4":15926,"NA":15928},{"trials":15915,"activeCount":101},[],{"trials":15917,"activeCount":101},[],{"trials":15919,"activeCount":101},[15920],{"nctId":15897,"briefTitle":15898,"status":107,"phases":15921,"primaryCompletion":162,"completion":2955,"start":6206,"enrollment":101,"conditions":15922,"interventions":15923},[90],[15901,15902],[15888,15904,15905],{"trials":15925,"activeCount":101},[],{"trials":15927,"activeCount":101},[],{"trials":15929,"activeCount":101},[],{"intervention":15905,"totalTrials":331,"cells":15931},{"EARLY_PHASE1":15932,"PHASE1":15934,"PHASE2":15936,"PHASE3":15942,"PHASE4":15944,"NA":15946},{"trials":15933,"activeCount":101},[],{"trials":15935,"activeCount":101},[],{"trials":15937,"activeCount":101},[15938],{"nctId":15897,"briefTitle":15898,"status":107,"phases":15939,"primaryCompletion":162,"completion":2955,"start":6206,"enrollment":101,"conditions":15940,"interventions":15941},[90],[15901,15902],[15888,15904,15905],{"trials":15943,"activeCount":101},[],{"trials":15945,"activeCount":101},[],{"trials":15947,"activeCount":101},[],{"intervention":15949,"totalTrials":331,"cells":15950},"Chemotherapy, multiple agents",{"EARLY_PHASE1":15951,"PHASE1":15953,"PHASE2":15955,"PHASE3":15964,"PHASE4":15966,"NA":15968},{"trials":15952,"activeCount":101},[],{"trials":15954,"activeCount":101},[],{"trials":15956,"activeCount":101},[15957],{"nctId":15958,"briefTitle":15959,"status":117,"phases":15960,"primaryCompletion":10956,"completion":8722,"start":15961,"enrollment":13087,"conditions":15962,"interventions":15963},"NCT00157560","Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma",[90],"2000-12",[3610,3612,14772],[15949],{"trials":15965,"activeCount":101},[],{"trials":15967,"activeCount":101},[],{"trials":15969,"activeCount":101},[],{"intervention":15971,"totalTrials":331,"cells":15972},"Iressa",{"EARLY_PHASE1":15973,"PHASE1":15975,"PHASE2":15977,"PHASE3":15989,"PHASE4":15991,"NA":15993},{"trials":15974,"activeCount":101},[],{"trials":15976,"activeCount":101},[],{"trials":15978,"activeCount":101},[15979],{"nctId":15980,"briefTitle":15981,"status":117,"phases":15982,"primaryCompletion":8690,"completion":8690,"start":15983,"enrollment":4443,"conditions":15984,"interventions":15987},"NCT00181688","Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer",[90],"2003-10",[3610,15985,15986],"Peritoneal Carcinoma","Tubal Carcinoma",[15971,15988],"Arimidex",{"trials":15990,"activeCount":101},[],{"trials":15992,"activeCount":101},[],{"trials":15994,"activeCount":101},[],{"intervention":15988,"totalTrials":331,"cells":15996},{"EARLY_PHASE1":15997,"PHASE1":15999,"PHASE2":16001,"PHASE3":16007,"PHASE4":16009,"NA":16011},{"trials":15998,"activeCount":101},[],{"trials":16000,"activeCount":101},[],{"trials":16002,"activeCount":101},[16003],{"nctId":15980,"briefTitle":15981,"status":117,"phases":16004,"primaryCompletion":8690,"completion":8690,"start":15983,"enrollment":4443,"conditions":16005,"interventions":16006},[90],[3610,15985,15986],[15971,15988],{"trials":16008,"activeCount":101},[],{"trials":16010,"activeCount":101},[],{"trials":16012,"activeCount":101},[],{"intervention":3647,"totalTrials":331,"cells":16014},{"EARLY_PHASE1":16015,"PHASE1":16017,"PHASE2":16019,"PHASE3":16025,"PHASE4":16027,"NA":16029},{"trials":16016,"activeCount":101},[],{"trials":16018,"activeCount":101},[],{"trials":16020,"activeCount":101},[16021],{"nctId":3641,"briefTitle":3642,"status":117,"phases":16022,"primaryCompletion":1889,"completion":3644,"start":751,"enrollment":366,"conditions":16023,"interventions":16024},[89,90],[3610,3612,3611],[3520,3647,3648,3649],{"trials":16026,"activeCount":101},[],{"trials":16028,"activeCount":101},[],{"trials":16030,"activeCount":101},[],{"intervention":3649,"totalTrials":331,"cells":16032},{"EARLY_PHASE1":16033,"PHASE1":16035,"PHASE2":16037,"PHASE3":16043,"PHASE4":16045,"NA":16047},{"trials":16034,"activeCount":101},[],{"trials":16036,"activeCount":101},[],{"trials":16038,"activeCount":101},[16039],{"nctId":3641,"briefTitle":3642,"status":117,"phases":16040,"primaryCompletion":1889,"completion":3644,"start":751,"enrollment":366,"conditions":16041,"interventions":16042},[89,90],[3610,3612,3611],[3520,3647,3648,3649],{"trials":16044,"activeCount":101},[],{"trials":16046,"activeCount":101},[],{"trials":16048,"activeCount":101},[],{"intervention":16050,"totalTrials":331,"cells":16051},"panitumumab, epirubicin, oxaliplatin, xeloda",{"EARLY_PHASE1":16052,"PHASE1":16054,"PHASE2":16056,"PHASE3":16066,"PHASE4":16068,"NA":16070},{"trials":16053,"activeCount":101},[],{"trials":16055,"activeCount":101},[],{"trials":16057,"activeCount":101},[16058],{"nctId":16059,"briefTitle":16060,"status":173,"phases":16061,"primaryCompletion":4464,"completion":309,"start":708,"enrollment":97,"conditions":16062,"interventions":16065},"NCT00667420","Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma",[89,90],[16063,16064],"Esophageal Adenocarcinoma","Gastric Adenocarcinoma",[16050],{"trials":16067,"activeCount":101},[],{"trials":16069,"activeCount":101},[],{"trials":16071,"activeCount":101},[],{"intervention":16073,"totalTrials":331,"cells":16074},"L-Threonic Acid Magnesium Salt",{"EARLY_PHASE1":16075,"PHASE1":16077,"PHASE2":16079,"PHASE3":16087,"PHASE4":16089,"NA":16091},{"trials":16076,"activeCount":101},[],{"trials":16078,"activeCount":101},[],{"trials":16080,"activeCount":101},[16081],{"nctId":16082,"briefTitle":16083,"status":117,"phases":16084,"primaryCompletion":4379,"completion":4379,"start":1846,"enrollment":194,"conditions":16085,"interventions":16086},"NCT02558790","L-Threonic Acid Magnesium Salt (L-TAMS) in ADHD",[90],[1938,6706],[16073],{"trials":16088,"activeCount":101},[],{"trials":16090,"activeCount":101},[],{"trials":16092,"activeCount":101},[],{"intervention":6624,"totalTrials":331,"cells":16094},{"EARLY_PHASE1":16095,"PHASE1":16097,"PHASE2":16099,"PHASE3":16105,"PHASE4":16107,"NA":16109},{"trials":16096,"activeCount":101},[],{"trials":16098,"activeCount":101},[],{"trials":16100,"activeCount":101},[16101],{"nctId":6612,"briefTitle":6613,"status":117,"phases":16102,"primaryCompletion":6615,"completion":6616,"start":6617,"enrollment":22,"conditions":16103,"interventions":16104},[90],[6619,26,6620,6621,6622],[6590,6624],{"trials":16106,"activeCount":101},[],{"trials":16108,"activeCount":101},[],{"trials":16110,"activeCount":101},[],{"intervention":16112,"totalTrials":331,"cells":16113},"Dexmedetomidine \u002F Ketamine \u002F Lidocaine",{"EARLY_PHASE1":16114,"PHASE1":16116,"PHASE2":16118,"PHASE3":16128,"PHASE4":16130,"NA":16132},{"trials":16115,"activeCount":101},[],{"trials":16117,"activeCount":101},[],{"trials":16119,"activeCount":101},[16120],{"nctId":16121,"briefTitle":16122,"status":117,"phases":16123,"primaryCompletion":16124,"completion":16124,"start":6853,"enrollment":1578,"conditions":16125,"interventions":16127},"NCT04724759","The Effect of Opioid-Free Anesthesia in TMJ Surgery",[90],"2023-04-23",[16126],"Temporomandibular Joint Disorders",[16112],{"trials":16129,"activeCount":101},[],{"trials":16131,"activeCount":101},[],{"trials":16133,"activeCount":101},[],{"intervention":16135,"totalTrials":331,"cells":16136},"Sarilumab",{"EARLY_PHASE1":16137,"PHASE1":16139,"PHASE2":16141,"PHASE3":16151,"PHASE4":16153,"NA":16155},{"trials":16138,"activeCount":101},[],{"trials":16140,"activeCount":101},[],{"trials":16142,"activeCount":101},[16143],{"nctId":16144,"briefTitle":16145,"status":107,"phases":16146,"primaryCompletion":16147,"completion":16147,"start":208,"enrollment":101,"conditions":16148,"interventions":16150},"NCT03679845","Study to Assess Sarilumab in Halting Progression of Morphea",[89,90],"2021-06-30",[16149],"Morphea, Plaque Form",[16135],{"trials":16152,"activeCount":101},[],{"trials":16154,"activeCount":101},[],{"trials":16156,"activeCount":101},[],{"intervention":16158,"totalTrials":331,"cells":16159},"GW468816",{"EARLY_PHASE1":16160,"PHASE1":16162,"PHASE2":16164,"PHASE3":16173,"PHASE4":16175,"NA":16177},{"trials":16161,"activeCount":101},[],{"trials":16163,"activeCount":101},[],{"trials":16165,"activeCount":101},[16166],{"nctId":16167,"briefTitle":16168,"status":117,"phases":16169,"primaryCompletion":397,"completion":397,"start":4463,"enrollment":16170,"conditions":16171,"interventions":16172},"NCT00218465","Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking",[90],264,[1947],[16158],{"trials":16174,"activeCount":101},[],{"trials":16176,"activeCount":101},[],{"trials":16178,"activeCount":101},[],{"intervention":16180,"totalTrials":331,"cells":16181},"Typically consists of at least one FDA-approved mood stabilizer",{"EARLY_PHASE1":16182,"PHASE1":16184,"PHASE2":16186,"PHASE3":16195,"PHASE4":16197,"NA":16199},{"trials":16183,"activeCount":101},[],{"trials":16185,"activeCount":101},[],{"trials":16187,"activeCount":101},[16188],{"nctId":16189,"briefTitle":16190,"status":117,"phases":16191,"primaryCompletion":13306,"completion":13306,"start":16192,"enrollment":6796,"conditions":16193,"interventions":16194},"NCT01615367","Nutrition, Exercise, and Wellness Treatment (NEW Tx) for Bipolar Disorder",[89,90],"2012-05-21",[24],[16180],{"trials":16196,"activeCount":101},[],{"trials":16198,"activeCount":101},[],{"trials":16200,"activeCount":101},[],{"intervention":3746,"totalTrials":331,"cells":16202},{"EARLY_PHASE1":16203,"PHASE1":16205,"PHASE2":16207,"PHASE3":16213,"PHASE4":16215,"NA":16217},{"trials":16204,"activeCount":101},[],{"trials":16206,"activeCount":101},[],{"trials":16208,"activeCount":101},[16209],{"nctId":3738,"briefTitle":3739,"status":117,"phases":16210,"primaryCompletion":3741,"completion":3741,"start":3742,"enrollment":413,"conditions":16211,"interventions":16212},[89,90],[2527,3744],[3746,3478],{"trials":16214,"activeCount":101},[],{"trials":16216,"activeCount":101},[],{"trials":16218,"activeCount":101},[],{"intervention":16220,"totalTrials":331,"cells":16221},"Paroxetine-CR",{"EARLY_PHASE1":16222,"PHASE1":16224,"PHASE2":16226,"PHASE3":16234,"PHASE4":16236,"NA":16238},{"trials":16223,"activeCount":101},[],{"trials":16225,"activeCount":101},[],{"trials":16227,"activeCount":101},[16228],{"nctId":16229,"briefTitle":16230,"status":117,"phases":16231,"completion":3516,"start":11151,"enrollment":1578,"conditions":16232,"interventions":16233},"NCT00121888","Trial of Paroxetine-CR for the Treatment of Patients With Post Traumatic Stress Disorder Remaining Symptomatic After Initial Exposure Therapy",[89,90],[734],[16220],{"trials":16235,"activeCount":101},[],{"trials":16237,"activeCount":101},[],{"trials":16239,"activeCount":101},[],{"intervention":16241,"totalTrials":331,"cells":16242},"Isradipine",{"EARLY_PHASE1":16243,"PHASE1":16245,"PHASE2":16247,"PHASE3":16255,"PHASE4":16257,"NA":16259},{"trials":16244,"activeCount":101},[],{"trials":16246,"activeCount":101},[],{"trials":16248,"activeCount":101},[16249],{"nctId":16250,"briefTitle":16251,"status":173,"phases":16252,"primaryCompletion":455,"completion":455,"start":4617,"enrollment":136,"conditions":16253,"interventions":16254},"NCT01784666","Adjunctive Isradipine for the Treatment of Bipolar Depression",[90],[24],[16241],{"trials":16256,"activeCount":101},[],{"trials":16258,"activeCount":101},[],{"trials":16260,"activeCount":101},[],{"intervention":16262,"totalTrials":331,"cells":16263},"Intravenous Acetaminophen",{"EARLY_PHASE1":16264,"PHASE1":16266,"PHASE2":16268,"PHASE3":16283,"PHASE4":16285,"NA":16287},{"trials":16265,"activeCount":101},[],{"trials":16267,"activeCount":101},[],{"trials":16269,"activeCount":101},[16270],{"nctId":16271,"briefTitle":16272,"status":117,"phases":16273,"primaryCompletion":16274,"completion":16275,"start":16276,"enrollment":16277,"conditions":16278,"interventions":16279},"NCT04291508","Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery",[90],"2023-04-27","2023-07-27","2021-10-13",488,[12021,7904,10578,12128],[16262,16280,16281,16282],"Intravenous Vitamin C","5% Dextrose","5% Dextrose refrigerated",{"trials":16284,"activeCount":101},[],{"trials":16286,"activeCount":101},[],{"trials":16288,"activeCount":101},[],{"intervention":16280,"totalTrials":331,"cells":16290},{"EARLY_PHASE1":16291,"PHASE1":16293,"PHASE2":16295,"PHASE3":16301,"PHASE4":16303,"NA":16305},{"trials":16292,"activeCount":101},[],{"trials":16294,"activeCount":101},[],{"trials":16296,"activeCount":101},[16297],{"nctId":16271,"briefTitle":16272,"status":117,"phases":16298,"primaryCompletion":16274,"completion":16275,"start":16276,"enrollment":16277,"conditions":16299,"interventions":16300},[90],[12021,7904,10578,12128],[16262,16280,16281,16282],{"trials":16302,"activeCount":101},[],{"trials":16304,"activeCount":101},[],{"trials":16306,"activeCount":101},[],{"intervention":16281,"totalTrials":331,"cells":16308},{"EARLY_PHASE1":16309,"PHASE1":16311,"PHASE2":16313,"PHASE3":16319,"PHASE4":16321,"NA":16323},{"trials":16310,"activeCount":101},[],{"trials":16312,"activeCount":101},[],{"trials":16314,"activeCount":101},[16315],{"nctId":16271,"briefTitle":16272,"status":117,"phases":16316,"primaryCompletion":16274,"completion":16275,"start":16276,"enrollment":16277,"conditions":16317,"interventions":16318},[90],[12021,7904,10578,12128],[16262,16280,16281,16282],{"trials":16320,"activeCount":101},[],{"trials":16322,"activeCount":101},[],{"trials":16324,"activeCount":101},[],{"intervention":16282,"totalTrials":331,"cells":16326},{"EARLY_PHASE1":16327,"PHASE1":16329,"PHASE2":16331,"PHASE3":16337,"PHASE4":16339,"NA":16341},{"trials":16328,"activeCount":101},[],{"trials":16330,"activeCount":101},[],{"trials":16332,"activeCount":101},[16333],{"nctId":16271,"briefTitle":16272,"status":117,"phases":16334,"primaryCompletion":16274,"completion":16275,"start":16276,"enrollment":16277,"conditions":16335,"interventions":16336},[90],[12021,7904,10578,12128],[16262,16280,16281,16282],{"trials":16338,"activeCount":101},[],{"trials":16340,"activeCount":101},[],{"trials":16342,"activeCount":101},[],{"intervention":16344,"totalTrials":331,"cells":16345},"TAS-102",{"EARLY_PHASE1":16346,"PHASE1":16348,"PHASE2":16350,"PHASE3":16360,"PHASE4":16362,"NA":16364},{"trials":16347,"activeCount":101},[],{"trials":16349,"activeCount":101},[],{"trials":16351,"activeCount":101},[16352],{"nctId":16353,"briefTitle":16354,"status":117,"phases":16355,"primaryCompletion":377,"completion":16356,"start":16357,"enrollment":2663,"conditions":16358,"interventions":16359},"NCT03223779","Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer",[89,90],"2025-10-02","2017-10-13",[6511],[16344],{"trials":16361,"activeCount":101},[],{"trials":16363,"activeCount":101},[],{"trials":16365,"activeCount":101},[],{"intervention":2529,"totalTrials":331,"cells":16367},{"EARLY_PHASE1":16368,"PHASE1":16370,"PHASE2":16372,"PHASE3":16378,"PHASE4":16380,"NA":16382},{"trials":16369,"activeCount":101},[],{"trials":16371,"activeCount":101},[],{"trials":16373,"activeCount":101},[16374],{"nctId":2521,"briefTitle":2522,"status":107,"phases":16375,"primaryCompletion":2524,"completion":2524,"start":2525,"enrollment":101,"conditions":16376,"interventions":16377},[90],[2527],[2529,57],{"trials":16379,"activeCount":101},[],{"trials":16381,"activeCount":101},[],{"trials":16383,"activeCount":101},[],{"intervention":14228,"totalTrials":331,"cells":16385},{"EARLY_PHASE1":16386,"PHASE1":16388,"PHASE2":16390,"PHASE3":16396,"PHASE4":16398,"NA":16400},{"trials":16387,"activeCount":101},[],{"trials":16389,"activeCount":101},[],{"trials":16391,"activeCount":101},[16392],{"nctId":14217,"briefTitle":14218,"status":2758,"phases":16393,"primaryCompletion":3915,"completion":6442,"start":14220,"enrollment":9,"conditions":16394,"interventions":16395},[89,90],[32,14222,14223,2646,14224,14225,14226],[14201,14228,14229,14230],{"trials":16397,"activeCount":101},[],{"trials":16399,"activeCount":101},[],{"trials":16401,"activeCount":101},[],{"intervention":14229,"totalTrials":331,"cells":16403},{"EARLY_PHASE1":16404,"PHASE1":16406,"PHASE2":16408,"PHASE3":16414,"PHASE4":16416,"NA":16418},{"trials":16405,"activeCount":101},[],{"trials":16407,"activeCount":101},[],{"trials":16409,"activeCount":101},[16410],{"nctId":14217,"briefTitle":14218,"status":2758,"phases":16411,"primaryCompletion":3915,"completion":6442,"start":14220,"enrollment":9,"conditions":16412,"interventions":16413},[89,90],[32,14222,14223,2646,14224,14225,14226],[14201,14228,14229,14230],{"trials":16415,"activeCount":101},[],{"trials":16417,"activeCount":101},[],{"trials":16419,"activeCount":101},[],{"intervention":14230,"totalTrials":331,"cells":16421},{"EARLY_PHASE1":16422,"PHASE1":16424,"PHASE2":16426,"PHASE3":16432,"PHASE4":16434,"NA":16436},{"trials":16423,"activeCount":101},[],{"trials":16425,"activeCount":101},[],{"trials":16427,"activeCount":101},[16428],{"nctId":14217,"briefTitle":14218,"status":2758,"phases":16429,"primaryCompletion":3915,"completion":6442,"start":14220,"enrollment":9,"conditions":16430,"interventions":16431},[89,90],[32,14222,14223,2646,14224,14225,14226],[14201,14228,14229,14230],{"trials":16433,"activeCount":101},[],{"trials":16435,"activeCount":101},[],{"trials":16437,"activeCount":101},[],{"intervention":2732,"totalTrials":331,"cells":16439},{"EARLY_PHASE1":16440,"PHASE1":16442,"PHASE2":16444,"PHASE3":16450,"PHASE4":16452,"NA":16454},{"trials":16441,"activeCount":101},[],{"trials":16443,"activeCount":101},[],{"trials":16445,"activeCount":101},[16446],{"nctId":2723,"briefTitle":2724,"status":173,"phases":16447,"primaryCompletion":2726,"completion":2726,"start":2727,"enrollment":2728,"conditions":16448,"interventions":16449},[90],[2730],[81,2732],{"trials":16451,"activeCount":101},[],{"trials":16453,"activeCount":101},[],{"trials":16455,"activeCount":101},[],{"intervention":16457,"totalTrials":331,"cells":16458},"Botulinum Toxin-A",{"EARLY_PHASE1":16459,"PHASE1":16461,"PHASE2":16463,"PHASE3":16473,"PHASE4":16475,"NA":16477},{"trials":16460,"activeCount":101},[],{"trials":16462,"activeCount":101},[],{"trials":16464,"activeCount":101},[16465],{"nctId":16466,"briefTitle":16467,"status":173,"phases":16468,"primaryCompletion":16469,"completion":16469,"start":554,"enrollment":331,"conditions":16470,"interventions":16472},"NCT02160288","Effects of Botox in Obstructed Defecation Syndrome",[90],"2019-06-11",[16471],"Obstructed Defecation Syndrome (ODS)",[16457,13667],{"trials":16474,"activeCount":101},[],{"trials":16476,"activeCount":101},[],{"trials":16478,"activeCount":101},[],{"intervention":16480,"totalTrials":331,"cells":16481},"BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD",{"EARLY_PHASE1":16482,"PHASE1":16484,"PHASE2":16486,"PHASE3":16496,"PHASE4":16498,"NA":16500},{"trials":16483,"activeCount":101},[],{"trials":16485,"activeCount":101},[],{"trials":16487,"activeCount":101},[16488],{"nctId":16489,"briefTitle":16490,"status":117,"phases":16491,"primaryCompletion":9865,"completion":9865,"start":740,"enrollment":16492,"conditions":16493,"interventions":16494},"NCT00705003","Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)",[90],142,[18],[16480,16495],"BCI-024",{"trials":16497,"activeCount":101},[],{"trials":16499,"activeCount":101},[],{"trials":16501,"activeCount":101},[],{"intervention":16495,"totalTrials":331,"cells":16503},{"EARLY_PHASE1":16504,"PHASE1":16506,"PHASE2":16508,"PHASE3":16514,"PHASE4":16516,"NA":16518},{"trials":16505,"activeCount":101},[],{"trials":16507,"activeCount":101},[],{"trials":16509,"activeCount":101},[16510],{"nctId":16489,"briefTitle":16490,"status":117,"phases":16511,"primaryCompletion":9865,"completion":9865,"start":740,"enrollment":16492,"conditions":16512,"interventions":16513},[90],[18],[16480,16495],{"trials":16515,"activeCount":101},[],{"trials":16517,"activeCount":101},[],{"trials":16519,"activeCount":101},[],{"intervention":13841,"totalTrials":331,"cells":16521},{"EARLY_PHASE1":16522,"PHASE1":16524,"PHASE2":16526,"PHASE3":16532,"PHASE4":16534,"NA":16536},{"trials":16523,"activeCount":101},[],{"trials":16525,"activeCount":101},[],{"trials":16527,"activeCount":101},[16528],{"nctId":13831,"briefTitle":13832,"status":117,"phases":16529,"primaryCompletion":13834,"completion":13834,"start":2847,"enrollment":6796,"conditions":16530,"interventions":16531},[89,90],[13836,13837,13838],[13840,13841,13842],{"trials":16533,"activeCount":101},[],{"trials":16535,"activeCount":101},[],{"trials":16537,"activeCount":101},[],{"intervention":13842,"totalTrials":331,"cells":16539},{"EARLY_PHASE1":16540,"PHASE1":16542,"PHASE2":16544,"PHASE3":16550,"PHASE4":16552,"NA":16554},{"trials":16541,"activeCount":101},[],{"trials":16543,"activeCount":101},[],{"trials":16545,"activeCount":101},[16546],{"nctId":13831,"briefTitle":13832,"status":117,"phases":16547,"primaryCompletion":13834,"completion":13834,"start":2847,"enrollment":6796,"conditions":16548,"interventions":16549},[89,90],[13836,13837,13838],[13840,13841,13842],{"trials":16551,"activeCount":101},[],{"trials":16553,"activeCount":101},[],{"trials":16555,"activeCount":101},[],{"intervention":16557,"totalTrials":331,"cells":16558},"L-serine",{"EARLY_PHASE1":16559,"PHASE1":16561,"PHASE2":16563,"PHASE3":16572,"PHASE4":16574,"NA":16576},{"trials":16560,"activeCount":101},[],{"trials":16562,"activeCount":101},[],{"trials":16564,"activeCount":101},[16565],{"nctId":16566,"briefTitle":16567,"status":117,"phases":16568,"primaryCompletion":46,"completion":3644,"start":627,"enrollment":209,"conditions":16569,"interventions":16571},"NCT01733407","L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1",[89,90],[16570],"Hereditary Sensory and Autonomic Neuropathy Type I",[16557],{"trials":16573,"activeCount":101},[],{"trials":16575,"activeCount":101},[],{"trials":16577,"activeCount":101},[],{"intervention":16579,"totalTrials":331,"cells":16580},"Omega-3 Fatty Acid",{"EARLY_PHASE1":16581,"PHASE1":16583,"PHASE2":16585,"PHASE3":16593,"PHASE4":16595,"NA":16597},{"trials":16582,"activeCount":101},[],{"trials":16584,"activeCount":101},[],{"trials":16586,"activeCount":101},[16587],{"nctId":16588,"briefTitle":16589,"status":173,"phases":16590,"primaryCompletion":626,"completion":626,"start":2847,"enrollment":270,"conditions":16591,"interventions":16592},"NCT01248130","Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders",[90],[479],[16579],{"trials":16594,"activeCount":101},[],{"trials":16596,"activeCount":101},[],{"trials":16598,"activeCount":101},[],{"intervention":4536,"totalTrials":331,"cells":16600},{"EARLY_PHASE1":16601,"PHASE1":16603,"PHASE2":16605,"PHASE3":16611,"PHASE4":16613,"NA":16615},{"trials":16602,"activeCount":101},[],{"trials":16604,"activeCount":101},[],{"trials":16606,"activeCount":101},[16607],{"nctId":4524,"briefTitle":4525,"status":117,"phases":16608,"primaryCompletion":4527,"completion":554,"start":751,"enrollment":3565,"conditions":16609,"interventions":16610},[90],[4529,4530,4531,4532,4501,123,4533],[4535,2806,201,4536,4537,200,4535,4514,4515,3789],{"trials":16612,"activeCount":101},[],{"trials":16614,"activeCount":101},[],{"trials":16616,"activeCount":101},[],{"intervention":4537,"totalTrials":331,"cells":16618},{"EARLY_PHASE1":16619,"PHASE1":16621,"PHASE2":16623,"PHASE3":16629,"PHASE4":16631,"NA":16633},{"trials":16620,"activeCount":101},[],{"trials":16622,"activeCount":101},[],{"trials":16624,"activeCount":101},[16625],{"nctId":4524,"briefTitle":4525,"status":117,"phases":16626,"primaryCompletion":4527,"completion":554,"start":751,"enrollment":3565,"conditions":16627,"interventions":16628},[90],[4529,4530,4531,4532,4501,123,4533],[4535,2806,201,4536,4537,200,4535,4514,4515,3789],{"trials":16630,"activeCount":101},[],{"trials":16632,"activeCount":101},[],{"trials":16634,"activeCount":101},[],{"intervention":16636,"totalTrials":331,"cells":16637},"neseritide",{"EARLY_PHASE1":16638,"PHASE1":16640,"PHASE2":16642,"PHASE3":16651,"PHASE4":16653,"NA":16655},{"trials":16639,"activeCount":101},[],{"trials":16641,"activeCount":101},[],{"trials":16643,"activeCount":101},[16644],{"nctId":16645,"briefTitle":16646,"status":117,"phases":16647,"primaryCompletion":8723,"completion":8723,"start":11151,"enrollment":194,"conditions":16648,"interventions":16650},"NCT00309868","Study of Nesiritide in Diastolic Heart Failure.",[89,90],[16649],"Diastolic Heart Failure",[16636],{"trials":16652,"activeCount":101},[],{"trials":16654,"activeCount":101},[],{"trials":16656,"activeCount":101},[],{"intervention":219,"totalTrials":331,"cells":16658},{"EARLY_PHASE1":16659,"PHASE1":16661,"PHASE2":16663,"PHASE3":16669,"PHASE4":16671,"NA":16673},{"trials":16660,"activeCount":101},[],{"trials":16662,"activeCount":101},[],{"trials":16664,"activeCount":101},[16665],{"nctId":204,"briefTitle":205,"status":173,"phases":16666,"primaryCompletion":207,"completion":207,"start":208,"enrollment":209,"conditions":16667,"interventions":16668},[90],[211,212,213,214,215,216,217],[219,96],{"trials":16670,"activeCount":101},[],{"trials":16672,"activeCount":101},[],{"trials":16674,"activeCount":101},[],{"intervention":14145,"totalTrials":331,"cells":16676},{"EARLY_PHASE1":16677,"PHASE1":16679,"PHASE2":16681,"PHASE3":16687,"PHASE4":16689,"NA":16691},{"trials":16678,"activeCount":101},[],{"trials":16680,"activeCount":101},[],{"trials":16682,"activeCount":101},[16683],{"nctId":14138,"briefTitle":14139,"status":117,"phases":16684,"primaryCompletion":14141,"completion":3491,"start":11429,"enrollment":8836,"conditions":16685,"interventions":16686},[90],[4500,4501,2030,14143],[3803,14145],{"trials":16688,"activeCount":101},[],{"trials":16690,"activeCount":101},[],{"trials":16692,"activeCount":101},[],{"intervention":16694,"totalTrials":331,"cells":16695},"Enbrel",{"EARLY_PHASE1":16696,"PHASE1":16698,"PHASE2":16700,"PHASE3":16709,"PHASE4":16711,"NA":16713},{"trials":16697,"activeCount":101},[],{"trials":16699,"activeCount":101},[],{"trials":16701,"activeCount":101},[16702],{"nctId":16703,"briefTitle":16704,"status":117,"phases":16705,"completion":175,"start":8611,"enrollment":1791,"conditions":16706,"interventions":16708},"NCT00135720","Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris",[90],[16707],"Pemphigus Vulgaris",[16694],{"trials":16710,"activeCount":101},[],{"trials":16712,"activeCount":101},[],{"trials":16714,"activeCount":101},[],{"intervention":13943,"totalTrials":331,"cells":16716},{"EARLY_PHASE1":16717,"PHASE1":16719,"PHASE2":16721,"PHASE3":16727,"PHASE4":16729,"NA":16731},{"trials":16718,"activeCount":101},[],{"trials":16720,"activeCount":101},[],{"trials":16722,"activeCount":101},[16723],{"nctId":13936,"briefTitle":13937,"status":173,"phases":16724,"primaryCompletion":397,"completion":397,"start":13746,"enrollment":13939,"conditions":16725,"interventions":16726},[90],[13941],[13943,13944],{"trials":16728,"activeCount":101},[],{"trials":16730,"activeCount":101},[],{"trials":16732,"activeCount":101},[],{"intervention":16734,"totalTrials":331,"cells":16735},"Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System",{"EARLY_PHASE1":16736,"PHASE1":16738,"PHASE2":16740,"PHASE3":16748,"PHASE4":16750,"NA":16752},{"trials":16737,"activeCount":101},[],{"trials":16739,"activeCount":101},[],{"trials":16741,"activeCount":101},[16742],{"nctId":16743,"briefTitle":16744,"status":173,"phases":16745,"primaryCompletion":121,"completion":2446,"start":2848,"enrollment":544,"conditions":16746,"interventions":16747},"NCT00706784","Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System Study",[89,90],[29],[16734],{"trials":16749,"activeCount":101},[],{"trials":16751,"activeCount":101},[],{"trials":16753,"activeCount":101},[],{"intervention":16755,"totalTrials":331,"cells":16756},"Fecal Inoculum",{"EARLY_PHASE1":16757,"PHASE1":16759,"PHASE2":16761,"PHASE3":16773,"PHASE4":16775,"NA":16777},{"trials":16758,"activeCount":101},[],{"trials":16760,"activeCount":101},[],{"trials":16762,"activeCount":101},[16763],{"nctId":16764,"briefTitle":16765,"status":107,"phases":16766,"primaryCompletion":283,"completion":16767,"start":282,"enrollment":101,"conditions":16768,"interventions":16770},"NCT03163784","SHIFT: Studying HIV Immunology After Fecal Transplant",[89,90],"2022-06",[14836,16769,821],"Dysbiosis",[16755,16771,16772],"Antibiotic","Antibiotic Placebo",{"trials":16774,"activeCount":101},[],{"trials":16776,"activeCount":101},[],{"trials":16778,"activeCount":101},[],{"intervention":16771,"totalTrials":331,"cells":16780},{"EARLY_PHASE1":16781,"PHASE1":16783,"PHASE2":16785,"PHASE3":16791,"PHASE4":16793,"NA":16795},{"trials":16782,"activeCount":101},[],{"trials":16784,"activeCount":101},[],{"trials":16786,"activeCount":101},[16787],{"nctId":16764,"briefTitle":16765,"status":107,"phases":16788,"primaryCompletion":283,"completion":16767,"start":282,"enrollment":101,"conditions":16789,"interventions":16790},[89,90],[14836,16769,821],[16755,16771,16772],{"trials":16792,"activeCount":101},[],{"trials":16794,"activeCount":101},[],{"trials":16796,"activeCount":101},[],{"intervention":16772,"totalTrials":331,"cells":16798},{"EARLY_PHASE1":16799,"PHASE1":16801,"PHASE2":16803,"PHASE3":16809,"PHASE4":16811,"NA":16813},{"trials":16800,"activeCount":101},[],{"trials":16802,"activeCount":101},[],{"trials":16804,"activeCount":101},[16805],{"nctId":16764,"briefTitle":16765,"status":107,"phases":16806,"primaryCompletion":283,"completion":16767,"start":282,"enrollment":101,"conditions":16807,"interventions":16808},[89,90],[14836,16769,821],[16755,16771,16772],{"trials":16810,"activeCount":101},[],{"trials":16812,"activeCount":101},[],{"trials":16814,"activeCount":101},[],{"intervention":16816,"totalTrials":331,"cells":16817},"M6620",{"EARLY_PHASE1":16818,"PHASE1":16820,"PHASE2":16822,"PHASE3":16834,"PHASE4":16836,"NA":16838},{"trials":16819,"activeCount":101},[],{"trials":16821,"activeCount":101},[],{"trials":16823,"activeCount":101},[16824],{"nctId":16825,"briefTitle":16826,"status":117,"phases":16827,"primaryCompletion":16828,"completion":16829,"start":16830,"enrollment":227,"conditions":16831,"interventions":16833},"NCT03718091","M6620 (VX-970) in Selected Solid Tumors",[90],"2020-06-01","2020-07-08","2019-01-08",[2486,6905,16832],"Osteosarcoma",[16816],{"trials":16835,"activeCount":101},[],{"trials":16837,"activeCount":101},[],{"trials":16839,"activeCount":101},[],{"intervention":7078,"totalTrials":331,"cells":16841},{"EARLY_PHASE1":16842,"PHASE1":16844,"PHASE2":16846,"PHASE3":16852,"PHASE4":16854,"NA":16856},{"trials":16843,"activeCount":101},[],{"trials":16845,"activeCount":101},[],{"trials":16847,"activeCount":101},[16848],{"nctId":7067,"briefTitle":7068,"status":107,"phases":16849,"primaryCompletion":7070,"completion":7071,"start":7072,"enrollment":101,"conditions":16850,"interventions":16851},[90],[7074,2474,7075,7076,2549,2546],[7078,7079],{"trials":16853,"activeCount":101},[],{"trials":16855,"activeCount":101},[],{"trials":16857,"activeCount":101},[],{"intervention":16859,"totalTrials":331,"cells":16860},"testosterone cypionate",{"EARLY_PHASE1":16861,"PHASE1":16863,"PHASE2":16865,"PHASE3":16874,"PHASE4":16876,"NA":16878},{"trials":16862,"activeCount":101},[],{"trials":16864,"activeCount":101},[],{"trials":16866,"activeCount":101},[16867],{"nctId":16868,"briefTitle":16869,"status":107,"phases":16870,"primaryCompletion":2581,"completion":2581,"start":9865,"enrollment":101,"conditions":16871,"interventions":16873},"NCT00853502","The Effect of Testosterone Replacement on Bone Mineral Density in Boys and Men With Anorexia Nervosa",[90],[16872],"Bone Metabolism",[16859],{"trials":16875,"activeCount":101},[],{"trials":16877,"activeCount":101},[],{"trials":16879,"activeCount":101},[],{"intervention":16881,"totalTrials":331,"cells":16882},"Fentanyl",{"EARLY_PHASE1":16883,"PHASE1":16885,"PHASE2":16887,"PHASE3":16898,"PHASE4":16900,"NA":16902},{"trials":16884,"activeCount":101},[],{"trials":16886,"activeCount":101},[],{"trials":16888,"activeCount":101},[16889],{"nctId":16890,"briefTitle":16891,"status":117,"phases":16892,"primaryCompletion":3658,"completion":3658,"start":4658,"enrollment":1578,"conditions":16893,"interventions":16895},"NCT00685295","Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain",[89,90],[16894],"Pain, Fracture, Sprain",[16881,16896,16897],"Lansoprazole","Oxycodone",{"trials":16899,"activeCount":101},[],{"trials":16901,"activeCount":101},[],{"trials":16903,"activeCount":101},[],{"intervention":16896,"totalTrials":331,"cells":16905},{"EARLY_PHASE1":16906,"PHASE1":16908,"PHASE2":16910,"PHASE3":16916,"PHASE4":16918,"NA":16920},{"trials":16907,"activeCount":101},[],{"trials":16909,"activeCount":101},[],{"trials":16911,"activeCount":101},[16912],{"nctId":16890,"briefTitle":16891,"status":117,"phases":16913,"primaryCompletion":3658,"completion":3658,"start":4658,"enrollment":1578,"conditions":16914,"interventions":16915},[89,90],[16894],[16881,16896,16897],{"trials":16917,"activeCount":101},[],{"trials":16919,"activeCount":101},[],{"trials":16921,"activeCount":101},[],{"intervention":16897,"totalTrials":331,"cells":16923},{"EARLY_PHASE1":16924,"PHASE1":16926,"PHASE2":16928,"PHASE3":16934,"PHASE4":16936,"NA":16938},{"trials":16925,"activeCount":101},[],{"trials":16927,"activeCount":101},[],{"trials":16929,"activeCount":101},[16930],{"nctId":16890,"briefTitle":16891,"status":117,"phases":16931,"primaryCompletion":3658,"completion":3658,"start":4658,"enrollment":1578,"conditions":16932,"interventions":16933},[89,90],[16894],[16881,16896,16897],{"trials":16935,"activeCount":101},[],{"trials":16937,"activeCount":101},[],{"trials":16939,"activeCount":101},[],{"intervention":14435,"totalTrials":331,"cells":16941},{"EARLY_PHASE1":16942,"PHASE1":16944,"PHASE2":16946,"PHASE3":16952,"PHASE4":16954,"NA":16956},{"trials":16943,"activeCount":101},[],{"trials":16945,"activeCount":101},[],{"trials":16947,"activeCount":101},[16948],{"nctId":14429,"briefTitle":14430,"status":117,"phases":16949,"primaryCompletion":10682,"completion":9525,"start":1779,"enrollment":136,"conditions":16950,"interventions":16951},[90],[14433,3066],[14435,4518,14436,14437],{"trials":16953,"activeCount":101},[],{"trials":16955,"activeCount":101},[],{"trials":16957,"activeCount":101},[],{"intervention":14436,"totalTrials":331,"cells":16959},{"EARLY_PHASE1":16960,"PHASE1":16962,"PHASE2":16964,"PHASE3":16970,"PHASE4":16972,"NA":16974},{"trials":16961,"activeCount":101},[],{"trials":16963,"activeCount":101},[],{"trials":16965,"activeCount":101},[16966],{"nctId":14429,"briefTitle":14430,"status":117,"phases":16967,"primaryCompletion":10682,"completion":9525,"start":1779,"enrollment":136,"conditions":16968,"interventions":16969},[90],[14433,3066],[14435,4518,14436,14437],{"trials":16971,"activeCount":101},[],{"trials":16973,"activeCount":101},[],{"trials":16975,"activeCount":101},[],{"intervention":16977,"totalTrials":331,"cells":16978},"estradiol 0.045 mg\u002Flevonorgestrel 0.015mg",{"EARLY_PHASE1":16979,"PHASE1":16981,"PHASE2":16983,"PHASE3":16992,"PHASE4":16994,"NA":16996},{"trials":16980,"activeCount":101},[],{"trials":16982,"activeCount":101},[],{"trials":16984,"activeCount":101},[16985],{"nctId":16986,"briefTitle":16987,"status":117,"phases":16988,"primaryCompletion":15855,"completion":16989,"start":1814,"enrollment":4618,"conditions":16990,"interventions":16991},"NCT02475265","Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa",[90],"2018-07-30",[772,380],[16977],{"trials":16993,"activeCount":101},[],{"trials":16995,"activeCount":101},[],{"trials":16997,"activeCount":101},[],{"intervention":3468,"totalTrials":331,"cells":16999},{"EARLY_PHASE1":17000,"PHASE1":17002,"PHASE2":17004,"PHASE3":17010,"PHASE4":17012,"NA":17014},{"trials":17001,"activeCount":101},[],{"trials":17003,"activeCount":101},[],{"trials":17005,"activeCount":101},[17006],{"nctId":3461,"briefTitle":3462,"status":107,"phases":17007,"primaryCompletion":238,"start":3464,"enrollment":101,"conditions":17008,"interventions":17009},[90],[3466],[2806,2576,3468],{"trials":17011,"activeCount":101},[],{"trials":17013,"activeCount":101},[],{"trials":17015,"activeCount":101},[],{"intervention":14622,"totalTrials":331,"cells":17017},{"EARLY_PHASE1":17018,"PHASE1":17020,"PHASE2":17022,"PHASE3":17028,"PHASE4":17030,"NA":17032},{"trials":17019,"activeCount":101},[],{"trials":17021,"activeCount":101},[],{"trials":17023,"activeCount":101},[17024],{"nctId":14615,"briefTitle":14616,"status":173,"phases":17025,"primaryCompletion":14618,"completion":14618,"start":14619,"enrollment":693,"conditions":17026,"interventions":17027},[90],[2038],[14606,14622],{"trials":17029,"activeCount":101},[],{"trials":17031,"activeCount":101},[],{"trials":17033,"activeCount":101},[],{"intervention":3826,"totalTrials":331,"cells":17035},{"EARLY_PHASE1":17036,"PHASE1":17038,"PHASE2":17040,"PHASE3":17046,"PHASE4":17048,"NA":17050},{"trials":17037,"activeCount":101},[],{"trials":17039,"activeCount":101},[],{"trials":17041,"activeCount":101},[17042],{"nctId":3821,"briefTitle":3822,"status":117,"phases":17043,"primaryCompletion":567,"completion":1877,"start":3607,"enrollment":227,"conditions":17044,"interventions":17045},[90],[3781],[3576,3787,3770,3826,2807,3789,3827,3828,3829],{"trials":17047,"activeCount":101},[],{"trials":17049,"activeCount":101},[],{"trials":17051,"activeCount":101},[],{"intervention":3827,"totalTrials":331,"cells":17053},{"EARLY_PHASE1":17054,"PHASE1":17056,"PHASE2":17058,"PHASE3":17064,"PHASE4":17066,"NA":17068},{"trials":17055,"activeCount":101},[],{"trials":17057,"activeCount":101},[],{"trials":17059,"activeCount":101},[17060],{"nctId":3821,"briefTitle":3822,"status":117,"phases":17061,"primaryCompletion":567,"completion":1877,"start":3607,"enrollment":227,"conditions":17062,"interventions":17063},[90],[3781],[3576,3787,3770,3826,2807,3789,3827,3828,3829],{"trials":17065,"activeCount":101},[],{"trials":17067,"activeCount":101},[],{"trials":17069,"activeCount":101},[],{"intervention":3829,"totalTrials":331,"cells":17071},{"EARLY_PHASE1":17072,"PHASE1":17074,"PHASE2":17076,"PHASE3":17082,"PHASE4":17084,"NA":17086},{"trials":17073,"activeCount":101},[],{"trials":17075,"activeCount":101},[],{"trials":17077,"activeCount":101},[17078],{"nctId":3821,"briefTitle":3822,"status":117,"phases":17079,"primaryCompletion":567,"completion":1877,"start":3607,"enrollment":227,"conditions":17080,"interventions":17081},[90],[3781],[3576,3787,3770,3826,2807,3789,3827,3828,3829],{"trials":17083,"activeCount":101},[],{"trials":17085,"activeCount":101},[],{"trials":17087,"activeCount":101},[],{"intervention":17089,"totalTrials":331,"cells":17090},"High-dose chemotherapy",{"EARLY_PHASE1":17091,"PHASE1":17093,"PHASE2":17095,"PHASE3":17104,"PHASE4":17106,"NA":17108},{"trials":17092,"activeCount":101},[],{"trials":17094,"activeCount":101},[],{"trials":17096,"activeCount":101},[17097],{"nctId":17098,"briefTitle":17099,"status":117,"phases":17100,"primaryCompletion":2800,"completion":268,"start":8925,"enrollment":227,"conditions":17101,"interventions":17103},"NCT01182415","High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma",[90],[4500,17102],"CNS Lymphoma",[17089],{"trials":17105,"activeCount":101},[],{"trials":17107,"activeCount":101},[],{"trials":17109,"activeCount":101},[],{"intervention":17111,"totalTrials":331,"cells":17112},"ofatumumab",{"EARLY_PHASE1":17113,"PHASE1":17115,"PHASE2":17117,"PHASE3":17125,"PHASE4":17127,"NA":17129},{"trials":17114,"activeCount":101},[],{"trials":17116,"activeCount":101},[],{"trials":17118,"activeCount":101},[17119],{"nctId":17120,"briefTitle":17121,"status":117,"phases":17122,"primaryCompletion":284,"completion":3706,"start":2994,"enrollment":742,"conditions":17123,"interventions":17124},"NCT01239394","Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma",[90],[212,216,124],[17111],{"trials":17126,"activeCount":101},[],{"trials":17128,"activeCount":101},[],{"trials":17130,"activeCount":101},[],{"intervention":13523,"totalTrials":331,"cells":17132},{"EARLY_PHASE1":17133,"PHASE1":17135,"PHASE2":17137,"PHASE3":17143,"PHASE4":17145,"NA":17147},{"trials":17134,"activeCount":101},[],{"trials":17136,"activeCount":101},[],{"trials":17138,"activeCount":101},[17139],{"nctId":13517,"briefTitle":13518,"status":117,"phases":17140,"primaryCompletion":13131,"completion":13131,"start":13520,"enrollment":36,"conditions":17141,"interventions":17142},[90],[13513],[4338,13523,13524],{"trials":17144,"activeCount":101},[],{"trials":17146,"activeCount":101},[],{"trials":17148,"activeCount":101},[],{"intervention":13524,"totalTrials":331,"cells":17150},{"EARLY_PHASE1":17151,"PHASE1":17153,"PHASE2":17155,"PHASE3":17161,"PHASE4":17163,"NA":17165},{"trials":17152,"activeCount":101},[],{"trials":17154,"activeCount":101},[],{"trials":17156,"activeCount":101},[17157],{"nctId":13517,"briefTitle":13518,"status":117,"phases":17158,"primaryCompletion":13131,"completion":13131,"start":13520,"enrollment":36,"conditions":17159,"interventions":17160},[90],[13513],[4338,13523,13524],{"trials":17162,"activeCount":101},[],{"trials":17164,"activeCount":101},[],{"trials":17166,"activeCount":101},[],{"intervention":17168,"totalTrials":331,"cells":17169},"20 mg of atorvastatin daily",{"EARLY_PHASE1":17170,"PHASE1":17172,"PHASE2":17174,"PHASE3":17182,"PHASE4":17184,"NA":17186},{"trials":17171,"activeCount":101},[],{"trials":17173,"activeCount":101},[],{"trials":17175,"activeCount":101},[17176],{"nctId":17177,"briefTitle":17178,"status":117,"phases":17179,"completion":6901,"start":2046,"enrollment":239,"conditions":17180,"interventions":17181},"NCT00403533","Assessment of the Antiviral Effect of Atorvastatin on Hepatitis C Virus",[90],[9820],[17168],{"trials":17183,"activeCount":101},[],{"trials":17185,"activeCount":101},[],{"trials":17187,"activeCount":101},[],{"intervention":17189,"totalTrials":331,"cells":17190},"Sulfasalazine",{"EARLY_PHASE1":17191,"PHASE1":17193,"PHASE2":17195,"PHASE3":17205,"PHASE4":17207,"NA":17209},{"trials":17192,"activeCount":101},[],{"trials":17194,"activeCount":101},[],{"trials":17196,"activeCount":101},[17197],{"nctId":17198,"briefTitle":17199,"status":173,"phases":17200,"primaryCompletion":17201,"completion":17201,"start":1876,"enrollment":1890,"conditions":17202,"interventions":17204},"NCT01667029","Study of Sulfasalazine in Treating Painful Neuropathy",[90],"2017-08-10",[17203],"Painful Neuropathy",[17189],{"trials":17206,"activeCount":101},[],{"trials":17208,"activeCount":101},[],{"trials":17210,"activeCount":101},[],{"intervention":584,"totalTrials":331,"cells":17212},{"EARLY_PHASE1":17213,"PHASE1":17215,"PHASE2":17217,"PHASE3":17223,"PHASE4":17225,"NA":17227},{"trials":17214,"activeCount":101},[],{"trials":17216,"activeCount":101},[],{"trials":17218,"activeCount":101},[17219],{"nctId":575,"briefTitle":576,"status":117,"phases":17220,"primaryCompletion":578,"completion":579,"start":580,"enrollment":581,"conditions":17221,"interventions":17222},[90],[380],[584,449],{"trials":17224,"activeCount":101},[],{"trials":17226,"activeCount":101},[],{"trials":17228,"activeCount":101},[],{"intervention":17230,"totalTrials":331,"cells":17231},"Recombinant human insulin like growth factor-1",{"EARLY_PHASE1":17232,"PHASE1":17234,"PHASE2":17236,"PHASE3":17245,"PHASE4":17247,"NA":17249},{"trials":17233,"activeCount":101},[],{"trials":17235,"activeCount":101},[],{"trials":17237,"activeCount":101},[17238],{"nctId":17239,"briefTitle":17240,"status":117,"phases":17241,"primaryCompletion":568,"completion":568,"start":3464,"enrollment":555,"conditions":17242,"interventions":17244},"NCT00720122","Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa",[90],[17243],"Disorder of Bone Density and Structure, Unspecified",[17230],{"trials":17246,"activeCount":101},[],{"trials":17248,"activeCount":101},[],{"trials":17250,"activeCount":101},[],{"intervention":17252,"totalTrials":331,"cells":17253},"synthetic hPTH 1-34",{"EARLY_PHASE1":17254,"PHASE1":17256,"PHASE2":17258,"PHASE3":17266,"PHASE4":17268,"NA":17270},{"trials":17255,"activeCount":101},[],{"trials":17257,"activeCount":101},[],{"trials":17259,"activeCount":101},[17260],{"nctId":17261,"briefTitle":17262,"status":117,"phases":17263,"primaryCompletion":3078,"completion":3078,"start":15128,"enrollment":732,"conditions":17264,"interventions":17265},"NCT00086619","Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women",[90],[368,380],[17252],{"trials":17267,"activeCount":101},[],{"trials":17269,"activeCount":101},[],{"trials":17271,"activeCount":101},[],{"intervention":14512,"totalTrials":331,"cells":17273},{"EARLY_PHASE1":17274,"PHASE1":17276,"PHASE2":17278,"PHASE3":17284,"PHASE4":17286,"NA":17288},{"trials":17275,"activeCount":101},[],{"trials":17277,"activeCount":101},[],{"trials":17279,"activeCount":101},[17280],{"nctId":14507,"briefTitle":14508,"status":173,"phases":17281,"primaryCompletion":135,"completion":1846,"start":456,"enrollment":544,"conditions":17282,"interventions":17283},[90],[3901],[14512,14491],{"trials":17285,"activeCount":101},[],{"trials":17287,"activeCount":101},[],{"trials":17289,"activeCount":101},[],{"intervention":17291,"totalTrials":331,"cells":17292},"Enoxaparin",{"EARLY_PHASE1":17293,"PHASE1":17295,"PHASE2":17297,"PHASE3":17307,"PHASE4":17309,"NA":17311},{"trials":17294,"activeCount":101},[],{"trials":17296,"activeCount":101},[],{"trials":17298,"activeCount":101},[17299],{"nctId":17300,"briefTitle":17301,"status":2758,"phases":17302,"primaryCompletion":17303,"completion":17303,"start":17304,"enrollment":5302,"conditions":17305,"interventions":17306},"NCT04377997","Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19",[90],"2022-06-01","2020-05-15",[11989,7210],[17291],{"trials":17308,"activeCount":101},[],{"trials":17310,"activeCount":101},[],{"trials":17312,"activeCount":101},[],{"intervention":17314,"totalTrials":331,"cells":17315},"Secukinumab",{"EARLY_PHASE1":17316,"PHASE1":17318,"PHASE2":17320,"PHASE3":17329,"PHASE4":17331,"NA":17333},{"trials":17317,"activeCount":101},[],{"trials":17319,"activeCount":101},[],{"trials":17321,"activeCount":101},[17322],{"nctId":17323,"briefTitle":17324,"status":107,"phases":17325,"primaryCompletion":16147,"completion":16147,"start":208,"enrollment":101,"conditions":17326,"interventions":17328},"NCT03866317","A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus",[90],[17327],"Discoid Lupus Erythematosus",[17314],{"trials":17330,"activeCount":101},[],{"trials":17332,"activeCount":101},[],{"trials":17334,"activeCount":101},[],{"intervention":17336,"totalTrials":331,"cells":17337},"Simvastatin",{"EARLY_PHASE1":17338,"PHASE1":17340,"PHASE2":17342,"PHASE3":17350,"PHASE4":17352,"NA":17354},{"trials":17339,"activeCount":101},[],{"trials":17341,"activeCount":101},[],{"trials":17343,"activeCount":101},[17344],{"nctId":17345,"briefTitle":17346,"status":173,"phases":17347,"primaryCompletion":3531,"completion":3531,"start":4442,"enrollment":798,"conditions":17348,"interventions":17349},"NCT01665950","Simvastatin Augmentation of Lithium Treatment in Bipolar Depression",[90],[24],[17336],{"trials":17351,"activeCount":101},[],{"trials":17353,"activeCount":101},[],{"trials":17355,"activeCount":101},[],{"intervention":17357,"totalTrials":331,"cells":17358},"Blinatumomab",{"EARLY_PHASE1":17359,"PHASE1":17361,"PHASE2":17363,"PHASE3":17372,"PHASE4":17374,"NA":17376},{"trials":17360,"activeCount":101},[],{"trials":17362,"activeCount":101},[],{"trials":17364,"activeCount":101},[17365],{"nctId":17366,"briefTitle":17367,"status":173,"phases":17368,"primaryCompletion":17369,"completion":2760,"start":8798,"enrollment":1509,"conditions":17370,"interventions":17371},"NCT02811679","A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma",[90],"2020-01-27",[4979],[17357],{"trials":17373,"activeCount":101},[],{"trials":17375,"activeCount":101},[],{"trials":17377,"activeCount":101},[],{"intervention":4791,"totalTrials":331,"cells":17379},{"EARLY_PHASE1":17380,"PHASE1":17382,"PHASE2":17384,"PHASE3":17390,"PHASE4":17392,"NA":17394},{"trials":17381,"activeCount":101},[],{"trials":17383,"activeCount":101},[],{"trials":17385,"activeCount":101},[17386],{"nctId":4784,"briefTitle":4785,"status":173,"phases":17387,"primaryCompletion":298,"completion":298,"start":1897,"enrollment":270,"conditions":17388,"interventions":17389},[90],[4788,4789],[66,4791,4293],{"trials":17391,"activeCount":101},[],{"trials":17393,"activeCount":101},[],{"trials":17395,"activeCount":101},[],{"intervention":17397,"totalTrials":331,"cells":17398},"Oat Flour",{"EARLY_PHASE1":17399,"PHASE1":17401,"PHASE2":17403,"PHASE3":17413,"PHASE4":17415,"NA":17417},{"trials":17400,"activeCount":101},[],{"trials":17402,"activeCount":101},[],{"trials":17404,"activeCount":101},[17405],{"nctId":17406,"briefTitle":17407,"status":117,"phases":17408,"primaryCompletion":17409,"completion":17409,"start":14706,"enrollment":2882,"conditions":17410,"interventions":17411},"NCT01750879","Tolerance Following Peanut Oral Immunotherapy",[89,90],"2017-07-11",[6165],[17412,17397],"Peanut Flour",{"trials":17414,"activeCount":101},[],{"trials":17416,"activeCount":101},[],{"trials":17418,"activeCount":101},[],{"intervention":17420,"totalTrials":331,"cells":17421},"Psilocybin",{"EARLY_PHASE1":17422,"PHASE1":17424,"PHASE2":17426,"PHASE3":17435,"PHASE4":17437,"NA":17439},{"trials":17423,"activeCount":101},[],{"trials":17425,"activeCount":101},[],{"trials":17427,"activeCount":101},[17428],{"nctId":17429,"briefTitle":17430,"status":107,"phases":17431,"primaryCompletion":10708,"completion":10708,"start":15570,"enrollment":101,"conditions":17432,"interventions":17434},"NCT05381974","The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD",[90],[17433],"Treatment-Resistant Major Depressive Disorder",[17420],{"trials":17436,"activeCount":101},[],{"trials":17438,"activeCount":101},[],{"trials":17440,"activeCount":101},[],{"intervention":3684,"totalTrials":331,"cells":17442},{"EARLY_PHASE1":17443,"PHASE1":17445,"PHASE2":17447,"PHASE3":17453,"PHASE4":17455,"NA":17457},{"trials":17444,"activeCount":101},[],{"trials":17446,"activeCount":101},[],{"trials":17448,"activeCount":101},[17449],{"nctId":3677,"briefTitle":3678,"status":117,"phases":17450,"primaryCompletion":3680,"completion":3680,"start":708,"enrollment":33,"conditions":17451,"interventions":17452},[90],[3682],[3520,3684,47],{"trials":17454,"activeCount":101},[],{"trials":17456,"activeCount":101},[],{"trials":17458,"activeCount":101},[],{"intervention":17460,"totalTrials":331,"cells":17461},"sodium nitroprusside",{"EARLY_PHASE1":17462,"PHASE1":17464,"PHASE2":17466,"PHASE3":17477,"PHASE4":17479,"NA":17481},{"trials":17463,"activeCount":101},[],{"trials":17465,"activeCount":101},[],{"trials":17467,"activeCount":101},[17468],{"nctId":17469,"briefTitle":17470,"status":117,"phases":17471,"primaryCompletion":17472,"completion":17473,"start":17474,"enrollment":1578,"conditions":17475,"interventions":17476},"NCT02164981","A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia",[90],"2017-03-31","2017-04-05","2015-05-01",[35],[17460],{"trials":17478,"activeCount":101},[],{"trials":17480,"activeCount":101},[],{"trials":17482,"activeCount":101},[],{"intervention":17484,"totalTrials":331,"cells":17485},"Xolair placebo",{"EARLY_PHASE1":17486,"PHASE1":17488,"PHASE2":17490,"PHASE3":17500,"PHASE4":17502,"NA":17504},{"trials":17487,"activeCount":101},[],{"trials":17489,"activeCount":101},[],{"trials":17491,"activeCount":101},[17492],{"nctId":17493,"briefTitle":17494,"status":117,"phases":17495,"primaryCompletion":1814,"completion":1814,"start":3078,"enrollment":457,"conditions":17496,"interventions":17498},"NCT01066104","Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis",[90],[17497,9666],"Chronic Rhinosinusitis",[17484,17499],"Xolair",{"trials":17501,"activeCount":101},[],{"trials":17503,"activeCount":101},[],{"trials":17505,"activeCount":101},[],{"intervention":17499,"totalTrials":331,"cells":17507},{"EARLY_PHASE1":17508,"PHASE1":17510,"PHASE2":17512,"PHASE3":17518,"PHASE4":17520,"NA":17522},{"trials":17509,"activeCount":101},[],{"trials":17511,"activeCount":101},[],{"trials":17513,"activeCount":101},[17514],{"nctId":17493,"briefTitle":17494,"status":117,"phases":17515,"primaryCompletion":1814,"completion":1814,"start":3078,"enrollment":457,"conditions":17516,"interventions":17517},[90],[17497,9666],[17484,17499],{"trials":17519,"activeCount":101},[],{"trials":17521,"activeCount":101},[],{"trials":17523,"activeCount":101},[],{"intervention":17525,"totalTrials":331,"cells":17526},"Omega 3",{"EARLY_PHASE1":17527,"PHASE1":17529,"PHASE2":17531,"PHASE3":17540,"PHASE4":17542,"NA":17544},{"trials":17528,"activeCount":101},[],{"trials":17530,"activeCount":101},[],{"trials":17532,"activeCount":101},[17533],{"nctId":17534,"briefTitle":17535,"status":117,"phases":17536,"primaryCompletion":1365,"completion":1365,"start":17537,"enrollment":1898,"conditions":17538,"interventions":17539},"NCT05774665","Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression",[90],"2025-01-30",[1783,821,12690],[17525],{"trials":17541,"activeCount":101},[],{"trials":17543,"activeCount":101},[],{"trials":17545,"activeCount":101},[],{"intervention":17547,"totalTrials":331,"cells":17548},"mRNA-transfected autologous dendritic cells",{"EARLY_PHASE1":17549,"PHASE1":17551,"PHASE2":17553,"PHASE3":17563,"PHASE4":17565,"NA":17567},{"trials":17550,"activeCount":101},[],{"trials":17552,"activeCount":101},[],{"trials":17554,"activeCount":101},[17555],{"nctId":17556,"briefTitle":17557,"status":117,"phases":17558,"primaryCompletion":4677,"completion":4677,"start":3607,"enrollment":2728,"conditions":17559,"interventions":17561},"NCT00833781","A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects",[89,90],[17560,8139],"HIV-1 Infection",[17547,17562],"autologous dendritic cells with no mRNA transfection",{"trials":17564,"activeCount":101},[],{"trials":17566,"activeCount":101},[],{"trials":17568,"activeCount":101},[],{"intervention":17562,"totalTrials":331,"cells":17570},{"EARLY_PHASE1":17571,"PHASE1":17573,"PHASE2":17575,"PHASE3":17581,"PHASE4":17583,"NA":17585},{"trials":17572,"activeCount":101},[],{"trials":17574,"activeCount":101},[],{"trials":17576,"activeCount":101},[17577],{"nctId":17556,"briefTitle":17557,"status":117,"phases":17578,"primaryCompletion":4677,"completion":4677,"start":3607,"enrollment":2728,"conditions":17579,"interventions":17580},[89,90],[17560,8139],[17547,17562],{"trials":17582,"activeCount":101},[],{"trials":17584,"activeCount":101},[],{"trials":17586,"activeCount":101},[],{"intervention":17588,"totalTrials":331,"cells":17589},"IPI-504",{"EARLY_PHASE1":17590,"PHASE1":17592,"PHASE2":17594,"PHASE3":17604,"PHASE4":17606,"NA":17608},{"trials":17591,"activeCount":101},[],{"trials":17593,"activeCount":101},[],{"trials":17595,"activeCount":101},[17596],{"nctId":17597,"briefTitle":17598,"status":173,"phases":17599,"primaryCompletion":9320,"completion":9320,"start":248,"enrollment":178,"conditions":17600,"interventions":17603},"NCT01228435","IPI-504 in NSCLC Patients With ALK Translocations",[90],[32,17601,17602],"Stage IIIb Lung Cancer","Stage IV Lung Cancer",[17588],{"trials":17605,"activeCount":101},[],{"trials":17607,"activeCount":101},[],{"trials":17609,"activeCount":101},[],{"intervention":17611,"totalTrials":331,"cells":17612},"GM-CSF, sargramostim",{"EARLY_PHASE1":17613,"PHASE1":17615,"PHASE2":17617,"PHASE3":17625,"PHASE4":17627,"NA":17629},{"trials":17614,"activeCount":101},[],{"trials":17616,"activeCount":101},[],{"trials":17618,"activeCount":101},[17619],{"nctId":17620,"briefTitle":17621,"status":117,"phases":17622,"primaryCompletion":8511,"completion":4581,"start":4425,"enrollment":3337,"conditions":17623,"interventions":17624},"NCT00157573","GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer",[90],[3610,3612],[17611],{"trials":17626,"activeCount":101},[],{"trials":17628,"activeCount":101},[],{"trials":17630,"activeCount":101},[],{"intervention":17632,"totalTrials":331,"cells":17633},"Aspirin 81 mg",{"EARLY_PHASE1":17634,"PHASE1":17636,"PHASE2":17638,"PHASE3":17650,"PHASE4":17652,"NA":17654},{"trials":17635,"activeCount":101},[],{"trials":17637,"activeCount":101},[],{"trials":17639,"activeCount":101},[17640],{"nctId":17641,"briefTitle":17642,"status":117,"phases":17643,"primaryCompletion":17644,"completion":17644,"start":17645,"enrollment":732,"conditions":17646,"interventions":17649},"NCT04031729","Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease",[89,90],"2023-02-23","2019-09-12",[17647,17648],"Nonalcoholic Fatty Liver","Nonalcoholic Steatohepatitis",[17632],{"trials":17651,"activeCount":101},[],{"trials":17653,"activeCount":101},[],{"trials":17655,"activeCount":101},[],{"intervention":17657,"totalTrials":331,"cells":17658},"LUM-201",{"EARLY_PHASE1":17659,"PHASE1":17661,"PHASE2":17663,"PHASE3":17675,"PHASE4":17677,"NA":17679},{"trials":17660,"activeCount":101},[],{"trials":17662,"activeCount":101},[],{"trials":17664,"activeCount":101},[17665],{"nctId":17666,"briefTitle":17667,"status":117,"phases":17668,"primaryCompletion":17669,"completion":17670,"start":17671,"enrollment":1791,"conditions":17672,"interventions":17674},"NCT05364684","The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease",[90],"2024-11-22","2024-12-23","2022-08-10",[17673,17647,2228],"NAFLD",[17657],{"trials":17676,"activeCount":101},[],{"trials":17678,"activeCount":101},[],{"trials":17680,"activeCount":101},[],{"intervention":17682,"totalTrials":331,"cells":17683},"Tanezumab",{"EARLY_PHASE1":17684,"PHASE1":17686,"PHASE2":17688,"PHASE3":17697,"PHASE4":17699,"NA":17701},{"trials":17685,"activeCount":101},[],{"trials":17687,"activeCount":101},[],{"trials":17689,"activeCount":101},[17690],{"nctId":17691,"briefTitle":17692,"status":2758,"phases":17693,"primaryCompletion":14648,"completion":2631,"start":17694,"enrollment":538,"conditions":17695,"interventions":17696},"NCT04163419","Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis",[90],"2020-04-30",[5718,1880],[17682],{"trials":17698,"activeCount":101},[],{"trials":17700,"activeCount":101},[],{"trials":17702,"activeCount":101},[],{"intervention":17704,"totalTrials":331,"cells":17705},"Amevive",{"EARLY_PHASE1":17706,"PHASE1":17708,"PHASE2":17710,"PHASE3":17719,"PHASE4":17721,"NA":17723},{"trials":17707,"activeCount":101},[],{"trials":17709,"activeCount":101},[],{"trials":17711,"activeCount":101},[17712],{"nctId":17713,"briefTitle":17714,"status":173,"phases":17715,"primaryCompletion":4425,"completion":4425,"start":4465,"enrollment":1509,"conditions":17716,"interventions":17718},"NCT00135733","A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus",[90],[17717],"Lichen Planus",[17704],{"trials":17720,"activeCount":101},[],{"trials":17722,"activeCount":101},[],{"trials":17724,"activeCount":101},[],{"intervention":17726,"totalTrials":331,"cells":17727},"Baricitinib",{"EARLY_PHASE1":17728,"PHASE1":17730,"PHASE2":17732,"PHASE3":17743,"PHASE4":17745,"NA":17747},{"trials":17729,"activeCount":101},[],{"trials":17731,"activeCount":101},[],{"trials":17733,"activeCount":101},[17734],{"nctId":17735,"briefTitle":17736,"status":117,"phases":17737,"primaryCompletion":17738,"completion":17739,"start":9073,"enrollment":97,"conditions":17740,"interventions":17742},"NCT05189106","Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial",[89,90],"2025-04-24","2025-06-20",[12453,5544,17741],"Mild Cognitive Impairment",[17726],{"trials":17744,"activeCount":101},[],{"trials":17746,"activeCount":101},[],{"trials":17748,"activeCount":101},[],{"intervention":17750,"totalTrials":331,"cells":17751},"Capmatinib",{"EARLY_PHASE1":17752,"PHASE1":17754,"PHASE2":17756,"PHASE3":17766,"PHASE4":17768,"NA":17770},{"trials":17753,"activeCount":101},[],{"trials":17755,"activeCount":101},[],{"trials":17757,"activeCount":101},[17758],{"nctId":17759,"briefTitle":17760,"status":117,"phases":17761,"primaryCompletion":17762,"completion":17762,"start":46,"enrollment":194,"conditions":17763,"interventions":17765},"NCT02750215","A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor",[90],"2021-05",[17764],"Malignant Non-small Cell Neoplasm of Lung Stage IV",[17750],{"trials":17767,"activeCount":101},[],{"trials":17769,"activeCount":101},[],{"trials":17771,"activeCount":101},[],{"intervention":3920,"totalTrials":331,"cells":17773},{"EARLY_PHASE1":17774,"PHASE1":17776,"PHASE2":17778,"PHASE3":17784,"PHASE4":17786,"NA":17788},{"trials":17775,"activeCount":101},[],{"trials":17777,"activeCount":101},[],{"trials":17779,"activeCount":101},[17780],{"nctId":3911,"briefTitle":3912,"status":2758,"phases":17781,"primaryCompletion":3914,"completion":3915,"start":3916,"enrollment":1847,"conditions":17782,"interventions":17783},[90],[3918],[2518,2519,3920],{"trials":17785,"activeCount":101},[],{"trials":17787,"activeCount":101},[],{"trials":17789,"activeCount":101},[],{"intervention":17791,"totalTrials":331,"cells":17792},"MBG453",{"EARLY_PHASE1":17793,"PHASE1":17795,"PHASE2":17797,"PHASE3":17808,"PHASE4":17810,"NA":17812},{"trials":17794,"activeCount":101},[],{"trials":17796,"activeCount":101},[],{"trials":17798,"activeCount":101},[17799],{"nctId":17800,"briefTitle":17801,"status":173,"phases":17802,"primaryCompletion":17803,"completion":17804,"start":17805,"enrollment":239,"conditions":17806,"interventions":17807},"NCT04823624","MBG453 in Lower Risk MDS",[90],"2024-11-12","2025-11-01","2022-01-27",[918],[17791],{"trials":17809,"activeCount":101},[],{"trials":17811,"activeCount":101},[],{"trials":17813,"activeCount":101},[],{"intervention":17815,"totalTrials":331,"cells":17816},"Panobinostat",{"EARLY_PHASE1":17817,"PHASE1":17819,"PHASE2":17821,"PHASE3":17831,"PHASE4":17833,"NA":17835},{"trials":17818,"activeCount":101},[],{"trials":17820,"activeCount":101},[],{"trials":17822,"activeCount":101},[17823],{"nctId":17824,"briefTitle":17825,"status":117,"phases":17826,"primaryCompletion":10144,"completion":2760,"start":46,"enrollment":97,"conditions":17827,"interventions":17829},"NCT02471430","Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy",[89,90],[17828],"HIV Infection",[17815,17830],"Pegylated Interferon-alpha2a",{"trials":17832,"activeCount":101},[],{"trials":17834,"activeCount":101},[],{"trials":17836,"activeCount":101},[],{"intervention":17830,"totalTrials":331,"cells":17838},{"EARLY_PHASE1":17839,"PHASE1":17841,"PHASE2":17843,"PHASE3":17849,"PHASE4":17851,"NA":17853},{"trials":17840,"activeCount":101},[],{"trials":17842,"activeCount":101},[],{"trials":17844,"activeCount":101},[17845],{"nctId":17824,"briefTitle":17825,"status":117,"phases":17846,"primaryCompletion":10144,"completion":2760,"start":46,"enrollment":97,"conditions":17847,"interventions":17848},[89,90],[17828],[17815,17830],{"trials":17850,"activeCount":101},[],{"trials":17852,"activeCount":101},[],{"trials":17854,"activeCount":101},[],{"intervention":17856,"totalTrials":331,"cells":17857},"CERC-501",{"EARLY_PHASE1":17858,"PHASE1":17860,"PHASE2":17862,"PHASE3":17872,"PHASE4":17874,"NA":17876},{"trials":17859,"activeCount":101},[],{"trials":17861,"activeCount":101},[],{"trials":17863,"activeCount":101},[17864],{"nctId":17865,"briefTitle":17866,"status":173,"phases":17867,"primaryCompletion":17868,"completion":17868,"start":17869,"enrollment":1890,"conditions":17870,"interventions":17871},"NCT01913535","Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression",[90],"2016-01-22","2013-09-12",[1783],[17856],{"trials":17873,"activeCount":101},[],{"trials":17875,"activeCount":101},[],{"trials":17877,"activeCount":101},[],{"intervention":17879,"totalTrials":331,"cells":17880},"Hyaluronic Acid",{"EARLY_PHASE1":17881,"PHASE1":17883,"PHASE2":17885,"PHASE3":17894,"PHASE4":17896,"NA":17898},{"trials":17882,"activeCount":101},[],{"trials":17884,"activeCount":101},[],{"trials":17886,"activeCount":101},[17887],{"nctId":17888,"briefTitle":17889,"status":117,"phases":17890,"primaryCompletion":268,"completion":268,"start":3531,"enrollment":22,"conditions":17891,"interventions":17893},"NCT02265575","Hylenex-Assisted Resuscitation in Kenya (HARK) Trial for the Management of Dehydration",[90],[17892],"Dehydration",[17879],{"trials":17895,"activeCount":101},[],{"trials":17897,"activeCount":101},[],{"trials":17899,"activeCount":101},[],{"intervention":3838,"totalTrials":331,"cells":17901},{"EARLY_PHASE1":17902,"PHASE1":17904,"PHASE2":17906,"PHASE3":17912,"PHASE4":17914,"NA":17916},{"trials":17903,"activeCount":101},[],{"trials":17905,"activeCount":101},[],{"trials":17907,"activeCount":101},[17908],{"nctId":3831,"briefTitle":3832,"status":117,"phases":17909,"primaryCompletion":1780,"completion":3834,"start":249,"enrollment":3565,"conditions":17910,"interventions":17911},[90],[3836],[3838,3770,3536],{"trials":17913,"activeCount":101},[],{"trials":17915,"activeCount":101},[],{"trials":17917,"activeCount":101},[],{"intervention":17919,"totalTrials":798,"cells":17920},"Fecal Microbiota Transplant",{"EARLY_PHASE1":17921,"PHASE1":17923,"PHASE2":17956,"PHASE3":17958,"PHASE4":17960,"NA":17962},{"trials":17922,"activeCount":101},[],{"trials":17924,"activeCount":101},[17925,17933,17940,17950],{"nctId":17926,"briefTitle":17927,"status":173,"phases":17928,"primaryCompletion":17929,"completion":17929,"start":225,"enrollment":178,"conditions":17930,"interventions":17932},"NCT02343328","Placebo Controlled Study of Fecal Microbiota Transplant (FMT) for a First or Second Episode of C. Difficile Infection in Adults Using a Frozen Encapsulated Inoculum",[89],"2016-07-29",[17931],"Clostridium Difficile",[17919],{"nctId":17934,"briefTitle":17935,"status":117,"phases":17936,"primaryCompletion":566,"completion":566,"start":4271,"enrollment":194,"conditions":17937,"interventions":17939},"NCT01704937","Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum",[89],[17938],"Clostridium Difficile Infection",[17919],{"nctId":17941,"briefTitle":17942,"status":117,"phases":17943,"primaryCompletion":17944,"completion":17945,"start":6853,"enrollment":239,"conditions":17946,"interventions":17949},"NCT04139577","FMT In High-Risk Acute GVHD After ALLO HCT",[89],"2022-08-03","2023-01-05",[17947,17948,17919],"Acute Graft-Versus-Host Disease (Gvhd) Grade","Hematopoietic Cell Transplantation",[17919],{"nctId":17951,"briefTitle":17952,"status":117,"phases":17953,"primaryCompletion":3531,"completion":3531,"start":14706,"enrollment":194,"conditions":17954,"interventions":17955},"NCT01914731","Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum",[89],[17938],[17919],{"trials":17957,"activeCount":101},[],{"trials":17959,"activeCount":101},[],{"trials":17961,"activeCount":101},[],{"trials":17963,"activeCount":101},[],{"intervention":17965,"totalTrials":178,"cells":17966},"RG1068",{"EARLY_PHASE1":17967,"PHASE1":17969,"PHASE2":17992,"PHASE3":17994,"PHASE4":17996,"NA":17998},{"trials":17968,"activeCount":101},[],{"trials":17970,"activeCount":101},[17971,17979,17985],{"nctId":17972,"briefTitle":17973,"status":173,"phases":17974,"primaryCompletion":9865,"completion":9865,"start":1926,"enrollment":101,"conditions":17975,"interventions":17978},"NCT00621283","Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population",[89],[17976,17977],"Acute Recurrent Pancreatitis","Chronic Pancreatitis",[17965],{"nctId":17980,"briefTitle":17981,"status":173,"phases":17982,"primaryCompletion":9865,"completion":9865,"start":1926,"enrollment":101,"conditions":17983,"interventions":17984},"NCT00620919","Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis",[89],[17977],[17965],{"nctId":17986,"briefTitle":17987,"status":173,"phases":17988,"primaryCompletion":9865,"completion":9865,"start":1926,"enrollment":136,"conditions":17989,"interventions":17991},"NCT00621556","Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas",[89],[17990],"Intraductal Papillary Mucinous Neoplasms",[17965],{"trials":17993,"activeCount":101},[],{"trials":17995,"activeCount":101},[],{"trials":17997,"activeCount":101},[],{"trials":17999,"activeCount":101},[],{"intervention":18001,"totalTrials":136,"cells":18002},"gonadotropin releasing hormone",{"EARLY_PHASE1":18003,"PHASE1":18005,"PHASE2":18025,"PHASE3":18027,"PHASE4":18029,"NA":18031},{"trials":18004,"activeCount":101},[],{"trials":18006,"activeCount":101},[18007,18016],{"nctId":18008,"briefTitle":18009,"status":117,"phases":18010,"primaryCompletion":18011,"completion":18011,"start":18012,"enrollment":18013,"conditions":18014,"interventions":18015},"NCT00392756","Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)",[89],"2019-05-16","1989-04",624,[11870,11847,11871],[18001],{"nctId":18017,"briefTitle":18018,"status":117,"phases":18019,"primaryCompletion":18020,"completion":18020,"start":18021,"enrollment":457,"conditions":18022,"interventions":18024},"NCT00493961","Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism",[89],"2009-11-17","1999-01",[11870,18023,11871],"Idiopathic Hypogonadotropic Hypogonadism",[18001],{"trials":18026,"activeCount":101},[],{"trials":18028,"activeCount":101},[],{"trials":18030,"activeCount":101},[],{"trials":18032,"activeCount":101},[],{"intervention":18034,"totalTrials":136,"cells":18035},"Lactobacillus rhamnosus GG ATCC 53103",{"EARLY_PHASE1":18036,"PHASE1":18038,"PHASE2":18053,"PHASE3":18055,"PHASE4":18057,"NA":18059},{"trials":18037,"activeCount":101},[],{"trials":18039,"activeCount":101},[18040,18046],{"nctId":18041,"briefTitle":18042,"status":117,"phases":18043,"primaryCompletion":2609,"completion":2609,"start":3078,"enrollment":366,"conditions":18044,"interventions":18045},"NCT00934453","Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) in Healthy Volunteers",[89],[29],[18034],{"nctId":18047,"briefTitle":18048,"status":117,"phases":18049,"primaryCompletion":2609,"completion":2609,"start":11845,"enrollment":555,"conditions":18050,"interventions":18052},"NCT01368029","Safety of Lactobacillus Rhamnosus GG Vs. Placebo in Elderly Subjects Receiving Trivalent Inactivated Influenza Vaccine",[89],[29,18051],"Elderly",[18034],{"trials":18054,"activeCount":101},[],{"trials":18056,"activeCount":101},[],{"trials":18058,"activeCount":101},[],{"trials":18060,"activeCount":101},[],{"intervention":2864,"totalTrials":136,"cells":18062},{"EARLY_PHASE1":18063,"PHASE1":18065,"PHASE2":18075,"PHASE3":18077,"PHASE4":18079,"NA":18081},{"trials":18064,"activeCount":101},[],{"trials":18066,"activeCount":101},[18067,18071],{"nctId":2854,"briefTitle":2855,"status":117,"phases":18068,"primaryCompletion":2857,"completion":2858,"start":135,"enrollment":2859,"conditions":18069,"interventions":18070},[89],[2861,2862],[127,2864],{"nctId":4340,"briefTitle":4341,"status":117,"phases":18072,"primaryCompletion":3741,"start":4343,"enrollment":33,"conditions":18073,"interventions":18074},[89],[916],[4346,3388,2807],{"trials":18076,"activeCount":101},[],{"trials":18078,"activeCount":101},[],{"trials":18080,"activeCount":101},[],{"trials":18082,"activeCount":101},[],{"intervention":18084,"totalTrials":136,"cells":18085},"Anastrozole Pill",{"EARLY_PHASE1":18086,"PHASE1":18088,"PHASE2":18107,"PHASE3":18109,"PHASE4":18111,"NA":18113},{"trials":18087,"activeCount":101},[],{"trials":18089,"activeCount":101},[18090,18100],{"nctId":18091,"briefTitle":18092,"status":173,"phases":18093,"primaryCompletion":18094,"completion":18094,"start":8504,"enrollment":1368,"conditions":18095,"interventions":18097},"NCT00438321","Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome",[89],"2010-02-26",[18096],"Metabolic Syndrome",[18098,18099,18084],"Zoladex","Testosterone gel",{"nctId":18101,"briefTitle":18102,"status":173,"phases":18103,"primaryCompletion":18104,"completion":18104,"start":1936,"enrollment":270,"conditions":18105,"interventions":18106},"NCT03118479","Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH)",[89],"2010-09-01",[11847,11870],[18084,573],{"trials":18108,"activeCount":101},[],{"trials":18110,"activeCount":101},[],{"trials":18112,"activeCount":101},[],{"trials":18114,"activeCount":101},[],{"intervention":18116,"totalTrials":331,"cells":18117},"Kisspeptin",{"EARLY_PHASE1":18118,"PHASE1":18120,"PHASE2":18130,"PHASE3":18132,"PHASE4":18134,"NA":18136},{"trials":18119,"activeCount":101},[],{"trials":18121,"activeCount":101},[18122],{"nctId":18123,"briefTitle":18124,"status":117,"phases":18125,"primaryCompletion":18126,"completion":18126,"start":18127,"enrollment":1805,"conditions":18128,"interventions":18129},"NCT04958109","Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test",[89],"2022-10-31","2021-10-28",[1220],[18116],{"trials":18131,"activeCount":101},[],{"trials":18133,"activeCount":101},[],{"trials":18135,"activeCount":101},[],{"trials":18137,"activeCount":101},[],{"intervention":18139,"totalTrials":331,"cells":18140},"Heliocare with Fernblock PLE technology",{"EARLY_PHASE1":18141,"PHASE1":18143,"PHASE2":18155,"PHASE3":18157,"PHASE4":18159,"NA":18161},{"trials":18142,"activeCount":101},[],{"trials":18144,"activeCount":101},[18145],{"nctId":18146,"briefTitle":18147,"status":107,"phases":18148,"primaryCompletion":18149,"completion":18149,"start":2416,"enrollment":101,"conditions":18150,"interventions":18154},"NCT02813902","A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors",[89],"2020-05",[18151,18152,18153],"Keratosis, Actinic","Keratosis","Skin Neoplasms",[18139],{"trials":18156,"activeCount":101},[],{"trials":18158,"activeCount":101},[],{"trials":18160,"activeCount":101},[],{"trials":18162,"activeCount":101},[],{"intervention":18164,"totalTrials":331,"cells":18165},"20 % Aminolevulinic Acid",{"EARLY_PHASE1":18166,"PHASE1":18168,"PHASE2":18180,"PHASE3":18182,"PHASE4":18184,"NA":18186},{"trials":18167,"activeCount":101},[],{"trials":18169,"activeCount":101},[18170],{"nctId":18171,"briefTitle":18172,"status":117,"phases":18173,"primaryCompletion":18174,"completion":18175,"start":18176,"enrollment":4443,"conditions":18177,"interventions":18179},"NCT01689935","Reduced Side-Effects of Photodynamic Therapy for the Treatment of Moderate to Severe Acne (i-PDT)",[89],"2013-09-01","2014-12-01","2009-11-01",[18178],"Acne Vulgaris",[18164],{"trials":18181,"activeCount":101},[],{"trials":18183,"activeCount":101},[],{"trials":18185,"activeCount":101},[],{"trials":18187,"activeCount":101},[],{"intervention":2929,"totalTrials":331,"cells":18189},{"EARLY_PHASE1":18190,"PHASE1":18192,"PHASE2":18198,"PHASE3":18200,"PHASE4":18202,"NA":18204},{"trials":18191,"activeCount":101},[],{"trials":18193,"activeCount":101},[18194],{"nctId":2921,"briefTitle":2922,"status":2758,"phases":18195,"primaryCompletion":2924,"completion":2925,"start":2926,"enrollment":227,"conditions":18196,"interventions":18197},[89],[32],[2901,2929],{"trials":18199,"activeCount":101},[],{"trials":18201,"activeCount":101},[],{"trials":18203,"activeCount":101},[],{"trials":18205,"activeCount":101},[],{"intervention":18207,"totalTrials":331,"cells":18208},"PTK787\u002FZK 222584",{"EARLY_PHASE1":18209,"PHASE1":18211,"PHASE2":18219,"PHASE3":18221,"PHASE4":18223,"NA":18225},{"trials":18210,"activeCount":101},[],{"trials":18212,"activeCount":101},[18213],{"nctId":18214,"briefTitle":18215,"status":117,"phases":18216,"primaryCompletion":11845,"completion":11845,"start":8504,"enrollment":2837,"conditions":18217,"interventions":18218},"NCT00385853","PTK787\u002FZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs",[89],[13574],[18207,13789],{"trials":18220,"activeCount":101},[],{"trials":18222,"activeCount":101},[],{"trials":18224,"activeCount":101},[],{"trials":18226,"activeCount":101},[],{"intervention":18228,"totalTrials":331,"cells":18229},"LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan",{"EARLY_PHASE1":18230,"PHASE1":18232,"PHASE2":18240,"PHASE3":18242,"PHASE4":18244,"NA":18246},{"trials":18231,"activeCount":101},[],{"trials":18233,"activeCount":101},[18234],{"nctId":18235,"briefTitle":18236,"status":117,"phases":18237,"primaryCompletion":2408,"completion":2408,"start":4290,"enrollment":4353,"conditions":18238,"interventions":18239},"NCT01485744","LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer",[89],[2748],[18228],{"trials":18241,"activeCount":101},[],{"trials":18243,"activeCount":101},[],{"trials":18245,"activeCount":101},[],{"trials":18247,"activeCount":101},[],{"intervention":8109,"totalTrials":331,"cells":18249},{"EARLY_PHASE1":18250,"PHASE1":18252,"PHASE2":18258,"PHASE3":18260,"PHASE4":18262,"NA":18264},{"trials":18251,"activeCount":101},[],{"trials":18253,"activeCount":101},[18254],{"nctId":8102,"briefTitle":8103,"status":117,"phases":18255,"primaryCompletion":2800,"completion":2507,"start":912,"enrollment":8105,"conditions":18256,"interventions":18257},[89],[8107],[8109,8077],{"trials":18259,"activeCount":101},[],{"trials":18261,"activeCount":101},[],{"trials":18263,"activeCount":101},[],{"trials":18265,"activeCount":101},[],{"intervention":3786,"totalTrials":331,"cells":18267},{"EARLY_PHASE1":18268,"PHASE1":18270,"PHASE2":18276,"PHASE3":18278,"PHASE4":18280,"NA":18282},{"trials":18269,"activeCount":101},[],{"trials":18271,"activeCount":101},[18272],{"nctId":3777,"briefTitle":3778,"status":117,"phases":18273,"primaryCompletion":2581,"completion":2408,"start":567,"enrollment":2837,"conditions":18274,"interventions":18275},[89],[3781,3782,3783,3784],[3786,3787,2807,3770,3788,201,3789],{"trials":18277,"activeCount":101},[],{"trials":18279,"activeCount":101},[],{"trials":18281,"activeCount":101},[],{"trials":18283,"activeCount":101},[],{"intervention":3788,"totalTrials":331,"cells":18285},{"EARLY_PHASE1":18286,"PHASE1":18288,"PHASE2":18294,"PHASE3":18296,"PHASE4":18298,"NA":18300},{"trials":18287,"activeCount":101},[],{"trials":18289,"activeCount":101},[18290],{"nctId":3777,"briefTitle":3778,"status":117,"phases":18291,"primaryCompletion":2581,"completion":2408,"start":567,"enrollment":2837,"conditions":18292,"interventions":18293},[89],[3781,3782,3783,3784],[3786,3787,2807,3770,3788,201,3789],{"trials":18295,"activeCount":101},[],{"trials":18297,"activeCount":101},[],{"trials":18299,"activeCount":101},[],{"trials":18301,"activeCount":101},[],{"intervention":923,"totalTrials":331,"cells":18303},{"EARLY_PHASE1":18304,"PHASE1":18306,"PHASE2":18312,"PHASE3":18314,"PHASE4":18316,"NA":18318},{"trials":18305,"activeCount":101},[],{"trials":18307,"activeCount":101},[18308],{"nctId":908,"briefTitle":909,"status":117,"phases":18309,"primaryCompletion":911,"completion":911,"start":912,"enrollment":829,"conditions":18310,"interventions":18311},[89],[914,915,916,211,917,918,919],[921,922,923,924,925,926,927,928,243,901],{"trials":18313,"activeCount":101},[],{"trials":18315,"activeCount":101},[],{"trials":18317,"activeCount":101},[],{"trials":18319,"activeCount":101},[],{"intervention":926,"totalTrials":331,"cells":18321},{"EARLY_PHASE1":18322,"PHASE1":18324,"PHASE2":18330,"PHASE3":18332,"PHASE4":18334,"NA":18336},{"trials":18323,"activeCount":101},[],{"trials":18325,"activeCount":101},[18326],{"nctId":908,"briefTitle":909,"status":117,"phases":18327,"primaryCompletion":911,"completion":911,"start":912,"enrollment":829,"conditions":18328,"interventions":18329},[89],[914,915,916,211,917,918,919],[921,922,923,924,925,926,927,928,243,901],{"trials":18331,"activeCount":101},[],{"trials":18333,"activeCount":101},[],{"trials":18335,"activeCount":101},[],{"trials":18337,"activeCount":101},[],{"intervention":2818,"totalTrials":331,"cells":18339},{"EARLY_PHASE1":18340,"PHASE1":18342,"PHASE2":18348,"PHASE3":18350,"PHASE4":18352,"NA":18354},{"trials":18341,"activeCount":101},[],{"trials":18343,"activeCount":101},[18344],{"nctId":2809,"briefTitle":2810,"status":173,"phases":18345,"primaryCompletion":268,"completion":268,"start":225,"enrollment":1890,"conditions":18346,"interventions":18347},[89],[2813,2814,2803,2815,2816],[127,2818,2807],{"trials":18349,"activeCount":101},[],{"trials":18351,"activeCount":101},[],{"trials":18353,"activeCount":101},[],{"trials":18355,"activeCount":101},[],{"intervention":7147,"totalTrials":331,"cells":18357},{"EARLY_PHASE1":18358,"PHASE1":18360,"PHASE2":18366,"PHASE3":18368,"PHASE4":18370,"NA":18372},{"trials":18359,"activeCount":101},[],{"trials":18361,"activeCount":101},[18362],{"nctId":7139,"briefTitle":7140,"status":117,"phases":18363,"primaryCompletion":7142,"completion":7142,"start":7143,"enrollment":194,"conditions":18364,"interventions":18365},[89],[7145],[7132,7147],{"trials":18367,"activeCount":101},[],{"trials":18369,"activeCount":101},[],{"trials":18371,"activeCount":101},[],{"trials":18373,"activeCount":101},[],{"intervention":18375,"totalTrials":331,"cells":18376},"Deoxycholic Acid",{"EARLY_PHASE1":18377,"PHASE1":18379,"PHASE2":18390,"PHASE3":18392,"PHASE4":18394,"NA":18396},{"trials":18378,"activeCount":101},[],{"trials":18380,"activeCount":101},[18381],{"nctId":18382,"briefTitle":18383,"status":117,"phases":18384,"primaryCompletion":18385,"completion":18385,"start":18386,"enrollment":1509,"conditions":18387,"interventions":18388},"NCT06132165","Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas",[89],"2025-07-31","2024-03-01",[7145],[18375,18389],"Polidocanol",{"trials":18391,"activeCount":101},[],{"trials":18393,"activeCount":101},[],{"trials":18395,"activeCount":101},[],{"trials":18397,"activeCount":101},[],{"intervention":18389,"totalTrials":331,"cells":18399},{"EARLY_PHASE1":18400,"PHASE1":18402,"PHASE2":18408,"PHASE3":18410,"PHASE4":18412,"NA":18414},{"trials":18401,"activeCount":101},[],{"trials":18403,"activeCount":101},[18404],{"nctId":18382,"briefTitle":18383,"status":117,"phases":18405,"primaryCompletion":18385,"completion":18385,"start":18386,"enrollment":1509,"conditions":18406,"interventions":18407},[89],[7145],[18375,18389],{"trials":18409,"activeCount":101},[],{"trials":18411,"activeCount":101},[],{"trials":18413,"activeCount":101},[],{"trials":18415,"activeCount":101},[],{"intervention":18417,"totalTrials":331,"cells":18418},"Nilotinib",{"EARLY_PHASE1":18419,"PHASE1":18421,"PHASE2":18431,"PHASE3":18433,"PHASE4":18435,"NA":18437},{"trials":18420,"activeCount":101},[],{"trials":18422,"activeCount":101},[18423],{"nctId":18424,"briefTitle":18425,"status":117,"phases":18426,"primaryCompletion":554,"completion":18427,"start":8799,"enrollment":753,"conditions":18428,"interventions":18430},"NCT01407198","Nilotinib With Radiation for High Risk Chordoma",[89],"2025-06",[18429],"Chordoma",[18417],{"trials":18432,"activeCount":101},[],{"trials":18434,"activeCount":101},[],{"trials":18436,"activeCount":101},[],{"trials":18438,"activeCount":101},[],{"intervention":18440,"totalTrials":331,"cells":18441},"F18-3F4AP",{"EARLY_PHASE1":18442,"PHASE1":18444,"PHASE2":18454,"PHASE3":18456,"PHASE4":18458,"NA":18460},{"trials":18443,"activeCount":101},[],{"trials":18445,"activeCount":101},[18446],{"nctId":18447,"briefTitle":18448,"status":2758,"phases":18449,"primaryCompletion":2495,"completion":2495,"start":18450,"enrollment":1890,"conditions":18451,"interventions":18453},"NCT04710550","Exploring the Utility of [18F]3F4AP for Demyelination Imaging in Controls, Neurodegeneration and Traumatic Brian Injury",[89],"2021-01-25",[529,18452,5544],"Demyelinating Disorder",[18440],{"trials":18455,"activeCount":101},[],{"trials":18457,"activeCount":101},[],{"trials":18459,"activeCount":101},[],{"trials":18461,"activeCount":101},[],{"intervention":18463,"totalTrials":331,"cells":18464},"L-arginine",{"EARLY_PHASE1":18465,"PHASE1":18467,"PHASE2":18478,"PHASE3":18480,"PHASE4":18482,"NA":18484},{"trials":18466,"activeCount":101},[],{"trials":18468,"activeCount":101},[18469],{"nctId":18470,"briefTitle":18471,"status":117,"phases":18472,"primaryCompletion":2609,"completion":2609,"start":11914,"enrollment":270,"conditions":18473,"interventions":18477},"NCT01388764","Safety, Tolerability and Effects of L-Arginine in Boys With Dystrophinopathy on Corticosteroids",[89],[18474,18475,18476],"Dystrophinopathy","Duchenne Muscular Dystrophy","Becker's Muscular Dystrophy",[18463],{"trials":18479,"activeCount":101},[],{"trials":18481,"activeCount":101},[],{"trials":18483,"activeCount":101},[],{"trials":18485,"activeCount":101},[],{"intervention":18487,"totalTrials":331,"cells":18488},"Demeclocycline",{"EARLY_PHASE1":18489,"PHASE1":18491,"PHASE2":18501,"PHASE3":18503,"PHASE4":18505,"NA":18507},{"trials":18490,"activeCount":101},[],{"trials":18492,"activeCount":101},[18493],{"nctId":18494,"briefTitle":18495,"status":2758,"phases":18496,"primaryCompletion":18497,"completion":18498,"start":1877,"enrollment":251,"conditions":18499,"interventions":18500},"NCT02740933","Demeclocycline Fluorescence for Intraoperative Delineation Brain Tumors",[89],"2019-01","2021-01",[13575],[18487],{"trials":18502,"activeCount":101},[],{"trials":18504,"activeCount":101},[],{"trials":18506,"activeCount":101},[],{"trials":18508,"activeCount":101},[],{"intervention":13620,"totalTrials":331,"cells":18510},{"EARLY_PHASE1":18511,"PHASE1":18513,"PHASE2":18519,"PHASE3":18521,"PHASE4":18523,"NA":18525},{"trials":18512,"activeCount":101},[],{"trials":18514,"activeCount":101},[18515],{"nctId":13615,"briefTitle":13616,"status":117,"phases":18516,"primaryCompletion":135,"completion":135,"start":8511,"enrollment":2610,"conditions":18517,"interventions":18518},[89],[13574],[4515,13620],{"trials":18520,"activeCount":101},[],{"trials":18522,"activeCount":101},[],{"trials":18524,"activeCount":101},[],{"trials":18526,"activeCount":101},[],{"intervention":18528,"totalTrials":331,"cells":18529},"Midostaurin",{"EARLY_PHASE1":18530,"PHASE1":18532,"PHASE2":18540,"PHASE3":18542,"PHASE4":18544,"NA":18546},{"trials":18531,"activeCount":101},[],{"trials":18533,"activeCount":101},[18534],{"nctId":18535,"briefTitle":18536,"status":117,"phases":18537,"primaryCompletion":3706,"completion":4380,"start":8799,"enrollment":2837,"conditions":18538,"interventions":18539},"NCT01282502","Midostaurin (PKC412) for Locally Advanced Rectal Cancer",[89],[4584],[18528],{"trials":18541,"activeCount":101},[],{"trials":18543,"activeCount":101},[],{"trials":18545,"activeCount":101},[],{"trials":18547,"activeCount":101},[],{"intervention":2999,"totalTrials":331,"cells":18549},{"EARLY_PHASE1":18550,"PHASE1":18552,"PHASE2":18558,"PHASE3":18560,"PHASE4":18562,"NA":18564},{"trials":18551,"activeCount":101},[],{"trials":18553,"activeCount":101},[18554],{"nctId":2991,"briefTitle":2992,"status":117,"phases":18555,"primaryCompletion":2994,"completion":2995,"start":175,"enrollment":1847,"conditions":18556,"interventions":18557},[89],[2997],[2999,2975],{"trials":18559,"activeCount":101},[],{"trials":18561,"activeCount":101},[],{"trials":18563,"activeCount":101},[],{"trials":18565,"activeCount":101},[],{"intervention":18567,"totalTrials":331,"cells":18568},"Kisspeptin-10",{"EARLY_PHASE1":18569,"PHASE1":18571,"PHASE2":18580,"PHASE3":18582,"PHASE4":18584,"NA":18586},{"trials":18570,"activeCount":101},[],{"trials":18572,"activeCount":101},[18573],{"nctId":18574,"briefTitle":18575,"status":107,"phases":18576,"primaryCompletion":1975,"completion":1975,"start":7503,"enrollment":101,"conditions":18577,"interventions":18579},"NCT05456854","Evaluation of Kisspeptin Stimulated Insulin Secretion With Hyperglycemic Clamp",[89],[18578],"Metabolic Disease",[18567],{"trials":18581,"activeCount":101},[],{"trials":18583,"activeCount":101},[],{"trials":18585,"activeCount":101},[],{"trials":18587,"activeCount":101},[],{"intervention":18589,"totalTrials":331,"cells":18590},"LDE225",{"EARLY_PHASE1":18591,"PHASE1":18593,"PHASE2":18601,"PHASE3":18603,"PHASE4":18605,"NA":18607},{"trials":18592,"activeCount":101},[],{"trials":18594,"activeCount":101},[18595],{"nctId":18596,"briefTitle":18597,"status":173,"phases":18598,"primaryCompletion":268,"completion":268,"start":455,"enrollment":97,"conditions":18599,"interventions":18600},"NCT02086513","Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT",[89],[915],[18589],{"trials":18602,"activeCount":101},[],{"trials":18604,"activeCount":101},[],{"trials":18606,"activeCount":101},[],{"trials":18608,"activeCount":101},[],{"intervention":18610,"totalTrials":331,"cells":18611},"Topical Calcipotriene Ointment",{"EARLY_PHASE1":18612,"PHASE1":18614,"PHASE2":18623,"PHASE3":18625,"PHASE4":18627,"NA":18629},{"trials":18613,"activeCount":101},[],{"trials":18615,"activeCount":101},[18616],{"nctId":18617,"briefTitle":18618,"status":173,"phases":18619,"primaryCompletion":3564,"completion":3564,"start":18620,"enrollment":742,"conditions":18621,"interventions":18622},"NCT03596073","Topical Calcipotriene Treatment for Breast Cancer Immunoprevention",[89],"2018-11-07",[21],[18610],{"trials":18624,"activeCount":101},[],{"trials":18626,"activeCount":101},[],{"trials":18628,"activeCount":101},[],{"trials":18630,"activeCount":101},[],{"intervention":18632,"totalTrials":331,"cells":18633},"Imiquimod 5% Cream",{"EARLY_PHASE1":18634,"PHASE1":18636,"PHASE2":18646,"PHASE3":18648,"PHASE4":18650,"NA":18652},{"trials":18635,"activeCount":101},[],{"trials":18637,"activeCount":101},[18638],{"nctId":18639,"briefTitle":18640,"status":117,"phases":18641,"primaryCompletion":4581,"completion":4677,"start":4441,"enrollment":4618,"conditions":18642,"interventions":18645},"NCT00865644","Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1",[89],[18643,18644],"Neurofibromatosis Type 1","Cutaneous Neurofibromas",[18632],{"trials":18647,"activeCount":101},[],{"trials":18649,"activeCount":101},[],{"trials":18651,"activeCount":101},[],{"trials":18653,"activeCount":101},[],{"intervention":18655,"totalTrials":331,"cells":18656},"Enasidenib",{"EARLY_PHASE1":18657,"PHASE1":18659,"PHASE2":18669,"PHASE3":18671,"PHASE4":18673,"NA":18675},{"trials":18658,"activeCount":101},[],{"trials":18660,"activeCount":101},[18661],{"nctId":18662,"briefTitle":18663,"status":117,"phases":18664,"primaryCompletion":61,"completion":18665,"start":18666,"enrollment":753,"conditions":18667,"interventions":18668},"NCT03515512","IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation",[89],"2023-02-13","2018-07-17",[2862,7395],[18655],{"trials":18670,"activeCount":101},[],{"trials":18672,"activeCount":101},[],{"trials":18674,"activeCount":101},[],{"trials":18676,"activeCount":101},[],{"intervention":18678,"totalTrials":331,"cells":18679},"Tc99m-MAA",{"EARLY_PHASE1":18680,"PHASE1":18682,"PHASE2":18691,"PHASE3":18693,"PHASE4":18695,"NA":18697},{"trials":18681,"activeCount":101},[],{"trials":18683,"activeCount":101},[18684],{"nctId":18685,"briefTitle":18686,"status":117,"phases":18687,"primaryCompletion":18688,"completion":7070,"start":527,"enrollment":1890,"conditions":18689,"interventions":18690},"NCT04105283","Tc99m-MAA Bronchial Artery Injection During Bronchial Embolization for Pulmonary Mass Induced Hemoptysis for Dosimetry Planning",[89],"2024-06-01",[32],[18678],{"trials":18692,"activeCount":101},[],{"trials":18694,"activeCount":101},[],{"trials":18696,"activeCount":101},[],{"trials":18698,"activeCount":101},[],{"intervention":18700,"totalTrials":331,"cells":18701},"BMB72",{"EARLY_PHASE1":18702,"PHASE1":18704,"PHASE2":18712,"PHASE3":18714,"PHASE4":18716,"NA":18718},{"trials":18703,"activeCount":101},[],{"trials":18705,"activeCount":101},[18706],{"nctId":18707,"briefTitle":18708,"status":117,"phases":18709,"primaryCompletion":9600,"completion":9600,"start":707,"enrollment":1890,"conditions":18710,"interventions":18711},"NCT01311817","Transcutaneous Immunization With an Attenuated Listeria Monocytogenes Vector Vaccine",[89],[8978],[18700],{"trials":18713,"activeCount":101},[],{"trials":18715,"activeCount":101},[],{"trials":18717,"activeCount":101},[],{"trials":18719,"activeCount":101},[],{"intervention":18721,"totalTrials":331,"cells":18722},"Heparin",{"EARLY_PHASE1":18723,"PHASE1":18725,"PHASE2":18737,"PHASE3":18739,"PHASE4":18741,"NA":18743},{"trials":18724,"activeCount":101},[],{"trials":18726,"activeCount":101},[18727],{"nctId":18728,"briefTitle":18729,"status":117,"phases":18730,"primaryCompletion":567,"completion":567,"start":8137,"enrollment":18731,"conditions":18732,"interventions":18735},"NCT01598883","Understanding \"Heparin Resistance\" in Cardiac Surgery",[89],504,[18733,18734],"Cardiopulmonary Bypass","Altered Heparin Response",[18721,18736],"ATryn",{"trials":18738,"activeCount":101},[],{"trials":18740,"activeCount":101},[],{"trials":18742,"activeCount":101},[],{"trials":18744,"activeCount":101},[],{"intervention":18736,"totalTrials":331,"cells":18746},{"EARLY_PHASE1":18747,"PHASE1":18749,"PHASE2":18755,"PHASE3":18757,"PHASE4":18759,"NA":18761},{"trials":18748,"activeCount":101},[],{"trials":18750,"activeCount":101},[18751],{"nctId":18728,"briefTitle":18729,"status":117,"phases":18752,"primaryCompletion":567,"completion":567,"start":8137,"enrollment":18731,"conditions":18753,"interventions":18754},[89],[18733,18734],[18721,18736],{"trials":18756,"activeCount":101},[],{"trials":18758,"activeCount":101},[],{"trials":18760,"activeCount":101},[],{"trials":18762,"activeCount":101},[],{"intervention":18764,"totalTrials":331,"cells":18765},"IVIg",{"EARLY_PHASE1":18766,"PHASE1":18768,"PHASE2":18781,"PHASE3":18783,"PHASE4":18785,"NA":18787},{"trials":18767,"activeCount":101},[],{"trials":18769,"activeCount":101},[18770],{"nctId":18771,"briefTitle":18772,"status":117,"phases":18773,"primaryCompletion":18774,"completion":18775,"start":46,"enrollment":1805,"conditions":18776,"interventions":18780},"NCT02659891","IVIg to Treat BK Viremia in Kidney Transplant Recipients",[89],"2020-12-10","2021-03-31",[18777,18778,18779],"Kidney Transplantation","BK Virus","Isoantibodies",[18764],{"trials":18782,"activeCount":101},[],{"trials":18784,"activeCount":101},[],{"trials":18786,"activeCount":101},[],{"trials":18788,"activeCount":101},[],{"intervention":14503,"totalTrials":331,"cells":18790},{"EARLY_PHASE1":18791,"PHASE1":18793,"PHASE2":18799,"PHASE3":18801,"PHASE4":18803,"NA":18805},{"trials":18792,"activeCount":101},[],{"trials":18794,"activeCount":101},[18795],{"nctId":14498,"briefTitle":14499,"status":173,"phases":18796,"primaryCompletion":224,"completion":224,"start":9600,"enrollment":178,"conditions":18797,"interventions":18798},[89],[3901],[14491,14503],{"trials":18800,"activeCount":101},[],{"trials":18802,"activeCount":101},[],{"trials":18804,"activeCount":101},[],{"trials":18806,"activeCount":101},[],{"intervention":18808,"totalTrials":331,"cells":18809},"Regorafenib",{"EARLY_PHASE1":18810,"PHASE1":18812,"PHASE2":18822,"PHASE3":18824,"PHASE4":18826,"NA":18828},{"trials":18811,"activeCount":101},[],{"trials":18813,"activeCount":101},[18814],{"nctId":18815,"briefTitle":18816,"status":117,"phases":18817,"primaryCompletion":7464,"completion":18818,"start":18819,"enrollment":1805,"conditions":18820,"interventions":18821},"NCT03042689","Study of Regorafenib in Patients With Advanced Myeloid Malignancies",[89],"2023-02-27","2017-04-17",[2862],[18808],{"trials":18823,"activeCount":101},[],{"trials":18825,"activeCount":101},[],{"trials":18827,"activeCount":101},[],{"trials":18829,"activeCount":101},[],{"intervention":18831,"totalTrials":331,"cells":18832},"Aspiration Marker",{"EARLY_PHASE1":18833,"PHASE1":18835,"PHASE2":18845,"PHASE3":18847,"PHASE4":18849,"NA":18851},{"trials":18834,"activeCount":101},[],{"trials":18836,"activeCount":101},[18837],{"nctId":18838,"briefTitle":18839,"status":107,"phases":18840,"primaryCompletion":18841,"completion":18841,"start":2800,"enrollment":101,"conditions":18842,"interventions":18844},"NCT02598713","Validation of Aspiration Markers in Intubated Patients",[89],"2024-06-30",[7905,18843],"Aspiration",[18831],{"trials":18846,"activeCount":101},[],{"trials":18848,"activeCount":101},[],{"trials":18850,"activeCount":101},[],{"trials":18852,"activeCount":101},[],{"intervention":4011,"totalTrials":331,"cells":18854},{"EARLY_PHASE1":18855,"PHASE1":18857,"PHASE2":18863,"PHASE3":18865,"PHASE4":18867,"NA":18869},{"trials":18856,"activeCount":101},[],{"trials":18858,"activeCount":101},[18859],{"nctId":4004,"briefTitle":4005,"status":117,"phases":18860,"primaryCompletion":4007,"completion":4007,"start":4008,"enrollment":1509,"conditions":18861,"interventions":18862},[89],[2527],[4011,3997,4012,4013],{"trials":18864,"activeCount":101},[],{"trials":18866,"activeCount":101},[],{"trials":18868,"activeCount":101},[],{"trials":18870,"activeCount":101},[],{"intervention":4012,"totalTrials":331,"cells":18872},{"EARLY_PHASE1":18873,"PHASE1":18875,"PHASE2":18881,"PHASE3":18883,"PHASE4":18885,"NA":18887},{"trials":18874,"activeCount":101},[],{"trials":18876,"activeCount":101},[18877],{"nctId":4004,"briefTitle":4005,"status":117,"phases":18878,"primaryCompletion":4007,"completion":4007,"start":4008,"enrollment":1509,"conditions":18879,"interventions":18880},[89],[2527],[4011,3997,4012,4013],{"trials":18882,"activeCount":101},[],{"trials":18884,"activeCount":101},[],{"trials":18886,"activeCount":101},[],{"trials":18888,"activeCount":101},[],{"intervention":4983,"totalTrials":331,"cells":18890},{"EARLY_PHASE1":18891,"PHASE1":18893,"PHASE2":18899,"PHASE3":18901,"PHASE4":18903,"NA":18905},{"trials":18892,"activeCount":101},[],{"trials":18894,"activeCount":101},[18895],{"nctId":4975,"briefTitle":4976,"status":117,"phases":18896,"primaryCompletion":4771,"completion":120,"start":3531,"enrollment":2837,"conditions":18897,"interventions":18898},[89],[4979,153,4980,212,4981],[76,4983],{"trials":18900,"activeCount":101},[],{"trials":18902,"activeCount":101},[],{"trials":18904,"activeCount":101},[],{"trials":18906,"activeCount":101},[],{"intervention":18908,"totalTrials":331,"cells":18909},"Lactobacillus Rhamnosus GG, ATCC 53103",{"EARLY_PHASE1":18910,"PHASE1":18912,"PHASE2":18920,"PHASE3":18922,"PHASE4":18924,"NA":18926},{"trials":18911,"activeCount":101},[],{"trials":18913,"activeCount":101},[18914],{"nctId":18915,"briefTitle":18916,"status":117,"phases":18917,"primaryCompletion":8799,"completion":8799,"start":2994,"enrollment":2728,"conditions":18918,"interventions":18919},"NCT01274598","Study to Evaluate the Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) in Elderly Subjects",[89],[29,18051],[18908],{"trials":18921,"activeCount":101},[],{"trials":18923,"activeCount":101},[],{"trials":18925,"activeCount":101},[],{"trials":18927,"activeCount":101},[],{"intervention":3007,"totalTrials":331,"cells":18929},{"EARLY_PHASE1":18930,"PHASE1":18932,"PHASE2":18938,"PHASE3":18940,"PHASE4":18942,"NA":18944},{"trials":18931,"activeCount":101},[],{"trials":18933,"activeCount":101},[18934],{"nctId":3001,"briefTitle":3002,"status":117,"phases":18935,"primaryCompletion":3004,"completion":3004,"start":2847,"enrollment":194,"conditions":18936,"interventions":18937},[89],[2510],[3007,2975],{"trials":18939,"activeCount":101},[],{"trials":18941,"activeCount":101},[],{"trials":18943,"activeCount":101},[],{"trials":18945,"activeCount":101},[],{"intervention":11861,"totalTrials":331,"cells":18947},{"EARLY_PHASE1":18948,"PHASE1":18950,"PHASE2":18956,"PHASE3":18958,"PHASE4":18960,"NA":18962},{"trials":18949,"activeCount":101},[],{"trials":18951,"activeCount":101},[18952],{"nctId":11853,"briefTitle":11854,"status":117,"phases":18953,"primaryCompletion":11856,"completion":11856,"start":11857,"enrollment":4874,"conditions":18954,"interventions":18955},[89],[11847],[11860,11861,11835],{"trials":18957,"activeCount":101},[],{"trials":18959,"activeCount":101},[],{"trials":18961,"activeCount":101},[],{"trials":18963,"activeCount":101},[],{"intervention":18965,"totalTrials":331,"cells":18966},"Drug therapy",{"EARLY_PHASE1":18967,"PHASE1":18969,"PHASE2":18978,"PHASE3":18980,"PHASE4":18982,"NA":18984},{"trials":18968,"activeCount":101},[],{"trials":18970,"activeCount":101},[18971],{"nctId":18972,"briefTitle":18973,"status":117,"phases":18974,"primaryCompletion":9292,"completion":9292,"start":18975,"enrollment":251,"conditions":18976,"interventions":18977},"NCT00050050","Cognitive Behavioral Therapy for Adult Attention Deficit Hyperactivity Disorder",[89],"2001-09",[9843],[18965],{"trials":18979,"activeCount":101},[],{"trials":18981,"activeCount":101},[],{"trials":18983,"activeCount":101},[],{"trials":18985,"activeCount":101},[],{"intervention":4356,"totalTrials":331,"cells":18987},{"EARLY_PHASE1":18988,"PHASE1":18990,"PHASE2":18996,"PHASE3":18998,"PHASE4":19000,"NA":19002},{"trials":18989,"activeCount":101},[],{"trials":18991,"activeCount":101},[18992],{"nctId":4348,"briefTitle":4349,"status":117,"phases":18993,"primaryCompletion":4351,"completion":4351,"start":4352,"enrollment":4353,"conditions":18994,"interventions":18995},[89],[2862],[4356,2807,3389],{"trials":18997,"activeCount":101},[],{"trials":18999,"activeCount":101},[],{"trials":19001,"activeCount":101},[],{"trials":19003,"activeCount":101},[],{"intervention":19005,"totalTrials":331,"cells":19006},"Diatoms Shells",{"EARLY_PHASE1":19007,"PHASE1":19009,"PHASE2":19018,"PHASE3":19020,"PHASE4":19022,"NA":19024},{"trials":19008,"activeCount":101},[],{"trials":19010,"activeCount":101},[19011],{"nctId":19012,"briefTitle":19013,"status":107,"phases":19014,"primaryCompletion":1846,"completion":1846,"start":554,"enrollment":101,"conditions":19015,"interventions":19017},"NCT02301845","Validation of Aspiration Markers",[89],[19016],"Pneumonia, Aspiration",[19005],{"trials":19019,"activeCount":101},[],{"trials":19021,"activeCount":101},[],{"trials":19023,"activeCount":101},[],{"trials":19025,"activeCount":101},[],{"intervention":19027,"totalTrials":331,"cells":19028},"Human recombinant hyaluronidase",{"EARLY_PHASE1":19029,"PHASE1":19031,"PHASE2":19041,"PHASE3":19043,"PHASE4":19045,"NA":19047},{"trials":19030,"activeCount":101},[],{"trials":19032,"activeCount":101},[19033],{"nctId":19034,"briefTitle":19035,"status":117,"phases":19036,"primaryCompletion":4441,"completion":4441,"start":3658,"enrollment":209,"conditions":19037,"interventions":19040},"NCT00740727","EASI Access II --- Follow-up Study to the EASI Access Trial",[89],[19038,19039,17892],"Disaster Medicine","Difficult Intravenous Access",[19027],{"trials":19042,"activeCount":101},[],{"trials":19044,"activeCount":101},[],{"trials":19046,"activeCount":101},[],{"trials":19048,"activeCount":101},[],{"intervention":3903,"totalTrials":331,"cells":19050},{"EARLY_PHASE1":19051,"PHASE1":19053,"PHASE2":19059,"PHASE3":19061,"PHASE4":19063,"NA":19065},{"trials":19052,"activeCount":101},[],{"trials":19054,"activeCount":101},[19055],{"nctId":3894,"briefTitle":3895,"status":173,"phases":19056,"primaryCompletion":3897,"completion":3898,"start":3899,"enrollment":331,"conditions":19057,"interventions":19058},[89],[3901],[2519,2518,3903],{"trials":19060,"activeCount":101},[],{"trials":19062,"activeCount":101},[],{"trials":19064,"activeCount":101},[],{"trials":19066,"activeCount":101},[],{"intervention":18098,"totalTrials":331,"cells":19068},{"EARLY_PHASE1":19069,"PHASE1":19071,"PHASE2":19077,"PHASE3":19079,"PHASE4":19081,"NA":19083},{"trials":19070,"activeCount":101},[],{"trials":19072,"activeCount":101},[19073],{"nctId":18091,"briefTitle":18092,"status":173,"phases":19074,"primaryCompletion":18094,"completion":18094,"start":8504,"enrollment":1368,"conditions":19075,"interventions":19076},[89],[18096],[18098,18099,18084],{"trials":19078,"activeCount":101},[],{"trials":19080,"activeCount":101},[],{"trials":19082,"activeCount":101},[],{"trials":19084,"activeCount":101},[],{"intervention":18099,"totalTrials":331,"cells":19086},{"EARLY_PHASE1":19087,"PHASE1":19089,"PHASE2":19095,"PHASE3":19097,"PHASE4":19099,"NA":19101},{"trials":19088,"activeCount":101},[],{"trials":19090,"activeCount":101},[19091],{"nctId":18091,"briefTitle":18092,"status":173,"phases":19092,"primaryCompletion":18094,"completion":18094,"start":8504,"enrollment":1368,"conditions":19093,"interventions":19094},[89],[18096],[18098,18099,18084],{"trials":19096,"activeCount":101},[],{"trials":19098,"activeCount":101},[],{"trials":19100,"activeCount":101},[],{"trials":19102,"activeCount":101},[],{"intervention":2635,"totalTrials":331,"cells":19104},{"EARLY_PHASE1":19105,"PHASE1":19107,"PHASE2":19113,"PHASE3":19115,"PHASE4":19117,"NA":19119},{"trials":19106,"activeCount":101},[],{"trials":19108,"activeCount":101},[19109],{"nctId":2627,"briefTitle":2628,"status":107,"phases":19110,"primaryCompletion":2630,"completion":2631,"start":2632,"enrollment":101,"conditions":19111,"interventions":19112},[89],[2030],[2635,2614,2599],{"trials":19114,"activeCount":101},[],{"trials":19116,"activeCount":101},[],{"trials":19118,"activeCount":101},[],{"trials":19120,"activeCount":101},[],{"intervention":19122,"totalTrials":331,"cells":19123},"Ga-68-DOTA-TOC",{"EARLY_PHASE1":19124,"PHASE1":19126,"PHASE2":19138,"PHASE3":19140,"PHASE4":19142,"NA":19144},{"trials":19125,"activeCount":101},[],{"trials":19127,"activeCount":101},[19128],{"nctId":19129,"briefTitle":19130,"status":107,"phases":19131,"primaryCompletion":19132,"completion":2630,"start":19133,"enrollment":101,"conditions":19134,"interventions":19136},"NCT03057509","A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors",[89],"2019-10-31","2018-11",[19135],"Small Bowel Carcinoid Tumor",[19122,19137],"LAR Octreotide",{"trials":19139,"activeCount":101},[],{"trials":19141,"activeCount":101},[],{"trials":19143,"activeCount":101},[],{"trials":19145,"activeCount":101},[],{"intervention":19137,"totalTrials":331,"cells":19147},{"EARLY_PHASE1":19148,"PHASE1":19150,"PHASE2":19156,"PHASE3":19158,"PHASE4":19160,"NA":19162},{"trials":19149,"activeCount":101},[],{"trials":19151,"activeCount":101},[19152],{"nctId":19129,"briefTitle":19130,"status":107,"phases":19153,"primaryCompletion":19132,"completion":2630,"start":19133,"enrollment":101,"conditions":19154,"interventions":19155},[89],[19135],[19122,19137],{"trials":19157,"activeCount":101},[],{"trials":19159,"activeCount":101},[],{"trials":19161,"activeCount":101},[],{"trials":19163,"activeCount":101},[],{"intervention":19165,"totalTrials":331,"cells":19166},"GM-K562 Vaccination",{"EARLY_PHASE1":19167,"PHASE1":19169,"PHASE2":19178,"PHASE3":19180,"PHASE4":19182,"NA":19184},{"trials":19168,"activeCount":101},[],{"trials":19170,"activeCount":101},[19171],{"nctId":19172,"briefTitle":19173,"status":117,"phases":19174,"primaryCompletion":3607,"completion":3607,"start":2848,"enrollment":4618,"conditions":19175,"interventions":19177},"NCT00694330","Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor",[89],[19176],"Glioma",[19165],{"trials":19179,"activeCount":101},[],{"trials":19181,"activeCount":101},[],{"trials":19183,"activeCount":101},[],{"trials":19185,"activeCount":101},[],{"intervention":19187,"totalTrials":331,"cells":19188},"GVAX",{"EARLY_PHASE1":19189,"PHASE1":19191,"PHASE2":19200,"PHASE3":19202,"PHASE4":19204,"NA":19206},{"trials":19190,"activeCount":101},[],{"trials":19192,"activeCount":101},[19193],{"nctId":19194,"briefTitle":19195,"status":173,"phases":19196,"primaryCompletion":11764,"completion":435,"start":19197,"enrollment":331,"conditions":19198,"interventions":19199},"NCT01952730","Pilot Study of GVAX in Colorectal Cancer Cells",[89],"2013-11-08",[6511],[19187],{"trials":19201,"activeCount":101},[],{"trials":19203,"activeCount":101},[],{"trials":19205,"activeCount":101},[],{"trials":19207,"activeCount":101},[],{"intervention":141,"totalTrials":331,"cells":19209},{"EARLY_PHASE1":19210,"PHASE1":19212,"PHASE2":19218,"PHASE3":19220,"PHASE4":19222,"NA":19224},{"trials":19211,"activeCount":101},[],{"trials":19213,"activeCount":101},[19214],{"nctId":130,"briefTitle":131,"status":117,"phases":19215,"primaryCompletion":133,"completion":134,"start":135,"enrollment":136,"conditions":19216,"interventions":19217},[89],[138,139],[141,142,96],{"trials":19219,"activeCount":101},[],{"trials":19221,"activeCount":101},[],{"trials":19223,"activeCount":101},[],{"trials":19225,"activeCount":101},[],{"intervention":142,"totalTrials":331,"cells":19227},{"EARLY_PHASE1":19228,"PHASE1":19230,"PHASE2":19236,"PHASE3":19238,"PHASE4":19240,"NA":19242},{"trials":19229,"activeCount":101},[],{"trials":19231,"activeCount":101},[19232],{"nctId":130,"briefTitle":131,"status":117,"phases":19233,"primaryCompletion":133,"completion":134,"start":135,"enrollment":136,"conditions":19234,"interventions":19235},[89],[138,139],[141,142,96],{"trials":19237,"activeCount":101},[],{"trials":19239,"activeCount":101},[],{"trials":19241,"activeCount":101},[],{"trials":19243,"activeCount":101},[],{"intervention":19245,"totalTrials":331,"cells":19246},"Cyclophosphamide, anti-thymocyte globulin",{"EARLY_PHASE1":19247,"PHASE1":19249,"PHASE2":19258,"PHASE3":19260,"PHASE4":19262,"NA":19264},{"trials":19248,"activeCount":101},[],{"trials":19250,"activeCount":101},[19251],{"nctId":19252,"briefTitle":19253,"status":117,"phases":19254,"primaryCompletion":6695,"completion":6695,"start":19255,"enrollment":239,"conditions":19256,"interventions":19257},"NCT00854139","Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)",[89],"2001-08",[2030,286],[19245],{"trials":19259,"activeCount":101},[],{"trials":19261,"activeCount":101},[],{"trials":19263,"activeCount":101},[],{"trials":19265,"activeCount":101},[],{"intervention":19267,"totalTrials":331,"cells":19268},"Temsirolimus",{"EARLY_PHASE1":19269,"PHASE1":19271,"PHASE2":19280,"PHASE3":19282,"PHASE4":19284,"NA":19286},{"trials":19270,"activeCount":101},[],{"trials":19272,"activeCount":101},[19273],{"nctId":19274,"briefTitle":19275,"status":173,"phases":19276,"primaryCompletion":4281,"completion":4281,"start":2027,"enrollment":693,"conditions":19277,"interventions":19279},"NCT00593008","Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer",[89],[19278],"Pancreatic Adenocarcinoma",[19267,3536],{"trials":19281,"activeCount":101},[],{"trials":19283,"activeCount":101},[],{"trials":19285,"activeCount":101},[],{"trials":19287,"activeCount":101},[],{"intervention":19289,"totalTrials":331,"cells":19290},"Squaric Acid solution",{"EARLY_PHASE1":19291,"PHASE1":19293,"PHASE2":19302,"PHASE3":19304,"PHASE4":19306,"NA":19308},{"trials":19292,"activeCount":101},[],{"trials":19294,"activeCount":101},[19295],{"nctId":19296,"briefTitle":19297,"status":117,"phases":19298,"primaryCompletion":1861,"completion":1861,"start":11429,"enrollment":6652,"conditions":19299,"interventions":19301},"NCT01971385","Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis",[89],[19300],"Herpes Labialis",[19289],{"trials":19303,"activeCount":101},[],{"trials":19305,"activeCount":101},[],{"trials":19307,"activeCount":101},[],{"trials":19309,"activeCount":101},[],{"intervention":19311,"totalTrials":331,"cells":19312},"Stem cell mobilization",{"EARLY_PHASE1":19313,"PHASE1":19315,"PHASE2":19323,"PHASE3":19325,"PHASE4":19327,"NA":19329},{"trials":19314,"activeCount":101},[],{"trials":19316,"activeCount":101},[19317],{"nctId":19318,"briefTitle":19319,"status":117,"phases":19320,"completion":4606,"start":8854,"enrollment":1791,"conditions":19321,"interventions":19322},"NCT00299780","Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization.",[89],[211,2030,2803],[19311],{"trials":19324,"activeCount":101},[],{"trials":19326,"activeCount":101},[],{"trials":19328,"activeCount":101},[],{"trials":19330,"activeCount":101},[],{"intervention":559,"totalTrials":331,"cells":19332},{"EARLY_PHASE1":19333,"PHASE1":19335,"PHASE2":19341,"PHASE3":19343,"PHASE4":19345,"NA":19347},{"trials":19334,"activeCount":101},[],{"trials":19336,"activeCount":101},[19337],{"nctId":551,"briefTitle":552,"status":117,"phases":19338,"primaryCompletion":554,"completion":554,"start":455,"enrollment":555,"conditions":19339,"interventions":19340},[89],[557],[543,559],{"trials":19342,"activeCount":101},[],{"trials":19344,"activeCount":101},[],{"trials":19346,"activeCount":101},[],{"trials":19348,"activeCount":101},[],{"intervention":19350,"totalTrials":331,"cells":19351},"Highly Active Antiretroviral Therapy",{"EARLY_PHASE1":19352,"PHASE1":19354,"PHASE2":19364,"PHASE3":19366,"PHASE4":19368,"NA":19370},{"trials":19353,"activeCount":101},[],{"trials":19355,"activeCount":101},[19356],{"nctId":19357,"briefTitle":19358,"status":117,"phases":19359,"primaryCompletion":19360,"completion":19361,"start":8511,"enrollment":1847,"conditions":19362,"interventions":19363},"NCT00705926","Effectiveness of Antiretroviral Therapy During Acute HIV Infection",[89],"2013-02-07","2017-07-16",[8139],[19350],{"trials":19365,"activeCount":101},[],{"trials":19367,"activeCount":101},[],{"trials":19369,"activeCount":101},[],{"trials":19371,"activeCount":101},[],{"intervention":19373,"totalTrials":331,"cells":19374},"T Regulatory Cell",{"EARLY_PHASE1":19375,"PHASE1":19377,"PHASE2":19387,"PHASE3":19389,"PHASE4":19391,"NA":19393},{"trials":19376,"activeCount":101},[],{"trials":19378,"activeCount":101},[19379],{"nctId":19380,"briefTitle":19381,"status":117,"phases":19382,"primaryCompletion":19383,"completion":19383,"start":566,"enrollment":798,"conditions":19384,"interventions":19386},"NCT02091232","Infusion of T-Regulatory Cells in Kidney Transplant Recipients (The ONE Study)",[89],"2016-03-02",[19385],"Kidney Failure, Kidney Transplant",[19373],{"trials":19388,"activeCount":101},[],{"trials":19390,"activeCount":101},[],{"trials":19392,"activeCount":101},[],{"trials":19394,"activeCount":101},[],{"intervention":4372,"totalTrials":331,"cells":19396},{"EARLY_PHASE1":19397,"PHASE1":19399,"PHASE2":19405,"PHASE3":19407,"PHASE4":19409,"NA":19411},{"trials":19398,"activeCount":101},[],{"trials":19400,"activeCount":101},[19401],{"nctId":4366,"briefTitle":4367,"status":107,"phases":19402,"primaryCompletion":1780,"completion":1780,"start":4369,"enrollment":101,"conditions":19403,"interventions":19404},[89],[2884],[4372,2807,3388],{"trials":19406,"activeCount":101},[],{"trials":19408,"activeCount":101},[],{"trials":19410,"activeCount":101},[],{"trials":19412,"activeCount":101},[],{"intervention":4560,"totalTrials":331,"cells":19414},{"EARLY_PHASE1":19415,"PHASE1":19421,"PHASE2":19423,"PHASE3":19425,"PHASE4":19427,"NA":19429},{"trials":19416,"activeCount":101},[19417],{"nctId":4553,"briefTitle":4554,"status":117,"phases":19418,"primaryCompletion":3644,"completion":2407,"start":477,"enrollment":1847,"conditions":19419,"interventions":19420},[88],[4557],[4559,4560],{"trials":19422,"activeCount":101},[],{"trials":19424,"activeCount":101},[],{"trials":19426,"activeCount":101},[],{"trials":19428,"activeCount":101},[],{"trials":19430,"activeCount":101},[],{"intervention":19432,"totalTrials":331,"cells":19433},"Multimodal analgesia",{"EARLY_PHASE1":19434,"PHASE1":19443,"PHASE2":19445,"PHASE3":19447,"PHASE4":19449,"NA":19451},{"trials":19435,"activeCount":101},[19436],{"nctId":19437,"briefTitle":19438,"status":107,"phases":19439,"primaryCompletion":19440,"completion":19440,"start":19440,"enrollment":101,"conditions":19441,"interventions":19442},"NCT03817034","Multimodal Analgesia for the Reduction of Postoperative Opioid Consumption",[88],"2021-03-11",[1880],[19432],{"trials":19444,"activeCount":101},[],{"trials":19446,"activeCount":101},[],{"trials":19448,"activeCount":101},[],{"trials":19450,"activeCount":101},[],{"trials":19452,"activeCount":101},[],{"intervention":19454,"totalTrials":331,"cells":19455},"ICG",{"EARLY_PHASE1":19456,"PHASE1":19464,"PHASE2":19466,"PHASE3":19468,"PHASE4":19470,"NA":19472},{"trials":19457,"activeCount":101},[19458],{"nctId":19459,"briefTitle":19460,"status":117,"phases":19461,"primaryCompletion":455,"completion":455,"start":11429,"enrollment":194,"conditions":19462,"interventions":19463},"NCT01962649","A Pilot Study of Optical Molecular Imaging for Percutaneous Biopsy of Hepatocellular Carcinoma Using Indocyanine Green",[88],[4031],[19454],{"trials":19465,"activeCount":101},[],{"trials":19467,"activeCount":101},[],{"trials":19469,"activeCount":101},[],{"trials":19471,"activeCount":101},[],{"trials":19473,"activeCount":101},[],{"intervention":19475,"totalTrials":331,"cells":19476},"micronized progesterone",{"EARLY_PHASE1":19477,"PHASE1":19488,"PHASE2":19490,"PHASE3":19492,"PHASE4":19494,"NA":19496},{"trials":19478,"activeCount":101},[19479],{"nctId":19480,"briefTitle":19481,"status":117,"phases":19482,"primaryCompletion":19483,"completion":19483,"start":3680,"enrollment":538,"conditions":19484,"interventions":19486},"NCT02486757","Investigation of Female Reproductive Hormone Dynamics During Adolescence",[88],"2016-03-01",[19485],"Menstruation Disturbances",[19475,19487],"transdermal estradiol",{"trials":19489,"activeCount":101},[],{"trials":19491,"activeCount":101},[],{"trials":19493,"activeCount":101},[],{"trials":19495,"activeCount":101},[],{"trials":19497,"activeCount":101},[],{"intervention":19487,"totalTrials":331,"cells":19499},{"EARLY_PHASE1":19500,"PHASE1":19506,"PHASE2":19508,"PHASE3":19510,"PHASE4":19512,"NA":19514},{"trials":19501,"activeCount":101},[19502],{"nctId":19480,"briefTitle":19481,"status":117,"phases":19503,"primaryCompletion":19483,"completion":19483,"start":3680,"enrollment":538,"conditions":19504,"interventions":19505},[88],[19485],[19475,19487],{"trials":19507,"activeCount":101},[],{"trials":19509,"activeCount":101},[],{"trials":19511,"activeCount":101},[],{"trials":19513,"activeCount":101},[],{"trials":19515,"activeCount":101},[],{"intervention":19517,"totalTrials":331,"cells":19518},"LC106",{"EARLY_PHASE1":19519,"PHASE1":19533,"PHASE2":19535,"PHASE3":19537,"PHASE4":19539,"NA":19541},{"trials":19520,"activeCount":101},[19521],{"nctId":19522,"briefTitle":19523,"status":117,"phases":19524,"primaryCompletion":19525,"completion":19526,"start":19527,"enrollment":886,"conditions":19528,"interventions":19530},"NCT06135974","Vaginal lIve Biotherapeutic RANdomized Trial",[88],"2024-12-26","2025-02-18","2024-02-01",[19529],"Bacterial Vaginosis",[19517,19531,19532],"LC115","Metronidazole",{"trials":19534,"activeCount":101},[],{"trials":19536,"activeCount":101},[],{"trials":19538,"activeCount":101},[],{"trials":19540,"activeCount":101},[],{"trials":19542,"activeCount":101},[],{"intervention":19531,"totalTrials":331,"cells":19544},{"EARLY_PHASE1":19545,"PHASE1":19551,"PHASE2":19553,"PHASE3":19555,"PHASE4":19557,"NA":19559},{"trials":19546,"activeCount":101},[19547],{"nctId":19522,"briefTitle":19523,"status":117,"phases":19548,"primaryCompletion":19525,"completion":19526,"start":19527,"enrollment":886,"conditions":19549,"interventions":19550},[88],[19529],[19517,19531,19532],{"trials":19552,"activeCount":101},[],{"trials":19554,"activeCount":101},[],{"trials":19556,"activeCount":101},[],{"trials":19558,"activeCount":101},[],{"trials":19560,"activeCount":101},[],{"intervention":19532,"totalTrials":331,"cells":19562},{"EARLY_PHASE1":19563,"PHASE1":19569,"PHASE2":19571,"PHASE3":19573,"PHASE4":19575,"NA":19577},{"trials":19564,"activeCount":101},[19565],{"nctId":19522,"briefTitle":19523,"status":117,"phases":19566,"primaryCompletion":19525,"completion":19526,"start":19527,"enrollment":886,"conditions":19567,"interventions":19568},[88],[19529],[19517,19531,19532],{"trials":19570,"activeCount":101},[],{"trials":19572,"activeCount":101},[],{"trials":19574,"activeCount":101},[],{"trials":19576,"activeCount":101},[],{"trials":19578,"activeCount":101},[],{"intervention":19580,"totalTrials":331,"cells":19581},"Topiramate or Placebo",{"EARLY_PHASE1":19582,"PHASE1":19592,"PHASE2":19594,"PHASE3":19596,"PHASE4":19598,"NA":19600},{"trials":19583,"activeCount":101},[19584],{"nctId":19585,"briefTitle":19586,"status":117,"phases":19587,"primaryCompletion":19588,"completion":19588,"start":912,"enrollment":36,"conditions":19589,"interventions":19591},"NCT00606411","Efficacy and Safety of Topiramate in the Treatment of Sleep-Related Eating Disorder",[88],"2018-11-29",[19590],"Sleep-Related Eating Disorder",[19580],{"trials":19593,"activeCount":101},[],{"trials":19595,"activeCount":101},[],{"trials":19597,"activeCount":101},[],{"trials":19599,"activeCount":101},[],{"trials":19601,"activeCount":101},[],{"intervention":19603,"totalTrials":331,"cells":19604},"Eovist",{"EARLY_PHASE1":19605,"PHASE1":19613,"PHASE2":19615,"PHASE3":19617,"PHASE4":19619,"NA":19621},{"trials":19606,"activeCount":101},[19607],{"nctId":19608,"briefTitle":19609,"status":107,"phases":19610,"primaryCompletion":1814,"completion":1814,"start":4677,"enrollment":101,"conditions":19611,"interventions":19612},"NCT01968629","24hr Imaging Of HCC After EOVIST",[88],[4031],[19603],{"trials":19614,"activeCount":101},[],{"trials":19616,"activeCount":101},[],{"trials":19618,"activeCount":101},[],{"trials":19620,"activeCount":101},[],{"trials":19622,"activeCount":101},[],{"intervention":19624,"totalTrials":331,"cells":19625},"Ranibizumab",{"EARLY_PHASE1":19626,"PHASE1":19634,"PHASE2":19636,"PHASE3":19638,"PHASE4":19640,"NA":19642},{"trials":19627,"activeCount":101},[19628],{"nctId":19629,"briefTitle":19630,"status":117,"phases":19631,"primaryCompletion":4281,"completion":4677,"start":8926,"enrollment":4618,"conditions":19632,"interventions":19633},"NCT00657202","Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1",[88],[18643,18644],[19624],{"trials":19635,"activeCount":101},[],{"trials":19637,"activeCount":101},[],{"trials":19639,"activeCount":101},[],{"trials":19641,"activeCount":101},[],{"trials":19643,"activeCount":101},[],{"intervention":19645,"totalTrials":331,"cells":19646},"Exparel",{"EARLY_PHASE1":19647,"PHASE1":19659,"PHASE2":19661,"PHASE3":19663,"PHASE4":19665,"NA":19667},{"trials":19648,"activeCount":101},[19649],{"nctId":19650,"briefTitle":19651,"status":173,"phases":19652,"primaryCompletion":19653,"completion":19653,"start":19654,"enrollment":544,"conditions":19655,"interventions":19658},"NCT03705637","Liposomal Bupivicaine for Skin Graft Donor Sites in Burn Patients",[88],"2020-03-24","2019-06-01",[19656,19657],"Burns","Postoperative Pain",[19645],{"trials":19660,"activeCount":101},[],{"trials":19662,"activeCount":101},[],{"trials":19664,"activeCount":101},[],{"trials":19666,"activeCount":101},[],{"trials":19668,"activeCount":101},[],{"intervention":12347,"totalTrials":1791,"cells":19670},{"EARLY_PHASE1":19671,"PHASE1":19681,"PHASE2":19683,"PHASE3":19685,"PHASE4":19704,"NA":19740},{"trials":19672,"activeCount":101},[19673],{"nctId":19674,"briefTitle":19675,"status":117,"phases":19676,"primaryCompletion":119,"completion":15088,"start":8610,"enrollment":7086,"conditions":19677,"interventions":19679},"NCT00842309","D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder",[88],[19678],"Body Dysmorphic Disorder",[19680],"d-cycloserine",{"trials":19682,"activeCount":101},[],{"trials":19684,"activeCount":101},[],{"trials":19686,"activeCount":101},[19687,19693,19697],{"nctId":19688,"briefTitle":19689,"status":117,"phases":19690,"primaryCompletion":11429,"completion":11429,"start":12241,"enrollment":1533,"conditions":19691,"interventions":19692},"NCT01399866","Cognitive Remediation With D-Cycloserine",[91],[711],[12347],{"nctId":12341,"briefTitle":12342,"status":107,"phases":19694,"primaryCompletion":6688,"completion":6688,"start":12344,"enrollment":101,"conditions":19695,"interventions":19696},[91],[35],[12347,12330,12348],{"nctId":19698,"briefTitle":19699,"status":117,"phases":19700,"primaryCompletion":13658,"completion":13658,"start":19701,"enrollment":1578,"conditions":19702,"interventions":19703},"NCT00000371","Trial of D-Cycloserine in Schizophrenia",[91],"1996-08",[35],[12347],{"trials":19705,"activeCount":101},[19706,19712,19718,19727,19734],{"nctId":19707,"briefTitle":19708,"status":117,"phases":19709,"primaryCompletion":238,"completion":2994,"start":8504,"enrollment":2508,"conditions":19710,"interventions":19711},"NCT00742079","Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia",[92],[35],[12347],{"nctId":19713,"briefTitle":19714,"status":107,"phases":19715,"primaryCompletion":4464,"completion":4464,"start":250,"enrollment":101,"conditions":19716,"interventions":19717},"NCT00964041","Once Weekly D-cycloserine for Schizophrenia",[92],[35],[12347],{"nctId":19719,"briefTitle":19720,"status":117,"phases":19721,"primaryCompletion":2827,"completion":2801,"start":110,"enrollment":19722,"conditions":19723,"interventions":19725},"NCT00633984","D-Cycloserine Enhancement of Exposure in Social Phobia",[92],169,[19724],"Social Anxiety Disorder",[19726],"D-Cycloserine",{"nctId":19728,"briefTitle":19729,"status":117,"phases":19730,"primaryCompletion":1008,"completion":1008,"start":6615,"enrollment":331,"conditions":19731,"interventions":19733},"NCT07542548","D-Cycloserine for Serine Palmitoyltransferase Inhibition",[92],[19732],"Hereditary Spastic Paraplegia",[12347],{"nctId":19735,"briefTitle":19736,"status":117,"phases":19737,"primaryCompletion":4606,"completion":4606,"start":8854,"enrollment":6796,"conditions":19738,"interventions":19739},"NCT00455702","Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia",[92],[35],[19680],{"trials":19741,"activeCount":101},[19742,19748,19755],{"nctId":19743,"briefTitle":19744,"status":117,"phases":19745,"completion":4666,"start":8723,"enrollment":366,"conditions":19746,"interventions":19747},"NCT00126282","A Medication Trial Combined With Behavior Therapy for Individuals With Obsessive-compulsive Disorder",[93],[10640],[19726],{"nctId":19749,"briefTitle":19750,"status":117,"phases":19751,"primaryCompletion":1861,"completion":268,"start":176,"enrollment":19752,"conditions":19753,"interventions":19754},"NCT01404208","2\u002F2 D-Cycloserine Augmentation of CBT for Pediatric OCD",[93],206,[10640],[19726],{"nctId":19756,"briefTitle":19757,"status":117,"phases":19758,"primaryCompletion":12241,"completion":4464,"start":3607,"enrollment":6652,"conditions":19759,"interventions":19760},"NCT00963924","D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia",[93],[35],[12347],{"intervention":2987,"totalTrials":538,"cells":19762},{"EARLY_PHASE1":19763,"PHASE1":19769,"PHASE2":19771,"PHASE3":19796,"PHASE4":19816,"NA":19826},{"trials":19764,"activeCount":101},[19765],{"nctId":2980,"briefTitle":2981,"status":2758,"phases":19766,"primaryCompletion":2983,"completion":2983,"start":2984,"enrollment":227,"conditions":19767,"interventions":19768},[88],[1793,29],[2987,2975],{"trials":19770,"activeCount":101},[],{"trials":19772,"activeCount":101},[19773,19782,19788],{"nctId":19774,"briefTitle":19775,"status":117,"phases":19776,"primaryCompletion":2963,"completion":19777,"start":19778,"enrollment":19779,"conditions":19780,"interventions":19781},"NCT03355053","Investigation of Sleep in the Intensive Care Unit",[90],"2023-03-24","2018-05-29",522,[2122,9568],[2987],{"nctId":19783,"briefTitle":19784,"status":117,"phases":19785,"primaryCompletion":282,"completion":282,"start":2581,"enrollment":2728,"conditions":19786,"interventions":19787},"NCT02818569","Repurposing Dexmedetomidine as an Orally Administered Sleep Therapeutic",[89,90],[9568,819],[2987],{"nctId":19789,"briefTitle":19790,"status":117,"phases":19791,"primaryCompletion":19792,"completion":19792,"start":19793,"enrollment":1890,"conditions":19794,"interventions":19795},"NCT00697788","Dexmedetomidine Cardiovascular Safety in Pediatric Burn Patients",[90],"2008-12-30","2007-07-16",[19656,2277],[2987],{"trials":19797,"activeCount":101},[19798,19806],{"nctId":19799,"briefTitle":19800,"status":117,"phases":19801,"primaryCompletion":5609,"completion":5609,"start":19802,"enrollment":97,"conditions":19803,"interventions":19805},"NCT04656470","Neuroimaging Study of Dexmedetomidine-Induced Analgesia",[90,91],"2022-03-04",[19804,1793],"Analgesia",[2987],{"nctId":19807,"briefTitle":19808,"status":117,"phases":19809,"primaryCompletion":19810,"completion":65,"start":19811,"enrollment":19812,"conditions":19813,"interventions":19815},"NCT02856594","Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep",[90,91],"2022-02-11","2017-03-06",469,[19814,9568,1793],"Postoperative Delirium",[2987],{"trials":19817,"activeCount":101},[19818],{"nctId":19819,"briefTitle":19820,"status":173,"phases":19821,"primaryCompletion":912,"completion":912,"start":13746,"enrollment":101,"conditions":19822,"interventions":19825},"NCT00409344","Dexmedetomidine for Postoperative Sedation in Patients Undergoing Repair of Thoracoabdominal Aortic Aneurysms",[92],[2277,19823,19824],"Respiration, Artificial","Length of Stay",[2987],{"trials":19827,"activeCount":101},[19828,19836],{"nctId":19829,"briefTitle":19830,"status":117,"phases":19831,"primaryCompletion":477,"completion":477,"start":2801,"enrollment":194,"conditions":19832,"interventions":19834},"NCT01485380","Combined Electroencephalogram, Magnetic Resonance Imaging-Positron Emission Tomography of Dexmedetomidine Induced Sleep",[93],[19833],"Dexmedetomidine Induced Sedation",[19835],"dexmedetomidine",{"nctId":19837,"briefTitle":19838,"status":117,"phases":19839,"primaryCompletion":19840,"completion":19841,"start":225,"enrollment":239,"conditions":19842,"interventions":19843},"NCT01485393","Polysomnographic Study Comparing the Use of Dexmedetomidine and Zolpidem to Induce Natural Sleep",[93],"2018-01-29","2018-06-29",[819],[2987,19844],"Zolpidem",{"intervention":573,"totalTrials":1890,"cells":19846},{"EARLY_PHASE1":19847,"PHASE1":19849,"PHASE2":19855,"PHASE3":19867,"PHASE4":19873,"NA":19875},{"trials":19848,"activeCount":101},[],{"trials":19850,"activeCount":101},[19851],{"nctId":18101,"briefTitle":18102,"status":173,"phases":19852,"primaryCompletion":18104,"completion":18104,"start":1936,"enrollment":270,"conditions":19853,"interventions":19854},[89],[11847,11870],[18084,573],{"trials":19856,"activeCount":101},[19857,19861],{"nctId":563,"briefTitle":564,"status":173,"phases":19858,"primaryCompletion":566,"completion":567,"start":568,"enrollment":30,"conditions":19859,"interventions":19860},[90],[570,571,380],[573,543],{"nctId":19862,"briefTitle":19863,"status":117,"phases":19864,"primaryCompletion":554,"completion":554,"start":4581,"enrollment":5840,"conditions":19865,"interventions":19866},"NCT01121211","Hormonal Factors in the Treatment of Anorexia Nervosa",[90],[772,12970,489,15],[573],{"trials":19868,"activeCount":101},[19869],{"nctId":12809,"briefTitle":12810,"status":117,"phases":19870,"primaryCompletion":708,"completion":708,"start":8544,"enrollment":4214,"conditions":19871,"interventions":19872},[90,91],[772],[573,12798],{"trials":19874,"activeCount":101},[],{"trials":19876,"activeCount":101},[19877,19884,19890,19898],{"nctId":19878,"briefTitle":19879,"status":117,"phases":19880,"primaryCompletion":19881,"completion":19881,"start":14706,"enrollment":2582,"conditions":19882,"interventions":19883},"NCT01783574","Testosterone Antidepressant Augmentation in Women",[93],"2017-01-27",[15],[573],{"nctId":19885,"briefTitle":19886,"status":117,"phases":19887,"primaryCompletion":8511,"completion":8511,"start":110,"enrollment":538,"conditions":19888,"interventions":19889},"NCT00676676","Effects of Testosterone in Women With Depression",[93],[15],[573],{"nctId":19891,"briefTitle":19892,"status":117,"phases":19893,"primaryCompletion":308,"completion":308,"start":741,"enrollment":19894,"conditions":19895,"interventions":19896},"NCT00114114","Dose-Response of Gonadal Steroids and Bone Turnover in Older Men",[93],177,[8978],[573,19897],"Goserelin acetate",{"nctId":19899,"briefTitle":19900,"status":107,"phases":19901,"primaryCompletion":554,"completion":554,"start":135,"enrollment":101,"conditions":19902,"interventions":19903},"NCT02269072","Testosterone Regulation of the Natriuretic Peptide System",[93],[5842],[573,19904,19905,9383],"Nesiritide","Leuprolide",{"intervention":3536,"totalTrials":1890,"cells":19907},{"EARLY_PHASE1":19908,"PHASE1":19910,"PHASE2":19916,"PHASE3":19942,"PHASE4":19944,"NA":19946},{"trials":19909,"activeCount":101},[],{"trials":19911,"activeCount":101},[19912],{"nctId":19274,"briefTitle":19275,"status":173,"phases":19913,"primaryCompletion":4281,"completion":4281,"start":2027,"enrollment":693,"conditions":19914,"interventions":19915},[89],[19278],[19267,3536],{"trials":19917,"activeCount":101},[19918,19922,19926,19930,19934,19938],{"nctId":4438,"briefTitle":4439,"status":117,"phases":19919,"primaryCompletion":4441,"completion":4442,"start":3689,"enrollment":4443,"conditions":19920,"interventions":19921},[90],[2730,4427],[47,3536,3626],{"nctId":4655,"briefTitle":4656,"status":117,"phases":19923,"primaryCompletion":4658,"completion":176,"start":4463,"enrollment":648,"conditions":19924,"interventions":19925},[90],[2748,4660],[47,42,3536],{"nctId":4447,"briefTitle":4448,"status":173,"phases":19927,"primaryCompletion":4450,"completion":250,"start":3689,"enrollment":2663,"conditions":19928,"interventions":19929},[89,90],[2748,4452],[3476,3449,3626,4454],{"nctId":13592,"briefTitle":13593,"status":117,"phases":19931,"primaryCompletion":4677,"completion":567,"start":4666,"enrollment":3337,"conditions":19932,"interventions":19933},[90],[6893,13596],[3536,6895],{"nctId":4460,"briefTitle":4461,"status":117,"phases":19935,"primaryCompletion":4463,"completion":4464,"start":4465,"enrollment":2610,"conditions":19936,"interventions":19937},[90],[4031],[3536,3626,47],{"nctId":3831,"briefTitle":3832,"status":117,"phases":19939,"primaryCompletion":1780,"completion":3834,"start":249,"enrollment":3565,"conditions":19940,"interventions":19941},[90],[3836],[3838,3770,3536],{"trials":19943,"activeCount":101},[],{"trials":19945,"activeCount":101},[],{"trials":19947,"activeCount":101},[19948],{"nctId":3528,"briefTitle":3529,"status":173,"phases":19949,"primaryCompletion":1846,"completion":1846,"start":3531,"enrollment":178,"conditions":19950,"interventions":19951},[93],[3533,3534],[3536,2576],{"intervention":4885,"totalTrials":270,"cells":19953},{"EARLY_PHASE1":19954,"PHASE1":19970,"PHASE2":19972,"PHASE3":19995,"PHASE4":19997,"NA":19999},{"trials":19955,"activeCount":101},[19956,19963],{"nctId":19957,"briefTitle":19958,"status":117,"phases":19959,"primaryCompletion":41,"completion":41,"start":3531,"enrollment":239,"conditions":19960,"interventions":19962},"NCT02276677","Oxytocin Effects on Food Motivation Pathways",[88],[19961],"Overweight and Obesity",[4885],{"nctId":19964,"briefTitle":19965,"status":117,"phases":19966,"primaryCompletion":224,"completion":224,"start":11914,"enrollment":1847,"conditions":19967,"interventions":19969},"NCT01513499","Effect of Intranasal Oxytocin on Appetite and Caloric Intake in Men and Women",[88],[19968],"Eating Behavior",[4885],{"trials":19971,"activeCount":101},[],{"trials":19973,"activeCount":101},[19974,19981,19989],{"nctId":19975,"briefTitle":19976,"status":117,"phases":19977,"primaryCompletion":4379,"completion":4379,"start":567,"enrollment":2882,"conditions":19978,"interventions":19980},"NCT02671266","Oxytocin Administration in BDD and OCD",[90],[19678,19979],"Obsessive-compulsive Disorder",[4885],{"nctId":19982,"briefTitle":19983,"status":117,"phases":19984,"primaryCompletion":14213,"completion":14213,"start":4352,"enrollment":19985,"conditions":19986,"interventions":19988},"NCT02505984","Preventing Postpartum Depression With Intranasal Oxytocin",[90],56,[19987,489],"Depression, Postpartum",[4885],{"nctId":19990,"briefTitle":19991,"status":117,"phases":19992,"primaryCompletion":269,"completion":269,"start":455,"enrollment":1009,"conditions":19993,"interventions":19994},"NCT01914939","A Randomized, Controlled Trial of Intranasal Oxytocin as an Adjunct to Behavioral Therapy for Autism Spectrum Disorder",[90],[540],[4885],{"trials":19996,"activeCount":101},[],{"trials":19998,"activeCount":101},[],{"trials":20000,"activeCount":101},[20001,20008],{"nctId":20002,"briefTitle":20003,"status":117,"phases":20004,"primaryCompletion":121,"completion":121,"start":3658,"enrollment":27,"conditions":20005,"interventions":20007},"NCT01551303","Effect of Intranasal Neuropeptide on Emotion Perception in Trait Anxiety",[93],[20006],"Social Intelligence",[4885],{"nctId":20009,"briefTitle":20010,"status":117,"phases":20011,"primaryCompletion":566,"completion":566,"start":568,"enrollment":1578,"conditions":20012,"interventions":20013},"NCT01466127","The Effect of Oxytocin on Fear Memory Consolidation Novel Intervention to Prevent Posttraumatic Stress Disorder (PTSD)",[93],[722],[4885],{"intervention":4514,"totalTrials":693,"cells":20015},{"EARLY_PHASE1":20016,"PHASE1":20018,"PHASE2":20024,"PHASE3":20041,"PHASE4":20043,"NA":20045},{"trials":20017,"activeCount":101},[],{"trials":20019,"activeCount":101},[20020],{"nctId":908,"briefTitle":909,"status":117,"phases":20021,"primaryCompletion":911,"completion":911,"start":912,"enrollment":829,"conditions":20022,"interventions":20023},[89],[914,915,916,211,917,918,919],[921,922,923,924,925,926,927,928,243,901],{"trials":20025,"activeCount":101},[20026,20030,20034],{"nctId":4506,"briefTitle":4507,"status":117,"phases":20027,"primaryCompletion":175,"completion":149,"start":2456,"enrollment":648,"conditions":20028,"interventions":20029},[90],[2030,4500,4510,4511,4512],[4514,4515,4516,4517,4518,200,4503],{"nctId":4524,"briefTitle":4525,"status":117,"phases":20031,"primaryCompletion":4527,"completion":554,"start":751,"enrollment":3565,"conditions":20032,"interventions":20033},[90],[4529,4530,4531,4532,4501,123,4533],[4535,2806,201,4536,4537,200,4535,4514,4515,3789],{"nctId":20035,"briefTitle":20036,"status":107,"phases":20037,"primaryCompletion":3915,"completion":3588,"start":20038,"enrollment":101,"conditions":20039,"interventions":20040},"NCT04263519","A Pilot Open Labeled Study of Tacrolimus in Alzheimer's Disease.",[90],"2021-12-01",[5544,17741],[4514],{"trials":20042,"activeCount":101},[],{"trials":20044,"activeCount":101},[],{"trials":20046,"activeCount":101},[20047],{"nctId":20048,"briefTitle":20049,"status":117,"phases":20050,"primaryCompletion":20051,"completion":20051,"start":135,"enrollment":136,"conditions":20052,"interventions":20054},"NCT02158052","Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease",[93],"2021-06-22",[2030,20053],"Amyloidosis",[4514,20055,20056],"Equine Anti-thymocyte globulin","Bone marrow transplant from a related donor",{"intervention":14437,"totalTrials":693,"cells":20058},{"EARLY_PHASE1":20059,"PHASE1":20061,"PHASE2":20063,"PHASE3":20073,"PHASE4":20075,"NA":20077},{"trials":20060,"activeCount":101},[],{"trials":20062,"activeCount":101},[],{"trials":20064,"activeCount":101},[20065,20069],{"nctId":15590,"briefTitle":15591,"status":117,"phases":20066,"primaryCompletion":436,"completion":8798,"start":150,"enrollment":270,"conditions":20067,"interventions":20068},[89,90],[3055],[15581,14437],{"nctId":14429,"briefTitle":14430,"status":117,"phases":20070,"primaryCompletion":10682,"completion":9525,"start":1779,"enrollment":136,"conditions":20071,"interventions":20072},[90],[14433,3066],[14435,4518,14436,14437],{"trials":20074,"activeCount":101},[],{"trials":20076,"activeCount":101},[],{"trials":20078,"activeCount":101},[20079,20085,20091],{"nctId":20080,"briefTitle":20081,"status":117,"phases":20082,"primaryCompletion":8450,"completion":8450,"start":4465,"enrollment":19985,"conditions":20083,"interventions":20084},"NCT00409318","Study of TNF-Antagonism in Metabolic Syndrome",[93],[18096],[14437],{"nctId":20086,"briefTitle":20087,"status":117,"phases":20088,"primaryCompletion":6891,"completion":6891,"start":177,"enrollment":251,"conditions":20089,"interventions":20090},"NCT00413400","Study of TNF-Antagonism in the Metabolic Syndrome (II)",[93],[18096],[14437],{"nctId":20092,"briefTitle":20093,"status":173,"phases":20094,"primaryCompletion":4677,"completion":4677,"start":752,"enrollment":209,"conditions":20095,"interventions":20098},"NCT00477191","Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis",[93],[20096,18096,20097,26,5842],"Psoriasis","Hyperlipidemia",[14437],{"intervention":20100,"totalTrials":798,"cells":20101},"Intranasal Oxytocin",{"EARLY_PHASE1":20102,"PHASE1":20104,"PHASE2":20115,"PHASE3":20117,"PHASE4":20130,"NA":20136},{"trials":20103,"activeCount":101},[],{"trials":20105,"activeCount":101},[20106],{"nctId":20107,"briefTitle":20108,"status":117,"phases":20109,"primaryCompletion":20110,"completion":20110,"start":20111,"enrollment":4443,"conditions":20112,"interventions":20113},"NCT03337035","Probiotics and Oxytocin Nasal Spray on Social Behaviors of Autism Spectrum Disorder (ASD) Children",[89],"2019-10-02","2018-12-01",[488],[20114],"intranasal oxytocin",{"trials":20116,"activeCount":101},[],{"trials":20118,"activeCount":101},[20119],{"nctId":20120,"briefTitle":20121,"status":117,"phases":20122,"primaryCompletion":20123,"completion":20123,"start":20124,"enrollment":270,"conditions":20125,"interventions":20129},"NCT02985749","A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder",[91],"2019-01-09","2017-10-09",[488,20126,20127,20128],"Pervasive Developmental Disorder","ASD","PDD",[20100],{"trials":20131,"activeCount":101},[20132],{"nctId":716,"briefTitle":717,"status":117,"phases":20133,"primaryCompletion":225,"completion":225,"start":719,"enrollment":720,"conditions":20134,"interventions":20135},[92],[722,686],[692,724,725],{"trials":20137,"activeCount":101},[20138],{"nctId":20139,"briefTitle":20140,"status":117,"phases":20141,"primaryCompletion":770,"completion":770,"start":11429,"enrollment":1890,"conditions":20142,"interventions":20144},"NCT01931033","An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders",[93],[540,20143,20127,20128],"Pervasive Developmental Disorders",[20100],{"intervention":20146,"totalTrials":798,"cells":20147},"Eszopiclone",{"EARLY_PHASE1":20148,"PHASE1":20150,"PHASE2":20152,"PHASE3":20154,"PHASE4":20156,"NA":20165},{"trials":20149,"activeCount":101},[],{"trials":20151,"activeCount":101},[],{"trials":20153,"activeCount":101},[],{"trials":20155,"activeCount":101},[],{"trials":20157,"activeCount":101},[20158],{"nctId":20159,"briefTitle":20160,"status":117,"phases":20161,"primaryCompletion":2848,"completion":2848,"start":3659,"enrollment":457,"conditions":20162,"interventions":20164},"NCT00120250","Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder",[92],[20163],"Post-Traumatic Stress Disorders",[20146],{"trials":20166,"activeCount":101},[20167,20175,20181],{"nctId":20168,"briefTitle":20169,"status":117,"phases":20170,"primaryCompletion":2800,"completion":2800,"start":9600,"enrollment":20171,"conditions":20172,"interventions":20173},"NCT01641900","Effects of Eszopiclone on Sleep and Memory in Schizophrenia",[93],59,[35],[20174],"eszopiclone",{"nctId":20176,"briefTitle":20177,"status":117,"phases":20178,"primaryCompletion":2801,"completion":2801,"start":8504,"enrollment":1847,"conditions":20179,"interventions":20180},"NCT00833547","Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia",[93],[35],[20174],{"nctId":20182,"briefTitle":20183,"status":117,"phases":20184,"primaryCompletion":4272,"completion":4272,"start":2046,"enrollment":20185,"conditions":20186,"interventions":20187},"NCT00374192","The Treatment of Insomnia in Symptomatic Peri- and Postmenopausal Women",[93],67,[8621,819],[20146],{"intervention":13789,"totalTrials":798,"cells":20189},{"EARLY_PHASE1":20190,"PHASE1":20192,"PHASE2":20202,"PHASE3":20208,"PHASE4":20210,"NA":20212},{"trials":20191,"activeCount":101},[],{"trials":20193,"activeCount":101},[20194,20198],{"nctId":18214,"briefTitle":18215,"status":117,"phases":20195,"primaryCompletion":11845,"completion":11845,"start":8504,"enrollment":2837,"conditions":20196,"interventions":20197},[89],[13574],[18207,13789],{"nctId":13778,"briefTitle":13779,"status":117,"phases":20199,"primaryCompletion":13781,"completion":13782,"start":13783,"enrollment":1914,"conditions":20200,"interventions":20201},[89],[13785,13786],[13788,13789,3625],{"trials":20203,"activeCount":101},[20204],{"nctId":15874,"briefTitle":15875,"status":117,"phases":20205,"primaryCompletion":15877,"completion":15877,"start":15878,"enrollment":33,"conditions":20206,"interventions":20207},[90],[13574],[13789,15865],{"trials":20209,"activeCount":101},[],{"trials":20211,"activeCount":101},[],{"trials":20213,"activeCount":101},[20214],{"nctId":20215,"briefTitle":20216,"status":173,"phases":20217,"primaryCompletion":9320,"completion":9320,"start":3464,"enrollment":2728,"conditions":20218,"interventions":20220},"NCT00756106","MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma",[93],[20219],"Brain and Central Nervous System Tumors",[20221],"temozolomide",{"intervention":20223,"totalTrials":798,"cells":20224},"somatropin",{"EARLY_PHASE1":20225,"PHASE1":20234,"PHASE2":20236,"PHASE3":20238,"PHASE4":20240,"NA":20242},{"trials":20226,"activeCount":101},[20227],{"nctId":20228,"briefTitle":20229,"status":117,"phases":20230,"primaryCompletion":4301,"completion":4301,"start":20231,"enrollment":886,"conditions":20232,"interventions":20233},"NCT02726542","Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents",[88],"2017-05-03",[17673],[20223],{"trials":20235,"activeCount":101},[],{"trials":20237,"activeCount":101},[],{"trials":20239,"activeCount":101},[],{"trials":20241,"activeCount":101},[],{"trials":20243,"activeCount":101},[20244,20252,20259],{"nctId":20245,"briefTitle":20246,"status":173,"phases":20247,"completion":9865,"start":3659,"enrollment":331,"conditions":20248,"interventions":20251},"NCT00121875","Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature",[],[20249,20250],"Turner Syndrome","Idiopathic Short Stature",[20223],{"nctId":20253,"briefTitle":20254,"status":2758,"phases":20255,"primaryCompletion":176,"completion":4290,"start":8722,"enrollment":1791,"conditions":20256,"interventions":20258},"NCT00120497","Study to Examine Insulin Resistance During Growth Hormone Treatment for Short Stature Due to Low Birthweight",[],[20257],"Fetal Growth Retardation",[20223],{"nctId":20260,"briefTitle":20261,"status":117,"phases":20262,"primaryCompletion":10956,"completion":10956,"start":11915,"enrollment":4099,"conditions":20263,"interventions":20264},"NCT00136032","Growth Hormone Administration and Its Effects on Cardiovascular Risk Factors in Growth Hormone Deficient Women",[93],[3082],[20265],"Somatropin",{"intervention":13667,"totalTrials":798,"cells":20267},{"EARLY_PHASE1":20268,"PHASE1":20270,"PHASE2":20272,"PHASE3":20282,"PHASE4":20288,"NA":20290},{"trials":20269,"activeCount":101},[],{"trials":20271,"activeCount":101},[],{"trials":20273,"activeCount":101},[20274,20278],{"nctId":16466,"briefTitle":16467,"status":173,"phases":20275,"primaryCompletion":16469,"completion":16469,"start":554,"enrollment":331,"conditions":20276,"interventions":20277},[90],[16471],[16457,13667],{"nctId":13662,"briefTitle":13648,"status":117,"phases":20279,"primaryCompletion":628,"completion":628,"start":741,"enrollment":4618,"conditions":20280,"interventions":20281},[90],[13652],[13638,13666,13667],{"trials":20283,"activeCount":101},[20284],{"nctId":12097,"briefTitle":12098,"status":2758,"phases":20285,"primaryCompletion":119,"completion":119,"start":1780,"enrollment":1466,"conditions":20286,"interventions":20287},[90,91],[10982,12101,12102,12103],[12079,12105,12106,12107],{"trials":20289,"activeCount":101},[],{"trials":20291,"activeCount":101},[20292],{"nctId":20293,"briefTitle":20294,"status":173,"phases":20295,"primaryCompletion":1244,"completion":1244,"start":707,"enrollment":2028,"conditions":20296,"interventions":20298},"NCT01304082","Clinical Study to Evaluate the Effect of pH on Pain Upon Local Anesthetic Administration.",[93],[20297],"Local Anesthetics",[20299,20300,20301],"Lidocaine","normal saline","alkalinized lidocaine",{"intervention":20303,"totalTrials":798,"cells":20304},"Gabapentin",{"EARLY_PHASE1":20305,"PHASE1":20307,"PHASE2":20309,"PHASE3":20311,"PHASE4":20313,"NA":20325},{"trials":20306,"activeCount":101},[],{"trials":20308,"activeCount":101},[],{"trials":20310,"activeCount":101},[],{"trials":20312,"activeCount":101},[],{"trials":20314,"activeCount":101},[20315],{"nctId":20316,"briefTitle":20317,"status":107,"phases":20318,"primaryCompletion":20319,"completion":134,"start":20320,"enrollment":101,"conditions":20321,"interventions":20324},"NCT02957097","Gabapentin as a Pre-emptive Analgesic in Oral and Maxillofacial Surgical Procedures",[92],"2021-06","2019-09",[10982,20322,20323],"Acute Pain","Facial Pain",[20303],{"trials":20326,"activeCount":101},[20327,20334,20341],{"nctId":20328,"briefTitle":20329,"status":117,"phases":20330,"primaryCompletion":4490,"completion":4490,"start":121,"enrollment":19985,"conditions":20331,"interventions":20332},"NCT01678586","Effect of Acupuncture and Pain Medication on Radicular Pain Using QST",[93],[1880],[20303,20333],"Sham Gabapentin",{"nctId":20335,"briefTitle":20336,"status":173,"phases":20337,"primaryCompletion":309,"completion":309,"start":1876,"enrollment":693,"conditions":20338,"interventions":20340},"NCT01623271","Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)",[93],[20339],"Complex Regional Pain Syndrome I (CRPS I)",[20303],{"nctId":20342,"briefTitle":20343,"status":117,"phases":20344,"primaryCompletion":249,"completion":249,"start":224,"enrollment":648,"conditions":20345,"interventions":20346},"NCT02040532","Gabapentin for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women",[93],[8621,9400,9567],[20303],{"intervention":20348,"totalTrials":798,"cells":20349},"bupropion SR",{"EARLY_PHASE1":20350,"PHASE1":20352,"PHASE2":20354,"PHASE3":20356,"PHASE4":20358,"NA":20384},{"trials":20351,"activeCount":101},[],{"trials":20353,"activeCount":101},[],{"trials":20355,"activeCount":101},[],{"trials":20357,"activeCount":101},[],{"trials":20359,"activeCount":101},[20360,20370,20378],{"nctId":20361,"briefTitle":20362,"status":117,"phases":20363,"completion":8723,"start":20364,"enrollment":20365,"conditions":20366,"interventions":20369},"NCT00181818","Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease",[92],"1999-10",248,[1930,7639,20367,20368],"Unstable Angina","Cardiovascular Disease",[20348],{"nctId":20371,"briefTitle":20372,"status":173,"phases":20373,"completion":8690,"start":8580,"enrollment":251,"conditions":20374,"interventions":20376},"NCT00119210","Pilot Study of Bupropion for Smoking Cessation in Postpartum Non-breastfeeding Women",[92],[20375],"Tobacco Use Disorder",[20377],"Bupropion SR",{"nctId":20379,"briefTitle":20380,"status":173,"phases":20381,"primaryCompletion":684,"start":13650,"enrollment":331,"conditions":20382,"interventions":20383},"NCT00181896","Bupropion SR for Major Depression and Depression NOS in Children and Adolescents With Bipolar Disorder",[92],[15,24],[20348],{"trials":20385,"activeCount":101},[20386],{"nctId":20387,"briefTitle":20388,"status":117,"phases":20389,"primaryCompletion":20390,"start":20391,"enrollment":648,"conditions":20392,"interventions":20393},"NCT01270555","Efficacy Of Bupropion For Attention Deficit Hyperactivity Disorder (ADHD) In Adults",[93],"2001-07","1999-05",[9322,1672],[20377],{"intervention":20395,"totalTrials":798,"cells":20396},"recombinant human growth hormone",{"EARLY_PHASE1":20397,"PHASE1":20399,"PHASE2":20401,"PHASE3":20416,"PHASE4":20418,"NA":20420},{"trials":20398,"activeCount":101},[],{"trials":20400,"activeCount":101},[],{"trials":20402,"activeCount":101},[20403,20409],{"nctId":20404,"briefTitle":20405,"status":117,"phases":20406,"primaryCompletion":626,"completion":567,"start":6900,"enrollment":2859,"conditions":20407,"interventions":20408},"NCT01169103","Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls",[90],[26],[20395],{"nctId":20410,"briefTitle":20411,"status":117,"phases":20412,"primaryCompletion":3658,"completion":3658,"start":11301,"enrollment":2508,"conditions":20413,"interventions":20414},"NCT00283595","Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa",[90],[772,571,380,5255],[20415],"Recombinant Human Growth Hormone",{"trials":20417,"activeCount":101},[],{"trials":20419,"activeCount":101},[],{"trials":20421,"activeCount":101},[20422,20429],{"nctId":20423,"briefTitle":20424,"status":117,"phases":20425,"primaryCompletion":2027,"completion":637,"start":8992,"enrollment":19985,"conditions":20426,"interventions":20428},"NCT00100698","Physiologic Growth Hormone Effects in HIV Lipodystrophy",[93],[20427,8139],"AIDS",[20395],{"nctId":3075,"briefTitle":3076,"status":117,"phases":20430,"primaryCompletion":3078,"completion":2994,"start":3079,"enrollment":872,"conditions":20431,"interventions":20432},[93],[3081,3082,3083],[3085,2975],{"intervention":20434,"totalTrials":178,"cells":20435},"Ergocalciferol",{"EARLY_PHASE1":20436,"PHASE1":20438,"PHASE2":20440,"PHASE3":20442,"PHASE4":20444,"NA":20446},{"trials":20437,"activeCount":101},[],{"trials":20439,"activeCount":101},[],{"trials":20441,"activeCount":101},[],{"trials":20443,"activeCount":101},[],{"trials":20445,"activeCount":101},[],{"trials":20447,"activeCount":101},[20448,20455,20462],{"nctId":20449,"briefTitle":20450,"status":117,"phases":20451,"primaryCompletion":3531,"completion":3531,"start":2847,"enrollment":20452,"conditions":20453,"interventions":20454},"NCT00892099","DIVINE: Dialysis Infection and Vitamin D In New England",[93],105,[286],[20434,20434],{"nctId":20456,"briefTitle":20457,"status":117,"phases":20458,"primaryCompletion":11914,"completion":11914,"start":4272,"enrollment":1781,"conditions":20459,"interventions":20460},"NCT00742235","hCAP18 Levels and Vitamin D Deficiency in Healthy Subjects",[93],[7882,12141],[20461],"ergocalciferol",{"nctId":20463,"briefTitle":20464,"status":107,"phases":20465,"primaryCompletion":6695,"completion":567,"start":3078,"enrollment":101,"conditions":20466,"interventions":20467},"NCT01026363","hCAP18 Levels and Vitamin D Deficiency in Chronic Kidney Disease",[93],[10168,12141],[20434,20468],"Calcitriol",{"intervention":654,"totalTrials":178,"cells":20470},{"EARLY_PHASE1":20471,"PHASE1":20473,"PHASE2":20475,"PHASE3":20477,"PHASE4":20479,"NA":20489},{"trials":20472,"activeCount":101},[],{"trials":20474,"activeCount":101},[],{"trials":20476,"activeCount":101},[],{"trials":20478,"activeCount":101},[],{"trials":20480,"activeCount":101},[20481,20485],{"nctId":9724,"briefTitle":9725,"status":107,"phases":20482,"primaryCompletion":135,"completion":3680,"start":626,"enrollment":101,"conditions":20483,"interventions":20484},[92],[18,489,9728],[9711,654],{"nctId":644,"briefTitle":645,"status":173,"phases":20486,"primaryCompletion":456,"completion":456,"start":647,"enrollment":648,"conditions":20487,"interventions":20488},[92],[650],[610,652,653,654],{"trials":20490,"activeCount":101},[20491],{"nctId":20492,"briefTitle":20493,"status":117,"phases":20494,"primaryCompletion":4606,"completion":4606,"start":8572,"enrollment":15129,"conditions":20495,"interventions":20496},"NCT00048815","Drug Therapy to Treat Minor Depression",[93],[15],[654,20497,1884],"St. John's Wort",{"intervention":20499,"totalTrials":178,"cells":20500},"Ramelteon",{"EARLY_PHASE1":20501,"PHASE1":20503,"PHASE2":20505,"PHASE3":20507,"PHASE4":20509,"NA":20517},{"trials":20502,"activeCount":101},[],{"trials":20504,"activeCount":101},[],{"trials":20506,"activeCount":101},[],{"trials":20508,"activeCount":101},[],{"trials":20510,"activeCount":101},[20511],{"nctId":20512,"briefTitle":20513,"status":117,"phases":20514,"primaryCompletion":6900,"completion":6900,"start":912,"enrollment":1847,"conditions":20515,"interventions":20516},"NCT00595504","Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia",[92],[35,1929,10899],[20499],{"trials":20518,"activeCount":101},[20519,20527],{"nctId":20520,"briefTitle":20521,"status":107,"phases":20522,"primaryCompletion":6900,"completion":238,"start":150,"enrollment":101,"conditions":20523,"interventions":20526},"NCT00907595","Treating Sleep\u002FWake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon",[93],[11938,7928,7930,20524,20525],"Sleep Disorders","Circadian Dysregulation",[20499],{"nctId":20528,"briefTitle":20529,"status":173,"phases":20530,"primaryCompletion":2994,"completion":4290,"start":647,"enrollment":753,"conditions":20531,"interventions":20533},"NCT00753623","Clinical Management of Neuropathic Pain With Ramelteon",[93],[20532],"Neuropathic Pain",[20499],{"intervention":20535,"totalTrials":178,"cells":20536},"drospirenone and ethinyl estradiol",{"EARLY_PHASE1":20537,"PHASE1":20539,"PHASE2":20541,"PHASE3":20550,"PHASE4":20558,"NA":20560},{"trials":20538,"activeCount":101},[],{"trials":20540,"activeCount":101},[],{"trials":20542,"activeCount":101},[20543],{"nctId":20544,"briefTitle":20545,"status":173,"phases":20546,"primaryCompletion":4290,"completion":4290,"start":8511,"enrollment":798,"conditions":20547,"interventions":20549},"NCT00722800","A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS",[90],[20548],"Hidradenitis Suppurativa",[20535],{"trials":20551,"activeCount":101},[20552],{"nctId":20553,"briefTitle":20554,"status":117,"phases":20555,"primaryCompletion":226,"completion":226,"start":637,"enrollment":227,"conditions":20556,"interventions":20557},"NCT00722761","Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne",[91],[18178],[20535],{"trials":20559,"activeCount":101},[],{"trials":20561,"activeCount":101},[20562],{"nctId":20563,"briefTitle":20564,"status":117,"phases":20565,"primaryCompletion":12241,"completion":12241,"start":1926,"enrollment":648,"conditions":20566,"interventions":20567},"NCT00633360","The Oral Contraceptive Pill for Premenstrual Worsening of Depression",[93],[10684,15],[20568],"Drospirenone and ethinyl estradiol",{"intervention":1884,"totalTrials":178,"cells":20570},{"EARLY_PHASE1":20571,"PHASE1":20573,"PHASE2":20575,"PHASE3":20577,"PHASE4":20583,"NA":20585},{"trials":20572,"activeCount":101},[],{"trials":20574,"activeCount":101},[],{"trials":20576,"activeCount":101},[],{"trials":20578,"activeCount":101},[20579],{"nctId":8884,"briefTitle":8885,"status":117,"phases":20580,"primaryCompletion":8887,"completion":8888,"start":8889,"enrollment":8890,"conditions":20581,"interventions":20582},[91],[8892],[6751,1884],{"trials":20584,"activeCount":101},[],{"trials":20586,"activeCount":101},[20587,20591],{"nctId":20492,"briefTitle":20493,"status":117,"phases":20588,"primaryCompletion":4606,"completion":4606,"start":8572,"enrollment":15129,"conditions":20589,"interventions":20590},[93],[15],[654,20497,1884],{"nctId":1873,"briefTitle":1874,"status":117,"phases":20592,"primaryCompletion":1876,"completion":1877,"start":647,"enrollment":1878,"conditions":20593,"interventions":20594},[93],[1880,1881,1882],[1649,1884],{"intervention":679,"totalTrials":178,"cells":20596},{"EARLY_PHASE1":20597,"PHASE1":20599,"PHASE2":20601,"PHASE3":20603,"PHASE4":20605,"NA":20615},{"trials":20598,"activeCount":101},[],{"trials":20600,"activeCount":101},[],{"trials":20602,"activeCount":101},[],{"trials":20604,"activeCount":101},[],{"trials":20606,"activeCount":101},[20607,20611],{"nctId":8851,"briefTitle":8852,"status":117,"phases":20608,"completion":8854,"start":8855,"enrollment":251,"conditions":20609,"interventions":20610},[92],[24,640],[8858,8859],{"nctId":669,"briefTitle":670,"status":117,"phases":20612,"primaryCompletion":672,"start":673,"enrollment":674,"conditions":20613,"interventions":20614},[92],[676],[678,679,610],{"trials":20616,"activeCount":101},[20617],{"nctId":20618,"briefTitle":20619,"status":173,"phases":20620,"primaryCompletion":4606,"completion":4606,"start":20621,"enrollment":7086,"conditions":20622,"interventions":20624},"NCT00183612","Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents",[93],"2000-05",[24,20623],"Psychotic Disorders",[679],{"intervention":9383,"totalTrials":178,"cells":20626},{"EARLY_PHASE1":20627,"PHASE1":20633,"PHASE2":20635,"PHASE3":20645,"PHASE4":20647,"NA":20649},{"trials":20628,"activeCount":101},[20629],{"nctId":9378,"briefTitle":9379,"status":107,"phases":20630,"primaryCompletion":554,"completion":554,"start":309,"enrollment":101,"conditions":20631,"interventions":20632},[88],[5842],[9373,9383],{"trials":20634,"activeCount":101},[],{"trials":20636,"activeCount":101},[20637],{"nctId":20638,"briefTitle":20639,"status":117,"phases":20640,"primaryCompletion":8511,"completion":4281,"start":3690,"enrollment":20641,"conditions":20642,"interventions":20643},"NCT00136695","Anastrozole Administration in Elderly Hypogonadal Men",[90],88,[570],[20644],"anastrozole",{"trials":20646,"activeCount":101},[],{"trials":20648,"activeCount":101},[],{"trials":20650,"activeCount":101},[20651],{"nctId":19899,"briefTitle":19900,"status":107,"phases":20652,"primaryCompletion":554,"completion":554,"start":135,"enrollment":101,"conditions":20653,"interventions":20654},[93],[5842],[573,19904,19905,9383],{"intervention":20656,"totalTrials":178,"cells":20657},"Growth hormone",{"EARLY_PHASE1":20658,"PHASE1":20660,"PHASE2":20662,"PHASE3":20674,"PHASE4":20676,"NA":20678},{"trials":20659,"activeCount":101},[],{"trials":20661,"activeCount":101},[],{"trials":20663,"activeCount":101},[20664],{"nctId":20665,"briefTitle":20666,"status":117,"phases":20667,"primaryCompletion":20668,"completion":20669,"start":20670,"enrollment":20671,"conditions":20672,"interventions":20673},"NCT02217345","Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease",[90],"2021-08-10","2021-09-13","2017-06-02",131,[6644],[20656],{"trials":20675,"activeCount":101},[],{"trials":20677,"activeCount":101},[],{"trials":20679,"activeCount":101},[20680,20687],{"nctId":20681,"briefTitle":20682,"status":117,"phases":20683,"primaryCompletion":4271,"completion":4271,"start":3658,"enrollment":1847,"conditions":20684,"interventions":20685},"NCT00795210","Effects of Short-term Growth Hormone in HIV-infected Patients",[93],[6654],[20656,20686],"Growth Hormone Releasing Hormone",{"nctId":20688,"briefTitle":20689,"status":117,"phases":20690,"primaryCompletion":20691,"completion":3834,"start":14706,"enrollment":4214,"conditions":20692,"interventions":20693},"NCT01724489","Study of Growth Hormone and Bone in Obesity",[93],"2018-11-15",[26,571],[20656],{"intervention":20695,"totalTrials":178,"cells":20696},"Memantine Hydrochloride",{"EARLY_PHASE1":20697,"PHASE1":20699,"PHASE2":20701,"PHASE3":20703,"PHASE4":20713,"NA":20722},{"trials":20698,"activeCount":101},[],{"trials":20700,"activeCount":101},[],{"trials":20702,"activeCount":101},[],{"trials":20704,"activeCount":101},[20705],{"nctId":20706,"briefTitle":20707,"status":173,"phases":20708,"primaryCompletion":20709,"completion":20709,"start":15284,"enrollment":1847,"conditions":20710,"interventions":20712},"NCT03553875","Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions",[91],"2025-11-25",[8714,488,20711],"Nonverbal Learning Disability",[20695],{"trials":20714,"activeCount":101},[20715],{"nctId":20716,"briefTitle":20717,"status":117,"phases":20718,"primaryCompletion":4281,"completion":4281,"start":110,"enrollment":36,"conditions":20719,"interventions":20720},"NCT00586573","Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS",[92],[6706],[20721],"memantine hydrochloride",{"trials":20723,"activeCount":101},[20724],{"nctId":20725,"briefTitle":20726,"status":117,"phases":20727,"primaryCompletion":477,"completion":14706,"start":2609,"enrollment":2610,"conditions":20728,"interventions":20730},"NCT01533493","Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study",[93],[9322,20729],"Executive Function Deficits (EFD)",[20695,11304],{"intervention":11304,"totalTrials":178,"cells":20732},{"EARLY_PHASE1":20733,"PHASE1":20735,"PHASE2":20737,"PHASE3":20739,"PHASE4":20745,"NA":20751},{"trials":20734,"activeCount":101},[],{"trials":20736,"activeCount":101},[],{"trials":20738,"activeCount":101},[],{"trials":20740,"activeCount":101},[20741],{"nctId":12873,"briefTitle":12874,"status":117,"phases":20742,"primaryCompletion":1780,"completion":12876,"start":566,"enrollment":27,"conditions":20743,"interventions":20744},[90,91],[8739],[12862,11304],{"trials":20746,"activeCount":101},[20747],{"nctId":11298,"briefTitle":11299,"status":117,"phases":20748,"primaryCompletion":3516,"completion":3516,"start":11301,"enrollment":30,"conditions":20749,"interventions":20750},[92],[29],[11304,11285],{"trials":20752,"activeCount":101},[20753],{"nctId":20725,"briefTitle":20726,"status":117,"phases":20754,"primaryCompletion":477,"completion":14706,"start":2609,"enrollment":2610,"conditions":20755,"interventions":20756},[93],[9322,20729],[20695,11304],{"intervention":9325,"totalTrials":136,"cells":20758},{"EARLY_PHASE1":20759,"PHASE1":20761,"PHASE2":20763,"PHASE3":20769,"PHASE4":20771,"NA":20773},{"trials":20760,"activeCount":101},[],{"trials":20762,"activeCount":101},[],{"trials":20764,"activeCount":101},[20765],{"nctId":9317,"briefTitle":9318,"status":117,"phases":20766,"primaryCompletion":269,"completion":269,"start":9320,"enrollment":136,"conditions":20767,"interventions":20768},[90],[9322,9323],[9308,9325],{"trials":20770,"activeCount":101},[],{"trials":20772,"activeCount":101},[],{"trials":20774,"activeCount":101},[20775],{"nctId":20776,"briefTitle":20777,"status":117,"phases":20778,"primaryCompletion":397,"completion":397,"start":8610,"enrollment":8836,"conditions":20779,"interventions":20780},"NCT00825994","Omega-3 for Peri- and Postmenopausal Depression",[93],[15],[9325],{"intervention":20782,"totalTrials":136,"cells":20783},"transdermal nicotine patch",{"EARLY_PHASE1":20784,"PHASE1":20786,"PHASE2":20788,"PHASE3":20790,"PHASE4":20792,"NA":20801},{"trials":20785,"activeCount":101},[],{"trials":20787,"activeCount":101},[],{"trials":20789,"activeCount":101},[],{"trials":20791,"activeCount":101},[],{"trials":20793,"activeCount":101},[20794],{"nctId":20795,"briefTitle":20796,"status":117,"phases":20797,"primaryCompletion":3855,"completion":3855,"start":4465,"enrollment":1578,"conditions":20798,"interventions":20799},"NCT00383747","The Effects of Nicotine on Cognition in Schizophrenia",[92],[35],[20782,20800],"Transdermal Nicotine Patch",{"trials":20802,"activeCount":101},[20803],{"nctId":20804,"briefTitle":20805,"status":117,"phases":20806,"primaryCompletion":298,"completion":8798,"start":968,"enrollment":13087,"conditions":20807,"interventions":20808},"NCT02565381","A Pilot Randomized Controlled Trial of Financial Incentives, Text Messaging, and Usual Care for Homeless Smokers",[93],[1930],[20809],"Transdermal nicotine patch",{"intervention":20811,"totalTrials":136,"cells":20812},"leuprolide",{"EARLY_PHASE1":20813,"PHASE1":20815,"PHASE2":20817,"PHASE3":20819,"PHASE4":20821,"NA":20832},{"trials":20814,"activeCount":101},[],{"trials":20816,"activeCount":101},[],{"trials":20818,"activeCount":101},[],{"trials":20820,"activeCount":101},[],{"trials":20822,"activeCount":101},[20823],{"nctId":20824,"briefTitle":20825,"status":117,"phases":20826,"primaryCompletion":20827,"completion":20828,"start":20829,"enrollment":2028,"conditions":20830,"interventions":20831},"NCT01116401","Impact of Hot Flashes on Sleep and Mood Disturbance",[92],"2011-12-29","2012-01-04","2009-11-03",[8621,15,9400],[20811],{"trials":20833,"activeCount":101},[20834],{"nctId":19899,"briefTitle":19900,"status":107,"phases":20835,"primaryCompletion":554,"completion":554,"start":135,"enrollment":101,"conditions":20836,"interventions":20837},[93],[5842],[573,19904,19905,9383],{"intervention":20839,"totalTrials":136,"cells":20840},"ferumoxytol",{"EARLY_PHASE1":20841,"PHASE1":20843,"PHASE2":20845,"PHASE3":20847,"PHASE4":20849,"NA":20851},{"trials":20842,"activeCount":101},[],{"trials":20844,"activeCount":101},[],{"trials":20846,"activeCount":101},[],{"trials":20848,"activeCount":101},[],{"trials":20850,"activeCount":101},[],{"trials":20852,"activeCount":101},[20853,20859],{"nctId":20854,"briefTitle":20855,"status":117,"phases":20856,"primaryCompletion":8504,"start":741,"enrollment":1898,"conditions":20857,"interventions":20858},"NCT00087347","Magnetic Resonance Imaging of Lymph Nodes Using Ferumoxytol in Patients With Primary Prostate or Breast Cancer",[],[21,2038],[20839],{"nctId":20860,"briefTitle":20861,"status":117,"phases":20862,"primaryCompletion":3680,"completion":1877,"start":9600,"enrollment":1791,"conditions":20863,"interventions":20867},"NCT01927887","Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study",[93],[20864,20865,20866],"Papillary Carcinoma of Thyroid Gland","Metastatic Medullary Thyroid Cancer","Follicular Thyroid Cancer Lymph Node Metastasis",[20868],"Ferumoxytol",{"intervention":1864,"totalTrials":136,"cells":20870},{"EARLY_PHASE1":20871,"PHASE1":20873,"PHASE2":20875,"PHASE3":20883,"PHASE4":20885,"NA":20887},{"trials":20872,"activeCount":101},[],{"trials":20874,"activeCount":101},[],{"trials":20876,"activeCount":101},[20877],{"nctId":20878,"briefTitle":20879,"status":173,"phases":20880,"primaryCompletion":9600,"completion":9600,"start":4581,"enrollment":270,"conditions":20881,"interventions":20882},"NCT01312844","A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)",[90],[15],[1864],{"trials":20884,"activeCount":101},[],{"trials":20886,"activeCount":101},[],{"trials":20888,"activeCount":101},[20889],{"nctId":1858,"briefTitle":1859,"status":107,"phases":20890,"primaryCompletion":1780,"completion":1780,"start":1861,"enrollment":101,"conditions":20891,"interventions":20892},[93],[18],[1649,1864],{"intervention":20894,"totalTrials":136,"cells":20895},"Lumacaftor-ivacaftor",{"EARLY_PHASE1":20896,"PHASE1":20898,"PHASE2":20900,"PHASE3":20902,"PHASE4":20904,"NA":20906},{"trials":20897,"activeCount":101},[],{"trials":20899,"activeCount":101},[],{"trials":20901,"activeCount":101},[],{"trials":20903,"activeCount":101},[],{"trials":20905,"activeCount":101},[],{"trials":20907,"activeCount":101},[20908,20916],{"nctId":20909,"briefTitle":20910,"status":107,"phases":20911,"primaryCompletion":20912,"completion":1790,"start":20913,"enrollment":101,"conditions":20914,"interventions":20915},"NCT02653027","Effect of Lumacaftor-ivacaftor on Glucose Handling and Tolerance in Cystic Fibrosis Phe508del",[93],"2018-02-01","2018-01-01",[8276,2204],[20894],{"nctId":20917,"briefTitle":20918,"status":173,"phases":20919,"primaryCompletion":1790,"completion":1790,"start":20920,"enrollment":331,"conditions":20921,"interventions":20922},"NCT02858843","The Effect of Combination Lumacaftor and Ivacaftor on Markers of Hyperglycemia",[93],"2016-08-01",[2204,8276],[20923],"lumacaftor-ivacaftor",{"intervention":20686,"totalTrials":136,"cells":20925},{"EARLY_PHASE1":20926,"PHASE1":20928,"PHASE2":20930,"PHASE3":20932,"PHASE4":20934,"NA":20936},{"trials":20927,"activeCount":101},[],{"trials":20929,"activeCount":101},[],{"trials":20931,"activeCount":101},[],{"trials":20933,"activeCount":101},[],{"trials":20935,"activeCount":101},[],{"trials":20937,"activeCount":101},[20938,20944],{"nctId":20939,"briefTitle":20940,"status":117,"phases":20941,"primaryCompletion":4581,"completion":4581,"start":3658,"enrollment":2728,"conditions":20942,"interventions":20943},"NCT00850564","Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men",[93],[8978],[20686],{"nctId":20681,"briefTitle":20682,"status":117,"phases":20945,"primaryCompletion":4271,"completion":4271,"start":3658,"enrollment":1847,"conditions":20946,"interventions":20947},[93],[6654],[20656,20686],{"intervention":8169,"totalTrials":136,"cells":20949},{"EARLY_PHASE1":20950,"PHASE1":20952,"PHASE2":20954,"PHASE3":20956,"PHASE4":20958,"NA":20964},{"trials":20951,"activeCount":101},[],{"trials":20953,"activeCount":101},[],{"trials":20955,"activeCount":101},[],{"trials":20957,"activeCount":101},[],{"trials":20959,"activeCount":101},[20960],{"nctId":8164,"briefTitle":8165,"status":117,"phases":20961,"primaryCompletion":4491,"completion":2418,"start":1846,"enrollment":151,"conditions":20962,"interventions":20963},[92],[2997],[8169,7997],{"trials":20965,"activeCount":101},[20966],{"nctId":20967,"briefTitle":20968,"status":117,"phases":20969,"primaryCompletion":15753,"completion":15753,"start":20970,"enrollment":20971,"conditions":20972,"interventions":20976},"NCT03655717","Using Imaging to Assess Effects of THC on Brain Activity",[93],"2018-11-05",316,[20973,20974,20975],"Intoxication Alcohol","Intoxication THC","Intoxication Combined Alcohol THC",[20977,8169],"Dronabinol",{"intervention":3648,"totalTrials":136,"cells":20979},{"EARLY_PHASE1":20980,"PHASE1":20982,"PHASE2":20984,"PHASE3":20990,"PHASE4":20992,"NA":20994},{"trials":20981,"activeCount":101},[],{"trials":20983,"activeCount":101},[],{"trials":20985,"activeCount":101},[20986],{"nctId":3641,"briefTitle":3642,"status":117,"phases":20987,"primaryCompletion":1889,"completion":3644,"start":751,"enrollment":366,"conditions":20988,"interventions":20989},[89,90],[3610,3612,3611],[3520,3647,3648,3649],{"trials":20991,"activeCount":101},[],{"trials":20993,"activeCount":101},[],{"trials":20995,"activeCount":101},[20996],{"nctId":20997,"briefTitle":20998,"status":117,"phases":20999,"primaryCompletion":21000,"completion":21000,"start":1244,"enrollment":4443,"conditions":21001,"interventions":21002},"NCT02312219","PET\u002FCT Imaging Companion Study To ACTG A5314",[],"2016-12-08",[1671,821,6775],[3648,21003],"Low Dose Methotrexate",{"intervention":8132,"totalTrials":136,"cells":21005},{"EARLY_PHASE1":21006,"PHASE1":21008,"PHASE2":21010,"PHASE3":21012,"PHASE4":21014,"NA":21016},{"trials":21007,"activeCount":101},[],{"trials":21009,"activeCount":101},[],{"trials":21011,"activeCount":101},[],{"trials":21013,"activeCount":101},[],{"trials":21015,"activeCount":101},[],{"trials":21017,"activeCount":101},[21018,21022],{"nctId":8125,"briefTitle":8126,"status":2758,"phases":21019,"primaryCompletion":8128,"completion":8128,"start":4464,"enrollment":1466,"conditions":21020,"interventions":21021},[93],[8130],[8132,8077],{"nctId":21023,"briefTitle":21024,"status":2758,"phases":21025,"primaryCompletion":11892,"completion":14900,"start":6695,"enrollment":194,"conditions":21026,"interventions":21027},"NCT02198417","Metformin Treatment in Polycystic Ovary Syndrome (PCOS)",[93],[8130],[8132],{"intervention":21029,"totalTrials":136,"cells":21030},"Rocuronium",{"EARLY_PHASE1":21031,"PHASE1":21033,"PHASE2":21035,"PHASE3":21037,"PHASE4":21039,"NA":21041},{"trials":21032,"activeCount":101},[],{"trials":21034,"activeCount":101},[],{"trials":21036,"activeCount":101},[],{"trials":21038,"activeCount":101},[],{"trials":21040,"activeCount":101},[],{"trials":21042,"activeCount":101},[21043,21054],{"nctId":21044,"briefTitle":21045,"status":117,"phases":21046,"primaryCompletion":968,"completion":968,"start":224,"enrollment":413,"conditions":21047,"interventions":21053},"NCT02025075","Hemodynamic and Respiratory Variations During Laparoscopic Surgery With and Without Deep Neuromuscular Blockade.",[93],[21048,21049,21050,21051,21052],"Intraoperative Complications","Postoperative Complications","Laparoscopy","Surgical Complications From General Anesthesia","Ventilator-Induced Lung Injury",[21029],{"nctId":21055,"briefTitle":21056,"status":117,"phases":21057,"primaryCompletion":477,"completion":135,"start":12241,"enrollment":2559,"conditions":21058,"interventions":21061},"NCT01441960","Optimal Dose of Succinylcholine and Rocuronium for Electroconvulsive Therapy (ECT)",[93],[21059,21060],"Neuromuscular Blockade","ECT",[21062,21029],"Succinylcholine",{"intervention":21064,"totalTrials":136,"cells":21065},"Medical Marijuana",{"EARLY_PHASE1":21066,"PHASE1":21068,"PHASE2":21070,"PHASE3":21072,"PHASE4":21074,"NA":21076},{"trials":21067,"activeCount":101},[],{"trials":21069,"activeCount":101},[],{"trials":21071,"activeCount":101},[],{"trials":21073,"activeCount":101},[],{"trials":21075,"activeCount":101},[],{"trials":21077,"activeCount":101},[21078,21090],{"nctId":21079,"briefTitle":21080,"status":117,"phases":21081,"primaryCompletion":21082,"completion":21083,"start":21084,"enrollment":21085,"conditions":21086,"interventions":21089},"NCT04827992","Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain",[93],"2025-05-01","2025-10-31","2021-08-23",87,[21087,1880,21088],"Opioid Use","Marijuana Use",[21064],{"nctId":21091,"briefTitle":21092,"status":117,"phases":21093,"primaryCompletion":21094,"completion":13156,"start":4873,"enrollment":21095,"conditions":21096,"interventions":21097},"NCT03224468","Effect of Medical Marijuana on Neurocognition and Escalation of Use",[93],"2021-02-05",269,[1880,819,15,489],[21064],{"intervention":20468,"totalTrials":136,"cells":21099},{"EARLY_PHASE1":21100,"PHASE1":21113,"PHASE2":21115,"PHASE3":21117,"PHASE4":21119,"NA":21121},{"trials":21101,"activeCount":101},[21102],{"nctId":21103,"briefTitle":21104,"status":117,"phases":21105,"primaryCompletion":6441,"completion":21106,"start":21107,"enrollment":1805,"conditions":21108,"interventions":21112},"NCT03748966","Calcitriol Monotherapy for X-Linked Hypophosphatemia",[88],"2026-02-26","2019-03-28",[21109,21110,21111],"X-linked Hypophosphatemia","Hypophosphatemic Rickets","Hypophosphatemic Rickets, X-Linked Dominant",[20468],{"trials":21114,"activeCount":101},[],{"trials":21116,"activeCount":101},[],{"trials":21118,"activeCount":101},[],{"trials":21120,"activeCount":101},[],{"trials":21122,"activeCount":101},[21123],{"nctId":20463,"briefTitle":20464,"status":107,"phases":21124,"primaryCompletion":6695,"completion":567,"start":3078,"enrollment":101,"conditions":21125,"interventions":21126},[93],[10168,12141],[20434,20468],{"intervention":21128,"totalTrials":136,"cells":21129},"rhIGF-1",{"EARLY_PHASE1":21130,"PHASE1":21132,"PHASE2":21134,"PHASE3":21143,"PHASE4":21145,"NA":21147},{"trials":21131,"activeCount":101},[],{"trials":21133,"activeCount":101},[],{"trials":21135,"activeCount":101},[21136],{"nctId":21137,"briefTitle":21138,"status":117,"phases":21139,"primaryCompletion":740,"completion":9865,"start":110,"enrollment":1805,"conditions":21140,"interventions":21141},"NCT00516386","Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents",[89,90],[772],[21142],"RhIGF-1",{"trials":21144,"activeCount":101},[],{"trials":21146,"activeCount":101},[],{"trials":21148,"activeCount":101},[21149],{"nctId":21150,"briefTitle":21151,"status":117,"phases":21152,"primaryCompletion":4335,"completion":4335,"start":568,"enrollment":21153,"conditions":21154,"interventions":21155},"NCT01406444","IGF-1 and Bone Loss in Women With Anorexia Nervosa",[93],148,[772,571,380],[21128,21156],"Risedronate",{"intervention":21158,"totalTrials":136,"cells":21159},"Atorvastatin",{"EARLY_PHASE1":21160,"PHASE1":21162,"PHASE2":21164,"PHASE3":21175,"PHASE4":21177,"NA":21179},{"trials":21161,"activeCount":101},[],{"trials":21163,"activeCount":101},[],{"trials":21165,"activeCount":101},[21166],{"nctId":21167,"briefTitle":21168,"status":117,"phases":21169,"primaryCompletion":21170,"completion":21171,"start":21172,"enrollment":5302,"conditions":21173,"interventions":21174},"NCT02943590","STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)",[90],"2022-09-16","2023-10-11","2017-01-13",[7638],[21158],{"trials":21176,"activeCount":101},[],{"trials":21178,"activeCount":101},[],{"trials":21180,"activeCount":101},[21181],{"nctId":21182,"briefTitle":21183,"status":117,"phases":21184,"primaryCompletion":224,"completion":224,"start":6891,"enrollment":251,"conditions":21185,"interventions":21187},"NCT00965185","Statin Therapy to Improve Atherosclerosis in HIV Patients",[93],[20368,1671,6775,821,21186,8139],"Statins, HMG-CoA",[21188],"atorvastatin",{"intervention":21190,"totalTrials":136,"cells":21191},"lamotrigine",{"EARLY_PHASE1":21192,"PHASE1":21194,"PHASE2":21196,"PHASE3":21198,"PHASE4":21200,"NA":21208},{"trials":21193,"activeCount":101},[],{"trials":21195,"activeCount":101},[],{"trials":21197,"activeCount":101},[],{"trials":21199,"activeCount":101},[],{"trials":21201,"activeCount":101},[21202],{"nctId":21203,"briefTitle":21204,"status":117,"phases":21205,"primaryCompletion":1926,"completion":708,"start":13650,"enrollment":22,"conditions":21206,"interventions":21207},"NCT00181844","Lamotrigine for the Treatment of Mania in Youth Ages 6-17 With Bipolar Disorder",[92],[24,640],[21190],{"trials":21209,"activeCount":101},[21210],{"nctId":21211,"briefTitle":21212,"status":117,"phases":21213,"primaryCompletion":2447,"completion":2447,"start":13746,"enrollment":8836,"conditions":21214,"interventions":21216},"NCT00916149","Cognitive Effects of Treatment of Interictal Discharges",[93],[21215],"Epilepsy",[21217,21218],"levetiracetam","Lamotrigine",{"intervention":17412,"totalTrials":136,"cells":21220},{"EARLY_PHASE1":21221,"PHASE1":21223,"PHASE2":21225,"PHASE3":21231,"PHASE4":21233,"NA":21235},{"trials":21222,"activeCount":101},[],{"trials":21224,"activeCount":101},[],{"trials":21226,"activeCount":101},[21227],{"nctId":17406,"briefTitle":17407,"status":117,"phases":21228,"primaryCompletion":17409,"completion":17409,"start":14706,"enrollment":2882,"conditions":21229,"interventions":21230},[89,90],[6165],[17412,17397],{"trials":21232,"activeCount":101},[],{"trials":21234,"activeCount":101},[],{"trials":21236,"activeCount":101},[21237],{"nctId":21238,"briefTitle":21239,"status":117,"phases":21240,"primaryCompletion":21241,"completion":21242,"start":21243,"enrollment":194,"conditions":21244,"interventions":21245},"NCT02698033","High Threshold Peanut Challenge Study",[],"2016-07-07","2019-08-22","2015-12-09",[6165],[21246],"Peanut flour",{"intervention":8695,"totalTrials":136,"cells":21248},{"EARLY_PHASE1":21249,"PHASE1":21251,"PHASE2":21253,"PHASE3":21255,"PHASE4":21257,"NA":21263},{"trials":21250,"activeCount":101},[],{"trials":21252,"activeCount":101},[],{"trials":21254,"activeCount":101},[],{"trials":21256,"activeCount":101},[],{"trials":21258,"activeCount":101},[21259],{"nctId":8687,"briefTitle":8688,"status":117,"phases":21260,"primaryCompletion":4290,"completion":4290,"start":8690,"enrollment":8691,"conditions":21261,"interventions":21262},[92],[8693],[653,8695,8665],{"trials":21264,"activeCount":101},[21265],{"nctId":21266,"briefTitle":21267,"status":117,"phases":21268,"primaryCompletion":2027,"completion":6900,"start":15128,"enrollment":21269,"conditions":21270,"interventions":21271},"NCT00084669","Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer",[93],119,[21,9400,20524],[21272,21273],"venlafaxine","zolpidem tartrate",{"intervention":21275,"totalTrials":331,"cells":21276},"Isotretinoin",{"EARLY_PHASE1":21277,"PHASE1":21279,"PHASE2":21281,"PHASE3":21283,"PHASE4":21285,"NA":21287},{"trials":21278,"activeCount":101},[],{"trials":21280,"activeCount":101},[],{"trials":21282,"activeCount":101},[],{"trials":21284,"activeCount":101},[],{"trials":21286,"activeCount":101},[],{"trials":21288,"activeCount":101},[21289],{"nctId":21290,"briefTitle":21291,"status":107,"phases":21292,"primaryCompletion":283,"completion":283,"start":4361,"enrollment":101,"conditions":21293,"interventions":21295},"NCT02795143","Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study",[93],[21294],"Toxic Epidermal Necrolysis",[21275],{"intervention":21297,"totalTrials":331,"cells":21298},"Peanut flour OIT",{"EARLY_PHASE1":21299,"PHASE1":21301,"PHASE2":21303,"PHASE3":21305,"PHASE4":21307,"NA":21309},{"trials":21300,"activeCount":101},[],{"trials":21302,"activeCount":101},[],{"trials":21304,"activeCount":101},[],{"trials":21306,"activeCount":101},[],{"trials":21308,"activeCount":101},[],{"trials":21310,"activeCount":101},[21311],{"nctId":21312,"briefTitle":21313,"status":117,"phases":21314,"primaryCompletion":46,"completion":7120,"start":3004,"enrollment":227,"conditions":21315,"interventions":21316},"NCT01324401","Oral Peanut Immunotherapy",[93],[6165],[21297],{"intervention":21318,"totalTrials":331,"cells":21319},"Subanesthetic ketamine",{"EARLY_PHASE1":21320,"PHASE1":21322,"PHASE2":21324,"PHASE3":21326,"PHASE4":21328,"NA":21330},{"trials":21321,"activeCount":101},[],{"trials":21323,"activeCount":101},[],{"trials":21325,"activeCount":101},[],{"trials":21327,"activeCount":101},[],{"trials":21329,"activeCount":101},[],{"trials":21331,"activeCount":101},[21332],{"nctId":21333,"briefTitle":21334,"status":117,"phases":21335,"primaryCompletion":9525,"completion":9525,"start":224,"enrollment":2728,"conditions":21336,"interventions":21340},"NCT01969227","The Effects of Ketamine on Respiratory Stimulation and Transpulmonary Pressures",[93],[21337,21338,21339],"Mechanical Ventilation","Airway Patency","Respiratory Depression",[21318],{"intervention":21342,"totalTrials":331,"cells":21343},"Stribild",{"EARLY_PHASE1":21344,"PHASE1":21346,"PHASE2":21348,"PHASE3":21350,"PHASE4":21352,"NA":21354},{"trials":21345,"activeCount":101},[],{"trials":21347,"activeCount":101},[],{"trials":21349,"activeCount":101},[],{"trials":21351,"activeCount":101},[],{"trials":21353,"activeCount":101},[],{"trials":21355,"activeCount":101},[21356],{"nctId":21357,"briefTitle":21358,"status":117,"phases":21359,"primaryCompletion":968,"completion":968,"start":224,"enrollment":239,"conditions":21360,"interventions":21362},"NCT01929759","Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen",[93],[21361],"HIV Disease",[21342],{"intervention":21364,"totalTrials":331,"cells":21365},"Cytomel",{"EARLY_PHASE1":21366,"PHASE1":21368,"PHASE2":21370,"PHASE3":21372,"PHASE4":21374,"NA":21376},{"trials":21367,"activeCount":101},[],{"trials":21369,"activeCount":101},[],{"trials":21371,"activeCount":101},[],{"trials":21373,"activeCount":101},[],{"trials":21375,"activeCount":101},[],{"trials":21377,"activeCount":101},[21378],{"nctId":21379,"briefTitle":21380,"status":117,"phases":21381,"completion":741,"start":21382,"enrollment":227,"conditions":21383,"interventions":21384},"NCT00562367","Biochemical Brain Changes Correlated With The Antidepressant Effect Of Thyroid Hormones",[93],"2001-10",[18],[21364],{"intervention":21386,"totalTrials":331,"cells":21387},"Pennsaid",{"EARLY_PHASE1":21388,"PHASE1":21390,"PHASE2":21392,"PHASE3":21394,"PHASE4":21396,"NA":21398},{"trials":21389,"activeCount":101},[],{"trials":21391,"activeCount":101},[],{"trials":21393,"activeCount":101},[],{"trials":21395,"activeCount":101},[],{"trials":21397,"activeCount":101},[],{"trials":21399,"activeCount":101},[21400],{"nctId":21401,"briefTitle":21402,"status":117,"phases":21403,"primaryCompletion":284,"completion":4352,"start":149,"enrollment":4443,"conditions":21404,"interventions":21409},"NCT01508676","Effects of Pennsaid on Clinical Neuropathic Pain",[93],[21405,21406,21407,21408],"Neuralgia","Postherpetic Neuralgia","Reflex Sympathetic Dystrophy","Complex Regional Pain Syndrome (CRPS)",[21386],{"intervention":21411,"totalTrials":331,"cells":21412},"BIBW 2992",{"EARLY_PHASE1":21413,"PHASE1":21415,"PHASE2":21417,"PHASE3":21419,"PHASE4":21421,"NA":21423},{"trials":21414,"activeCount":101},[],{"trials":21416,"activeCount":101},[],{"trials":21418,"activeCount":101},[],{"trials":21420,"activeCount":101},[],{"trials":21422,"activeCount":101},[],{"trials":21424,"activeCount":101},[21425],{"nctId":21426,"briefTitle":21427,"status":117,"phases":21428,"primaryCompletion":4771,"completion":4771,"start":2995,"enrollment":886,"conditions":21429,"interventions":21431},"NCT01074177","Understanding Mechanisms of Acquired Resistance to BIBW2992",[93],[3682,21430],"EGFR Mutations",[21411],{"intervention":21433,"totalTrials":331,"cells":21434},"Tramadol Extended Release Oral",{"EARLY_PHASE1":21435,"PHASE1":21437,"PHASE2":21439,"PHASE3":21441,"PHASE4":21443,"NA":21445},{"trials":21436,"activeCount":101},[],{"trials":21438,"activeCount":101},[],{"trials":21440,"activeCount":101},[],{"trials":21442,"activeCount":101},[],{"trials":21444,"activeCount":101},[],{"trials":21446,"activeCount":101},[21447],{"nctId":21448,"briefTitle":21449,"status":173,"phases":21450,"primaryCompletion":4666,"completion":4666,"start":3516,"enrollment":270,"conditions":21451,"interventions":21452},"NCT00505531","Pain Study to See if Ultram ER Will Provide Relief to Subjects Whose Pain is Not Well Controlled by Narcotics",[],[1881],[21433,21453],"Benadryl",{"intervention":21453,"totalTrials":331,"cells":21455},{"EARLY_PHASE1":21456,"PHASE1":21458,"PHASE2":21460,"PHASE3":21462,"PHASE4":21464,"NA":21466},{"trials":21457,"activeCount":101},[],{"trials":21459,"activeCount":101},[],{"trials":21461,"activeCount":101},[],{"trials":21463,"activeCount":101},[],{"trials":21465,"activeCount":101},[],{"trials":21467,"activeCount":101},[21468],{"nctId":21448,"briefTitle":21449,"status":173,"phases":21469,"primaryCompletion":4666,"completion":4666,"start":3516,"enrollment":270,"conditions":21470,"interventions":21471},[],[1881],[21433,21453],{"intervention":21473,"totalTrials":331,"cells":21474},"Paricalcitol",{"EARLY_PHASE1":21475,"PHASE1":21477,"PHASE2":21479,"PHASE3":21481,"PHASE4":21483,"NA":21485},{"trials":21476,"activeCount":101},[],{"trials":21478,"activeCount":101},[],{"trials":21480,"activeCount":101},[],{"trials":21482,"activeCount":101},[],{"trials":21484,"activeCount":101},[],{"trials":21486,"activeCount":101},[21487],{"nctId":21488,"briefTitle":21489,"status":107,"phases":21490,"primaryCompletion":566,"completion":309,"start":2436,"enrollment":101,"conditions":21491,"interventions":21492},"NCT01630408","The Effects of Active VItamin D on Left Atrial Volume Index",[93],[7638],[21473],{"intervention":21494,"totalTrials":331,"cells":21495},"pitavastatin",{"EARLY_PHASE1":21496,"PHASE1":21498,"PHASE2":21500,"PHASE3":21502,"PHASE4":21504,"NA":21506},{"trials":21497,"activeCount":101},[],{"trials":21499,"activeCount":101},[],{"trials":21501,"activeCount":101},[],{"trials":21503,"activeCount":101},[],{"trials":21505,"activeCount":101},[],{"trials":21507,"activeCount":101},[21508],{"nctId":21509,"briefTitle":21510,"status":117,"phases":21511,"primaryCompletion":21512,"completion":21512,"start":21513,"enrollment":366,"conditions":21514,"interventions":21516},"NCT02290106","Effects of Pitavastatin on Insulin Sensitivity and Liver Fat",[93],"2018-04-30","2015-03-02",[26,21515],"Fatty Liver, Nonalcoholic",[21494],{"intervention":21518,"totalTrials":331,"cells":21519},"Steroid (dexamethasone)",{"EARLY_PHASE1":21520,"PHASE1":21522,"PHASE2":21524,"PHASE3":21526,"PHASE4":21528,"NA":21530},{"trials":21521,"activeCount":101},[],{"trials":21523,"activeCount":101},[],{"trials":21525,"activeCount":101},[],{"trials":21527,"activeCount":101},[],{"trials":21529,"activeCount":101},[],{"trials":21531,"activeCount":101},[21532],{"nctId":21533,"briefTitle":21534,"status":117,"phases":21535,"primaryCompletion":1936,"completion":1936,"start":11720,"enrollment":19,"conditions":21536,"interventions":21538},"NCT00438672","Corticosteroid Injection for Common Upper Extremity Problems",[93],[21537],"Lateral Elbow Pain",[21518],{"intervention":1970,"totalTrials":331,"cells":21540},{"EARLY_PHASE1":21541,"PHASE1":21543,"PHASE2":21545,"PHASE3":21547,"PHASE4":21549,"NA":21551},{"trials":21542,"activeCount":101},[],{"trials":21544,"activeCount":101},[],{"trials":21546,"activeCount":101},[],{"trials":21548,"activeCount":101},[],{"trials":21550,"activeCount":101},[],{"trials":21552,"activeCount":101},[21553],{"nctId":1963,"briefTitle":1964,"status":117,"phases":21554,"primaryCompletion":456,"completion":456,"start":110,"enrollment":1966,"conditions":21555,"interventions":21556},[93],[1968],[1970,1902],{"intervention":21558,"totalTrials":331,"cells":21559},"Raltegravir",{"EARLY_PHASE1":21560,"PHASE1":21562,"PHASE2":21564,"PHASE3":21566,"PHASE4":21568,"NA":21570},{"trials":21561,"activeCount":101},[],{"trials":21563,"activeCount":101},[],{"trials":21565,"activeCount":101},[],{"trials":21567,"activeCount":101},[],{"trials":21569,"activeCount":101},[],{"trials":21571,"activeCount":101},[21572],{"nctId":21573,"briefTitle":21574,"status":117,"phases":21575,"primaryCompletion":4369,"completion":1779,"start":224,"enrollment":239,"conditions":21576,"interventions":21579},"NCT01978743","Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen",[93],[1671,21577,21578],"HIV-associated Neurocognitive Disorder","Neurotoxicity",[21558],{"intervention":21581,"totalTrials":331,"cells":21582},"PET\u002FMRI with radiotracer ([18F]- fluorodeoxyglucose) and a gadolinium-based contrast agent",{"EARLY_PHASE1":21583,"PHASE1":21585,"PHASE2":21587,"PHASE3":21589,"PHASE4":21591,"NA":21593},{"trials":21584,"activeCount":101},[],{"trials":21586,"activeCount":101},[],{"trials":21588,"activeCount":101},[],{"trials":21590,"activeCount":101},[],{"trials":21592,"activeCount":101},[],{"trials":21594,"activeCount":101},[21595],{"nctId":21596,"briefTitle":21597,"status":107,"phases":21598,"primaryCompletion":21599,"completion":6206,"start":21600,"enrollment":101,"conditions":21601,"interventions":21607},"NCT05390021","PET\u002FMRI in Endometrial Cancer",[93],"2025-02-01","2024-03-30",[21602,21603,21604,21605,21606],"Cytoreductive Surgery","Grade 3 Endometrial Endometrioid Adenocarcinoma","High Grade Serous Carcinoma","Endometrial Undifferentiated Carcinoma","Endometrial Mixed Cell Adenocarcinoma",[21581],{"intervention":20333,"totalTrials":331,"cells":21609},{"EARLY_PHASE1":21610,"PHASE1":21612,"PHASE2":21614,"PHASE3":21616,"PHASE4":21618,"NA":21620},{"trials":21611,"activeCount":101},[],{"trials":21613,"activeCount":101},[],{"trials":21615,"activeCount":101},[],{"trials":21617,"activeCount":101},[],{"trials":21619,"activeCount":101},[],{"trials":21621,"activeCount":101},[21622],{"nctId":20328,"briefTitle":20329,"status":117,"phases":21623,"primaryCompletion":4490,"completion":4490,"start":121,"enrollment":19985,"conditions":21624,"interventions":21625},[93],[1880],[20303,20333],{"intervention":21627,"totalTrials":331,"cells":21628},"1 Transdermal Testosterone",{"EARLY_PHASE1":21629,"PHASE1":21631,"PHASE2":21633,"PHASE3":21635,"PHASE4":21637,"NA":21639},{"trials":21630,"activeCount":101},[],{"trials":21632,"activeCount":101},[],{"trials":21634,"activeCount":101},[],{"trials":21636,"activeCount":101},[],{"trials":21638,"activeCount":101},[],{"trials":21640,"activeCount":101},[21641],{"nctId":21642,"briefTitle":21643,"status":117,"phases":21644,"primaryCompletion":708,"completion":3658,"start":741,"enrollment":1847,"conditions":21645,"interventions":21646},"NCT00095212","Androgen Effects in HIV-infected Women",[93],[17828],[21627,21647],"2 Placebo Patch",{"intervention":21647,"totalTrials":331,"cells":21649},{"EARLY_PHASE1":21650,"PHASE1":21652,"PHASE2":21654,"PHASE3":21656,"PHASE4":21658,"NA":21660},{"trials":21651,"activeCount":101},[],{"trials":21653,"activeCount":101},[],{"trials":21655,"activeCount":101},[],{"trials":21657,"activeCount":101},[],{"trials":21659,"activeCount":101},[],{"trials":21661,"activeCount":101},[21662],{"nctId":21642,"briefTitle":21643,"status":117,"phases":21663,"primaryCompletion":708,"completion":3658,"start":741,"enrollment":1847,"conditions":21664,"interventions":21665},[93],[17828],[21627,21647],{"intervention":21667,"totalTrials":331,"cells":21668},"Guanfacine",{"EARLY_PHASE1":21669,"PHASE1":21671,"PHASE2":21673,"PHASE3":21675,"PHASE4":21677,"NA":21679},{"trials":21670,"activeCount":101},[],{"trials":21672,"activeCount":101},[],{"trials":21674,"activeCount":101},[],{"trials":21676,"activeCount":101},[],{"trials":21678,"activeCount":101},[],{"trials":21680,"activeCount":101},[21681],{"nctId":21682,"briefTitle":21683,"status":173,"phases":21684,"primaryCompletion":80,"completion":80,"start":1897,"enrollment":1890,"conditions":21685,"interventions":21686},"NCT02192398","Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH)",[93],[1881],[21667],{"intervention":21688,"totalTrials":331,"cells":21689},"PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability.",{"EARLY_PHASE1":21690,"PHASE1":21692,"PHASE2":21694,"PHASE3":21696,"PHASE4":21698,"NA":21700},{"trials":21691,"activeCount":101},[],{"trials":21693,"activeCount":101},[],{"trials":21695,"activeCount":101},[],{"trials":21697,"activeCount":101},[],{"trials":21699,"activeCount":101},[],{"trials":21701,"activeCount":101},[21702],{"nctId":21703,"briefTitle":21704,"status":117,"phases":21705,"primaryCompletion":16147,"completion":21706,"start":21707,"enrollment":33,"conditions":21708,"interventions":21710},"NCT05007860","Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia",[],"2023-06-30","2020-07-16",[21709],"Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[21688],{"intervention":21712,"totalTrials":331,"cells":21713},"Inspiratory oxygen",{"EARLY_PHASE1":21714,"PHASE1":21716,"PHASE2":21718,"PHASE3":21720,"PHASE4":21722,"NA":21724},{"trials":21715,"activeCount":101},[],{"trials":21717,"activeCount":101},[],{"trials":21719,"activeCount":101},[],{"trials":21721,"activeCount":101},[],{"trials":21723,"activeCount":101},[],{"trials":21725,"activeCount":101},[21726],{"nctId":21727,"briefTitle":21728,"status":2758,"phases":21729,"primaryCompletion":436,"start":13746,"enrollment":21730,"conditions":21731,"interventions":21736},"NCT02399878","Intra-operative Inspiratory Oxygen Fraction and Postoperative Respiratory Complications",[],70000,[10578,21732,21733,7905,21734,21735],"Acute Respiratory Failure Requiring Intubation","Pulmonary Edema","Surgical Wound Infection","Mortality",[21712],{"intervention":21738,"totalTrials":331,"cells":21739},"Nifedipine",{"EARLY_PHASE1":21740,"PHASE1":21742,"PHASE2":21744,"PHASE3":21746,"PHASE4":21748,"NA":21750},{"trials":21741,"activeCount":101},[],{"trials":21743,"activeCount":101},[],{"trials":21745,"activeCount":101},[],{"trials":21747,"activeCount":101},[],{"trials":21749,"activeCount":101},[],{"trials":21751,"activeCount":101},[21752],{"nctId":21753,"briefTitle":21754,"status":2758,"phases":21755,"primaryCompletion":20319,"completion":20319,"start":21756,"enrollment":1805,"conditions":21757,"interventions":21761},"NCT04288219","Non-Invasive Positive Pressure Ventilation Management of High Altitude Pulmonary Edema",[93],"2020-03-01",[21758,21759,21760],"High Altitude Pulmonary Edema","Non-Invasive Positive Pressure Ventilation","Hypoxia",[21738],{"intervention":21763,"totalTrials":331,"cells":21764},"standard vs. glutamine enteral or parenteral feeding.",{"EARLY_PHASE1":21765,"PHASE1":21767,"PHASE2":21769,"PHASE3":21771,"PHASE4":21773,"NA":21775},{"trials":21766,"activeCount":101},[],{"trials":21768,"activeCount":101},[],{"trials":21770,"activeCount":101},[],{"trials":21772,"activeCount":101},[],{"trials":21774,"activeCount":101},[],{"trials":21776,"activeCount":101},[21777],{"nctId":21778,"briefTitle":21779,"status":107,"phases":21780,"primaryCompletion":248,"completion":248,"start":2847,"enrollment":101,"conditions":21781,"interventions":21782},"NCT00181753","Study of Glutamate and Glutamine Metabolism in Burn Patients Receiving Enteral or Parenteral Nutrition",[93],[19656],[21763],{"intervention":21003,"totalTrials":331,"cells":21784},{"EARLY_PHASE1":21785,"PHASE1":21787,"PHASE2":21789,"PHASE3":21791,"PHASE4":21793,"NA":21795},{"trials":21786,"activeCount":101},[],{"trials":21788,"activeCount":101},[],{"trials":21790,"activeCount":101},[],{"trials":21792,"activeCount":101},[],{"trials":21794,"activeCount":101},[],{"trials":21796,"activeCount":101},[21797],{"nctId":20997,"briefTitle":20998,"status":117,"phases":21798,"primaryCompletion":21000,"completion":21000,"start":1244,"enrollment":4443,"conditions":21799,"interventions":21800},[],[1671,821,6775],[3648,21003],{"intervention":21802,"totalTrials":331,"cells":21803},"Fentanyl dose administration",{"EARLY_PHASE1":21804,"PHASE1":21806,"PHASE2":21808,"PHASE3":21810,"PHASE4":21812,"NA":21814},{"trials":21805,"activeCount":101},[],{"trials":21807,"activeCount":101},[],{"trials":21809,"activeCount":101},[],{"trials":21811,"activeCount":101},[],{"trials":21813,"activeCount":101},[],{"trials":21815,"activeCount":101},[21816],{"nctId":21817,"briefTitle":21818,"status":2758,"phases":21819,"primaryCompletion":21820,"completion":21821,"start":21822,"enrollment":21823,"conditions":21824,"interventions":21826},"NCT03198208","Intraoperative Fentanyl Dose on Respiratory Complications",[],"2015-12-31","2018-06-30","2007-01-01",183396,[16881,21087,9019,21825],"Respiratory Complication",[21802],{"intervention":21828,"totalTrials":331,"cells":21829},"Site specific standard of care comparison",{"EARLY_PHASE1":21830,"PHASE1":21832,"PHASE2":21834,"PHASE3":21836,"PHASE4":21838,"NA":21840},{"trials":21831,"activeCount":101},[],{"trials":21833,"activeCount":101},[],{"trials":21835,"activeCount":101},[],{"trials":21837,"activeCount":101},[],{"trials":21839,"activeCount":101},[],{"trials":21841,"activeCount":101},[21842],{"nctId":21843,"briefTitle":21844,"status":107,"phases":21845,"primaryCompletion":21846,"completion":21846,"start":5101,"enrollment":101,"conditions":21847,"interventions":21850},"NCT03585946","Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis",[],"2040-12-31",[21848,21294,21849],"Stevens-Johnson Syndrome","Drug Reaction",[21828],{"intervention":21852,"totalTrials":331,"cells":21853},"Cholecalciferol",{"EARLY_PHASE1":21854,"PHASE1":21856,"PHASE2":21858,"PHASE3":21860,"PHASE4":21862,"NA":21864},{"trials":21855,"activeCount":101},[],{"trials":21857,"activeCount":101},[],{"trials":21859,"activeCount":101},[],{"trials":21861,"activeCount":101},[],{"trials":21863,"activeCount":101},[],{"trials":21865,"activeCount":101},[21866],{"nctId":21867,"briefTitle":21868,"status":117,"phases":21869,"primaryCompletion":11429,"completion":11429,"start":2994,"enrollment":21870,"conditions":21871,"interventions":21873},"NCT01240512","DAYLIGHT: Vitamin D Therapy in Individuals at High Risk of Hypertension",[93],534,[5842,12141,21872],"Pre-Hypertension",[21852],{"intervention":21875,"totalTrials":331,"cells":21876},"Temazepam",{"EARLY_PHASE1":21877,"PHASE1":21879,"PHASE2":21881,"PHASE3":21883,"PHASE4":21885,"NA":21887},{"trials":21878,"activeCount":101},[],{"trials":21880,"activeCount":101},[],{"trials":21882,"activeCount":101},[],{"trials":21884,"activeCount":101},[],{"trials":21886,"activeCount":101},[],{"trials":21888,"activeCount":101},[21889],{"nctId":21890,"briefTitle":21891,"status":117,"phases":21892,"primaryCompletion":9600,"completion":3706,"start":2827,"enrollment":36,"conditions":21893,"interventions":21895},"NCT01519544","Comparison of Temazepam and Acetazolamide to Treat Difficulty Sleeping at High Altitude",[93],[21894],"High-altitude Sleep Disturbance",[21875,21896],"Acetazolamide",{"intervention":21896,"totalTrials":331,"cells":21898},{"EARLY_PHASE1":21899,"PHASE1":21901,"PHASE2":21903,"PHASE3":21905,"PHASE4":21907,"NA":21909},{"trials":21900,"activeCount":101},[],{"trials":21902,"activeCount":101},[],{"trials":21904,"activeCount":101},[],{"trials":21906,"activeCount":101},[],{"trials":21908,"activeCount":101},[],{"trials":21910,"activeCount":101},[21911],{"nctId":21890,"briefTitle":21891,"status":117,"phases":21912,"primaryCompletion":9600,"completion":3706,"start":2827,"enrollment":36,"conditions":21913,"interventions":21914},[93],[21894],[21875,21896],{"intervention":6954,"totalTrials":331,"cells":21916},{"EARLY_PHASE1":21917,"PHASE1":21919,"PHASE2":21921,"PHASE3":21923,"PHASE4":21925,"NA":21927},{"trials":21918,"activeCount":101},[],{"trials":21920,"activeCount":101},[],{"trials":21922,"activeCount":101},[],{"trials":21924,"activeCount":101},[],{"trials":21926,"activeCount":101},[],{"trials":21928,"activeCount":101},[21929],{"nctId":6948,"briefTitle":6949,"status":117,"phases":21930,"primaryCompletion":3491,"completion":3491,"start":4527,"enrollment":4618,"conditions":21931,"interventions":21932},[93],[6952],[47,6954],{"intervention":21934,"totalTrials":331,"cells":21935},"Albumin bound paclitaxel",{"EARLY_PHASE1":21936,"PHASE1":21938,"PHASE2":21940,"PHASE3":21942,"PHASE4":21944,"NA":21946},{"trials":21937,"activeCount":101},[],{"trials":21939,"activeCount":101},[],{"trials":21941,"activeCount":101},[],{"trials":21943,"activeCount":101},[],{"trials":21945,"activeCount":101},[],{"trials":21947,"activeCount":101},[21948],{"nctId":21949,"briefTitle":21950,"status":173,"phases":21951,"primaryCompletion":1897,"completion":1897,"start":4271,"enrollment":693,"conditions":21952,"interventions":21954},"NCT01698710","Endoscopic Abraxane Injection Into Pancreatic Cysts",[93],[21953],"Pancreatic Cysts",[21934],{"intervention":20977,"totalTrials":331,"cells":21956},{"EARLY_PHASE1":21957,"PHASE1":21959,"PHASE2":21961,"PHASE3":21963,"PHASE4":21965,"NA":21967},{"trials":21958,"activeCount":101},[],{"trials":21960,"activeCount":101},[],{"trials":21962,"activeCount":101},[],{"trials":21964,"activeCount":101},[],{"trials":21966,"activeCount":101},[],{"trials":21968,"activeCount":101},[21969],{"nctId":20967,"briefTitle":20968,"status":117,"phases":21970,"primaryCompletion":15753,"completion":15753,"start":20970,"enrollment":20971,"conditions":21971,"interventions":21972},[93],[20973,20974,20975],[20977,8169],{"intervention":21974,"totalTrials":331,"cells":21975},"Xeris Xerisol glucagon",{"EARLY_PHASE1":21976,"PHASE1":21978,"PHASE2":21980,"PHASE3":21982,"PHASE4":21984,"NA":21986},{"trials":21977,"activeCount":101},[],{"trials":21979,"activeCount":101},[],{"trials":21981,"activeCount":101},[],{"trials":21983,"activeCount":101},[],{"trials":21985,"activeCount":101},[],{"trials":21987,"activeCount":101},[21988],{"nctId":21989,"briefTitle":21990,"status":173,"phases":21991,"primaryCompletion":7120,"completion":7120,"start":1846,"enrollment":194,"conditions":21992,"interventions":21994},"NCT02701257","The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas",[93],[21993],"Diabetes Mellitus Type 1",[21974,21995],"Lilly glucagon",{"intervention":21995,"totalTrials":331,"cells":21997},{"EARLY_PHASE1":21998,"PHASE1":22000,"PHASE2":22002,"PHASE3":22004,"PHASE4":22006,"NA":22008},{"trials":21999,"activeCount":101},[],{"trials":22001,"activeCount":101},[],{"trials":22003,"activeCount":101},[],{"trials":22005,"activeCount":101},[],{"trials":22007,"activeCount":101},[],{"trials":22009,"activeCount":101},[22010],{"nctId":21989,"briefTitle":21990,"status":173,"phases":22011,"primaryCompletion":7120,"completion":7120,"start":1846,"enrollment":194,"conditions":22012,"interventions":22013},[93],[21993],[21974,21995],{"intervention":22015,"totalTrials":331,"cells":22016},"Ganaxolone",{"EARLY_PHASE1":22017,"PHASE1":22019,"PHASE2":22021,"PHASE3":22023,"PHASE4":22025,"NA":22027},{"trials":22018,"activeCount":101},[],{"trials":22020,"activeCount":101},[],{"trials":22022,"activeCount":101},[],{"trials":22024,"activeCount":101},[],{"trials":22026,"activeCount":101},[],{"trials":22028,"activeCount":101},[22029],{"nctId":22030,"briefTitle":22031,"status":117,"phases":22032,"primaryCompletion":22033,"completion":22033,"start":4361,"enrollment":239,"conditions":22034,"interventions":22035},"NCT02900092","Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone",[93],"2018-01-12",[18],[22015],{"intervention":22037,"totalTrials":331,"cells":22038},"Androgen deprivation therapy",{"EARLY_PHASE1":22039,"PHASE1":22041,"PHASE2":22043,"PHASE3":22045,"PHASE4":22047,"NA":22049},{"trials":22040,"activeCount":101},[],{"trials":22042,"activeCount":101},[],{"trials":22044,"activeCount":101},[],{"trials":22046,"activeCount":101},[],{"trials":22048,"activeCount":101},[],{"trials":22050,"activeCount":101},[22051],{"nctId":22052,"briefTitle":22053,"status":117,"phases":22054,"primaryCompletion":3689,"completion":3689,"start":8683,"enrollment":1578,"conditions":22055,"interventions":22056},"NCT00455624","Prospective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate Cancer",[],[2038],[22037],{"intervention":22058,"totalTrials":331,"cells":22059},"Sofosbuvir\u002FLedipasvir FDC",{"EARLY_PHASE1":22060,"PHASE1":22062,"PHASE2":22064,"PHASE3":22066,"PHASE4":22068,"NA":22070},{"trials":22061,"activeCount":101},[],{"trials":22063,"activeCount":101},[],{"trials":22065,"activeCount":101},[],{"trials":22067,"activeCount":101},[],{"trials":22069,"activeCount":101},[],{"trials":22071,"activeCount":101},[22072],{"nctId":22073,"briefTitle":22074,"status":173,"phases":22075,"primaryCompletion":12876,"completion":4335,"start":22076,"enrollment":1898,"conditions":22077,"interventions":22078},"NCT02503735","Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)",[93],"2015-07-15",[9820,10168],[22058],{"intervention":22080,"totalTrials":331,"cells":22081},"Whole Genome Sequencing",{"EARLY_PHASE1":22082,"PHASE1":22084,"PHASE2":22086,"PHASE3":22088,"PHASE4":22090,"NA":22092},{"trials":22083,"activeCount":101},[],{"trials":22085,"activeCount":101},[],{"trials":22087,"activeCount":101},[],{"trials":22089,"activeCount":101},[],{"trials":22091,"activeCount":101},[],{"trials":22093,"activeCount":101},[22094],{"nctId":22095,"briefTitle":22096,"status":117,"phases":22097,"primaryCompletion":14533,"completion":14533,"start":22098,"enrollment":1466,"conditions":22099,"interventions":22102},"NCT03829176","Investigating the Feasibility and Implementation of Whole Genome Sequencing in Patients With Suspected Genetic Disorder",[93],"2018-03-01",[22100,22101],"Hereditary Disease","Genetic Predisposition to Disease",[22080],{"intervention":22104,"totalTrials":331,"cells":22105},"Galantamine-CR",{"EARLY_PHASE1":22106,"PHASE1":22108,"PHASE2":22110,"PHASE3":22112,"PHASE4":22114,"NA":22116},{"trials":22107,"activeCount":101},[],{"trials":22109,"activeCount":101},[],{"trials":22111,"activeCount":101},[],{"trials":22113,"activeCount":101},[],{"trials":22115,"activeCount":101},[],{"trials":22117,"activeCount":101},[22118],{"nctId":22119,"briefTitle":22120,"status":117,"phases":22121,"completion":3492,"enrollment":1847,"conditions":22122,"interventions":22123},"NCT00181636","Galantamine-CR and Cognitive Dysfunction in Bipolar Disorder",[93],[24],[22104],{"intervention":19844,"totalTrials":331,"cells":22125},{"EARLY_PHASE1":22126,"PHASE1":22128,"PHASE2":22130,"PHASE3":22132,"PHASE4":22134,"NA":22136},{"trials":22127,"activeCount":101},[],{"trials":22129,"activeCount":101},[],{"trials":22131,"activeCount":101},[],{"trials":22133,"activeCount":101},[],{"trials":22135,"activeCount":101},[],{"trials":22137,"activeCount":101},[22138],{"nctId":19837,"briefTitle":19838,"status":117,"phases":22139,"primaryCompletion":19840,"completion":19841,"start":225,"enrollment":239,"conditions":22140,"interventions":22141},[93],[819],[2987,19844],{"intervention":22143,"totalTrials":331,"cells":22144},"Dofetilide and\u002For sotalol",{"EARLY_PHASE1":22145,"PHASE1":22147,"PHASE2":22149,"PHASE3":22151,"PHASE4":22153,"NA":22155},{"trials":22146,"activeCount":101},[],{"trials":22148,"activeCount":101},[],{"trials":22150,"activeCount":101},[],{"trials":22152,"activeCount":101},[],{"trials":22154,"activeCount":101},[],{"trials":22156,"activeCount":101},[22157],{"nctId":22158,"briefTitle":22159,"status":2758,"phases":22160,"primaryCompletion":22161,"completion":22162,"start":224,"enrollment":22163,"conditions":22164,"interventions":22166},"NCT02439658","Genetics of QT Prolongation With Antiarrhythmics",[],"2022-12-31","2023-04-30",1000,[22165,3572],"Long QT Syndrome",[22143],{"intervention":22168,"totalTrials":331,"cells":22169},"Nutropin AQ growth hormone",{"EARLY_PHASE1":22170,"PHASE1":22172,"PHASE2":22174,"PHASE3":22176,"PHASE4":22178,"NA":22180},{"trials":22171,"activeCount":101},[],{"trials":22173,"activeCount":101},[],{"trials":22175,"activeCount":101},[],{"trials":22177,"activeCount":101},[],{"trials":22179,"activeCount":101},[],{"trials":22181,"activeCount":101},[22182],{"nctId":22183,"briefTitle":22184,"status":117,"phases":22185,"primaryCompletion":4271,"completion":2446,"start":22186,"enrollment":16492,"conditions":22187,"interventions":22188},"NCT00131378","Growth Hormone, Cardiovascular Risk, and Visceral Adiposity",[93],"2004-11",[26],[22168],{"intervention":22190,"totalTrials":331,"cells":22191},"Amphetamine\u002Fdextroamphetamine",{"EARLY_PHASE1":22192,"PHASE1":22194,"PHASE2":22196,"PHASE3":22198,"PHASE4":22200,"NA":22202},{"trials":22193,"activeCount":101},[],{"trials":22195,"activeCount":101},[],{"trials":22197,"activeCount":101},[],{"trials":22199,"activeCount":101},[],{"trials":22201,"activeCount":101},[],{"trials":22203,"activeCount":101},[22204],{"nctId":22205,"briefTitle":22206,"status":173,"phases":22207,"primaryCompletion":6695,"completion":1814,"start":9320,"enrollment":693,"conditions":22208,"interventions":22209},"NCT01478113","Stimulant Enhancement of Well-Being Therapy for Depression",[93],[18],[22190],{"intervention":22211,"totalTrials":331,"cells":22212},"Eplerenone",{"EARLY_PHASE1":22213,"PHASE1":22215,"PHASE2":22217,"PHASE3":22219,"PHASE4":22221,"NA":22223},{"trials":22214,"activeCount":101},[],{"trials":22216,"activeCount":101},[],{"trials":22218,"activeCount":101},[],{"trials":22220,"activeCount":101},[],{"trials":22222,"activeCount":101},[],{"trials":22224,"activeCount":101},[22225],{"nctId":22226,"briefTitle":22227,"status":117,"phases":22228,"primaryCompletion":22229,"completion":22229,"start":1779,"enrollment":251,"conditions":22230,"interventions":22231},"NCT02740179","Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)",[93],"2022-03-17",[1671],[22211],{"intervention":22233,"totalTrials":331,"cells":22234},"Curcumin",{"EARLY_PHASE1":22235,"PHASE1":22237,"PHASE2":22239,"PHASE3":22241,"PHASE4":22243,"NA":22245},{"trials":22236,"activeCount":101},[],{"trials":22238,"activeCount":101},[],{"trials":22240,"activeCount":101},[],{"trials":22242,"activeCount":101},[],{"trials":22244,"activeCount":101},[],{"trials":22246,"activeCount":101},[22247],{"nctId":22248,"briefTitle":22249,"status":117,"phases":22250,"primaryCompletion":22251,"completion":22251,"start":2456,"enrollment":544,"conditions":22252,"interventions":22253},"NCT00181662","Pharmacokinetics of Curcumin in Healthy Volunteers",[93],"2007-10-17",[29],[22233],{"intervention":22255,"totalTrials":331,"cells":22256},"microarray analysis",{"EARLY_PHASE1":22257,"PHASE1":22259,"PHASE2":22261,"PHASE3":22263,"PHASE4":22265,"NA":22267},{"trials":22258,"activeCount":101},[],{"trials":22260,"activeCount":101},[],{"trials":22262,"activeCount":101},[],{"trials":22264,"activeCount":101},[],{"trials":22266,"activeCount":101},[],{"trials":22268,"activeCount":101},[22269],{"nctId":22270,"briefTitle":22271,"status":2758,"phases":22272,"start":579,"enrollment":22273,"conditions":22274,"interventions":22275},"NCT00897065","Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17",[],957,[21],[22255,22276,22277],"polymerase chain reaction","protein expression analysis",{"intervention":22276,"totalTrials":331,"cells":22279},{"EARLY_PHASE1":22280,"PHASE1":22282,"PHASE2":22284,"PHASE3":22286,"PHASE4":22288,"NA":22290},{"trials":22281,"activeCount":101},[],{"trials":22283,"activeCount":101},[],{"trials":22285,"activeCount":101},[],{"trials":22287,"activeCount":101},[],{"trials":22289,"activeCount":101},[],{"trials":22291,"activeCount":101},[22292],{"nctId":22270,"briefTitle":22271,"status":2758,"phases":22293,"start":579,"enrollment":22273,"conditions":22294,"interventions":22295},[],[21],[22255,22276,22277],{"intervention":22277,"totalTrials":331,"cells":22297},{"EARLY_PHASE1":22298,"PHASE1":22300,"PHASE2":22302,"PHASE3":22304,"PHASE4":22306,"NA":22308},{"trials":22299,"activeCount":101},[],{"trials":22301,"activeCount":101},[],{"trials":22303,"activeCount":101},[],{"trials":22305,"activeCount":101},[],{"trials":22307,"activeCount":101},[],{"trials":22309,"activeCount":101},[22310],{"nctId":22270,"briefTitle":22271,"status":2758,"phases":22311,"start":579,"enrollment":22273,"conditions":22312,"interventions":22313},[],[21],[22255,22276,22277],{"intervention":22315,"totalTrials":331,"cells":22316},"Zolpidem CR",{"EARLY_PHASE1":22317,"PHASE1":22319,"PHASE2":22321,"PHASE3":22323,"PHASE4":22325,"NA":22327},{"trials":22318,"activeCount":101},[],{"trials":22320,"activeCount":101},[],{"trials":22322,"activeCount":101},[],{"trials":22324,"activeCount":101},[],{"trials":22326,"activeCount":101},[],{"trials":22328,"activeCount":101},[22329],{"nctId":22330,"briefTitle":22331,"status":117,"phases":22332,"primaryCompletion":4677,"completion":4677,"start":9865,"enrollment":194,"conditions":22333,"interventions":22336},"NCT00814502","Zolpidem CR and Hospitalized Patients With Dementia",[93],[22334,5544,22335,20524,20525],"Dementia","Dementia, Vascular",[22315],{"intervention":22338,"totalTrials":331,"cells":22339},"[18F] GE-180",{"EARLY_PHASE1":22340,"PHASE1":22342,"PHASE2":22344,"PHASE3":22346,"PHASE4":22348,"NA":22350},{"trials":22341,"activeCount":101},[],{"trials":22343,"activeCount":101},[],{"trials":22345,"activeCount":101},[],{"trials":22347,"activeCount":101},[],{"trials":22349,"activeCount":101},[],{"trials":22351,"activeCount":101},[22352],{"nctId":22353,"briefTitle":22354,"status":117,"phases":22355,"primaryCompletion":6163,"completion":6163,"start":1869,"enrollment":3517,"conditions":22356,"interventions":22358},"NCT02559869","Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis",[],[22357],"Amyotrophic Lateral Sclerosis (ALS)",[22338],{"intervention":20497,"totalTrials":331,"cells":22360},{"EARLY_PHASE1":22361,"PHASE1":22363,"PHASE2":22365,"PHASE3":22367,"PHASE4":22369,"NA":22371},{"trials":22362,"activeCount":101},[],{"trials":22364,"activeCount":101},[],{"trials":22366,"activeCount":101},[],{"trials":22368,"activeCount":101},[],{"trials":22370,"activeCount":101},[],{"trials":22372,"activeCount":101},[22373],{"nctId":20492,"briefTitle":20493,"status":117,"phases":22374,"primaryCompletion":4606,"completion":4606,"start":8572,"enrollment":15129,"conditions":22375,"interventions":22376},[93],[15],[654,20497,1884],{"intervention":19897,"totalTrials":331,"cells":22378},{"EARLY_PHASE1":22379,"PHASE1":22381,"PHASE2":22383,"PHASE3":22385,"PHASE4":22387,"NA":22389},{"trials":22380,"activeCount":101},[],{"trials":22382,"activeCount":101},[],{"trials":22384,"activeCount":101},[],{"trials":22386,"activeCount":101},[],{"trials":22388,"activeCount":101},[],{"trials":22390,"activeCount":101},[22391],{"nctId":19891,"briefTitle":19892,"status":117,"phases":22392,"primaryCompletion":308,"completion":308,"start":741,"enrollment":19894,"conditions":22393,"interventions":22394},[93],[8978],[573,19897],{"intervention":21156,"totalTrials":331,"cells":22396},{"EARLY_PHASE1":22397,"PHASE1":22399,"PHASE2":22401,"PHASE3":22403,"PHASE4":22405,"NA":22407},{"trials":22398,"activeCount":101},[],{"trials":22400,"activeCount":101},[],{"trials":22402,"activeCount":101},[],{"trials":22404,"activeCount":101},[],{"trials":22406,"activeCount":101},[],{"trials":22408,"activeCount":101},[22409],{"nctId":21150,"briefTitle":21151,"status":117,"phases":22410,"primaryCompletion":4335,"completion":4335,"start":568,"enrollment":21153,"conditions":22411,"interventions":22412},[93],[772,571,380],[21128,21156],{"intervention":22414,"totalTrials":331,"cells":22415},"Standardized Cat Allergen Extract and Standardized Dust Mite Allergen",{"EARLY_PHASE1":22416,"PHASE1":22418,"PHASE2":22420,"PHASE3":22422,"PHASE4":22424,"NA":22426},{"trials":22417,"activeCount":101},[],{"trials":22419,"activeCount":101},[],{"trials":22421,"activeCount":101},[],{"trials":22423,"activeCount":101},[],{"trials":22425,"activeCount":101},[],{"trials":22427,"activeCount":101},[22428],{"nctId":22429,"briefTitle":22430,"status":117,"phases":22431,"primaryCompletion":11429,"completion":11429,"start":2609,"enrollment":270,"conditions":22432,"interventions":22434},"NCT01547286","Imaging Study of the Lungs During an Allergic Asthma Attack",[93],[1058,22433],"Atopy",[22414,22435],"Nebulized methacholine inhalation",{"intervention":22435,"totalTrials":331,"cells":22437},{"EARLY_PHASE1":22438,"PHASE1":22440,"PHASE2":22442,"PHASE3":22444,"PHASE4":22446,"NA":22448},{"trials":22439,"activeCount":101},[],{"trials":22441,"activeCount":101},[],{"trials":22443,"activeCount":101},[],{"trials":22445,"activeCount":101},[],{"trials":22447,"activeCount":101},[],{"trials":22449,"activeCount":101},[22450],{"nctId":22429,"briefTitle":22430,"status":117,"phases":22451,"primaryCompletion":11429,"completion":11429,"start":2609,"enrollment":270,"conditions":22452,"interventions":22453},[93],[1058,22433],[22414,22435],{"intervention":22455,"totalTrials":331,"cells":22456},"Treatment as usual",{"EARLY_PHASE1":22457,"PHASE1":22459,"PHASE2":22461,"PHASE3":22463,"PHASE4":22465,"NA":22467},{"trials":22458,"activeCount":101},[],{"trials":22460,"activeCount":101},[],{"trials":22462,"activeCount":101},[],{"trials":22464,"activeCount":101},[],{"trials":22466,"activeCount":101},[],{"trials":22468,"activeCount":101},[22469],{"nctId":22470,"briefTitle":22471,"status":117,"phases":22472,"primaryCompletion":567,"completion":567,"start":2446,"enrollment":36,"conditions":22473,"interventions":22474},"NCT01892306","Pilot Study of Cognitive Behavioral Therapy for Anxiety and Bipolar I Disorder",[93],[24,8452],[22455],{"intervention":20299,"totalTrials":331,"cells":22476},{"EARLY_PHASE1":22477,"PHASE1":22479,"PHASE2":22481,"PHASE3":22483,"PHASE4":22485,"NA":22487},{"trials":22478,"activeCount":101},[],{"trials":22480,"activeCount":101},[],{"trials":22482,"activeCount":101},[],{"trials":22484,"activeCount":101},[],{"trials":22486,"activeCount":101},[],{"trials":22488,"activeCount":101},[22489],{"nctId":20293,"briefTitle":20294,"status":173,"phases":22490,"primaryCompletion":1244,"completion":1244,"start":707,"enrollment":2028,"conditions":22491,"interventions":22492},[93],[20297],[20299,20300,20301],{"intervention":20301,"totalTrials":331,"cells":22494},{"EARLY_PHASE1":22495,"PHASE1":22497,"PHASE2":22499,"PHASE3":22501,"PHASE4":22503,"NA":22505},{"trials":22496,"activeCount":101},[],{"trials":22498,"activeCount":101},[],{"trials":22500,"activeCount":101},[],{"trials":22502,"activeCount":101},[],{"trials":22504,"activeCount":101},[],{"trials":22506,"activeCount":101},[22507],{"nctId":20293,"briefTitle":20294,"status":173,"phases":22508,"primaryCompletion":1244,"completion":1244,"start":707,"enrollment":2028,"conditions":22509,"interventions":22510},[93],[20297],[20299,20300,20301],{"intervention":22512,"totalTrials":331,"cells":22513},"Methylphenidate HCl ER tablets 1",{"EARLY_PHASE1":22514,"PHASE1":22516,"PHASE2":22518,"PHASE3":22520,"PHASE4":22522,"NA":22524},{"trials":22515,"activeCount":101},[],{"trials":22517,"activeCount":101},[],{"trials":22519,"activeCount":101},[],{"trials":22521,"activeCount":101},[],{"trials":22523,"activeCount":101},[],{"trials":22525,"activeCount":101},[22526],{"nctId":22527,"briefTitle":22528,"status":117,"phases":22529,"primaryCompletion":3148,"completion":3148,"start":46,"enrollment":20641,"conditions":22530,"interventions":22531},"NCT02536105","PK\u002FPD Pediatric ADHD Classroom Study",[93],[8739],[22512,22532,22533],"Methylphenidate HCl ER tablets 2","Methylphenidate HCl ER for suspension",{"intervention":22532,"totalTrials":331,"cells":22535},{"EARLY_PHASE1":22536,"PHASE1":22538,"PHASE2":22540,"PHASE3":22542,"PHASE4":22544,"NA":22546},{"trials":22537,"activeCount":101},[],{"trials":22539,"activeCount":101},[],{"trials":22541,"activeCount":101},[],{"trials":22543,"activeCount":101},[],{"trials":22545,"activeCount":101},[],{"trials":22547,"activeCount":101},[22548],{"nctId":22527,"briefTitle":22528,"status":117,"phases":22549,"primaryCompletion":3148,"completion":3148,"start":46,"enrollment":20641,"conditions":22550,"interventions":22551},[93],[8739],[22512,22532,22533],{"intervention":22533,"totalTrials":331,"cells":22553},{"EARLY_PHASE1":22554,"PHASE1":22556,"PHASE2":22558,"PHASE3":22560,"PHASE4":22562,"NA":22564},{"trials":22555,"activeCount":101},[],{"trials":22557,"activeCount":101},[],{"trials":22559,"activeCount":101},[],{"trials":22561,"activeCount":101},[],{"trials":22563,"activeCount":101},[],{"trials":22565,"activeCount":101},[22566],{"nctId":22527,"briefTitle":22528,"status":117,"phases":22567,"primaryCompletion":3148,"completion":3148,"start":46,"enrollment":20641,"conditions":22568,"interventions":22569},[93],[8739],[22512,22532,22533],{"intervention":22571,"totalTrials":331,"cells":22572},"Radioactive dye",{"EARLY_PHASE1":22573,"PHASE1":22575,"PHASE2":22577,"PHASE3":22579,"PHASE4":22581,"NA":22583},{"trials":22574,"activeCount":101},[],{"trials":22576,"activeCount":101},[],{"trials":22578,"activeCount":101},[],{"trials":22580,"activeCount":101},[],{"trials":22582,"activeCount":101},[],{"trials":22584,"activeCount":101},[22585],{"nctId":22586,"briefTitle":22587,"status":117,"phases":22588,"primaryCompletion":268,"completion":4380,"start":455,"enrollment":3565,"conditions":22589,"interventions":22591},"NCT02130271","PET\u002FMRI Imaging of Neuraxial Inflammation in Sciatica Patients",[],[22590],"Sciatica",[22571],{"intervention":22593,"totalTrials":331,"cells":22594},"TheraDerm",{"EARLY_PHASE1":22595,"PHASE1":22597,"PHASE2":22599,"PHASE3":22601,"PHASE4":22603,"NA":22605},{"trials":22596,"activeCount":101},[],{"trials":22598,"activeCount":101},[],{"trials":22600,"activeCount":101},[],{"trials":22602,"activeCount":101},[],{"trials":22604,"activeCount":101},[],{"trials":22606,"activeCount":101},[22607],{"nctId":22608,"briefTitle":22609,"status":117,"phases":22610,"completion":4425,"start":18975,"enrollment":366,"conditions":22611,"interventions":22612},"NCT00027430","Androgen Replacement Therapy in Women With Hypopituitarism",[93],[7859],[22593],{"intervention":19904,"totalTrials":331,"cells":22614},{"EARLY_PHASE1":22615,"PHASE1":22617,"PHASE2":22619,"PHASE3":22621,"PHASE4":22623,"NA":22625},{"trials":22616,"activeCount":101},[],{"trials":22618,"activeCount":101},[],{"trials":22620,"activeCount":101},[],{"trials":22622,"activeCount":101},[],{"trials":22624,"activeCount":101},[],{"trials":22626,"activeCount":101},[22627],{"nctId":19899,"briefTitle":19900,"status":107,"phases":22628,"primaryCompletion":554,"completion":554,"start":135,"enrollment":101,"conditions":22629,"interventions":22630},[93],[5842],[573,19904,19905,9383],{"intervention":20055,"totalTrials":331,"cells":22632},{"EARLY_PHASE1":22633,"PHASE1":22635,"PHASE2":22637,"PHASE3":22639,"PHASE4":22641,"NA":22643},{"trials":22634,"activeCount":101},[],{"trials":22636,"activeCount":101},[],{"trials":22638,"activeCount":101},[],{"trials":22640,"activeCount":101},[],{"trials":22642,"activeCount":101},[],{"trials":22644,"activeCount":101},[22645],{"nctId":20048,"briefTitle":20049,"status":117,"phases":22646,"primaryCompletion":20051,"completion":20051,"start":135,"enrollment":136,"conditions":22647,"interventions":22648},[93],[2030,20053],[4514,20055,20056],{"intervention":20056,"totalTrials":331,"cells":22650},{"EARLY_PHASE1":22651,"PHASE1":22653,"PHASE2":22655,"PHASE3":22657,"PHASE4":22659,"NA":22661},{"trials":22652,"activeCount":101},[],{"trials":22654,"activeCount":101},[],{"trials":22656,"activeCount":101},[],{"trials":22658,"activeCount":101},[],{"trials":22660,"activeCount":101},[],{"trials":22662,"activeCount":101},[22663],{"nctId":20048,"briefTitle":20049,"status":117,"phases":22664,"primaryCompletion":20051,"completion":20051,"start":135,"enrollment":136,"conditions":22665,"interventions":22666},[93],[2030,20053],[4514,20055,20056],{"intervention":22668,"totalTrials":331,"cells":22669},"Ibuprofen",{"EARLY_PHASE1":22670,"PHASE1":22672,"PHASE2":22674,"PHASE3":22676,"PHASE4":22678,"NA":22680},{"trials":22671,"activeCount":101},[],{"trials":22673,"activeCount":101},[],{"trials":22675,"activeCount":101},[],{"trials":22677,"activeCount":101},[],{"trials":22679,"activeCount":101},[],{"trials":22681,"activeCount":101},[22682],{"nctId":22683,"briefTitle":22684,"status":117,"phases":22685,"primaryCompletion":22686,"completion":22687,"start":22688,"enrollment":5302,"conditions":22689,"interventions":22692},"NCT01522326","Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness",[93],"2017-03-01","2017-03-30","2012-03-01",[22690,22691],"Acute Mountain Sickness","High Altitude Headache",[22668,22693],"Metoclopramide",{"intervention":22693,"totalTrials":331,"cells":22695},{"EARLY_PHASE1":22696,"PHASE1":22698,"PHASE2":22700,"PHASE3":22702,"PHASE4":22704,"NA":22706},{"trials":22697,"activeCount":101},[],{"trials":22699,"activeCount":101},[],{"trials":22701,"activeCount":101},[],{"trials":22703,"activeCount":101},[],{"trials":22705,"activeCount":101},[],{"trials":22707,"activeCount":101},[22708],{"nctId":22683,"briefTitle":22684,"status":117,"phases":22709,"primaryCompletion":22686,"completion":22687,"start":22688,"enrollment":5302,"conditions":22710,"interventions":22711},[93],[22690,22691],[22668,22693],{"intervention":6762,"totalTrials":331,"cells":22713},{"EARLY_PHASE1":22714,"PHASE1":22716,"PHASE2":22718,"PHASE3":22720,"PHASE4":22722,"NA":22724},{"trials":22715,"activeCount":101},[],{"trials":22717,"activeCount":101},[],{"trials":22719,"activeCount":101},[],{"trials":22721,"activeCount":101},[],{"trials":22723,"activeCount":101},[],{"trials":22725,"activeCount":101},[22726],{"nctId":6755,"briefTitle":6756,"status":117,"phases":22727,"primaryCompletion":6758,"completion":2644,"start":6759,"enrollment":251,"conditions":22728,"interventions":22729},[93],[2038],[6762,3576],{"intervention":22731,"totalTrials":331,"cells":22732},"Growth hormone treatment",{"EARLY_PHASE1":22733,"PHASE1":22735,"PHASE2":22737,"PHASE3":22739,"PHASE4":22741,"NA":22743},{"trials":22734,"activeCount":101},[],{"trials":22736,"activeCount":101},[],{"trials":22738,"activeCount":101},[],{"trials":22740,"activeCount":101},[],{"trials":22742,"activeCount":101},[],{"trials":22744,"activeCount":101},[22745],{"nctId":22746,"briefTitle":22747,"status":117,"phases":22748,"primaryCompletion":284,"completion":284,"start":11845,"enrollment":2728,"conditions":22749,"interventions":22752},"NCT01421589","Growth Hormone Treatment on Phosphocreatine Recovery in Obesity",[93],[22750,22751],"Obese","Growth Hormone Secretion Abnormality",[22731],{"intervention":22754,"totalTrials":331,"cells":22755},"Cancer Immunotherapy",{"EARLY_PHASE1":22756,"PHASE1":22758,"PHASE2":22760,"PHASE3":22762,"PHASE4":22764,"NA":22766},{"trials":22757,"activeCount":101},[],{"trials":22759,"activeCount":101},[],{"trials":22761,"activeCount":101},[],{"trials":22763,"activeCount":101},[],{"trials":22765,"activeCount":101},[],{"trials":22767,"activeCount":101},[22768],{"nctId":22769,"briefTitle":22770,"status":117,"phases":22771,"primaryCompletion":14141,"completion":14141,"start":41,"enrollment":4618,"conditions":22772,"interventions":22774},"NCT02431572","A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy",[93],[22773,13574,3901],"Intracranial Tumors",[22754],{"intervention":22776,"totalTrials":331,"cells":22777},"Angiotensin II",{"EARLY_PHASE1":22778,"PHASE1":22780,"PHASE2":22782,"PHASE3":22784,"PHASE4":22786,"NA":22788},{"trials":22779,"activeCount":101},[],{"trials":22781,"activeCount":101},[],{"trials":22783,"activeCount":101},[],{"trials":22785,"activeCount":101},[],{"trials":22787,"activeCount":101},[],{"trials":22789,"activeCount":101},[22790],{"nctId":22791,"briefTitle":22792,"status":117,"phases":22793,"primaryCompletion":3706,"start":11914,"enrollment":227,"conditions":22794,"interventions":22796},"NCT01407237","Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV",[],[22795],"HIV-infection",[22776],{"intervention":21217,"totalTrials":331,"cells":22798},{"EARLY_PHASE1":22799,"PHASE1":22801,"PHASE2":22803,"PHASE3":22805,"PHASE4":22807,"NA":22809},{"trials":22800,"activeCount":101},[],{"trials":22802,"activeCount":101},[],{"trials":22804,"activeCount":101},[],{"trials":22806,"activeCount":101},[],{"trials":22808,"activeCount":101},[],{"trials":22810,"activeCount":101},[22811],{"nctId":21211,"briefTitle":21212,"status":117,"phases":22812,"primaryCompletion":2447,"completion":2447,"start":13746,"enrollment":8836,"conditions":22813,"interventions":22814},[93],[21215],[21217,21218],{"intervention":21062,"totalTrials":331,"cells":22816},{"EARLY_PHASE1":22817,"PHASE1":22819,"PHASE2":22821,"PHASE3":22823,"PHASE4":22825,"NA":22827},{"trials":22818,"activeCount":101},[],{"trials":22820,"activeCount":101},[],{"trials":22822,"activeCount":101},[],{"trials":22824,"activeCount":101},[],{"trials":22826,"activeCount":101},[],{"trials":22828,"activeCount":101},[22829],{"nctId":21055,"briefTitle":21056,"status":117,"phases":22830,"primaryCompletion":477,"completion":135,"start":12241,"enrollment":2559,"conditions":22831,"interventions":22832},[93],[21059,21060],[21062,21029],{"intervention":22834,"totalTrials":331,"cells":22835},"5-aminolevulinic acid",{"EARLY_PHASE1":22836,"PHASE1":22838,"PHASE2":22840,"PHASE3":22842,"PHASE4":22844,"NA":22846},{"trials":22837,"activeCount":101},[],{"trials":22839,"activeCount":101},[],{"trials":22841,"activeCount":101},[],{"trials":22843,"activeCount":101},[],{"trials":22845,"activeCount":101},[],{"trials":22847,"activeCount":101},[22848],{"nctId":22849,"briefTitle":22850,"status":2758,"phases":22851,"primaryCompletion":4490,"completion":4490,"start":134,"enrollment":251,"conditions":22852,"interventions":22854},"NCT04390802","A Pilot Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Pituitary Adenomas",[],[22853],"Pituitary Adenoma",[22834],{"intervention":22856,"totalTrials":331,"cells":22857},"Lanthanum Carbonate",{"EARLY_PHASE1":22858,"PHASE1":22860,"PHASE2":22862,"PHASE3":22864,"PHASE4":22866,"NA":22868},{"trials":22859,"activeCount":101},[],{"trials":22861,"activeCount":101},[],{"trials":22863,"activeCount":101},[],{"trials":22865,"activeCount":101},[],{"trials":22867,"activeCount":101},[],{"trials":22869,"activeCount":101},[22870],{"nctId":22871,"briefTitle":22872,"status":117,"phases":22873,"primaryCompletion":6696,"completion":6696,"start":13746,"enrollment":1805,"conditions":22874,"interventions":22875},"NCT00438932","Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease",[93],[10168],[22856],{"intervention":22877,"totalTrials":331,"cells":22878},"GSK2118436",{"EARLY_PHASE1":22879,"PHASE1":22881,"PHASE2":22883,"PHASE3":22885,"PHASE4":22887,"NA":22889},{"trials":22880,"activeCount":101},[],{"trials":22882,"activeCount":101},[],{"trials":22884,"activeCount":101},[],{"trials":22886,"activeCount":101},[],{"trials":22888,"activeCount":101},[],{"trials":22890,"activeCount":101},[22891],{"nctId":22892,"briefTitle":22893,"status":117,"phases":22894,"primaryCompletion":2436,"completion":2436,"start":9600,"enrollment":239,"conditions":22895,"interventions":22897},"NCT01534897","Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436",[93],[22896],"Papillary Thyroid Carcinoma",[22877],{"intervention":22899,"totalTrials":331,"cells":22900},"Sedatives and muscle relaxants given in the ICU",{"EARLY_PHASE1":22901,"PHASE1":22903,"PHASE2":22905,"PHASE3":22907,"PHASE4":22909,"NA":22911},{"trials":22902,"activeCount":101},[],{"trials":22904,"activeCount":101},[],{"trials":22906,"activeCount":101},[],{"trials":22908,"activeCount":101},[],{"trials":22910,"activeCount":101},[],{"trials":22912,"activeCount":101},[22913],{"nctId":22914,"briefTitle":22915,"status":2758,"phases":22916,"primaryCompletion":268,"completion":268,"start":176,"enrollment":366,"conditions":22917,"interventions":22920},"NCT02112604","Predictors of Upper Airway Function and Sleep-disordered Breathing in the Critically Ill",[],[22918,22919],"Critically Ill","Obstructive Sleep Apnea",[22899],{"intervention":22922,"totalTrials":331,"cells":22923},"Eplerenone and lifestyle",{"EARLY_PHASE1":22924,"PHASE1":22926,"PHASE2":22928,"PHASE3":22930,"PHASE4":22932,"NA":22934},{"trials":22925,"activeCount":101},[],{"trials":22927,"activeCount":101},[],{"trials":22929,"activeCount":101},[],{"trials":22931,"activeCount":101},[],{"trials":22933,"activeCount":101},[],{"trials":22935,"activeCount":101},[22936],{"nctId":22937,"briefTitle":22938,"status":117,"phases":22939,"primaryCompletion":20231,"completion":308,"start":11914,"enrollment":829,"conditions":22940,"interventions":22941},"NCT01405456","Eplerenone in HIV Associated Abdominal Fat Accumulation",[93],[1671],[22922],{"intervention":22943,"totalTrials":331,"cells":22944},"500 mg vitamin c, 1 pill per day for 6 weeks",{"EARLY_PHASE1":22945,"PHASE1":22947,"PHASE2":22949,"PHASE3":22951,"PHASE4":22953,"NA":22955},{"trials":22946,"activeCount":101},[],{"trials":22948,"activeCount":101},[],{"trials":22950,"activeCount":101},[],{"trials":22952,"activeCount":101},[],{"trials":22954,"activeCount":101},[],{"trials":22956,"activeCount":101},[22957],{"nctId":22958,"briefTitle":22959,"status":117,"phases":22960,"primaryCompletion":22961,"completion":22961,"start":436,"enrollment":22962,"conditions":22963,"interventions":22966},"NCT02216812","Does Vitamin C Reduce Finger Stiffness After Distal Radius Fractures?",[93],"2017-12-22",134,[22964,22965],"Finger Stiffness","Distal Radius Fracture",[22943,22967],"1 placebo pill for 6 weeks",{"intervention":22967,"totalTrials":331,"cells":22969},{"EARLY_PHASE1":22970,"PHASE1":22972,"PHASE2":22974,"PHASE3":22976,"PHASE4":22978,"NA":22980},{"trials":22971,"activeCount":101},[],{"trials":22973,"activeCount":101},[],{"trials":22975,"activeCount":101},[],{"trials":22977,"activeCount":101},[],{"trials":22979,"activeCount":101},[],{"trials":22981,"activeCount":101},[22982],{"nctId":22958,"briefTitle":22959,"status":117,"phases":22983,"primaryCompletion":22961,"completion":22961,"start":436,"enrollment":22962,"conditions":22984,"interventions":22985},[93],[22964,22965],[22943,22967],{"intervention":22987,"totalTrials":331,"cells":22988},"Psychotropic medication",{"EARLY_PHASE1":22989,"PHASE1":22991,"PHASE2":22993,"PHASE3":22995,"PHASE4":22997,"NA":22999},{"trials":22990,"activeCount":101},[],{"trials":22992,"activeCount":101},[],{"trials":22994,"activeCount":101},[],{"trials":22996,"activeCount":101},[],{"trials":22998,"activeCount":101},[],{"trials":23000,"activeCount":101},[23001],{"nctId":23002,"briefTitle":23003,"status":117,"phases":23004,"primaryCompletion":175,"completion":175,"start":8504,"enrollment":538,"conditions":23005,"interventions":23006},"NCT00505518","Investigating the Effectiveness of Telepsychiatry for Treating Major Depression in a Chinese American Nursing Home",[93],[18],[22987],{"intervention":23008,"totalTrials":331,"cells":23009},"Tisseel Fibrin Sealant",{"EARLY_PHASE1":23010,"PHASE1":23012,"PHASE2":23014,"PHASE3":23016,"PHASE4":23018,"NA":23020},{"trials":23011,"activeCount":101},[],{"trials":23013,"activeCount":101},[],{"trials":23015,"activeCount":101},[],{"trials":23017,"activeCount":101},[],{"trials":23019,"activeCount":101},[],{"trials":23021,"activeCount":101},[23022],{"nctId":23023,"briefTitle":23024,"status":117,"phases":23025,"primaryCompletion":684,"completion":175,"start":23026,"enrollment":1847,"conditions":23027,"interventions":23028},"NCT00181974","Efficacy of a Fibrin Sealant in Burn Surgery",[93],"2000-03",[19656],[23008],{"intervention":21273,"totalTrials":331,"cells":23030},{"EARLY_PHASE1":23031,"PHASE1":23033,"PHASE2":23035,"PHASE3":23037,"PHASE4":23039,"NA":23041},{"trials":23032,"activeCount":101},[],{"trials":23034,"activeCount":101},[],{"trials":23036,"activeCount":101},[],{"trials":23038,"activeCount":101},[],{"trials":23040,"activeCount":101},[],{"trials":23042,"activeCount":101},[23043],{"nctId":21266,"briefTitle":21267,"status":117,"phases":23044,"primaryCompletion":2027,"completion":6900,"start":15128,"enrollment":21269,"conditions":23045,"interventions":23046},[93],[21,9400,20524],[21272,21273],{"intervention":23048,"totalTrials":331,"cells":23049},"Leptin administration",{"EARLY_PHASE1":23050,"PHASE1":23052,"PHASE2":23054,"PHASE3":23056,"PHASE4":23058,"NA":23060},{"trials":23051,"activeCount":101},[],{"trials":23053,"activeCount":101},[],{"trials":23055,"activeCount":101},[],{"trials":23057,"activeCount":101},[],{"trials":23059,"activeCount":101},[],{"trials":23061,"activeCount":101},[23062],{"nctId":23063,"briefTitle":23064,"status":117,"phases":23065,"primaryCompletion":8723,"completion":8723,"start":8683,"enrollment":194,"conditions":23066,"interventions":23067},"NCT01257841","Secondary Analysis of Gut Hormones and Inflammatory Cytokines in Fasting Subjects",[93],[29],[23048],{"intervention":23069,"totalTrials":331,"cells":23070},"Gonadotropin Releasing Hormone Agonist Therapy",{"EARLY_PHASE1":23071,"PHASE1":23073,"PHASE2":23075,"PHASE3":23077,"PHASE4":23079,"NA":23081},{"trials":23072,"activeCount":101},[],{"trials":23074,"activeCount":101},[],{"trials":23076,"activeCount":101},[],{"trials":23078,"activeCount":101},[],{"trials":23080,"activeCount":101},[],{"trials":23082,"activeCount":101},[23083],{"nctId":23084,"briefTitle":23085,"status":117,"phases":23086,"primaryCompletion":2801,"completion":2801,"start":4463,"enrollment":33,"conditions":23087,"interventions":23088},"NCT00456144","Prospective Observation Study of Insulin Sensitivity During and After Gonadotropin Releasing Hormone Agonist Therapy for Prostate Cancer",[],[2038],[23069],{"intervention":23090,"totalTrials":331,"cells":23091},"Genotyping assays",{"EARLY_PHASE1":23092,"PHASE1":23094,"PHASE2":23096,"PHASE3":23098,"PHASE4":23100,"NA":23102},{"trials":23093,"activeCount":101},[],{"trials":23095,"activeCount":101},[],{"trials":23097,"activeCount":101},[],{"trials":23099,"activeCount":101},[],{"trials":23101,"activeCount":101},[],{"trials":23103,"activeCount":101},[23104],{"nctId":23105,"briefTitle":23106,"status":173,"phases":23107,"primaryCompletion":9600,"completion":9600,"start":4290,"enrollment":798,"conditions":23108,"interventions":23109},"NCT01555021","Pharmacogenomics for Antidepressant Guidance and Education",[],[1783],[23090],{"intervention":23111,"totalTrials":331,"cells":23112},"atazanavir\u002Fritonavir",{"EARLY_PHASE1":23113,"PHASE1":23115,"PHASE2":23117,"PHASE3":23119,"PHASE4":23121,"NA":23123},{"trials":23114,"activeCount":101},[],{"trials":23116,"activeCount":101},[],{"trials":23118,"activeCount":101},[],{"trials":23120,"activeCount":101},[],{"trials":23122,"activeCount":101},[],{"trials":23124,"activeCount":101},[23125],{"nctId":23126,"briefTitle":23127,"status":117,"phases":23128,"primaryCompletion":9865,"completion":9865,"start":3689,"enrollment":2728,"conditions":23129,"interventions":23130},"NCT00413153","Metabolic Effects of Switching Kaletra to Boosted Reyataz",[93],[8139],[23111,23131],"lopinavir\u002Fritonavir",{"intervention":23131,"totalTrials":331,"cells":23133},{"EARLY_PHASE1":23134,"PHASE1":23136,"PHASE2":23138,"PHASE3":23140,"PHASE4":23142,"NA":23144},{"trials":23135,"activeCount":101},[],{"trials":23137,"activeCount":101},[],{"trials":23139,"activeCount":101},[],{"trials":23141,"activeCount":101},[],{"trials":23143,"activeCount":101},[],{"trials":23145,"activeCount":101},[23146],{"nctId":23126,"briefTitle":23127,"status":117,"phases":23147,"primaryCompletion":9865,"completion":9865,"start":3689,"enrollment":2728,"conditions":23148,"interventions":23149},[93],[8139],[23111,23131]]